Treatment None None O
effects None None O
on None None O
nigrostriatal None None O
projection None None O
integrity None None O
in None None O
partial None None O
6 None None O
- None None O
OHDA None None O
lesions None None O
: None None O
comparison None None O
of None None O
L None None O
- None None O
DOPA None None O
and None None O
pramipexole None None O
. None None O

There None None O
is None None O
controversy None None O
over None None O
potential None None O
effects None None O
of None None O
dopaminergic None None O
replacement None None O
therapies None None O
on None None O
the None None O
partially None None O
lesioned None None O
nigrostriatal None None O
dopaminergic None None O
projection None None O
. None None O

We None None O
evaluated None None O
indirect None None O
( None None O
levodopa None None O
, None None O
L None None O
- None None O
DOPA None None O
) None None O
versus None None O
direct None None O
( None None O
pramipexole None None O
, None None O
PRA None None O
) None None O
dopaminergic None None O
treatment None None O
effects None None O
on None None O
nigrostriatal None None O
lesion None None O
severity None None O
as None None O
measured None None O
with None None O
vesicular None None O
monoamine None None O
transporter None None O
type None None O
- None None O
2 None None O
( None None O
VMAT2 None None O
) None None O
binding None None O
. None None O

Prior None None O
studies None None O
have None None O
shown None None O
that None None O
striatal None None O
VMAT2 None None O
density None None O
provides None None O
an None None O
objective None None O
estimate None None O
of None None O
dopaminergic None None O
neuronal None None O
integrity None None O
, None None O
without None None O
confounding None None O
effects None None O
of None None O
compensatory None None O
regulation None None O
. None None O

Partial None None O
unilateral None None O
median None None O
forebrain None None O
bundle None None O
lesions None None O
were None None O
made None None O
by None None O
injection None None O
of None None O
6 None None O
- None None O
hydroxydopamine None None O
in None None O
adult None None O
male None None O
Sprague None None O
- None None O
Dawley None None O
rats None None O
. None None O

Lesion None None O
severity None None O
was None None O
estimated None None O
using None None O
rotational None None O
behavior None None O
after None None O
injections None None O
of None None O
apomorphine None None O
and None None O
amphetamine None None O
. None None O

Rats None None O
were None None O
ranked None None O
and None None O
matched None None O
in None None O
pairs None None O
by None None O
rotation None None O
and None None O
assigned None None O
to None None O
receive None None O
either None None O
PRA None None O
( None None O
1 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
) None None O
or None None O
L None None O
- None None O
DOPA None None O
/ None None O
benserazide None None O
( None None O
100 None None O
/ None None O
25 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
) None None O
ip None None O
via None None O
osmotic None None O
pump None None O
. None None O

After None None O
4 None None O
weeks None None O
of None None O
drug None None O
treatment None None O
, None None O
in None None O
vitro None None O
autoradiography None None O
was None None O
performed None None O
with None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
methoxytetrabenazine None None O
to None None O
measure None None O
striatal None None O
VMAT2 None None O
binding None None O
density None None O
. None None O

Lesion None None O
- None None O
to None None O
- None None O
intact None None O
VMAT2 None None O
density None None O
correlated None None O
with None None O
rotation None None O
in None None O
both None None O
treatment None None O
groups None None O
. None None O

There None None O
was None None O
no None None O
treatment None None O
effect None None O
on None None O
VMAT2 None None O
expression None None O
in None None O
the None None O
partially None None O
lesioned None None O
striatum None None O
and None None O
thus None None O
no None None O
differential None None O
effect None None O
of None None O
indirect None None O
versus None None O
direct None None O
dopamimetic None None O
treatment None None O
on None None O
nigrostriatal None None O
integrity None None O
. None None O

Relationship None None O
and None None O
prognostic None None O
significance None None O
of None None O
SPARC None None O
and None None O
VEGF None None O
protein None None O
expression None None O
in None None O
colon None None O
cancer None None O
. None None O

BACKGROUND None None O
: None None O
SPARC None None O
( None None O
secreted None None O
protein None None O
, None None O
acidic None None O
and None None O
rich None None O
in None None O
cysteine None None O
) None None O
is None None O
closely None None O
related None None O
with None None O
the None None O
progress None None O
, None None O
invasion None None O
and None None O
metastasis None None O
of None None O
malignant None None O
tumor None None O
and None None O
angiogenesis None None O
. None None O

METHODS None None O
: None None O
Using None None O
human None None O
colon None None O
adenocarcinoma None None O
tissues None None O
( None None O
hereinafter None None O
referred None None O
to None None O
as None None O
colon None None O
cancer None None O
) None None O
and None None O
their None None O
corresponding None None O
non None None O
- None None O
diseased None None O
colon None None O
from None None O
114 None None O
patients None None O
' None None O
biopsies None None O
, None None O
the None None O
expression None None O
of None None O
SPARC None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
were None None O
investigated None None O
by None None O
immunohistochemistry None None O
staining None None O
to None None O
assessment None None O
the None None O
relationship None None O
between None None O
SPARC None None O
and None None O
VEGF None None O
, None None O
as None None O
well None None O
as None None O
their None None O
prognostic None None O
significance None None O
in None None O
patients None None O
. None None O

Evaluation None None O
of None None O
VEGF None None O
expression None None O
level None None O
with None None O
the None None O
same None None O
tissues None None O
was None None O
used None None O
to None None O
establish None None O
the None None O
antigenic None None O
profiles None None O
, None None O
and None None O
the None None O
marker None None O
of None None O
CD34 None None O
staining None None O
was None None O
used None None O
as None None O
an None None O
indicator None None O
of None None O
microvessel None None O
density None None O
( None None O
MVD None None O
) None None O
. None None O

RESULTS None None O
: None None O
SPARC None None O
expression None None O
was None None O
mainly None None O
in None None O
the None None O
stromal None None O
cells None None O
surrounding None None O
the None None O
colon None None O
cancer None None O
, None None O
and None None O
was None None O
significant None None O
difference None None O
in None None O
those None None O
tissues None None O
with None None O
the None None O
lymph None None O
node None None O
metastasis None None O
and None None O
differentiation None None O
degree None None O
of None None O
tumor None None O
. None None O

Expression None None O
of None None O
SPARC None None O
was None None O
significantly None None O
correlated None None O
with None None O
the None None O
expression None None O
of None None O
VEGF None None O
and None None O
MVD None None O
in None None O
colon None None O
cancer None None O
tissues None None O
. None None O

Patients None None O
with None None O
low None None O
or None None O
absence None None O
expressing None None O
SPARC None None O
had None None O
significantly None None O
worse None None O
overall None None O
survival None None O
and None None O
disease None None O
- None None O
free None None O
survival None None O
in None None O
a None None O
Single None None O
Factor None None O
Analysis None None O
; None None O
Cox None None O
Regression None None O
Analysis None None O
, None None O
SPARC None None O
emerged None None O
as None None O
an None None O
overall None None O
survival None None O
and None None O
disease None None O
- None None O
free None None O
survival None None O
independent None None O
prognostic None None O
factor None None O
for None None O
colon None None O
cancer None None O
. None None O

CONCLUSION None None O
: None None O
The None None O
low None None O
expression None None O
or None None O
absence None None O
of None None O
stromal None None O
SPARC None None O
was None None O
an None None O
independent None None O
prognostic None None O
factor None None O
for None None O
poor None None O
prognosis None None O
of None None O
colon None None O
cancer None None O
. None None O

SPARC None None O
maybe None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
anti None None O
- None None O
angiogenesis None None O
by None None O
which None None O
it None None O
may None None O
serve None None O
as None None O
a None None O
novel None None O
target None None O
for None None O
colon None None O
cancer None None O
treatment None None O
as None None O
well None None O
as None None O
a None None O
novel None None O
distinctive None None O
marker None None O
. None None O

Do None None O
we None None O
know None None O
how None None O
much None None O
people None None O
like None None O
one None None O
another None None O
? None None O

Metaperception None None O
is None None O
a None None O
person None None O
' None None O
s None None O
perception None None O
about None None O
a None None O
second None None O
person None None O
' None None O
s None None O
perception None None O
of None None O
a None None O
third None None O
person None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
article None None O
is None None O
to None None O
examine None None O
the None None O
accuracy None None O
of None None O
metaperceptions None None O
of None None O
liking None None O
. None None O

A None None O
related None None O
question None None O
concerns None None O
whether None None O
the None None O
heuristics None None O
of None None O
balance None None O
, None None O
reciprocity None None O
, None None O
and None None O
agreement None None O
are None None O
used None None O
by None None O
perceivers None None O
when None None O
forming None None O
such None None O
judgments None None O
. None None O

The None None O
authors None None O
present None None O
analyses None None O
from None None O
5 None None O
diverse None None O
research None None O
studies None None O
that None None O
used None None O
an None None O
adaptation None None O
of None None O
the None None O
social None None O
relations None None O
model None None O
for None None O
triads None None O
( None None O
C None None O
. None None O
F None None O
. None None O
Bond None None O
, None None O
E None None O
. None None O
M None None O
. None None O
Horn None None O
, None None O
& None None O
D None None O
. None None O
A None None O
. None None O
Kenny None None O
, None None O
in None None O
press None None O
) None None O
. None None O

The None None O
results None None O
indicate None None O
that None None O
people None None O
know None None O
how None None O
much None None O
people None None O
like None None O
one None None O
another None None O
, None None O
even None None O
with None None O
small None None O
amounts None None O
of None None O
information None None O
. None None O

Although None None O
there None None O
is None None O
evidence None None O
for None None O
the None None O
use None None O
of None None O
heuristics None None O
, None None O
particularly None None O
reciprocity None None O
and None None O
agreement None None O
, None None O
accuracy None None O
is None None O
sometimes None None O
enhanced None None O
by None None O
using None None O
these None None O
heuristics None None O
. None None O

Management None None O
of None None O
early None None O
and None None O
advanced None None O
colorectal None None O
cancer None None O
: None None O
therapeutic None None O
issues None None O
. None None O

PURPOSE None None O
: None None O
The None None O
staging None None O
of None None O
colorectal None None O
cancer None None O
, None None O
therapeutic None None O
decision None None O
making None None O
in None None O
the None None O
management None None O
of None None O
early None None O
and None None O
advanced None None O
colorectal None None O
cancer None None O
, None None O
and None None O
dilemmas None None O
posed None None O
by None None O
drug None None O
- None None O
related None None O
toxicity None None O
are None None O
discussed None None O
. None None O

SUMMARY None None O
: None None O
Staging None None O
of None None O
colorectal None None O
cancer None None O
occurs None None O
after None None O
surgery None None O
and None None O
is None None O
based None None O
on None None O
the None None O
extent None None O
of None None O
disease None None O
invasiveness None None O
and None None O
dissemination None None O
. None None O

Surgery None None O
is None None O
the None None O
primary None None O
treatment None None O
for None None O
stage None None O
I None None O
disease None None O
. None None O

Adjuvant None None O
chemotherapy None None O
is None None O
recommended None None O
after None None O
resection None None O
in None None O
selected None None O
high None None O
- None None O
risk None None O
patients None None O
with None None O
stage None None O
II None None O
disease None None O
and None None O
in None None O
all None None O
patients None None O
with None None O
stage None None O
III None None O
disease None None O
. None None O

Convenience None None O
of None None O
administration None None O
, None None O
tolerability None None O
, None None O
and None None O
patient None None O
factors None None O
not None None O
necessarily None None O
age None None O
may None None O
be None None O
considerations None None O
in None None O
decisions None None O
about None None O
adjuvant None None O
therapy None None O
after None None O
resection None None O
. None None O

Treatment None None O
of None None O
stage None None O
IV None None O
colorectal None None O
cancer None None O
is None None O
based None None O
on None None O
the None None O
type None None O
of None None O
prior None None O
therapy None None O
and None None O
patient None None O
- None None O
specific None None O
factors None None O
. None None O

Recently None None O
, None None O
significant None None O
improvements None None O
in None None O
survival None None O
have None None O
been None None O
achieved None None O
through None None O
the None None O
use None None O
of None None O
combination None None O
chemotherapy None None O
and None None O
monoclonal None None O
antibody None None O
regimens None None O
. None None O

Bevacizumab None None O
in None None O
combination None None O
with None None O
chemotherapy None None O
is None None O
first None None O
- None None O
line None None O
therapy None None O
for None None O
stage None None O
IV None None O
disease None None O
. None None O

Age None None O
alone None None O
should None None O
not None None O
preclude None None O
the None None O
use None None O
of None None O
chemotherapy None None O
in None None O
stage None None O
IV None None O
colorectal None None O
cancer None None O
, None None O
although None None O
the None None O
ability None None O
to None None O
tolerate None None O
drug None None O
- None None O
related None None O
toxicity None None O
may None None O
be None None O
a None None O
consideration None None O
. None None O

The None None O
optimal None None O
duration None None O
of None None O
chemotherapy None None O
in None None O
patients None None O
with None None O
early None None O
and None None O
metastatic None None O
colorectal None None O
cancer None None O
is None None O
unclear None None O
. None None O

CONCLUSION None None O
: None None O
The None None O
optimal None None O
approach None None O
to None None O
the None None O
treatment None None O
of None None O
colorectal None None O
cancer None None O
depends None None O
on None None O
several None None O
considerations None None O
, None None O
including None None O
patient None None O
- None None O
specific None None O
factors None None O
. None None O

Measurement None None O
of None None O
serum None None O
glycosylated None None O
proteins None None O
and None None O
glycosylated None None O
low None None O
density None None O
lipoprotein None None O
fraction None None O
in None None O
diabetes None None O
mellitus None None O
. None None O

A None None O
simple None None O
method None None O
was None None O
developed None None O
for None None O
estimating None None O
serum None None O
glycosylated None None O
protein None None O
levels None None O
using None None O
gel None None O
filtration None None O
with None None O
Bio None None O
- None None O
Gel None None O
P6 None None O
by None None O
determining None None O
the None None O
protein None None O
and None None O
sugar None None O
content None None O
in None None O
the None None O
void None None O
volume None None O
fraction None None O
. None None O

The None None O
glycosylated None None O
protein None None O
levels None None O
( None None O
GSP None None O
) None None O
correlated None None O
well None None O
with None None O
fasting None None O
blood None None O
sugar None None O
levels None None O
and None None O
glycosylated None None O
albumin None None O
level None None O
( None None O
G None None O
- None None O
ALB None None O
) None None O
determined None None O
by None None O
affinity None None O
chromatography None None O
with None None O
Blue None None O
Sepharose None None O
CL6B None None O
. None None O

The None None O
glycosylation None None O
level None None O
of None None O
heparin None None O
- None None O
citrate None None O
precipitable None None O
fraction None None O
of None None O
serum None None O
which None None O
predominantly None None O
contained None None O
low None None O
density None None O
lipoprotein None None O
( None None O
G None None O
- None None O
LDL None None O
) None None O
also None None O
correlated None None O
well None None O
with None None O
GSP None None O
and None None O
LDL None None O
- None None O
cholesterol None None O
levels None None O
. None None O

Significantly None None O
different None None O
values None None O
were None None O
obtained None None O
for None None O
GSP None None O
, None None O
G None None O
- None None O
ALB None None O
, None None O
and None None O
G None None O
- None None O
LDL None None O
between None None O
normals None None O
and None None O
diabetics None None O
. None None O

Methods None None O

Therefore None None O
, None None O
we None None O
developed None None O
a None None O
reciprocal None None O
system None None O
of None None O
a None None O
full None None O
- None None O
length None None O
HIV None None O
packaging None None O
cell None None O
line None None O
and None None O
a None None O
shortened None None O
HI None None O
- None None O
viral None None O
shuttle None None O
vector None None O
. None None O

The None None O
Tat None None O
- None None O
deficient None None O
packaging None None O
construct None None O
is None None O
stably None None O
integrated None None O
in None None O
a None None O
VSVG None None O
- None None O
pseudotyped None None O
cell None None O
line None None O
and None None O
transactivated None None O
by None None O
the None None O
shuttle None None O
vector None None O
by None None O
expression None None O
of None None O
TATGFP None None O
from None None O
a None None O
heterologous None None O
promoter None None O
which None None O
also None None O
indicates None None O
positive None None O
cells None None O
. None None O

Expression None None O
of None None O
the None None O
HI None None O
- None None O
viral None None O
structure None None O
proteins None None O
is None None O
driven None None O
by None None O
a None None O
natural None None O
5 None None O
' None None O
LTR None None O
promoter None None O
and None None O
a None None O
3 None None O
' None None O
polyadenylation None None O
signal None None O
, None None O
whereas None None O
the None None O
envelope None None O
expression None None O
out None None O
of None None O
the None None O
shuttle None None O
vector None None O
is None None O
achieved None None O
by None None O
an None None O
IRES None None O
. None None O

This None None O
system None None O
of None None O
two None None O
vectors None None O
is None None O
tightly None None O
controllable None None O
and None None O
bypasses None None O
the None None O
problem None None O
of None None O
limited None None O
packaging None None O
capacity None None O
into None None O
HIV None None O
- None None O
1 None None O
virions None None O
. None None O

Stimulation None None O
of None None O
the None None O
sodium None None O
pump None None O
by None None O
azide None None O
and None None O
high None None O
internal None None O
sodium None None O
: None None O
changes None None O
in None None O
the None None O
number None None O
of None None O
pumping None None O
sites None None O
and None None O
turnover None None O
rate None None O
. None None O

1 None None O
. None None O

The None None O
effects None None O
of None None O
5 None None O
mM None None O
azide None None O
on None None O
[ None None O
3H None None O
] None None O
ouabain None None O
uptake None None O
and None None O
22Na None None O
efflux None None O
were None None O
determined None None O
. None None O

Both None None O
glycoside None None O
uptake None None O
and None None O
22Na None None O
efflux None None O
were None None O
enhanced None None O
by None None O
azide None None O
. None None O

2 None None O
. None None O

Azide None None O
stimulated None None O
the None None O
Na None None O
pump None None O
in None None O
muscles None None O
whose None None O
pumping None None O
sites None None O
had None None O
been None None O
inhibited None None O
by None None O
ouabain None None O
and None None O
then None None O
transferred None None O
to None None O
a None None O
glycoside None None O
- None None O
free None None O
solution None None O
. None None O

This None None O
stimulation None None O
was None None O
observed None None O
before None None O
detecting None None O
any None None O
recovery None None O
of None None O
the None None O
initial None None O
pumping None None O
activity None None O
. None None O

3 None None O
. None None O

When None None O
both None None O
the None None O
resting None None O
and None None O
the None None O
azide None None O
- None None O
stimulated None None O
22Na None None O
efflux None None O
had None None O
been None None O
blocked None None O
by None None O
ouabain None None O
, None None O
an None None O
additional None None O
exposure None None O
to None None O
azide None None O
, None None O
in None None O
a None None O
ouabain None None O
- None None O
free None None O
solution None None O
, None None O
had None None O
no None None O
further None None O
effects None None O
on None None O
22Na None None O
efflux None None O
. None None O

4 None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
the None None O
increase None None O
in None None O
Na None None O
pumping None None O
caused None None O
by None None O
azide None None O
is None None O
due None None O
in None None O
part None None O
to None None O
an None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
pumping None None O
sites None None O
. None None O

5 None None O
. None None O

[ None None O
3H None None O
] None None O
ouabain None None O
binding None None O
was None None O
measured None None O
in None None O
muscles None None O
with None None O
different None None O
intracellular None None O
alkali None None O
cation None None O
concentrations None None O
. None None O

Variations None None O
in None None O
[ None None O
Na None None O
] None None O
i None None O
from None None O
15 None None O
up None None O
to None None O
50 None None O
mM None None O
did None None O
not None None O
significantly None None O
affect None None O
the None None O
amount None None O
of None None O
glycoside None None O
bound None None O
. None None O

A None None O
substantial None None O
increase None None O
in None None O
binding None None O
occurred None None O
when None None O
[ None None O
Na None None O
] None None O
i None None O
reached None None O
70 None None O
mM None None O
. None None O

6 None None O
. None None O

It None None O
is None None O
proposed None None O
that None None O
the None None O
increase None None O
in None None O
Na None None O
extrusion None None O
that None None O
occurs None None O
during None None O
the None None O
recovery None None O
of None None O
Na None None O
loaded None None O
muscles None None O
mostly None None O
results None None O
from None None O
an None None O
increased None None O
turnover None None O
rate None None O
of None None O
the None None O
pump None None O
rather None None O
than None None O
from None None O
an None None O
increase None None O
in None None O
number None None O
of None None O
pumping None None O
sites None None O
. None None O

Absence None None O
of None None O
effect None None O
of None None O
prenatal None None O
ethanol None None O
on None None O
adult None None O
emotionality None None O
and None None O
ethanol None None O
consumption None None O
in None None O
rats None None O
. None None O

Lower None None O
peak None None O
blood None None O
ethanol None None O
concentrations None None O
after None None O
1 None None O
and None None O
2 None None O
g None None O
of None None O
ethanol None None O
per None None O
kg None None O
were None None O
found None None O
in None None O
pregnant None None O
rats None None O
than None None O
in None None O
virgin None None O
females None None O
. None None O

No None None O
significant None None O
differences None None O
in None None O
adult None None O
" None None O
emotionality None None O
" None None O
or None None O
ethanol None None O
consumption None None O
were None None O
found None None O
in None None O
rats None None O
exposed None None O
to None None O
prenatal None None O
alcohol None None O
and None None O
in None None O
pair None None O
- None None O
fed None None O
and None None O
untreated None None O
controls None None O
. None None O

Discussion None None O

Among None None O
adolescent None None O
boys None None O
in None None O
Chapaevsk None None O
, None None O
Russia None None O
, None None O
higher None None O
serum None None O
levels None None O
of None None O
sum None None O
of None None O
dioxin None None O
- None None O
like None None O
compounds None None O
and None None O
sum None None O
of None None O
dioxin None None O
TEQs None None O
were None None O
positively None None O
associated None None O
with None None O
increased None None O
age None None O
, None None O
consumption None None O
of None None O
fish None None O
, None None O
local None None O
meats None None O
other None None O
than None None O
chicken None None O
, None None O
and None None O
inversely None None O
with None None O
weeks None None O
of None None O
gestation None None O
. None None O

The None None O
age None None O
association None None O
was None None O
found None None O
despite None None O
a None None O
narrow None None O
age None None O
range None None O
of None None O
slightly None None O
over None None O
two None None O
years None None O
in None None O
our None None O
study None None O
. None None O

Although None None O
not None None O
statistically None None O
significant None None O
, None None O
the None None O
distance None None O
the None None O
boy None None O
lived None None O
from None None O
the None None O
Khimprom None None O
factory None None O
at None None O
the None None O
time None None O
of None None O
blood None None O
draw None None O
was None None O
inversely None None O
associated None None O
with None None O
serum None None O
levels None None O
of None None O
sum None None O
of None None O
dioxin None None O
- None None O
like None None O
compounds None None O
and None None O
sum None None O
of None None O
dioxin None None O
TEQs None None O
. None None O

As None None O
expected None None O
, None None O
serum None None O
PCBs None None O
, None None O
specifically None None O
PCB None None O
118 None None O
, None None O
were None None O
strongly None None O
associated None None O
with None None O
both None None O
sum None None O
of None None O
dioxin None None O
- None None O
like None None O
compounds None None O
and None None O
sum None None O
of None None O
dioxin None None O
TEQs None None O
. None None O

There None None O
was None None O
no None None O
association None None O
between None None O
the None None O
distance None None O
of None None O
the None None O
residence None None O
from None None O
the None None O
Khimprom None None O
plant None None O
during None None O
the None None O
pregnancy None None O
and None None O
subsequent None None O
serum None None O
dioxin None None O
levels None None O
. None None O

One None None O
potential None None O
explanation None None O
for None None O
the None None O
lack None None O
of None None O
association None None O
may None None O
include None None O
misclassification None None O
of None None O
distance None None O
since None None O
the None None O
mother None None O
was None None O
asked None None O
to None None O
recall None None O
a None None O
time None None O
period None None O
more None None O
than None None O
14 None None O
years None None O
prior None None O
to None None O
the None None O
study None None O
. None None O

However None None O
, None None O
we None None O
would None None O
expect None None O
that None None O
the None None O
mother None None O
would None None O
be None None O
able None None O
to None None O
recall None None O
residential None None O
history None None O
at None None O
the None None O
time None None O
of None None O
the None None O
birth None None O
of None None O
their None None O
son None None O
. None None O

Mother None None O
' None None O
s None None O
self None None O
- None None O
reported None None O
estimates None None O
of None None O
current None None O
residential None None O
distance None None O
from None None O
Khimprom None None O
was None None O
generally None None O
accurate None None O
; None None O
twenty None None O
- None None O
one None None O
of None None O
twenty None None O
- None None O
nine None None O
mothers None None O
correctly None None O
categorized None None O
their None None O
current None None O
residential None None O
distance None None O
from None None O
the None None O
Khimprom None None O
plants None None O
based None None O
on None None O
cross None None O
- None None O
referencing None None O
using None None O
GIS None None O
mapping None None O
. None None O

Other None None O
explanations None None O
include None None O
that None None O
prenatal None None O
exposure None None O
14 None None O
or None None O
more None None O
years None None O
prior None None O
to None None O
the None None O
current None None O
serum None None O
sample None None O
is None None O
not None None O
as None None O
strong None None O
a None None O
predictor None None O
as None None O
are None None O
exposures None None O
resulting None None O
from None None O
present None None O
residential None None O
location None None O
. None None O

Although None None O
there None None O
was None None O
no None None O
association None None O
of None None O
case None None O
status None None O
( None None O
cryptorchidism None None O
or None None O
hypospadias None None O
) None None O
with None None O
dioxin None None O
levels None None O
, None None O
we None None O
did None None O
not None None O
have None None O
sufficient None None O
power None None O
to None None O
definitively None None O
assess None None O
this None None O
relationship None None O
. None None O

Perinatal None None O
history None None O
( None None O
e None None O
. None None O
g None None O
. None None O
weeks None None O
of None None O
breastfeeding None None O
) None None O
was None None O
generally None None O
not None None O
associated None None O
with None None O
exposure None None O
measures None None O
in None None O
this None None O
population None None O
; None None O
this None None O
may None None O
be None None O
a None None O
function None None O
of None None O
older None None O
age None None O
of None None O
the None None O
children None None O
. None None O

However None None O
, None None O
there None None O
are None None O
limited None None O
data None None O
on None None O
the None None O
relationship None None O
of None None O
perinatal None None O
factors None None O
with None None O
organochlorine None None O
exposures None None O
in None None O
this None None O
age None None O
group None None O
so None None O
a None None O
null None None O
finding None None O
is None None O
of None None O
interest None None O
given None None O
reports None None O
that None None O
differences None None O
in None None O
organochlorine None None O
levels None None O
among None None O
breastfed None None O
and None None O
non None None O
- None None O
breastfed None None O
are None None O
generally None None O
no None None O
longer None None O
discernable None None O
by None None O
early None None O
school None None O
age None None O
[ None None O
24 None None O
, None None O
25 None None O
] None None O
and None None O
, None None O
furthermore None None O
, None None O
that None None O
dietary None None O
intake None None O
after None None O
this None None O
age None None O
contributes None None O
significantly None None O
to None None O
total None None O
dioxin None None O
intake None None O
[ None None O
26 None None O
] None None O
. None None O

In None None O
prior None None O
studies None None O
, None None O
substantial None None O
emphasis None None O
has None None O
been None None O
placed None None O
on None None O
pre None None O
- None None O
and None None O
early None None O
postnatal None None O
( None None O
via None None O
breastfeeding None None O
) None None O
exposures None None O
because None None O
of None None O
particular None None O
vulnerability None None O
during None None O
fetal None None O
and None None O
early None None O
infant None None O
development None None O
. None None O

The None None O
exposure None None O
risk None None O
factors None None O
during None None O
peri None None O
- None None O
adolescence None None O
, None None O
another None None O
period None None O
of None None O
potential None None O
developmental None None O
vulnerability None None O
, None None O
has None None O
not None None O
been None None O
studied None None O
in None None O
- None None O
detail None None O
, None None O
therefore None None O
, None None O
the None None O
identification None None O
of None None O
exposure None None O
risk None None O
factors None None O
specific None None O
to None None O
this None None O
period None None O
will None None O
enhance None None O
our None None O
understanding None None O
of None None O
this None None O
critical None None O
period None None O
. None None O

Although None None O
data None None O
on None None O
levels None None O
of None None O
PCDD None None O
/ None None O
PCDFs None None O
in None None O
children None None O
is None None O
limited None None O
, None None O
our None None O
results None None O
suggest None None O
that None None O
the None None O
mean None None O
total None None O
TEQs None None O
among None None O
Chapaevsk None None O
adolescents None None O
were None None O
higher None None O
than None None O
most None None O
values None None O
previously None None O
reported None None O
in None None O
non None None O
- None None O
occupationally None None O
exposed None None O
populations None None O
of None None O
comparable None None O
or None None O
even None None O
older None None O
ages None None O
. None None O

Figure None None O
2 None None O
shows None None O
a None None O
comparison None None O
of None None O
the None None O
mean None None O
PCDD None None O
/ None None O
PCDFs None None O
TEQ None None O
levels None None O
in None None O
Chapaevsk None None O
boys None None O
with None None O
other None None O
populations None None O
( None None O
TEQ None None O
from None None O
dioxin None None O
- None None O
like None None O
PCBs None None O
was None None O
not None None O
included None None O
, None None O
since None None O
some None None O
of None None O
these None None O
studies None None O
did None None O
not None None O
report None None O
them None None O
) None None O
. None None O

The None None O
mean None None O
TEQs None None O
of None None O
pooled None None O
blood None None O
samples None None O
from None None O
10 None None O
year None None O
- None None O
old None None O
German None None O
boys None None O
in None None O
rural None None O
and None None O
urban None None O
settings None None O
was None None O
8 None None O
. None None O
2 None None O
pg None None O
TEQ None None O
/ None None O
g None None O
lipid None None O
for None None O
an None None O
urban None None O
industrial None None O
area None None O
, None None O
9 None None O
. None None O
0 None None O
pg None None O
TEQ None None O
/ None None O
g None None O
lipid None None O
for None None O
an None None O
industrial None None O
area None None O
within None None O
a None None O
rural None None O
setting None None O
, None None O
and None None O
10 None None O
. None None O
1 None None O
pg None None O
TEQ None None O
/ None None O
g None None O
lipid None None O
for None None O
a None None O
rural None None O
area None None O
[ None None O
27 None None O
] None None O
. None None O

In None None O
comparison None None O
, None None O
the None None O
mean None None O
TEQ None None O
in None None O
the None None O
Chapevsk None None O
boys None None O
was None None O
19 None None O
. None None O
3 None None O
pg None None O
TEQ None None O
/ None None O
g None None O
lipid None None O
. None None O

With None None O
the None None O
exception None None O
of None None O
children None None O
described None None O
by None None O
Wuthe None None O
et None None O
al None None O
. None None O

[ None None O
27 None None O
] None None O
, None None O
subjects None None O
in None None O
the None None O
other None None O
studies None None O
in None None O
Figure None None O
2 None None O
were None None O
significantly None None O
older None None O
than None None O
the None None O
Chapaevsk None None O
boys None None O
. None None O

Despite None None O
age None None O
differences None None O
, None None O
the None None O
mean None None O
TEQ None None O
in None None O
Chapaevsk None None O
boys None None O
was None None O
comparable None None O
to None None O
or None None O
even None None O
higher None None O
than None None O
the None None O
mean None None O
TEQ None None O
in None None O
older None None O
populations None None O
from None None O
other None None O
countries None None O
. None None O

For None None O
example None None O
, None None O
they None None O
were None None O
higher None None O
than None None O
mean None None O
TEQs None None O
of None None O
18 None None O
. None None O
4 None None O
pg None None O
TEQ None None O
/ None None O
g None None O
lipid None None O
in None None O
adults None None O
( None None O
40 None None O
. None None O
6 None None O
years None None O
old None None O
average None None O
) None None O
from None None O
South None None O
Germany None None O
[ None None O
27 None None O
] None None O
or None None O
16 None None O
. None None O
4 None None O
pg None None O
TEQ None None O
/ None None O
g None None O
lipid None None O
from None None O
20 None None O
year None None O
old None None O
Japanese None None O
women None None O
[ None None O
28 None None O
] None None O
or None None O
pooled None None O
samples None None O
from None None O
randomly None None O
selected None None O
males None None O
and None None O
females None None O
18 None None O
- None None O
69 None None O
years None None O
of None None O
age None None O
from None None O
the None None O
Spanish None None O
city None None O
of None None O
Mataro None None O
[ None None O
29 None None O
] None None O
, None None O
which None None O
were None None O
12 None None O
. None None O
5 None None O
and None None O
14 None None O
. None None O
7 None None O
pg None None O
TEQ None None O
/ None None O
g None None O
lipid None None O
respectively None None O
. None None O

The None None O
mean None None O
levels None None O
in None None O
adult None None O
female None None O
( None None O
mean None None O
age None None O
41 None None O
years None None O
) None None O
non None None O
- None None O
factory None None O
workers None None O
in None None O
the None None O
Russian None None O
city None None O
of None None O
Shelekhovo None None O
were None None O
also None None O
lower None None O
at None None O
14 None None O
. None None O
5 None None O
pg None None O
TEQ None None O
/ None None O
g None None O
lipid None None O
[ None None O
30 None None O
] None None O
. None None O

Mean None None O
TEQs None None O
for None None O
the None None O
general None None O
population None None O
( None None O
mean None None O
age None None O
44 None None O
. None None O
2 None None O
years None None O
) None None O
in None None O
Germany None None O
, None None O
collected None None O
in None None O
1997 None None O
- None None O
98 None None O
[ None None O
31 None None O
] None None O
, None None O
and None None O
median None None O
TEQs None None O
for None None O
long None None O
- None None O
term None None O
workers None None O
of None None O
pulp None None O
and None None O
paper None None O
mill None None O
and None None O
non None None O
- None None O
workers None None O
in None None O
the None None O
U None None O
. None None O
S None None O
. None None O
in None None O
1996 None None O
[ None None O
32 None None O
] None None O
were None None O
similar None None O
to None None O
levels None None O
found None None O
in None None O
the None None O
Chapaevsk None None O
boys None None O
. None None O

The None None O
mean None None O
levels None None O
in None None O
the None None O
study None None O
in None None O
Germany None None O
were None None O
20 None None O
. None None O
71 None None O
pg None None O
TEQ None None O
/ None None O
g None None O
lipid None None O
and None None O
in None None O
the None None O
U None None O
. None None O
S None None O
. None None O
the None None O
median None None O
levels None None O
were None None O
19 None None O
. None None O
1 None None O
pg None None O
TEQ None None O
/ None None O
g None None O
lipid None None O
for None None O
community None None O
residents None None O
and None None O
21 None None O
. None None O
2 None None O
pg None None O
TEQ None None O
/ None None O
g None None O
lipid None None O
for None None O
low None None O
exposure None None O
workers None None O
. None None O

Figure None None O
2 None None O

Mean None None O
PCDD None None O
/ None None O
PCDFs None None O
TEQ None None O
levels None None O
in None None O
Chapaevsk None None O
boys None None O
in None None O
comparison None None O
with None None O
other None None O
populations None None O
. None None O

Although None None O
TCDD None None O
was None None O
largely None None O
below None None O
the None None O
detection None None O
limits None None O
in None None O
this None None O
small None None O
pilot None None O
sample None None O
, None None O
the None None O
two None None O
boys None None O
with None None O
detectable None None O
values None None O
had None None O
high None None O
TCDD None None O
levels None None O
( None None O
17 None None O
. None None O
9 None None O
and None None O
21 None None O
. None None O
7 None None O
pg None None O
/ None None O
g None None O
lipid None None O
) None None O
, None None O
suggesting None None O
that None None O
exposure None None O
for None None O
at None None O
least None None O
some None None O
portion None None O
of None None O
this None None O
population None None O
is None None O
substantially None None O
higher None None O
than None None O
typical None None O
of None None O
this None None O
age None None O
group None None O
. None None O

In None None O
comparison None None O
, None None O
in None None O
a None None O
cohort None None O
of None None O
adult None None O
( None None O
mean None None O
age None None O
of None None O
58 None None O
years None None O
) None None O
fishermen None None O
from None None O
a None None O
polluted None None O
region None None O
of None None O
Finland None None O
, None None O
the None None O
mean None None O
TCDD None None O
concentration None None O
was None None O
19 None None O
pg None None O
/ None None O
g None None O
lipid None None O
[ None None O
33 None None O
] None None O
. None None O

In None None O
adult None None O
( None None O
mean None None O
age None None O
of None None O
53 None None O
years None None O
) None None O
residents None None O
from None None O
Calcasieu None None O
Parish None None O
, None None O
Louisiana None None O
, None None O
which None None O
is None None O
near None None O
a None None O
chemical None None O
industrial None None O
complex None None O
, None None O
the None None O
mean None None O
TCDD None None O
level None None O
was None None O
7 None None O
. None None O
6 None None O
pg None None O
/ None None O
g None None O
lipid None None O
[ None None O
34 None None O
] None None O
. None None O

Not None None O
only None None O
were None None O
the None None O
dioxin None None O
levels None None O
in None None O
these None None O
two None None O
children None None O
higher None None O
than None None O
those None None O
found None None O
in None None O
these None None O
studies None None O
, None None O
but None None O
the None None O
adults None None O
in None None O
the None None O
previous None None O
studies None None O
were None None O
several None None O
decades None None O
older None None O
and None None O
therefore None None O
would None None O
be None None O
expected None None O
to None None O
have None None O
higher None None O
dioxin None None O
body None None O
burdens None None O
than None None O
younger None None O
children None None O
[ None None O
35 None None O
] None None O
. None None O

Potential None None O
explanations None None O
for None None O
the None None O
large None None O
number None None O
of None None O
non None None O
- None None O
detectable None None O
samples None None O
for None None O
TCDD None None O
include None None O
the None None O
small None None O
sample None None O
volume None None O
and None None O
young None None O
age None None O
of None None O
the None None O
subjects None None O
. None None O

In None None O
our None None O
future None None O
studies None None O
in None None O
this None None O
population None None O
, None None O
we None None O
will None None O
collect None None O
larger None None O
volumes None None O
of None None O
serum None None O
for None None O
dioxin None None O
analysis None None O
. None None O

In None None O
one None None O
of None None O
the None None O
few None None O
studies None None O
on None None O
dioxin None None O
- None None O
like None None O
compounds None None O
in None None O
which None None O
children None None O
were None None O
included None None O
, None None O
Eskenazi None None O
and None None O
coworkers None None O
[ None None O
36 None None O
] None None O
evaluated None None O
the None None O
relationship None None O
between None None O
serum None None O
TCDD None None O
concentrations None None O
and None None O
age None None O
at None None O
exposure None None O
of None None O
female None None O
residents None None O
of None None O
Seveso None None O
, None None O
Italy None None O
. None None O

Residents None None O
near None None O
the None None O
ICMESA None None O
chemical None None O
plant None None O
in None None O
Seveso None None O
were None None O
exposed None None O
to None None O
some None None O
of None None O
the None None O
highest None None O
known None None O
residential None None O
levels None None O
of None None O
2 None None O
, None None O
3 None None O
, None None O
7 None None O
, None None O
8 None None O
- None None O
TCDD None None O
as None None O
a None None O
result None None O
of None None O
an None None O
explosion None None O
at None None O
the None None O
plant None None O
. None None O

Archived None None O
serum None None O
collected None None O
near None None O
the None None O
time None None O
of None None O
the None None O
accident None None O
was None None O
used None None O
to None None O
measure None None O
exposures None None O
. None None O

Residents None None O
closest None None O
to None None O
the None None O
plant None None O
had None None O
a None None O
median None None O
2 None None O
, None None O
3 None None O
, None None O
7 None None O
, None None O
8 None None O
- None None O
TCDD None None O
level None None O
of None None O
272 None None O
ppt None None O
( None None O
IQR None None O
92 None None O
- None None O
883 None None O
ppt None None O
) None None O
. None None O

Residential None None O
proximity None None O
to None None O
the None None O
plant None None O
and None None O
younger None None O
age None None O
( None None O
up None None O
to None None O
13 None None O
years None None O
old None None O
) None None O
were None None O
the None None O
strongest None None O
predictors None None O
of None None O
an None None O
individual None None O
' None None O
s None None O
serum None None O
2 None None O
, None None O
3 None None O
, None None O
7 None None O
, None None O
8 None None O
- None None O
TCDD None None O
level None None O
. None None O

Other None None O
predictors None None O
included None None O
being None None O
outdoors None None O
at None None O
the None None O
time None None O
of None None O
explosion None None O
and None None O
consumption None None O
of None None O
homegrown None None O
food None None O
. None None O

The None None O
higher None None O
levels None None O
found None None O
in None None O
children None None O
were None None O
most None None O
likely None None O
a None None O
result None None O
of None None O
increased None None O
exposure None None O
as None None O
a None None O
result None None O
of None None O
activity None None O
patterns None None O
and None None O
a None None O
greater None None O
proportionate None None O
consumption None None O
of None None O
food None None O
, None None O
water None None O
and None None O
air None None O
than None None O
adults None None O
[ None None O
37 None None O
] None None O
. None None O

Although None None O
the None None O
exposure None None O
scenario None None O
( None None O
an None None O
acute None None O
high None None O
exposure None None O
event None None O
) None None O
is None None O
different None None O
than None None O
the None None O
chronic None None O
low None None O
/ None None O
moderate None None O
exposure None None O
occurring None None O
in None None O
Chapaevsk None None O
, None None O
the None None O
results None None O
from None None O
Seveso None None O
suggest None None O
that None None O
children None None O
may None None O
be None None O
at None None O
increased None None O
risk None None O
for None None O
high None None O
dioxin None None O
exposure None None O
from None None O
environmental None None O
contamination None None O
. None None O

In None None O
our None None O
study None None O
, None None O
although None None O
distance None None O
from None None O
the None None O
Khimprom None None O
plants None None O
was None None O
a None None O
weak None None O
predictor None None O
of None None O
serum None None O
dioxin None None O
- None None O
like None None O
compounds None None O
, None None O
consumption None None O
of None None O
local None None O
foods None None O
( None None O
specifically None None O
meat None None O
and None None O
fish None None O
) None None O
, None None O
as None None O
in None None O
the None None O
Seveso None None O
study None None O
, None None O
was None None O
a None None O
strong None None O
predictor None None O
of None None O
sum None None O
of None None O
dioxin None None O
- None None O
like None None O
compounds None None O
and None None O
dioxin None None O
TEQs None None O
. None None O

This None None O
finding None None O
is None None O
notable None None O
given None None O
concerns None None O
regarding None None O
environmental None None O
dioxin None None O
contamination None None O
in None None O
the None None O
community None None O
and None None O
suggests None None O
that None None O
food None None O
may None None O
be None None O
one None None O
of None None O
the None None O
more None None O
, None None O
if None None O
not None None O
most None None O
, None None O
important None None O
routes None None O
of None None O
environmental None None O
contaminant None None O
exposure None None O
for None None O
residents None None O
in None None O
this None None O
setting None None O
. None None O

In None None O
other None None O
settings None None O
, None None O
contaminated None None O
food None None O
generally None None O
contributes None None O
much None None O
more None None O
substantially None None O
to None None O
human None None O
organochlorine None None O
burden None None O
than None None O
air None None O
or None None O
soil None None O
( None None O
which None None O
may None None O
be None None O
related None None O
to None None O
residential None None O
proximity None None O
to None None O
pollutant None None O
sources None None O
) None None O
[ None None O
6 None None O
] None None O
. None None O

We None None O
will None None O
investigate None None O
this None None O
issue None None O
in None None O
more None None O
detail None None O
in None None O
our None None O
ongoing None None O
study None None O
. None None O

Structure None None O
of None None O
the None None O
genetic None None O
code None None O
suggested None None O
by None None O
the None None O
hydropathy None None O
correlation None None O
between None None O
anticodons None None O
and None None O
amino None None O
acid None None O
residues None None O
. None None O

The None None O
correlation None None O
between None None O
hydropathies None None O
of None None O
anticodons None None O
and None None O
amino None None O
acids None None O
, None None O
detected None None O
by None None O
other None None O
authors None None O
utilizing None None O
scales None None O
of None None O
amino None None O
acid None None O
molecules None None O
in None None O
solution None None O
, None None O
was None None O
improved None None O
with None None O
the None None O
utilization None None O
of None None O
scales None None O
of None None O
amino None None O
acid None None O
residues None None O
in None None O
proteins None None O
. None None O

Three None None O
partitions None None O
were None None O
discerned None None O
in None None O
the None None O
correlation None None O
plot None None O
with None None O
the None None O
principal None None O
dinucleotides None None O
of None None O
anticodons None None O
( None None O
pDiN None None O
, None None O
excluding None None O
the None None O
wobble None None O
position None None O
) None None O
. None None O

( None None O
a None None O
) None None O
The None None O
set None None O
of None None O
outliers None None O
of None None O
the None None O
correlation None None O
: None None O
Gly None None O
- None None O
CC None None O
, None None O
Pro None None O
- None None O
GG None None O
, None None O
Ser None None O
- None None O
GA None None O
and None None O
Ser None None O
- None None O
CU None None O
. None None O

The None None O
amino None None O
acids None None O
are None None O
consistently None None O
small None None O
, None None O
hydro None None O
- None None O
apathetic None None O
, None None O
stabilizers None None O
of None None O
protein None None O
N None None O
- None None O
ends None None O
, None None O
preferred None None O
in None None O
aperiodic None None O
protein None None O
conformations None None O
and None None O
belong None None O
to None None O
synthetases None None O
class None None O
II None None O
. None None O

The None None O
pDiN None None O
sequences None None O
are None None O
representative None None O
of None None O
the None None O
homogeneous None None O
sector None None O
( None None O
triplets None None O
NRR None None O
and None None O
NYY None None O
) None None O
, None None O
distinguished None None O
from None None O
the None None O
mixed None None O
sector None None O
( None None O
triplets None None O
NRY None None O
and None None O
NYR None None O
) None None O
, None None O
that None None O
depict None None O
a None None O
70 None None O
% None None O
correspondence None None O
to None None O
the None None O
synthetases None None O
class None None O
II None None O
and None None O
I None None O
, None None O
respectively None None O
. None None O

The None None O
triplet None None O
pairs None None O
proposed None None O
to None None O
be None None O
responsible None None O
for None None O
the None None O
coherence None None O
in None None O
the None None O
set None None O
of None None O
outliers None None O
are None None O
of None None O
the None None O
palindromic None None O
kind None None O
, None None O
where None None O
the None None O
lateral None None O
bases None None O
are None None O
the None None O
same None None O
, None None O
CCC None None O
: None None O
GGG None None O
and None None O
AGA None None O
: None None O
UCU None None O
. None None O

This None None O
suggests None None O
that None None O
UCU None None O
previously None None O
belonged None None O
to None None O
Ser None None O
, None None O
adding None None O
to None None O
other None None O
indications None None O
that None None O
the None None O
attribution None None O
of None None O
Arg None None O
to None None O
YCU None None O
was None None O
due None None O
to None None O
an None None O
expansion None None O
of None None O
the None None O
Arg None None O
- None None O
tRNA None None O
synthetase None None O
specificity None None O
. None None O

The None None O
other None None O
attributions None None O
produced None None O
two None None O
correlation None None O
sets None None O
. None None O

( None None O
b None None O
) None None O
One None None O
corresponds None None O
to None None O
the None None O
remaining None None O
pDiN None None O
of None None O
the None None O
homogeneous None None O
sector None None O
, None None O
containing None None O
both None None O
synthetase None None O
classes None None O
; None None O
its None None O
regression None None O
line None None O
overlapped None None O
the None None O
one None None O
formed None None O
by None None O
the None None O
remaining None None O
attributions None None O
to None None O
class None None O
II None None O
. None None O

( None None O
c None None O
) None None O
The None None O
other None None O
contains None None O
the None None O
pDiN None None O
of None None O
the None None O
mixed None None O
sector None None O
and None None O
produced None None O
steeper None None O
slopes None None O
, None None O
especially None None O
with None None O
the None None O
class None None O
I None None O
attributions None None O
. None None O

It None None O
is None None O
suggested None None O
that None None O
the None None O
correlation None None O
was None None O
established None None O
when None None O
the None None O
amino None None O
acid None None O
composition None None O
of None None O
the None None O
protein None None O
synthetases None None O
became None None O
progressively None None O
enriched None None O
and None None O
that None None O
the None None O
set None None O
of None None O
outliers None None O
were None None O
the None None O
earliest None None O
to None None O
have None None O
been None None O
fixed None None O
. None None O

The None None O
presence None None O
of None None O
nitrite None None O
during None None O
UVA None None O
irradiation None None O
protects None None O
from None None O
apoptosis None None O
. None None O

Nitrite None None O
occurs None None O
ubiquitously None None O
in None None O
biological None None O
fluids None None O
such None None O
as None None O
blood None None O
and None None O
sweat None None O
, None None O
representing None None O
an None None O
oxidation None None O
product None None O
of None None O
nitric None None O
oxide None None O
. None None O

Nitrite None None O
has None None O
been None None O
associated None None O
with None None O
a None None O
variety None None O
of None None O
adverse None None O
effects None None O
such None None O
as None None O
mutagenicity None None O
, None None O
carcinogenesis None None O
, None None O
and None None O
toxicity None None O
. None None O

In None None O
contrast None None O
, None None O
here None None O
we None None O
demonstrate None None O
that None None O
the None None O
presence None None O
of None None O
nitrite None None O
, None None O
but None None O
not None None O
nitrate None None O
, None None O
during None None O
irradiation None None O
of None None O
endothelial None None O
cells None None O
in None None O
culture None None O
exerts None None O
a None None O
potent None None O
and None None O
concentration None None O
- None None O
dependent None None O
protection None None O
against None None O
UVA None None O
- None None O
induced None None O
apoptotic None None O
cell None None O
death None None O
. None None O

Protection None None O
is None None O
half None None O
- None None O
maximal None None O
at None None O
a None None O
concentration None None O
of None None O
3 None None O
mM None None O
, None None O
and None None O
complete None None O
rescue None None O
is None None O
observed None None O
at None None O
10 None None O
mM None None O
. None None O

Nitrite None None O
- None None O
mediated None None O
protection None None O
is None None O
mediated None None O
via None None O
inhibition None None O
of None None O
lipid None None O
peroxidation None None O
in None None O
a None None O
similar None None O
manner None None O
as None None O
seen None None O
with None None O
butylated None None O
hydroxytoluene None None O
, None None O
a None None O
known None None O
inhibitor None None O
of None None O
lipid None None O
peroxidation None None O
. None None O

Interestingly None None O
, None None O
nitrite None None O
- None None O
mediated None None O
protection None None O
is None None O
completely None None O
abolished None None O
by None None O
coincubation None None O
with None None O
the None None O
NO None None O
scavenger None None O
cPTIO None None O
. None None O

Using None None O
electron None None O
paramagnetic None None O
resonance None None O
( None None O
EPR None None O
) None None O
spectroscopy None None O
or None None O
Faraday None None O
modulation None None O
spectroscopy None None O
, None None O
we None None O
directly None None O
prove None None O
UVA None None O
- None None O
induced None None O
NO None None O
formation None None O
in None None O
solutions None None O
containing None None O
nitrite None None O
. None None O

In None None O
conclusion None None O
, None None O
evidence None None O
is None None O
presented None None O
that None None O
nitrite None None O
represents None None O
a None None O
protective None None O
agent None None O
against None None O
UVA None None O
- None None O
induced None None O
apoptosis None None O
due None None O
to None None O
photodecomposition None None O
of None None O
nitrite None None O
and None None O
subsequent None None O
formation None None O
of None None O
NO None None O
. None None O

Dominant None None O
negative None None O
interference None None O
of None None O
transcription None None O
factor None None O
AP None None O
- None None O
2 None None O
causes None None O
inhibition None None O
of None None O
ErbB None None O
- None None O
3 None None O
expression None None O
and None None O
suppresses None None O
malignant None None O
cell None None O
growth None None O
. None None O

ErbB None None O
- None None O
3 None None O
( None None O
HER3 None None O
) None None O
is None None O
a None None O
member None None O
of None None O
the None None O
epidermal None None O
growth None None O
factor None None O
receptor None None O
family None None O
. None None O

Increasing None None O
evidence None None O
suggests None None O
that None None O
elevated None None O
expression None None O
of None None O
ErbB None None O
- None None O
3 None None O
is None None O
important None None O
for None None O
malignancy None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
found None None O
that None None O
elevated None None O
levels None None O
of None None O
ErbB None None O
- None None O
3 None None O
expression None None O
did None None O
not None None O
occur None None O
in None None O
the None None O
absence None None O
of None None O
AP None None O
- None None O
2gamma None None O
in None None O
a None None O
panel None None O
of None None O
human None None O
mammary None None O
epithelial None None O
and None None O
fibroblasts None None O
cell None None O
lines None None O
. None None O

In None None O
contrast None None O
, None None O
there None None O
was None None O
no None None O
association None None O
between None None O
the None None O
expression None None O
of None None O
AP None None O
- None None O
2alpha None None O
or None None O
AP None None O
- None None O
2beta None None O
and None None O
the None None O
level None None O
of None None O
ErbB None None O
- None None O
3 None None O
, None None O
or None None O
between None None O
AP None None O
- None None O
2alpha None None O
and None None O
AP None None O
- None None O
2gamma None None O
double None None O
positivity None None O
and None None O
ErbB None None O
- None None O
3 None None O
expression None None O
. None None O

In None None O
co None None O
- None None O
transfection None None O
experiments None None O
, None None O
exogenous None None O
expression None None O
of None None O
AP None None O
- None None O
2gamma None None O
robustly None None O
activated None None O
ErbB None None O
- None None O
3 None None O
promoter None None O
activity None None O
. None None O

Moreover None None O
, None None O
expression None None O
of None None O
a None None O
dominant None None O
negative None None O
AP None None O
- None None O
2 None None O
protein None None O
, None None O
AP None None O
- None None O
2delta None None O
( None None O
deleted None None O
residues None None O
31 None None O
- None None O
117 None None O
) None None O
, None None O
not None None O
only None None O
repressed None None O
the None None O
ErbB None None O
- None None O
3 None None O
promoter None None O
activity None None O
but None None O
also None None O
suppressed None None O
endogenous None None O
ErbB None None O
- None None O
3 None None O
transcription None None O
in None None O
the None None O
ErbB None None O
- None None O
3 None None O
overexpressing None None O
cell None None O
line None None O
MRC None None I-Cell-line-name
- None None I-Cell-line-name
5VA None None I-Cell-line-name
. None None O

Overexpression None None O
of None None O
AP None None O
- None None O
2A None None O
resulted None None O
in None None O
a None None O
decreased None None O
proliferation None None O
rate None None O
and None None O
inhibitin None None O
of None None O
colony None None O
formation None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
data None None O
strongly None None O
support None None O
a None None O
role None None O
for None None O
the None None O
AP None None O
- None None O
2 None None O
gene None None O
family None None O
, None None O
in None None O
particular None None O
, None None O
AP None None O
- None None O
2gamma None None O
, None None O
in None None O
the None None O
control None None O
of None None O
ErbB None None O
- None None O
3 None None O
expression None None O
. None None O

Interference None None O
with None None O
the None None O
function None None O
of None None O
transcription None None O
factor None None O
AP None None O
- None None O
2 None None O
might None None O
provide None None O
a None None O
potential None None O
strategy None None O
for None None O
modulation None None O
of None None O
the None None O
malignant None None O
phenotype None None O
. None None O

The None None O
Kaposi None None O
' None None O
s None None O
sarcoma None None O
- None None O
associated None None O
herpesvirus None None O
G None None O
protein None None O
- None None O
coupled None None O
receptor None None O
as None None O
a None None O
therapeutic None None O
target None None O
for None None O
the None None O
treatment None None O
of None None O
Kaposi None None O
' None None O
s None None O
sarcoma None None O
. None None O

The None None O
Kaposi None None O
' None None O
s None None O
sarcoma None None O
- None None O
associated None None O
herpesvirus None None O
( None None O
KSHV None None O
) None None O
encodes None None O
a None None O
G None None O
protein None None O
- None None O
coupled None None O
receptor None None O
( None None O
vGPCR None None O
) None None O
that None None O
has None None O
been None None O
implicated None None O
in None None O
the None None O
initiation None None O
of None None O
Kaposi None None O
' None None O
s None None O
sarcoma None None O
, None None O
identifying None None O
vGPCR None None O
as None None O
an None None O
attractive None None O
target None None O
for None None O
preventing None None O
Kaposi None None O
' None None O
s None None O
sarcoma None None O
. None None O

However None None O
, None None O
as None None O
only None None O
a None None O
fraction None None O
of None None O
cells None None O
in None None O
advanced None None O
Kaposi None None O
' None None O
s None None O
sarcoma None None O
lesions None None O
express None None O
vGPCR None None O
, None None O
it None None O
is None None O
unclear None None O
whether None None O
this None None O
unique None None O
viral None None O
oncogene None None O
contributes None None O
to None None O
Kaposi None None O
' None None O
s None None O
sarcoma None None O
progression None None O
. None None O

We None None O
therefore None None O
set None None O
out None None O
to None None O
determine None None O
whether None None O
the None None O
few None None O
cells None None O
that None None O
express None None O
vGPCR None None O
in None None O
established None None O
tumors None None O
represent None None O
an None None O
appropriate None None O
therapeutic None None O
target None None O
for None None O
the None None O
treatment None None O
of None None O
patients None None O
with None None O
preexisting None None O
Kaposi None None O
' None None O
s None None O
sarcoma None None O
. None None O

To None None O
this None None O
end None None O
, None None O
we None None O
generated None None O
endothelial None None O
cell None None O
lines None None O
stably None None O
expressing None None O
vGPCR None None O
or None None O
key None None O
KSHV None None O
latently None None O
expressed None None O
proteins None None O
( None None O
vCyclin None None O
, None None O
vFlip None None O
, None None O
and None None O
LANA1 None None O
) None None O
. None None O

The None None O
endothelial None None O
cell None None O
line None None O
expressing None None O
vGPCR None None O
was None None O
rendered None None O
sensitive None None O
to None None O
treatment None None O
with None None O
the None None O
nucleoside None None O
analogue None None O
ganciclovir None None O
by None None O
using None None O
a None None O
bicistronic None None O
construct None None O
coexpressing None None O
the None None O
herpes None None O
simplex None None O
virus None None O
1 None None O
thymidine None None O
kinase None None O
. None None O

S None None O
. None None O
c None None O
. None None O
injection None None O
into None None O
nude None None O
mice None None O
with None None O
mixed None None O
- None None O
cell None None O
populations None None O
formed None None O
tumors None None O
that None None O
approximate None None O
the None None O
ratio None None O
of None None O
vGPCR None None O
- None None O
expressing None None O
and None None O
KSHV None None O
latent None None O
gene None None O
- None None O
expressing None None O
cells None None O
. None None O

These None None O
mice None None O
were None None O
then None None O
treated None None O
with None None O
ganciclovir None None O
to None None O
specifically None None O
target None None O
only None None O
the None None O
vGPCR None None O
- None None O
expressing None None O
cells None None O
. None None O

Surprisingly None None O
, None None O
despite None None O
the None None O
expression None None O
of None None O
KSHV None None O
latent None None O
genes None None O
in None None O
the None None O
vast None None O
majority None None O
of None None O
tumor None None O
cells None None O
, None None O
specifically None None O
targeting None None O
only None None O
the None None O
few None None O
vGPCR None None O
- None None O
expressing None None O
cells None None O
in None None O
established None None O
tumors None None O
resulted None None O
in None None O
tumor None None O
regression None None O
. None None O

Moreover None None O
, None None O
we None None O
observed None None O
an None None O
increase None None O
in None None O
apoptosis None None O
of None None O
latent None None O
gene None None O
- None None O
expressing None None O
cells None None O
after None None O
the None None O
pharmacologic None None O
deletion None None O
of None None O
the None None O
vGPCR None None O
- None None O
expressing None None O
cells None None O
. None None O

These None None O
findings None None O
indicate None None O
that None None O
vGPCR None None O
may None None O
play None None O
a None None O
key None None O
role None None O
in None None O
Kaposi None None O
' None None O
s None None O
sarcoma None None O
progression None None O
and None None O
provide None None O
experimental None None O
justification None None O
for None None O
developing None None O
molecular None None O
- None None O
based None None O
therapies None None O
specifically None None O
targeting None None O
vGPCR None None O
and None None O
its None None O
effectors None None O
for None None O
the None None O
treatment None None O
of None None O
Kaposi None None O
' None None O
s None None O
sarcoma None None O
patients None None O
. None None O

Clinical None None O
significance None None O
of None None O
plasma None None O
endostatin None None O
in None None O
acute None None O
myeloid None None O
leukemia None None O
/ None None O
myelodysplastic None None O
syndrome None None O
. None None O

BACKGROUND None None O
: None None O
Endostatin None None O
, None None O
a None None O
C None None O
- None None O
terminal None None O
fragment None None O
of None None O
collagen None None O
XVIII None None O
, None None O
is None None O
an None None O
endogenous None None O
angiogenesis None None O
inhibitor None None O
. None None O

While None None O
endostatin None None O
is None None O
being None None O
investigated None None O
for None None O
its None None O
usefulness None None O
in None None O
treating None None O
solid None None O
tumors None None O
, None None O
its None None O
significance None None O
in None None O
hematologic None None O
malignancies None None O
is None None O
unknown None None O
. None None O

METHODS None None O
: None None O
The None None O
authors None None O
evaluated None None O
plasma None None O
endostatin None None O
( None None O
PE None None O
) None None O
levels None None O
using None None O
an None None O
enzyme None None O
linked None None O
immunoassay None None O
in None None O
71 None None O
patients None None O
with None None O
acute None None O
myeloid None None O
leukemia None None O
( None None O
AML None None O
) None None O
and None None O
43 None None O
patients None None O
with None None O
myelodysplastic None None O
syndrome None None O
( None None O
MDS None None O
) None None O
, None None O
and None None O
correlated None None O
PE None None O
with None None O
various None None O
clinical None None O
parameters None None O
. None None O

RESULTS None None O
: None None O
There None None O
was None None O
no None None O
significant None None O
difference None None O
in None None O
the None None O
median None None O
PE None None O
level None None O
between None None O
AML None None O
/ None None O
MDS None None O
patients None None O
and None None O
the None None O
normal None None O
controls None None O
. None None O

Nevertheless None None O
, None None O
patients None None O
who None None O
achieved None None O
complete None None O
remission None None O
( None None O
CR None None O
) None None O
had None None O
a None None O
significantly None None O
lower None None O
median None None O
PE None None O
level None None O
compared None None O
to None None O
those None None O
who None None O
did None None O
not None None O
. None None O

In None None O
multivariate None None O
analysis None None O
, None None O
PE None None O
was None None O
found None None O
to None None O
be None None O
a None None O
significant None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
03 None None O
) None None O
predictor None None O
of None None O
overall None None O
survival None None O
( None None O
OS None None O
) None None O
with None None O
adjustment None None O
of None None O
the None None O
other None None O
baseline None None O
covariates None None O
, None None O
including None None O
patient None None O
age None None O
, None None O
history None None O
of None None O
antecedent None None O
hematologic None None O
disorders None None O
, None None O
and None None O
the None None O
use None None O
of None None O
protective None None O
environments None None O
. None None O

The None None O
prognostic None None O
value None None O
of None None O
PE None None O
was None None O
also None None O
evaluated None None O
by None None O
dividing None None O
MDS None None O
/ None None O
AML None None O
patients None None O
into None None O
high None None O
and None None O
low None None O
PE None None O
groups None None O
using None None O
the None None O
median None None O
PE None None O
level None None O
of None None O
normal None None O
controls None None O
as None None O
the None None O
cut None None O
- None None O
off None None O
. None None O

The None None O
authors None None O
found None None O
that None None O
patients None None O
in None None O
the None None O
high None None O
PE None None O
group None None O
survived None None O
for None None O
a None None O
significantly None None O
shorter None None O
time None None O
than None None O
those None None O
patients None None O
in None None O
the None None O
low None None O
PE None None O
group None None O
. None None O

CONCLUSIONS None None O
: None None O
PE None None O
is None None O
a None None O
useful None None O
prognostic None None O
predictor None None O
of None None O
CR None None O
and None None O
OS None None O
for None None O
AML None None O
/ None None O
MDS None None O
patients None None O
. None None O

The None None O
mechanism None None O
underlying None None O
the None None O
association None None O
between None None O
high None None O
PE None None O
and None None O
poor None None O
clinical None None O
outcome None None O
is None None O
unclear None None O
, None None O
although None None O
it None None O
may None None O
be None None O
related None None O
to None None O
the None None O
possible None None O
PE None None O
reflection None None O
of None None O
tumor None None O
burden None None O
. None None O

Analysis None None O
of None None O
processivity None None O
of None None O
mungbean None None O
dideoxynucleotide None None O
- None None O
sensitive None None O
DNA None None O
polymerase None None O
and None None O
detection None None O
of None None O
the None None O
activity None None O
and None None O
expression None None O
of None None O
the None None O
enzyme None None O
in None None O
the None None O
meristematic None None O
and None None O
meiotic None None O
tissues None None O
and None None O
following None None O
DNA None None O
damaging None None O
agent None None O
. None None O

Analysis None None O
of None None O
the None None O
processivity None None O
of None None O
mungbean None None O
ddNTP None None O
- None None O
sensitive None None O
DNA None None O
polymerase None None O
showed None None O
the None None O
incorporation None None O
of None None O
approximately None None O
35 None None O
- None None O
40 None None O
nucleotides None None O
per None None O
binding None None O
event None None O
in None None O
the None None O
replication None None O
assays None None O
involving None None O
M13 None None O
ss None None O
DNA None None O
template None None O
with None None O
5 None None O
' None None O
- None None O
labeled None None O
17 None None O
- None None O
mer None None O
primer None None O
. None None O

Optimal None None O
processivity None None O
was None None O
obtained None None O
with None None O
100 None None O
- None None O
150 None None O
mM None None O
KCl None None O
and None None O
6 None None O
- None None O
8 None None O
mM None None O
Mg2 None None O
+ None None O
at None None O
pH None None O
7 None None O
. None None O
5 None None O
. None None O

The None None O
enzyme None None O
showed None None O
preference None None O
for None None O
Mg2 None None O
+ None None O
over None None O
Mn2 None None O
+ None None O
as None None O
the None None O
metal None None O
activator None None O
for None None O
processivity None None O
. None None O

2 None None O
' None None O
, None None O
3 None None O
' None None O
dideoxythymidine None None O
5 None None O
' None None O
triphosphate None None O
( None None O
ddTTP None None O
) None None O
and None None O
rat None None O
DNA None None O
pol None None O
beta None None O
antibody None None O
strongly None None O
influenced None None O
distributive None None O
synthesis None None O
. None None O

Considerable None None O
enhancement None None O
in None None O
processivity None None O
was None None O
noticed None None O
at None None O
1mM None None O
ATP None None O
and None None O
2 None None O
- None None O
4 None None O
mM None None O
spermidine None None O
while None None O
higher None None O
concentrations None None O
of None None O
spermidine None None O
caused None None O
distributive None None O
synthesis None None O
. None None O

The None None O
enzyme None None O
was None None O
found None None O
to None None O
be None None O
active None None O
in None None O
both None None O
meristematic None None O
and None None O
meiotic None None O
tissues None None O
and None None O
distinctly None None O
induced None None O
by None None O
EMS None None O
treatment None None O
. None None O

DNA None None O
- None None O
binding None None O
assays None None O
revealed None None O
distinct None None O
binding None None O
ability None None O
of None None O
the None None O
enzyme None None O
to None None O
template None None O
/ None None O
primer None None O
and None None O
damaged None None O
DNA None None O
substrate None None O
. None None O

Together None None O
these None None O
observations None None O
illustrate None None O
the None None O
probable None None O
involvement None None O
of None None O
the None None O
enzyme None None O
in None None O
replication None None O
and None None O
repair None None O
machinery None None O
in None None O
higher None None O
plants None None O
. None None O

Results None None O

primary None None O
pancreatic None None O
sarcomas None None O
are None None O
extremely None None O
rare None None O
. None None O

Pancreatic None None O
sarcomas None None O
are None None O
more None None O
aggressive None None O
than None None O
other None None O
pancreatic None None O
neoplasms None None O
. None None O

The None None O
effect None None O
of None None O
translocations None None O
on None None O
the None None O
cellular None None O
myc None None O
gene None None O
in None None O
Burkitt None None O
lymphomas None None O
. None None O

Chromosomal None None O
translocations None None O
are None None O
found None None O
to None None O
be None None O
a None None O
characteristic None None O
feature None None O
of None None O
Burkitt None None O
lymphomas None None O
. None None O

Similar None None O
translocations None None O
are None None O
found None None O
in None None O
mouse None None O
plasmacytomas None None O
and None None O
both None None O
diseases None None O
involve None None O
interchanges None None O
between None None O
one None None O
of None None O
the None None O
immunoglobulin None None O
loci None None O
and None None O
DNA None None O
in None None O
the None None O
vicinity None None O
of None None O
the None None O
myc None None O
gene None None O
. None None O

The None None O
structure None None O
of None None O
the None None O
myc None None O
gene None None O
has None None O
been None None O
elucidated None None O
from None None O
studies None None O
on None None O
translocated None None O
versions None None O
of None None O
the None None O
gene None None O
. None None O

Activation None None O
of None None O
the None None O
myc None None O
gene None None O
may None None O
play None None O
a None None O
role None None O
in None None O
transformation None None O
by None None O
promoting None None O
growth None None O
of None None O
the None None O
cells None None O
bearing None None O
the None None O
rearranged None None O
chromosomes None None O
. None None O

Therapeutic None None O
targeting None None O
of None None O
the None None O
survivin None None O
pathway None None O
in None None O
cancer None None O
: None None O
initiation None None O
of None None O
mitochondrial None None O
apoptosis None None O
and None None O
suppression None None O
of None None O
tumor None None O
- None None O
associated None None O
angiogenesis None None O
. None None O

PURPOSE None None O
: None None O
Molecular None None O
antagonists None None O
of None None O
the None None O
inhibitor None None O
of None None O
apoptosis None None O
protein None None O
survivin None None O
have None None O
shown None None O
promise None None O
as None None O
novel None None O
anticancer None None O
strategies None None O
for None None O
triggering None None O
tumor None None O
cell None None O
apoptosis None None O
, None None O
dysregulating None None O
mitotic None None O
progression None None O
, None None O
and None None O
inhibiting None None O
tumor None None O
growth None None O
in None None O
preclinical None None O
models None None O
. None None O

However None None O
, None None O
how None None O
survivin None None O
couples None None O
to None None O
the None None O
cell None None O
death None None O
machinery None None O
has None None O
remained None None O
elusive None None O
, None None O
and None None O
the None None O
relevant None None O
cellular None None O
targets None None O
of None None O
survivin None None O
antagonists None None O
have None None O
not None None O
been None None O
completely None None O
elucidated None None O
. None None O

Experimental None None O
Design None None O
: None None O
Human None None O
umbilical None None O
vein None None O
and None None O
dermal None None O
microvascular None None O
endothelial None None O
cells None None O
were None None O
infected None None O
with None None O
replication None None O
- None None O
deficient None None O
adenoviruses None None O
encoding None None O
survivin None None O
( None None O
pAd None None O
- None None O
Survivin None None O
) None None O
, None None O
green None None O
fluorescent None None O
protein None None O
( None None O
pAd None None O
- None None O
GFP None None O
) None None O
, None None O
or None None O
a None None O
phosphorylation None None O
- None None O
defective None None O
survivin None None O
Thr None None O
( None None O
34 None None O
) None None O
- None None O
- None None O
> None None O
Ala None None O
( None None O
pAd None None O
- None None O
T34A None None O
) None None O
dominant None None O
negative None None O
mutant None None O
. None None O

The None None O
effect None None O
of None None O
wild None None O
- None None O
type None None O
or None None O
mutant None None O
survivin None None O
was None None O
investigated None None O
on None None O
capillary None None O
network None None O
stability None None O
, None None O
endothelial None None O
cell None None O
viability None None O
, None None O
and None None O
caspase None None O
activation None None O
in None None O
vitro None None O
and None None O
on None None O
kinetics None None O
of None None O
tumor None None O
growth None None O
and None None O
development None None O
of None None O
angiogenesis None None O
in None None O
a None None O
breast None None O
cancer None None O
xenograft None None O
model None None O
in None None O
vivo None None O
. None None O

The None None O
cell None None O
death None None O
pathway None None O
initiated None None O
by None None O
survivin None None O
targeting None None O
was None None O
mapped None None O
with None None O
respect None None O
to None None O
cytochrome None None O
c None None O
release None None O
, None None O
changes None None O
in None None O
mitochondrial None None O
transmembrane None None O
potential None None O
, None None O
and None None O
apoptosome None None O
requirements None None O
using None None O
mouse None None O
embryonic None None O
fibroblasts None None O
deficient None None O
in None None O
Apaf None None O
- None None O
1 None None O
or None None O
caspase None None O
- None None O
9 None None O
. None None O

RESULTS None None O
: None None O
Adenoviral None None O
transduction None None O
of None None O
endothelial None None O
cells None None O
with None None O
pAd None None O
- None None O
Survivin None None O
inhibited None None O
growth None None O
factor None None O
deprivation None None O
- None None O
or None None O
ceramide None None O
- None None O
induced None None O
apoptosis None None O
, None None O
reduced None None O
caspase None None O
- None None O
3 None None O
and None None O
- None None O
7 None None O
generation None None O
, None None O
and None None O
stabilized None None O
three None None O
- None None O
dimensional None None O
capillary None None O
networks None None O
in None None O
vitro None None O
. None None O

Conversely None None O
, None None O
expression None None O
of None None O
pAd None None O
- None None O
T34A None None O
caused None None O
apoptosis None None O
in None None O
umbilical None None O
vein None None O
and None None O
dermal None None O
microvascular None None O
endothelial None None O
cells None None O
and None None O
resulted None None O
in None None O
caspase None None O
- None None O
3 None None O
activity None None O
. None None O

Cell None None O
death None None O
induced None None O
by None None O
survivin None None O
targeting None None O
exhibited None None O
the None None O
hallmarks None None O
of None None O
mitochondrial None None O
- None None O
dependent None None O
apoptosis None None O
with None None O
release None None O
of None None O
cytochrome None None O
c None None O
and None None O
loss None None O
of None None O
mitochondrial None None O
transmembrane None None O
potential None None O
and None None O
was None None O
suppressed None None O
in None None O
Apaf None None O
- None None O
1 None None O
or None None O
caspase None None O
- None None O
9 None None O
knockout None None O
mouse None None O
embryonic None None O
fibroblasts None None O
. None None O

When None None O
injected None None O
in None None O
human None None O
breast None None O
cancer None None O
xenografts None None O
, None None O
pAd None None O
- None None O
T34A None None O
inhibited None None O
growth None None O
of None None O
established None None O
tumors None None O
and None None O
triggered None None O
tumor None None O
cell None None O
apoptosis None None O
in None None O
vivo None None O
. None None O

This None None O
was None None O
associated None None O
with None None O
a None None O
approximately None None O
60 None None O
% None None O
reduction None None O
in None None O
tumor None None O
- None None O
derived None None O
blood None None O
vessels None None O
by None None O
quantitative None None O
morphometry None None O
of None None O
CD31 None None O
- None None O
stained None None O
tumor None None O
areas None None O
, None None O
and None None O
appearance None None O
of None None O
endothelial None None O
cell None None O
apoptosis None None O
by None None O
internucleosomal None None O
DNA None None O
fragmentation None None O
in None None O
vivo None None O
. None None O

CONCLUSIONS None None O
: None None O
Survivin None None O
functions None None O
as None None O
a None None O
novel None None O
upstream None None O
regulator None None O
of None None O
mitochondrial None None O
- None None O
dependent None None O
apoptosis None None O
, None None O
and None None O
molecular None None O
targeting None None O
of None None O
this None None O
pathway None None O
results None None O
in None None O
anticancer None None O
activity None None O
via None None O
a None None O
dual None None O
mechanism None None O
of None None O
induction None None O
of None None O
tumor None None O
cell None None O
apoptosis None None O
and None None O
suppression None None O
of None None O
angiogenesis None None O
. None None O

2 None None O
. None None O
1 None None O
. None None O

Biological None None O
samples None None O

Placental None None O
tissues None None O
from None None O
the None None O
first None None O
trimester None None O
legally None None O
induced None None O
abortions None None O
( None None O
8 None None O
- None None O
12 None None O
weeks None None O
of None None O
gestation None None O
) None None O
were None None O
obtained None None O
from None None O
the None None O
Department None None O
of None None O
Obstetrics None None O
and None None O
Gynecology None None O
at None None O
the None None O
Broussais None None O
, None None O
Saint None None O
Vincent None None O
de None None O
Paul None None O
and None None O
Cochin None None O
Hospitals None None O
. None None O

Second None None O
trimester None None O
placental None None O
tissues None None O
were None None O
collected None None O
at None None O
the None None O
time None None O
of None None O
termination None None O
of None None O
pregnancy None None O
at None None O
15 None None O
and None None O
25 None None O
weeks None None O
of None None O
gestation None None O
( None None O
in None None O
weeks None None O
of None None O
amenorrhea None None O
) None None O
in None None O
trisomy None None O
21 None None O
- None None O
affected None None O
pregnancies None None O
. None None O

Fetal None None O
Down None None O
syndrome None None O
was None None O
diagnosed None None O
by None None O
karyotyping None None O
of None None O
amniotic None None O
fluid None None O
cells None None O
. None None O

The None None O
indication None None O
of None None O
amniocentesis None None O
was None None O
the None None O
maternal None None O
age None None O
. None None O

Term None None O
placentas None None O
were None None O
obtained None None O
after None None O
elective None None O
cesarean None None O
section None None O
from None None O
healthy None None O
mothers None None O
near None None O
term None None O
with None None O
uncomplicated None None O
pregnancies None None O
. None None O

With None None O
written None None O
informed None None O
consent None None O
of None None O
the None None O
pregnant None None O
woman None None O
, None None O
the None None O
following None None O
samples None None O
were None None O
collected None None O
at None None O
term None None O
: None None O
a None None O
fragment None None O
of None None O
the None None O
placenta None None O
, None None O
umbilical None None O
cord None None O
fetal None None O
blood None None O
and None None O
maternal None None O
blood None None O
. None None O

The None None O
placenta None None O
biopsy None None O
sample None None O
was None None O
collected None None O
at None None O
a None None O
depth None None O
of None None O
1 None None O
cm None None O
and None None O
at None None O
a None None O
distance None None O
of None None O
8 None None O
cm None None O
from None None O
the None None O
edge None None O
of None None O
the None None O
placenta None None O
, None None O
with None None O
the None None O
maternal None None O
side None None O
facing None None O
upward None None O
. None None O

The None None O
use None None O
of None None O
these None None O
biological None None O
samples None None O
was None None O
approved None None O
by None None O
local None None O
ethical None None O
committee None None O
. None None O

Villous None None O
cytotrophoblastic None None O
cells None None O
were None None O
isolated None None O
by None None O
sequential None None O
enzymatic None None O
digestion None None O
of None None O
chorionic None None O
villi None None O
from None None O
the None None O
first None None O
trimester None None O
, None None O
second None None O
trimester None None O
and None None O
term None None O
placenta None None O
and None None O
purified None None O
on None None O
a None None O
discontinuous None None O
percoll None None O
gradient None None O
, None None O
as None None O
described None None O
previously None None O
. None None O
47 None None O
- None None O
49 None None O
These None None O
cells None None O
were None None O
positively None None O
stained None None O
for None None O
cytokeratin None None O
7 None None O
at None None O
95 None None O
% None None O
, None None O
indicating None None O
the None None O
cytotrophoblastic None None O
origin None None O
of None None O
the None None O
cells None None O
. None None O

Placental None None O
fibroblasts None None O
were None None O
isolated None None O
by None None O
prolonged None None O
enzymatic None None O
digestion None None O
from None None O
first None None O
trimester None None O
chorionic None None O
villi None None O
as None None O
in None None O
Malassine None None O
et None None O
al None None O
. None None O
50 None None O
Fibroblastic None None O
cells None None O
( None None O
1 None None O
. None None O
25 None None O
x None None O
105 None None O
cells None None O
/ None None O
mL None None O
) None None O
were None None O
plated None None O
on None None O
35 None None O
- None None O
mm None None O
plastic None None O
dishes None None O
( None None O
TPP None None O
, None None O
Switzerland None None O
) None None O
and None None O
cultured None None O
for None None O
48 None None O
h None None O
, None None O
and None None O
the None None O
culture None None O
medium None None O
was None None O
changed None None O
daily None None O
. None None O

These None None O
cultured None None O
fibroblasts None None O
were None None O
characterized None None O
using None None O
immunocytochemistry None None O
. None None O

It None None O
was None None O
found None None O
that None None O
98 None None O
% None None O
of None None O
the None None O
cells None None O
were None None O
vimentin None None O
positive None None O
and None None O
also None None O
positive None None O
for None None O
a None None O
monoclonal None None O
antibody None None O
against None None O
specific None None O
fibroblast None None O
antigen None None O
( None None O
clone None None O
ASO2 None None O
, None None O
Dianova None None O
, None None O
Hamburg None None O
, None None O
Germany None None O
) None None O
. None None O

Owing None None O
to None None O
the None None O
limited None None O
amount None None O
of None None O
cells None None O
, None None O
only None None O
DNA None None O
was None None O
extracted None None O
. None None O

Role None None O
of None None O
interleukin None None O
1 None None O
in None None O
antigen None None O
- None None O
specific None None O
T None None O
cell None None O
proliferation None None O
. None None O

The None None O
role None None O
of None None O
interleukin None None O
1 None None O
( None None O
IL None None O
1 None None O
) None None O
in None None O
human None None O
antigen None None O
- None None O
specific None None O
T None None O
cell None None O
proliferation None None O
was None None O
examined None None O
. None None O

Nylon None None O
wool None None O
- None None O
purified None None O
T None None O
cells None None O
proliferated None None O
in None None O
the None None O
presence None None O
of None None O
autologous None None O
monocytes None None O
( None None O
Mo None None O
. None None O
) None None O
pulsed None None O
for None None O
18 None None O
h None None O
with None None O
tetanus None None O
toxoid None None O
( None None O
TT None None O
) None None O
antigen None None O
( None None O
Mo None None O
. None None O
TT None None O
) None None O
. None None O

Irradiation None None O
of None None O
Mo None None O
. None None O
TT None None O
with None None O
ultraviolet None None O
( None None O
UV None None O
) None None O
light None None O
( None None O
72 None None O
J None None O
/ None None O
m2 None None O
) None None O
abolished None None O
their None None O
capacity None None O
to None None O
support None None O
T None None O
cell None None O
proliferation None None O
and None None O
drastically None None O
reduced None None O
their None None O
capacity None None O
to None None O
secrete None None O
IL None None O
1 None None O
after None None O
stimulation None None O
with None None O
Staphylococcus None None O
albus None None O
. None None O

The None None O
defect None None O
in None None O
antigen None None O
presentation None None O
induced None None O
by None None O
UV None None O
irradiation None None O
of None None O
Mo None None O
. None None O
TT None None O
was None None O
reversed None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
by None None O
the None None O
addition None None O
of None None O
two None None O
different None None O
preparations None None O
containing None None O
human None None O
interleukin None None O
1 None None O
( None None O
IL None None O
1 None None O
) None None O
. None None O

The None None O
first None None O
preparation None None O
consisted None None O
of None None O
supernatants None None O
of None None O
Mo None None O
. None None O
stimulated None None O
with None None O
Con None None O
A None None O
for None None O
18 None None O
hr None None O
and None None O
in None None O
which None None O
Con None None O
A None None O
activity None None O
was None None O
blocked None None O
by None None O
alpha None None O
- None None O
D None None O
- None None O
methyl None None O
- None None O
mannoside None None O
( None None O
Mo None None O
. None None O
- None None O
Con None None O
A None None O
- None None O
Sup None None O
) None None O
. None None O

The None None O
second None None O
preparation None None O
consisted None None O
of None None O
human None None O
IL None None O
1 None None O
partially None None O
purified None None O
from None None O
supernatants None None O
of None None O
human None None O
peripheral None None O
blood None None O
mononuclear None None O
cells None None O
stimulated None None O
with None None O
S None None O
. None None O
albus None None O
. None None O

This None None O
IL None None O
1 None None O
copurified None None O
with None None O
human None None O
leukocyte None None O
pyrogen None None O
( None None O
LP None None O
) None None O
and None None O
was None None O
termed None None O
IL None None O
1 None None O
/ None None O
LP None None O
. None None O

Both None None O
IL None None O
1 None None O
- None None O
containing None None O
preparations None None O
enhanced None None O
the None None O
response None None O
of None None O
C57BL None None O
/ None None O
6 None None O
mouse None None O
thymocytes None None O
to None None O
phytohemagglutinin None None O
. None None O

A None None O
rabbit None None O
antibody None None O
to None None O
human None None O
IL None None O
1 None None O
/ None None O
LP None None O
inhibited None None O
the None None O
capacity None None O
of None None O
T None None O
cells None None O
to None None O
proliferate None None O
in None None O
response None None O
to None None O
Mo None None O
. None None O
TT None None O
and None None O
inhibited None None O
the None None O
capacity None None O
of None None O
Mo None None O
. None None O
- None None O
Con None None O
A None None O
- None None O
Sup None None O
to None None O
reconstitute None None O
the None None O
T None None O
cell None None O
response None None O
to None None O
UV None None O
- None None O
irradiated None None O
Mo None None O
. None None O
TT None None O
. None None O

IL None None O
1 None None O
/ None None O
LP None None O
was None None O
not None None O
necessary None None O
for None None O
T None None O
cells None None O
to None None O
recognize None None O
the None None O
immunogenic None None O
moiety None None O
presented None None O
by None None O
Mo None None O
. None None O
, None None O
because None None O
monolayers None None O
of None None O
UV None None O
- None None O
irradiated None None O
Mo None None O
. None None O
TT None None O
were None None O
equivalent None None O
to None None O
monolayers None None O
of None None O
unirradiated None None O
MO None None O
. None None O
TT None None O
in None None O
their None None O
capacity None None O
to None None O
adsorb None None O
TT None None O
- None None O
reactive None None O
T None None O
cells None None O
specifically None None O
. None None O

Furthermore None None O
, None None O
the None None O
addition None None O
of None None O
rabbit None None O
antibody None None O
to None None O
IL None None O
1 None None O
/ None None O
LP None None O
did None None O
not None None O
interfere None None O
with None None O
the None None O
capacity None None O
of None None O
UV None None O
- None None O
irradiated None None O
Mo None None O
. None None O
TT None None O
to None None O
adsorb None None O
TT None None O
- None None O
reactive None None O
T None None O
cells None None O
. None None O

The None None O
results None None O
obtained None None O
in None None O
this None None O
study None None O
indicate None None O
that None None O
IL None None O
1 None None O
is None None O
involved None None O
in None None O
optimal None None O
antigen None None O
- None None O
driven None None O
proliferation None None O
of None None O
human None None O
T None None O
lymphocytes None None O
. None None O

Diverse None None O
cell None None O
signaling None None O
events None None O
modulated None None O
by None None O
perlecan None None O
. None None O

Perlecan None None O
is None None O
a None None O
ubiquitous None None O
pericellular None None O
proteoglycan None None O
ideally None None O
placed None None O
to None None O
mediate None None O
cell None None O
signaling None None O
events None None O
controlling None None O
migration None None O
, None None O
proliferation None None O
, None None O
and None None O
differentiation None None O
. None None O

Its None None O
control None None O
of None None O
growth None None O
factor None None O
signaling None None O
usually None None O
involves None None O
interactions None None O
with None None O
the None None O
heparan None None O
sulfate None None O
chains None None O
covalently None None O
coupled None None O
to None None O
the None None O
protein None None O
core None None O
' None None O
s None None O
N None None O
- None None O
terminus None None O
. None None O

However None None O
, None None O
this None None O
modular None None O
protein None None O
core None None O
also None None O
binds None None O
with None None O
relatively None None O
high None None O
affinity None None O
to None None O
a None None O
number None None O
of None None O
growth None None O
factors None None O
and None None O
surface None None O
receptors None None O
, None None O
thereby None None O
stabilizing None None O
cell None None O
- None None O
matrix None None O
links None None O
. None None O

This None None O
review None None O
will None None O
focus None None O
on None None O
perlecan None None O
- None None O
growth None None O
factor None None O
interactions None None O
and None None O
describe None None O
recent None None O
advances None None O
in None None O
our None None O
understanding None None O
of None None O
this None None O
highly None None O
conserved None None O
proteoglycan None None O
during None None O
development None None O
, None None O
cancer None None O
growth None None O
, None None O
and None None O
angiogenesis None None O
. None None O

The None None O
pro None None O
- None None O
angiogenic None None O
capacities None None O
of None None O
perlecan None None O
that None None O
involve None None O
proliferative None None O
and None None O
migratory None None O
signals None None O
in None None O
response None None O
to None None O
bound None None O
growth None None O
factors None None O
will None None O
be None None O
explored None None O
, None None O
as None None O
well None None O
as None None O
the None None O
anti None None O
- None None O
angiogenic None None O
signals None None O
resulting None None O
from None None O
interactions None None O
between None None O
the None None O
C None None O
- None None O
terminal None None O
domain None None O
known None None O
as None None O
endorepellin None None O
and None None O
integrins None None O
that None None O
control None None O
adhesion None None O
of None None O
cells None None O
to None None O
the None None O
extracellular None None O
matrix None None O
. None None O

These None None O
two None None O
somewhat None None O
diametrically None None O
opposed None None O
roles None None O
will None None O
be None None O
discussed None None O
in None None O
light None None O
of None None O
new None None O
data None None O
emerging None None O
from None None O
various None None O
fields None None O
which None None O
converge None None O
on None None O
perlecan None None O
as None None O
a None None O
key None None O
regulator None None O
of None None O
cell None None O
growth None None O
and None None O
angiogenesis None None O
. None None O

Prevention None None O
of None None O
hepatic None None O
tumor None None O
metastases None None O
in None None O
rats None None O
with None None O
herpes None None O
viral None None O
vaccines None None O
and None None O
gamma None None O
- None None O
interferon None None O
. None None O

Previous None None O
studies None None O
showed None None O
that None None O
gammaIFN None None O
decreases None None O
metastatic None None O
hepatic None None O
tumor None None O
growth None None O
by None None O
stimulating None None O
Kupffer None None O
cells None None O
( None None O
KC None None O
) None None O
. None None O

The None None O
present None None O
studies None None O
examine None None O
whether None None O
lymphocyte None None O
stimulation None None O
via None None O
cells None None O
engineered None None O
to None None O
secrete None None O
GM None None O
- None None O
CSF None None O
or None None O
IL None None O
- None None O
2 None None O
decreases None None O
hepatic None None O
tumor None None O
growth None None O
, None None O
and None None O
whether None None O
stimulation None None O
of None None O
both None None O
macrophages None None O
and None None O
lymphocytes None None O
is None None O
more None None O
effective None None O
than None None O
either None None O
individually None None O
. None None O

Rats None None O
were None None O
immunized None None O
with None None O
irradiated None None O
hepatoma None None O
cells None None O
transduced None None O
by None None O
herpes None None O
viral None None O
amplicon None None O
vectors None None O
containing None None O
the None None O
genes None None O
for None None O
GM None None O
- None None O
CSF None None O
, None None O
IL None None O
- None None O
2 None None O
or None None O
LacZ None None O
. None None O

On None None O
day None None O
18 None None O
, None None O
half None None O
of None None O
each None None O
group None None O
was None None O
treated None None O
with None None O
5 None None O
x None None O
10 None None O
( None None O
4 None None O
) None None O
U None None O
gammaIFN None None O
, None None O
or None None O
saline None None O
intraperitoneally None None O
for None None O
3 None None O
d None None O
. None None O

On None None O
day None None O
21 None None O
, None None O
all None None O
rats None None O
received None None O
5 None None O
x None None O
10 None None O
( None None O
5 None None O
) None None O
hepatoma None None O
cells None None O
intrasplenically None None O
. None None O

On None None O
day None None O
41 None None O
, None None O
rats None None O
were None None O
killed None None O
and None None O
tumor None None O
nodules None None O
were None None O
counted None None O
. None None O

Separate None None O
rats None None O
underwent None None O
splenocyte None None O
and None None O
KC None None O
harvest None None O
for None None O
assessment None None O
of None None O
lymphocyte None None O
- None None O
and None None O
macrophage None None O
- None None O
mediated None None O
tumor None None O
cell None None O
kill None None O
in None None O
vitro None None O
. None None O

GM None None O
- None None O
CSF None None O
or None None O
IL None None O
- None None O
2 None None O
vaccines None None O
or None None O
gammaIFN None None O
decreased None None O
tumor None None O
nodules None None O
significantly None None O
( None None O
GM None None O
- None None O
CSF None None O
13 None None O
+ None None O
/ None None O
- None None O
4 None None O
, None None O
IL None None O
- None None O
2 None None O
14 None None O
+ None None O
/ None None O
- None None O
6 None None O
vs None None O
. None None O
control None None O
75 None None O
+ None None O
/ None None O
- None None O
24 None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

Combination None None O
therapy None None O
was None None O
more None None O
effective None None O
, None None O
and None None O
completely None None O
eliminated None None O
tumor None None O
in None None O
4 None None O
of None None O
12 None None O
IFN None None O
- None None O
GM None None O
- None None O
CSF None None O
and None None O
8 None None O
of None None O
11 None None O
IFN None None O
- None None O
IL None None O
- None None O
2 None None O
animals None None O
. None None O

Additional None None O
rats None None O
underwent None None O
partial None None O
hepatectomy None None O
, None None O
an None None O
immunosuppressive None None O
procedure None None O
known None None O
to None None O
accelerate None None O
the None None O
growth None None O
of None None O
hepatic None None O
tumor None None O
, None None O
following None None O
tumor None None O
challenge None None O
. None None O

Therapy None None O
was None None O
equally None None O
effective None None O
in None None O
this None None O
immunosuppressive None None O
setting None None O
. None None O

Vaccination None None O
is None None O
associated None None O
with None None O
enhancement None None O
of None None O
splenocyte None None O
- None None O
mediated None None O
tumoricidal None None O
activity None None O
, None None O
whereas None None O
the None None O
effect None None O
of None None O
gammaIFN None None O
is None None O
mediated None None O
by None None O
KC None None O
. None None O

GM None None O
- None None O
CSF None None O
and None None O
IL None None O
- None None O
2 None None O
vaccine None None O
therapy None None O
and None None O
pretreatment None None O
with None None O
gammaIFN None None O
represent None None O
effective None None O
strategies None None O
in None None O
reducing None None O
hepatic None None O
tumor None None O
. None None O

Combination None None O
therapy None None O
targets None None O
both None None O
lymphocytes None None O
and None None O
macrophages None None O
, None None O
and None None O
is None None O
more None None O
effective None None O
in None None O
reducing None None O
tumor None None O
than None None O
either None None O
therapy None None O
alone None None O
. None None O

Expression None None O
of None None O
CD154 None None O
on None None O
renal None None O
cell None None O
carcinomas None None O
and None None O
effect None None O
on None None O
cell None None O
proliferation None None O
, None None O
motility None None O
and None None O
platelet None None O
- None None O
activating None None O
factor None None O
synthesis None None O
. None None O

CD40 None None O
activation None None O
by None None O
CD154 None None O
may None None O
trigger None None O
diverse None None O
cellular None None O
responses None None O
, None None O
ranging None None O
from None None O
proliferation None None O
and None None O
differentiation None None O
to None None O
growth None None O
suppression None None O
and None None O
cell None None O
death None None O
, None None O
in None None O
normal None None O
and None None O
malignant None None O
cells None None O
. None None O

However None None O
, None None O
the None None O
pathophysiologic None None O
role None None O
of None None O
CD154 None None O
expressed None None O
by None None O
tumor None None O
cells None None O
remains None None O
unclear None None O
. None None O

We None None O
have None None O
investigated None None O
the None None O
expression None None O
of None None O
the None None O
CD40 None None O
- None None O
CD154 None None O
system None None O
in None None O
24 None None O
primary None None O
cultures None None O
derived None None O
from None None O
renal None None O
cell None None O
carcinomas None None O
, None None O
its None None O
correlation None None O
with None None O
tumor None None O
stage None None O
and None None O
its None None O
potential None None O
functional None None O
significance None None O
. None None O

We None None O
found None None O
coexpression None None O
of None None O
CD40 None None O
and None None O
CD154 None None O
in None None O
most None None O
of None None O
the None None O
renal None None O
carcinoma None None O
cell None None O
lines None None O
. None None O

CD154 None None O
, None None O
but None None O
not None None O
CD40 None None O
expression None None O
, None None O
significantly None None O
correlated None None O
with None None O
tumor None None O
stage None None O
. None None O

Moreover None None O
, None None O
renal None None O
carcinoma None None O
cell None None O
lines None None O
also None None O
released None None O
the None None O
soluble None None O
form None None O
of None None O
CD154 None None O
into None None O
the None None O
supernatant None None O
. None None O

CD40 None None O
engagement None None O
by None None O
CD154 None None O
did None None O
not None None O
affect None None O
apoptosis None None O
or None None O
survival None None O
. None None O

On None None O
the None None O
contrary None None O
, None None O
CD154 None None O
stimulated None None O
cell None None O
proliferation None None O
, None None O
motility None None O
and None None O
production None None O
of None None O
PAF None None O
, None None O
a None None O
phospholipid None None O
mediator None None O
of None None O
inflammation None None O
with None None O
angiogenic None None O
properties None None O
. None None O

Furthermore None None O
, None None O
the None None O
renal None None O
carcinoma None None O
cell None None O
lines None None O
expressed None None O
PAF None None O
- None None O
R None None O
. None None O

Blockade None None O
of None None O
PAF None None O
- None None O
R None None O
by None None O
WEB None None O
- None None O
2170 None None O
, None None O
a None None O
PAF None None O
- None None O
R None None O
antagonist None None O
, None None O
abolished None None O
the None None O
CD154 None None O
- None None O
dependent None None O
motility None None O
, None None O
indicating None None O
a None None O
role None None O
for None None O
PAF None None O
synthesized None None O
after None None O
CD154 None None O
stimulation None None O
in None None O
renal None None O
carcinoma None None O
cell None None O
motility None None O
. None None O

In None None O
conclusion None None O
, None None O
this None None O
study None None O
identifies None None O
new None None O
functional None None O
properties None None O
for None None O
CD154 None None O
, None None O
which None None O
are None None O
potentially None None O
relevant None None O
for None None O
the None None O
growth None None O
and None None O
dissemination None None O
of None None O
renal None None O
carcinoma None None O
cells None None O
. None None O

Autocrine None None O
angiogenic None None O
vascular None None O
prosthesis None None O
with None None O
bone None None O
marrow None None O
transplantation None None O
. None None O

Synthetic None None O
vascular None None O
prostheses None None O
are None None O
foreign None None O
bodies None None O
, None None O
so None None O
that None None O
blood None None O
coagulation None None O
can None None O
occur None None O
on None None O
their None None O
luminal None None O
surfaces None None O
, None None O
causing None None O
graft None None O
occlusion None None O
very None None O
frequently None None O
in None None O
prostheses None None O
of None None O
small None None O
diameter None None O
. None None O

A None None O
vascular None None O
prosthesis None None O
needs None None O
angiogenesis None None O
for None None O
endothelialization None None O
of None None O
the None None O
luminal None None O
surface None None O
, None None O
as None None O
endothelial None None O
cells None None O
have None None O
natural None None O
and None None O
permanent None None O
antithrombogenic None None O
properties None None O
. None None O

To None None O
induce None None O
capillary None None O
growth None None O
into None None O
the None None O
graft None None O
, None None O
we None None O
developed None None O
a None None O
method None None O
of None None O
transplanting None None O
bone None None O
marrow None None O
cells None None O
, None None O
which None None O
are None None O
primitive None None O
, None None O
strong None None O
enough None None O
to None None O
survive None None O
, None None O
and None None O
create None None O
blood None None O
cells None None O
, None None O
resulting None None O
in None None O
the None None O
inducement None None O
of None None O
capillary None None O
growth None None O
. None None O

In None None O
an None None O
animal None None O
experiment None None O
, None None O
marrow None None O
cells None None O
were None None O
infiltrated None None O
into None None O
the None None O
walls None None O
of None None O
long None None O
- None None O
fibril None None O
expanded None None O
polytetrafluoroethylene None None O
( None None O
ePTFE None None O
) None None O
vascular None None O
grafts None None O
. None None O

The None None O
grafts None None O
were None None O
implanted None None O
in None None O
the None None O
abdominal None None O
aortic None None O
position None None O
of None None O
24 None None O
dogs None None O
autologously None None O
. None None O

Marrow None None O
cells None None O
survived None None O
and None None O
continued None None O
exogenous None None O
hemopoiesis None None O
for None None O
up None None O
to None None O
six None None O
months None None O
and None None O
were None None O
immunohistochemically None None O
reactive None None O
to None None O
basic None None O
fibroblast None None O
growth None None O
factor None None O
( None None O
bFGF None None O
) None None O
. None None O

All None None O
the None None O
grafts None None O
older None None O
than None None O
three None None O
weeks None None O
had None None O
complete None None O
endothelialization None None O
and None None O
maintained None None O
their None None O
patency None None O
. None None O

Twenty None None O
grafts None None O
without None None O
bone None None O
marrow None None O
were None None O
implanted None None O
as None None O
controls None None O
. None None O

Endothelialization None None O
was None None O
present None None O
at None None O
anastomotic None None O
sites None None O
, None None O
but None None O
other None None O
areas None None O
were None None O
covered None None O
with None None O
fresh None None O
thrombi None None O
. None None O

Four None None O
out None None O
of None None O
seven None None O
control None None O
grafts None None O
were None None O
patent None None O
with None None O
endothelial None None O
cell None None O
lining None None O
at None None O
six None None O
months None None O
, None None O
but None None O
three None None O
were None None O
occluded None None O
and None None O
one None None O
of None None O
the None None O
four None None O
grafts None None O
was None None O
still None None O
covered None None O
with None None O
a None None O
thrombus None None O
layer None None O
. None None O

Bone None None O
marrow None None O
with None None O
its None None O
unique None None O
native None None O
properties None None O
produced None None O
autocrine None None O
angiogenicity None None O
in None None O
the None None O
graft None None O
. None None O

The None None O
proenkephalin None None O
- None None O
A None None O
- None None O
derivative None None O
Met None None O
- None None O
enkephalin None None O
- None None O
Arg None None O
- None None O
Gly None None O
- None None O
Leu None None O
is None None O
not None None O
present None None O
in None None O
the None None O
feline None None O
species None None O
. None None O

No None None O
opioid None None O
octapeptide None None O
Met None None O
- None None O
enkephalin None None O
- None None O
Arg None None O
- None None O
Gly None None O
- None None O
Leu None None O
was None None O
detected None None O
either None None O
in None None O
the None None O
brain None None O
or None None O
in None None O
the None None O
adrenal None None O
gland None None O
of None None O
the None None O
cat None None O
using None None O
a None None O
specific None None O
radioimmunoassay None None O
. None None O

Whereas None None O
it None None O
was None None O
possible None None O
to None None O
determine None None O
the None None O
Met None None O
- None None O
enkephalin None None O
and None None O
Leu None None O
- None None O
enkephalin None None O
contents None None O
. None None O

The None None O
Met None None O
- None None O
enkephalin None None O
versus None None O
Leu None None O
- None None O
enkephalin None None O
concentration None None O
ratio None None O
was None None O
around None None O
five None None O
in None None O
each None None O
area None None O
of None None O
the None None O
brain None None O
assayed None None O
. None None O

The None None O
presence None None O
of None None O
authentic None None O
Met None None O
- None None O
enkephalin None None O
and None None O
Leu None None O
- None None O
enkephalin None None O
was None None O
confirmed None None O
by None None O
high None None O
performance None None O
liquid None None O
chromatography None None O
analysis None None O
. None None O

All None None O
in None None O
all None None O
, None None O
these None None O
data None None O
seem None None O
to None None O
indicate None None O
that None None O
the None None O
cat None None O
proenkephalin None None O
is None None O
partly None None O
different None None O
from None None O
that None None O
previously None None O
analysed None None O
in None None O
mammalian None None O
species None None O
including None None O
humans None None O
, None None O
rats None None O
and None None O
cows None None O
. None None O

Subject None None O
disposition None None O
. None None O

Data None None O
from None None O
110 None None O
enrolled None None O
subjects None None O
were None None O
eligible None None O
for None None O
analysis None None O
. None None O

The None None O
demographics None None O
of None None O
the None None O
study None None O
subjects None None O
, None None O
by None None O
site None None O
, None None O
are None None O
recorded None None O
in None None O
Table None None O
1 None None O
. None None O

The None None O
population None None O
studied None None O
was None None O
predominantly None None O
not None None O
HIV None None O
infected None None O
( None None O
92 None None O
% None None O
) None None O
, None None O
and None None O
by None None O
the None None O
study None None O
entry None None O
criteria None None O
, None None O
their None None O
probability None None O
of None None O
infection None None O
was None None O
considered None None O
to None None O
be None None O
low None None O
. None None O

The None None O
risk None None O
categories None None O
assigned None None O
at None None O
the None None O
time None None O
of None None O
study None None O
entry None None O
were None None O
combined None None O
into None None O
groups None None O
for None None O
analysis None None O
, None None O
based None None O
on None None O
the None None O
predisposition None None O
for None None O
PCP None None O
. None None O

The None None O
analysis None None O
groups None None O
were None None O
as None None O
follows None None O
: None None O
( None None O
i None None O
) None None O
HIV None None O
/ None None O
AIDS None None O
, None None O
( None None O
ii None None O
) None None O
lung None None O
transplant None None O
( None None O
one None None O
subject None None O
with None None O
a None None O
dual None None O
organ None None O
transplant None None O
[ None None O
lung None None O
/ None None O
kidney None None O
] None None O
was None None O
included None None O
in None None O
this None None O
category None None O
) None None O
, None None O
( None None O
iii None None O
) None None O
all None None O
other None None O
organ None None O
transplants None None O
and None None O
allogeneic None None O
hematopoietic None None O
stem None None O
cell None None O
transplants None None O
( None None O
HSCT None None O
) None None O
, None None O
( None None O
iv None None O
) None None O
leukemia None None O
, None None O
other None None O
hematological None None O
disorders None None O
, None None O
and None None O
autologous None None O
HSCT None None O
, None None O
( None None O
v None None O
) None None O
other None None O
solid None None O
tumors None None O
, None None O
and None None O
( None None O
vi None None O
) None None O
other None None O
nonmalignant None None O
conditions None None O
. None None O

Table None None O
1 None None O
. None None O

Subject None None O
enrollment None None O
, None None O
disposition None None O
, None None O
and None None O
demographics None None O
by None None O
sitea None None O

Characteristic None None O
Valueb None None O

Site None None O
1 None None O
Site None None O
2 None None O
Site None None O
3 None None O
Site None None O
4 None None O

Enrollment None None O

Unique None None O
subjects None None O
18 None None O
29 None None O
22 None None O
62 None None O

Subjects None None O
entering None None O
into None None O
primary None None O
analysisc None None O
18 None None O
22 None None O
22 None None O
48 None None O

Subjects None None O
with None None O
repeat None None O
visits None None O
0 None None O
0 None None O
0 None None O
16 None None O

No None None O
. None None O
of None None O
samples None None O
assayed None None O
18 None None O
22 None None O
22 None None O
70 None None O

Gender None None O

Male None None O
7 None None O
10 None None O
13 None None O
29 None None O

Female None None O
11 None None O
12 None None O
9 None None O
19 None None O

Race None None O

Caucasian None None O
12 None None O
4 None None O
0 None None O
48 None None O

Black None None O
6 None None O
13 None None O
0 None None O
0 None None O

Other None None O
( None None O
nonwhite None None O
) None None O
0 None None O
5 None None O
0 None None O
0 None None O

No None None O
data None None O
0 None None O
0 None None O
22 None None O
0 None None O

Mean None None O
( None None O
range None None O
) None None O
age None None O
( None None O
yr None None O
) None None O
57 None None O
( None None O
26 None None O
- None None O
78 None None O
) None None O
54 None None O
( None None O
21 None None O
- None None O
75 None None O
) None None O
52 None None O
( None None O
26 None None O
- None None O
74 None None O
) None None O
56 None None O
( None None O
23 None None O
- None None O
73 None None O
) None None O

Pretest None None O
probability None None O
of None None O
PCP None None O

Moderate None None O
0 None None O
3 None None O
4 None None O
0 None None O

Low None None O
18 None None O
19 None None O
18 None None O
48 None None O

Sample None None O
type None None O

BAL None None O
18 None None O
20 None None O
20 None None O
43 None None O

Sputum None None O
0 None None O
1 None None O
1 None None O
0 None None O

Other None None O
LRT None None O
0 None None O
1 None None O
1 None None O
5 None None O

At None None O
- None None O
risk None None O
group None None O

HIV None None O
/ None None O
AIDS None None O
0 None None O
3 None None O
6 None None O
0 None None O

Lung None None O
transplant None None O
8 None None O
0 None None O
1 None None O
31 None None O

Other None None O
transplants None None O
1 None None O
7 None None O
3 None None O
0 None None O

Leukemia None None O
1 None None O
1 None None O
7 None None O
0 None None O

Other None None O
solid None None O
tumors None None O
2 None None O
1 None None O
1 None None O
7 None None O

Other None None O
nonmalignant None None O
conditions None None O
6 None None O
10 None None O
4 None None O
10 None None O

a None None O

The None None O
testing None None O
and None None O
enrollment None None O
sites None None O
for None None O
the None None O
study None None O
were None None O
Duke None None O
University None None O
School None None O
of None None O
Medicine None None O
, None None O
Durham None None O
, None None O
NC None None O
; None None O
Albert None None O
Einstein None None O
College None None O
of None None O
Medicine None None O
and None None O
Montefiore None None O
Medical None None O
Center None None O
, None None O
Bronx None None O
, None None O
NY None None O
; None None O
Centre None None O
Hospitalier None None O
Universitaire None None O
Vaudois None None O
and None None O
University None None O
of None None O
Lausanne None None O
, None None O
Lausanne None None O
, None None O
Switzerland None None O
; None None O
and None None O
Medizinische None None O
Universitat None None O
and None None O
Landeskrankenhaus None None O
Natters None None O
, None None O
Innsbruck None None O
, None None O
Austria None None O
. None None O

b None None O

Except None None O
where None None O
otherwise None None O
indicated None None O
, None None O
values None None O
are None None O
numbers None None O
of None None O
patients None None O
. None None O

c None None O

Subjects None None O
were None None O
excluded None None O
from None None O
analysis None None O
if None None O
they None None O
withdrew None None O
consent None None O
or None None O
if None None O
there None None O
was None None O
inadequate None None O
sample None None O
left None None O
for None None O
PCR None None O
testing None None O
. None None O

Enhanced None None O
expression None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
by None None O
periodontal None None O
pathogens None None O
in None None O
gingival None None O
fibroblasts None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
has None None O
recently None None O
attracted None None O
attention None None O
as None None O
a None None O
potent None None O
inducer None None O
of None None O
vascular None None O
permeability None None O
and None None O
angiogenesis None None O
. None None O

Aberrant None None O
angiogenesis None None O
is None None O
often None None O
associated None None O
with None None O
lesion None None O
formation None None O
in None None O
chronic None None O
periodontitis None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
properties None None O
of None None O
VEGF None None O
expression None None O
in None None O
human None None O
gingival None None O
fibroblasts None None O
( None None O
HGF None None O
) None None O
culture None None O
. None None O

HGF None None O
were None None O
stimulated None None O
with None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
, None None O
vesicle None None O
( None None O
Ve None None O
) None None O
and None None O
outer None None O
membrane None None O
protein None None O
( None None O
OMP None None O
) None None O
from None None O
Actinobacillus None None O
actinomycetemcomitans None None O
and None None O
Porphyromonas None None O
gingivalis None None O
. None None O

HGF None None O
constitutively None None O
produced None None O
VEGF None None O
and None None O
levels None None O
were None None O
significantly None None O
enhanced None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
) None None O
by None None O
stimulation None None O
with None None O
Ve None None O
and None None O
OMP None None O
from None None O
A None None O
. None None O
actinomycetemcomitans None None O
and None None O
P None None O
. None None O
gingivalis None None O
at None None O
concentrations None None O
of None None O
10 None None O
microg None None O
/ None None O
ml None None O
or None None O
higher None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
VEGF None None O
levels None None O
were None None O
not None None O
increased None None O
by None None O
LPS None None O
stimulation None None O
. None None O

VEGF None None O
mRNA None None O
expression None None O
was None None O
also None None O
observed None None O
in None None O
Ve None None O
- None None O
and None None O
OMP None None O
- None None O
stimulated None None O
HGF None None O
. None None O

A None None O
vascular None None O
permeability None None O
enhancement None None O
( None None O
VPE None None O
) None None O
assay None None O
was None None O
performed None None O
using None None O
guinea None None O
pigs None None O
to None None O
ascertain None None O
whether None None O
supernatant None None O
from None None O
cultures None None O
of None None O
Ve None None O
- None None O
and None None O
OMP None None O
- None None O
stimulated None None O
HGF None None O
enhance None None O
vascular None None O
permeability None None O
in None None O
vivo None None O
. None None O

Supernatant None None O
from None None O
cultures None None O
of None None O
Ve None None O
- None None O
and None None O
OMP None None O
- None None O
stimulated None None O
HGF None None O
strongly None None O
induced None None O
VPE None None O
. None None O

This None None O
was None None O
markedly None None O
suppressed None None O
upon None None O
simultaneous None None O
injection None None O
of None None O
anti None None O
- None None O
VEGF None None O
polyclonal None None O
antibodies None None O
with None None O
the None None O
supernatant None None O
. None None O

Heating None None O
and None None O
protease None None O
treatment None None O
of None None O
the None None O
stimulants None None O
reduced None None O
the None None O
VEGF None None O
enhancing None None O
levels None None O
in None None O
Ve None None O
and None None O
OMP None None O
in None None O
vitro None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
Ve None None O
and None None O
OMP None None O
may None None O
be None None O
crucial None None O
heat None None O
- None None O
labile None None O
and None None O
protease None None O
- None None O
sensitive None None O
components None None O
of None None O
periodontal None None O
pathogens None None O
that None None O
enhance None None O
VEGF None None O
expression None None O
. None None O

In None None O
addition None None O
, None None O
VEGF None None O
might None None O
be None None O
associated None None O
with None None O
the None None O
etiology None None O
of None None O
periodontitis None None O
in None None O
its None None O
early None None O
stages None None O
according None None O
to None None O
neovascularization None None O
stimulated None None O
by None None O
periodontal None None O
pathogens None None O
causing None None O
swelling None None O
and None None O
edema None None O
. None None O

Inhibition None None O
by None None O
N None None O
- None None O
( None None O
phosphonacetyl None None O
) None None O
- None None O
L None None O
- None None O
aspartate None None O
of None None O
Ehrlich None None O
ascites None None O
tumour None None O
growth None None O
and None None O
glucose None None O
transport None None O
. None None O

N None None O
- None None O
( None None O
Phosphonacetyl None None O
) None None O
- None None O
L None None O
- None None O
aspartate None None O
( None None O
PALA None None O
) None None O
suppressed None None O
the None None O
growth None None O
of None None O
Ehrlich None None O
ascites None None O
tumour None None O
cells None None O
in None None O
vivo None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
. None None O

Simultaneously None None O
as None None O
the None None O
growth None None O
rate None None O
decreased None None O
, None None O
the None None O
cellular None None O
uptake None None O
of None None O
glucose None None O
and None None O
the None None O
density None None O
of None None O
a None None O
class None None O
of None None O
glucose None None O
- None None O
reversible None None O
binding None None O
sites None None O
for None None O
cytochalasin None None O
B None None O
on None None O
the None None O
cell None None O
surface None None O
were None None O
also None None O
found None None O
to None None O
be None None O
reduced None None O
. None None O

There None None O
is None None O
a None None O
highly None None O
significant None None O
correlation None None O
between None None O
the None None O
magnitude None None O
of None None O
changes None None O
in None None O
the None None O
number None None O
of None None O
cytochalasin None None O
B None None O
binding None None O
sites None None O
and None None O
the None None O
magnitude None None O
of None None O
changes None None O
in None None O
glucose None None O
uptake None None O
. None None O

The None None O
physiological None None O
significance None None O
of None None O
these None None O
observations None None O
are None None O
discussed None None O
. None None O

Acknowledgments None None O
and None None O
Funding None None O

The None None O
authors None None O
thank None None O
CRB None None O
GADIE None None O
( None None O
Diane None None O
Esquerre None None O
) None None O
for None None O
BAC None None O
clones None None O
handling None None O
and None None O
Brian None None O
Smith None None O
, None None O
Renee None None O
Fincham None None O
and None None O
Kristy None None O
Shewbridge None None O
for None None O
microsatellites None None O
genotyping None None O
. None None O

We None None O
are None None O
grateful None None O
to None None O
Yann None None O
Guiguen None None O
for None None O
help None None O
and None None O
precious None None O
contribution None None O
to None None O
fund None None O
raising None None O
for None None O
this None None O
study None None O
. None None O

This None None O
work None None O
was None None O
made None None O
possible None None O
by None None O
financial None None O
support None None O
of None None O
Genoscope None None O
. None None O

We None None O
acknowledge None None O
Rene None None O
Guyomard None None O
for None None O
his None None O
initial None None O
contribution None None O
in None None O
BAC None None O
library None None O
procurement None None O
. None None O

The None None O
microsatellites None None O
genotyping None None O
was None None O
supported None None O
by None None O
NRI None None O
Grant None None O
No None None O
. None None O
2007 None None O
- None None O
35616 None None O
- None None O
17875 None None O
from None None O
the None None O
USDA None None O
National None None O
Institute None None O
of None None O
Food None None O
and None None O
Agriculture None None O
. None None O

KISS1 None None O
methylation None None O
and None None O
expression None None O
as None None O
tumor None None O
stratification None None O
biomarkers None None O
and None None O
clinical None None O
outcome None None O
prognosticators None None O
for None None O
bladder None None O
cancer None None O
patients None None O
. None None O

KISS1 None None O
is None None O
a None None O
metastasis None None O
suppressor None None O
gene None None O
that None None O
is None None O
lost None None O
in None None O
several None None O
malignancies None None O
, None None O
including None None O
bladder None None O
cancer None None O
. None None O

We None None O
tested None None O
the None None O
epigenetic None None O
silencing None None O
hypothesis None None O
and None None O
evaluated None None O
the None None O
biological None None O
influence None None O
of None None O
KISS1 None None O
methylation None None O
on None None O
its None None O
expression None None O
and None None O
clinical None None O
relevance None None O
in None None O
bladder None None O
cancer None None O
. None None O

KISS1 None None O
hypermethylation None None O
was None None O
frequent None None O
in None None O
bladder None None O
cancer None None O
cells None None O
analyzed None None O
by None None O
methylation None None O
- None None O
specific None None O
PCR None None O
and None None O
bisulfite None None O
sequencing None None O
and None None O
was None None O
associated None None O
with None None O
low None None O
gene None None O
expression None None O
, None None O
being None None O
restored None None O
in None None O
vitro None None O
by None None O
demethylating None None O
azacytidine None None O
. None None O

Hypermethylation None None O
was None None O
also None None O
frequently None None O
observed None None O
in None None O
a None None O
large None None O
series None None O
of None None O
bladder None None O
tumors None None O
( None None O
83 None None O
. None None O
1 None None O
% None None O
, None None O
n None None O
= None None O
804 None None O
) None None O
. None None O

KISS1 None None O
methylation None None O
was None None O
associated None None O
with None None O
increasing None None O
stage None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
001 None None O
) None None O
and None None O
tumor None None O
grade None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
010 None None O
) None None O
. None None O

KISS1 None None O
methylation None None O
was None None O
associated None None O
with None None O
low None None O
KISS1 None None O
transcript None None O
expression None None O
by None None O
quantitative None None O
RT None None O
- None None O
PCR None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
037 None None O
) None None O
. None None O

KISS1 None None O
transcript None None O
expression None None O
was None None O
also None None O
associated None None O
with None None O
histopathological None None O
tumor None None O
stage None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
0005 None None O
) None None O
. None None O

Low None None O
transcript None None O
expression None None O
alone None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
003 None None O
) None None O
or None None O
combined None None O
with None None O
methylation None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
019 None None O
) None None O
was None None O
associated None None O
with None None O
poor None None O
disease None None O
- None None O
specific None None O
survival None None O
( None None O
n None None O
= None None O
205 None None O
) None None O
. None None O

KISS1 None None O
transcript None None O
expression None None O
remained None None O
an None None O
independent None None O
prognosticator None None O
in None None O
multivariate None None O
analyses None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
017 None None O
) None None O
. None None O

KISS1 None None O
hypermethylation None None O
was None None O
identified None None O
in None None O
bladder None None O
cancer None None O
, None None O
providing None None O
a None None O
potential None None O
mechanistic None None O
explanation None None O
( None None O
epigenetic None None O
silencing None None O
) None None O
for None None O
the None None O
observed None None O
loss None None O
of None None O
KISS1 None None O
in None None O
uroepithelial None None O
malignancies None None O
. None None O

Associations None None O
of None None O
KISS1 None None O
methylation None None O
and None None O
its None None O
expression None None O
with None None O
histopathological None None O
variables None None O
and None None O
poor None None O
survival None None O
suggest None None O
the None None O
utility None None O
of None None O
incorporating None None O
KISS1 None None O
measurement None None O
using None None O
paraffin None None O
- None None O
embedded None None O
material None None O
for None None O
tumor None None O
stratification None None O
and None None O
clinical None None O
outcome None None O
prognosis None None O
of None None O
patients None None O
with None None O
uroepithelial None None O
neoplasias None None O
. None None O

The None None O
Met None None O
proto None None O
- None None O
oncogene None None O
mesenchymal None None O
to None None O
epithelial None None O
cell None None O
conversion None None O
. None None O

Coexpression None None O
of None None O
the None None O
human None None O
Met None None O
receptor None None O
and None None O
its None None O
ligand None None O
, None None O
hepatocyte None None O
growth None None O
factor None None O
/ None None O
scatter None None O
factor None None O
( None None O
HGF None None O
/ None None O
SF None None O
) None None O
, None None O
in None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
fibroblasts None None O
causes None None O
the None None O
cells None None O
to None None O
become None None O
tumorigenic None None O
in None None O
nude None None O
mice None None O
. None None O

The None None O
resultant None None O
tumors None None O
display None None O
lumen None None O
- None None O
like None None O
morphology None None O
, None None O
contain None None O
carcinoma None None O
- None None O
like None None O
focal None None O
areas None None O
with None None O
intercellular None None O
junctions None None O
resembling None None O
desmosomes None None O
, None None O
and None None O
coexpress None None O
epithelial None None O
( None None O
cytokeratin None None O
) None None O
and None None O
mesenchymal None None O
( None None O
vimentin None None O
) None None O
cytoskeletal None None O
markers None None O
. None None O

The None None O
tumor None None O
cells None None O
also None None O
display None None O
enhanced None None O
expression None None O
of None None O
desmosomal None None O
and None None O
tight None None O
- None None O
junction None None O
proteins None None O
. None None O

The None None O
apparent None None O
mesenchymal None None O
to None None O
epithelial None None O
conversion None None O
of None None O
the None None O
tumor None None O
cells None None O
mimics None None O
the None None O
conversion None None O
that None None O
occurs None None O
during None None O
embryonic None None O
kidney None None O
development None None O
, None None O
suggesting None None O
that None None O
Met None None O
- None None O
HGF None None O
/ None None O
SF None None O
signaling None None O
plays None None O
a None None O
role None None O
in None None O
this None None O
process None None O
as None None O
well None None O
as None None O
in None None O
tumors None None O
that None None O
express None None O
both None None O
epithelial None None O
and None None O
mesenchymal None None O
markers None None O
. None None O

A None None O
randomized None None O
pilot None None O
study None None O
of None None O
the None None O
Engaging None None O
Moms None None O
Program None None O
for None None O
family None None O
drug None None O
court None None O
. None None O

In None None O
response None None O
to None None O
the None None O
need None None O
for None None O
effective None None O
drug None None O
court None None O
interventions None None O
, None None O
the None None O
effectiveness None None O
of None None O
the None None O
Engaging None None O
Moms None None O
Program None None O
( None None O
EMP None None O
) None None O
versus None None O
Intensive None None O
Case None None O
Management None None O
Services None None O
( None None O
ICMS None None O
) None None O
on None None O
multiple None None O
outcomes None None O
for None None O
mothers None None O
enrolled None None O
in None None O
family None None O
drug None None O
court None None O
was None None O
investigated None None O
. None None O

In None None O
this None None O
intent None None O
- None None O
to None None O
- None None O
treat None None O
study None None O
, None None O
mothers None None O
( None None O
N None None O
= None None O
62 None None O
) None None O
were None None O
randomly None None O
assigned None None O
to None None O
either None None O
usual None None O
drug None None O
court None None O
care None None O
or None None O
the None None O
Engaging None None O
Moms None None O
drug None None O
court None None O
program None None O
. None None O

Mothers None None O
were None None O
assessed None None O
at None None O
intake None None O
and None None O
3 None None O
, None None O
6 None None O
, None None O
12 None None O
, None None O
and None None O
18 None None O
months None None O
following None None O
intake None None O
. None None O

Results None None O
indicated None None O
that None None O
at None None O
18 None None O
months None None O
post None None O
drug None None O
court None None O
enrollment None None O
, None None O
77 None None O
% None None O
of None None O
mothers None None O
assigned None None O
to None None O
EMP None None O
versus None None O
55 None None O
% None None O
of None None O
mothers None None O
assigned None None O
to None None O
ICMS None None O
had None None O
positive None None O
child None None O
welfare None None O
dispositions None None O
. None None O

There None None O
were None None O
statistically None None O
significant None None O
time None None O
effects None None O
for None None O
both None None O
intervention None None O
groups None None O
on None None O
multiple None None O
outcomes None None O
including None None O
substance None None O
use None None O
, None None O
mental None None O
health None None O
, None None O
parenting None None O
practices None None O
, None None O
and None None O
family None None O
functioning None None O
. None None O

EMP None None O
showed None None O
equal None None O
or None None O
better None None O
improvement None None O
than None None O
ICMS None None O
on None None O
all None None O
outcomes None None O
. None None O

The None None O
results None None O
suggest None None O
that None None O
EMP None None O
in None None O
family None None O
drug None None O
court None None O
is None None O
a None None O
viable None None O
and None None O
promising None None O
intervention None None O
approach None None O
to None None O
reduce None None O
maternal None None O
addiction None None O
and None None O
child None None O
maltreatment None None O
. None None O

Impact None None O
of None None O
dexamethasone None None O
- None None O
induced None None O
immunosuppression None None O
on None None O
the None None O
duration None None O
and None None O
level None None O
of None None O
shedding None None O
of None None O
Escherichia None None O
coli None None O
O157 None None O
: None None O
H7 None None O
in None None O
calves None None O
. None None O

The None None O
goal None None O
of None None O
this None None O
study None None O
was None None O
to None None O
determine None None O
whether None None O
immunosuppression None None O
plays None None O
a None None O
role None None O
in None None O
the None None O
level None None O
and None None O
duration None None O
of None None O
fecal None None O
shedding None None O
of None None O
Escherichia None None O
coli None None O
O157 None None O
. None None O

Immunosuppression None None O
was None None O
induced None None O
in None None O
calves None None O
by None None O
administering None None O
dexamethasone None None O
. None None O

Six None None O
1 None None O
- None None O
week None None O
- None None O
old None None O
Holstein None None O
bull None None O
calves None None O
were None None O
injected None None O
intramuscularly None None O
with None None O
dexamethasone None None O
and None None O
orally None None O
inoculated None None O
with None None O
10 None None O
( None None O
9 None None O
) None None O
CFU None None O
of None None O
a None None O
mixture None None O
of None None O
three None None O
nalidixic None None O
- None None O
acid None None O
resistant None None O
strains None None O
of None None O
E None None O
. None None O
coli None None O
O157 None None O
: None None O
H7 None None O
. None None O

Five None None O
1 None None O
- None None O
week None None O
- None None O
old None None O
Holstein None None O
bull None None O
calves None None O
that None None O
were None None O
given None None O
the None None O
same None None O
oral None None O
inoculation None None O
of None None O
E None None O
. None None O
coli None None O
O157 None None O
: None None O
H7 None None O
, None None O
but None None O
not None None O
the None None O
dexamethasone None None O
injections None None O
, None None O
served None None O
as None None O
controls None None O
. None None O

All None None O
calves None None O
were None None O
examined None None O
daily None None O
and None None O
fecal None None O
samples None None O
were None None O
collected None None O
three None None O
times None None O
a None None O
week None None O
for None None O
detection None None O
and None None O
enumeration None None O
of None None O
the None None O
nalidixic None None O
- None None O
acid None None O
resistant None None O
E None None O
. None None O
coli None None O
O157 None None O
. None None O

Four None None O
weeks None None O
after None None O
the None None O
last None None O
calf None None O
stopped None None O
shedding None None O
, None None O
all None None O
calves None None O
were None None O
necropsied None None O
and None None O
samples None None O
from None None O
the None None O
gastrointestinal None None O
tract None None O
were None None O
taken None None O
for None None O
the None None O
detection None None O
of None None O
the None None O
nalidixic None None O
- None None O
acid None None O
resistant None None O
E None None O
. None None O
coli None None O
O157 None None O
. None None O

Dexamethasone None None O
- None None O
injected None None O
calves None None O
shed None None O
at None None O
higher None None O
levels None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
04 None None O
) None None O
on None None O
days None None O
4 None None O
and None None O
7 None None O
postinoculation None None O
, None None O
but None None O
not None None O
thereafter None None O
. None None O

None None None O
of None None O
the None None O
samples None None O
collected None None O
at None None O
necropsy None None O
were None None O
positive None None O
for None None O
E None None O
. None None O
coli None None O
O157 None None O
. None None O

Data None None O
from None None O
this None None O
study None None O
suggest None None O
that None None O
there None None O
may None None O
be None None O
a None None O
time None None O
- None None O
dependent None None O
relationship None None O
between None None O
dexamethasone None None O
immunosuppression None None O
and None None O
the None None O
fecal None None O
concentration None None O
of None None O
E None None O
. None None O
coli None None O
O157 None None O
but None None O
that None None O
transient None None O
immunosuppression None None O
does None None O
not None None O
appear None None O
to None None O
prolong None None O
shedding None None O
of None None O
E None None O
. None None O
coli None None O
O157 None None O
. None None O

A None None O
pivotal None None O
role None None O
for None None O
p53 None None O
: None None O
balancing None None O
aerobic None None O
respiration None None O
and None None O
glycolysis None None O
. None None O

The None None O
genetic None None O
basis None None O
of None None O
increased None None O
glycolytic None None O
activity None None O
observed None None O
in None None O
cancer None None O
cells None None O
is None None O
likely None None O
to None None O
be None None O
the None None O
result None None O
of None None O
complex None None O
interactions None None O
of None None O
multiple None None O
regulatory None None O
pathways None None O
. None None O

Here None None O
we None None O
review None None O
the None None O
recent None None O
evidence None None O
of None None O
a None None O
simple None None O
genetic None None O
mechanism None None O
by None None O
which None None O
tumor None None O
suppressor None None O
p53 None None O
regulates None None O
mitochondrial None None O
respiration None None O
with None None O
secondary None None O
changes None None O
in None None O
glycolysis None None O
that None None O
are None None O
reminiscent None None O
of None None O
the None None O
Warburg None None O
effect None None O
. None None O

The None None O
biological None None O
significance None None O
of None None O
this None None O
regulation None None O
of None None O
the None None O
two None None O
major None None O
pathways None None O
of None None O
energy None None O
generation None None O
by None None O
p53 None None O
remains None None O
to None None O
be None None O
seen None None O
. None None O

Suppression None None O
of None None O
tumor None None O
growth None None O
by None None O
the None None O
3 None None O
' None None O
untranslated None None O
region None None O
of None None O
mel None None O
- None None O
18 None None O
in None None O
3Y1 None None I-Cell-line-name
cells None None O
transformed None None O
by None None O
the None None O
E6 None None O
and None None O
E7 None None O
genes None None O
of None None O
human None None O
papillomavirus None None O
type None None O
18 None None O
. None None O

By None None O
introducing None None O
a None None O
cDNA None None O
library None None O
derived None None O
from None None O
rat None None O
embryonic None None O
fibroblast None None O
cells None None O
, None None O
we None None O
isolated None None O
several None None O
morphologically None None O
flat None None O
revertants None None O
of None None O
rat None None O
3Y1 None None I-Cell-line-name
cells None None O
transformed None None O
by None None O
the None None O
E6 None None O
and None None O
E7 None None O
genes None None O
of None None O
human None None O
papillomavirus None None O
type None None O
18 None None O
( None None O
HPV18 None None O
) None None O
. None None O

From None None O
one None None O
of None None O
the None None O
revertants None None O
, None None O
we None None O
recovered None None O
a None None O
0 None None O
. None None O
2 None None O
- None None O
kb None None O
cDNA None None O
, None None O
N56 None None O
, None None O
that None None O
suppresses None None O
the None None O
tumor None None O
growth None None O
of None None O
the None None O
transformed None None O
3Y1 None None I-Cell-line-name
cells None None O
irrespective None None O
of None None O
the None None O
expression None None O
of None None O
the None None O
E6 None None O
and None None O
E7 None None O
genes None None O
. None None O

The None None O
nucleotide None None O
sequence None None O
of None None O
the None None O
cDNA None None O
was None None O
shown None None O
to None None O
be None None O
identical None None O
to None None O
that None None O
of None None O
the None None O
3 None None O
' None None O
untranslated None None O
region None None O
of None None O
a None None O
putative None None O
mammalian None None O
polycomb None None O
group None None O
gene None None O
, None None O
mel None None O
- None None O
18 None None O
. None None O

Implications None None O
for None None O
Psychological None None O
Models None None O
of None None O
Interval None None O
Timing None None O

Several None None O
models None None O
have None None O
been None None O
previously None None O
applied None None O
to None None O
interpret None None O
data None None O
obtained None None O
in None None O
interval None None O
- None None O
timing None None O
experiments None None O
involving None None O
gaps None None O
( None None O
retention None None O
- None None O
intervals None None O
) None None O
. None None O

A None None O
switch None None O
model None None O
, None None O
assuming None None O
that None None O
during None None O
the None None O
gap None None O
time None None O
fails None None O
to None None O
accumulate None None O
due None None O
to None None O
the None None O
opening None None O
of None None O
a None None O
stimulus None None O
- None None O
controlled None None O
switch None None O
, None None O
predicts None None O
that None None O
, None None O
irrespective None None O
of None None O
gap None None O
and None None O
criterion None None O
durations None None O
, None None O
subjects None None O
should None None O
use None None O
a None None O
stop None None O
rule None None O
[ None None O
14 None None O
] None None O
, None None O
[ None None O
15 None None O
] None None O
, None None O
[ None None O
30 None None O
] None None O
, None None O
[ None None O
31 None None O
] None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
present None None O
data None None O
indicate None None O
that None None O
rats None None O
flexibly None None O
change None None O
their None None O
behavior None None O
with None None O
both None None O
gap None None O
and None None O
criterion None None O
duration None None O
. None None O

An None None O
instructional None None O
- None None O
ambiguity None None O
model None None O
proposing None None O
that None None O
subjects None None O
perceive None None O
the None None O
gap None None O
as None None O
an None None O
ambiguous None None O
, None None O
ITI None None O
- None None O
like None None O
event None None O
, None None O
predicts None None O
that None None O
manipulations None None O
that None None O
render None None O
the None None O
gap None None O
similar None None O
to None None O
the None None O
ITI None None O
should None None O
reset None None O
the None None O
clock None None O
, None None O
while None None O
manipulations None None O
that None None O
render None None O
the None None O
gap None None O
dissimilar None None O
from None None O
the None None O
ITI None None O
should None None O
stop None None O
the None None O
clock None None O
[ None None O
37 None None O
] None None O
. None None O

Because None None O
in None None O
our None None O
experiment None None O
the None None O
gap None None O
and None None O
ITI None None O
were None None O
identical None None O
( None None O
dark None None O
) None None O
this None None O
hypothesis None None O
predicts None None O
the None None O
use None None O
of None None O
the None None O
same None None O
rule None None O
( None None O
reset None None O
) None None O
at None None O
all None None O
gap None None O
and None None O
criteria None None O
durations None None O
, None None O
in None None O
contrast None None O
to None None O
the None None O
current None None O
data None None O
showing None None O
the None None O
use None None O
of None None O
different None None O
rules None None O
for None None O
different None None O
temporal None None O
criteria None None O
. None None O

To None None O
account None None O
for None None O
the None None O
flexible None None O
use None None O
of None None O
the None None O
run None None O
/ None None O
stop None None O
/ None None O
reset None None O
rules None None O
by None None O
rats None None O
and None None O
pigeons None None O
, None None O
Cabeza None None O
de None None O
Vaca None None O
et None None O
al None None O
. None None O

[ None None O
38 None None O
] None None O
proposed None None O
a None None O
passive None None O
memory None None O
- None None O
decay None None O
model None None O
which None None O
assumes None None O
that None None O
subjective None None O
time None None O
- None None O
- None None O
stored None None O
in None None O
WM None None O
- None None O
- None None O
decays None None O
passively None None O
during None None O
the None None O
gap None None O
. None None O

This None None O
model None None O
predicts None None O
that None None O
the None None O
effect None None O
of None None O
a None None O
gap None None O
should None None O
depend None None O
solely None None O
on None None O
absolute None None O
gap None None O
duration None None O
, None None O
but None None O
not None None O
on None None O
criterion None None O
duration None None O
, None None O
as None None O
found None None O
here None None O
( None None O
Fig None None O
. None None O
1B None None O
- None None O
D None None O
) None None O
. None None O

These None None O
models None None O
can None None O
not None None O
account None None O
for None None O
the None None O
differential None None O
effects None None O
of None None O
gaps None None O
on None None O
multiple None None O
intervals None None O
. None None O

In None None O
contrast None None O
to None None O
these None None O
alternatives None None O
, None None O
the None None O
present None None O
resource None None O
allocation None None O
model None None O
assumes None None O
that None None O
during None None O
the None None O
gaps None None O
resources None None O
are None None O
re None None O
- None None O
allocated None None O
( None None O
diverted None None O
away None None O
from None None O
timing None None O
) None None O
, None None O
each None None O
clock None None O
is None None O
unable None None O
to None None O
maintain None None O
its None None O
current None None O
subjective None None O
time None None O
in None None O
WM None None O
, None None O
and None None O
the None None O
response None None O
is None None O
delayed None None O
[ None None O
16 None None O
] None None O
, None None O
[ None None O
17 None None O
] None None O
, None None O
[ None None O
27 None None O
] None None O
in None None O
proportion None None O
to None None O
the None None O
perceived None None O
salience None None O
of None None O
the None None O
distracter None None O
relative None None O
to None None O
the None None O
times None None O
signal None None O
[ None None O
34 None None O
] None None O
, None None O
[ None None O
35 None None O
] None None O
. None None O

Indeed None None O
, None None O
the None None O
effect None None O
of None None O
a None None O
gap None None O
is None None O
affected None None O
by None None O
the None None O
contrast None None O
in None None O
intensity None None O
between None None O
the None None O
gap None None O
and None None O
the None None O
timed None None O
signal None None O
[ None None O
27 None None O
] None None O
, None None O
[ None None O
34 None None O
] None None O
, None None O
[ None None O
39 None None O
] None None O
and None None O
by None None O
the None None O
perceptual None None O
acuity None None O
of None None O
the None None O
subjects None None O
[ None None O
27 None None O
] None None O
. None None O

Importantly None None O
, None None O
the None None O
predictions None None O
of None None O
this None None O
resource None None O
re None None O
- None None O
allocation None None O
model None None O
are None None O
not None None O
restricted None None O
to None None O
retention None None O
- None None O
intervals None None O
( None None O
i None None O
. None None O
e None None O
. None None O
, None None O
gaps None None O
) None None O
, None None O
but None None O
extend None None O
to None None O
distracters None None O
presented None None O
during None None O
the None None O
continuous None None O
presentation None None O
of None None O
a None None O
timed None None O
signal None None O
. None None O

Previous None None O
data None None O
were None None O
quantitatively None None O
accounted None None O
for None None O
by None None O
assuming None None O
that None None O
during None None O
a None None O
gap None None O
and None None O
/ None None O
or None None O
distracter None None O
the None None O
accumulated None None O
time None None O
decays None None O
at None None O
a None None O
rate None None O
that None None O
varies None None O
with None None O
the None None O
relative None None O
salience None None O
of None None O
the None None O
distracter None None O
to None None O
the None None O
timed None None O
signal None None O
[ None None O
25 None None O
] None None O
, None None O
[ None None O
26 None None O
] None None O
, None None O
[ None None O
35 None None O
] None None O
. None None O

Here None None O
we None None O
found None None O
that None None O
the None None O
comparison None None O
between None None O
the None None O
gap None None O
and None None O
the None None O
( None None O
multiple None None O
) None None O
timed None None O
signal None None O
( None None O
s None None O
) None None O
extends None None O
to None None O
the None None O
temporal None None O
domain None None O
. None None O

Simulations None None O
indicate None None O
that None None O
both None None O
the None None O
differential None None O
effect None None O
of None None O
the None None O
gap None None O
on None None O
multiple None None O
durations None None O
, None None O
and None None O
the None None O
gradual None None O
hierarchical None None O
reset None None O
due None None O
to None None O
increasing None None O
gap None None O
duration None None O
can None None O
be None None O
quantitatively None None O
accounted None None O
for None None O
assuming None None O
that None None O
the None None O
three None None O
clocks None None O
have None None O
separate None None O
resources None None O
re None None O
- None None O
allocated None None O
independently None None O
during None None O
a None None O
gap None None O
at None None O
a None None O
rate None None O
proportional None None O
to None None O
the None None O
ratio None None O
g None None O
/ None None O
Tk None None O
between None None O
the None None O
duration None None O
of None None O
the None None O
gap None None O
and None None O
each None None O
criterion None None O
duration None None O
( None None O
Fig None None O
. None None O
2A None None O
: None None O
D None None O
- None None O
Model None None O
) None None O
. None None O

Antisense None None O
technologies None None O
have None None O
a None None O
future None None O
fighting None None O
neurodegenerative None None O
diseases None None O
. None None O

Our None None O
growing None None O
understanding None None O
of None None O
the None None O
role None None O
that None None O
unfavorable None None O
patterns None None O
of None None O
gene None None O
expression None None O
play None None O
in None None O
the None None O
etiology None None O
of None None O
neurodegenerative None None O
disease None None O
emphasizes None None O
the None None O
need None None O
for None None O
strategies None None O
to None None O
selectively None None O
block None None O
the None None O
biosynthesis None None O
of None None O
harmful None None O
proteins None None O
in None None O
the None None O
brain None None O
. None None O

Antisense None None O
technologies None None O
are None None O
ideally None None O
suited None None O
to None None O
this None None O
purpose None None O
. None None O

Tailor None None O
- None None O
designed None None O
to None None O
target None None O
specific None None O
RNA None None O
, None None O
antisense None None O
oligonucleotides None None O
and None None O
ribozymes None None O
offer None None O
tools None None O
to None None O
suppress None None O
the None None O
production None None O
of None None O
proteins None None O
mediating None None O
neurodegeneration None None O
. None None O

Although None None O
technical None None O
limitations None None O
must None None O
still None None O
be None None O
overcome None None O
, None None O
the None None O
antisense None None O
approach None None O
represents None None O
a None None O
novel None None O
and None None O
exciting None None O
strategy None None O
for None None O
intervention None None O
in None None O
diseases None None O
of None None O
the None None O
central None None O
nervous None None O
system None None O
. None None O

COMMENTS None None O

Recurrent None None O
anterior None None O
vaginal None None O
wall None None O
prolapse None None O
can None None O
develop None None O
in None None O
more None None O
than None None O
20 None None O
% None None O
of None None O
patients None None O
undergoing None None O
traditional None None O
anterior None None O
colporrhaphy None None O
. None None O

In None None O
light None None O
of None None O
this None None O
high None None O
recurrence None None O
rate None None O
many None None O
surgeons None None O
have None None O
been None None O
incorporating None None O
synthetic None None O
or None None O
allograft None None O
mesh None None O
to None None O
augment None None O
the None None O
repair None None O
. None None O

In None None O
this None None O
study None None O
there None None O
are None None O
some None None O
shortcomings None None O
, None None O
including None None O
retrospective None None O
design None None O
, None None O
short None None O
follow None None O
- None None O
up None None O
for None None O
a None None O
study None None O
spanning None None O
almost None None O
six None None O
years None None O
and None None O
a None None O
lack None None O
of None None O
validated None None O
questionnaires None None O
. None None O

Authors None None O
report None None O
a None None O
negative None None O
experience None None O
with None None O
porcine None None O
dermis None None O
, None None O
both None None O
in None None O
terms None None O
of None None O
success None None O
and None None O
extrusion None None O
rate None None O
. None None O

However None None O
, None None O
others None None O
have None None O
reported None None O
better None None O
outcome None None O
[ None None O
1 None None O
] None None O
which None None O
may None None O
be None None O
due None None O
to None None O
different None None O
follow None None O
- None None O
up None None O
times None None O
and None None O
outcome None None O
measures None None O
. None None O

Apart None None O
from None None O
this None None O
, None None O
biological None None O
grafts None None O
are None None O
also None None O
associated None None O
with None None O
allergic None None O
reactions None None O
and None None O
disease None None O
transmission None None O
. None None O

There None None O
is None None O
paucity None None O
of None None O
data None None O
regarding None None O
prospective None None O
randomized None None O
trials None None O
on None None O
the None None O
use None None O
of None None O
these None None O
biomaterials None None O
prior None None O
to None None O
their None None O
widespread None None O
human None None O
need None None O
which None None O
might None None O
help None None O
in None None O
reducing None None O
such None None O
type None None O
of None None O
experiences None None O
. None None O

Unless None None O
such None None O
data None None O
are None None O
available None None O
surgeons None None O
should None None O
give None None O
serious None None O
thought None None O
prior None None O
to None None O
embarking None None O
on None None O
the None None O
use None None O
of None None O
such None None O
biological None None O
materials None None O
. None None O
[ None None O
2 None None O
] None None O

Images None None O

Figure None None O
5 None None O

Fas None None O
- None None O
signaling None None O
and None None O
effects None None O
on None None O
receptor None None O
tyrosine None None O
kinase None None O
signal None None O
transduction None None O
in None None O
human None None O
breast None None O
epithelial None None O
cells None None O
. None None O

Fas None None O
- None None O
mediated None None O
cell None None O
death None None O
was None None O
examined None None O
in None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
10AT None None I-Cell-line-name
preneoplastic None None O
human None None O
breast None None O
epithelial None None O
cells None None O
. None None O

Treatment None None O
with None None O
anti None None O
- None None O
Fas None None O
for None None O
48 None None O
h None None O
induced None None O
apoptosis None None O
with None None O
cells None None O
exhibiting None None O
typical None None O
apoptotic None None O
features None None O
including None None O
loss None None O
of None None O
cell None None O
contact None None O
, None None O
condensation None None O
of None None O
chromatin None None O
, None None O
and None None O
increased None None O
staining None None O
of None None O
the None None O
nuclear None None O
membrane None None O
. None None O

DNA None None O
fragmentation None None O
occurred None None O
in None None O
response None None O
to None None O
anti None None O
- None None O
Fas None None O
treatment None None O
. None None O

Anti None None O
- None None O
Fas None None O
treatment None None O
resulted None None O
in None None O
decreased None None O
p53 None None O
protein None None O
levels None None O
, None None O
while None None O
bcl None None O
- None None O
2 None None O
and None None O
bax None None O
protein None None O
levels None None O
remained None None O
unaffected None None O
. None None O

Cells None None O
treated None None O
with None None O
anti None None O
- None None O
Fas None None O
also None None O
exhibited None None O
increased None None O
tyrosine None None O
phosphorylation None None O
of None None O
the None None O
c None None O
- None None O
met None None O
growth None None O
factor None None O
receptor None None O
tyrosine None None O
kinase None None O
. None None O

Immunoprecipitation None None O
experiments None None O
demonstrated None None O
that None None O
Fas None None O
associated None None O
with None None O
c None None O
- None None O
erbB2 None None O
and None None O
c None None O
- None None O
met None None O
in None None O
untreated None None O
cells None None O
. None None O

Treatment None None O
with None None O
anti None None O
- None None O
Fas None None O
, None None O
however None None O
, None None O
significantly None None O
decreased None None O
Fas None None O
- None None O
c None None O
- None None O
erbB2 None None O
and None None O
Fas None None O
- None None O
c None None O
- None None O
met None None O
association None None O
. None None O

Anti None None O
- None None O
Fas None None O
treatment None None O
of None None O
these None None O
cells None None O
caused None None O
a None None O
significant None None O
decrease None None O
in None None O
p120 None None O
- None None O
GAP None None O
levels None None O
, None None O
ERK None None O
- None None O
1 None None O
levels None None O
, None None O
and None None O
phosphorylation None None O
, None None O
as None None O
well None None O
as None None O
Grb2 None None O
- None None O
Sosl None None O
and None None O
MEK None None O
- None None O
1 None None O
- None None O
ERK None None O
- None None O
1 None None O
association None None O
. None None O

These None None O
results None None O
show None None O
that None None O
Fas None None O
- None None O
signaling None None O
exerted None None O
a None None O
suppressive None None O
effect None None O
on None None O
p53 None None O
levels None None O
and None None O
on None None O
downstream None None O
effectors None None O
of None None O
receptor None None O
tyrosine None None O
kinase None None O
signal None None O
transduction None None O
, None None O
thereby None None O
ensuring None None O
cell None None O
death None None O
. None None O

The None None O
septic None None O
abscess None None O
wall None None O
: None None O
a None None O
cytokine None None O
- None None O
generating None None O
organ None None O
associated None None O
with None None O
portal None None O
venous None None O
cytokinemia None None O
, None None O
hepatic None None O
outflow None None O
fibrosis None None O
, None None O
sinusoidal None None O
congestion None None O
, None None O
inflammatory None None O
cell None None O
sequestration None None O
, None None O
hepatocellular None None O
lipid None None O
deposition None None O
, None None O
and None None O
focal None None O
cell None None O
death None None O
. None None O

An None None O
acute None None O
septic None None O
inflammatory None None O
response None None O
with None None O
access None None O
to None None O
the None None O
portal None None O
circulation None None O
was None None O
created None None O
in None None O
a None None O
rat None None O
model None None O
using None None O
an None None O
intra None None O
- None None O
abdominal None None O
abscess None None O
composed None None O
of None None O
a None None O
sterile None None O
agar None None O
pellet None None O
, None None O
or None None O
one None None O
contaminated None None O
with None None O
102 None None O
Escherichia None None O
coli None None O
( None None O
E None None O
. None None O
coli None None O
) None None O
and None None O
109 None None O
Bacteriodes None None O
fragilis None None O
( None None O
B None None O
. None None O
fragilis None None O
) None None O
. None None O

After None None O
3 None None O
days None None O
postimplantation None None O
, None None O
a None None O
well None None O
- None None O
formed None None O
intra None None O
- None None O
abdominal None None O
abscess None None O
occurred None None O
whose None None O
wall None None O
showed None None O
IL None None O
- None None O
6 None None O
DNA None None O
by None None O
PCR None None O
and None None O
IL None None O
- None None O
6 None None O
mRNA None None O
by None None O
in None None O
situ None None O
hybridization None None O
. None None O

Portal None None O
venous None None O
blood None None O
draining None None O
into None None O
the None None O
liver None None O
from None None O
the None None O
intra None None O
- None None O
abdominal None None O
abscess None None O
had None None O
increased None None O
levels None None O
of None None O
TNF None None O
- None None O
alpha None None O
, None None O
IL None None O
- None None O
1beta None None O
, None None O
and None None O
IL None None O
- None None O
6 None None O
in None None O
both None None O
sterile None None O
and None None O
septic None None O
groups None None O
compared None None O
with None None O
a None None O
control None None O
normal None None O
animal None None O
group None None O
. None None O

Increased None None O
levels None None O
of None None O
these None None O
cytokines None None O
were None None O
also None None O
found None None O
in None None O
suprahepatic None None O
inferior None None O
vena None None O
caval None None O
blood None None O
, None None O
but None None O
were None None O
correlated None None O
with None None O
the None None O
higher None None O
portal None None O
vein None None O
levels None None O
, None None O
suggesting None None O
a None None O
gradient None None O
from None None O
abscess None None O
wall None None O
to None None O
portal None None O
vein None None O
into None None O
the None None O
systemic None None O
circulation None None O
via None None O
the None None O
liver None None O
. None None O

Liver None None O
histology None None O
demonstrated None None O
sinusoidal None None O
congestion None None O
centering None None O
on None None O
the None None O
central None None O
vein None None O
, None None O
growing None None O
worse None None O
with None None O
progression None None O
from None None O
normal None None O
in None None O
control None None O
, None None O
to None None O
sterile None None O
, None None O
to None None O
septic None None O
. None None O

Similarly None None O
, None None O
the None None O
degree None None O
of None None O
intrahepatic None None O
myeloperoxidase None None O
- None None O
positive None None O
inflammatory None None O
cell None None O
infiltration None None O
and None None O
hepatocellular None None O
lipid None None O
deposition None None O
and None None O
apoptosis None None O
also None None O
increased None None O
from None None O
control None None O
, None None O
to None None O
sterile None None O
, None None O
to None None O
septic None None O
. None None O

Gene None None O
expression None None O
by None None O
in None None O
situ None None O
hybridization None None O
demonstrated None None O
a None None O
significant None None O
increase None None O
in None None O
IL None None O
- None None O
6 None None O
and None None O
fibrinogen None None O
mRNAs None None O
in None None O
cells None None O
surrounding None None O
the None None O
central None None O
vein None None O
in None None O
sterile None None O
and None None O
septic None None O
animals None None O
, None None O
being None None O
greatest None None O
in None None O
animals None None O
with None None O
sepsis None None O
, None None O
associated None None O
with None None O
an None None O
increased None None O
deposition None None O
of None None O
collagen None None O
in None None O
the None None O
central None None O
vein None None O
area None None O
, None None O
most None None O
prominent None None O
in None None O
the None None O
septic None None O
liver None None O
. None None O

The None None O
pericentral None None O
vein None None O
cells None None O
with None None O
IL None None O
- None None O
6 None None O
and None None O
fibrinogen None None O
mRNA None None O
increases None None O
paralleled None None O
the None None O
increases None None O
in None None O
cells None None O
containing None None O
IL None None O
- None None O
6 None None O
and None None O
fibrinogen None None O
mRNAs None None O
in None None O
the None None O
abscess None None O
walls None None O
of None None O
sterile None None O
and None None O
septic None None O
animals None None O
, None None O
respectively None None O
. None None O

The None None O
data None None O
suggest None None O
that None None O
an None None O
intra None None O
- None None O
abdominal None None O
abscess None None O
, None None O
especially None None O
when None None O
contaminated None None O
with None None O
gram None None O
- None None O
negative None None O
bacteria None None O
, None None O
induces None None O
mRNA None None O
- None None O
generated None None O
cytokine None None O
responses None None O
in None None O
the None None O
abscess None None O
wall None None O
that None None O
are None None O
related None None O
to None None O
increased None None O
portal None None O
venous None None O
levels None None O
of None None O
the None None O
inflammatory None None O
cytokines None None O
TNF None None O
- None None O
alpha None None O
, None None O
IL None None O
- None None O
1beta None None O
, None None O
and None None O
IL None None O
- None None O
6 None None O
perfusing None None O
the None None O
liver None None O
. None None O

These None None O
, None None O
in None None O
turn None None O
, None None O
induce None None O
localized None None O
production None None O
of None None O
IL None None O
- None None O
6 None None O
and None None O
fibrinogen None None O
mRNAs None None O
in None None O
cells None None O
at None None O
the None None O
central None None O
vein None None O
area None None O
with None None O
resultant None None O
outflow None None O
fibrosis None None O
and None None O
increased None None O
inflammatory None None O
cell None None O
sequestration None None O
within None None O
the None None O
liver None None O
lobular None None O
sinuses None None O
. None None O

This None None O
is None None O
associated None None O
with None None O
a None None O
generalized None None O
inflammatory None None O
response None None O
and None None O
intrahepatic None None O
portal None None O
sinusoid None None O
congestion None None O
. None None O

There None None O
is None None O
also None None O
increased None None O
hepatocellular None None O
lipid None None O
deposition None None O
and None None O
apoptosis None None O
. None None O

Thus None None O
, None None O
the None None O
cytokine None None O
production None None O
of None None O
the None None O
abscess None None O
wall None None O
itself None None O
appears None None O
to None None O
be None None O
a None None O
major None None O
mediator None None O
of None None O
the None None O
septic None None O
hepatic None None O
response None None O
. None None O

Immunohistochemical None None O
staining None None O
for None None O
thyroid None None O
transcription None None O
factor None None O
- None None O
1 None None O
: None None O
a None None O
helpful None None O
aid None None O
in None None O
discerning None None O
primary None None O
site None None O
of None None O
tumor None None O
origin None None O
in None None O
patients None None O
with None None O
brain None None O
metastases None None O
. None None O

Metastatic None None O
carcinoma None None O
of None None O
unknown None None O
primary None None O
origin None None O
is None None O
a None None O
perplexing None None O
but None None O
common None None O
problem None None O
, None None O
accounting None None O
for None None O
up None None O
to None None O
10 None None O
% None None O
to None None O
15 None None O
% None None O
of None None O
all None None O
solid None None O
tumors None None O
at None None O
presentation None None O
. None None O

Many None None O
of None None O
these None None O
metastases None None O
presumably None None O
arise None None O
from None None O
primary None None O
lung None None O
carcinomas None None O
, None None O
but None None O
the None None O
morphologic None None O
features None None O
and None None O
immunohistochemical None None O
profile None None O
of None None O
lung None None O
cancer None None O
is None None O
often None None O
too None None O
nonspecific None None O
to None None O
permit None None O
unequivocal None None O
confirmation None None O
. None None O

Thyroid None None O
transcription None None O
factor None None O
- None None O
1 None None O
( None None O
TTF None None O
- None None O
1 None None O
) None None O
is None None O
expressed None None O
in None None O
lung None None O
adenocarcinomas None None O
and None None O
thyroid None None O
carcinomas None None O
but None None O
not None None O
in None None O
adenocarcinomas None None O
arising None None O
from None None O
other None None O
sites None None O
. None None O

For None None O
patients None None O
with None None O
adenocarcinomas None None O
in None None O
the None None O
lung None None O
, None None O
TTF None None O
- None None O
1 None None O
staining None None O
is None None O
now None None O
routinely None None O
used None None O
to None None O
distinguish None None O
a None None O
primary None None O
lung None None O
cancer None None O
from None None O
a None None O
lung None None O
metastasis None None O
. None None O

Along None None O
these None None O
same None None O
lines None None O
, None None O
TTF None None O
- None None O
1 None None O
staining None None O
might None None O
prove None None O
useful None None O
in None None O
localizing None None O
the None None O
tumor None None O
origin None None O
of None None O
adenocarcinomas None None O
encountered None None O
outside None None O
of None None O
the None None O
lung None None O
. None None O

The None None O
archival None None O
surgical None None O
pathology None None O
files None None O
of None None O
The None None O
Johns None None O
Hopkins None None O
Hospital None None O
were None None O
searched None None O
for None None O
cases None None O
of None None O
brain None None O
metastases None None O
biopsied None None O
between None None O
1990 None None O
and None None O
2000 None None O
. None None O

Tissue None None O
blocks None None O
were None None O
obtained None None O
and None None O
immunoperoxidase None None O
staining None None O
was None None O
performed None None O
using None None O
the None None O
TTF None None O
- None None O
1 None None O
antibody None None O
. None None O

The None None O
medical None None O
records None None O
were None None O
reviewed None None O
independent None None O
of None None O
the None None O
staining None None O
results None None O
to None None O
determine None None O
site None None O
of None None O
tumor None None O
origin None None O
. None None O

Seventy None None O
- None None O
five None None O
patients None None O
underwent None None O
biopsies None None O
of None None O
carcinomas None None O
metastatic None None O
to None None O
the None None O
brain None None O
. None None O

At None None O
the None None O
time None None O
of None None O
brain None None O
biopsy None None O
, None None O
the None None O
primary None None O
site None None O
of None None O
tumor None None O
origin None None O
was None None O
known None None O
in None None O
45 None None O
cases None None O
and None None O
unknown None None O
in None None O
30 None None O
cases None None O
. None None O

Ultimately None None O
, None None O
the None None O
primary None None O
site None None O
was None None O
established None None O
on None None O
clinical None None O
and None None O
radiographic None None O
grounds None None O
in None None O
71 None None O
cases None None O
( None None O
95 None None O
% None None O
) None None O
. None None O

These None None O
included None None O
40 None None O
( None None O
56 None None O
% None None O
) None None O
metastases None None O
from None None O
a None None O
primary None None O
lung None None O
carcinoma None None O
and None None O
31 None None O
( None None O
44 None None O
% None None O
) None None O
metastases None None O
from None None O
some None None O
nonpulmonary None None O
carcinoma None None O
. None None O

TTF None None O
- None None O
1 None None O
staining None None O
was None None O
present None None O
in None None O
31 None None O
of None None O
the None None O
40 None None O
( None None O
78 None None O
% None None O
) None None O
metastatic None None O
lung None None O
carcinomas None None O
, None None O
but None None O
in None None O
only None None O
1 None None O
of None None O
the None None O
31 None None O
( None None O
3 None None O
% None None O
) None None O
metastatic None None O
nonpulmonary None None O
carcinomas None None O
( None None O
a None None O
small None None O
- None None O
cell None None O
carcinoma None None O
of None None O
the None None O
sinonasal None None O
tract None None O
) None None O
. None None O

When None None O
the None None O
metastatic None None O
lung None None O
carcinomas None None O
were None None O
subtyped None None O
, None None O
TTF None None O
- None None O
1 None None O
staining None None O
was None None O
noted None None O
in None None O
11 None None O
of None None O
11 None None O
( None None O
100 None None O
% None None O
) None None O
adenocarcinomas None None O
, None None O
in None None O
6 None None O
of None None O
7 None None O
( None None O
86 None None O
% None None O
) None None O
small None None O
- None None O
cell None None O
carcinomas None None O
, None None O
in None None O
15 None None O
of None None O
19 None None O
( None None O
79 None None O
% None None O
) None None O
large None None O
- None None O
cell None None O
carcinomas None None O
, None None O
and None None O
in None None O
none None None O
of None None O
3 None None O
( None None O
0 None None O
% None None O
) None None O
squamous None None O
cell None None O
carcinomas None None O
. None None O

TTF None None O
- None None O
1 None None O
staining None None O
is None None O
very None None O
reliable None None O
in None None O
discerning None None O
whether None None O
a None None O
brain None None O
metastasis None None O
has None None O
arisen None None O
from None None O
a None None O
pulmonary None None O
or None None O
nonpulmonary None None O
site None None O
, None None O
particularly None None O
when None None O
dealing None None O
with None None O
adenocarcinomas None None O
and None None O
large None None O
- None None O
cell None None O
carcinomas None None O
. None None O

TTF None None O
- None None O
1 None None O
immunohistochemistry None None O
could None None O
focus None None O
the None None O
search None None O
for None None O
the None None O
primary None None O
tumor None None O
for None None O
patients None None O
presenting None None O
with None None O
brain None None O
metastasis None None O
as None None O
the None None O
initial None None O
manifestation None None O
. None None O

Effect None None O
of None None O
platelet None None O
- None None O
rich None None O
plasma None None O
and None None O
fibrin None None O
glue None None O
on None None O
healing None None O
of None None O
critical None None O
- None None O
size None None O
calvarial None None O
bone None None O
defects None None O
. None None O

Despite None None O
the None None O
insufficient None None O
number None None O
of None None O
experimental None None O
studies None None O
, None None O
platelet None None O
- None None O
rich None None O
plasma None None O
( None None O
PRP None None O
) None None O
including None None O
high None None O
amounts None None O
of None None O
growth None None O
factors None None O
is None None O
introduced None None O
to None None O
clinical None None O
use None None O
rapidly None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
compare None None O
the None None O
effects None None O
of None None O
PRP None None O
and None None O
platelet None None O
- None None O
poor None None O
plasma None None O
( None None O
PPP None None O
) None None O
on None None O
healing None None O
of None None O
critical None None O
- None None O
size None None O
bone None None O
defects None None O
. None None O
Bilateral None None O
full None None O
- None None O
thickness None None O
, None None O
critical None None O
- None None O
size None None O
bone None None O
defects None None O
were None None O
created None None O
in None None O
the None None O
parietal None None O
bones None None O
of None None O
32 None None O
rabbits None None O
, None None O
which None None O
had None None O
been None None O
studied None None O
in None None O
4 None None O
groups None None O
. None None O

Saline None None O
, None None O
thrombin None None O
solution None None O
, None None O
PPP None None O
, None None O
and None None O
PRP None None O
were None None O
applied None None O
to None None O
the None None O
created None None O
defects None None O
before None None O
closure None None O
. None None O

Radiologic None None O
defect None None O
area None None O
measurement None None O
results None None O
at None None O
0 None None O
, None None O
4 None None O
, None None O
and None None O
16 None None O
weeks None None O
were None None O
compared None None O
between None None O
the None None O
groups None None O
. None None O

In None None O
addition None None O
, None None O
densities None None O
of None None O
the None None O
newly None None O
formed None None O
bones None None O
at None None O
16th None None O
week None None O
were None None O
studied None None O
. None None O

Histologic None None O
parameters None None O
( None None O
primary None None O
and None None O
secondary None None O
bone None None O
trabecula None None O
, None None O
neovascularization None None O
, None None O
and None None O
bone None None O
marrow None None O
and None None O
connective None None O
tissue None None O
formation None None O
) None None O
were None None O
compared None None O
between None None O
4 None None O
- None None O
and None None O
16 None None O
- None None O
week None None O
groups None None O
. None None O
More None None O
rapid None None O
decrease None None O
in None None O
defect None None O
size None None O
was None None O
observed None None O
in None None O
groups None None O
3 None None O
and None None O
4 None None O
than None None O
in None None O
groups None None O
1 None None O
and None None O
2 None None O
, None None O
both None None O
in None None O
the None None O
4th None None O
and None None O
16th None None O
weeks None None O
. None None O

Newly None None O
formed None None O
bone None None O
densities None None O
were None None O
also None None O
found None None O
to None None O
be None None O
higher None None O
in None None O
these None None O
2 None None O
groups None None O
. None None O

New None None O
bone None None O
formation None None O
was None None O
detected None None O
to None None O
be None None O
more None None O
rapid None None O
considering None None O
histologic None None O
parameters None None O
, None None O
in None None O
groups None None O
3 None None O
and None None O
4 None None O
at None None O
4th None None O
and None None O
16th None None O
weeks None None O
. None None O
Study None None O
demonstrates None None O
that None None O
PRP None None O
and None None O
PPP None None O
might None None O
have None None O
favorable None None O
effects None None O
on None None O
bone None None O
healing None None O
. None None O

Although None None O
we None None O
cannot None None O
reveal None None O
any None None O
statistical None None O
difference None None O
between None None O
these None None O
2 None None O
substances None None O
considering None None O
osteoinductive None None O
potential None None O
, None None O
PRP None None O
group None None O
has None None O
demonstrated None None O
superior None None O
results None None O
compared None None O
with None None O
fibrin None None O
glue None None O
group None None O
. None None O

Higher None None O
platelet None None O
concentrations None None O
may None None O
expose None None O
beneficial None None O
effects None None O
of None None O
PRP None None O
. None None O

Pathological None None O
animal None None O
models None None O
in None None O
the None None O
experimental None None O
evaluation None None O
of None None O
tumour None None O
microvasculature None None O
with None None O
magnetic None None O
resonance None None O
imaging None None O
. None None O

PURPOSE None None O
: None None O
The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
evaluate None None O
the None None O
applications None None O
of None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
MRI None None O
) None None O
, None None O
and None None O
in None None O
particular None None O
, None None O
dynamic None None O
contrast None None O
- None None O
enhanced None None O
MRI None None O
( None None O
DCE None None O
- None None O
MRI None None O
) None None O
, None None O
in None None O
the None None O
assessment None None O
of None None O
tumour None None O
microvasculature None None O
by None None O
means None None O
of None None O
animal None None O
tumour None None O
models None None O
evaluated None None O
before None None O
and None None O
after None None O
antiangiogenic None None O
treatment None None O
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O
Forty None None O
- None None O
two None None O
MRI None None O
exams None None O
were None None O
performed None None O
with None None O
intravascular None None O
contrast None None O
media None None O
in None None O
21 None None O
rats None None O
: None None O
tumours None None O
were None None O
induced None None O
by None None O
subcutaneous None None O
injection None None O
of None None O
colon None None O
carcinoma None None O
cells None None O
in None None O
7 None None O
rats None None O
and None None O
mammary None None O
adenocarcinoma None None O
cells None None O
in None None O
14 None None O
rats None None O
. None None O

Perfusion None None O
and None None O
permeability None None O
parameters None None O
of None None O
the None None O
implanted None None O
tumours None None O
were None None O
evaluated None None O
by None None O
using None None O
two None None O
contrast None None O
media None None O
( None None O
B22956 None None O
/ None None O
1 None None O
and None None O
Gd None None O
- None None O
DTPA37 None None O
- None None O
albumin None None O
) None None O
to None None O
establish None None O
response None None O
to None None O
treatment None None O
with None None O
two None None O
different None None O
antiangiogenic None None O
drugs None None O
( None None O
tamoxifen None None O
and None None O
SU6668 None None O
) None None O
. None None O

These None None O
parameters None None O
were None None O
correlated None None O
with None None O
histology None None O
to None None O
obtain None None O
a None None O
radiological None None O
- None None O
histological None None O
map None None O
of None None O
tumour None None O
microvasculature None None O
. None None O

RESULTS None None O
: None None O
DCE None None O
- None None O
MRI None None O
revealed None None O
greater None None O
enhancement None None O
in None None O
the None None O
peripheral None None O
area None None O
than None None O
in None None O
the None None O
central None None O
area None None O
in None None O
all None None O
the None None O
examined None None O
animal None None O
models None None O
. None None O

In None None O
the None None O
mammary None None O
carcinoma None None O
experiment None None O
, None None O
vascular None None O
permeability None None O
measured None None O
by None None O
means None None O
of None None O
B22956 None None O
/ None None O
1 None None O
in None None O
the None None O
animals None None O
treated None None O
with None None O
the None None O
antiangiogenic None None O
drug None None O
( None None O
0 None None O
. None None O
0043317 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
0040418 None None O
ml None None O
/ None None O
min None None O
( None None O
- None None O
1 None None O
) None None O
/ None None O
ml None None O
( None None O
- None None O
1 None None O
) None None O
) None None O
was None None O
significantly None None O
less None None O
than None None O
in None None O
untreated None None O
animals None None O
( None None O
0 None None O
. None None O
0090460 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
0043680 None None O
ml None None O
/ None None O
min None None O
( None None O
- None None O
1 None None O
) None None O
/ None None O
ml None None O
( None None O
- None None O
1 None None O
) None None O
) None None O
, None None O
whereas None None O
no None None O
significant None None O
difference None None O
was None None O
observed None None O
with None None O
Gd None None O
- None None O
DTPA None None O
- None None O
albumin None None O
( None None O
13 None None O
. None None O
14 None None O
+ None None O
/ None None O
- None None O
13 None None O
. None None O
94 None None O
ml None None O
/ None None O
min None None O
( None None O
- None None O
1 None None O
) None None O
/ None None O
ml None None O
( None None O
- None None O
1 None None O
) None None O
in None None O
treated None None O
animals None None O
and None None O
18 None None O
. None None O
07 None None O
+ None None O
/ None None O
- None None O
11 None None O
. None None O
92 None None O
ml None None O
/ None None O
min None None O
( None None O
- None None O
1 None None O
) None None O
/ None None O
ml None None O
( None None O
- None None O
1 None None O
) None None O
in None None O
untreated None None O
animals None None O
) None None O
. None None O

In None None O
the None None O
colon None None O
carcinoma None None O
experiment None None O
, None None O
mean None None O
permeability None None O
and None None O
perfusion None None O
decreased None None O
by None None O
51 None None O
% None None O
( None None O
from None None O
5 None None O
. None None O
2 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
1 None None O
to None None O
2 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
8 None None O
ml None None O
/ None None O
100 None None O
ml None None O
) None None O
and None None O
59 None None O
% None None O
( None None O
from None None O
0 None None O
. None None O
00165 None None O
+ None None O
/ None None O
- None None O
5 None None O
. None None O
1 None None O
to None None O
0 None None O
. None None O
0067 None None O
+ None None O
/ None None O
- None None O
4 None None O
. None None O
8 None None O
ml None None O
/ None None O
min None None O
( None None O
- None None O
1 None None O
) None None O
/ None None O
ml None None O
( None None O
- None None O
1 None None O
) None None O
of None None O
tissue None None O
) None None O
, None None O
respectively None None O
, None None O
in None None O
all None None O
animals None None O
after None None O
antiangiogenic None None O
drug None None O
administration None None O
. None None O

CONCLUSIONS None None O
: None None O
DCE None None O
- None None O
MRI None None O
permits None None O
a None None O
noninvasive None None O
evaluation None None O
of None None O
tumour None None O
microcirculation None None O
and None None O
in None None O
particular None None O
of None None O
its None None O
dynamic None None O
characteristics None None O
and None None O
vascularity None None O
before None None O
and None None O
after None None O
antiangiogenic None None O
treatment None None O
. None None O

SUMMARY None None O

Both None None O
the None None O
innate None None O
and None None O
adaptive None None O
immune None None O
subsystems None None O
are None None O
necessary None None O
to None None O
provide None None O
an None None O
effective None None O
immune None None O
response None None O
whether None None O
to None None O
an None None O
actual None None O
pathogenic None None O
agent None None O
or None None O
to None None O
an None None O
immunization None None O
. None None O

Further None None O
, None None O
effective None None O
immunizations None None O
must None None O
induce None None O
long None None O
- None None O
term None None O
stimulation None None O
of None None O
both None None O
the None None O
humoral None None O
and None None O
cell None None O
- None None O
mediated None None O
arms None None O
of None None O
the None None O
adaptive None None O
system None None O
by None None O
the None None O
production None None O
of None None O
effector None None O
cells None None O
for None None O
the None None O
current None None O
infection None None O
and None None O
memory None None O
cells None None O
for None None O
future None None O
infections None None O
with None None O
the None None O
pathogenic None None O
agent None None O
. None None O

At None None O
least None None O
seven None None O
different None None O
types None None O
of None None O
vaccines None None O
are None None O
currently None None O
in None None O
use None None O
or None None O
in None None O
development None None O
that None None O
produce None None O
this None None O
effective None None O
immunity None None O
and None None O
have None None O
contributed None None O
greatly None None O
to None None O
the None None O
prevention None None O
of None None O
infectious None None O
disease None None O
around None None O
the None None O
world None None O
. None None O

Requirement None None O
of None None O
estrogen None None O
receptor None None O
expression None None O
and None None O
function None None O
for None None O
[ None None O
12Val None None O
] None None O
K None None O
- None None O
Ras None None O
- None None O
mediated None None O
NIH3T3 None None I-Cell-line-name
cell None None O
transformation None None O
. None None O

We None None O
investigated None None O
the None None O
biological None None O
significance None None O
of None None O
estrogen None None O
receptors None None O
( None None O
ERs None None O
) None None O
in None None O
NIH3T3 None None I-Cell-line-name
cell None None O
transformation None None O
by None None O
the None None O
[ None None O
12Val None None O
] None None O
K None None O
- None None O
Ras None None O
mutant None None O
. None None O

This None None O
mutant None None O
enhanced None None O
the None None O
steady None None O
- None None O
level None None O
and None None O
transcriptional None None O
activity None None O
of None None O
ER None None O
. None None O

Coexpression None None O
of None None O
the None None O
progesterone None None O
receptor None None O
with None None O
mutant None None O
K None None O
- None None O
Ras None None O
led None None O
to None None O
suppression None None O
of None None O
tumorigenicity None None O
and None None O
inhibition None None O
of None None O
the None None O
activation None None O
of None None O
ER None None O
. None None O

The None None O
antisense None None O
oligomers None None O
complementary None None O
to None None O
the None None O
ER None None O
suppressed None None O
proliferation None None O
and None None O
transformed None None O
phenotypes None None O
of None None O
K12V None None I-Cell-line-name
cells None None O
. None None O

These None None O
observations None None O
support None None O
the None None O
importance None None O
of None None O
ER None None O
in None None O
Ras None None O
- None None O
mediated None None O
cell None None O
transformation None None O
. None None O

A None None O
novel None None O
role None None O
of None None O
thrombospondin None None O
- None None O
1 None None O
in None None O
cervical None None O
carcinogenesis None None O
: None None O
inhibit None None O
stroma None None O
reaction None None O
by None None O
inhibiting None None O
activated None None O
fibroblasts None None O
from None None O
invading None None O
cancer None None O
. None None O

Thrombospondin None None O
( None None O
TSP None None O
) None None O
- None None O
1 None None O
, None None O
a None None O
potent None None O
angiogenesis None None O
inhibitor None None O
, None None O
has None None O
been None None O
shown None None O
to None None O
exert None None O
different None None O
biological None None O
functions None None O
on None None O
various None None O
cell None None O
types None None O
. None None O

Here None None O
, None None O
we None None O
investigate None None O
the None None O
role None None O
of None None O
TSP None None O
- None None O
1 None None O
in None None O
tumor None None O
- None None O
stroma None None O
reaction None None O
, None None O
which None None O
is None None O
mainly None None O
characterized None None O
by None None O
fibroblast None None O
activation None None O
to None None O
create None None O
a None None O
permissive None None O
microenvironment None None O
for None None O
tumor None None O
progression None None O
. None None O

Immunohistochemistry None None O
examinations None None O
in None None O
the None None O
human None None O
surgical None None O
specimens None None O
have None None O
shown None None O
that None None O
a None None O
downregulation None None O
of None None O
TSP None None O
- None None O
1 None None O
during None None O
the None None O
progression None None O
of None None O
cervical None None O
carcinogenesis None None O
was None None O
accompanied None None O
by None None O
an None None O
emergence None None O
in None None O
the None None O
upregulation None None O
of None None O
stroma None None O
markers None None O
, None None O
alpha None None O
- None None O
smooth None None O
muscle None None O
actin None None O
( None None O
alpha None None O
- None None O
SMA None None O
) None None O
and None None O
desmin None None O
. None None O

Transfection None None O
of None None O
SiHa None None I-Cell-line-name
cervical None None O
cancer None None O
cells None None O
with None None O
a None None O
plasmid None None O
expressing None None O
the None None O
TSP None None O
- None None O
1 None None O
protein None None O
exhibited None None O
antiangiogenic None None O
activity None None O
in None None O
vitro None None O
and None None O
resulted None None O
in None None O
reduced None None O
tumor None None O
growth None None O
in None None O
severe None None O
combined None None O
immunodeficiency None None O
( None None O
SCID None None O
) None None O
mice None None O
, None None O
which None None O
was None None O
accompanied None None O
by None None O
a None None O
decrease None None O
in None None O
tumor None None O
vascularization None None O
and None None O
lower None None O
expressions None None O
of None None O
alpha None None O
- None None O
SMA None None O
and None None O
desmin None None O
than None None O
those None None O
in None None O
the None None O
vector None None O
controls None None O
. None None O

Transfection None None O
with None None O
TSP None None O
- None None O
1 None None O
and None None O
purified None None O
TSP None None O
- None None O
1 None None O
added None None O
to None None O
NIH3T3 None None I-Cell-line-name
cells None None O
did None None O
not None None O
alter None None O
the None None O
protein None None O
levels None None O
of None None O
alpha None None O
- None None O
SMA None None O
and None None O
desmin None None O
but None None O
significantly None None O
inhibited None None O
matrix None None O
metalloprotease None None O
- None None O
2 None None O
activity None None O
. None None O

Transforming None None O
growth None None O
factor None None O
- None None O
beta None None O
( None None O
TGF None None O
- None None O
beta None None O
) None None O
, None None O
a None None O
major None None O
factor None None O
in None None O
the None None O
activation None None O
of None None O
fibroblasts None None O
, None None O
increased None None O
alpha None None O
- None None O
SMA None None O
and None None O
desmin None None O
expression None None O
and None None O
the None None O
ability None None O
of None None O
cell None None O
migration None None O
and None None O
invasion None None O
in None None O
NIH3T3 None None I-Cell-line-name
cells None None O
. None None O

The None None O
increased None None O
migration None None O
ability None None O
and None None O
the None None O
invasive None None O
ability None None O
into None None O
tumor None None O
cluster None None O
of None None O
TGF None None O
- None None O
beta None None O
- None None O
treated None None O
NIH3T3 None None I-Cell-line-name
cells None None O
were None None O
dose None None O
dependently None None O
inhibited None None O
by None None O
TSP None None O
- None None O
1 None None O
. None None O

In None None O
contrast None None O
, None None O
ectopic None None O
TSP None None O
- None None O
1 None None O
expression None None O
in None None O
SiHa None None I-Cell-line-name
cells None None O
has None None O
little None None O
effect None None O
on None None O
the None None O
invasive None None O
ability None None O
of None None O
the None None O
NIH3T3 None None I-Cell-line-name
cells None None O
. None None O

Together None None O
, None None O
our None None O
findings None None O
demonstrate None None O
a None None O
novel None None O
role None None O
of None None O
TSP None None O
- None None O
1 None None O
to None None O
inhibit None None O
tumor None None O
- None None O
stroma None None O
reaction None None O
that None None O
could None None O
be None None O
attributed None None O
to None None O
the None None O
blockage None None O
of None None O
activated None None O
fibroblasts None None O
from None None O
invading None None O
cancer None None O
cells None None O
. None None O

Chemokine None None O
receptor None None O
CXCR4 None None O
expression None None O
, None None O
function None None O
, None None O
and None None O
clinical None None O
implications None None O
in None None O
gastric None None O
cancer None None O
. None None O

The None None O
chemokine None None O
receptor None None O
CXCR4 None None O
is None None O
associated None None O
with None None O
the None None O
biological None None O
behavior None None O
of None None O
cancer None None O
, None None O
but None None O
few None None O
studies None None O
have None None O
addressed None None O
the None None O
expression None None O
and None None O
function None None O
of None None O
CXCR4 None None O
in None None O
human None None O
gastric None None O
cancer None None O
and None None O
its None None O
impact None None O
on None None O
disease None None O
prognosis None None O
. None None O

We None None O
studied None None O
the None None O
expression None None O
of None None O
CXCR4 None None O
using None None O
RT None None O
- None None O
PCR None None O
, None None O
Western None None O
blotting None None O
, None None O
flow None None O
cytometry None None O
, None None O
and None None O
confocal None None O
microscopy None None O
in None None O
five None None O
gastric None None O
cancer None None O
cell None None O
lines None None O
. None None O

We None None O
also None None O
examined None None O
cell None None O
proliferation None None O
, None None O
migration None None O
, None None O
and None None O
anti None None O
- None None O
apoptotic None None O
activity None None O
in None None O
response None None O
to None None O
stromal None None O
cell None None O
- None None O
derived None None O
factor None None O
( None None O
SDF None None O
) None None O
- None None O
1alpha None None O
and None None O
evaluated None None O
SDF None None O
- None None O
1alpha None None O
/ None None O
CXCR4 None None O
signaling None None O
pathways None None O
. None None O

Furthermore None None O
, None None O
we None None O
investigated None None O
the None None O
correlation None None O
between None None O
CXCR4 None None O
expression None None O
and None None O
the None None O
clinical None None O
features None None O
of None None O
221 None None O
gastric None None O
cancer None None O
tissue None None O
samples None None O
. None None O

CXCR4 None None O
transcripts None None O
and None None O
proteins None None O
were None None O
detectable None None O
in None None O
all None None O
five None None O
gastric None None O
cancer None None O
cell None None O
lines None None O
. None None O

However None None O
, None None O
MKN None None I-Cell-line-name
- None None I-Cell-line-name
28 None None I-Cell-line-name
, None None O
MKN None None I-Cell-line-name
- None None I-Cell-line-name
45 None None I-Cell-line-name
, None None O
MKN None None I-Cell-line-name
- None None I-Cell-line-name
74 None None I-Cell-line-name
, None None O
and None None O
SNU16 None None I-Cell-line-name
cells None None O
did None None O
not None None O
express None None O
membrane None None O
CXCR4 None None O
. None None O

In None None O
contrast None None O
, None None O
KATO None None I-Cell-line-name
III None None I-Cell-line-name
cells None None O
expressed None None O
membrane None None O
CXCR4 None None O
. None None O

In None None O
these None None O
cells None None O
, None None O
SDF None None O
- None None O
1alpha None None O
- None None O
induced None None O
migration None None O
was None None O
observed None None O
and None None O
was None None O
blocked None None O
by None None O
AMD3100 None None O
, None None O
a None None O
specific None None O
inhibitor None None O
of None None O
CXCR4 None None O
. None None O

SDF None None O
- None None O
1alpha None None O
induced None None O
rapid None None O
phosphorylation None None O
of None None O
Erk1 None None O
/ None None O
2 None None O
MAPK None None O
but None None O
did None None O
not None None O
promote None None O
phosphorylation None None O
of None None O
Stat3 None None O
or None None O
Akt None None O
. None None O

Gastric None None O
cancer None None O
tissue None None O
samples None None O
expressed None None O
CXCR4 None None O
with None None O
variable None None O
intensities None None O
. None None O

Strong None None O
CXCR4 None None O
expression None None O
was None None O
significantly None None O
associated None None O
with None None O
lymph None None O
node None None O
metastases None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
028 None None O
) None None O
and None None O
higher None None O
stages None None O
III None None O
/ None None O
IV None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
047 None None O
) None None O
, None None O
and None None O
further None None O
tended None None O
to None None O
be None None O
correlated None None O
with None None O
a None None O
reduced None None O
5 None None O
- None None O
year None None O
survival None None O
rate None None O
( None None O
42 None None O
. None None O
6 None None O
% None None O
vs None None O
. None None O
53 None None O
. None None O
9 None None O
% None None O
; None None O
P None None O
= None None O
0 None None O
. None None O
1 None None O
) None None O
. None None O

In None None O
conclusion None None O
, None None O
CXCR4 None None O
expression None None O
is None None O
associated None None O
with None None O
gastric None None O
cancer None None O
cell None None O
migration None None O
in None None O
vitro None None O
, None None O
and None None O
strong None None O
expression None None O
of None None O
CXCR4 None None O
by None None O
gastric None None O
cancer None None O
cells None None O
is None None O
significantly None None O
associated None None O
with None None O
lymphatic None None O
metastasis None None O
in None None O
patients None None O
with None None O
gastric None None O
cancer None None O
, None None O
suggesting None None O
that None None O
CXCR4 None None O
plays None None O
an None None O
important None None O
role None None O
during None None O
gastric None None O
cancer None None O
progression None None O
. None None O

Pre None None O
- None None O
publication None None O
history None None O

The None None O
pre None None O
- None None O
publication None None O
history None None O
for None None O
this None None O
paper None None O
can None None O
be None None O
accessed None None O
here None None O
: None None O

http None None O
: None None O
/ None None O
/ None None O
www None None O
. None None O
biomedcentral None None O
. None None O
com None None O
/ None None O
1471 None None O
- None None O
2377 None None O
/ None None O
9 None None O
/ None None O
57 None None O
/ None None O
prepub None None O

Antishock None None O
trousers None None O
: None None O
a None None O
collective None None O
review None None O
. None None O

Antishock None None O
trousers None None O
have None None O
become None None O
an None None O
integral None None O
part None None O
of None None O
emergency None None O
medical None None O
care None None O
for None None O
many None None O
traumatic None None O
and None None O
life None None O
- None None O
threatening None None O
emergencies None None O
. None None O

This None None O
article None None O
represents None None O
a None None O
summary None None O
of None None O
the None None O
current None None O
state None None O
of None None O
knowledge None None O
concerning None None O
the None None O
use None None O
of None None O
this None None O
device None None O
. None None O

A None None O
brief None None O
history None None O
of None None O
the None None O
development None None O
of None None O
antishock None None O
garments None None O
is None None O
discussed None None O
. None None O

This None None O
is None None O
followed None None O
by None None O
a None None O
discussion None None O
of None None O
human None None O
clinical None None O
studies None None O
and None None O
results None None O
of None None O
clinical None None O
research None None O
on None None O
hemodynamics None None O
, None None O
respiration None None O
, None None O
use None None O
in None None O
head None None O
injury None None O
, None None O
and None None O
effects None None O
on None None O
vascular None None O
hemostasis None None O
. None None O

Indications None None O
, None None O
contraindications None None O
, None None O
complications None None O
, None None O
and None None O
recommended None None O
procedure None None O
for None None O
use None None O
are None None O
discussed None None O
. None None O

Based None None O
on None None O
randomized None None O
prospective None None O
studies None None O
, None None O
antishock None None O
garments None None O
have None None O
not None None O
, None None O
as None None O
yet None None O
, None None O
been None None O
shown None None O
to None None O
improve None None O
patient None None O
morbidity None None O
or None None O
mortality None None O
. None None O

Proper None None O
use None None O
of None None O
antishock None None O
garments None None O
requires None None O
an None None O
understanding None None O
of None None O
both None None O
their None None O
function None None O
and None None O
their None None O
limitations None None O
. None None O

Absence None None O
of None None O
microbiota None None O
( None None O
germ None None O
- None None O
free None None O
conditions None None O
) None None O
accelerates None None O
the None None O
atherosclerosis None None O
in None None O
ApoE None None O
- None None O
deficient None None O
mice None None O
fed None None O
standard None None O
low None None O
cholesterol None None O
diet None None O
. None None O

AIM None None O
: None None O

The None None O
aim None None O
of None None O
our None None O
work None None O
was None None O
to None None O
determine None None O
the None None O
influence None None O
of None None O
intestinal None None O
bacteria None None O
on None None O
the None None O
development None None O
of None None O
atherosclerotic None None O
lesions None None O
using None None O
apolipoprotein None None O
E None None O
( None None O
ApoE None None O
) None None O
- None None O
deficient None None O
knockout None None O
mice None None O
. None None O

METHODS None None O
: None None O

The None None O
experiments None None O
were None None O
performed None None O
on None None O
ApoE None None O
- None None O
/ None None O
- None None O
- None None O
deficient None None O
mouse None None O
strain None None O
C57BL None None O
/ None None O
6 None None O
, None None O
bred None None O
under None None O
germ None None O
- None None O
free None None O
( None None O
GF None None O
) None None O
conditions None None O
for None None O
two None None O
generations None None O
or None None O
under None None O
conventional None None O
conditions None None O
with None None O
defined None None O
microflora None None O
( None None O
CV None None O
) None None O
. None None O

The None None O
mice None None O
were None None O
fed None None O
a None None O
standard None None O
low None None O
cholesterol None None O
diet None None O
or None None O
cholesterol None None O
- None None O
rich None None O
diet None None O
for None None O
3 None None O
- None None O
4 None None O
months None None O
. None None O

We None None O
studied None None O
the None None O
development None None O
of None None O
advanced None None O
lesions None None O
in None None O
the None None O
thoracic None None O
and None None O
abdominal None None O
aorta None None O
by None None O
histological None None O
, None None O
morphometric None None O
and None None O
immunohistological None None O
methods None None O
. None None O

RESULTS None None O
: None None O

Conventionally None None O
reared None None O
ApoE None None O
- None None O
/ None None O
- None None O
mice None None O
( None None O
containing None None O
no None None O
pathogenic None None O
intestinal None None O
microbiota None None O
) None None O
and None None O
fed None None O
a None None O
standard None None O
low None None O
cholesterol None None O
diet None None O
in None None O
contrast None None O
to None None O
a None None O
high None None O
cholesterol None None O
diet None None O
did None None O
not None None O
develop None None O
atherosclerotic None None O
aortic None None O
plaques None None O
. None None O

In None None O
contrast None None O
, None None O
ApoE None None O
- None None O
/ None None O
- None None O
mice None None O
reared None None O
under None None O
germfree None None O
conditions None None O
for None None O
2 None None O
generations None None O
and None None O
fed None None O
a None None O
low None None O
cholesterol None None O
diet None None O
exhibited None None O
atherosclerotic None None O
plaques None None O
in None None O
the None None O
aorta None None O
. None None O

Characteristic None None O
lipid None None O
deposition None None O
with None None O
foam None None O
cells None None O
and None None O
macrophages None None O
was None None O
found None None O
in None None O
their None None O
arterial None None O
walls None None O
. None None O

CONCLUSION None None O
: None None O

In None None O
contrast None None O
to None None O
the None None O
absence None None O
of None None O
atherosclerotic None None O
plaques None None O
in None None O
conventionally None None O
reared None None O
ApoE None None O
- None None O
deficient None None O
mice None None O
, None None O
germ None None O
- None None O
free None None O
ApoE None None O
- None None O
/ None None O
- None None O
mice None None O
consuming None None O
the None None O
same None None O
low None None O
cholesterol None None O
standard None None O
diet None None O
developed None None O
atherosclerotic None None O
plaques None None O
in None None O
the None None O
aorta None None O
. None None O

Differences None None O
in None None O
atherosclerotic None None O
plaques None None O
between None None O
GF None None O
and None None O
CV None None O
ApoE None None O
- None None O
/ None None O
- None None O
mice None None O
are None None O
not None None O
so None None O
apparent None None O
when None None O
mice None None O
are None None O
fed None None O
a None None O
high None None O
cholesterol None None O
diet None None O
. None None O

Our None None O
findings None None O
thus None None O
document None None O
the None None O
protective None None O
effect None None O
of None None O
microbiota None None O
( None None O
commensal None None O
bacteria None None O
) None None O
on None None O
atherosclerosis None None O
development None None O
. None None O

Background None None O

Opioid None None O
analgesics None None O
are None None O
generally None None O
used None None O
to None None O
combat None None O
the None None O
pain None None O
associated None None O
with None None O
cancerous None None O
conditions None None O
. None None O

These None None O
agents None None O
not None None O
only None None O
inhibit None None O
respiratory None None O
function None None O
and None None O
cause None None O
constipation None None O
, None None O
but None None O
also None None O
induce None None O
other None None O
significant None None O
side None None O
effects None None O
such None None O
as None None O
addiction None None O
and None None O
tolerance None None O
, None None O
all None None O
of None None O
which None None O
further None None O
contribute None None O
to None None O
a None None O
reduced None None O
quality None None O
of None None O
life None None O
for None None O
cancer None None O
patients None None O
. None None O

Thus None None O
, None None O
in None None O
the None None O
present None None O
study None None O
, None None O
the None None O
effects None None O
of None None O
electro None None O
- None None O
acupuncture None None O
treatment None None O
( None None O
EA None None O
) None None O
on None None O
mechanical None None O
allodynia None None O
were None None O
examined None None O
in None None O
a None None O
cancer None None O
pain None None O
mouse None None O
model None None O
. None None O

In None None O
vitro None None O
cytotoxic None None O
potential None None O
and None None O
mechanism None None O
of None None O
action None None O
of None None O
selected None None O
coumarins None None O
, None None O
using None None O
human None None O
renal None None O
cell None None O
lines None None O
. None None O

This None None O
study None None O
determined None None O
the None None O
selective None None O
cytotoxicity None None O
of None None O
eight None None O
coumarin None None O
compounds None None O
to None None O
human None None O
renal None None O
carcinoma None None O
cells None None O
, None None O
relative None None O
to None None O
non None None O
- None None O
carcinoma None None O
proximal None None O
tubular None None O
cells None None O
. None None O

Selectivity None None O
cytotoxicity None None O
was None None O
observed None None O
following None None O
exposure None None O
to None None O
6 None None O
- None None O
nitro None None O
- None None O
7 None None O
- None None O
hydroxycoumarin None None O
( None None O
6 None None O
- None None O
NO None None O
( None None O
2 None None O
) None None O
- None None O
7 None None O
- None None O
OHC None None O
) None None O
and None None O
7 None None O
, None None O
8 None None O
- None None O
dihydroxycoumarin None None O
( None None O
7 None None O
, None None O
8 None None O
- None None O
OHC None None O
) None None O
. None None O

6 None None O
- None None O
NO None None O
( None None O
2 None None O
) None None O
- None None O
7 None None O
- None None O
OHC None None O
induced None None O
cytotoxicity None None O
was None None O
irreversible None None O
in None None O
both None None O
cell None None O
lines None None O
, None None O
unlike None None O
7 None None O
, None None O
8 None None O
- None None O
OHC None None O
, None None O
which None None O
was None None O
reversible None None O
in None None O
the None None O
carcinoma None None O
cells None None O
only None None O
. None None O

Mobility None None O
shift None None O
and None None O
BrdU None None O
incorporation None None O
assays None None O
showed None None O
that None None O
both None None O
compounds None None O
did None None O
not None None O
intercalate None None O
DNA None None O
but None None O
had None None O
a None None O
concentration None None O
- None None O
dependent None None O
inhibitory None None O
effect None None O
on None None O
its None None O
synthesis None None O
. None None O

All None None O
coumarins None None O
studied None None O
were None None O
found None None O
to None None O
be None None O
non None None O
- None None O
mutagenic None None O
using None None O
the None None O
standard None None O
Ames None None O
test None None O
. None None O

These None None O
results None None O
would None None O
suggest None None O
that None None O
6 None None O
- None None O
NO None None O
( None None O
2 None None O
) None None O
- None None O
7 None None O
- None None O
OHC None None O
and None None O
7 None None O
, None None O
8 None None O
- None None O
OHC None None O
might None None O
have None None O
a None None O
therapeutic None None O
role None None O
to None None O
play None None O
in None None O
the None None O
treatment None None O
of None None O
renal None None O
cell None None O
carcinoma None None O
. None None O

The None None O
myoadipose None None O
flap None None O
: None None O
a None None O
new None None O
composite None None O
. None None O

A None None O
prefabricated None None O
composite None None O
fat None None O
flap None None O
consisting None None O
of None None O
muscle None None O
woven None None O
into None None O
an None None O
anatomically None None O
distinct None None O
fat None None O
pad None None O
was None None O
studied None None O
in None None O
a None None O
rabbit None None O
model None None O
. None None O

In None None O
17 None None O
rabbits None None O
, None None O
a None None O
2 None None O
- None None O
cm None None O
strip None None O
of None None O
latissimus None None O
dorsi None None O
was None None O
woven None None O
into None None O
the None None O
parascapular None None O
fat None None O
pad None None O
on None None O
one None None O
side None None O
, None None O
with None None O
the None None O
contralateral None None O
fat None None O
pad None None O
serving None None O
as None None O
a None None O
control None None O
. None None O

At None None O
3 None None O
weeks None None O
, None None O
the None None O
endogenous None None O
blood None None O
supply None None O
of None None O
both None None O
the None None O
control None None O
and None None O
the None None O
experimental None None O
fat None None O
pads None None O
was None None O
isolated None None O
and None None O
ligated None None O
, None None O
and None None O
the None None O
composite None None O
fat None None O
/ None None O
muscle None None O
flap None None O
was None None O
transferred None None O
to None None O
the None None O
chest None None O
wall None None O
. None None O

At None None O
6 None None O
weeks None None O
, None None O
animals None None O
were None None O
killed None None O
, None None O
and None None O
flaps None None O
were None None O
analyzed None None O
for None None O
length None None O
, None None O
width None None O
, None None O
and None None O
weight None None O
; None None O
perfused None None O
with None None O
fluorescein None None O
or None None O
lead None None O
oxide None None O
; None None O
and None None O
examined None None O
histologically None None O
. None None O

Significant None None O
differences None None O
were None None O
found None None O
between None None O
the None None O
control None None O
and None None O
experimental None None O
fat None None O
pads None None O
with None None O
regard None None O
to None None O
weight None None O
and None None O
length None None O
. None None O

Experimental None None O
flaps None None O
were None None O
found None None O
to None None O
be None None O
perfused None None O
fully None None O
with None None O
fluorescein None None O
and None None O
lead None None O
oxide None None O
; None None O
control None None O
fat None None O
pads None None O
were None None O
found None None O
not None None O
to None None O
be None None O
perfused None None O
. None None O

The None None O
lead None None O
oxide None None O
group None None O
revealed None None O
extensive None None O
growth None None O
of None None O
blood None None O
vessels None None O
from None None O
the None None O
latissimus None None O
graft None None O
into None None O
the None None O
experimental None None O
fat None None O
pad None None O
. None None O

No None None O
vessels None None O
were None None O
visualized None None O
in None None O
the None None O
controls None None O
. None None O

Finally None None O
, None None O
sections None None O
of None None O
the None None O
control None None O
and None None O
experimental None None O
flaps None None O
were None None O
analyzed None None O
histologically None None O
. None None O

A None None O
preponderance None None O
of None None O
viable None None O
fat None None O
, None None O
with None None O
evidence None None O
of None None O
neovascularization None None O
, None None O
was None None O
found None None O
in None None O
experimental None None O
flaps None None O
, None None O
compared None None O
with None None O
the None None O
necrotic None None O
fat None None O
that None None O
characterized None None O
the None None O
controls None None O
. None None O

We None None O
conclude None None O
that None None O
prefabrication None None O
of None None O
a None None O
fat None None O
flap None None O
is None None O
possible None None O
and None None O
may None None O
have None None O
extensive None None O
application None None O
in None None O
various None None O
areas None None O
of None None O
plastic None None O
surgery None None O
. None None O

Participation None None O
of None None O
p53 None None O
cellular None None O
tumour None None O
antigen None None O
in None None O
transformation None None O
of None None O
normal None None O
embryonic None None O
cells None None O
. None None O

The None None O
cellular None None O
tumour None None O
antigen None None O
p53 None None O
is None None O
found None None O
at None None O
elevated None None O
levels None None O
in None None O
a None None O
wide None None O
variety None None O
of None None O
transformed None None O
cells None None O
( None None O
for None None O
reviews None None O
see None None O
refs None None O
1 None None O
, None None O
2 None None O
) None None O
. None None O

Very None None O
little None None O
is None None O
yet None None O
known None None O
about None None O
the None None O
precise None None O
relationship None None O
of None None O
p53 None None O
to None None O
malignant None None O
transformation None None O
. None None O

Although None None O
the None None O
increase None None O
in None None O
p53 None None O
levels None None O
could None None O
be None None O
a None None O
secondary None None O
by None None O
- None None O
product None None O
of None None O
the None None O
transformed None None O
state None None O
, None None O
it None None O
is None None O
equally None None O
possible None None O
that None None O
p53 None None O
is None None O
actively None None O
involved None None O
in None None O
altering None None O
cellular None None O
growth None None O
properties None None O
, None None O
especially None None O
as None None O
it None None O
has None None O
been None None O
implicated None None O
in None None O
the None None O
regulation None None O
of None None O
normal None None O
cell None None O
proliferation None None O
. None None O

We None None O
sought None None O
to None None O
test None None O
whether None None O
p53 None None O
could None None O
behave None None O
in None None O
a None None O
manner None None O
similar None None O
to None None O
known None None O
genes None None O
in None None O
a None None O
biological None None O
test None None O
system None None O
, None None O
and None None O
we None None O
demonstrate None None O
here None None O
that None None O
p53 None None O
can None None O
cooperate None None O
with None None O
the None None O
activated None None O
Ha None None O
- None None O
ras None None O
oncogene None None O
to None None O
transform None None O
normal None None O
embryonic None None O
cells None None O
. None None O

The None None O
resultant None None O
foci None None O
contain None None O
cells None None O
of None None O
a None None O
markedly None None O
altered None None O
morphology None None O
which None None O
produce None None O
high None None O
levels None None O
of None None O
p53 None None O
. None None O

Cell None None O
lines None None O
established None None O
from None None O
such None None O
foci None None O
elicit None None O
tumours None None O
in None None O
syngeneic None None O
animals None None O
. None None O

SUMMARY None None O

This None None O
is None None O
a None None O
prospective None None O
study None None O
carried None None O
out None None O
to None None O
determine None None O
the None None O
outcome None None O
of None None O
patients None None O
who None None O
refuse None None O
cystectomy None None O
after None None O
receiving None None O
neoadjuvant None None O
chemotherapy None None O
for None None O
muscle None None O
- None None O
invasive None None O
bladder None None O
cancer None None O
. None None O

Sixty None None O
- None None O
three None None O
patients None None O
were None None O
evaluated None None O
between None None O
1995 None None O
and None None O
2001 None None O
who None None O
declined None None O
to None None O
undergo None None O
a None None O
planned None None O
cystectomy None None O
because None None O
they None None O
achieved None None O
a None None O
complete None None O
clinical None None O
response None None O
to None None O
neoadjuvant None None O
cisplatin None None O
- None None O
based None None O
chemotherapy None None O
. None None O

Herr None None O
assessed None None O
patient None None O
, None None O
tumor None None O
and None None O
treatment None None O
features None None O
for None None O
a None None O
median None None O
follow None None O
- None None O
up None None O
of None None O
86 None None O
months None None O
, None None O
all None None O
patients None None O
being None None O
followed None None O
- None None O
up None None O
for None None O
more None None O
than None None O
5 None None O
years None None O
. None None O

Forty None None O
patients None None O
( None None O
64 None None O
% None None O
) None None O
survived None None O
, None None O
with None None O
54 None None O
% None None O
of None None O
them None None O
having None None O
an None None O
intact None None O
functioning None None O
bladder None None O
. None None O

The None None O
number None None O
and None None O
size None None O
of None None O
invasive None None O
tumors None None O
were None None O
strongly None None O
associated None None O
with None None O
the None None O
overall None None O
survival None None O
. None None O

The None None O
most None None O
significant None None O
treatment None None O
variable None None O
predicting None None O
better None None O
survival None None O
was None None O
complete None None O
resection None None O
of None None O
the None None O
invasive None None O
tumor None None O
on None None O
restaging None None O
transurethral None None O
resection None None O
( None None O
TUR None None O
) None None O
before None None O
starting None None O
chemotherapy None None O
. None None O

Of None None O
23 None None O
patients None None O
( None None O
36 None None O
% None None O
) None None O
who None None O
subsequently None None O
died None None O
of None None O
disease None None O
, None None O
19 None None O
( None None O
30 None None O
% None None O
) None None O
relapsed None None O
with None None O
invasive None None O
cancer None None O
in None None O
the None None O
bladder None None O
. None None O

Over None None O
90 None None O
% None None O
of None None O
the None None O
surviving None None O
patients None None O
had None None O
solitary None None O
, None None O
small None None O
and None None O
low None None O
- None None O
stage None None O
invasive None None O
tumors None None O
completely None None O
resected None None O
and None None O
83 None None O
% None None O
survived None None O
without None None O
relapses None None O
in None None O
the None None O
bladder None None O
. None None O
[ None None O
1 None None O
] None None O

Range None None O
of None None O
motion None None O
limitation None None O
after None None O
rotator None None O
cuff None None O
repair None None O
. None None O

HYPOTHESIS None None O
: None None O

This None None O
study None None O
was None None O
conducted None None O
to None None O
identify None None O
preoperative None None O
factors None None O
correlating None None O
with None None O
limited None None O
motion None None O
after None None O
rotator None None O
cuff None None O
repair None None O
( None None O
RCR None None O
) None None O
and None None O
to None None O
evaluate None None O
the None None O
affect None None O
of None None O
loss None None O
of None None O
motion None None O
on None None O
outcome None None O
. None None O

We None None O
hypothesized None None O
that None None O
patients None None O
with None None O
preoperative None None O
ROM None None O
loss None None O
, None None O
diabetes None None O
, None None O
and None None O
workman None None O
' None None O
s None None O
compensation None None O
claims None None O
would None None O
exhibit None None O
postoperative None None O
ROM None None O
loss None None O
at None None O
3 None None O
months None None O
. None None O

MATERIAL None None O
AND None None O
METHODS None None O
: None None O

Preoperative None None O
and None None O
postoperative None None O
evaluations None None O
, None None O
including None None O
outcomes None None O
assessment None None O
and None None O
physical None None O
examination None None O
parameters None None O
, None None O
were None None O
reviewed None None O
for None None O
345 None None O
patients None None O
who None None O
underwent None None O
RCR None None O
. None None O

Correlations None None O
between None None O
demographic None None O
, None None O
physical None None O
examination None None O
, None None O
and None None O
surgical None None O
variables None None O
and None None O
postoperative None None O
limitation None None O
of None None O
motion None None O
and None None O
need None None O
for None None O
capsular None None O
release None None O
were None None O
determined None None O
. None None O

RESULTS None None O
: None None O

At None None O
3 None None O
- None None O
month None None O
follow None None O
- None None O
up None None O
, None None O
mean None None O
active None None O
forward None None O
elevation None None O
( None None O
AFE None None O
) None None O
, None None O
active None None O
external None None O
rotation None None O
( None None O
AER None None O
) None None O
, None None O
and None None O
passive None None O
internal None None O
rotation None None O
( None None O
PIR None None O
) None None O
were None None O
90 None None O
% None None O
, None None O
78 None None O
% None None O
, None None O
and None None O
80 None None O
% None None O
of None None O
the None None O
contralateral None None O
side None None O
. None None O

Limitation None None O
of None None O
preoperative None None O
motion None None O
correlated None None O
with None None O
limitation None None O
of None None O
postoperative None None O
AFE None None O
, None None O
AER None None O
, None None O
and None None O
PIR None None O
( None None O
P None None O
< None None O
. None None O
001 None None O
) None None O
. None None O

Forty None None O
- None None O
seven None None O
patients None None O
considered None None O
clinically None None O
stiff None None O
were None None O
followed None None O
at None None O
1 None None O
year None None O
postoperatively None None O
. None None O

Three None None O
patients None None O
required None None O
arthroscopic None None O
capsular None None O
release None None O
for None None O
persistent None None O
range None None O
of None None O
motion None None O
loss None None O
. None None O

CONCLUSION None None O
: None None O

Early None None O
postoperative None None O
limitation None None O
of None None O
motion None None O
after None None O
RCR None None O
is None None O
associated None None O
with None None O
restricted None None O
preoperative None None O
motion None None O
. None None O

Other None None O
factors None None O
, None None O
including None None O
diabetes None None O
mellitus None None O
and None None O
worker None None O
' None None O
s None None O
compensation None None O
claim None None O
, None None O
are None None O
also None None O
associated None None O
with None None O
range None None O
of None None O
motion None None O
loss None None O
. None None O

Most None None O
shoulders None None O
with None None O
early None None O
motion None None O
loss None None O
recover None None O
motion None None O
and None None O
rarely None None O
require None None O
capsular None None O
release None None O
. None None O

Conclusion None None O

Artificial None None O
addition None None O
of None None O
siderophores None None O
and None None O
HSLs None None O
may None None O
be None None O
a None None O
possible None None O
method None None O
to None None O
aid None None O
in None None O
the None None O
identification None None O
and None None O
isolation None None O
of None None O
marine None None O
bacterial None None O
species None None O
which None None O
are None None O
thought None None O
to None None O
be None None O
unknown None None O
. None None O

Confocal None None O
and None None O
scanning None None O
microscopic None None O
images None None O
of None None O
mammoth None None O
' None None O
s None None O
and None None O
human None None O
hair None None O
. None None O

Taphonomic None None O
changes None None O
, None None O
indicated None None O
by None None O
arrow None None O
- None None O
heads None None O
and None None O
straight None None O
white None None O
arrow None None O
in None None O
the None None O
confocal None None O
image None None O
. None None O

Bacterial None None O
- None None O
fungal None None O
colonies None None O
are None None O
shown None None O
by None None O
broken None None O
arrows None None O
. None None O

Red None None O
arrow None None O
indicates None None O
space None None O
between None None O
cuticle None None O
and None None O
hair None None O
shaft None None O
due None None O
to None None O
shrinkage None None O
. None None O

Extensive None None O
taphonomic None None O
changes None None O
in None None O
YUK None None O
are None None O
evident None None O
. None None O

Note None None O
the None None O
preservation None None O
of None None O
the None None O
cuticle None None O
in None None O
the None None O
human None None O
hair None None O
in None None O
contrast None None O
to None None O
the None None O
craters None None O
in None None O
the None None O
cuticles None None O
of None None O
the None None O
mammoth None None O
' None None O
s None None O
hair None None O
. None None O

Bacterial None None O
biofilms None None O
are None None O
a None None O
feature None None O
of None None O
human None None O
hair None None O
; None None O
mammoth None None O
' None None O
s None None O
hair None None O
was None None O
protected None None O
from None None O
bacterial None None O
invasion None None O
in None None O
permafrost None None O
. None None O

Tumor None None O
Angiogenesis None None O
: None None O
Initiation None None O
and None None O
Targeting None None O
- None None O
Therapeutic None None O
Targeting None None O
of None None O
an None None O
FGF None None O
- None None O
Binding None None O
Protein None None O
, None None O
an None None O
Angiogenic None None O
Switch None None O
Molecule None None O
, None None O
and None None O
Indicator None None O
of None None O
Early None None O
Stages None None O
of None None O
Gastrointestinal None None O
Adenocarcinomas None None O
- None None O
. None None O

Tumor None None O
angiogenesis None None O
has None None O
been None None O
related None None O
to None None O
the None None O
initiation None None O
as None None O
well None None O
as None None O
progression None None O
toward None None O
more None None O
aggressive None None O
behavior None None O
of None None O
human None None O
tumors None None O
. None None O

In None None O
particular None None O
, None None O
the None None O
activity None None O
of None None O
angiogenic None None O
factors None None O
is None None O
crucial None None O
for None None O
tumor None None O
progression None None O
. None None O

We None None O
previously None None O
characterized None None O
a None None O
secreted None None O
fibroblast None None O
growth None None O
factor None None O
- None None O
binding None None O
protein None None O
( None None O
FGF None None O
- None None O
BP None None O
) None None O
as None None O
a None None O
chaperone None None O
molecule None None O
, None None O
which None None O
binds None None O
to None None O
various None None O
FGFs None None O
, None None O
enhances None None O
FGF None None O
- None None O
mediated None None O
biochemical None None O
and None None O
biologic None None O
events None None O
and None None O
importantly None None O
is None None O
a None None O
crucial None None O
rate None None O
- None None O
limiting None None O
factor None None O
for None None O
tumor None None O
- None None O
dependent None None O
angiogenesis None None O
. None None O

We None None O
generated None None O
monoclonal None None O
antibodies None None O
that None None O
target None None O
FGF None None O
- None None O
BP None None O
protein None None O
and None None O
used None None O
them None None O
as None None O
a None None O
tool None None O
to None None O
evaluate None None O
frequency None None O
and None None O
pattern None None O
of None None O
FGF None None O
- None None O
BP None None O
expression None None O
during None None O
the None None O
malignant None None O
progression None None O
of None None O
pancreas None None O
and None None O
colorectal None None O
carcinoma None None O
in None None O
archival None None O
tissue None None O
samples None None O
. None None O

We None None O
found None None O
that None None O
FGF None None O
- None None O
BP None None O
is None None O
dramatically None None O
upregulated None None O
during None None O
the None None O
initiation None None O
of None None O
colorectal None None O
and None None O
pancreatic None None O
adenocarcinoma None None O
. None None O

Crucial None None O
genetic None None O
events None None O
underlying None None O
the None None O
initiation None None O
and None None O
progression None None O
of None None O
colorectal None None O
and None None O
pancreatic None None O
adenocarcinoma None None O
with None None O
a None None O
particular None None O
focus None None O
on None None O
the None None O
modulation None None O
of None None O
angiogenesis None None O
and None None O
antiangiogenic None None O
therapies None None O
are None None O
discussed None None O
. None None O

We None None O
propose None None O
that None None O
the None None O
upregulation None None O
of None None O
the None None O
secreted None None O
FGF None None O
- None None O
BP None None O
protein None None O
during None None O
early None None O
phases None None O
of None None O
pancreas None None O
and None None O
colon None None O
cancer None None O
could None None O
make None None O
this None None O
protein None None O
a None None O
possible None None O
serum None None O
marker None None O
indicating None None O
the None None O
presence None None O
of None None O
high None None O
- None None O
risk None None O
premalignant None None O
lesions None None O
. None None O

Furthermore None None O
, None None O
the None None O
biological None None O
activity None None O
of None None O
FGF None None O
- None None O
BP None None O
is None None O
neutralized None None O
by None None O
monoclonal None None O
antibodies None None O
suggesting None None O
the None None O
potential None None O
for None None O
antibody None None O
- None None O
based None None O
therapeutic None None O
targeting None None O
. None None O

Protein None None O
expression None None O
profile None None O
of None None O
primary None None O
human None None O
squamous None None O
cell None None O
lung None None O
carcinomas None None O
indicative None None O
of None None O
the None None O
incidence None None O
of None None O
metastases None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
investigation None None O
was None None O
to None None O
evaluate None None O
firstly None None O
whether None None O
different None None O
protein None None O
expression None None O
patterns None None O
exist None None O
in None None O
primary None None O
squamous None None O
cell None None O
lung None None O
carcinomas None None O
of None None O
patients None None O
with None None O
and None None O
without None None O
lymph None None O
node None None O
involvement None None O
and None None O
secondly None None O
, None None O
whether None None O
or None None O
not None None O
different None None O
patterns None None O
exist None None O
in None None O
tumours None None O
with None None O
positive None None O
lymph None None O
nodes None None O
. None None O

For None None O
this None None O
reason None None O
, None None O
formalin None None O
- None None O
fixed None None O
, None None O
paraffin None None O
- None None O
embedded None None O
specimens None None O
from None None O
130 None None O
patients None None O
with None None O
squamous None None O
cell None None O
lung None None O
carcinomas None None O
were None None O
analyzed None None O
by None None O
immunohistochemistry None None O
. None None O

In None None O
a None None O
first None None O
step None None O
, None None O
proteins None None O
were None None O
selected None None O
which None None O
showed None None O
a None None O
relationship None None O
to None None O
lymph None None O
node None None O
involvement None None O
. None None O

The None None O
expression None None O
of None None O
JUN None None O
, None None O
ERBB2 None None O
, None None O
MYC None None O
, None None O
cyclin None None O
D None None O
, None None O
PCNA None None O
, None None O
bFGF None None O
, None None O
VEGF None None O
and None None O
Hsp70 None None O
proteins None None O
revealed None None O
a None None O
positive None None O
correlation None None O
to None None O
lymph None None O
node None None O
involvement None None O
. None None O

In None None O
contrast None None O
, None None O
caspase None None O
- None None O
3 None None O
, None None O
Fas None None O
ligand None None O
, None None O
Fas None None O
/ None None O
CD95 None None O
, None None O
and None None O
PAI None None O
showed None None O
an None None O
inverse None None O
correlation None None O
to None None O
lymph None None O
node None None O
involvement None None O
. None None O

In None None O
a None None O
second None None O
step None None O
, None None O
these None None O
parameters None None O
were None None O
further None None O
analyzed None None O
by None None O
hierarchical None None O
cluster None None O
analyses None None O
. None None O

The None None O
resulting None None O
clusters None None O
were None None O
correlated None None O
to None None O
patients None None O
with None None O
or None None O
without None None O
lymph None None O
node None None O
involvement None None O
. None None O

The None None O
data None None O
show None None O
that None None O
different None None O
protein None None O
expression None None O
patterns None None O
exist None None O
between None None O
primary None None O
squamous None None O
cell None None O
lung None None O
carcinomas None None O
with None None O
and None None O
without None None O
lymph None None O
node None None O
involvement None None O
and None None O
within None None O
carcinomas None None O
with None None O
lymph None None O
node None None O
involvement None None O
. None None O

The None None O
data None None O
suggest None None O
that None None O
various None None O
metastasis None None O
profiles None None O
exist None None O
. None None O

Involvement None None O
of None None O
de None None O
novo None None O
ceramide None None O
synthesis None None O
in None None O
radiocontrast None None O
- None None O
induced None None O
renal None None O
tubular None None O
cell None None O
injury None None O
. None None O

We None None O
reported None None O
previously None None O
that None None O
various None None O
radiocontrast None None O
media None None O
cause None None O
apoptosis None None O
in None None O
porcine None None O
proximal None None O
tubular None None O
( None None O
LLC None None O
- None None O
PK None None O
( None None O
1 None None O
) None None O
) None None O
cells None None O
, None None O
in None None O
which None None O
reduction None None O
in None None O
B None None O
- None None O
cell None None O
lymphoma None None O
( None None O
Bcl None None O
) None None O
- None None O
2 None None O
expression None None O
and None None O
caspase None None O
- None None O
3 None None O
activation None None O
are None None O
implicated None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
investigated None None O
a None None O
role None None O
for None None O
ceramide None None O
in None None O
radiocontrast None None O
media None None O
- None None O
induced None None O
apoptosis None None O
in None None O
renal None None O
tubular None None O
cells None None O
. None None O

LLC None None O
- None None O
PK None None O
( None None O
1 None None O
) None None O
cells None None O
were None None O
exposed None None O
to None None O
radiocontrast None None O
media None None O
for None None O
30 None None O
min None None O
, None None O
followed None None O
by None None O
incubation None None O
for None None O
24 None None O
h None None O
in None None O
normal None None O
medium None None O
. None None O

Cell None None O
viability None None O
was None None O
assessed None None O
by None None O
2 None None O
- None None O
( None None O
2 None None O
- None None O
methoxy None None O
- None None O
4 None None O
- None None O
nitrophenyl None None O
) None None O
- None None O
3 None None O
- None None O
( None None O
4 None None O
- None None O
nitrophenyl None None O
) None None O
- None None O
5 None None O
- None None O
( None None O
2 None None O
, None None O
4 None None O
- None None O
disulfophenyl None None O
) None None O
- None None O
2H None None O
- None None O
tetrazolium None None O
monosodium None None O
salt None None O
assay None None O
, None None O
while None None O
apoptosis None None O
was None None O
determined None None O
by None None O
terminal None None O
deoxynucleotidyl None None O
transferase None None O
- None None O
mediated None None O
dUTP None None O
nick None None O
end None None O
labeling None None O
stain None None O
. None None O

Immunofluorescent None None O
stains None None O
were None None O
performed None None O
using None None O
antibodies None None O
against None None O
phosphorylated None None O
Akt None None O
( None None O
pAkt None None O
) None None O
and None None O
cAMP None None O
response None None O
element None None O
binding None None O
protein None None O
( None None O
CREB None None O
) None None O
( None None O
pCREB None None O
) None None O
, None None O
and None None O
ceramide None None O
. None None O

The None None O
mRNA None None O
expression None None O
and None None O
protein None None O
content None None O
of None None O
Bcl None None O
- None None O
2 None None O
were None None O
determined None None O
by None None O
reverse None None O
transcriptase None None O
- None None O
polymerase None None O
chain None None O
reaction None None O
and None None O
enzyme None None O
immunoassay None None O
, None None O
respectively None None O
. None None O

In None None O
vivo None None O
model None None O
of None None O
contrast None None O
- None None O
induced None None O
renal None None O
injury None None O
was None None O
induced None None O
in None None O
mice None None O
with None None O
unilateral None None O
renal None None O
occlusion None None O
. None None O

The None None O
cell None None O
injury None None O
induced None None O
by None None O
the None None O
nonionic None None O
radiocontrast None None O
medium None None O
ioversol None None O
was None None O
reversed None None O
by None None O
inhibiting None None O
de None None O
novo None None O
ceramide None None O
synthesis None None O
with None None O
fumonisin None None O
B None None O
( None None O
1 None None O
) None None O
( None None O
FB None None O
( None None O
1 None None O
) None None O
) None None O
and None None O
L None None O
- None None O
cycloserine None None O
, None None O
but None None O
not None None O
by None None O
suppressing None None O
sphingomyelin None None O
breakdown None None O
with None None O
D609 None None O
. None None O

FB None None O
( None None O
1 None None O
) None None O
reversed None None O
ioversol None None O
- None None O
induced None None O
decrease None None O
in None None O
the None None O
immunoreactivities None None O
of None None O
pAkt None None O
and None None O
pCREB None None O
, None None O
reduction None None O
in None None O
Bcl None None O
- None None O
2 None None O
expression None None O
and None None O
caspase None None O
- None None O
3 None None O
activation None None O
. None None O

Like None None O
ioversol None None O
, None None O
C2 None None O
ceramide None None O
and None None O
the None None O
Akt None None O
inhibitor None None O
Src None None O
homology None None O
- None None O
6 None None O
induced None None O
apoptosis None None O
by None None O
reducing None None O
pAkt None None O
and None None O
pCREB None None O
- None None O
like None None O
immunoreactivities None None O
, None None O
lowering None None O
Bcl None None O
- None None O
2 None None O
expression None None O
and None None O
enhancing None None O
caspase None None O
- None None O
3 None None O
activity None None O
. None None O

Indeed None None O
, None None O
various None None O
radiocontrast None None O
media None None O
, None None O
excluding None None O
iodixanol None None O
which None None O
showed None None O
the None None O
least None None O
nephrotoxicity None None O
, None None O
enhanced None None O
ceramide None None O
- None None O
like None None O
immunoreactivity None None O
. None None O

The None None O
role None None O
for None None O
de None None O
novo None None O
ceramide None None O
synthesis None None O
was None None O
also None None O
shown None None O
in None None O
the None None O
in None None O
vivo None None O
model None None O
of None None O
radiocontrast None None O
nephropathy None None O
. None None O

We None None O
demonstrated None None O
here None None O
for None None O
the None None O
first None None O
time None None O
that None None O
the None None O
enhancement None None O
of None None O
de None None O
novo None None O
ceramide None None O
synthesis None None O
contributes None None O
to None None O
radiocontrast None None O
nephropathy None None O
. None None O

Netrin None None O
- None None O
1 None None O
up None None O
- None None O
regulation None None O
in None None O
inflammatory None None O
bowel None None O
diseases None None O
is None None O
required None None O
for None None O
colorectal None None O
cancer None None O
progression None None O
. None None O

Chronic None None O
inflammation None None O
and None None O
cancer None None O
are None None O
intimately None None O
associated None None O
. None None O

This None None O
is None None O
particularly None None O
true None None O
for None None O
inflammatory None None O
bowel None None O
diseases None None O
( None None O
IBD None None O
) None None O
, None None O
such None None O
as None None O
ulcerative None None O
colitis None None O
and None None O
Crohn None None O
' None None O
s None None O
disease None None O
, None None O
which None None O
show None None O
a None None O
major None None O
increased None None O
risk None None O
for None None O
colorectal None None O
cancer None None O
. None None O

While None None O
the None None O
understanding None None O
of None None O
the None None O
molecular None None O
pathogenesis None None O
of None None O
IBD None None O
has None None O
recently None None O
improved None None O
, None None O
the None None O
mechanisms None None O
that None None O
link None None O
these None None O
chronic None None O
inflammatory None None O
states None None O
to None None O
colorectal None None O
cancer None None O
development None None O
are None None O
in None None O
large None None O
part None None O
unknown None None O
. None None O

One None None O
of None None O
these None None O
mechanisms None None O
is None None O
NF None None O
- None None O
kappaB None None O
pathway None None O
activation None None O
which None None O
in None None O
turn None None O
may None None O
contribute None None O
to None None O
tumor None None O
formation None None O
by None None O
providing None None O
anti None None O
- None None O
apoptotic None None O
survival None None O
signals None None O
to None None O
the None None O
epithelial None None O
cells None None O
. None None O

Based None None O
on None None O
the None None O
observation None None O
that None None O
netrin None None O
- None None O
1 None None O
, None None O
the None None O
anti None None O
- None None O
apoptotic None None O
ligand None None O
for None None O
the None None O
dependence None None O
receptors None None O
DCC None None O
and None None O
UNC5H None None O
is None None O
up None None O
- None None O
regulated None None O
in None None O
colonic None None O
crypts None None O
in None None O
response None None O
to None None O
NF None None O
- None None O
kappaB None None O
, None None O
we None None O
show None None O
here None None O
that None None O
colorectal None None O
cancers None None O
from None None O
inflammatory None None O
bowel None None O
diseases None None O
patients None None O
have None None O
selected None None O
up None None O
- None None O
regulation None None O
of None None O
netrin None None O
- None None O
1 None None O
. None None O

Moreover None None O
, None None O
we None None O
demonstrate None None O
that None None O
this None None O
inflammation None None O
- None None O
driven None None O
netrin None None O
- None None O
1 None None O
up None None O
- None None O
regulation None None O
is None None O
causal None None O
for None None O
colorectal None None O
cancer None None O
development None None O
as None None O
interference None None O
with None None O
netrin None None O
- None None O
1 None None O
autocrine None None O
loop None None O
in None None O
a None None O
mouse None None O
model None None O
for None None O
ulcerative None None O
colitis None None O
- None None O
associated None None O
colorectal None None O
cancer None None O
, None None O
while None None O
showing None None O
no None None O
effect None None O
on None None O
inflammation None None O
, None None O
inhibits None None O
colorectal None None O
cancer None None O
progression None None O
. None None O

The None None O
origin None None O
of None None O
yolk None None O
- None None O
DNA None None O
in None None O
Xenopus None None O
laevis None None O
. None None O

Xenopus None None O
laevis None None O
serum None None O
and None None O
plasma None None O
was None None O
found None None O
to None None O
contain None None O
an None None O
average None None O
of None None O
25 None None O
microgram None None O
DNA None None O
/ None None O
ml None None O
. None None O

Isolated None None O
X None None O
. None None O
laevis None None O
oocytes None None O
incubated None None O
in None None O
medium None None O
containing None None O
25 None None O
microgram None None O
DNA None None O
/ None None O
ml None None O
labeled None None O
with None None O
either None None O
125I None None O
, None None O
32P None None O
or None None O
14C None None O
and None None O
from None None O
three None None O
different None None O
sources None None O
( None None O
bovine None None O
, None None O
E None None O
. None None O
coli None None O
and None None O
X None None O
. None None O
laevis None None O
) None None O
, None None O
incorporated None None O
the None None O
label None None O
at None None O
an None None O
average None None O
rate None None O
of None None O
0 None None O
. None None O
11 None None O
ng None None O
. None None O
mm None None O
- None None O
2 None None O
. None None O
hr None None O
- None None O
1 None None O
. None None O

Sucrose None None O
gradient None None O
fractionation None None O
of None None O
oocytes None None O
revealed None None O
that None None O
40 None None O
- None None O
75 None None O
% None None O
of None None O
the None None O
acid None None O
- None None O
precipitable None None O
label None None O
incorporated None None O
was None None O
associated None None O
with None None O
the None None O
yolk None None O
platelets None None O
. None None O

Additional None None O
incubations None None O
of None None O
oocytes None None O
in None None O
unlabeled None None O
medium None None O
demonstrated None None O
that None None O
the None None O
DNA None None O
incorporated None None O
into None None O
the None None O
yolk None None O
platelets None None O
was None None O
undergoing None None O
turnover None None O
; None None O
only None None O
20 None None O
% None None O
of None None O
the None None O
yolk None None O
- None None O
associated None None O
DNA None None O
was None None O
still None None O
present None None O
after None None O
a None None O
one None None O
- None None O
week None None O
incubation None None O
. None None O

Our None None O
data None None O
suggest None None O
that None None O
yolk None None O
- None None O
DNA None None O
arises None None O
by None None O
the None None O
adventitious None None O
uptake None None O
of None None O
DNA None None O
present None None O
in None None O
the None None O
maternal None None O
serum None None O
by None None O
vitellogenic None None O
oocytes None None O
. None None O

Selenoperoxidase None None O
- None None O
dependent None None O
glutathione None None O
cycle None None O
activity None None O
in None None O
peroxide None None O
- None None O
challenged None None O
leukemia None None O
cells None None O
. None None O

Murine None None O
leukemia None None O
L1210 None None I-Cell-line-name
cells None None O
rendered None None O
deficient None None O
in None None O
glutathione None None O
peroxidase None None O
( None None O
GPX None None O
) None None O
and None None O
phospholipid None None O
hydroperoxide None None O
glutathione None None O
peroxidase None None O
( None None O
PHGPX None None O
) None None O
by None None O
Se None None O
deprivation None None O
( None None O
L None None O
. None None O
Se None None O
( None None O
- None None O
) None None O
cells None None O
) None None O
were None None O
found None None O
to None None O
be None None O
more None None O
sensitive None None O
to None None O
tert None None O
- None None O
butyl None None O
hydroperoxide None None O
( None None O
t None None O
- None None O
BuOOH None None O
) None None O
cytotoxicity None None O
than None None O
Se None None O
- None None O
replete None None O
controls None None O
( None None O
L None None O
. None None O
Se None None O
( None None O
+ None None O
) None None O
cells None None O
) None None O
. None None O

Human None None O
K562 None None I-Cell-line-name
cells None None O
, None None O
which None None O
express None None O
PHGPX None None O
, None None O
but None None O
not None None O
GPX None None O
, None None O
were None None O
also None None O
more None None O
sensitive None None O
to None None O
t None None O
- None None O
BuOOH None None O
in None None O
the None None O
Se None None O
- None None O
deficient None None O
( None None O
K None None O
. None None O
Se None None O
( None None O
- None None O
) None None O
) None None O
than None None O
Se None None O
- None None O
satisfied None None O
( None None O
K None None O
. None None O
Se None None O
( None None O
+ None None O
) None None O
) None None O
condition None None O
. None None O

In None None O
examining None None O
the None None O
metabolic None None O
basis None None O
for None None O
selenoperoxidase None None O
- None None O
dependent None None O
resistance None None O
, None None O
we None None O
found None None O
that None None O
glucose None None O
- None None O
replete None None O
Se None None O
( None None O
- None None O
) None None O
cells None None O
reduce None None O
t None None O
- None None O
BuOOH None None O
to None None O
t None None O
- None None O
butanol None None O
far None None O
more None None O
slowly None None O
than None None O
Se None None O
( None None O
+ None None O
) None None O
cells None None O
, None None O
the None None O
ratio None None O
of None None O
the None None O
first None None O
- None None O
order None None O
rate None None O
constants None None O
approximating None None O
that None None O
of None None O
the None None O
GPX None None O
activities None None O
( None None O
L1210 None None I-Cell-line-name
cells None None O
) None None O
or None None O
PHGPX None None O
activities None None O
( None None O
K562 None None I-Cell-line-name
cells None None O
) None None O
. None None O

Monitoring None None O
peroxide None None O
- None None O
induced None None O
changes None None O
in None None O
GSH None None O
and None None O
GSSG None None O
gave None None O
consistent None None O
results None None O
; None None O
e None None O
. None None O
g None None O
. None None O
, None None O
glucose None None O
- None None O
depleted None None O
L None None O
. None None O
Se None None O
( None None O
+ None None O
) None None O
cells None None O
exhibited None None O
a None None O
first None None O
order None None O
loss None None O
of None None O
GSH None None O
that None None O
was None None O
substantially None None O
faster None None O
than None None O
that None None O
of None None O
glucose None None O
- None None O
depleted None None O
L None None O
. None None O
Se None None O
( None None O
- None None O
) None None O
cells None None O
. None None O

Under None None O
the None None O
conditions None None O
used None None O
, None None O
peroxide None None O
- None None O
induced None None O
conversion None None O
of None None O
GSH None None O
to None None O
GSSG None None O
could None None O
be None None O
stoichiometrically None None O
reversed None None O
by None None O
resupplying None None O
D None None O
- None None O
glucose None None O
, None None O
indicating None None O
that None None O
no None None O
significant None None O
lysis None None O
or None None O
GSSG None None O
efflux None None O
and None None O
/ None None O
or None None O
interchange None None O
had None None O
taken None None O
place None None O
. None None O

The None None O
apparent None None O
first None None O
- None None O
order None None O
rate None None O
constant None None O
for None None O
GSH None None O
decay None None O
increased None None O
progressively None None O
for None None O
L1210 None None I-Cell-line-name
cells None None O
expressing None None O
a None None O
range None None O
of None None O
GPX None None O
activities None None O
from None None O
approximately None None O
5 None None O
% None None O
to None None O
100 None None O
% None None O
, None None O
demonstrating None None O
that None None O
peroxide None None O
detoxification None None O
is None None O
strictly None None O
dependent None None O
on None None O
enzyme None None O
content None None O
. None None O

The None None O
initial None None O
rate None None O
of None None O
14CO2 None None O
release None None O
from None None O
D None None O
- None None O
[ None None O
1 None None O
- None None O
14C None None O
] None None O
glucose None None O
supplied None None O
in None None O
the None None O
medium None None O
was None None O
much None None O
greater None None O
for None None O
L None None O
. None None O
Se None None O
( None None O
+ None None O
) None None O
or None None O
K None None O
. None None O
Se None None O
( None None O
+ None None O
) None None O
cells None None O
than None None O
for None None O
their None None O
respective None None O
Se None None O
( None None O
- None None O
) None None O
counterparts None None O
, None None O
consistent None None O
with None None O
greater None None O
hexose None None O
monophosphate None None O
shunt None None O
activity None None O
in None None O
the None None O
former None None O
. None None O

These None None O
results None None O
highlight None None O
the None None O
importance None None O
of None None O
selenoperoxidase None None O
action None None O
in None None O
the None None O
glutathione None None O
cycle None None O
as None None O
a None None O
means None None O
by None None O
which None None O
tumor None None O
cells None None O
cope None None O
with None None O
hydroperoxide None None O
stress None None O
. None None O

Focal None None O
congenital None None O
alveolar None None O
proteinosis None None O
associated None None O
with None None O
abnormal None None O
surfactant None None O
protein None None O
B None None O
messenger None None O
RNA None None O
. None None O

Two None None O
siblings None None O
presented None None O
with None None O
typical None None O
clinical None None O
features None None O
of None None O
congenital None None O
pulmonary None None O
alveolar None None O
proteinosis None None O
( None None O
PAP None None O
) None None O
. None None O

Necropsy None None O
of None None O
one None None O
sibling None None O
revealed None None O
scattered None None O
foci None None O
of None None O
the None None O
diagnostic None None O
histologic None None O
changes None None O
in None None O
the None None O
lung None None O
tissue None None O
. None None O

In None None O
contrast None None O
to None None O
infantile None None O
and None None O
adult None None O
PAP None None O
, None None O
focal None None O
distribution None None O
is None None O
uncommon None None O
in None None O
congenital None None O
PAP None None O
. None None O

Defective None None O
expression None None O
of None None O
the None None O
granulocyte None None O
- None None O
macrophage None None O
colony None None O
- None None O
stimulating None None O
factor None None O
receptor None None O
was None None O
ruled None None O
out None None O
. None None O

The None None O
surfactant None None O
protein None None O
B None None O
( None None O
SP None None O
- None None O
B None None O
) None None O
content None None O
in None None O
the None None O
lung None None O
tissue None None O
of None None O
the None None O
autopsied None None O
patient None None O
was None None O
low None None O
, None None O
and None None O
a None None O
deletion None None O
in None None O
the None None O
SP None None O
- None None O
B None None O
messenger None None O
RNA None None O
was None None O
detected None None O
. None None O

We None None O
speculate None None O
that None None O
the None None O
PAP None None O
in None None O
our None None O
patients None None O
was None None O
related None None O
to None None O
the None None O
reduced None None O
quantity None None O
and None None O
/ None None O
or None None O
to None None O
the None None O
altered None None O
quality None None O
of None None O
SP None None O
- None None O
B None None O
. None None O

Neurohypophyseal None None O
granulomatous None None O
germinoma None None O
invading None None O
the None None O
right None None O
cavernous None None O
sinus None None O
: None None O
case None None O
report None None O
and None None O
review None None O
of None None O
the None None O
literature None None O
. None None O

We None None O
encountered None None O
a None None O
rare None None O
case None None O
of None None O
neurohypophyseal None None O
germinoma None None O
with None None O
a None None O
prominent None None O
granulomatous None None O
reaction None None O
, None None O
which None None O
invaded None None O
the None None O
right None None O
cavernous None None O
sinus None None O
. None None O

The None None O
neuroimaging None None O
and None None O
histopathology None None O
features None None O
in None None O
this None None O
case None None O
were None None O
unique None None O
, None None O
distinguishing None None O
it None None O
from None None O
other None None O
types None None O
of None None O
suprasellar None None O
lesions None None O
. None None O

A None None O
13 None None O
- None None O
year None None O
- None None O
old None None O
boy None None O
presented None None O
with None None O
loss None None O
of None None O
appetite None None O
and None None O
polyuria None None O
; None None O
both None None O
symptoms None None O
were None None O
present None None O
for None None O
1 None None O
year None None O
, None None O
and None None O
headache None None O
, None None O
general None None O
fatigue None None O
and None None O
blurred None None O
vision None None O
present None None O
for None None O
the None None O
prior None None O
2 None None O
months None None O
. None None O

On None None O
admission None None O
, None None O
neurological None None O
examination None None O
indicated None None O
bitemporal None None O
hemianopsia None None O
and None None O
optic None None O
atrophy None None O
. None None O

Endocrinological None None O
exam None None O
showed None None O
panhypopituitarism None None O
. None None O

Tumor None None O
markers None None O
such None None O
as None None O
alpha None None O
- None None O
fetoprotein None None O
, None None O
human None None O
growth None None O
hormone None None O
, None None O
carcinoembryonic None None O
antigen None None O
, None None O
and None None O
placental None None O
alkaline None None O
phosphatase None None O
were None None O
negative None None O
. None None O

Brain None None O
CT None None O
revealed None None O
a None None O
suprasellar None None O
tumor None None O
with None None O
calcification None None O
. None None O

MR None None O
T None None O
( None None O
1 None None O
) None None O
- None None O
weighted None None O
and None None O
T None None O
( None None O
2 None None O
) None None O
- None None O
weighted None None O
images None None O
showed None None O
the None None O
tumor None None O
to None None O
be None None O
isointense None None O
to None None O
normal None None O
brain None None O
parenchyma None None O
and None None O
to None None O
be None None O
enhanced None None O
densely None None O
. None None O

The None None O
tumor None None O
also None None O
involved None None O
the None None O
right None None O
cavernous None None O
sinus None None O
, None None O
so None None O
that None None O
a None None O
biopsy None None O
was None None O
performed None None O
by None None O
the None None O
transsphenoidal None None O
approach None None O
. None None O

On None None O
pathologic None None O
examination None None O
of None None O
the None None O
specimen None None O
, None None O
typical None None O
large None None O
tumor None None O
cells None None O
with None None O
lymphocytic None None O
cell None None O
infiltration None None O
and None None O
prominent None None O
granulomatous None None O
reaction None None O
were None None O
observed None None O
. None None O

Neurohypophyseal None None O
granulomatous None None O
germinoma None None O
was None None O
diagnosed None None O
. None None O

Radiotherapy None None O
was None None O
performed None None O
with None None O
a None None O
total None None O
dose None None O
of None None O
51 None None O
Gy None None O
and None None O
the None None O
tumor None None O
shrank None None O
remarkably None None O
. None None O

The None None O
patient None None O
returned None None O
to None None O
school None None O
under None None O
hormone None None O
replacement None None O
therapy None None O
. None None O

2 None None O
. None None O
1 None None O
. None None O

Genome None None O
sequencing None None O
, None None O
assembly None None O
and None None O
validation None None O

DNA None None O
shotgun None None O
libraries None None O
with None None O
average None None O
insert None None O
sizes None None O
of None None O
1 None None O
. None None O
6 None None O
and None None O
6 None None O
. None None O
5 None None O
kb None None O
were None None O
constructed None None O
in None None O
pUC118 None None O
( None None O
TaKaRa None None O
) None None O
, None None O
whereas None None O
a None None O
fosmid None None O
library None None O
with None None O
average None None O
insert None None O
size None None O
of None None O
37 None None O
kb None None O
was None None O
constructed None None O
in None None O
pCC1FOS None None O
( None None O
EPICENTRE None None O
) None None O
as None None O
described None None O
previously None None O
. None None O
18 None None O
, None None O
19 None None O
A None None O
total None None O
of None None O
50 None None O
400 None None O
clones None None O
( None None O
34 None None O
560 None None O
, None None O
10 None None O
752 None None O
and None None O
5088 None None O
clones None None O
from None None O
libraries None None O
with None None O
1 None None O
. None None O
6 None None O
, None None O
6 None None O
. None None O
5 None None O
and None None O
37 None None O
kb None None O
inserts None None O
, None None O
respectively None None O
) None None O
were None None O
subjected None None O
to None None O
sequencing None None O
from None None O
both None None O
ends None None O
of None None O
the None None O
inserts None None O
on None None O
either None None O
ABI None None O
3730xl None None O
DNA None None O
Analyzer None None O
( None None O
Applied None None O
Biosystems None None O
) None None O
or None None O
Base None None O
Station None None O
DNA None None O
Fragment None None O
Analyzer None None O
BST None None O
- None None O
0100 None None O
( None None O
MJ None None O
Research None None O
, None None O
Inc None None O
. None None O
) None None O
. None None O

Sequence None None O
reads None None O
were None None O
trimmed None None O
at None None O
a None None O
threshold None None O
quality None None O
value None None O
of None None O
20 None None O
by None None O
Phred None None O
and None None O
assembled None None O
by None None O
Phrap None None O
and None None O
CONSED None None O
assembly None None O
tools None None O
. None None O
20 None None O
, None None O
21 None None O
For None None O
alignment None None O
and None None O
validation None None O
of None None O
contigs None None O
, None None O
Optical None None O
Mapping None None O
( None None O
OpGen None None O
) None None O
was None None O
used None None O
. None None O

Gaps None None O
between None None O
contigs None None O
were None None O
closed None None O
by None None O
sequencing None None O
PCR None None O
products None None O
, None None O
which None None O
bridge None None O
two None None O
neighboring None None O
contigs None None O
. None None O

Finally None None O
, None None O
each None None O
base None None O
of None None O
K None None O
. None None O
setae None None O
NBRC None None O
14216T None None O
genome None None O
was None None O
ensured None None O
to None None O
be None None O
sequenced None None O
from None None O
multiple None None O
clones None None O
and None None O
from None None O
both None None O
directions None None O
with None None O
Phrap None None O
quality None None O
score None None O
> None None O
= None None O
70 None None O
or None None O
from None None O
one None None O
direction None None O
with None None O
Phrap None None O
quality None None O
score None None O
> None None O
= None None O
40 None None O
. None None O

Chromosomal None None O
terminus None None O
was None None O
determined None None O
after None None O
attaching None None O
adenine None None O
and None None O
thymine None None O
homopolymers None None O
to None None O
the None None O
naked None None O
3 None None O
' None None O
ends None None O
of None None O
the None None O
chromosome None None O
as None None O
described None None O
previously None None O
. None None O
5 None None O

Activation None None O
of None None O
signal None None O
transducer None None O
and None None O
activator None None O
of None None O
transcription None None O
3 None None O
through None None O
a None None O
phosphomimetic None None O
serine None None O
727 None None O
promotes None None O
prostate None None O
tumorigenesis None None O
independent None None O
of None None O
tyrosine None None O
705 None None O
phosphorylation None None O
. None None O

Aberrantly None None O
activated None None O
signal None None O
transducer None None O
and None None O
activator None None O
of None None O
transcription None None O
3 None None O
( None None O
Stat3 None None O
) None None O
is None None O
implicated None None O
in None None O
the None None O
development None None O
of None None O
various None None O
human None None O
cancers None None O
. None None O

Y705 None None O
phosphorylation None None O
is None None O
conventionally None None O
thought None None O
to None None O
be None None O
required None None O
for None None O
Stat3 None None O
signal None None O
- None None O
dependent None None O
activation None None O
and None None O
seems None None O
to None None O
play None None O
an None None O
essential None None O
role None None O
in None None O
some None None O
malignancies None None O
. None None O

Recently None None O
, None None O
it None None O
was None None O
shown None None O
that None None O
Stat3 None None O
is None None O
activated None None O
through None None O
novel None None O
and None None O
noncanonical None None O
mechanisms None None O
, None None O
including None None O
phosphorylation None None O
at None None O
S727 None None O
. None None O

Here None None O
, None None O
we None None O
investigate None None O
S727 None None O
phosphorylation None None O
of None None O
Stat3 None None O
and None None O
its None None O
subsequent None None O
effects None None O
in None None O
prostate None None O
cancer None None O
development None None O
, None None O
independent None None O
of None None O
Y705 None None O
phosphorylation None None O
, None None O
using None None O
mutated None None O
Stat3 None None O
in None None O
the None None O
human None None O
prostate None None O
cancer None None O
cell None None O
line None None O
LNCaP None None I-Cell-line-name
. None None O

We None None O
show None None O
mutation None None O
of None None O
S727 None None O
to None None O
the None None O
phosphomimetic None None O
residue None None O
Glu None None O
, None None O
and None None O
inactivation None None O
of None None O
Y705 None None O
( None None O
Y705F None None O
/ None None O
S727E None None O
) None None O
resulted None None O
in None None O
a None None O
remarkable None None O
growth None None O
advantage None None O
in None None O
low None None O
- None None O
serum None None O
, None None O
enhanced None None O
anchorage None None O
- None None O
independent None None O
growth None None O
in None None O
soft None None O
agar None None O
, None None O
and None None O
increased None None O
tumorigenicity None None O
in None None O
nonobese None None O
diabetic None None O
/ None None O
severe None None O
combined None None O
immunodeficient None None O
( None None O
NOD None None O
/ None None O
SCID None None O
) None None O
mice None None O
, None None O
possibly None None O
by None None O
direct None None O
activation None None O
of None None O
downstream None None O
proto None None O
- None None O
oncogenes None None O
c None None O
- None None O
myc None None O
, None None O
mcl None None O
- None None O
1 None None O
, None None O
and None None O
survivin None None O
. None None O

Y705F None None O
/ None None O
S727E None None O
mutant None None O
cells None None O
were None None O
more None None O
invasive None None O
than None None O
Y705F None None O
/ None None O
S727A None None O
( None None O
inactivation None None O
of None None O
Y705 None None O
and None None O
S727 None None O
) None None O
mutant None None O
cells None None O
, None None O
and None None O
more None None O
Y705F None None O
/ None None O
S727E None None O
mutant None None O
Stat3 None None O
was None None O
localized None None O
in None None O
the None None O
nuclei None None O
relative None None O
to None None O
Y705F None None O
/ None None O
S727A None None O
mutant None None O
Stat3 None None O
at None None O
the None None O
steady None None O
state None None O
. None None O

Furthermore None None O
, None None O
the None None O
Y705F None None O
/ None None O
S727E None None O
but None None O
not None None O
the None None O
Y705F None None O
/ None None O
S727A None None O
mutant None None O
induced None None O
anchorage None None O
- None None O
independent None None O
growth None None O
of None None O
noncancerous None None O
prostate None None O
epithelial None None O
cells None None O
( None None O
RWPE None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
) None None O
. None None O

We None None O
further None None O
show None None O
that None None O
Stat3 None None O
is None None O
phosphorylated None None O
at None None O
S727 None None O
in None None O
65 None None O
% None None O
of None None O
malignant None None O
prostate None None O
tissues None None O
( None None O
n None None O
= None None O
20 None None O
) None None O
relative None None O
to None None O
25 None None O
% None None O
of None None O
normal None None O
prostate None None O
tissues None None O
( None None O
n None None O
= None None O
4 None None O
) None None O
. None None O

Moreover None None O
, None None O
there None None O
is None None O
a None None O
positive None None O
correlation None None O
between None None O
phosphoS727 None None O
- None None O
Stat3 None None O
expression None None O
and None None O
Gleason None None O
score None None O
in None None O
these None None O
prostate None None O
cancer None None O
tissues None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Our None None O
data None None O
suggest None None O
for None None O
the None None O
first None None O
time None None O
that None None O
S727 None None O
phosphorylation None None O
is None None O
sufficient None None O
to None None O
activate None None O
Stat3 None None O
, None None O
thereby None None O
driving None None O
prostate None None O
tumorigenesis None None O
independent None None O
of None None O
Y705 None None O
phosphorylation None None O
. None None O

Use None None O
of None None O
uteroglobin None None O
for None None O
the None None O
engineering None None O
of None None O
polyvalent None None O
, None None O
polyspecific None None O
fusion None None O
proteins None None O
. None None O

We None None O
report None None O
a None None O
novel None None O
strategy None None O
to None None O
engineer None None O
and None None O
express None None O
stable None None O
and None None O
soluble None None O
human None None O
recombinant None None O
polyvalent None None O
/ None None O
polyspecific None None O
fusion None None O
proteins None None O
. None None O

The None None O
procedure None None O
is None None O
based None None O
on None None O
the None None O
use None None O
of None None O
a None None O
central None None O
skeleton None None O
of None None O
uteroglobin None None O
, None None O
a None None O
small None None O
and None None O
very None None O
soluble None None O
covalently None None O
linked None None O
homodimeric None None O
protein None None O
that None None O
is None None O
very None None O
resistant None None O
to None None O
proteolytic None None O
enzymes None None O
and None None O
to None None O
pH None None O
variations None None O
. None None O

Using None None O
a None None O
human None None O
recombinant None None O
antibody None None O
( None None O
scFv None None O
) None None O
specific None None O
for None None O
the None None O
angiogenesis None None O
marker None None O
domain None None O
B None None O
of None None O
fibronectin None None O
, None None O
interleukin None None O
2 None None O
, None None O
and None None O
an None None O
scFv None None O
able None None O
to None None O
neutralize None None O
tumor None None O
necrosis None None O
factor None None O
- None None O
alpha None None O
, None None O
we None None O
expressed None None O
various None None O
biologically None None O
active None None O
uteroglobin None None O
fusion None None O
proteins None None O
. None None O

The None None O
results None None O
demonstrate None None O
the None None O
possibility None None O
to None None O
generate None None O
monospecific None None O
divalent None None O
and None None O
tetravalent None None O
antibodies None None O
, None None O
immunocytokines None None O
, None None O
and None None O
dual None None O
specificity None None O
tetravalent None None O
antibodies None None O
. None None O

Furthermore None None O
, None None O
compared None None O
with None None O
similar None None O
fusion None None O
proteins None None O
in None None O
which None None O
uteroglobin None None O
was None None O
not None None O
used None None O
, None None O
the None None O
use None None O
of None None O
uteroglobin None None O
improved None None O
properties None None O
of None None O
solubility None None O
and None None O
stability None None O
. None None O

Indeed None None O
, None None O
in None None O
the None None O
reported None None O
cases None None O
it None None O
was None None O
possible None None O
to None None O
vacuum None None O
dry None None O
and None None O
reconstitute None None O
the None None O
proteins None None O
without None None O
any None None O
aggregation None None O
or None None O
loss None None O
in None None O
protein None None O
and None None O
biological None None O
activity None None O
. None None O

VEGF165 None None O
mediates None None O
formation None None O
of None None O
complexes None None O
containing None None O
VEGFR None None O
- None None O
2 None None O
and None None O
neuropilin None None O
- None None O
1 None None O
that None None O
enhance None None O
VEGF165 None None O
- None None O
receptor None None O
binding None None O
. None None O

Co None None O
- None None O
expression None None O
of None None O
NRP1 None None O
and None None O
( None None O
VEGFR None None O
- None None O
2 None None O
) None None O
KDR None None O
on None None O
the None None O
surface None None O
of None None O
endothelial None None O
cells None None O
( None None O
EC None None O
) None None O
enhances None None O
VEGF165 None None O
binding None None O
to None None O
KDR None None O
and None None O
EC None None O
chemotaxis None None O
in None None O
response None None O
to None None O
VEGF165 None None O
. None None O

Overexpression None None O
of None None O
NRP1 None None O
by None None O
prostate None None O
tumor None None O
cells None None O
in None None O
vivo None None O
results None None O
in None None O
increased None None O
tumor None None O
angiogenesis None None O
and None None O
growth None None O
. None None O

We None None O
investigated None None O
the None None O
molecular None None O
mechanisms None None O
underlying None None O
NRP1 None None O
- None None O
mediated None None O
angiogenesis None None O
by None None O
analyzing None None O
the None None O
association None None O
of None None O
NRP1 None None O
and None None O
KDR None None O
. None None O

An None None O
intracellular None None O
complex None None O
containing None None O
NRP1 None None O
and None None O
KDR None None O
was None None O
immunoprecipitated None None O
from None None O
EC None None O
by None None O
anti None None O
- None None O
NRP1 None None O
antibodies None None O
only None None O
in None None O
the None None O
presence None None O
of None None O
VEGF165 None None O
. None None O

In None None O
contrast None None O
, None None O
VEGF121 None None O
, None None O
which None None O
does None None O
not None None O
bind None None O
to None None O
NRP1 None None O
, None None O
did None None O
not None None O
support None None O
complex None None O
formation None None O
. None None O

Complexes None None O
containing None None O
VEGF165 None None O
, None None O
NRP1 None None O
, None None O
and None None O
KDR None None O
were None None O
also None None O
formed None None O
in None None O
an None None O
intercellular None None O
fashion None None O
by None None O
co None None O
- None None O
culture None None O
of None None O
EC None None O
expressing None None O
KDR None None O
only None None O
, None None O
with None None O
cells None None O
expressing None None O
NRP1 None None O
only None None O
, None None O
for None None O
example None None O
, None None O
breast None None O
carcinoma None None O
cells None None O
. None None O

VEGF165 None None O
also None None O
mediated None None O
the None None O
binding None None O
of None None O
a None None O
soluble None None O
NRP1 None None O
dimer None None O
to None None O
cells None None O
expressing None None O
KDR None None O
only None None O
, None None O
confirming None None O
the None None O
formation None None O
of None None O
such None None O
complexes None None O
. None None O

Furthermore None None O
, None None O
the None None O
formation None None O
of None None O
complexes None None O
containing None None O
KDR None None O
and None None O
NRP1 None None O
markedly None None O
increased None None O
125I None None O
- None None O
VEGF165 None None O
binding None None O
to None None O
KDR None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
formation None None O
of None None O
a None None O
ternary None None O
complex None None O
of None None O
VEGF165 None None O
, None None O
KDR None None O
, None None O
and None None O
NRP1 None None O
potentiates None None O
VEGF165 None None O
binding None None O
to None None O
KDR None None O
. None None O

These None None O
complexes None None O
are None None O
formed None None O
on None None O
the None None O
surface None None O
of None None O
EC None None O
and None None O
in None None O
a None None O
juxtacrine None None O
manner None None O
via None None O
association None None O
of None None O
tumor None None O
cell None None O
NRP1 None None O
and None None O
EC None None O
KDR None None O
. None None O

Calretinin None None O
. None None O

A None None O
selective None None O
marker None None O
of None None O
normal None None O
and None None O
neoplastic None None O
mesothelial None None O
cells None None O
in None None O
serous None None O
effusions None None O
. None None O

OBJECTIVE None None O
: None None O
To None None O
document None None O
that None None O
a None None O
polyclonal None None O
antiserum None None O
to None None O
calretinin None None O
, None None O
a None None O
29 None None O
- None None O
kd None None O
calcium None None O
- None None O
binding None None O
protein None None O
, None None O
consistently None None O
decorates None None O
normal None None O
and None None O
tumor None None O
mesothelial None None O
cells None None O
in None None O
cytologic None None O
preparations None None O
. None None O

STUDY None None O
DESIGN None None O
: None None O
Thirty None None O
- None None O
three None None O
archival None None O
cytologic None None O
specimens None None O
from None None O
eight None None O
patients None None O
with None None O
histologically None None O
confirmed None None O
malignant None None O
mesothelioma None None O
and None None O
13 None None O
from None None O
patients None None O
with None None O
metastatic None None O
serous None None O
effusions None None O
were None None O
destained None None O
and None None O
then None None O
immunostained None None O
with None None O
anticalretinin None None O
antiserum None None O
. None None O

For None None O
investigation None None O
of None None O
cell None None O
suspensions None None O
, None None O
four None None O
pleural None None O
fluids None None O
were None None O
incubated None None O
with None None O
anticalretinin None None O
antiserum None None O
. None None O

After None None O
cytocentrifugation None None O
the None None O
specimens None None O
were None None O
stained None None O
in None None O
accordance None None O
with None None O
the None None O
alkaline None None O
phosphatase None None O
anti None None O
- None None O
alkaline None None O
phosphatase None None O
( None None O
APAAP None None O
) None None O
method None None O
. None None O

For None None O
electron None None O
microscopic None None O
examination None None O
the None None O
cell None None O
suspensions None None O
were None None O
then None None O
incubated None None O
with None None O
gold None None O
- None None O
labeled None None O
antirabbit None None O
antibody None None O
. None None O

RESULTS None None O
: None None O
The None None O
diagnostic None None O
sensitivity None None O
of None None O
this None None O
new None None O
immunocytochemical None None O
approach None None O
reached None None O
100 None None O
% None None O
for None None O
the None None O
eight None None O
malignant None None O
mesotheliomas None None O
investigated None None O
. None None O

Only None None O
3 None None O
of None None O
the None None O
13 None None O
adenocarcinomas None None O
metastatic None None O
to None None O
the None None O
serous None None O
membranes None None O
included None None O
in None None O
this None None O
study None None O
were None None O
weakly None None O
reactive None None O
, None None O
accounting None None O
for None None O
81 None None O
% None None O
specificity None None O
. None None O

Binding None None O
of None None O
anticalretinin None None O
antiserum None None O
to None None O
living None None O
mesothelial None None O
cells None None O
was None None O
consistently None None O
documented None None O
in None None O
all None None O
four None None O
cases None None O
investigated None None O
. None None O

CONCLUSION None None O
: None None O
Calretinin None None O
is None None O
a None None O
very None None O
useful None None O
marker None None O
for None None O
positive None None O
identification None None O
of None None O
normal None None O
and None None O
tumor None None O
mesothelial None None O
cells None None O
in None None O
serous None None O
effusions None None O
. None None O

Printing None None O
solution None None O

Several None None O
transfection None None O
reagents None None O
were None None O
tested None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
, None None O
and None None O
we None None O
found None None O
that None None O
the None None O
X None None O
- None None O
tremeGENE None None O
siRNA None None O
transfection None None O
reagent None None O
( None None O
Roche None None O
) None None O
gave None None O
good None None O
transfection None None O
efficiencies None None O
both None None O
for None None O
plasmids None None O
and None None O
siRNAs None None O
, None None O
and None None O
chose None None O
to None None O
use None None O
this None None O
reagent None None O
for None None O
all None None O
transfected None None O
cell None None O
microarray None None O
experiments None None O
in None None O
the None None O
present None None O
study None None O
. None None O

For None None O
printing None None O
the None None O
arrays None None O
, None None O
one None None O
major None None O
challenge None None O
is None None O
to None None O
find None None O
a None None O
good None None O
balance None None O
between None None O
high None None O
transfection None None O
efficiency None None O
and None None O
spatially None None O
confined None None O
spots None None O
to None None O
avoid None None O
cross None None O
- None None O
contamination None None O
between None None O
the None None O
spots None None O
. None None O

In None None O
order None None O
to None None O
optimize None None O
the None None O
reverse None None O
transfection None None O
protocol None None O
for None None O
HEK None None O
293ind None None O
- None None O
ICER None None O
IIgamma None None O
cells None None O
( None None O
see None None O
below None None O
) None None O
and None None O
X None None O
- None None O
tremeGENE None None O
transfection None None O
reagent None None O
, None None O
we None None O
investigated None None O
the None None O
effect None None O
of None None O
varying None None O
the None None O
concentrations None None O
of None None O
gelatine None None O
and None None O
sucrose None None O
in None None O
the None None O
printing None None O
solution None None O
. None None O

These None None O
reagents None None O
have None None O
been None None O
reported None None O
to None None O
influence None None O
both None None O
the None None O
transfection None None O
efficiency None None O
and None None O
spot None None O
integrity None None O
( None None O
6 None None O
, None None O
27 None None O
) None None O
. None None O

Sucrose None None O
was None None O
observed None None O
to None None O
be None None O
specifically None None O
beneficial None None O
for None None O
obtaining None None O
high None None O
transfection None None O
efficiency None None O
when None None O
storing None None O
the None None O
arrays None None O
for None None O
several None None O
weeks None None O
before None None O
use None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

Figure None None O
1A None None O
and None None O
B None None O
show None None O
representative None None O
images None None O
of None None O
the None None O
observed None None O
effects None None O
of None None O
varying None None O
the None None O
concentrations None None O
of None None O
gelatine None None O
and None None O
sucrose None None O
. None None O

We None None O
observed None None O
that None None O
the None None O
transfection None None O
efficiency None None O
increased None None O
with None None O
increasing None None O
gelatine None None O
concentration None None O
( None None O
tested None None O
in None None O
the None None O
range None None O
0 None None O
. None None O
01 None None O
- None None O
0 None None O
. None None O
40 None None O
% None None O
) None None O
. None None O

However None None O
, None None O
an None None O
increased None None O
disturbance None None O
of None None O
the None None O
spatial None None O
definition None None O
of None None O
the None None O
spots None None O
was None None O
observed None None O
with None None O
increasing None None O
concentrations None None O
of None None O
gelatine None None O
or None None O
sucrose None None O
( None None O
tested None None O
in None None O
the None None O
range None None O
0 None None O
- None None O
100 None None O
mM None None O
) None None O
. None None O

A None None O
combined None None O
effect None None O
of None None O
the None None O
concentrations None None O
of None None O
gelatine None None O
and None None O
sucrose None None O
was None None O
also None None O
observed None None O
, None None O
as None None O
low None None O
concentrations None None O
of None None O
gelatine None None O
allowed None None O
us None None O
to None None O
use None None O
higher None None O
concentrations None None O
of None None O
sucrose None None O
than None None O
with None None O
higher None None O
concentrations None None O
of None None O
gelatine None None O
before None None O
cells None None O
spread None None O
outside None None O
the None None O
spots None None O
. None None O

Based None None O
on None None O
several None None O
optimizing None None O
experiments None None O
, None None O
we None None O
found None None O
that None None O
3 None None O
microl None None O
X None None O
- None None O
tremeGENE None None O
solution None None O
per None None O
microgram None None O
nucleic None None O
acid None None O
, None None O
25 None None O
mM None None O
sucrose None None O
and None None O
0 None None O
. None None O
1 None None O
% None None O
gelatine None None O
in None None O
the None None O
final None None O
printing None None O
solution None None O
reproducibly None None O
gave None None O
spatial None None O
restricted None None O
transfection None None O
with None None O
high None None O
transfection None None O
efficiency None None O
printing None None O
the None None O
arrays None None O
with None None O
both None None O
a None None O
pipette None None O
tip None None O
and None None O
a None None O
hand None None O
- None None O
held None None O
arrayer None None O
( None None O
see None None O
below None None O
) None None O
. None None O

Figure None None O
1 None None O
. None None O

Effects None None O
of None None O
sucrose None None O
and None None O
gelatine None None O
concentrations None None O
on None None O
spot None None O
integrity None None O
and None None O
transfection None None O
efficiency None None O
. None None O

( None None O
A None None O
) None None O
Array None None O
printed None None O
with None None O
pDsRed None None O
( None None O
50 None None O
ng None None O
/ None None O
microl None None O
) None None O
in None None O
a None None O
printing None None O
solution None None O
with None None O
different None None O
gelatine None None O
and None None O
sucrose None None O
concentrations None None O
. None None O

Scanning None None O
image None None O
of None None O
the None None O
whole None None O
array None None O
and None None O
magnifications None None O
of None None O
specific None None O
spots None None O
. None None O

( None None O
B None None O
) None None O
Array None None O
printed None None O
with None None O
pEGFP None None O
( None None O
50 None None O
ng None None O
/ None None O
microl None None O
) None None O
in None None O
a None None O
printing None None O
solution None None O
with None None O
25 None None O
mM None None O
sucrose None None O
and None None O
four None None O
different None None O
concentrations None None O
of None None O
gelatine None None O
. None None O

Top None None O
: None None O
Box None None O
plot None None O
of None None O
the None None O
fluorescence None None O
intensities None None O
in None None O
each None None O
spot None None O
( None None O
n None None O
= None None O
32 None None O
- None None O
34 None None O
) None None O
. None None O

Bottom None None O
: None None O
Scanning None None O
image None None O
showing None None O
squares None None O
of None None O
seven None None O
times None None O
five None None O
spots None None O
for None None O
the None None O
four None None O
gelatine None None O
concentrations None None O
. None None O

From None None O
left None None O
to None None O
right None None O
: None None O
0 None None O
. None None O
01 None None O
, None None O
0 None None O
. None None O
05 None None O
, None None O
0 None None O
. None None O
1 None None O
and None None O
0 None None O
. None None O
2 None None O
% None None O
gelatine None None O
. None None O

The None None O
DNA None None O
- None None O
lipid None None O
- None None O
gelatine None None O
- None None O
sucrose None None O
solutions None None O
were None None O
printed None None O
manually None None O
with None None O
a None None O
10 None None O
microl None None O
pipette None None O
tip None None O
( None None O
A None None O
) None None O
or None None O
by None None O
MicroCasterTM None None O
manual None None O
arrayer None None O
system None None O
( None None O
B None None O
) None None O
. None None O

In None None O
a None None O
1 None None O
. None None O
5 None None O
ml None None O
microcentrifuge None None O
tube None None O
, None None O
plasmid None None O
( None None O
1 None None O
microg None None O
/ None None O
microl None None O
) None None O
and None None O
siRNA None None O
were None None O
mixed None None O
with None None O
growth None None O
medium None None O
without None None O
fetal None None O
calf None None O
serum None None O
( None None O
FCS None None O
) None None O
, None None O
0 None None O
. None None O
5 None None O
microl None None O
1 None None O
. None None O
5 None None O
M None None O
sucrose None None O
and None None O
3 None None O
microl None None O
X None None O
- None None O
tremeGENE None None O
per None None O
microgram None None O
nucleic None None O
acid None None O
to None None O
a None None O
final None None O
volume None None O
of None None O
22 None None O
. None None O
5 None None O
microl None None O
. None None O

After None None O
15 None None O
- None None O
20 None None O
min None None O
of None None O
incubation None None O
, None None O
7 None None O
. None None O
5 None None O
microl None None O
0 None None O
. None None O
4 None None O
% None None O
gelatine None None O
( None None O
Type None None O
B None None O
, None None O
G9391 None None O
, None None O
Sigma None None O
) None None O
was None None O
added None None O
to None None O
give None None O
30 None None O
microl None None O
printing None None O
solution None None O
. None None O

The None None O
gelatine None None O
solution None None O
was None None O
prepared None None O
as None None O
described None None O
by None None O
Ziauddin None None O
and None None O
Sabatini None None O
( None None O
1 None None O
) None None O
. None None O

To None None O
achieve None None O
sufficient None None O
level None None O
of None None O
expression None None O
from None None O
the None None O
transfected None None O
plasmids None None O
, None None O
25 None None O
- None None O
50 None None O
ng None None O
/ None None O
microl None None O
pEGFP None None O
- None None O
N1 None None O
or None None O
pDsRed None None O
- None None O
express None None O
- None None O
N1 None None O
and None None O
50 None None O
- None None O
75 None None O
ng None None O
/ None None O
microl None None O
of None None O
CRE None None O
or None None O
NFkappaB None None O
reporter None None O
plasmids None None O
was None None O
used None None O
. None None O

For None None O
siRNA None None O
studies None None O
, None None O
2 None None O
- None None O
30 None None O
ng None None O
/ None None O
microl None None O
siRNA None None O
in None None O
the None None O
final None None O
printing None None O
solution None None O
was None None O
used None None O
. None None O

On None None O
the None None O
relationship None None O
between None None O
the None None O
population None None O
structure None None O
and None None O
national None None O
economic None None O
development None None O
in None None O
China None None O
. None None O

The None None O
authors None None O
examine None None O
the None None O
relationship None None O
between None None O
population None None O
reproduction None None O
and None None O
the None None O
production None None O
of None None O
material None None O
goods None None O
, None None O
with None None O
particular None None O
reference None None O
to None None O
the None None O
effect None None O
of None None O
changes None None O
in None None O
the None None O
age None None O
composition None None O
of None None O
the None None O
population None None O
on None None O
the None None O
national None None O
economy None None O
and None None O
national None None O
income None None O
. None None O

An None None O
analysis None None O
of None None O
the None None O
population None None O
structure None None O
of None None O
China None None O
is None None O
presented None None O
, None None O
with None None O
consideration None None O
given None None O
to None None O
age None None O
characteristics None None O
, None None O
occupation None None O
, None None O
and None None O
urban None None O
and None None O
rural None None O
population None None O
. None None O

Suggestions None None O
for None None O
improving None None O
the None None O
population None None O
structure None None O
to None None O
achieve None None O
maximum None None O
rates None None O
of None None O
economic None None O
development None None O
are None None O
presented None None O
. None None O

Regional None None O
differences None None O
in None None O
population None None O
structure None None O
are None None O
also None None O
discussed None None O
. None None O

Abbreviations None None O

ARDS None None O
: None None O
acute None None O
respiratory None None O
distress None None O
syndrome None None O
; None None O
CMV None None O
: None None O
conventional None None O
mechanical None None O
ventilation None None O
; None None O
HFOV None None O
: None None O
high None None O
- None None O
frequency None None O
oscillation None None O
ventilation None None O
; None None O
LPS None None O
: None None O
lipopolysaccharide None None O
; None None O
PEEP None None O
: None None O
positive None None O
end None None O
- None None O
expiratory None None O
pressure None None O
; None None O
VILI None None O
: None None O
ventilator None None O
- None None O
induced None None O
lung None None O
injury None None O
. None None O

The None None O
role None None O
of None None O
p53 None None O
in None None O
pigmentation None None O
, None None O
tanning None None O
and None None O
melanoma None None O
. None None O

p53 None None O
has None None O
a None None O
central None None O
role None None O
in None None O
skin None None O
pigmentation None None O
and None None O
may None None O
impact None None O
on None None O
melanoma None None O
at None None O
all None None O
stages None None O
, None None O
however None None O
, None None O
as None None O
it None None O
' None None O
s None None O
mutation None None O
frequency None None O
in None None O
melanoma None None O
is None None O
low None None O
, None None O
it None None O
' None None O
s None None O
role None None O
has None None O
been None None O
somewhat None None O
under None None O
- None None O
appreciated None None O
. None None O

During None None O
normal None None O
skin None None O
function None None O
, None None O
p53 None None O
in None None O
the None None O
keratinocyte None None O
is None None O
a None None O
transducer None None O
of None None O
the None None O
skin None None O
tanning None None O
signal None None O
and None None O
an None None O
essential None None O
component None None O
of None None O
what None None O
is None None O
effectively None None O
a None None O
keratinocyte None None O
- None None O
melanocyte None None O
signaling None None O
cycle None None O
that None None O
regulates None None O
skin None None O
pigmentation None None O
. None None O

It None None O
is None None O
clear None None O
that None None O
this None None O
cycle None None O
functions None None O
optimally None None O
in None None O
skin None None O
of None None O
dark None None O
pigmentation None None O
. None None O

When None None O
melanin None None O
biosynthesis None None O
is None None O
genetically None None O
disrupted None None O
in None None O
skin None None O
of None None O
white None None O
complexion None None O
, None None O
we None None O
propose None None O
that None None O
this None None O
cycle None None O
operates None None O
as None None O
a None None O
promoter None None O
of None None O
melanocyte None None O
proliferation None None O
. None None O

The None None O
cell None None O
autonomous None None O
function None None O
of None None O
p53 None None O
in None None O
melanocytes None None O
is None None O
not None None O
well None None O
described None None O
, None None O
however None None O
, None None O
the None None O
balance None None O
of None None O
the None None O
evidence None None O
suggests None None O
that None None O
p53 None None O
is None None O
an None None O
effective None None O
tumor None None O
suppressor None None O
and None None O
the None None O
myriad None None O
of None None O
mechanisms None None O
by None None O
which None None O
the None None O
p53 None None O
pathway None None O
may None None O
be None None O
dysregulated None None O
in None None O
tumors None None O
attests None None O
to None None O
it None None O
importance None None O
as None None O
a None None O
tumor None None O
suppressor None None O
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
outline None None O
the None None O
known None None O
mechanisms None None O
that None None O
impair None None O
p53 None None O
itself None None O
and None None O
its None None O
immediate None None O
regulators None None O
or None None O
target None None O
genes None None O
during None None O
melanomagenesis None None O
. None None O

Due None None O
to None None O
the None None O
importance None None O
of None None O
this None None O
pathway None None O
, None None O
it None None O
is None None O
clear None None O
that None None O
p53 None None O
disruptions None None O
may None None O
relate None None O
directly None None O
to None None O
a None None O
patient None None O
' None None O
s None None O
prognosis None None O
. None None O

This None None O
pathway None None O
will None None O
continue None None O
to None None O
be None None O
a None None O
focus None None O
of None None O
investigation None None O
, None None O
particularly None None O
with None None O
respect None None O
to None None O
targeted None None O
experimental None None O
chemotherapeutics None None O
. None None O

Insulin None None O
- None None O
like None None O
growth None None O
factor None None O
- None None O
I None None O
receptor None None O
- None None O
mediated None None O
vasculogenesis None None O
/ None None O
angiogenesis None None O
in None None O
human None None O
lung None None O
development None None O
. None None O

The None None O
structural None None O
and None None O
functional None None O
development None None O
of None None O
the None None O
pulmonary None None O
system None None O
is None None O
dependent None None O
upon None None O
appropriate None None O
early None None O
vascularization None None O
of None None O
the None None O
embryonic None None O
lung None None O
. None None O

Our None None O
previous None None O
in None None O
vitro None None O
studies None None O
in None None O
a None None O
rat None None O
model None None O
indicated None None O
that None None O
insulin None None O
- None None O
like None None O
growth None None O
factor None None O
- None None O
I None None O
( None None O
IGF None None O
- None None O
I None None O
) None None O
is None None O
a None None O
potent None None O
angiogenic None None O
agent None None O
for None None O
fetal None None O
lung None None O
endothelial None None O
cells None None O
. None None O

To None None O
assess None None O
its None None O
role None None O
on None None O
human None None O
vascular None None O
lung None None O
development None None O
, None None O
we None None O
first None None O
examined None None O
the None None O
expression None None O
of None None O
IGF None None O
- None None O
I None None O
/ None None O
II None None O
and None None O
IGF None None O
receptor None None O
type None None O
I None None O
( None None O
IGF None None O
- None None O
IR None None O
) None None O
in None None O
human None None O
embryonic None None O
and None None O
fetal None None O
lung None None O
tissues None None O
at None None O
4 None None O
- None None O
12 None None O
wk None None O
of None None O
gestation None None O
. None None O

Immunohistochemical None None O
and None None O
in None None O
situ None None O
hybridization None None O
studies None None O
revealed None None O
the None None O
presence None None O
of None None O
IGF None None O
- None None O
I None None O
/ None None O
II None None O
- None None O
IGF None None O
- None None O
IR None None O
ligands None None O
and None None O
mRNA None None O
transcripts None None O
in None None O
embryonic None None O
lungs None None O
as None None O
early None None O
as None None O
4 None None O
wk None None O
gestation None None O
. None None O

Immunotargeting None None O
using None None O
an None None O
anti None None O
- None None O
IGF None None O
- None None O
IR None None O
neutralizing None None O
antibody None None O
on None None O
human None None O
fetal None None O
lung None None O
explants None None O
demonstrated None None O
a None None O
significant None None O
blockade None None O
of None None O
IGF None None O
- None None O
IR None None O
signaling None None O
. None None O

Inactivation None None O
of None None O
IGF None None O
- None None O
IR None None O
resulted None None O
in None None O
a None None O
loss None None O
of None None O
endothelial None None O
cells None None O
, None None O
accompanied None None O
by None None O
dramatic None None O
changes None None O
in None None O
fetal None None O
lung None None O
explant None None O
morphology None None O
. None None O

Terminal None None O
transferase None None O
dUTP None None O
end None None O
- None None O
labeling None None O
assay None None O
and None None O
TEM None None O
studies None None O
of None None O
anti None None O
- None None O
IGF None None O
- None None O
IR None None O
- None None O
treated None None O
lungs None None O
demonstrated None None O
numerous None None O
apoptotic None None O
mesenchymal None None O
cells None None O
. None None O

Rat None None O
embryonic None None O
lung None None O
explant None None O
studies None None O
further None None O
validated None None O
the None None O
importance None None O
of None None O
the None None O
IGF None None O
- None None O
IGF None None O
- None None O
IR None None O
system None None O
for None None O
lung None None O
vascular None None O
development None None O
. None None O

These None None O
data None None O
provide None None O
the None None O
first None None O
demonstration None None O
of None None O
IGF None None O
- None None O
I None None O
/ None None O
II None None O
expression None None O
in None None O
the None None O
human None None O
lung None None O
in None None O
early None None O
gestation None None O
and None None O
indicate None None O
that None None O
the None None O
IGF None None O
family None None O
of None None O
growth None None O
factors None None O
, None None O
acting None None O
through None None O
the None None O
IGF None None O
- None None O
IR None None O
, None None O
is None None O
required None None O
as None None O
a None None O
survival None None O
factor None None O
during None None O
normal None None O
human None None O
lung None None O
vascularization None None O
. None None O

1 None None O
. None None O

Introduction None None O

Phase None None O
I None None O
clinical None None O
trials None None O
of None None O
new None None O
anticancer None None O
agents None None O
have None None O
been None None O
commonly None None O
conducted None None O
using None None O
the None None O
method None None O
of None None O
modified None None O
Fibonacci None None O
[ None None O
1 None None O
] None None O
. None None O

In None None O
brief None None O
, None None O
3 None None O
patients None None O
are None None O
treated None None O
at None None O
a None None O
starting None None O
dose None None O
which None None O
is None None O
typically None None O
one None None O
tenth None None O
of None None O
the None None O
dose None None O
that None None O
is None None O
lethal None None O
to None None O
10 None None O
% None None O
of None None O
animals None None O
defined None None O
in None None O
preclinical None None O
studies None None O
. None None O

If None None O
none None None O
of None None O
the None None O
3 None None O
patients None None O
experiences None None O
DLT None None O
, None None O
then None None O
the None None O
next None None O
3 None None O
patients None None O
will None None O
be None None O
treated None None O
at None None O
the None None O
next None None O
higher None None O
dose None None O
. None None O

If None None O
DLT None None O
is None None O
observed None None O
, None None O
additional None None O
patients None None O
will None None O
be None None O
treated None None O
at None None O
the None None O
same None None O
or None None O
lower None None O
dose None None O
level None None O
to None None O
determine None None O
MTD None None O
according None None O
to None None O
a None None O
predetermined None None O
schema None None O
. None None O

The None None O
MTD None None O
is None None O
defined None None O
as None None O
the None None O
highest None None O
dose None None O
reached None None O
for None None O
which None None O
the None None O
incidence None None O
of None None O
DLT None None O
occurs None None O
in None None O
less None None O
than None None O
33 None None O
% None None O
of None None O
the None None O
subjects None None O
. None None O

Typically None None O
, None None O
intrapatient None None O
dose None None O
escalation None None O
is None None O
not None None O
allowed None None O
. None None O

There None None O
are None None O
several None None O
shortcomings None None O
associated None None O
with None None O
the None None O
modified None None O
- None None O
Fibonacci None None O
design None None O
. None None O

It None None O
has None None O
long None None O
been None None O
recognized None None O
that None None O
a None None O
substantial None None O
number None None O
of None None O
patients None None O
are None None O
likely None None O
to None None O
be None None O
treated None None O
at None None O
subtherapeutic None None O
doses None None O
[ None None O
2 None None O
, None None O
3 None None O
] None None O
. None None O

This None None O
is None None O
particularly None None O
true None None O
for None None O
drugs None None O
with None None O
potential None None O
anticancer None None O
activity None None O
. None None O

Since None None O
the None None O
primary None None O
purpose None None O
of None None O
phase None None O
I None None O
trials None None O
is None None O
to None None O
determine None None O
DLT None None O
and None None O
MTD None None O
, None None O
the None None O
efficacy None None O
of None None O
the None None O
drug None None O
may None None O
not None None O
be None None O
evident None None O
for None None O
certain None None O
tumor None None O
types None None O
as None None O
there None None O
are None None O
only None None O
a None None O
small None None O
number None None O
of None None O
patients None None O
enrolled None None O
into None None O
the None None O
trial None None O
. None None O

Furthermore None None O
, None None O
the None None O
modified None None O
- None None O
Fibonacci None None O
design None None O
does None None O
not None None O
take None None O
into None None O
account None None O
individual None None O
variations None None O
in None None O
therapeutic None None O
and None None O
toxicologic None None O
responses None None O
due None None O
to None None O
genomic None None O
polymorphisms None None O
[ None None O
4 None None O
, None None O
5 None None O
] None None O
. None None O

In None None O
addition None None O
, None None O
since None None O
there None None O
is None None O
a None None O
limit None None O
of None None O
3 None None O
subjects None None O
allowed None None O
for None None O
each None None O
cohort None None O
, None None O
a None None O
waiting None None O
period None None O
of None None O
up None None O
to None None O
four None None O
weeks None None O
is None None O
commonly None None O
required None None O
before None None O
enrollment None None O
of None None O
the None None O
next None None O
cohort None None O
of None None O
subjects None None O
. None None O

This None None O
latter None None O
requirement None None O
creates None None O
anxiety None None O
of None None O
waiting None None O
for None None O
eligible None None O
patients None None O
. None None O

Several None None O
alternative None None O
phase None None O
I None None O
designs None None O
have None None O
been None None O
proposed None None O
which None None O
limit None None O
the None None O
number None None O
of None None O
patients None None O
accrued None None O
at None None O
each None None O
dose None None O
level None None O
and None None O
accelerate None None O
the None None O
dose None None O
escalation None None O
process None None O
[ None None O
1 None None O
, None None O
6 None None O
] None None O
. None None O

There None None O
has None None O
also None None O
been None None O
an None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
clinical None None O
trials None None O
that None None O
include None None O
a None None O
component None None O
of None None O
intrapatient None None O
dose None None O
escalation None None O
although None None O
no None None O
formal None None O
validation None None O
with None None O
the None None O
modified None None O
- None None O
Fibonacci None None O
approach None None O
has None None O
been None None O
reported None None O
[ None None O
7 None None O
- None None O
9 None None O
] None None O
. None None O

We None None O
have None None O
pioneered None None O
a None None O
population None None O
- None None O
based None None O
design None None O
to None None O
maximize None None O
therapeutic None None O
efficacy None None O
, None None O
to None None O
provide None None O
preliminary None None O
efficacy None None O
information None None O
and None None O
to None None O
allow None None O
derivation None None O
of None None O
a None None O
pMTD None None O
for None None O
subsequent None None O
phase None None O
II None None O
trials None None O
. None None O

Irinotecan None None O
and None None O
cisplatin None None O
have None None O
been None None O
shown None None O
to None None O
have None None O
promising None None O
efficacy None None O
in None None O
patients None None O
with None None O
small None None O
- None None O
cell None None O
lung None None O
cancer None None O
in None None O
phase None None O
III None None O
trial None None O
where None None O
irinotecan None None O
was None None O
given None None O
on None None O
a None None O
weekly None None O
schedule None None O
[ None None O
10 None None O
] None None O
. None None O

We None None O
wished None None O
to None None O
perform None None O
a None None O
population None None O
- None None O
based None None O
phase None None O
I None None O
trial None None O
of None None O
irinotecan None None O
, None None O
given None None O
every None None O
3 None None O
weeks None None O
, None None O
and None None O
carboplatin None None O
, None None O
a None None O
platinated None None O
anticancer None None O
drug None None O
which None None O
is None None O
generally None None O
better None None O
tolerated None None O
than None None O
its None None O
cisplatin None None O
analog None None O
. None None O

Experimental None None O
investigation None None O
of None None O
equibiaxial None None O
extension None None O
and None None O
breakup None None O
of None None O
drops None None O
in None None O
a None None O
molten None None O
two None None O
- None None O
phase None None O
polymer None None O
blend None None O
. None None O

We None None O
experimentally None None O
investigate None None O
the None None O
breakup None None O
of None None O
an None None O
equibiaxially None None O
elongated None None O
polystyrene None None O
( None None O
PS None None O
) None None O
drop None None O
in None None O
a None None O
poly None None O
( None None O
methyl None None O
methacrylate None None O
) None None O
( None None O
PMMA None None O
) None None O
matrix None None O
during None None O
relaxation None None O
after None None O
melt None None O
elongation None None O
. None None O

In None None O
equibiaxial None None O
elongation None None O
, None None O
the None None O
initially None None O
spherical None None O
PS None None O
drop None None O
is None None O
deformed None None O
into None None O
an None None O
ellipsoidal None None O
disclike None None O
shape None None O
for None None O
our None None O
test None None O
parameters None None O
. None None O

Using None None O
a None None O
hotstage None None O
in None None O
combination None None O
with None None O
a None None O
light None None O
microscope None None O
, None None O
we None None O
observe None None O
the None None O
evolution None None O
of None None O
the None None O
drop None None O
shape None None O
during None None O
relaxation None None O
. None None O

In None None O
the None None O
initial None None O
stage None None O
of None None O
relaxation None None O
, None None O
fingers None None O
and None None O
holes None None O
are None None O
formed None None O
. None None O

The None None O
holes None None O
are None None O
located None None O
preferentially None None O
near None None O
the None None O
rim None None O
of None None O
the None None O
drop None None O
. None None O

The None None O
number None None O
and None None O
the None None O
size None None O
of None None O
the None None O
holes None None O
increase None None O
with None None O
time None None O
such None None O
that None None O
the None None O
elongated None None O
PS None None O
drop None None O
attains None None O
a None None O
complex None None O
shape None None O
during None None O
relaxation None None O
. None None O

The None None O
fingers None None O
form None None O
bulbous None None O
ends None None O
which None None O
separate None None O
from None None O
the None None O
fingers None None O
. None None O

We None None O
discuss None None O
the None None O
dynamics None None O
of None None O
this None None O
breakup None None O
process None None O
by None None O
taking None None O
into None None O
account None None O
the None None O
interfacial None None O
energy None None O
between None None O
PS None None O
and None None O
PMMA None None O
. None None O

Our None None O
analysis None None O
shows None None O
that None None O
a None None O
very None None O
large None None O
number None None O
of None None O
small None None O
PS None None O
droplets None None O
can None None O
be None None O
generated None None O
by None None O
the None None O
sequential None None O
breakup None None O
of None None O
the None None O
elongated None None O
PS None None O
drop None None O
. None None O

Inhibition None None O
of None None O
calmodulin None None O
- None None O
dependent None None O
myosin None None O
light None None O
- None None O
chain None None O
kinase None None O
by None None O
growth None None O
- None None O
hormone None None O
- None None O
releasing None None O
factor None None O
and None None O
vasoactive None None O
intestinal None None O
peptide None None O
. None None O

In None None O
view None None O
of None None O
the None None O
ability None None O
of None None O
calmodulin None None O
to None None O
bind None None O
vasoactive None None O
intestinal None None O
peptide None None O
( None None O
VIP None None O
) None None O
and None None O
growth None None O
- None None O
hormone None None O
- None None O
releasing None None O
factor None None O
( None None O
GRF None None O
) None None O
with None None O
high None None O
affinity None None O
[ None None O
Stallwood None None O
, None None O
Brugger None None O
, None None O
Baggenstoss None None O
, None None O
Stemmer None None O
, None None O
Shiraga None None O
, None None O
Landers None None O
and None None O
Paul None None O
( None None O
1992 None None O
) None None O
J None None O
. None None O
Biol None None O
. None None O
Chem None None O
. None None O
267 None None O
, None None O
19617 None None O
- None None O
19621 None None O
] None None O
, None None O
the None None O
effects None None O
of None None O
these None None O
neuropeptides None None O
on None None O
a None None O
model None None O
calmodulin None None O
- None None O
dependent None None O
enzyme None None O
, None None O
myosin None None O
light None None O
- None None O
chain None None O
kinase None None O
( None None O
MLCK None None O
) None None O
, None None O
were None None O
studied None None O
. None None O

Both None None O
peptides None None O
were None None O
potent None None O
inhibitors None None O
of None None O
MLCK None None O
activity None None O
. None None O

The None None O
inhibition None None O
of None None O
enzyme None None O
activity None None O
by None None O
VIP None None O
and None None O
GRF None None O
was None None O
progressively None None O
overcome None None O
with None None O
increasing None None O
calmodulin None None O
concentrations None None O
, None None O
with None None O
no None None O
inhibition None None O
observed None None O
at None None O
a None None O
saturating None None O
calmodulin None None O
concentration None None O
. None None O

Nanomolar None None O
concentrations None None O
of None None O
MLCK None None O
blocked None None O
the None None O
formation None None O
of None None O
calmodulin None None O
- None None O
[ None None O
125I None None O
- None None O
Tyr10 None None O
] None None O
VIP None None O
complexes None None O
. None None O

These None None O
data None None O
provide None None O
support None None O
for None None O
a None None O
functional None None O
role None None O
of None None O
VIP None None O
and None None O
GRF None None O
binding None None O
by None None O
calmodulin None None O
. None None O

[ None None O
H None None O
. None None O
pylori None None O
infection None None O
. None None O
Our None None O
experience None None O
with None None O
the None None O
quadruple None None O
and None None O
triple None None O
therapy None None O
as None None O
first None None O
pharmacologic None None O
approach None None O
] None None O
. None None O

For None None O
now None None O
the None None O
most None None O
used None None O
pharmacological None None O
treatment None None O
of None None O
first None None O
instance None None O
to None None O
eradication None None O
of None None O
Hp None None O
foresees None None O
utilization None None O
of None None O
triple None None O
therapy None None O
( None None O
PPI None None O
+ None None O
two None None O
antibiotics None None O
) None None O
. None None O

In None None O
our None None O
study None None O
we None None O
have None None O
compared None None O
this None None O
kind None None O
of None None O
treatment None None O
with None None O
the None None O
quadruple None None O
therapy None None O
( None None O
PPI None None O
+ None None O
three None None O
antibiotics None None O
) None None O
, None None O
that None None O
have None None O
showed None None O
a None None O
taller None None O
percentage None None O
of None None O
eradication None None O
at None None O
the None None O
end None None O
of None None O
first None None O
therapeutical None None O
cycle None None O
with None None O
a None None O
shorter None None O
time None None O
and None None O
lower None None O
price None None O
of None None O
treatment None None O
. None None O

Colorimetrical None None O
rate None None O
assay None None O
for None None O
urinary None None O
dipeptidyl None None O
peptidase None None O
IV None None O
( None None O
DPPIV None None O
) None None O
activity None None O
using None None O
a None None O
new None None O
substrate None None O
. None None O

We None None O
synthesized None None O
a None None O
new None None O
substrate None None O
glycyl None None O
- None None O
L None None O
- None None O
proline None None O
3 None None O
, None None O
5 None None O
- None None O
dibromo None None O
- None None O
4 None None O
- None None O
hydroxyanilide None None O
( None None O
Gly None None O
- None None O
Pro None None O
- None None O
DBAP None None O
) None None O
, None None O
for None None O
dipeptidyl None None O
peptidase None None O
IV None None O
( None None O
DPPIV None None O
) None None O
. None None O

Its None None O
hydrolysis None None O
by None None O
DPPIV None None O
resulted None None O
in None None O
the None None O
formation None None O
of None None O
a None None O
chromophore None None O
, None None O
2 None None O
, None None O
6 None None O
- None None O
dibromophenol None None O
- None None O
indo None None O
- None None O
p None None O
- None None O
xylenol None None O
, None None O
and None None O
its None None O
maximal None None O
absorption None None O
wavelength None None O
( None None O
600 None None O
nm None None O
) None None O
was None None O
longer None None O
than None None O
that None None O
of None None O
p None None O
- None None O
nitroaniline None None O
( None None O
415 None None O
nm None None O
) None None O
released None None O
from None None O
conventional None None O
substrate None None O
, None None O
glycyl None None O
- None None O
L None None O
- None None O
proline None None O
p None None O
- None None O
nitroanilide None None O
( None None O
Gly None None O
- None None O
Pro None None O
- None None O
pNA None None O
) None None O
. None None O

We None None O
also None None O
established None None O
the None None O
rate None None O
assay None None O
for None None O
urinary None None O
DPPIV None None O
activity None None O
using None None O
Gly None None O
- None None O
Pro None None O
- None None O
DBAP None None O
. None None O

The None None O
optimum None None O
pH None None O
was None None O
between None None O
8 None None O
. None None O
5 None None O
and None None O
9 None None O
. None None O
0 None None O
. None None O

The None None O
apparent None None O
Km None None O
was None None O
1 None None O
. None None O
1 None None O
mmol None None O
/ None None O
1 None None O
. None None O

The None None O
detectable None None O
range None None O
was None None O
2 None None O
. None None O
5 None None O
- None None O
350 None None O
U None None O
/ None None O
l None None O
. None None O

No None None O
changes None None O
in None None O
blank None None O
values None None O
occurred None None O
throughout None None O
the None None O
enzyme None None O
reaction None None O
in None None O
the None None O
optimum None None O
pH None None O
. None None O

Its None None O
value None None O
was None None O
also None None O
much None None O
lower None None O
than None None O
Gly None None O
- None None O
Pro None None O
- None None O
pNA None None O
. None None O

CVs None None O
for None None O
within None None O
- None None O
run None None O
and None None O
between None None O
- None None O
run None None O
were None None O
1 None None O
. None None O
1 None None O
% None None O
( None None O
n None None O
= None None O
10 None None O
) None None O
and None None O
3 None None O
. None None O
0 None None O
% None None O
( None None O
n None None O
= None None O
10 None None O
) None None O
, None None O
respectively None None O
. None None O

Among None None O
tested None None O
peptidases None None O
, None None O
only None None O
DPPIV None None O
could None None O
hydrolyze None None O
Gly None None O
- None None O
Pro None None O
- None None O
DBAP None None O
. None None O

Among None None O
the None None O
protease None None O
inhibitors None None O
, None None O
only None None O
two None None O
, None None O
diprotin None None O
- None None O
A None None O
and None None O
phenylmethylsulfonyl None None O
fluoride None None O
( None None O
PMSA None None O
) None None O
, None None O
could None None O
inhibit None None O
DPPIV None None O
activity None None O
. None None O

The None None O
present None None O
method None None O
did None None O
not None None O
interfere None None O
with None None O
urinary None None O
ingredients None None O
such None None O
as None None O
hemoglobin None None O
. None None O

The None None O
correlation None None O
between None None O
the None None O
present None None O
( None None O
y None None O
) None None O
and None None O
conventional None None O
( None None O
x None None O
) None None O
methods None None O
is None None O
presented None None O
by None None O
the None None O
equation None None O
y None None O
= None None O
1 None None O
. None None O
121x None None O
+ None None O
0 None None O
. None None O
096 None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
993 None None O
) None None O
. None None O

Thus None None O
the None None O
present None None O
method None None O
provides None None O
practical None None O
advantages None None O
over None None O
the None None O
conventional None None O
method None None O
for None None O
routine None None O
laboratory None None O
use None None O
. None None O

Clinical None None O
implication None None O
of None None O
expression None None O
of None None O
cyclooxygenase None None O
- None None O
2 None None O
and None None O
peroxisome None None O
proliferator None None O
activated None None O
- None None O
receptor None None O
gamma None None O
in None None O
epithelial None None O
ovarian None None O
tumours None None O
. None None O

Expression None None O
of None None O
cyclooxygenase None None O
( None None O
COX None None O
) None None O
- None None O
2 None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
tumorigenesis None None O
and None None O
development None None O
and None None O
peroxisome None None O
proliferator None None O
- None None O
activated None None O
receptor None None O
gamma None None O
( None None O
PPARgamma None None O
) None None O
has None None O
been None None O
implicated None None O
in None None O
the None None O
control None None O
of None None O
COX None None O
- None None O
2 None None O
expression None None O
in None None O
some None None O
tissues None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
is None None O
to None None O
investigate None None O
( None None O
1 None None O
) None None O
whether None None O
expression None None O
of None None O
COX None None O
- None None O
2 None None O
and None None O
PPARgamma None None O
is None None O
associated None None O
with None None O
ovarian None None O
carcinogenesis None None O
and None None O
progression None None O
of None None O
ovarian None None O
tumours None None O
and None None O
( None None O
2 None None O
) None None O
whether None None O
COX None None O
- None None O
2 None None O
expression None None O
is None None O
controlled None None O
through None None O
ligand None None O
- None None O
mediated None None O
activation None None O
of None None O
PPARgamma None None O
in None None O
ovarian None None O
carcinoma None None O
cells None None O
. None None O

For None None O
this None None O
purpose None None O
, None None O
the None None O
presence None None O
of None None O
COX None None O
- None None O
2 None None O
and None None O
PPARgamma None None O
was None None O
immunohistochemically None None O
examined None None O
in None None O
71 None None O
epithelial None None O
ovarian None None O
carcinomas None None O
, None None O
18 None None O
borderline None None O
tumours None None O
and None None O
23 None None O
benign None None O
tumours None None O
and None None O
the None None O
levels None None O
of None None O
COX None None O
- None None O
2 None None O
and None None O
PPARgamma None None O
proteins None None O
were None None O
determined None None O
by None None O
enzyme None None O
immunoassay None None O
in None None O
four None None O
benign None None O
tumours None None O
, None None O
three None None O
borderline None None O
tumours None None O
and None None O
12 None None O
carcinomas None None O
. None None O

The None None O
frequency None None O
of None None O
COX None None O
- None None O
2 None None O
and None None O
PPARgamma None None O
detection None None O
was None None O
significantly None None O
increased None None O
and None None O
decreased None None O
as None None O
lesions None None O
progressed None None O
to None None O
carcinoma None None O
, None None O
respectively None None O
. None None O

The None None O
COX None None O
- None None O
2 None None O
protein None None O
was None None O
not None None O
detected None None O
in None None O
the None None O
three None None O
borderline None None O
tumours None None O
, None None O
whereas None None O
PPARgamma None None O
protein None None O
was None None O
detected None None O
in None None O
all None None O
of None None O
them None None O
. None None O

COX None None O
- None None O
2 None None O
protein None None O
was None None O
detected None None O
in None None O
eight None None O
of None None O
the None None O
12 None None O
carcinomas None None O
, None None O
whereas None None O
PPARgamma None None O
protein None None O
was None None O
detected None None O
in None None O
only None None O
two None None O
cases None None O
. None None O

In None None O
addition None None O
, None None O
PPARgamma None None O
protein None None O
was None None O
not None None O
detected None None O
in None None O
all None None O
of None None O
the None None O
eight None None O
carcinomas None None O
in None None O
which None None O
COX None None O
- None None O
2 None None O
protein None None O
was None None O
detected None None O
, None None O
suggesting None None O
that None None O
expression None None O
of None None O
PPARgamma None None O
and None None O
COX None None O
- None None O
2 None None O
was None None O
in None None O
a None None O
reciprocal None None O
relationship None None O
. None None O

Furthermore None None O
, None None O
in None None O
cultured None None O
ovarian None None O
carcinoma None None O
cells None None O
, None None O
Western None None O
blot None None O
revealed None None O
that None None O
PPARgamma None None O
and None None O
COX None None O
- None None O
2 None None O
expression None None O
was None None O
regulated None None O
conversely None None O
as None None O
a None None O
result None None O
of None None O
stimulation None None O
by None None O
15 None None O
- None None O
deoxy None None O
- None None O
Delta None None O
( None None O
12 None None O
, None None O
14 None None O
) None None O
PGJ None None O
( None None O
2 None None O
) None None O
( None None O
15 None None O
- None None O
PGJ None None O
( None None O
2 None None O
) None None O
) None None O
, None None O
a None None O
PPARgamma None None O
activator None None O
. None None O

In None None O
addition None None O
, None None O
15d None None O
- None None O
PGJ None None O
( None None O
2 None None O
) None None O
suppressed None None O
tumour None None O
necrosis None None O
factor None None O
- None None O
alpha None None O
- None None O
induced None None O
- None None O
COX None None O
- None None O
2 None None O
expression None None O
, None None O
confirming None None O
the None None O
reciprocal None None O
correlation None None O
between None None O
COX None None O
- None None O
2 None None O
and None None O
PPARgamma None None O
. None None O

From None None O
these None None O
results None None O
, None None O
it None None O
was None None O
suggested None None O
that None None O
PPARgamma None None O
activation None None O
might None None O
suppress None None O
COX None None O
- None None O
2 None None O
expression None None O
via None None O
the None None O
nuclear None None O
factor None None O
- None None O
kappaB None None O
pathway None None O
in None None O
the None None O
ovarian None None O
carcinoma None None O
cells None None O
and None None O
that None None O
low None None O
expression None None O
of None None O
PPARgamma None None O
and None None O
high None None O
expression None None O
of None None O
COX None None O
- None None O
2 None None O
might None None O
be None None O
involved None None O
in None None O
carcinogenesis None None O
and None None O
progression None None O
of None None O
ovarian None None O
tumours None None O
. None None O

Is None None O
there None None O
an None None O
upper None None O
limit None None O
of None None O
intracranial None None O
pressure None None O
in None None O
patients None None O
with None None O
severe None None O
head None None O
injury None None O
if None None O
cerebral None None O
perfusion None None O
pressure None None O
is None None O
maintained None None O
? None None O

Authors None None O
of None None O
recent None None O
studies None None O
have None None O
championed None None O
the None None O
importance None None O
of None None O
maintaining None None O
cerebral None None O
perfusion None None O
pressure None None O
( None None O
CPP None None O
) None None O
to None None O
prevent None None O
secondary None None O
brain None None O
injury None None O
following None None O
traumatic None None O
head None None O
injury None None O
. None None O

Data None None O
from None None O
these None None O
studies None None O
have None None O
provided None None O
little None None O
information None None O
regarding None None O
outcome None None O
following None None O
severe None None O
head None None O
injury None None O
in None None O
patients None None O
with None None O
an None None O
intracranial None None O
pressure None None O
( None None O
ICP None None O
) None None O
greater None None O
than None None O
40 None None O
mm None None O
Hg None None O
, None None O
however None None O
, None None O
in None None O
July None None O
1997 None None O
the None None O
authors None None O
instituted None None O
a None None O
protocol None None O
for None None O
the None None O
management None None O
of None None O
severe None None O
head None None O
injury None None O
in None None O
patients None None O
with None None O
a None None O
Glasgow None None O
Coma None None O
Scale None None O
score None None O
lower None None O
than None None O
9 None None O
. None None O

The None None O
protocol None None O
was None None O
focused None None O
on None None O
resuscitation None None O
from None None O
acidosis None None O
, None None O
maintenance None None O
of None None O
a None None O
CPP None None O
greater None None O
than None None O
60 None None O
mm None None O
Hg None None O
through None None O
whatever None None O
means None None O
necessary None None O
as None None O
well None None O
as None None O
elevation None None O
of None None O
the None None O
head None None O
of None None O
the None None O
bed None None O
, None None O
mannitol None None O
infusion None None O
, None None O
and None None O
ventriculostomy None None O
with None None O
cerebrospinal None None O
fluid None None O
drainage None None O
for None None O
control None None O
of None None O
ICP None None O
. None None O

Since None None O
the None None O
institution None None O
of None None O
this None None O
protocol None None O
, None None O
nine None None O
patients None None O
had None None O
a None None O
sustained None None O
ICP None None O
greater None None O
than None None O
40 None None O
mm None None O
Hg None None O
for None None O
2 None None O
or None None O
more None None O
hours None None O
, None None O
and None None O
five None None O
of None None O
these None None O
had None None O
an None None O
ICP None None O
greater None None O
than None None O
75 None None O
mm None None O
Hg None None O
on None None O
insertion None None O
of None None O
the None None O
ICP None None O
monitor None None O
and None None O
later None None O
experienced None None O
herniation None None O
and None None O
expired None None O
within None None O
24 None None O
hours None None O
. None None O

Because None None O
of None None O
the None None O
severe None None O
nature None None O
of None None O
the None None O
injuries None None O
demonstrated None None O
on None None O
computerized None None O
tomography None None O
scans None None O
and None None O
their None None O
physical None None O
examinations None None O
, None None O
these None None O
patients None None O
were None None O
not None None O
aggressively None None O
treated None None O
under None None O
this None None O
protocol None None O
. None None O

The None None O
authors None None O
vigorously None None O
attempted None None O
to None None O
maintain None None O
a None None O
CPP None None O
greater None None O
than None None O
60 None None O
mm None None O
Hg None None O
with None None O
intensive None None O
fluid None None O
resuscitation None None O
and None None O
the None None O
administration None None O
of None None O
pressor None None O
agents None None O
in None None O
the None None O
four None None O
remaining None None O
patients None None O
who None None O
had None None O
developed None None O
an None None O
ICP None None O
higher None None O
than None None O
40 None None O
mm None None O
Hg None None O
after None None O
placement None None O
of None None O
the None None O
ICP None None O
monitor None None O
. None None O

Two None None O
patients None None O
had None None O
an None None O
episodic None None O
ICP None None O
greater None None O
than None None O
40 None None O
mm None None O
Hg None None O
for None None O
more None None O
than None None O
36 None None O
hours None None O
, None None O
the None None O
third None None O
patient None None O
had None None O
an None None O
episodic None None O
ICP None None O
greater None None O
than None None O
of None None O
50 None None O
mm None None O
Hg None None O
for None None O
more None None O
than None None O
36 None None O
hours None None O
, None None O
and None None O
the None None O
fourth None None O
patient None None O
had None None O
an None None O
episodic None None O
ICP None None O
greater None None O
than None None O
50 None None O
mm None None O
Hg None None O
for None None O
more None None O
than None None O
48 None None O
hours None None O
. None None O

On None None O
discharge None None O
, None None O
all None None O
four None None O
patients None None O
were None None O
able None None O
to None None O
perform None None O
normal None None O
activities None None O
of None None O
daily None None O
living None None O
with None None O
minimal None None O
assistance None None O
and None None O
experience None None O
ongoing None None O
improvement None None O
. None None O

Data None None O
from None None O
this None None O
preliminary None None O
study None None O
indicate None None O
that None None O
intense None None O
, None None O
aggressive None None O
management None None O
of None None O
CPP None None O
can None None O
lead None None O
to None None O
good None None O
neurological None None O
outcomes None None O
despite None None O
extremely None None O
high None None O
ICP None None O
. None None O

Aggressive None None O
CPP None None O
therapy None None O
should None None O
be None None O
performed None None O
and None None O
maintained None None O
even None None O
though None None O
apparently None None O
lethal None None O
ICP None None O
levels None None O
may None None O
be None None O
present None None O
. None None O

Further None None O
study None None O
is None None O
needed None None O
to None None O
support None None O
these None None O
encouraging None None O
results None None O
. None None O

Oxidation None None O
in None None O
rheumatoid None None O
arthritis None None O
. None None O

Oxygen None None O
metabolism None None O
has None None O
an None None O
important None None O
role None None O
in None None O
the None None O
pathogenesis None None O
of None None O
rheumatoid None None O
arthritis None None O
. None None O

Reactive None None O
oxygen None None O
species None None O
( None None O
ROS None None O
) None None O
produced None None O
in None None O
the None None O
course None None O
of None None O
cellular None None O
oxidative None None O
phosphorylation None None O
, None None O
and None None O
by None None O
activated None None O
phagocytic None None O
cells None None O
during None None O
oxidative None None O
bursts None None O
, None None O
exceed None None O
the None None O
physiological None None O
buffering None None O
capacity None None O
and None None O
result None None O
in None None O
oxidative None None O
stress None None O
. None None O

The None None O
excessive None None O
production None None O
of None None O
ROS None None O
can None None O
damage None None O
protein None None O
, None None O
lipids None None O
, None None O
nucleic None None O
acids None None O
, None None O
and None None O
matrix None None O
components None None O
. None None O

They None None O
also None None O
serve None None O
as None None O
important None None O
intracellular None None O
signaling None None O
molecules None None O
that None None O
amplify None None O
the None None O
synovial None None O
inflammatory None None O
- None None O
proliferative None None O
response None None O
. None None O

Repetitive None None O
cycles None None O
of None None O
hypoxia None None O
and None None O
reoxygenation None None O
associated None None O
with None None O
changes None None O
in None None O
synovial None None O
perfusion None None O
are None None O
postulated None None O
to None None O
activate None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
- None None O
1alpha None None O
and None None O
nuclear None None O
factor None None O
- None None O
kappaB None None O
, None None O
two None None O
key None None O
transcription None None O
factors None None O
that None None O
are None None O
regulated None None O
by None None O
changes None None O
in None None O
cellular None None O
oxygenation None None O
and None None O
cytokine None None O
stimulation None None O
, None None O
and None None O
that None None O
in None None O
turn None None O
orchestrate None None O
the None None O
expression None None O
of None None O
a None None O
spectrum None None O
of None None O
genes None None O
critical None None O
to None None O
the None None O
persistence None None O
of None None O
synovitis None None O
. None None O

An None None O
understanding None None O
of None None O
the None None O
complex None None O
interactions None None O
involved None None O
in None None O
these None None O
pathways None None O
might None None O
allow None None O
the None None O
development None None O
of None None O
novel None None O
therapeutic None None O
strategies None None O
for None None O
rheumatoid None None O
arthritis None None O
. None None O

Neurotrophin None None O
p75 None None O
receptor None None O
( None None O
p75NTR None None O
) None None O
promotes None None O
endothelial None None O
cell None None O
apoptosis None None O
and None None O
inhibits None None O
angiogenesis None None O
: None None O
implications None None O
for None None O
diabetes None None O
- None None O
induced None None O
impaired None None O
neovascularization None None O
in None None O
ischemic None None O
limb None None O
muscles None None O
. None None O

Diabetes None None O
impairs None None O
endothelial None None O
function None None O
and None None O
reparative None None O
neovascularization None None O
. None None O

The None None O
p75 None None O
receptor None None O
of None None O
neurotrophins None None O
( None None O
p75 None None O
( None None O
NTR None None O
) None None O
) None None O
, None None O
which None None O
is None None O
scarcely None None O
present None None O
in None None O
healthy None None O
endothelial None None O
cells None None O
( None None O
ECs None None O
) None None O
, None None O
becomes None None O
strongly None None O
expressed None None O
by None None O
capillary None None O
ECs None None O
after None None O
induction None None O
of None None O
peripheral None None O
ischemia None None O
in None None O
type None None O
- None None O
1 None None O
diabetic None None O
mice None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
gene None None O
transfer None None O
- None None O
induced None None O
p75 None None O
( None None O
NTR None None O
) None None O
expression None None O
impairs None None O
the None None O
survival None None O
, None None O
proliferation None None O
, None None O
migration None None O
, None None O
and None None O
adhesion None None O
capacities None None O
of None None O
cultured None None O
ECs None None O
and None None O
endothelial None None O
progenitor None None O
cells None None O
( None None O
EPCs None None O
) None None O
and None None O
inhibits None None O
angiogenesis None None O
in None None O
vitro None None O
. None None O

Moreover None None O
, None None O
intramuscular None None O
p75 None None O
( None None O
NTR None None O
) None None O
gene None None O
delivery None None O
impairs None None O
neovascularization None None O
and None None O
blood None None O
flow None None O
recovery None None O
in None None O
a None None O
mouse None None O
model None None O
of None None O
limb None None O
ischemia None None O
. None None O

These None None O
disturbed None None O
functions None None O
are None None O
associated None None O
with None None O
suppression None None O
of None None O
signaling None None O
mechanisms None None O
implicated None None O
in None None O
EC None None O
survival None None O
and None None O
angiogenesis None None O
. None None O

In None None O
fact None None O
, None None O
p75 None None O
( None None O
NTR None None O
) None None O
depresses None None O
the None None O
VEGF None None O
- None None O
A None None O
/ None None O
Akt None None O
/ None None O
eNOS None None O
/ None None O
NO None None O
pathway None None O
and None None O
additionally None None O
reduces None None O
the None None O
mRNA None None O
levels None None O
of None None O
ITGB1 None None O
[ None None O
beta None None O
( None None O
1 None None O
) None None O
integrin None None O
] None None O
, None None O
BIRC5 None None O
( None None O
survivin None None O
) None None O
, None None O
PTTG1 None None O
( None None O
securin None None O
) None None O
and None None O
VEZF1 None None O
. None None O

Diabetic None None O
mice None None O
, None None O
which None None O
typically None None O
show None None O
impaired None None O
postischemic None None O
muscular None None O
neovascularization None None O
and None None O
blood None None O
perfusion None None O
recovery None None O
, None None O
have None None O
these None None O
defects None None O
corrected None None O
by None None O
intramuscular None None O
gene None None O
transfer None None O
of None None O
a None None O
dominant None None O
negative None None O
mutant None None O
form None None O
of None None O
p75 None None O
( None None O
NTR None None O
) None None O
. None None O

Collectively None None O
, None None O
our None None O
data None None O
newly None None O
demonstrate None None O
the None None O
antiangiogenic None None O
action None None O
of None None O
p75 None None O
( None None O
NTR None None O
) None None O
and None None O
open None None O
new None None O
avenues None None O
for None None O
the None None O
therapeutic None None O
use None None O
of None None O
p75 None None O
( None None O
NTR None None O
) None None O
inhibition None None O
to None None O
combat None None O
diabetes None None O
- None None O
induced None None O
microvascular None None O
liabilities None None O
. None None O

Tumour None None O
- None None O
specific None None O
distribution None None O
of None None O
BRCA1 None None O
promoter None None O
region None None O
methylation None None O
supports None None O
a None None O
pathogenetic None None O
role None None O
in None None O
breast None None O
and None None O
ovarian None None O
cancer None None O
. None None O

The None None O
role None None O
of None None O
BRCA1 None None O
in None None O
sporadic None None O
breast None None O
and None None O
ovarian None None O
cancers None None O
remains None None O
elusive None None O
. None None O

Direct None None O
involvement None None O
of None None O
BRCA1 None None O
in None None O
the None None O
development None None O
of None None O
breast None None O
and None None O
ovarian None None O
cancer None None O
is None None O
suggested None None O
by None None O
the None None O
finding None None O
that None None O
the None None O
BRCA1 None None O
promoter None None O
region None None O
CpG None None O
island None None O
is None None O
methylated None None O
in None None O
a None None O
proportion None None O
of None None O
breast None None O
and None None O
ovarian None None O
cancers None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
compare None None O
the None None O
incidence None None O
of None None O
BRCA1 None None O
promoter None None O
region None None O
methylation None None O
in None None O
tumours None None O
in None None O
which None None O
loss None None O
of None None O
BRCA1 None None O
has None None O
been None None O
shown None None O
to None None O
play None None O
a None None O
role None None O
in None None O
pathogenesis None None O
( None None O
breast None None O
and None None O
ovarian None None O
carcinomas None None O
) None None O
with None None O
the None None O
incidence None None O
in None None O
tumours None None O
in None None O
which None None O
BRCA1 None None O
is None None O
unlikely None None O
to None None O
play None None O
a None None O
role None None O
in None None O
pathogenesis None None O
. None None O

Promoter None None O
region None None O
hypermethylation None None O
was None None O
significantly None None O
more None None O
common None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
008 None None O
) None None O
in None None O
breast None None O
and None None O
ovarian None None O
cancer None None O
( None None O
6 None None O
/ None None O
38 None None O
tumours None None O
methylated None None O
) None None O
than None None O
in None None O
colon None None O
cancer None None O
( None None O
0 None None O
/ None None O
35 None None O
tumours None None O
methylated None None O
) None None O
or None None O
in None None O
leukaemias None None O
( None None O
0 None None O
/ None None O
19 None None O
samples None None O
methylated None None O
) None None O
. None None O

The None None O
restriction None None O
of None None O
BRCA1 None None O
promoter None None O
region None None O
hypermethylation None None O
to None None O
breast None None O
and None None O
ovarian None None O
cancer None None O
is None None O
consistent None None O
with None None O
a None None O
pathogenetic None None O
role None None O
of None None O
BRCA1 None None O
promoter None None O
methylation None None O
in None None O
these None None O
tumours None None O
. None None O

We None None O
suggest None None O
that None None O
the None None O
rarity None None O
of None None O
observed None None O
BRCA1 None None O
mutations None None O
in None None O
sporadic None None O
breast None None O
and None None O
ovarian None None O
cancer None None O
is None None O
due None None O
to None None O
the None None O
greater None None O
likelihood None None O
of None None O
BRCA1 None None O
inactivation None None O
by None None O
non None None O
- None None O
mutational None None O
mechanisms None None O
such None None O
as None None O
methylation None None O
. None None O

Statistical None None O
results None None O
showing None None O
significant None None O
differences None None O
between None None O
habitats None None O
. None None O

Abbreviations None None O

Ac None None O
- None None O
DEVD None None O
- None None O
AMC None None O
= None None O
N None None O
- None None O
acetyl None None O
- None None O
Asp None None O
- None None O
Glu None None O
- None None O
Val None None O
- None None O
Asp None None O
- None None O
7 None None O
- None None O
amino None None O
- None None O
4 None None O
- None None O
methylcoumarin None None O
; None None O
Ac None None O
- None None O
DEVD None None O
- None None O
CHO None None O
= None None O
N None None O
- None None O
acetyl None None O
- None None O
Asp None None O
- None None O
Glu None None O
- None None O
Val None None O
- None None O
Asp None None O
- None None O
aldehyde None None O
; None None O
COX None None O
= None None O
cyclooxygenase None None O
; None None O
Deltapsim None None O
= None None O
mitochondrial None None O
membrane None None O
potential None None O
; None None O
DAPI None None O
= None None O
4 None None O
' None None O
, None None O
6 None None O
- None None O
diamidino None None O
- None None O
2 None None O
- None None O
phenylindole None None O
; None None O
DMEM None None O
= None None O
Dulbecco None None O
' None None O
s None None O
modified None None O
Eagle None None O
' None None O
s None None O
medium None None O
; None None O
ELISA None None O
= None None O
enzyme None None O
- None None O
linked None None O
immunosorbent None None O
assay None None O
; None None O
FCS None None O
= None None O
fetal None None O
calf None None O
serum None None O
; None None O
FLS None None O
= None None O
fibroblast None None O
- None None O
like None None O
synoviocytes None None O
; None None O
IL None None O
= None None O
interleukin None None O
; None None O
JC None None O
- None None O
1 None None O
= None None O
5 None None O
, None None O
5 None None O
' None None O
, None None O
6 None None O
, None None O
6 None None O
' None None O
- None None O
tetrachloro None None O
- None None O
1 None None O
, None None O
1 None None O
' None None O
, None None O
3 None None O
, None None O
3 None None O
' None None O
- None None O
tetraethylbenzimidazole None None O
carbocyanide None None O
iodide None None O
; None None O
MTT None None O
= None None O
3 None None O
- None None O
( None None O
4 None None O
, None None O
5 None None O
- None None O
dimethylthiazol None None O
- None None O
2 None None O
- None None O
yl None None O
) None None O
- None None O
2 None None O
, None None O
5 None None O
- None None O
diphenyltetrazolium None None O
bromide None None O
; None None O
PBS None None O
= None None O
phosphate None None O
- None None O
buffered None None O
saline None None O
; None None O
PGE2 None None O
= None None O
prostaglandin None None O
E2 None None O
; None None O
RA None None O
= None None O
rheumatoid None None O
arthritis None None O
. None None O

Nuclear None None O
translocation None None O
of None None O
a None None O
clusterin None None O
isoform None None O
is None None O
associated None None O
with None None O
induction None None O
of None None O
anoikis None None O
in None None O
SV40 None None O
- None None O
immortalized None None O
human None None O
prostate None None O
epithelial None None O
cells None None O
. None None O

Clusterin None None O
gene None None O
expression None None O
is None None O
potently None None O
induced None None O
in None None O
experimental None None O
models None None O
in None None O
which None None O
apoptosis None None O
is None None O
activated None None O
, None None O
such None None O
as None None O
rat None None O
prostate None None O
involution None None O
following None None O
castration None None O
. None None O

Nevertheless None None O
, None None O
its None None O
precise None None O
physiological None None O
role None None O
has None None O
not None None O
yet None None O
been None None O
established None None O
, None None O
and None None O
both None None O
anti None None O
- None None O
apoptotic None None O
and None None O
pro None None O
- None None O
apoptotic None None O
functions None None O
have None None O
been None None O
suggested None None O
for None None O
this None None O
gene None None O
. None None O

Clusterin None None O
expression None None O
level None None O
depends None None O
on None None O
cell None None O
proliferation None None O
state None None O
, None None O
and None None O
we None None O
recently None None O
showed None None O
that None None O
its None None O
over None None O
- None None O
expression None None O
inhibited None None O
cell None None O
cycle None None O
progression None None O
of None None O
SV40 None None O
- None None O
immortalized None None O
human None None O
prostate None None O
epithelial None None O
cells None None O
PNT2 None None I-Cell-line-name
and None None O
PNT1a None None I-Cell-line-name
. None None O

Here None None O
we None None O
studied None None O
clusterin None None O
expression None None O
in None None O
PNT1a None None I-Cell-line-name
cells None None O
subjected None None O
to None None O
serum None None O
- None None O
starvation None None O
with None None O
the None None O
aim None None O
of None None O
defining None None O
clusterin None None O
early None None O
molecular None None O
changes None None O
following None None O
apoptosis None None O
induction None None O
. None None O

Under None None O
serum None None O
- None None O
starvation None None O
conditions None None O
, None None O
decreased None None O
growth None None O
rate None None O
, None None O
slow None None O
rounding None None O
- None None O
up None None O
of None None O
cells None None O
, None None O
cell None None O
detachment None None O
, None None O
and None None O
formation None None O
of None None O
apoptotic None None O
bodies None None O
indicative None None O
of None None O
anoikis None None O
( None None O
detachment None None O
- None None O
induced None None O
apoptosis None None O
) None None O
were None None O
preceded None None O
by None None O
significant None None O
downregulation None None O
of None None O
70 None None O
kDa None None O
clusterin None None O
precursor None None O
and None None O
upregulation None None O
of None None O
45 None None O
- None None O
40 None None O
kDa None None O
isoforms None None O
. None None O

On None None O
the None None O
8th None None O
day None None O
of None None O
serum None None O
- None None O
free None None O
culturing None None O
, None None O
only None None O
the None None O
higher None None O
molecular None None O
weight None None O
protein None None O
- None None O
band None None O
of None None O
about None None O
45 None None O
kDa None None O
was None None O
clearly None None O
induced None None O
and None None O
accumulated None None O
in None None O
detached None None O
cells None None O
and None None O
apoptotic None None O
bodies None None O
in None None O
which None None O
PARP None None O
was None None O
activated None None O
. None None O

Anoikis None None O
was None None O
preceded None None O
by None None O
induction None None O
and None None O
transloction None None O
of None None O
a None None O
45 None None O
- None None O
kDa None None O
clusterin None None O
isoform None None O
to None None O
the None None O
nucleus None None O
. None None O

Thus None None O
, None None O
nuclear None None O
targeting None None O
of None None O
a None None O
specific None None O
45 None None O
- None None O
kDa None None O
isoform None None O
of None None O
clusterin None None O
appeared None None O
to None None O
be None None O
an None None O
early None None O
and None None O
specific None None O
molecular None None O
signal None None O
triggering None None O
anoikis None None O
- None None O
death None None O
. None None O

Considering None None O
also None None O
that None None O
clusterin None None O
is None None O
downregulated None None O
during None None O
prostate None None O
cancer None None O
onset None None O
and None None O
progression None None O
, None None O
and None None O
that None None O
its None None O
upregulation None None O
has None None O
inhibited None None O
DNA None None O
synthesis None None O
and None None O
cell None None O
cycle None None O
progression None None O
of None None O
immortalized None None O
human None None O
prostate None None O
epithelial None None O
cells None None O
, None None O
we None None O
suggest None None O
that None None O
clusterin None None O
might None None O
be None None O
a None None O
new None None O
anti None None O
- None None O
oncogene None None O
in None None O
the None None O
prostate None None O
. None None O

Antisocial None None O
patients None None O
: None None O
a None None O
comparison None None O
of None None O
those None None O
with None None O
and None None O
those None None O
without None None O
childhood None None O
conduct None None O
disorder None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
compare None None O
persons None None O
with None None O
antisocial None None O
personality None None O
disorder None None O
( None None O
ASP None None O
) None None O
with None None O
those None None O
who None None O
meet None None O
the None None O
adult None None O
criteria None None O
for None None O
ASP None None O
but None None O
fail None None O
to None None O
meet None None O
the None None O
criteria None None O
for None None O
childhood None None O
conduct None None O
disorder None None O
. None None O

Sociodemographic None None O
data None None O
, None None O
medical None None O
history None None O
, None None O
and None None O
psychiatric None None O
symptoms None None O
exhibited None None O
during None None O
a None None O
recent None None O
hospital None None O
admission None None O
were None None O
compared None None O
in None None O
the None None O
two None None O
groups None None O
by None None O
chart None None O
review None None O
. None None O

The None None O
two None None O
groups None None O
were None None O
virtually None None O
indistinguishable None None O
, None None O
except None None O
that None None O
patients None None O
without None None O
childhood None None O
conduct None None O
disorder None None O
were None None O
less None None O
likely None None O
to None None O
smoke None None O
or None None O
consume None None O
alcohol None None O
, None None O
were None None O
less None None O
likely None None O
to None None O
have None None O
spent None None O
time None None O
in None None O
a None None O
training None None O
school None None O
/ None None O
boot None None O
camp None None O
as None None O
a None None O
child None None O
or None None O
adolescent None None O
, None None O
were None None O
less None None O
likely None None O
to None None O
have None None O
been None None O
admitted None None O
for None None O
a None None O
recent None None O
suicide None None O
attempt None None O
, None None O
and None None O
were None None O
less None None O
likely None None O
to None None O
have None None O
conned None None O
others None None O
. None None O

We None None O
conclude None None O
that None None O
persons None None O
meeting None None O
the None None O
adult None None O
criteria None None O
for None None O
ASP None None O
but None None O
not None None O
the None None O
childhood None None O
conduct None None O
disorder None None O
criteria None None O
essentially None None O
suffer None None O
the None None O
same None None O
disorder None None O
as None None O
those None None O
who None None O
meet None None O
full None None O
ASP None None O
criteria None None O
but None None O
are None None O
less None None O
severely None None O
affected None None O
. None None O

Microscopic None None O
technique None None O
for None None O
the None None O
detection None None O
of None None O
nitric None None O
oxide None None O
- None None O
dependent None None O
angiogenesis None None O
in None None O
an None None O
animal None None O
model None None O
. None None O

Nitric None None O
oxide None None O
( None None O
NO None None O
) None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
maintaining None None O
vascular None None O
homeostasis None None O
. None None O

The None None O
importance None None O
of None None O
NO None None O
in None None O
the None None O
vasculature None None O
is None None O
demonstrated None None O
by None None O
several None None O
experimental None None O
conditions None None O
, None None O
such None None O
as None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
- None None O
induced None None O
angiogenesis None None O
. None None O

Thus None None O
, None None O
the None None O
NO None None O
metabolic None None O
pathway None None O
in None None O
endothelial None None O
cells None None O
could None None O
be None None O
one None None O
of None None O
the None None O
main None None O
contributing None None O
factors None None O
for None None O
angiogenesis None None O
. None None O

Although None None O
several None None O
methods None None O
have None None O
been None None O
used None None O
for None None O
measuring None None O
in None None O
vitro None None O
angiogenesis None None O
, None None O
a None None O
proper None None O
technique None None O
has None None O
not None None O
been None None O
developed None None O
for None None O
identifying None None O
in None None O
vivo None None O
NO None None O
- None None O
dependent None None O
angiogenesis None None O
. None None O

This None None O
chapter None None O
provides None None O
a None None O
new None None O
intravital None None O
microscopic None None O
method None None O
for None None O
detecting None None O
and None None O
measuring None None O
NO None None O
- None None O
dependent None None O
angiogenesis None None O
in None None O
a None None O
mouse None None O
model None None O
. None None O

This None None O
technique None None O
showed None None O
strong None None O
abdominal None None O
neovascularization None None O
in None None O
wild None None O
- None None O
type None None O
mice None None O
, None None O
but None None O
not None None O
eNOS None None O
knockout None None O
mice None None O
, None None O
locally None None O
injected None None O
with None None O
VEGF None None O
, None None O
as None None O
well None None O
as None None O
stimulation None None O
of None None O
angiogenesis None None O
in None None O
NO None None O
donor None None O
- None None O
injected None None O
mice None None O
. None None O

This None None O
technique None None O
also None None O
revealed None None O
the None None O
inhibitory None None O
effect None None O
of None None O
the None None O
NOS None None O
inhibitor None None O
N None None O
( None None O
G None None O
) None None O
- None None O
iminoethyl None None O
- None None O
L None None O
- None None O
ornithine None None O
in None None O
VEGF None None O
- None None O
mediated None None O
in None None O
vivo None None O
angiogenesis None None O
. None None O

This None None O
chapter None None O
describes None None O
intravital None None O
microscopy None None O
as None None O
a None None O
new None None O
imaging None None O
technique None None O
for None None O
detecting None None O
NO None None O
- None None O
dependent None None O
angiogenesis None None O
in None None O
an None None O
animal None None O
model None None O
. None None O

Positron None None O
emission None None O
tomography None None O
in None None O
a None None O
case None None O
of None None O
intracranial None None O
hemangiopericytoma None None O
. None None O

Due None None O
to None None O
the None None O
low None None O
prevalence None None O
of None None O
hemangiopericytomas None None O
( None None O
HPCs None None O
) None None O
, None None O
data None None O
on None None O
the None None O
biophysiological None None O
characteristics None None O
of None None O
this None None O
tumor None None O
are None None O
rare None None O
. None None O

Positron None None O
emission None None O
tomography None None O
( None None O
PET None None O
) None None O
demonstrated None None O
a None None O
sixfold None None O
increased None None O
uptake None None O
of None None O
[ None None O
11C None None O
] None None O
methionine None None O
and None None O
hyperperfusion None None O
in None None O
the None None O
HPC None None O
, None None O
whereas None None O
glucose None None O
utilization None None O
was None None O
decreased None None O
in None None O
this None None O
area None None O
. None None O

This None None O
low None None O
glucose None None O
utilization None None O
is None None O
in None None O
contrast None None O
to None None O
the None None O
high None None O
[ None None O
11C None None O
] None None O
methionine None None O
uptake None None O
and None None O
the None None O
malignancy None None O
of None None O
these None None O
tumors None None O
. None None O

The None None O
characteristics None None O
of None None O
HPCs None None O
in None None O
PET None None O
described None None O
herein None None O
for None None O
the None None O
first None None O
time None None O
offer None None O
additional None None O
diagnostic None None O
criteria None None O
and None None O
may None None O
help None None O
especially None None O
to None None O
differentiate None None O
these None None O
tumors None None O
from None None O
meningiomas None None O
. None None O

Inhibition None None O
by None None O
retinoic None None O
acid None None O
of None None O
type None None O
IV None None O
collagenolysis None None O
and None None O
invasion None None O
through None None O
reconstituted None None O
basement None None O
membrane None None O
by None None O
metastatic None None O
rat None None O
mammary None None O
adenocarcinoma None None O
cells None None O
. None None O

The None None O
activity None None O
of None None O
type None None O
IV None None O
collagenase None None O
, None None O
which None None O
enables None None O
tumor None None O
cells None None O
to None None O
degrade None None O
collagen None None O
type None None O
IV None None O
found None None O
in None None O
the None None O
subendothelial None None O
basement None None O
membrane None None O
, None None O
has None None O
been None None O
correlated None None O
with None None O
the None None O
metastatic None None O
potential None None O
in None None O
several None None O
tumor None None O
types None None O
, None None O
including None None O
the None None O
rat None None O
13762NF None None I-Cell-line-name
mammary None None O
adenocarcinoma None None O
cell None None O
line None None O
and None None O
its None None O
clones None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
examined None None O
whether None None O
all None None O
- None None O
trans None None O
- None None O
retinoic None None O
acid None None O
( None None O
all None None O
- None None O
trans None None O
- None None O
RA None None O
) None None O
and None None O
other None None O
retinoids None None O
, None None O
which None None O
exhibit None None O
antitumor None None O
activity None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
, None None O
affect None None O
the None None O
collagenolytic None None O
activity None None O
of None None O
metastatic None None O
rat None None O
13762NF None None I-Cell-line-name
mammary None None O
adenocarcinoma None None O
cells None None O
. None None O

Cells None None O
of None None O
the None None O
highly None None O
metastatic None None O
lung None None O
- None None O
colonizing None None O
clone None None O
MTF7 None None I-Cell-line-name
. None None I-Cell-line-name
T35 None None I-Cell-line-name
. None None I-Cell-line-name
3 None None I-Cell-line-name
, None None O
derived None None O
from None None O
the None None O
13762NF None None I-Cell-line-name
cell None None O
line None None O
, None None O
were None None O
treated None None O
for None None O
3 None None O
days None None O
with None None O
0 None None O
. None None O
1 None None O
, None None O
1 None None O
, None None O
or None None O
10 None None O
microM None None O
all None None O
- None None O
trans None None O
- None None O
RA None None O
, None None O
harvested None None O
, None None O
and None None O
seeded None None O
on None None O
[ None None O
3H None None O
] None None O
proline None None O
- None None O
labeled None None O
extracellular None None O
matrix None None O
deposited None None O
by None None O
cultured None None O
rat None None O
lung None None O
endothelial None None O
cells None None O
or None None O
on None None O
a None None O
film None None O
of None None O
purified None None O
[ None None O
3H None None O
] None None O
proline None None O
- None None O
labeled None None O
type None None O
IV None None O
collagen None None O
. None None O

The None None O
amount None None O
of None None O
radioactivity None None O
released None None O
into None None O
the None None O
medium None None O
during None None O
the None None O
subsequent None None O
24 None None O
to None None O
72 None None O
h None None O
was None None O
measured None None O
, None None O
and None None O
it None None O
was None None O
found None None O
that None None O
all None None O
- None None O
trans None None O
- None None O
RA None None O
treatment None None O
inhibited None None O
degradation None None O
of None None O
extracellular None None O
matrix None None O
and None None O
type None None O
IV None None O
collagen None None O
by None None O
50 None None O
to None None O
60 None None O
% None None O
. None None O

This None None O
effect None None O
was None None O
observed None None O
whether None None O
the None None O
cells None None O
had None None O
been None None O
treated None None O
with None None O
all None None O
- None None O
trans None None O
- None None O
RA None None O
in None None O
serum None None O
- None None O
free None None O
medium None None O
or None None O
in None None O
medium None None O
supplemented None None O
with None None O
heat None None O
- None None O
inactivated None None O
or None None O
acid None None O
- None None O
treated None None O
fetal None None O
bovine None None O
serum None None O
. None None O

The None None O
growth None None O
of None None O
the None None O
cells None None O
was None None O
not None None O
inhibited None None O
under None None O
these None None O
conditions None None O
, None None O
except None None O
after None None O
treatment None None O
with None None O
10 None None O
microM None None O
all None None O
- None None O
trans None None O
- None None O
RA None None O
in None None O
serum None None O
- None None O
free None None O
medium None None O
. None None O

The None None O
reduction None None O
in None None O
collagenolytic None None O
activity None None O
was None None O
observed None None O
in None None O
viable None None O
cells None None O
as None None O
well None None O
as None None O
in None None O
conditioned None None O
medium None None O
. None None O

A None None O
24 None None O
- None None O
h None None O
exposure None None O
of None None O
cells None None O
to None None O
all None None O
- None None O
trans None None O
- None None O
RA None None O
was None None O
sufficient None None O
to None None O
cause None None O
a None None O
30 None None O
% None None O
decrease None None O
in None None O
the None None O
collagenolytic None None O
activity None None O
, None None O
and None None O
this None None O
inhibitory None None O
effect None None O
was None None O
reversible None None O
. None None O

The None None O
direct None None O
addition None None O
of None None O
all None None O
- None None O
trans None None O
- None None O
RA None None O
to None None O
conditioned None None O
medium None None O
had None None O
no None None O
effect None None O
on None None O
secreted None None O
collagenase None None O
activity None None O
. None None O

The None None O
apparent None None O
molecular None None O
weights None None O
of None None O
the None None O
collagenolytic None None O
enzymes None None O
were None None O
determined None None O
by None None O
electrophoresis None None O
of None None O
cell None None O
extracts None None O
and None None O
concentrated None None O
conditioned None None O
medium None None O
in None None O
type None None O
IV None None O
collagen None None O
- None None O
embedded None None O
polyacrylamide None None O
gels None None O
followed None None O
by None None O
renaturation None None O
and None None O
activation None None O
of None None O
the None None O
enzymes None None O
within None None O
the None None O
gels None None O
. None None O

Two None None O
major None None O
type None None O
IV None None O
collagenolytic None None O
metalloproteinases None None O
exhibiting None None O
molecular None None O
weights None None O
of None None O
64 None None O
, None None O
000 None None O
and None None O
88 None None O
, None None O
000 None None O
, None None O
respectively None None O
, None None O
were None None O
detected None None O
by None None O
this None None O
method None None O
. None None O

These None None O
two None None O
enzymes None None O
were None None O
also None None O
found None None O
to None None O
have None None O
specificity None None O
for None None O
gelatin None None O
. None None O

The None None O
Mr None None O
64 None None O
, None None O
000 None None O
enzyme None None O
could None None O
be None None O
extracted None None O
from None None O
viable None None O
cells None None O
( None None O
presumably None None O
from None None O
the None None O
cell None None O
membrane None None O
) None None O
by None None O
2 None None O
% None None O
1 None None O
- None None O
butanol None None O
. None None O

Treatment None None O
with None None O
all None None O
- None None O
trans None None O
- None None O
RA None None O
decreased None None O
the None None O
level None None O
of None None O
these None None O
enzymes None None O
in None None O
the None None O
cellular None None O
, None None O
cell None None O
membrane None None O
, None None O
and None None O
conditioned None None O
medium None None O
compartments None None O
. None None O
( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

Basic None None O
fibroblast None None O
growth None None O
factor None None O
: None None O
a None None O
missing None None O
link None None O
between None None O
collagen None None O
VII None None O
, None None O
increased None None O
collagenase None None O
, None None O
and None None O
squamous None None O
cell None None O
carcinoma None None O
in None None O
recessive None None O
dystrophic None None O
epidermolysis None None O
bullosa None None O
. None None O

BACKGROUND None None O
: None None O
Patients None None O
with None None O
recessive None None O
dystrophic None None O
epidermolysis None None O
bullosa None None O
( None None O
RDEB None None O
) None None O
have None None O
deficiencies None None O
of None None O
collagen None None O
type None None O
VII None None O
and None None O
have None None O
elevated None None O
levels None None O
of None None O
fibroblast None None O
collagenase None None O
, None None O
and None None O
a None None O
greatly None None O
increased None None O
risk None None O
of None None O
cutaneous None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

Patients None None O
with None None O
other None None O
genetic None None O
blistering None None O
disorders None None O
do None None O
not None None O
have None None O
elevated None None O
collagenase None None O
or None None O
an None None O
increased None None O
risk None None O
of None None O
squamous None None O
cell None None O
carcinoma None None O
, None None O
despite None None O
chronic None None O
wounding None None O
. None None O

The None None O
connection None None O
between None None O
collagen None None O
type None None O
VII None None O
deficiency None None O
, None None O
increased None None O
collagenase None None O
, None None O
and None None O
squamous None None O
cell None None O
carcinoma None None O
is None None O
not None None O
understood None None O
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O
Urine None None O
from None None O
81 None None O
patients None None O
with None None O
RDEB None None O
( None None O
39 None None O
patients None None O
) None None O
, None None O
junctional None None O
epidermolysis None None O
bullosa None None O
( None None O
JEB None None O
; None None O
12 None None O
patients None None O
) None None O
, None None O
and None None O
epidermolysis None None O
bullosa None None O
simplex None None O
( None None O
EBS None None O
; None None O
30 None None O
patients None None O
) None None O
, None None O
as None None O
well None None O
as None None O
unaffected None None O
family None None O
members None None O
of None None O
RDEB None None O
patients None None O
( None None O
33 None None O
patients None None O
) None None O
, None None O
was None None O
tested None None O
for None None O
the None None O
presence None None O
of None None O
basic None None O
fibroblast None None O
growth None None O
factor None None O
( None None O
bFGF None None O
) None None O
using None None O
a None None O
sensitive None None O
radioimmunoassay None None O
. None None O

These None None O
patients None None O
included None None O
many None None O
who None None O
were None None O
enrolled None None O
in None None O
the None None O
Epidermolysis None None O
Bullosa None None O
Registry None None O
and None None O
others None None O
who None None O
were None None O
referred None None O
by None None O
their None None O
physicians None None O
. None None O

RESULTS None None O
: None None O
Fifty None None O
- None None O
one None None O
percent None None O
of None None O
patients None None O
with None None O
RDEB None None O
had None None O
elevated None None O
levels None None O
( None None O
greater None None O
than None None O
5000 None None O
pg None None O
/ None None O
g None None O
) None None O
of None None O
urinary None None O
bFGF None None O
. None None O

In None None O
contrast None None O
, None None O
none None None O
of None None O
the None None O
patients None None O
with None None O
JEB None None O
had None None O
elevated None None O
levels None None O
of None None O
bFGF None None O
. None None O

Twenty None None O
- None None O
one None None O
percent None None O
of None None O
clinically None None O
unaffected None None O
family None None O
members None None O
had None None O
elevated None None O
levels None None O
of None None O
bFGF None None O
, None None O
and None None O
13 None None O
% None None O
of None None O
patients None None O
with None None O
EBS None None O
had None None O
elevated None None O
levels None None O
of None None O
bFGF None None O
. None None O

The None None O
frequency None None O
of None None O
elevated None None O
bFGF None None O
values None None O
among None None O
all None None O
groups None None O
was None None O
statistically None None O
significant None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
002 None None O
) None None O
, None None O
and None None O
the None None O
levels None None O
of None None O
bFGF None None O
in None None O
RDEB None None O
patients None None O
were None None O
significantly None None O
elevated None None O
compared None None O
with None None O
those None None O
of None None O
other None None O
groups None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O
We None None O
have None None O
found None None O
that None None O
patients None None O
with None None O
RDEB None None O
have None None O
elevated None None O
levels None None O
of None None O
bFGF None None O
, None None O
which None None O
may None None O
contribute None None O
to None None O
increased None None O
fibroblast None None O
collagenase None None O
and None None O
the None None O
development None None O
of None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

These None None O
results None None O
suggest None None O
a None None O
novel None None O
treatment None None O
for None None O
RDEB None None O
, None None O
namely None None O
, None None O
angiogenesis None None O
inhibitors None None O
, None None O
which None None O
may None None O
antagonize None None O
the None None O
effects None None O
of None None O
bFGF None None O
in None None O
this None None O
disorder None None O
. None None O

There None None O
are None None O
currently None None O
no None None O
other None None O
means None None O
of None None O
treatment None None O
for None None O
this None None O
disorder None None O
, None None O
which None None O
has None None O
a None None O
high None None O
morbidity None None O
and None None O
mortality None None O
rate None None O
. None None O

Oesophageal None None O
candidiasis None None O
and None None O
croup None None O
in None None O
a None None O
child None None O
with None None O
defective None None O
neutrophil None None O
motility None None O
. None None O

Severe None None O
oesophageal None None O
candidiasis None None O
and None None O
croup None None O
due None None O
to None None O
involvement None None O
of None None O
the None None O
larynx None None O
developed None None O
insidiously None None O
in None None O
a None None O
girl None None O
aged None None O
20 None None O
months None None O
. None None O

There None None O
had None None O
been None None O
delayed None None O
separation None None O
of None None O
the None None O
umbilical None None O
cord None None O
and None None O
repeated None None O
infections None None O
associated None None O
with None None O
a None None O
defect None None O
of None None O
neutrophil None None O
motility None None O
. None None O

The None None O
significance None None O
of None None O
the None None O
early None None O
clinical None None O
features None None O
was None None O
not None None O
fully None None O
appreciated None None O
and None None O
the None None O
diagnosis None None O
considered None None O
only None None O
when None None O
stricture None None O
of None None O
the None None O
oesophagus None None O
became None None O
evident None None O
. None None O

She None None O
was None None O
treated None None O
with None None O
oral None None O
ketoconazole None None O
100 None None O
mg None None O
daily None None O
. None None O

After None None O
one None None O
month None None O
' None None O
s None None O
treatment None None O
there None None O
was None None O
striking None None O
radiological None None O
improvement None None O
apart None None O
from None None O
the None None O
persistence None None O
of None None O
the None None O
oesophageal None None O
stricture None None O
. None None O

The None None O
croup None None O
resolved None None O
completely None None O
but None None O
there None None O
was None None O
only None None O
partial None None O
relief None None O
of None None O
dysphagia None None O
because None None O
of None None O
the None None O
residual None None O
stricture None None O
. None None O

We None None O
would None None O
emphasis None None O
that None None O
candidiasis None None O
should None None O
be None None O
anticipated None None O
and None None O
treated None None O
vigorously None None O
in None None O
children None None O
with None None O
such None None O
a None None O
defect None None O
of None None O
neutrophil None None O
motility None None O
. None None O

Cisplatin None None O
reduces None None O
endothelial None None O
cell None None O
migration None None O
via None None O
regulation None None O
of None None O
type None None O
2 None None O
- None None O
matrix None None O
metalloproteinase None None O
activity None None O
. None None O

AIMS None None O
: None None O
In None None O
this None None O
study None None O
we None None O
investigated None None O
the None None O
effect None None O
of None None O
cisplatin None None O
on None None O
endothelial None None O
cell None None O
migration None None O
, None None O
an None None O
essential None None O
process None None O
for None None O
vascular None None O
remodeling None None O
and None None O
regeneration None None O
in None None O
several None None O
physiological None None O
and None None O
pathological None None O
situations None None O
. None None O

MATERIAL None None O
AND None None O
METHODS None None O
: None None O
Human None None O
umbilical None None O
vein None None O
endothelial None None O
cells None None O
( None None O
HUVEC None None O
) None None O
were None None O
treated None None O
with None None O
cisplatin None None O
and None None O
endothelial None None O
cell None None O
migration None None O
analyzed None None O
by None None O
fluorescence None None O
and None None O
scratch None None O
- None None O
wound None None O
migration None None O
assay None None O
. None None O

MMP2 None None O
and None None O
MMP9 None None O
activity None None O
were None None O
determined None None O
by None None O
zymographic None None O
assay None None O
, None None O
and None None O
MAPK None None O
activation None None O
by None None O
Western None None O
blotting None None O
analysis None None O
. None None O

RESULTS None None O
: None None O
We None None O
demonstrated None None O
that None None O
cisplatin None None O
provoked None None O
a None None O
time None None O
- None None O
and None None O
dose None None O
- None None O
dependent None None O
decrease None None O
of None None O
HUVEC None None O
migration None None O
; None None O
this None None O
effect None None O
was None None O
clearly None None O
independent None None O
from None None O
its None None O
well None None O
known None None O
cytotoxic None None O
activity None None O
. None None O

In None None O
addition None None O
, None None O
cisplatin None None O
markedly None None O
reduced None None O
MMP2 None None O
activity None None O
in None None O
both None None O
conditioned None None O
media None None O
and None None O
cell None None O
lysates None None O
, None None O
increased None None O
p38 None None O
MAPK None None O
and None None O
JNK None None O
phosphorylation None None O
, None None O
but None None O
did None None O
not None None O
affect None None O
ERK None None O
phosphorylation None None O
. None None O

Endothelial None None O
cell None None O
migration None None O
was None None O
attenuated None None O
by None None O
treatment None None O
of None None O
cells None None O
with None None O
GM6001 None None O
, None None O
a None None O
non None None O
- None None O
specific None None O
inhibitor None None O
of None None O
MMPs None None O
, None None O
or None None O
by None None O
a None None O
selective None None O
anti None None O
- None None O
MMP2 None None O
antibody None None O
. None None O

However None None O
, None None O
treatment None None O
of None None O
cells None None O
with None None O
SB202190 None None O
or None None O
SP600125 None None O
, None None O
inhibitors None None O
of None None O
p38 None None O
MAPK None None O
and None None O
JNK None None O
respectively None None O
, None None O
did None None O
not None None O
affect None None O
HUVEC None None O
migration None None O
. None None O

CONCLUSION None None O
: None None O
These None None O
results None None O
suggested None None O
that None None O
cisplatin None None O
induced None None O
a None None O
reduction None None O
of None None O
endothelial None None O
cell None None O
migration None None O
through None None O
an None None O
inhibition None None O
of None None O
MMP2 None None O
activity None None O
by None None O
downstream None None O
signal None None O
transduction None None O
pathways None None O
independent None None O
of None None O
JNK None None O
and None None O
p38 None None O
MAPK None None O
activation None None O
. None None O

Silencing None None O
of None None O
directional None None O
migration None None O
in None None O
roundabout4 None None O
knockdown None None O
endothelial None None O
cells None None O
. None None O

BACKGROUND None None O
: None None O
Roundabouts None None O
are None None O
axon None None O
guidance None None O
molecules None None O
that None None O
have None None O
recently None None O
been None None O
identified None None O
to None None O
play None None O
a None None O
role None None O
in None None O
vascular None None O
guidance None None O
as None None O
well None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
have None None O
investigated None None O
gene None None O
knockdown None None O
analysis None None O
of None None O
endothelial None None O
Robos None None O
, None None O
in None None O
particular None None O
roundabout None None O
4 None None O
( None None O
robo4 None None O
) None None O
, None None O
the None None O
predominant None None O
Robo None None O
in None None O
endothelial None None O
cells None None O
using None None O
small None None O
interfering None None O
RNA None None O
technology None None O
in None None O
vitro None None O
. None None O

RESULTS None None O
: None None O
Robo1 None None O
and None None O
Robo4 None None O
knockdown None None O
cells None None O
display None None O
distinct None None O
activity None None O
in None None O
endothelial None None O
cell None None O
migration None None O
assay None None O
. None None O

The None None O
knockdown None None O
of None None O
robo4 None None O
abrogated None None O
the None None O
chemotactic None None O
response None None O
of None None O
endothelial None None O
cells None None O
to None None O
serum None None O
but None None O
enhanced None None O
a None None O
chemokinetic None None O
response None None O
to None None O
Slit2 None None O
, None None O
while None None O
robo1 None None O
knockdown None None O
cells None None O
do None None O
not None None O
display None None O
chemotactic None None O
response None None O
to None None O
serum None None O
or None None O
VEGF None None O
. None None O

Robo4 None None O
knockdown None None O
endothelial None None O
cells None None O
unexpectedly None None O
show None None O
up None None O
regulation None None O
of None None O
Rho None None O
GTPases None None O
. None None O

Zebrafish None None O
Robo4 None None O
rescues None None O
both None None O
Rho None None O
GTPase None None O
homeostasis None None O
and None None O
serum None None O
reduced None None O
chemotaxis None None O
in None None O
robo4 None None O
knockdown None None O
cells None None O
. None None O

Robo1 None None O
and None None O
Robo4 None None O
interact None None O
and None None O
share None None O
molecules None None O
such None None O
as None None O
Slit2 None None O
, None None O
Mena None None O
and None None O
Vilse None None O
, None None O
a None None O
Cdc42 None None O
- None None O
GAP None None O
. None None O

In None None O
addition None None O
, None None O
this None None O
study None None O
mechanistically None None O
implicates None None O
IRSp53 None None O
in None None O
the None None O
signaling None None O
nexus None None O
between None None O
activated None None O
Cdc42 None None O
and None None O
Mena None None O
, None None O
both None None O
of None None O
which None None O
have None None O
previously None None O
been None None O
shown None None O
to None None O
be None None O
involved None None O
with None None O
Robo4 None None O
signaling None None O
in None None O
endothelial None None O
cells None None O
. None None O

CONCLUSION None None O
: None None O
This None None O
study None None O
identifies None None O
specific None None O
components None None O
of None None O
the None None O
Robo None None O
signaling None None O
apparatus None None O
that None None O
work None None O
together None None O
to None None O
guide None None O
directional None None O
migration None None O
of None None O
endothelial None None O
cells None None O
. None None O

Role None None O
of None None O
osteopontin None None O
in None None O
adhesion None None O
, None None O
migration None None O
, None None O
cell None None O
survival None None O
and None None O
bone None None O
remodeling None None O
. None None O

Osteopontin None None O
( None None O
OPN None None O
) None None O
is None None O
a None None O
secreted None None O
adhesive None None O
glycophosphoprotein None None O
expressed None None O
by None None O
several None None O
cell None None O
types None None O
. None None O

It None None O
is None None O
normally None None O
produced None None O
in None None O
bone None None O
, None None O
teeth None None O
, None None O
kidney None None O
and None None O
epithelial None None O
lining None None O
tissues None None O
and None None O
is None None O
found None None O
in None None O
plasma None None O
and None None O
breast None None O
milk None None O
. None None O

It None None O
is None None O
involved None None O
in None None O
a None None O
number None None O
of None None O
physiologic None None O
and None None O
pathologic None None O
events None None O
including None None O
angiogenesis None None O
, None None O
apoptosis None None O
, None None O
inflammation None None O
, None None O
wound None None O
healing None None O
and None None O
tumor None None O
metastasis None None O
. None None O

In None None O
this None None O
review None None O
focus None None O
will None None O
be None None O
on None None O
OPN None None O
in None None O
bone None None O
and None None O
its None None O
role None None O
in None None O
adhesion None None O
, None None O
migration None None O
and None None O
cell None None O
survival None None O
. None None O

These None None O
aspects None None O
of None None O
OPN None None O
biology None None O
are None None O
important None None O
in None None O
tumorigenesis None None O
. None None O

The None None O
modulation None None O
of None None O
platelet None None O
and None None O
endothelial None None O
cell None None O
adhesion None None O
to None None O
vascular None None O
graft None None O
materials None None O
by None None O
perlecan None None O
. None None O

Controlled None None O
neo None None O
- None None O
endothelialisation None None O
is None None O
critical None None O
to None None O
the None None O
patency None None O
of None None O
small None None O
diameter None None O
vascular None None O
grafts None None O
. None None O

Endothelialisation None None O
and None None O
platelet None None O
adhesion None None O
to None None O
purified None None O
endothelial None None O
cell None None O
- None None O
derived None None O
perlecan None None O
, None None O
the None None O
major None None O
heparan None None O
sulfate None None O
( None None O
HS None None O
) None None O
proteoglycan None None O
in None None O
basement None None O
membranes None None O
, None None O
were None None O
investigated None None O
using None None O
in None None O
vivo None None O
and None None O
in None None O
vitro None None O
assays None None O
. None None O

Expanded None None O
polytetrafluoroethylene None None O
( None None O
ePTFE None None O
) None None O
vascular None None O
grafts None None O
were None None O
coated None None O
with None None O
perlecan None None O
and None None O
tested None None O
in None None O
an None None O
ovine None None O
carotid None None O
interposition None None O
model None None O
for None None O
a None None O
period None None O
of None None O
6 None None O
weeks None None O
and None None O
assessed None None O
using None None O
light None None O
and None None O
scanning None None O
microscopy None None O
. None None O

Enhanced None None O
endothelial None None O
cell None None O
growth None None O
and None None O
reduced None None O
platelet None None O
adhesion None None O
were None None O
observed None None O
on None None O
the None None O
perlecan None None O
coated None None O
grafts None None O
when None None O
compared None None O
to None None O
uncoated None None O
controls None None O
implanted None None O
in None None O
the None None O
same None None O
sheep None None O
( None None O
n None None O
= None None O
5 None None O
) None None O
. None None O

Perlecan None None O
was None None O
also None None O
found None None O
to None None O
stimulate None None O
endothelial None None O
cell None None O
proliferation None None O
in None None O
vitro None None O
over None None O
a None None O
period None None O
of None None O
6 None None O
days None None O
in None None O
the None None O
presence None None O
of None None O
plasma None None O
proteins None None O
and None None O
fibroblastic None None O
growth None None O
factor None None O
2 None None O
( None None O
FGF None None O
- None None O
2 None None O
) None None O
, None None O
however None None O
in None None O
the None None O
absence None None O
of None None O
FGF None None O
- None None O
2 None None O
endothelial None None O
cell None None O
growth None None O
could None None O
not None None O
be None None O
maintained None None O
during None None O
this None None O
period None None O
. None None O

Perlecan None None O
was None None O
found None None O
to None None O
be None None O
anti None None O
- None None O
adhesive None None O
for None None O
platelets None None O
, None None O
however None None O
after None None O
removal None None O
of None None O
the None None O
HS None None O
chains None None O
attached None None O
to None None O
perlecan None None O
, None None O
platelet None None O
adhesion None None O
and None None O
aggregation None None O
were None None O
supported None None O
. None None O

These None None O
results None None O
suggest None None O
a None None O
role None None O
for None None O
HS None None O
chains None None O
of None None O
perlecan None None O
in None None O
improving None None O
graft None None O
patency None None O
by None None O
selectively None None O
promoting None None O
endothelial None None O
cell None None O
proliferation None None O
while None None O
modulating None None O
platelet None None O
adhesion None None O
. None None O

Ca None None O
+ None None O
+ None None O
distribution None None O
after None None O
Na None None O
+ None None O
pump None None O
inhibition None None O
in None None O
cultured None None O
neonatal None None O
rat None None O
myocardial None None O
cells None None O
. None None O

The None None O
influence None None O
of None None O
inhibition None None O
of None None O
the None None O
Na None None O
+ None None O
pump None None O
, None None O
with None None O
secondary None None O
stimulation None None O
of None None O
Na None None O
+ None None O
- None None O
Ca None None O
+ None None O
+ None None O
exchange None None O
, None None O
on None None O
cellular None None O
Ca None None O
+ None None O
+ None None O
distribution None None O
is None None O
examined None None O
using None None O
the None None O
on None None O
- None None O
line None None O
scintillation None None O
disk None None O
technique None None O
and None None O
cultured None None O
neonatal None None O
rat None None O
myocardial None None O
cells None None O
. None None O

Under None None O
control None None O
conditions None None O
, None None O
La None None O
+ None None O
+ None None O
+ None None O
displaced None None O
78 None None O
. None None O
1 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
13 None None O
% None None O
( None None O
SEM None None O
) None None O
of None None O
the None None O
total None None O
cell None None O
associated None None O
45Ca None None O
. None None O

Application None None O
of None None O
1 None None O
mm None None O
ouabain None None O
or None None O
reduction None None O
of None None O
[ None None O
K None None O
+ None None O
] None None O
o None None O
to None None O
0 None None O
. None None O
5 None None O
mM None None O
resulted None None O
in None None O
a None None O
net None None O
increase None None O
of None None O
10 None None O
. None None O
6 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
3 None None O
% None None O
and None None O
13 None None O
. None None O
8 None None O
+ None None O
/ None None O
- None None O
2 None None O
% None None O
, None None O
respectively None None O
, None None O
in None None O
total None None O
cell None None O
- None None O
associated None None O
Ca None None O
+ None None O
+ None None O
. None None O

Of None None O
this None None O
added None None O
45Ca None None O
, None None O
75 None None O
. None None O
9 None None O
+ None None O
/ None None O
- None None O
2 None None O
. None None O
7 None None O
% None None O
and None None O
78 None None O
. None None O
4 None None O
+ None None O
/ None None O
- None None O
2 None None O
. None None O
1 None None O
% None None O
, None None O
respectively None None O
remained None None O
La None None O
+ None None O
+ None None O
+ None None O
- None None O
displaceable None None O
. None None O

The None None O
45Ca None None O
- None None O
binding None None O
characteristics None None O
of None None O
isolated None None O
sarcolemma None None O
, None None O
prepared None None O
from None None O
the None None O
cultured None None O
neonatal None None O
rat None None O
myocardial None None O
cells None None O
using None None O
the None None O
gas None None O
dissection None None O
technique None None O
, None None O
were None None O
examined None None O
. None None O

When None None O
treated None None O
with None None O
either None None O
ouabain None None O
or None None O
low None None O
[ None None O
K None None O
+ None None O
] None None O
o None None O
solutions None None O
, None None O
sarcolemmal None None O
45Ca None None O
binding None None O
did None None O
not None None O
change None None O
. None None O

This None None O
result None None O
indicates None None O
that None None O
functional None None O
, None None O
intact None None O
tissue None None O
is None None O
necessary None None O
to None None O
observe None None O
the None None O
Ca None None O
+ None None O
+ None None O
increase None None O
. None None O

Treatment None None O
of None None O
the None None O
cells None None O
with None None O
verapamil None None O
before None None O
and None None O
during None None O
ouabain None None O
exposure None None O
failed None None O
to None None O
inhibit None None O
the None None O
ouabain None None O
- None None O
induced None None O
increase None None O
in None None O
cell None None O
- None None O
associated None None O
45Ca None None O
. None None O

The None None O
evidence None None O
indicates None None O
that None None O
inhibition None None O
of None None O
the None None O
Na None None O
+ None None O
- None None O
pump None None O
, None None O
and None None O
secondary None None O
stimulation None None O
of None None O
Na None None O
+ None None O
- None None O
Ca None None O
+ None None O
+ None None O
exchange None None O
, None None O
result None None O
in None None O
a None None O
net None None O
increase None None O
of None None O
11 None None O
- None None O
15 None None O
% None None O
in None None O
cell None None O
- None None O
associated None None O
Ca None None O
+ None None O
+ None None O
, None None O
78 None None O
% None None O
of None None O
which None None O
remains None None O
La None None O
+ None None O
+ None None O
+ None None O
- None None O
displaceable None None O
and None None O
is None None O
, None None O
therefore None None O
, None None O
localized None None O
to None None O
the None None O
sarcolemma None None O
- None None O
glycocalyx None None O
complex None None O
. None None O

VEGFR1 None None O
- None None O
positive None None O
haematopoietic None None O
bone None None O
marrow None None O
progenitors None None O
initiate None None O
the None None O
pre None None O
- None None O
metastatic None None O
niche None None O
. None None O

The None None O
cellular None None O
and None None O
molecular None None O
mechanisms None None O
by None None O
which None None O
a None None O
tumour None None O
cell None None O
undergoes None None O
metastasis None None O
to None None O
a None None O
predetermined None None O
location None None O
are None None O
largely None None O
unknown None None O
. None None O

Here None None O
we None None O
demonstrate None None O
that None None O
bone None None O
marrow None None O
- None None O
derived None None O
haematopoietic None None O
progenitor None None O
cells None None O
that None None O
express None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
1 None None O
( None None O
VEGFR1 None None O
; None None O
also None None O
known None None O
as None None O
Flt1 None None O
) None None O
home None None O
to None None O
tumour None None O
- None None O
specific None None O
pre None None O
- None None O
metastatic None None O
sites None None O
and None None O
form None None O
cellular None None O
clusters None None O
before None None O
the None None O
arrival None None O
of None None O
tumour None None O
cells None None O
. None None O

Preventing None None O
VEGFR1 None None O
function None None O
using None None O
antibodies None None O
or None None O
by None None O
the None None O
removal None None O
of None None O
VEGFR1 None None O
( None None O
+ None None O
) None None O
cells None None O
from None None O
the None None O
bone None None O
marrow None None O
of None None O
wild None None O
- None None O
type None None O
mice None None O
abrogates None None O
the None None O
formation None None O
of None None O
these None None O
pre None None O
- None None O
metastatic None None O
clusters None None O
and None None O
prevents None None O
tumour None None O
metastasis None None O
, None None O
whereas None None O
reconstitution None None O
with None None O
selected None None O
Id3 None None O
( None None O
inhibitor None None O
of None None O
differentiation None None O
3 None None O
) None None O
- None None O
competent None None O
VEGFR1 None None O
+ None None O
cells None None O
establishes None None O
cluster None None O
formation None None O
and None None O
tumour None None O
metastasis None None O
in None None O
Id3 None None O
knockout None None O
mice None None O
. None None O

We None None O
also None None O
show None None O
that None None O
VEGFR1 None None O
+ None None O
cells None None O
express None None O
VLA None None O
- None None O
4 None None O
( None None O
also None None O
known None None O
as None None O
integrin None None O
alpha4beta1 None None O
) None None O
, None None O
and None None O
that None None O
tumour None None O
- None None O
specific None None O
growth None None O
factors None None O
upregulate None None O
fibronectin None None O
- None None O
- None None O
a None None O
VLA None None O
- None None O
4 None None O
ligand None None O
- None None O
- None None O
in None None O
resident None None O
fibroblasts None None O
, None None O
providing None None O
a None None O
permissive None None O
niche None None O
for None None O
incoming None None O
tumour None None O
cells None None O
. None None O

Conditioned None None O
media None None O
obtained None None O
from None None O
distinct None None O
tumour None None O
types None None O
with None None O
unique None None O
patterns None None O
of None None O
metastatic None None O
spread None None O
redirected None None O
fibronectin None None O
expression None None O
and None None O
cluster None None O
formation None None O
, None None O
thereby None None O
transforming None None O
the None None O
metastatic None None O
profile None None O
. None None O

These None None O
findings None None O
demonstrate None None O
a None None O
requirement None None O
for None None O
VEGFR1 None None O
+ None None O
haematopoietic None None O
progenitors None None O
in None None O
the None None O
regulation None None O
of None None O
metastasis None None O
, None None O
and None None O
suggest None None O
that None None O
expression None None O
patterns None None O
of None None O
fibronectin None None O
and None None O
VEGFR1 None None O
+ None None O
VLA None None O
- None None O
4 None None O
+ None None O
clusters None None O
dictate None None O
organ None None O
- None None O
specific None None O
tumour None None O
spread None None O
. None None O

Costs None None O
of None None O
hip None None O
fracture None None O
. None None O

Rehabilitation None None O
of None None O
180 None None O
patients None None O
in None None O
primary None None O
health None None O
care None None O
. None None O

Costs None None O
related None None O
to None None O
functional None None O
status None None O
were None None O
calculated None None O
for None None O
180 None None O
consecutive None None O
hip None None O
fracture None None O
patients None None O
( None None O
mean None None O
age None None O
78 None None O
years None None O
) None None O
who None None O
were None None O
admitted None None O
from None None O
their None None O
own None None O
home None None O
and None None O
rehabilitated None None O
in None None O
primary None None O
health None None O
care None None O
. None None O

Within None None O
4 None None O
months None None O
after None None O
the None None O
fracture None None O
, None None O
75 None None O
percent None None O
of None None O
the None None O
patients None None O
had None None O
been None None O
discharged None None O
to None None O
their None None O
own None None O
home None None O
, None None O
9 None None O
percent None None O
were None None O
dead None None O
, None None O
and None None O
the None None O
short None None O
- None None O
term None None O
medical None None O
treatment None None O
costs None None O
per None None O
patient None None O
were None None O
SEK None None O
43 None None O
, None None O
000 None None O
, None None O
whereas None None O
the None None O
total None None O
costs None None O
including None None O
communal None None O
help None None O
and None None O
costs None None O
for None None O
living None None O
accommodations None None O
after None None O
discharge None None O
were None None O
twice None None O
as None None O
high None None O
. None None O

The None None O
total None None O
costs None None O
per None None O
patient None None O
for None None O
long None None O
- None None O
term None None O
medical None None O
treatment None None O
( None None O
from None None O
4 None None O
months None None O
up None None O
to None None O
3 None None O
years None None O
after None None O
fracture None None O
) None None O
were None None O
7 None None O
percent None None O
of None None O
the None None O
short None None O
- None None O
term None None O
medical None None O
treatment None None O
costs None None O
. None None O

Patients None None O
with None None O
a None None O
cervical None None O
fracture None None O
discharged None None O
to None None O
their None None O
own None None O
home None None O
and None None O
with None None O
good None None O
functional None None O
status None None O
consumed None None O
only None None O
one None None O
fifth None None O
of None None O
the None None O
resources None None O
that None None O
patients None None O
with None None O
a None None O
trochanteric None None O
fracture None None O
discharged None None O
to None None O
institutional None None O
care None None O
and None None O
who None None O
had None None O
reduced None None O
functional None None O
status None None O
consumed None None O
. None None O

A None None O
substantial None None O
part None None O
of None None O
the None None O
costs None None O
can None None O
be None None O
saved None None O
by None None O
improved None None O
organization None None O
of None None O
rehabilitation None None O
after None None O
discharge None None O
from None None O
the None None O
hospital None None O
. None None O

A None None O
further None None O
cost None None O
reduction None None O
would None None O
require None None O
a None None O
combination None None O
of None None O
technologic None None O
, None None O
social None None O
, None None O
and None None O
organizational None None O
changes None None O
aimed None None O
at None None O
early None None O
discharge None None O
and None None O
continued None None O
follow None None O
- None None O
up None None O
in None None O
primary None None O
health None None O
care None None O
. None None O

Cell None None O
type None None O
- None None O
specific None None O
regulation None None O
of None None O
angiogenic None None O
growth None None O
factor None None O
gene None None O
expression None None O
and None None O
induction None None O
of None None O
angiogenesis None None O
in None None O
nonischemic None None O
tissue None None O
by None None O
a None None O
constitutively None None O
active None None O
form None None O
of None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
1 None None O
. None None O

Understanding None None O
molecular None None O
mechanisms None None O
regulating None None O
angiogenesis None None O
may None None O
lead None None O
to None None O
novel None None O
therapies None None O
for None None O
ischemic None None O
disorders None None O
. None None O

Hypoxia None None O
- None None O
inducible None None O
factor None None O
1 None None O
( None None O
HIF None None O
- None None O
1 None None O
) None None O
activates None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
gene None None O
expression None None O
in None None O
hypoxic None None O
/ None None O
ischemic None None O
tissue None None O
. None None O

In None None O
this None None O
study None None O
we None None O
demonstrate None None O
that None None O
exposure None None O
of None None O
primary None None O
cultures None None O
of None None O
cardiac None None O
and None None O
vascular None None O
cells None None O
to None None O
hypoxia None None O
or None None O
AdCA5 None None O
, None None O
an None None O
adenovirus None None O
encoding None None O
a None None O
constitutively None None O
active None None O
form None None O
of None None O
HIF None None O
- None None O
1alpha None None O
, None None O
modulates None None O
the None None O
expression None None O
of None None O
genes None None O
encoding None None O
the None None O
angiogenic None None O
factors None None O
angiopoietin None None O
- None None O
1 None None O
( None None O
ANGPT1 None None O
) None None O
, None None O
ANGPT2 None None O
, None None O
placental None None O
growth None None O
factor None None O
, None None O
and None None O
platelet None None O
- None None O
derived None None O
growth None None O
factor None None O
- None None O
B None None O
. None None O

Loss None None O
- None None O
of None None O
- None None O
function None None O
effects None None O
were None None O
also None None O
observed None None O
in None None O
HIF None None O
- None None O
1alpha None None O
- None None O
null None None O
embryonic None None O
stem None None O
cells None None O
. None None O

Depending None None O
on None None O
the None None O
cell None None O
type None None O
, None None O
expression None None O
of None None O
ANGPT1 None None O
and None None O
ANGPT2 None None O
was None None O
either None None O
activated None None O
or None None O
repressed None None O
in None None O
response None None O
to None None O
hypoxia None None O
or None None O
AdCA5 None None O
. None None O

In None None O
all None None O
cases None None O
, None None O
there None None O
was None None O
complete None None O
concordance None None O
between None None O
the None None O
effects None None O
of None None O
hypoxia None None O
and None None O
AdCA5 None None O
. None None O

Injection None None O
of None None O
AdCA5 None None O
into None None O
mouse None None O
eyes None None O
induced None None O
neovascularization None None O
in None None O
multiple None None O
capillary None None O
beds None None O
, None None O
including None None O
those None None O
not None None O
responsive None None O
to None None O
VEGF None None O
alone None None O
. None None O

Analysis None None O
of None None O
gene None None O
expression None None O
revealed None None O
increased None None O
expression None None O
of None None O
ANGPT1 None None O
, None None O
ANGPT2 None None O
, None None O
platelet None None O
- None None O
derived None None O
growth None None O
factor None None O
- None None O
B None None O
, None None O
placental None None O
growth None None O
factor None None O
, None None O
and None None O
VEGF None None O
mRNA None None O
in None None O
AdCA5 None None O
- None None O
injected None None O
eyes None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
HIF None None O
- None None O
1 None None O
functions None None O
as None None O
a None None O
master None None O
regulator None None O
of None None O
angiogenesis None None O
by None None O
controlling None None O
the None None O
expression None None O
of None None O
multiple None None O
angiogenic None None O
growth None None O
factors None None O
and None None O
that None None O
adenovirus None None O
- None None O
mediated None None O
expression None None O
of None None O
a None None O
constitutively None None O
active None None O
form None None O
of None None O
HIF None None O
- None None O
1alpha None None O
is None None O
sufficient None None O
to None None O
induce None None O
angiogenesis None None O
in None None O
nonischemic None None O
tissue None None O
of None None O
an None None O
adult None None O
animal None None O
. None None O

Vitamin None None O
E None None O
inhibits None None O
experimental None None O
carcinogenesis None None O
and None None O
tumour None None O
angiogenesis None None O
. None None O

In None None O
an None None O
experiment None None O
in None None O
which None None O
vitamin None None O
E None None O
inhibited None None O
carcinogenesis None None O
, None None O
it None None O
was None None O
found None None O
that None None O
tumour None None O
angiogenesis None None O
and None None O
tumour None None O
growth None None O
- None None O
factor None None O
alpha None None O
( None None O
TGF None None O
alpha None None O
) None None O
expression None None O
were None None O
also None None O
inhibited None None O
. None None O

Forty None None O
male None None O
golden None None O
hamsters None None O
were None None O
divided None None O
into None None O
four None None O
equal None None O
groups None None O
. None None O

Group None None O
1 None None O
animals None None O
had None None O
the None None O
left None None O
buccal None None O
pouches None None O
painted None None O
three None None O
times None None O
weekly None None O
with None None O
7 None None O
, None None O
12 None None O
- None None O
dimethylbenz None None O
( None None O
a None None O
) None None O
anthracene None None O
( None None O
DMBA None None O
) None None O
for None None O
14 None None O
weeks None None O
. None None O

Group None None O
2 None None O
animals None None O
had None None O
the None None O
same None None O
procedure None None O
of None None O
DMBA None None O
applications None None O
but None None O
also None None O
received None None O
alpha None None O
tocopherol None None O
. None None O

Groups None None O
3 None None O
and None None O
4 None None O
were None None O
vitamin None None O
E None None O
and None None O
untreated None None O
controls None None O
. None None O

Angiogenesis None None O
was None None O
studied None None O
with None None O
factor None None O
8 None None O
- None None O
related None None O
antigen None None O
( None None O
F8 None None O
- None None O
RA None None O
) None None O
which None None O
identifies None None O
endothelial None None O
cells None None O
. None None O

TGF None None O
alpha None None O
was None None O
studied None None O
with None None O
the None None O
appropriate None None O
antibody None None O
. None None O

Staining None None O
was None None O
effected None None O
by None None O
the None None O
standard None None O
avidin None None O
- None None O
biotin None None O
horseradish None None O
peroxidase None None O
system None None O
. None None O

Mean None None O
tumour None None O
volume None None O
was None None O
significantly None None O
lower None None O
in None None O
the None None O
DMBA None None O
- None None O
vitamin None None O
E None None O
group None None O
compared None None O
to None None O
the None None O
tumour None None O
control None None O
group None None O
. None None O

Angiogenesis None None O
was None None O
significantly None None O
inhibited None None O
in None None O
the None None O
DMBA None None O
- None None O
vitamin None None O
E None None O
group None None O
and None None O
TGF None None O
alpha None None O
expression None None O
was None None O
also None None O
inhibited None None O
. None None O

It None None O
is None None O
suggested None None O
that None None O
inhibition None None O
of None None O
tumour None None O
angiogenesis None None O
by None None O
vitamin None None O
E None None O
may None None O
be None None O
an None None O
additional None None O
mechanism None None O
for None None O
the None None O
anticancer None None O
action None None O
of None None O
vitamin None None O
E None None O
. None None O

Supporting None None O
Information None None O

Table None None O
S1 None None O

Supplementary None None O
Information None None O
on None None O
Genes None None O
in None None O
the None None O
Three None None O
Gene None None O
Sets None None O

( None None O
219 None None O
KB None None O
PDF None None O
) None None O

Click None None O
here None None O
for None None O
additional None None O
data None None O
file None None O
. None None O

Table None None O
S2 None None O

UFW None None O
Primers None None O
for None None O
Gene None None O
Set None None O
I None None O

( None None O
36 None None O
KB None None O
PDF None None O
) None None O

Click None None O
here None None O
for None None O
additional None None O
data None None O
file None None O
. None None O

Table None None O
S3 None None O

UFW None None O
Primers None None O
for None None O
Gene None None O
Set None None O
II None None O

( None None O
44 None None O
KB None None O
PDF None None O
) None None O

Click None None O
here None None O
for None None O
additional None None O
data None None O
file None None O
. None None O

Table None None O
S4 None None O

UFW None None O
Primers None None O
for None None O
Gene None None O
Set None None O
III None None O

( None None O
31 None None O
KB None None O
PDF None None O
) None None O

Click None None O
here None None O
for None None O
additional None None O
data None None O
file None None O
. None None O

Table None None O
S5 None None O

Transposable None None O
Element None None O
- None None O
Specific None None O
Primers None None O
for None None O
Additional None None O
Screens None None O

( None None O
80 None None O
KB None None O
PDF None None O
) None None O

Click None None O
here None None O
for None None O
additional None None O
data None None O
file None None O
. None None O

Table None None O
S6 None None O

Primers None None O
for None None O
Intergenic None None O
Regions None None O

( None None O
58 None None O
KB None None O
PDF None None O
) None None O

Click None None O
here None None O
for None None O
additional None None O
data None None O
file None None O
. None None O

Table None None O
S7 None None O

P None None O
Element None None O
- None None O
Specific None None O
Primers None None O
for None None O
Orientation None None O
and None None O
Length None None O
Determination None None O

( None None O
299 None None O
KB None None O
PDF None None O
) None None O

Click None None O
here None None O
for None None O
additional None None O
data None None O
file None None O
. None None O

Levels None None O
of None None O
expression None None O
of None None O
CYR61 None None O
and None None O
CTGF None None O
are None None O
prognostic None None O
for None None O
tumor None None O
progression None None O
and None None O
survival None None O
of None None O
individuals None None O
with None None O
gliomas None None O
. None None O

The None None O
biological None None O
properties None None O
of None None O
CCN None None O
proteins None None O
include None None O
stimulation None None O
of None None O
cell None None O
proliferation None None O
, None None O
migration None None O
, None None O
and None None O
adhesion None None O
, None None O
as None None O
well None None O
as None None O
angiogenesis None None O
and None None O
tumorigenesis None None O
. None None O

We None None O
quantified None None O
CYR61 None None O
, None None O
CTGF None None O
, None None O
WISP None None O
- None None O
1 None None O
, None None O
and None None O
NOV None None O
mRNA None None O
expression None None O
levels None None O
in None None O
samples None None O
from None None O
sixty None None O
- None None O
six None None O
primary None None O
gliomas None None O
and None None O
five None None O
normal None None O
brain None None O
samples None None O
using None None O
quantitative None None O
real None None O
- None None O
time None None O
PCR None None O
assay None None O
. None None O

Statistical None None O
analysis None None O
was None None O
performed None None O
to None None O
explore None None O
the None None O
links None None O
between None None O
expression None None O
of None None O
the None None O
CCN None None O
genes None None O
and None None O
clinical None None O
and None None O
pathological None None O
parameters None None O
. None None O

Overexpression None None O
of None None O
CYR61 None None O
, None None O
CTGF None None O
, None None O
WISP None None O
- None None O
1 None None O
, None None O
and None None O
NOV None None O
occurred None None O
in None None O
48 None None O
% None None O
( None None O
32 None None O
of None None O
66 None None O
) None None O
, None None O
58 None None O
% None None O
( None None O
38 None None O
of None None O
66 None None O
) None None O
, None None O
36 None None O
% None None O
( None None O
24 None None O
of None None O
66 None None O
) None None O
, None None O
and None None O
15 None None O
% None None O
( None None O
10 None None O
of None None O
66 None None O
) None None O
of None None O
primary None None O
gliomas None None O
, None None O
respectively None None O
. None None O

Interestingly None None O
, None None O
significant None None O
associations None None O
were None None O
found None None O
between None None O
CYR61 None None O
expression None None O
versus None None O
tumor None None O
grade None None O
, None None O
pathology None None O
, None None O
gender None None O
, None None O
and None None O
age None None O
at None None O
diagnosis None None O
. None None O

Also None None O
, None None O
a None None O
significant None None O
correlation None None O
existed None None O
between None None O
CTGF None None O
mRNA None None O
levels None None O
versus None None O
tumor None None O
grade None None O
, None None O
gender None None O
, None None O
and None None O
pathology None None O
. None None O

In None None O
contrast None None O
to None None O
CYR61 None None O
and None None O
CTGF None None O
, None None O
no None None O
significant None None O
association None None O
was None None O
found None None O
between None None O
expression None None O
of None None O
either None None O
WISP None None O
- None None O
1 None None O
or None None O
NOV None None O
versus None None O
any None None O
of None None O
the None None O
pathological None None O
features None None O
. None None O

Furthermore None None O
, None None O
Cox None None O
regression None None O
analysis None None O
showed None None O
that None None O
CYR61 None None O
and None None O
CTGF None None O
expression None None O
had None None O
a None None O
significant None None O
correlation None None O
with None None O
patient None None O
survival None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
CYR61 None None O
and None None O
CTGF None None O
may None None O
play None None O
a None None O
role None None O
in None None O
the None None O
progression None None O
of None None O
gliomas None None O
; None None O
their None None O
levels None None O
at None None O
diagnosis None None O
may None None O
have None None O
prognostic None None O
significance None None O
; None None O
and None None O
these None None O
proteins None None O
might None None O
serve None None O
as None None O
valuable None None O
targets None None O
for None None O
therapeutic None None O
intervention None None O
. None None O

Management None None O
of None None O
extremity None None O
trauma None None O
and None None O
related None None O
infections None None O
occurring None None O
in None None O
the None None O
aquatic None None O
environment None None O
. None None O

Wounds None None O
sustained None None O
in None None O
oceans None None O
, None None O
lakes None None O
, None None O
and None None O
streams None None O
are None None O
exposed None None O
to None None O
a None None O
milieu None None O
of None None O
bacteria None None O
rarely None None O
encountered None None O
in None None O
typical None None O
land None None O
- None None O
based None None O
injuries None None O
. None None O

These None None O
include None None O
Vibrio None None O
species None None O
, None None O
Aeromonas None None O
hydrophila None None O
, None None O
Pseudomonas None None O
and None None O
Plesiomonas None None O
species None None O
, None None O
Erysipelothrix None None O
rhusiopathiae None None O
, None None O
Mycobacterium None None O
marinum None None O
, None None O
and None None O
other None None O
microbes None None O
. None None O

Failure None None O
to None None O
recognize None None O
and None None O
treat None None O
these None None O
less None None O
common None None O
pathogens None None O
in None None O
a None None O
timely None None O
manner None None O
may None None O
result None None O
in None None O
significant None None O
morbidity None None O
or None None O
death None None O
. None None O

Initial None None O
antibiotic None None O
therapy None None O
should None None O
address None None O
common None None O
gram None None O
- None None O
positive None None O
and None None O
gram None None O
- None None O
negative None None O
aquatic None None O
bacteria None None O
, None None O
depending None None O
on None None O
the None None O
environment None None O
. None None O

Trauma None None O
occurring None None O
in None None O
brackish None None O
or None None O
salt None None O
water None None O
should None None O
be None None O
treated None None O
with None None O
doxycycline None None O
and None None O
ceftazidime None None O
, None None O
or None None O
a None None O
fluoroquinolone None None O
( None None O
eg None None O
, None None O
ciprofloxacin None None O
or None None O
levofloxacin None None O
) None None O
. None None O

Freshwater None None O
wounds None None O
should None None O
be None None O
managed None None O
with None None O
ciprofloxacin None None O
, None None O
levofloxacin None None O
, None None O
or None None O
a None None O
third None None O
- None None O
or None None O
fourth None None O
- None None O
generation None None O
cephalosporin None None O
( None None O
eg None None O
, None None O
ceftazidime None None O
) None None O
. None None O

Injuries None None O
sustained None None O
in None None O
a None None O
marine None None O
or None None O
freshwater None None O
environment None None O
may None None O
result None None O
from None None O
bites None None O
or None None O
venomous None None O
stings None None O
of None None O
aquatic None None O
organisms None None O
as None None O
well None None O
as None None O
from None None O
accidental None None O
trauma None None O
. None None O

Musculoskeletal None None O
trauma None None O
caused None None O
by None None O
venomous None None O
underwater None None O
species None None O
( None None O
eg None None O
, None None O
stingrays None None O
, None None O
stinging None None O
fish None None O
, None None O
sea None None O
urchins None None O
, None None O
and None None O
coral None None O
) None None O
requires None None O
immediate None None O
neutralization None None O
of None None O
the None None O
heat None None O
- None None O
labile None None O
toxin None None O
with None None O
immersion None None O
in None None O
nonscalding None None O
water None None O
for None None O
30 None None O
to None None O
90 None None O
minutes None None O
. None None O

Appropriate None None O
management None None O
of None None O
aquatic None None O
wounds None None O
requires None None O
recognition None None O
of None None O
the None None O
mechanism None None O
of None None O
injury None None O
, None None O
neutralization None None O
of None None O
venom None None O
, None None O
antibiotic None None O
administration None None O
, None None O
radiographic None None O
assessment None None O
, None None O
surgical None None O
debridement None None O
with None None O
irrigation None None O
, None None O
wound None None O
cultures None None O
, None None O
and None None O
structural None None O
repair None None O
or None None O
amputation None None O
as None None O
indicated None None O
by None None O
the None None O
severity None None O
of None None O
the None None O
injury None None O
. None None O

[ None None O
Anomalous None None O
origin None None O
of None None O
the None None O
right None None O
coronary None None O
artery None None O
from None None O
the None None O
left None None O
sinus None None O
of None None O
Valsalva None None O
: None None O
case None None O
report None None O
and None None O
literature None None O
review None None O
] None None O
. None None O

We None None O
describe None None O
the None None O
case None None O
of None None O
a None None O
patient None None O
in None None O
whom None None O
evaluation None None O
of None None O
effort None None O
angina None None O
revealed None None O
a None None O
tight None None O
stenosis None None O
of None None O
a None None O
right None None O
coronary None None O
artery None None O
anomalously None None O
arising None None O
from None None O
the None None O
left None None O
sinus None None O
of None None O
Valsalva None None O
, None None O
which None None O
was None None O
successfully None None O
treated None None O
by None None O
stent None None O
implantation None None O
. None None O

The None None O
abnormal None None O
origin None None O
of None None O
the None None O
right None None O
coronary None None O
artery None None O
from None None O
the None None O
left None None O
aortic None None O
sinus None None O
coursing None None O
between None None O
the None None O
aorta None None O
and None None O
the None None O
pulmonary None None O
trunk None None O
is None None O
a None None O
rare None None O
congenital None None O
anomaly None None O
. None None O

It None None O
may None None O
remain None None O
asymptomatic None None O
, None None O
but None None O
can None None O
also None None O
cause None None O
major None None O
cardiac None None O
events None None O
, None None O
even None None O
in None None O
the None None O
absence None None O
of None None O
coronary None None O
atherosclerosis None None O
. None None O

We None None O
discuss None None O
the None None O
clinical None None O
importance None None O
of None None O
this None None O
anomaly None None O
and None None O
review None None O
the None None O
literature None None O
concerning None None O
current None None O
views None None O
and None None O
therapy None None O
. None None O

Percutaneous None None O
coronary None None O
intervention None None O
for None None O
the None None O
very None None O
late None None O
stent None None O
thrombosis None None O
in None None O
right None None O
coronary None None O
artery None None O
. None None O

A None None O
: None None O
a None None O
balloon None None O
angioplasty None None O
was None None O
performed None None O
to None None O
treat None None O
total None None O
occlusion None None O
of None None O
the None None O
stented None None O
right None None O
coronary None None O
artery None None O
. None None O

B None None O
: None None O
final None None O
coronary None None O
angiogram None None O
showed None None O
good None None O
distal None None O
flow None None O
without None None O
residual None None O
stenosis None None O
. None None O

Discussion None None O

The None None O
two None None O
most None None O
important None None O
factors None None O
leading None None O
to None None O
the None None O
development None None O
of None None O
hypoxia None None O
are None None O
biological None None O
processes None None O
that None None O
determine None None O
the None None O
amount None None O
of None None O
organic None None O
matter None None O
available None None O
to None None O
be None None O
degraded None None O
and None None O
physical None None O
factors None None O
creating None None O
stratification None None O
. None None O

Stratification None None O
in None None O
most None None O
areas None None O
of None None O
the None None O
coastal None None O
zone None None O
of None None O
the None None O
Baltic None None O
Sea None None O
is None None O
due None None O
to None None O
seasonal None None O
temperature None None O
changes None None O
, None None O
although None None O
stratification None None O
by None None O
occasional None None O
inflowing None None O
saltier None None O
water None None O
does None None O
occur None None O
in None None O
some None None O
estuaries None None O
. None None O
( None None O
14 None None O
) None None O
Hypoxia None None O
is None None O
common None None O
in None None O
estuaries None None O
located None None O
in None None O
the None None O
Danish None None O
Straits None None O
due None None O
to None None O
the None None O
large None None O
load None None O
of None None O
nutrients None None O
sustaining None None O
algal None None O
production None None O
and None None O
the None None O
strong None None O
stratification None None O
caused None None O
by None None O
large None None O
differences None None O
in None None O
surface None None O
and None None O
bottom None None O
water None None O
salinity None None O
. None None O
( None None O
5 None None O
) None None O
Hypoxia None None O
in None None O
the None None O
Swedish None None O
and None None O
Finnish None None O
archipelagos None None O
are None None O
influenced None None O
by None None O
phytoplankton None None O
growth None None O
stimulated None None O
by None None O
nutrient None None O
loads None None O
from None None O
urban None None O
and None None O
agricultural None None O
sources None None O
, None None O
but None None O
also None None O
by None None O
restricted None None O
water None None O
circulation None None O
. None None O

The None None O
Finnish None None O
Archipelago None None O
Sea None None O
is None None O
impacted None None O
by None None O
drifting None None O
algal None None O
mats None None O
that None None O
consume None None O
oxygen None None O
during None None O
their None None O
decomposition None None O
when None None O
they None None O
sink None None O
to None None O
the None None O
bottom None None O
. None None O
( None None O
15 None None O
) None None O
By None None O
contrast None None O
, None None O
hypoxia None None O
is None None O
rare None None O
in None None O
the None None O
northern None None O
Baltic None None O
Sea None None O
estuaries None None O
located None None O
in None None O
the None None O
Bothnian None None O
Sea None None O
coastal None None O
zone None None O
where None None O
nutrient None None O
loads None None O
are None None O
lower None None O
. None None O

Hypoxia None None O
is None None O
uncommon None None O
along None None O
the None None O
eastern None None O
shore None None O
from None None O
Estonia None None O
to None None O
Poland None None O
due None None O
to None None O
enhanced None None O
circulation None None O
of None None O
water None None O
in None None O
open None None O
areas None None O
along None None O
the None None O
coastline None None O
( None None O
Figure None None O
1 None None O
) None None O
. None None O

There None None O
are None None O
very None None O
limited None None O
data None None O
available None None O
to None None O
examine None None O
how None None O
far None None O
back None None O
in None None O
time None None O
hypoxia None None O
has None None O
occurred None None O
. None None O

A None None O
key None None O
question None None O
in None None O
this None None O
ecosystem None None O
affected None None O
daily None None O
by None None O
over None None O
85 None None O
million None None O
people None None O
could None None O
be None None O
" None None O
Is None None O
hypoxia None None O
a None None O
natural None None O
phenomenon None None O
? None None O
" None None O
. None None O
( None None O
16 None None O
) None None O
The None None O
large None None O
numbers None None O
of None None O
enclosed None None O
areas None None O
, None None O
in None None O
many None None O
cases None None O
with None None O
shallow None None O
sills None None O
that None None O
restrict None None O
the None None O
exchange None None O
of None None O
bottom None None O
water None None O
and None None O
often None None O
in None None O
combination None None O
with None None O
large None None O
irregular None None O
changes None None O
in None None O
salinity None None O
, None None O
might None None O
mean None None O
that None None O
hypoxia None None O
has None None O
always None None O
been None None O
present None None O
in None None O
the None None O
coastal None None O
zone None None O
. None None O

However None None O
, None None O
sediment None None O
laminations None None O
from None None O
Stockholm None None O
Archipelago None None O
, None None O
an None None O
indicator None None O
of None None O
past None None O
hypoxia None None O
, None None O
( None None O
17 None None O
) None None O
have None None O
been None None O
shown None None O
to None None O
be None None O
a None None O
recent None None O
phenomenon None None O
with None None O
very None None O
few None None O
areas None None O
with None None O
laminated None None O
sediments None None O
prior None None O
to None None O
1900 None None O
. None None O
17 None None O
, None None O
18 None None O
The None None O
long None None O
- None None O
term None None O
millennial None None O
trends None None O
in None None O
coastal None None O
hypoxia None None O
remain None None O
unknown None None O
, None None O
although None None O
hypoxia None None O
has None None O
occurred None None O
intermittently None None O
throughout None None O
the None None O
last None None O
8000 None None O
years None None O
in None None O
offshore None None O
deep None None O
waters None None O
of None None O
the None None O
Baltic None None O
Sea None None O
. None None O
( None None O
10 None None O
) None None O
Further None None O
sediment None None O
studies None None O
are None None O
necessary None None O
, None None O
similar None None O
to None None O
those None None O
carried None None O
out None None O
in None None O
the None None O
open None None O
Baltic None None O
Sea None None O
, None None O
( None None O
10 None None O
) None None O
to None None O
ascertain None None O
how None None O
far None None O
back None None O
in None None O
time None None O
hypoxia None None O
was None None O
observed None None O
in None None O
the None None O
coastal None None O
zone None None O
. None None O

Key None None O
uncertainties None None O
remain None None O
including None None O
how None None O
have None None O
the None None O
driving None None O
forces None None O
for None None O
hypoxia None None O
, None None O
e None None O
. None None O
g None None O
. None None O
, None None O
climate None None O
( None None O
19 None None O
) None None O
and None None O
nutrient None None O
loading None None O
, None None O
changed None None O
through None None O
time None None O
in None None O
the None None O
Baltic None None O
Sea None None O
coastal None None O
zone None None O
, None None O
and None None O
do None None O
they None None O
vary None None O
during None None O
the None None O
same None None O
time None None O
periods None None O
that None None O
hypoxia None None O
varies None None O
in None None O
the None None O
open None None O
waters None None O
? None None O
( None None O
16 None None O
) None None O

An None None O
important None None O
consideration None None O
in None None O
determining None None O
the None None O
number None None O
of None None O
ecosystems None None O
experiencing None None O
hypoxia None None O
is None None O
the None None O
size None None O
of None None O
the None None O
assessment None None O
unit None None O
. None None O

We None None O
combined None None O
numerous None None O
monitoring None None O
points None None O
and None None O
sites None None O
to None None O
form None None O
a None None O
coherent None None O
coastal None None O
unit None None O
when None None O
bottom None None O
waters None None O
were None None O
physically None None O
connected None None O
to None None O
each None None O
other None None O
. None None O

This None None O
means None None O
that None None O
assessment None None O
units None None O
considered None None O
hypoxic None None O
might None None O
occur None None O
in None None O
the None None O
same None None O
geographical None None O
region None None O
and None None O
could None None O
be None None O
in None None O
close None None O
proximately None None O
to None None O
each None None O
other None None O
, None None O
if None None O
their None None O
bottom None None O
waters None None O
were None None O
physically None None O
disconnected None None O
. None None O

The None None O
Baltic None None O
Sea None None O
archipelagos None None O
have None None O
a None None O
complex None None O
topography None None O
with None None O
many None None O
basins None None O
disjoined None None O
by None None O
shallow None None O
sills None None O
resulting None None O
in None None O
many None None O
distinct None None O
sites None None O
, None None O
although None None O
they None None O
are None None O
all None None O
affected None None O
by None None O
similar None None O
mechanisms None None O
. None None O

In None None O
fact None None O
, None None O
the None None O
Stockholm None None O
and None None O
Finnish None None O
archipelagos None None O
contributed None None O
21 None None O
% None None O
of None None O
the None None O
total None None O
assessment None None O
units None None O
, None None O
a None None O
relatively None None O
large None None O
share None None O
compared None None O
to None None O
the None None O
total None None O
Baltic None None O
Sea None None O
coastal None None O
zone None None O
, None None O
but None None O
> None None O
40 None None O
% None None O
of None None O
the None None O
hypoxic None None O
sites None None O
. None None O

The None None O
coastal None None O
stretches None None O
of None None O
the None None O
Western None None O
Gotland None None O
Basin None None O
and None None O
Gulf None None O
of None None O
Finland None None O
that None None O
have None None O
a None None O
substantial None None O
number None None O
of None None O
hypoxic None None O
sites None None O
are None None O
also None None O
archipelagos None None O
, None None O
which None None O
are None None O
more None None O
prone None None O
to None None O
hypoxia None None O
because None None O
of None None O
the None None O
complex None None O
topography None None O
, None None O
proximity None None O
to None None O
development None None O
, None None O
and None None O
consequently None None O
more None None O
sensitive None None O
to None None O
enhanced None None O
nutrient None None O
inputs None None O
from None None O
land None None O
. None None O

Surprisingly None None O
only None None O
4 None None O
. None None O
0 None None O
% None None O
of None None O
all None None O
sites None None O
were None None O
classified None None O
as None None O
seasonally None None O
hypoxic None None O
according None None O
to None None O
our None None O
definition None None O
when None None O
> None None O
50 None None O
% None None O
and None None O
< None None O
80 None None O
% None None O
of None None O
profiles None None O
during None None O
the None None O
stratified None None O
period None None O
have None None O
oxygen None None O
concentrations None None O
less None None O
than None None O
2 None None O
mg None None O
L None None O
- None None O
1 None None O
. None None O

A None None O
statistically None None O
rigorous None None O
definition None None O
of None None O
what None None O
constitutes None None O
seasonal None None O
hypoxia None None O
does None None O
not None None O
currently None None O
exist None None O
and None None O
in None None O
fact None None O
should None None O
be None None O
linked None None O
to None None O
ecological None None O
consequences None None O
for None None O
it None None O
to None None O
be None None O
ecologically None None O
relevant None None O
and None None O
not None None O
just None None O
connected None None O
to None None O
absolute None None O
concentrations None None O
. None None O
( None None O
3 None None O
) None None O
Currently None None O
coastal None None O
marine None None O
ecosystems None None O
that None None O
experience None None O
hypoxia None None O
for None None O
a None None O
period None None O
of None None O
days None None O
to None None O
months None None O
every None None O
year None None O
are None None O
often None None O
considered None None O
to None None O
be None None O
seasonally None None O
hypoxic None None O
, None None O
although None None O
we None None O
have None None O
categorized None None O
them None None O
here None None O
as None None O
being None None O
episodic None None O
, None None O
because None None O
we None None O
required None None O
the None None O
monitoring None None O
units None None O
to None None O
be None None O
hypoxic None None O
for None None O
most None None O
of None None O
the None None O
stratified None None O
period None None O
. None None O

However None None O
, None None O
in None None O
Limfjorden None None O
, None None O
Denmark None None O
, None None O
bottom None None O
water None None O
oxygen None None O
concentrations None None O
can None None O
vary None None O
greatly None None O
between None None O
weekly None None O
samplings None None O
( None None O
SI None None O
Figure None None O
S6 None None O
) None None O
, None None O
although None None O
nearly None None O
every None None O
year None None O
hypoxic None None O
conditions None None O
are None None O
observed None None O
somewhere None None O
in None None O
the None None O
Limfjorden None None O
. None None O

Our None None O
statistical None None O
estimation None None O
is None None O
that None None O
Limfjorden None None O
is None None O
episodically None None O
hypoxic None None O
. None None O

Diaz None None O
and None None O
Rosenberg None None O
( None None O
1 None None O
) None None O
would None None O
classify None None O
Limfjorden None None O
as None None O
periodically None None O
hypoxic None None O
, None None O
although None None O
we None None O
have None None O
found None None O
it None None O
difficult None None O
to None None O
create None None O
a None None O
statistically None None O
robust None None O
indicator None None O
that None None O
would None None O
classify None None O
systems None None O
as None None O
periodically None None O
hypoxic None None O
. None None O

Periodic None None O
hypoxia None None O
is None None O
problematic None None O
because None None O
it None None O
never None None O
allows None None O
for None None O
re None None O
- None None O
establishment None None O
of None None O
benthic None None O
communities None None O
. None None O
( None None O
20 None None O
) None None O

Currently None None O
, None None O
there None None O
are None None O
416 None None O
areas None None O
in None None O
the None None O
world None None O
with None None O
reported None None O
coastal None None O
hypoxia None None O
with None None O
about None None O
30 None None O
previously None None O
reported None None O
sites None None O
in None None O
the None None O
Baltic None None O
Sea None None O
region None None O
, None None O
which None None O
includes None None O
both None None O
coastal None None O
zone None None O
hypoxia None None O
and None None O
deep None None O
water None None O
sites None None O
in None None O
the None None O
Baltic None None O
Sea None None O
. None None O
( None None O
1 None None O
) None None O
We None None O
have None None O
identified None None O
an None None O
additional None None O
96 None None O
sites None None O
that None None O
have None None O
experienced None None O
hypoxia None None O
, None None O
increasing None None O
the None None O
global None None O
total None None O
to None None O
nearly None None O
500 None None O
sites None None O
. None None O

Of None None O
all None None O
the None None O
known None None O
sites None None O
around None None O
the None None O
world None None O
, None None O
around None None O
20 None None O
% None None O
of None None O
the None None O
sites None None O
are None None O
found None None O
in None None O
the None None O
Baltic None None O
Sea None None O
region None None O
. None None O

Most None None O
sites None None O
experienced None None O
episodic None None O
hypoxia None None O
, None None O
which None None O
is None None O
a None None O
precursor None None O
to None None O
development None None O
of None None O
seasonal None None O
hypoxia None None O
. None None O
( None None O
20 None None O
) None None O
The None None O
large None None O
number None None O
of None None O
sites None None O
partially None None O
reflects None None O
the None None O
fact None None O
that None None O
the None None O
Baltic None None O
Sea None None O
is None None O
one None None O
of None None O
the None None O
most None None O
data None None O
rich None None O
regions None None O
of None None O
the None None O
world None None O
with None None O
no None None O
tidal None None O
mixing None None O
and None None O
complex None None O
bottom None None O
topography None None O
creating None None O
conditions None None O
favorable None None O
for None None O
hypoxia None None O
, None None O
although None None O
these None None O
are None None O
only None None O
the None None O
" None None O
monitored None None O
areas None None O
" None None O
and None None O
many None None O
more None None O
hypoxic None None O
sites None None O
probably None None O
exist None None O
in None None O
the None None O
Baltic None None O
Sea None None O
coastal None None O
zone None None O
. None None O

In None None O
contrast None None O
, None None O
there None None O
was None None O
no None None O
evidence None None O
of None None O
hypoxia None None O
at None None O
95 None None O
stations None None O
in None None O
estuarine None None O
and None None O
coastal None None O
waters None None O
around None None O
Ireland None None O
due None None O
to None None O
sufficient None None O
tidal None None O
mixing None None O
. None None O
( None None O
21 None None O
) None None O
If None None O
such None None O
detailed None None O
data None None O
existed None None O
for None None O
other None None O
coastal None None O
regions None None O
around None None O
the None None O
world None None O
, None None O
it None None O
is None None O
likely None None O
that None None O
the None None O
number None None O
of None None O
areas None None O
would None None O
increase None None O
globally None None O
. None None O

Oxygen None None O
is None None O
an None None O
important None None O
parameter None None O
in None None O
water None None O
quality None None O
assessments None None O
since None None O
sufficient None None O
oxygen None None O
is None None O
essential None None O
to None None O
aquatic None None O
life None None O
and None None O
is None None O
necessary None None O
to None None O
support None None O
healthy None None O
biological None None O
communities None None O
. None None O
( None None O
3 None None O
) None None O
For None None O
example None None O
, None None O
oxygen None None O
concentration None None O
is None None O
a None None O
supporting None None O
element None None O
to None None O
the None None O
biological None None O
quality None None O
elements None None O
in None None O
the None None O
European None None O
Water None None O
Framework None None O
Directive None None O
, None None O
( None None O
21 None None O
) None None O
is None None O
one None None O
of None None O
the None None O
ecological None None O
objectives None None O
in None None O
the None None O
Helsinki None None O
Commission None None O
' None None O
s None None O
( None None O
HELCOM None None O
) None None O
eutrophication None None O
assessment None None O
of None None O
the None None O
Baltic None None O
Sea None None O
, None None O
and None None O
is None None O
included None None O
in None None O
the None None O
European None None O
Marine None None O
Strategy None None O
Framework None None O
Directive None None O
as None None O
an None None O
effect None None O
parameter None None O
of None None O
eutrophication None None O
. None None O

Accurate None None O
data None None O
for None None O
the None None O
concentration None None O
of None None O
dissolved None None O
oxygen None None O
are None None O
essential None None O
for None None O
documenting None None O
environmental None None O
changes None None O
in None None O
water None None O
resources None None O
resulting None None O
from None None O
natural None None O
phenomena None None O
and None None O
human None None O
activities None None O
. None None O

Reports None None O
of None None O
hypoxia None None O
globally None None O
are None None O
increasing1 None None O
, None None O
22 None None O
both None None O
due None None O
to None None O
the None None O
recognition None None O
of None None O
the None None O
seriousness None None O
of None None O
hypoxia None None O
on None None O
ecosystem None None O
functioning None None O
and None None O
as None None O
decades None None O
- None None O
long None None O
monitoring None None O
records None None O
become None None O
available None None O
in None None O
databases None None O
. None None O

How None None O
the None None O
large None None O
number None None O
of None None O
newly None None O
identified None None O
hypoxic None None O
areas None None O
influences None None O
nutrient None None O
biogeochemical None None O
cycles None None O
and None None O
ecosystem None None O
services None None O
in None None O
the None None O
coastal None None O
zone None None O
in None None O
the None None O
Baltic None None O
Sea None None O
is None None O
currently None None O
unknown None None O
, None None O
although None None O
the None None O
functioning None None O
of None None O
the None None O
coastal None None O
filter None None O
certainly None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
how None None O
adjacent None None O
marine None None O
systems None None O
respond None None O
to None None O
changes None None O
in None None O
nutrient None None O
loading None None O
. None None O

Presently None None O
about None None O
40 None None O
% None None O
of None None O
the None None O
world None None O
' None None O
s None None O
population None None O
lives None None O
within None None O
100 None None O
km None None O
of None None O
the None None O
coastal None None O
zone None None O
strongly None None O
impacting None None O
ocean None None O
health None None O
, None None O
( None None O
24 None None O
) None None O
including None None O
increasing None None O
the None None O
occurrence None None O
of None None O
hypoxic None None O
areas None None O
. None None O
1 None None O
, None None O
2 None None O
What None None O
is None None O
currently None None O
lacking None None O
is None None O
the None None O
link None None O
to None None O
the None None O
driving None None O
factors None None O
of None None O
hypoxia None None O
including None None O
nutrient None None O
enrichment None None O
, None None O
organic None None O
carbon None None O
loading None None O
and None None O
climate None None O
change None None O
, None None O
( None None O
25 None None O
) None None O
and None None O
a None None O
determination None None O
of None None O
appropriate None None O
nutrient None None O
loading None None O
targets None None O
for None None O
guidance None None O
to None None O
managers None None O
to None None O
ameliorate None None O
the None None O
devastating None None O
impact None None O
of None None O
hypoxia None None O
. None None O
( None None O
24 None None O
) None None O

Sensitization None None O
to None None O
gimatecan None None O
- None None O
induced None None O
apoptosis None None O
by None None O
tumor None None O
necrosis None None O
factor None None O
- None None O
related None None O
apoptosis None None O
inducing None None O
ligand None None O
in None None O
prostate None None O
carcinoma None None O
cells None None O
. None None O

Since None None O
the None None O
intrinsic None None O
resistance None None O
of None None O
prostate None None O
carcinoma None None O
likely None None O
reflects None None O
a None None O
low None None O
susceptibility None None O
to None None O
drug None None O
- None None O
induced None None O
apoptosis None None O
, None None O
in None None O
this None None O
study None None O
we None None O
explored None None O
the None None O
possibility None None O
of None None O
sensitizing None None O
prostate None None O
carcinoma None None O
cells None None O
to None None O
apoptosis None None O
by None None O
combination None None O
of None None O
TRAIL None None O
with None None O
camptothecins None None O
. None None O

Indeed None None O
, None None O
these None None O
agents None None O
are None None O
known None None O
to None None O
activate None None O
different None None O
pathways None None O
of None None O
apoptosis None None O
. None None O

Topotecan None None O
- None None O
and None None O
gimatecan None None O
induced None None O
moderate None None O
up None None O
- None None O
regulation None None O
of None None O
TRAIL None None O
- None None O
R1 None None O
and None None O
- None None O
R2 None None O
which None None O
resulted None None O
in None None O
a None None O
different None None O
cell None None O
response None None O
to None None O
the None None O
combination None None O
in None None O
androgen None None O
- None None O
independent None None O
cells None None O
( None None O
DU None None I-Cell-line-name
- None None I-Cell-line-name
145 None None I-Cell-line-name
and None None O
PC None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
) None None O
. None None O

In None None O
DU None None I-Cell-line-name
- None None I-Cell-line-name
145 None None I-Cell-line-name
cells None None O
apoptosis None None O
was None None O
increased None None O
by None None O
lower None None O
TRAIL None None O
concentrations None None O
and None None O
was None None O
earlier None None O
than None None O
in None None O
PC None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
cells None None O
, None None O
as None None O
shown None None O
using None None O
Annexin None None O
V None None O
- None None O
binding None None O
assay None None O
. None None O

The None None O
relative None None O
resistance None None O
of None None O
PC None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
cells None None O
to None None O
drug None None O
- None None O
induced None None O
apoptosis None None O
was None None O
associated None None O
with None None O
constitutive None None O
Akt None None O
activation None None O
, None None O
higher None None O
levels None None O
of None None O
cFLIP None None O
- None None O
L None None O
and None None O
Bcl None None O
- None None O
2 None None O
, None None O
and None None O
lower None None O
levels None None O
of None None O
Bax None None O
. None None O

The None None O
different None None O
expression None None O
/ None None O
activation None None O
of None None O
apoptosis None None O
- None None O
related None None O
factors None None O
appears None None O
to None None O
influence None None O
the None None O
sensitization None None O
of None None O
prostate None None O
carcinoma None None O
cells None None O
by None None O
TRAIL None None O
. None None O

Potentiation None None O
of None None O
camptothecin None None O
- None None O
induced None None O
apoptosis None None O
by None None O
TRAIL None None O
appears None None O
dependent None None O
on None None O
cooperation None None O
between None None O
extrinsic None None O
and None None O
intrinsic None None O
pathways None None O
, None None O
as None None O
documented None None O
by None None O
loss None None O
of None None O
the None None O
sensitization None None O
to None None O
apoptosis None None O
following None None O
reduction None None O
of None None O
caspase None None O
8 None None O
after None None O
small None None O
interfering None None O
RNA None None O
transfection None None O
. None None O

The None None O
efficacy None None O
of None None O
the None None O
approach None None O
may None None O
be None None O
critically None None O
dependent None None O
on None None O
the None None O
intrinsic None None O
susceptibility None None O
to None None O
apoptosis None None O
of None None O
different None None O
tumors None None O
. None None O

These None None O
observations None None O
support None None O
that None None O
the None None O
activation None None O
of None None O
multiple None None O
signals None None O
could None None O
enhance None None O
apoptotic None None O
response None None O
and None None O
suggest None None O
the None None O
therapeutic None None O
interest None None O
of None None O
the None None O
TRAIL None None O
/ None None O
camptothecin None None O
combination None None O
. None None O

Conditional None None O
deletion None None O
of None None O
Smad1 None None O
and None None O
Smad5 None None O
in None None O
somatic None None O
cells None None O
of None None O
male None None O
and None None O
female None None O
gonads None None O
leads None None O
to None None O
metastatic None None O
tumor None None O
development None None O
in None None O
mice None None O
. None None O

The None None O
transforming None None O
growth None None O
factor None None O
beta None None O
( None None O
TGFbeta None None O
) None None O
family None None O
has None None O
critical None None O
roles None None O
in None None O
the None None O
regulation None None O
of None None O
fertility None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
pathogenesis None None O
of None None O
some None None O
human None None O
cancers None None O
is None None O
attributed None None O
to None None O
misregulation None None O
of None None O
TGFbeta None None O
function None None O
and None None O
SMAD2 None None O
or None None O
SMAD4 None None O
mutations None None O
. None None O

There None None O
are None None O
limited None None O
mouse None None O
models None None O
for None None O
the None None O
BMP None None O
signaling None None O
SMADs None None O
( None None O
BR None None O
- None None O
SMADs None None O
) None None O
1 None None O
, None None O
5 None None O
, None None O
and None None O
8 None None O
because None None O
of None None O
embryonic None None O
lethality None None O
and None None O
suspected None None O
genetic None None O
redundancy None None O
. None None O

Using None None O
tissue None None O
- None None O
specific None None O
ablation None None O
in None None O
mice None None O
, None None O
we None None O
deleted None None O
the None None O
BR None None O
- None None O
SMADs None None O
from None None O
somatic None None O
cells None None O
of None None O
ovaries None None O
and None None O
testes None None O
. None None O

Single None None O
conditional None None O
knockouts None None O
for None None O
Smad1 None None O
or None None O
Smad5 None None O
or None None O
mice None None O
homozygous None None O
null None None O
for None None O
Smad8 None None O
are None None O
viable None None O
and None None O
fertile None None O
. None None O

Female None None O
double None None O
Smad1 None None O
Smad5 None None O
and None None O
triple None None O
Smad1 None None O
Smad5 None None O
Smad8 None None O
conditional None None O
knockout None None O
mice None None O
become None None O
infertile None None O
and None None O
develop None None O
metastatic None None O
granulosa None None O
cell None None O
tumors None None O
. None None O

Male None None O
double None None O
Smad1 None None O
Smad5 None None O
conditional None None O
knockout None None O
mice None None O
are None None O
fertile None None O
but None None O
demonstrate None None O
metastatic None None O
testicular None None O
tumor None None O
development None None O
. None None O

Microarray None None O
analysis None None O
indicated None None O
significant None None O
alterations None None O
in None None O
expression None None O
of None None O
genes None None O
related None None O
to None None O
the None None O
TGFbeta None None O
pathway None None O
, None None O
as None None O
well None None O
as None None O
genes None None O
involved None None O
in None None O
infertility None None O
and None None O
extracellular None None O
matrix None None O
production None None O
. None None O

These None None O
data None None O
strongly None None O
implicate None None O
the None None O
BR None None O
- None None O
SMADs None None O
as None None O
part None None O
of None None O
a None None O
critical None None O
developmental None None O
pathway None None O
in None None O
ovaries None None O
and None None O
testis None None O
that None None O
, None None O
when None None O
disrupted None None O
, None None O
leads None None O
to None None O
malignant None None O
transformation None None O
. None None O

Targeting None None O
a None None O
tumor None None O
- None None O
specific None None O
laminin None None O
domain None None O
critical None None O
for None None O
human None None O
carcinogenesis None None O
. None None O

Laminin None None O
- None None O
332 None None O
is None None O
critical None None O
for None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
SCC None None O
) None None O
tumorigenesis None None O
, None None O
but None None O
targeting None None O
it None None O
for None None O
cancer None None O
therapy None None O
has None None O
been None None O
unachievable None None O
due None None O
to None None O
key None None O
role None None O
of None None O
laminin None None O
- None None O
332 None None O
in None None O
promoting None None O
tissue None None O
integrity None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
a None None O
portion None None O
of None None O
laminin None None O
- None None O
332 None None O
, None None O
termed None None O
G45 None None O
, None None O
which None None O
is None None O
proteolytically None None O
removed None None O
and None None O
absent None None O
in None None O
normal None None O
tissues None None O
, None None O
is None None O
prominently None None O
expressed None None O
in None None O
most None None O
human None None O
SCC None None I-Cell-line-name
tumors None None O
and None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
human None None O
SCC None None O
tumorigenesis None None O
. None None O

Primary None None O
human None None O
keratinocytes None None O
lacking None None O
G45 None None O
( None None O
DeltaG45 None None O
) None None O
showed None None O
alterations None None O
of None None O
basal None None O
receptor None None O
organization None None O
, None None O
impaired None None O
matrix None None O
deposition None None O
, None None O
and None None O
increased None None O
migration None None O
. None None O

After None None O
SCC None None O
transformation None None O
, None None O
the None None O
absence None None O
of None None O
G45 None None O
domain None None O
in None None O
DeltaG45 None None O
cells None None O
was None None O
associated None None O
with None None O
deficient None None O
extracellular None None O
signal None None O
- None None O
regulated None None O
kinase None None O
and None None O
phosphotidylinositol None None O
3 None None O
- None None O
kinase None None O
( None None O
PI3K None None O
) None None O
pathway None None O
activation None None O
, None None O
impaired None None O
invasion None None O
, None None O
deficient None None O
metalloproteinase None None O
activity None None O
, None None O
and None None O
absent None None O
tumorgenicity None None O
in None None O
vivo None None O
. None None O

Expression None None O
of None None O
G45 None None O
or None None O
activated None None O
PI3K None None O
subunit None None O
in None None O
DeltaG45 None None O
cells None None O
reversed None None O
these None None O
abnormalities None None O
. None None O

G45 None None O
antibody None None O
treatment None None O
induced None None O
SCC None None O
tumor None None O
apoptosis None None O
, None None O
decreased None None O
SCC None None O
tumor None None O
proliferation None None O
, None None O
and None None O
markedly None None O
impaired None None O
human None None O
SCC None None O
tumorigenesis None None O
in None None O
vivo None None O
without None None O
affecting None None O
normal None None O
tissue None None O
adhesion None None O
. None None O

These None None O
results None None O
show None None O
a None None O
remarkable None None O
selectivity None None O
of None None O
expression None None O
and None None O
function None None O
for None None O
laminin None None O
- None None O
332 None None O
G45 None None O
in None None O
human None None O
SCC None None O
tumorigenesis None None O
and None None O
implicate None None O
it None None O
as None None O
a None None O
specific None None O
target None None O
for None None O
anticancer None None O
therapy None None O
. None None O

c None None O
- None None O
Met None None O
expression None None O
is None None O
regulated None None O
by None None O
Mitf None None O
in None None O
the None None O
melanocyte None None O
lineage None None O
. None None O

Hepatocyte None None O
growth None None O
factor None None O
( None None O
HGF None None O
) None None O
/ None None O
c None None O
- None None O
Met None None O
signaling None None O
is None None O
thought None None O
to None None O
be None None O
a None None O
key None None O
pathway None None O
in None None O
both None None O
melanocyte None None O
development None None O
and None None O
melanoma None None O
metastasis None None O
. None None O

Here None None O
, None None O
HGF None None O
stimulation None None O
of None None O
melanocytes None None O
was None None O
seen None None O
to None None O
up None None O
- None None O
regulate None None O
c None None O
- None None O
Met None None O
expression None None O
. None None O

In None None O
an None None O
effort None None O
to None None O
decipher None None O
the None None O
mechanism None None O
by None None O
which None None O
HGF None None O
up None None O
- None None O
regulates None None O
its None None O
receptor None None O
, None None O
we None None O
found None None O
that None None O
c None None O
- None None O
Met None None O
is None None O
a None None O
direct None None O
transcriptional None None O
target None None O
of None None O
Mitf None None O
. None None O

This None None O
was None None O
confirmed None None O
with None None O
chromatin None None O
immunoprecipitation None None O
experiments None None O
of None None O
the None None O
human None None O
c None None O
- None None O
Met None None O
promoter None None O
, None None O
as None None O
well None None O
as None None O
by None None O
the None None O
ability None None O
of None None O
adenovirally None None O
expressed None None O
Mitf None None O
to None None O
modulate None None O
endogenous None None O
c None None O
- None None O
Met None None O
protein None None O
levels None None O
in None None O
melanocytes None None O
. None None O

Disruption None None O
of None None O
Mitf None None O
blocked None None O
HGF None None O
- None None O
dependent None None O
increases None None O
in None None O
endogenous None None O
c None None O
- None None O
Met None None O
message None None O
and None None O
protein None None O
levels None None O
, None None O
indicating None None O
that None None O
HGF None None O
regulates None None O
its None None O
own None None O
receptor None None O
levels None None O
via None None O
Mitf None None O
. None None O

Finally None None O
, None None O
dominant None None O
- None None O
negative None None O
inhibition None None O
of None None O
Mitf None None O
resulted None None O
in None None O
profound None None O
resistance None None O
of None None O
melanocytes None None O
and None None O
melanoma None None O
cells None None O
to None None O
HGF None None O
- None None O
dependent None None O
matrix None None O
invasion None None O
, None None O
suggesting None None O
a None None O
physiologic None None O
role None None O
for None None O
this None None O
pathway None None O
in None None O
melanocytic None None O
development None None O
and None None O
melanoma None None O
. None None O

Lysophosphatidic None None O
acid None None O
downregulates None None O
tissue None None O
inhibitor None None O
of None None O
metalloproteinases None None O
, None None O
which None None O
are None None O
negatively None None O
involved None None O
in None None O
lysophosphatidic None None O
acid None None O
- None None O
induced None None O
cell None None O
invasion None None O
. None None O

Ovarian None None O
cancer None None O
is None None O
a None None O
highly None None O
metastatic None None O
disease None None O
. None None O

Lysophosphatidic None None O
acid None None O
( None None O
LPA None None O
) None None O
levels None None O
are None None O
elevated None None O
in None None O
ascites None None O
from None None O
ovarian None None O
cancer None None O
patients None None O
, None None O
but None None O
its None None O
potential None None O
role None None O
in None None O
ovarian None None O
cancer None None O
metastasis None None O
has None None O
just None None O
begun None None O
to None None O
be None None O
revealed None None O
. None None O

In None None O
this None None O
work None None O
, None None O
we None None O
show None None O
that None None O
LPA None None O
stimulates None None O
invasion None None O
of None None O
primary None None O
ovarian None None O
cancer None None O
cells None None O
, None None O
but None None O
not None None O
ovarian None None O
epithelial None None O
or None None O
borderline None None O
ovarian None None O
tumor None None O
cells None None O
, None None O
although None None O
these None None O
benign None None O
cells None None O
indeed None None O
respond None None O
to None None O
LPA None None O
in None None O
cell None None O
migration None None O
. None None O

We None None O
have None None O
found None None O
that None None O
LPA None None O
downregulates None None O
tissue None None O
inhibitor None None O
of None None O
metalloproteinases None None O
( None None O
TIMPs None None O
) None None O
. None None O

TIMP2 None None O
and None None O
TIMP3 None None O
play None None O
functional None None O
role None None O
in None None O
LPA None None O
- None None O
induced None None O
invasion None None O
as None None O
negative None None O
regulators None None O
. None None O

G None None O
( None None O
i None None O
) None None O
protein None None O
, None None O
phosphatidylinositol None None O
- None None O
3 None None O
kinase None None O
( None None O
PI3K None None O
) None None O
, None None O
p38 None None O
mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
( None None O
MAPK None None O
) None None O
, None None O
cytosolic None None O
phospholipase None None O
A None None O
( None None O
2 None None O
) None None O
and None None O
urokinase None None O
type None None O
plasminogen None None O
activator None None O
( None None O
uPA None None O
) None None O
are None None O
required None None O
for None None O
LPA None None O
- None None O
induced None None O
cells None None O
invasion None None O
. None None O

TIMP3 None None O
may None None O
affect None None O
two None None O
independent None None O
downstream None None O
targets None None O
, None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
and None None O
p38 None None O
MAPK None None O
. None None O

In None None O
vivo None None O
, None None O
LPA None None O
stimulates None None O
tumor None None O
metastasis None None O
in None None O
an None None O
orthotopic None None O
ovarian None None O
tumor None None O
model None None O
, None None O
which None None O
can None None O
be None None O
inhibited None None O
by None None O
a None None O
PI3K None None O
inhibitor None None O
, None None O
LY294002 None None O
. None None O

In None None O
summary None None O
, None None O
LPA None None O
is None None O
likely None None O
a None None O
key None None O
component None None O
for None None O
promoting None None O
ovarian None None O
metastasis None None O
in None None O
vivo None None O
. None None O

LPA None None O
downregulates None None O
TIMP3 None None O
, None None O
which None None O
may None None O
have None None O
targets None None O
other None None O
than None None O
metalloproteinases None None O
. None None O

Our None None O
in None None O
vivo None None O
metastasis None None O
mouse None None O
model None None O
is None None O
useful None None O
for None None O
studying None None O
the None None O
efficacy None None O
of None None O
therapeutic None None O
regimes None None O
of None None O
ovarian None None O
cancer None None O
. None None O

( None None O
iii None None O
) None None O
HIV None None O
testing None None O
response None None O
rate None None O
by None None O
educational None None O
attainment None None O
and None None O
gender None None O
. None None O

Melanoma None None O
/ None None O
skin None None O
cancer None None O
screening None None O
clinics None None O
: None None O
experiences None None O
in None None O
The None None O
Netherlands None None O
. None None O

In None None O
1989 None None O
and None None O
1990 None None O
we None None O
conducted None None O
two None None O
free None None O
melanoma None None O
/ None None O
skin None None O
screening None None O
clinics None None O
in None None O
Oss None None O
and None None O
Arnhem None None O
in None None O
the None None O
Netherlands None None O
. None None O

The None None O
study None None O
was None None O
carried None None O
out None None O
along None None O
the None None O
lines None None O
of None None O
the None None O
recent None None O
campaigns None None O
supported None None O
by None None O
the None None O
American None None O
Academy None None O
of None None O
Dermatology None None O
. None None O

Of None None O
2564 None None O
persons None None O
screened None None O
, None None O
53 None None O
had None None O
melanoma None None O
or None None O
nonmelanoma None None O
skin None None O
cancer None None O
( None None O
2 None None O
. None None O
1 None None O
% None None O
) None None O
. None None O

Compliance None None O
with None None O
follow None None O
- None None O
up None None O
for None None O
persons None None O
with None None O
suspected None None O
melanoma None None O
/ None None O
skin None None O
cancer None None O
was None None O
adequate None None O
( None None O
93 None None O
of None None O
103 None None O
; None None O
90 None None O
. None None O
3 None None O
% None None O
) None None O
. None None O

Expression None None O
of None None O
EphA2 None None O
and None None O
E None None O
- None None O
cadherin None None O
in None None O
colorectal None None O
cancer None None O
: None None O
correlation None None O
with None None O
cancer None None O
metastasis None None O
. None None O

Recently None None O
, None None O
overexpression None None O
of None None O
EphA2 None None O
, None None O
a None None O
member None None O
of None None O
the None None O
Eph None None O
family None None O
of None None O
receptor None None O
tyrosine None None O
kinases None None O
, None None O
has None None O
been None None O
reported None None O
in None None O
several None None O
cancers None None O
. None None O

Reduced None None O
expression None None O
of None None O
E None None O
- None None O
cadherin None None O
, None None O
an None None O
intercellular None None O
adhesion None None O
molecule None None O
of None None O
epithelial None None O
cells None None O
, None None O
has None None O
been None None O
reported None None O
to None None O
be None None O
associated None None O
with None None O
aggressive None None O
clinicopathological None None O
phenotypes None None O
in None None O
various None None O
cancers None None O
. None None O

In None None O
epithelial None None O
cells None None O
, None None O
EphA2 None None O
and None None O
E None None O
- None None O
cadherin None None O
co None None O
- None None O
localize None None O
to None None O
sites None None O
of None None O
cell None None O
- None None O
cell None None O
contact None None O
, None None O
and None None O
it None None O
has None None O
been None None O
shown None None O
that None None O
E None None O
- None None O
cadherin None None O
regulates None None O
EphA2 None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
clarify None None O
the None None O
relationship None None O
between None None O
the None None O
expression None None O
of None None O
the None None O
EphA2 None None O
and None None O
E None None O
- None None O
cadherin None None O
proteins None None O
and None None O
clinicopathological None None O
characteristics None None O
, None None O
with None None O
reference None None O
to None None O
the None None O
expression None None O
levels None None O
of None None O
both None None O
EphA2 None None O
and None None O
E None None O
- None None O
cadherin None None O
, None None O
in None None O
patients None None O
with None None O
colorectal None None O
cancer None None O
. None None O

We None None O
performed None None O
immunohistochemical None None O
staining None None O
of None None O
EphA2 None None O
and None None O
E None None O
- None None O
cadherin None None O
with None None O
EphA2 None None O
and None None O
E None None O
- None None O
cadherin None None O
monoclonal None None O
antibodies None None O
in None None O
samples None None O
from None None O
194 None None O
primary None None O
lesions None None O
of None None O
colorectal None None O
cancer None None O
. None None O

The None None O
expression None None O
level None None O
of None None O
EphA2 None None O
had None None O
a None None O
statistically None None O
significant None None O
relationship None None O
with None None O
liver None None O
metastasis None None O
, None None O
lymphatic None None O
vessel None None O
invasion None None O
and None None O
clinical None None O
stage None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
0477 None None O
, None None O
0 None None O
. None None O
0316 None None O
and None None O
0 None None O
. None None O
0467 None None O
, None None O
respectively None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
positivity None None O
rate None None O
of None None O
EphA2 None None O
was None None O
significantly None None O
higher None None O
in None None O
primary None None O
lesions None None O
with None None O
lymph None None O
node None None O
metastasis None None O
than None None O
in None None O
those None None O
without None None O
metastasis None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
0014 None None O
) None None O
. None None O

However None None O
, None None O
the None None O
expression None None O
level None None O
of None None O
E None None O
- None None O
cadherin None None O
had None None O
an None None O
inverse None None O
relationship None None O
with None None O
both None None O
differentiation None None O
level None None O
of None None O
the None None O
tumor None None O
and None None O
lymphatic None None O
vessel None None O
invasion None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
0430 None None O
and None None O
0 None None O
. None None O
0320 None None O
, None None O
respectively None None O
) None None O
. None None O

Furthermore None None O
, None None O
a None None O
significant None None O
relationship None None O
between None None O
the None None O
expression None None O
of None None O
EphA2 None None O
and None None O
E None None O
- None None O
cadherin None None O
was None None O
observed None None O
. None None O

In None None O
conclusion None None O
, None None O
our None None O
study None None O
revealed None None O
that None None O
the None None O
overexpression None None O
of None None O
EphA2 None None O
protein None None O
in None None O
colorectal None None O
carcinoma None None O
tissue None None O
correlates None None O
closely None None O
with None None O
cancer None None O
progression None None O
and None None O
hematogenous None None O
and None None O
lymphogenous None None O
metastasis None None O
, None None O
suggesting None None O
that None None O
both None None O
EphA2 None None O
and None None O
E None None O
- None None O
cadherin None None O
may None None O
play None None O
an None None O
important None None O
role None None O
in None None O
tumor None None O
metastasis None None O
in None None O
colorectal None None O
cancer None None O
. None None O

CCL16 None None O
activates None None O
an None None O
angiogenic None None O
program None None O
in None None O
vascular None None O
endothelial None None O
cells None None O
. None None O

Besides None None O
regulating None None O
leukocyte None None O
trafficking None None O
in None None O
normal None None O
and None None O
injured None None O
tissues None None O
, None None O
several None None O
chemokines None None O
may None None O
positively None None O
or None None O
negatively None None O
regulate None None O
angiogenesis None None O
. None None O

Here None None O
we None None O
report None None O
that None None O
CCL16 None None O
activates None None O
an None None O
angiogenic None None O
program None None O
in None None O
vascular None None O
endothelial None None O
cells None None O
by None None O
activating None None O
CCR1 None None O
. None None O

CCL16 None None O
induces None None O
dose None None O
- None None O
dependent None None O
random None None O
and None None O
directional None None O
migration None None O
of None None O
endothelial None None O
cells None None O
isolated None None O
from None None O
large None None O
vessels None None O
and None None O
liver None None O
capillaries None None O
without None None O
inducing None None O
their None None O
proliferation None None O
. None None O

It None None O
also None None O
promotes None None O
endothelial None None O
differentiation None None O
into None None O
capillary None None O
- None None O
like None None O
structures None None O
in None None O
an None None O
in None None O
vitro None None O
assay None None O
and None None O
is None None O
angiogenic None None O
in None None O
the None None O
chick None None O
chorionallantoic None None O
membrane None None O
. None None O

These None None O
angiogenic None None O
activities None None O
are None None O
neutralized None None O
by None None O
a None None O
specific None None O
antibody None None O
against None None O
CCL16 None None O
. None None O

The None None O
direct None None O
angiogenic None None O
activity None None O
of None None O
CCL16 None None O
is None None O
further None None O
amplified None None O
by None None O
its None None O
ability None None O
to None None O
prime None None O
endothelium None None O
to None None O
a None None O
mitogen None None O
signal None None O
induced None None O
by None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
A None None O
and None None O
to None None O
raise None None O
their None None O
basal None None O
production None None O
of None None O
CXCL8 None None O
and None None O
CCL2 None None O
, None None O
2 None None O
other None None O
angiogenic None None O
chemokines None None O
. None None O

BX471 None None O
( None None O
R None None O
- None None O
N None None O
- None None O
[ None None O
5 None None O
- None None O
chloro None None O
- None None O
2 None None O
- None None O
[ None None O
2 None None O
- None None O
[ None None O
4 None None O
( None None O
4 None None O
- None None O
fluorophenyl None None O
) None None O
methyl None None O
] None None O
- None None O
2 None None O
- None None O
methyl None None O
- None None O
1 None None O
- None None O
piperazinyl None None O
] None None O
- None None O
2 None None O
- None None O
oxoethoxy None None O
] None None O
phenyl None None O
] None None O
urea None None O
hydrochloric None None O
acid None None O
salt None None O
) None None O
, None None O
a None None O
CCR1 None None O
antagonist None None O
, None None O
inhibits None None O
angiogenic None None O
properties None None O
of None None O
CCL16 None None O
, None None O
whereas None None O
blocking None None O
of None None O
CCR8 None None O
or None None O
desensitizing None None O
CCR2 None None O
, None None O
which None None O
are None None O
both None None O
well None None O
known None None O
receptors None None O
for None None O
CCL16 None None O
, None None O
did None None O
not None None O
abolish None None O
endothelial None None O
activation None None O
. None None O

CCL16 None None O
may None None O
be None None O
specifically None None O
cross None None O
- None None O
linked None None O
to None None O
CCR1 None None O
expressed None None O
on None None O
endothelial None None O
cells None None O
. None None O

The None None O
largely None None O
restricted None None O
CCL16 None None O
expression None None O
in None None O
the None None O
liver None None O
suggests None None O
that None None O
this None None O
chemokine None None O
may None None O
play None None O
a None None O
role None None O
in None None O
hepatic None None O
vascular None None O
formation None None O
during None None O
development None None O
and None None O
in None None O
angiogenesis None None O
associated None None O
to None None O
hepatic None None O
diseases None None O
. None None O

Importing None None O
citations None None O
in None None O
different None None O
formats None None O
using None None O
Google None None O
Scholar None None O

Segmental None None O
atrial None None O
contraction None None O
in None None O
patients None None O
restored None None O
to None None O
sinus None None O
rhythm None None O
after None None O
cardioversion None None O
for None None O
chronic None None O
atrial None None O
fibrillation None None O
: None None O
a None None O
colour None None O
Doppler None None O
tissue None None O
imaging None None O
study None None O
. None None O

AIMS None None O
: None None O

There None None O
is None None O
little None None O
known None None O
about None None O
segmental None None O
atrial None None O
function None None O
in None None O
patients None None O
with None None O
atrial None None O
arrhythmias None None O
. None None O

We None None O
evaluated None None O
segmental None None O
atrial None None O
contractility None None O
using None None O
colour None None O
Doppler None None O
tissue None None O
imaging None None O
( None None O
CDTI None None O
) None None O
in None None O
patients None None O
with None None O
chronic None None O
atrial None None O
fibrillation None None O
( None None O
CAF None None O
) None None O
who None None O
were None None O
successfully None None O
restored None None O
and None None O
maintained None None O
in None None O
sinus None None O
rhythm None None O
( None None O
SR None None O
) None None O
. None None O

METHODS None None O
AND None None O
RESULTS None None O
: None None O

We None None O
compared None None O
the None None O
segmental None None O
atrial None None O
contractility None None O
in None None O
39 None None O
CAF None None O
patients None None O
who None None O
were None None O
successfully None None O
cardioverted None None O
and None None O
maintained None None O
in None None O
SR None None O
for None None O
6 None None O
months None None O
. None None O

Follow None None O
up None None O
echocardiograms None None O
were None None O
performed None None O
at None None O
baseline None None O
, None None O
1 None None O
week None None O
, None None O
1 None None O
month None None O
and None None O
6 None None O
months None None O
and None None O
compared None None O
to None None O
a None None O
normal None None O
age None None O
matched None None O
cohort None None O
( None None O
n None None O
= None None O
34 None None O
) None None O
. None None O

Using None None O
CDTI None None O
, None None O
mean None None O
peak None None O
velocities None None O
of None None O
atrial None None O
contraction None None O
were None None O
measured None None O
from None None O
annular None None O
, None None O
mid None None O
and None None O
superior None None O
segments None None O
of None None O
lateral None None O
and None None O
septal None None O
walls None None O
of None None O
the None None O
left None None O
atrium None None O
and None None O
right None None O
atrium None None O
in None None O
the None None O
apical None None O
four None None O
- None None O
chamber None None O
view None None O
. None None O

Segmental None None O
velocities None None O
from None None O
the None None O
posterior None None O
and None None O
anterior None None O
walls None None O
of None None O
the None None O
left None None O
atrium None None O
were None None O
measured None None O
from None None O
the None None O
apical None None O
two None None O
- None None O
chamber None None O
view None None O
. None None O

Segmental None None O
left None None O
atrial None None O
velocities None None O
improved None None O
over None None O
time None None O
in None None O
the None None O
CAF None None O
group None None O
, None None O
with None None O
the None None O
majority None None O
of None None O
the None None O
recovery None None O
occurring None None O
in None None O
the None None O
first None None O
month None None O
, None None O
but None None O
failed None None O
to None None O
normalise None None O
even None None O
at None None O
6 None None O
months None None O
. None None O

In None None O
comparison None None O
, None None O
the None None O
right None None O
atrial None None O
velocities None None O
in None None O
the None None O
AF None None O
group None None O
had None None O
normalised None None O
at None None O
1 None None O
month None None O
. None None O

CONCLUSION None None O
: None None O

Patients None None O
with None None O
CAF None None O
have None None O
persistent None None O
segmental None None O
left None None O
atrial None None O
dysfunction None None O
even None None O
6 None None O
months None None O
after None None O
restoration None None O
and None None O
maintenance None None O
of None None O
SR None None O
, None None O
though None None O
right None None O
atrial None None O
velocities None None O
appear None None O
to None None O
normalise None None O
. None None O

This None None O
differential None None O
recovery None None O
indicates None None O
that None None O
left None None O
atrial None None O
function None None O
remains None None O
subnormal None None O
in None None O
patients None None O
with None None O
CAF None None O
despite None None O
maintenance None None O
of None None O
SR None None O
, None None O
suggesting None None O
underlying None None O
atrial None None O
myopathy None None O
or None None O
fibrosis None None O
as None None O
a None None O
consequence None None O
of None None O
CAF None None O
. None None O

High None None O
frequency None None O
of None None O
hypermethylation None None O
at None None O
the None None O
14 None None O
- None None O
3 None None O
- None None O
3 None None O
sigma None None O
locus None None O
leads None None O
to None None O
gene None None O
silencing None None O
in None None O
breast None None O
cancer None None O
. None None O

Expression None None O
of None None O
14 None None O
- None None O
3 None None O
- None None O
3 None None O
final None None O
sigma None None O
( None None O
final None None O
sigma None None O
) None None O
is None None O
induced None None O
in None None O
response None None O
to None None O
DNA None None O
damage None None O
, None None O
and None None O
causes None None O
cells None None O
to None None O
arrest None None O
in None None O
G None None O
( None None O
2 None None O
) None None O
. None None O

By None None O
SAGE None None O
( None None O
serial None None O
analysis None None O
of None None O
gene None None O
expression None None O
) None None O
analysis None None O
, None None O
we None None O
identified None None O
final None None O
sigma None None O
as None None O
a None None O
gene None None O
whose None None O
expression None None O
is None None O
7 None None O
- None None O
fold None None O
lower None None O
in None None O
breast None None O
carcinoma None None O
cells None None O
than None None O
in None None O
normal None None O
breast None None O
epithelium None None O
. None None O

We None None O
verified None None O
this None None O
finding None None O
by None None O
Northern None None O
blot None None O
analysis None None O
. None None O

Remarkably None None O
, None None O
final None None O
sigma None None O
mRNA None None O
was None None O
undetectable None None O
in None None O
45 None None O
of None None O
48 None None O
primary None None O
breast None None O
carcinomas None None O
. None None O

Genetic None None O
alterations None None O
at None None O
final None None O
sigma None None O
such None None O
as None None O
loss None None O
of None None O
heterozygosity None None O
were None None O
rare None None O
( None None O
1 None None O
/ None None O
20 None None O
informative None None O
cases None None O
) None None O
, None None O
and None None O
no None None O
mutations None None O
were None None O
detected None None O
( None None O
0 None None O
/ None None O
34 None None O
) None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
hypermethylation None None O
of None None O
CpG None None O
islands None None O
in None None O
the None None O
final None None O
sigma None None O
gene None None O
was None None O
detected None None O
in None None O
91 None None O
% None None O
( None None O
75 None None O
/ None None O
82 None None O
) None None O
of None None O
breast None None O
tumors None None O
and None None O
was None None O
associated None None O
with None None O
lack None None O
of None None O
gene None None O
expression None None O
. None None O

Hypermethylation None None O
of None None O
final None None O
sigma None None O
is None None O
functionally None None O
important None None O
, None None O
because None None O
treatment None None O
of None None O
final None None O
sigma None None O
- None None O
non None None O
- None None O
expressing None None O
breast None None O
cancer None None O
cell None None O
lines None None O
with None None O
the None None O
drug None None O
5 None None O
- None None O
aza None None O
- None None O
2 None None O
' None None O
- None None O
deoxycytidine None None O
resulted None None O
in None None O
demethylation None None O
of None None O
the None None O
gene None None O
and None None O
synthesis None None O
of None None O
final None None O
sigma None None O
mRNA None None O
. None None O

Breast None None O
cancer None None O
cells None None O
lacking None None O
final None None O
sigma None None O
expression None None O
showed None None O
increased None None O
number None None O
of None None O
chromosomal None None O
breaks None None O
and None None O
gaps None None O
when None None O
exposed None None O
to None None O
gamma None None O
- None None O
irradiation None None O
. None None O

Therefore None None O
, None None O
it None None O
is None None O
possible None None O
that None None O
loss None None O
of None None O
final None None O
sigma None None O
expression None None O
contributes None None O
to None None O
malignant None None O
transformation None None O
by None None O
impairing None None O
the None None O
G None None O
( None None O
2 None None O
) None None O
cell None None O
cycle None None O
checkpoint None None O
function None None O
, None None O
thus None None O
allowing None None O
an None None O
accumulation None None O
of None None O
genetic None None O
defects None None O
. None None O

Hypermethylation None None O
and None None O
loss None None O
of None None O
final None None O
sigma None None O
expression None None O
are None None O
the None None O
most None None O
consistent None None O
molecular None None O
alterations None None O
in None None O
breast None None O
cancer None None O
identified None None O
so None None O
far None None O
. None None O

Effects None None O
of None None O
4 None None O
- None None O
alkylmorpholine None None O
N None None O
- None None O
oxides None None O
on None None O
ATP None None O
- None None O
producing None None O
processes None None O
in None None O
Ehrlich None None O
ascites None None O
and None None O
L1210 None None I-Cell-line-name
leukaemia None None O
cells None None O
. None None O

The None None O
main None None O
purpose None None O
of None None O
the None None O
present None None O
investigation None None O
was None None O
to None None O
study None None O
the None None O
effect None None O
of None None O
the None None O
homologous None None O
series None None O
of None None O
4 None None O
- None None O
alkylmorpholine None None O
N None None O
- None None O
oxides None None O
on None None O
ATP None None O
- None None O
producing None None O
processes None None O
in None None O
Ehrlich None None O
ascites None None O
and None None O
L1210 None None I-Cell-line-name
murine None None O
leukaemia None None O
cells None None O
. None None O

The None None O
effects None None O
on None None O
aerobic None None O
glucose None None O
consumption None None O
, None None O
lactic None None O
acid None None O
formation None None O
, None None O
content None None O
of None None O
total None None O
( None None O
T None None O
- None None O
SH None None O
) None None O
and None None O
non None None O
- None None O
protein None None O
thiol None None O
groups None None O
( None None O
NP None None O
- None None O
SH None None O
) None None O
, None None O
endogenous None None O
and None None O
exogenous None None O
respiration None None O
and None None O
the None None O
level None None O
of None None O
ATP None None O
in None None O
tumour None None O
cells None None O
incubated None None O
in None None O
vitro None None O
were None None O
investigated None None O
. None None O

4 None None O
- None None O
Dodecylmorpholine None None O
N None None O
- None None O
oxide None None O
( None None O
DMNO None None O
) None None O
, None None O
one None None O
of None None O
the None None O
most None None O
active None None O
compounds None None O
, None None O
decreased None None O
the None None O
level None None O
of None None O
ATP None None O
immediately None None O
after None None O
addition None None O
to None None O
the None None O
suspension None None O
of None None O
Ehrlich None None O
cells None None O
in None None O
an None None O
ice None None O
bath None None O
. None None O

After None None O
2 None None O
h None None O
incubation None None O
at None None O
37 None None O
degrees None None O
C None None O
the None None O
drop None None O
in None None O
the None None O
ATP None None O
level None None O
was None None O
much None None O
lower None None O
. None None O

A None None O
possible None None O
explanation None None O
for None None O
the None None O
decrease None None O
in None None O
the None None O
ATP None None O
level None None O
might None None O
be None None O
interaction None None O
of None None O
the None None O
amine None None O
oxide None None O
with None None O
the None None O
cell None None O
membrane None None O
. None None O

ICAM None None O
- None None O
3 None None O
enhances None None O
the None None O
migratory None None O
and None None O
invasive None None O
potential None None O
of None None O
human None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
cancer None None O
cells None None O
by None None O
inducing None None O
MMP None None O
- None None O
2 None None O
and None None O
MMP None None O
- None None O
9 None None O
via None None O
Akt None None O
and None None O
CREB None None O
. None None O

We None None O
have None None O
previously None None O
reported None None O
that None None O
intercellular None None O
adhesion None None O
molecule None None O
- None None O
3 None None O
( None None O
ICAM None None O
- None None O
3 None None O
) None None O
is None None O
associated None None O
with None None O
an None None O
increase None None O
of None None O
cellular None None O
radio None None O
- None None O
resistance None None O
and None None O
cancer None None O
cell None None O
proliferation None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
hypothesized None None O
that None None O
ICAM None None O
- None None O
3 None None O
has None None O
an None None O
additional None None O
effect None None O
on None None O
cancer None None O
cell None None O
migration None None O
and None None O
invasion None None O
because None None O
molecules None None O
induced None None O
by None None O
ICAM None None O
- None None O
3 None None O
are None None O
known None None O
as None None O
regulators None None O
of None None O
cell None None O
migration None None O
and None None O
invasion None None O
. None None O

To None None O
examine None None O
this None None O
hypothesis None None O
, None None O
we None None O
used None None O
NCI None None I-Cell-line-name
- None None I-Cell-line-name
H1299 None None I-Cell-line-name
non None None O
- None None O
small None None O
cell None None O
lung None None O
cancer None None O
( None None O
NSCLC None None O
) None None O
cell None None O
line None None O
( None None O
p53 None None O
and None None O
PTEN None None O
null None None O
cell None None O
) None None O
and None None O
constructed None None O
an None None O
ICAM None None O
- None None O
3 None None O
- None None O
over None None O
- None None O
expressing None None O
stable None None O
transfectant None None O
, None None O
which None None O
exhibited None None O
increased None None O
cell None None O
migration None None O
and None None O
invasion None None O
. None None O

The None None O
increased None None O
migration None None O
and None None O
invasion None None O
resulted None None O
from None None O
up None None O
- None None O
regulation None None O
of None None O
expression None None O
and None None O
activities None None O
of None None O
MMP None None O
- None None O
2 None None O
and None None O
MMP None None O
- None None O
9 None None O
. None None O

ICAM None None O
- None None O
3 None None O
also None None O
increased None None O
Akt None None O
phosphorylation None None O
, None None O
which None None O
caused None None O
an None None O
increase None None O
in None None O
cellular None None O
migration None None O
/ None None O
invasion None None O
and None None O
MMP None None O
activities None None O
. None None O

Activity None None O
of None None O
several None None O
transcriptional None None O
factors None None O
located None None O
downstream None None O
in None None O
the None None O
Akt None None O
pathway None None O
was None None O
also None None O
tested None None O
, None None O
and None None O
constitutive None None O
activation None None O
of None None O
adenosine None None O
3 None None O
' None None O
, None None O
5 None None O
' None None O
- None None O
monophosphate None None O
response None None O
element None None O
- None None O
binding None None O
protein None None O
( None None O
CREB None None O
) None None O
by None None O
ICAM None None O
- None None O
3 None None O
was None None O
detected None None O
. None None O

Blockage None None O
of None None O
the None None O
Akt None None O
pathway None None O
attenuated None None O
CREB None None O
activation None None O
, None None O
and None None O
a None None O
decrease None None O
in None None O
CREB None None O
expression None None O
reduced None None O
cellular None None O
migration None None O
/ None None O
invasion None None O
and None None O
activity None None O
of None None O
MMPs None None O
. None None O

This None None O
result None None O
indicates None None O
that None None O
CREB None None O
functions None None O
in None None O
the None None O
signaling None None O
pathway None None O
between None None O
Akt None None O
and None None O
MMP None None O
. None None O

We None None O
also None None O
showed None None O
ICAM None None O
- None None O
3 None None O
- None None O
induced None None O
cell None None O
migration None None O
and None None O
invasion None None O
in None None O
NCI None None I-Cell-line-name
- None None I-Cell-line-name
H460 None None I-Cell-line-name
NSCLC None None O
cells None None O
( None None O
wild None None O
- None None O
type None None O
p53 None None O
and None None O
PTEN None None O
cell None None O
) None None O
through None None O
the None None O
same None None O
signaling None None O
pathway None None O
. None None O

Taken None None O
together None None O
, None None O
our None None O
findings None None O
suggest None None O
that None None O
ICAM None None O
- None None O
3 None None O
stimulates None None O
cancer None None O
cell None None O
migration None None O
/ None None O
invasion None None O
via None None O
ICAM None None O
- None None O
3 None None O
/ None None O
Akt None None O
/ None None O
CREB None None O
/ None None O
MMP None None O
pathway None None O
regardless None None O
of None None O
p53 None None O
and None None O
PTEN None None O
status None None O
, None None O
and None None O
this None None O
reflects None None O
the None None O
possibility None None O
that None None O
ICAM None None O
- None None O
3 None None O
could None None O
be None None O
considered None None O
as None None O
a None None O
candidate None None O
for None None O
anti None None O
- None None O
cancer None None O
drug None None O
development None None O
and None None O
as None None O
a None None O
cancer None None O
diagnostic None None O
marker None None O
. None None O

RhoA None None O
activation None None O
promotes None None O
transformation None None O
and None None O
loss None None O
of None None O
thyroid None None O
cell None None O
differentiation None None O
interfering None None O
with None None O
thyroid None None O
transcription None None O
factor None None O
- None None O
1 None None O
activity None None O
. None None O

Highly None None O
specialized None None O
cells None None O
, None None O
the None None O
thyrocytes None None O
, None None O
express None None O
a None None O
thyroid None None O
- None None O
specific None None O
set None None O
of None None O
genes None None O
for None None O
thyroglobulin None None O
( None None O
Tg None None O
) None None O
, None None O
thyroperoxidase None None O
, None None O
and None None O
the None None O
transcription None None O
factors None None O
TTF None None O
- None None O
1 None None O
, None None O
TTF None None O
- None None O
2 None None O
, None None O
and None None O
Pax None None O
- None None O
8 None None O
. None None O

The None None O
implication None None O
of None None O
the None None O
small None None O
GTPase None None O
RhoA None None O
in None None O
TSH None None O
- None None O
mediated None None O
proliferation None None O
of None None O
FRTL None None I-Cell-line-name
- None None I-Cell-line-name
5 None None I-Cell-line-name
rat None None O
thyroid None None O
cells None None O
has None None O
been None None O
previously None None O
demonstrated None None O
. None None O

To None None O
further None None O
analyze None None O
RhoA None None O
function None None O
in None None O
thyroid None None O
cell None None O
proliferation None None O
and None None O
differentiation None None O
patterns None None O
, None None O
we None None O
combined None None O
transient None None O
and None None O
stable None None O
transfection None None O
assays None None O
to None None O
express None None O
different None None O
mutant None None O
RhoA None None O
forms None None O
in None None O
FRTL None None I-Cell-line-name
- None None I-Cell-line-name
5 None None I-Cell-line-name
cells None None O
. None None O

Constitutively None None O
active None None O
RhoA None None O
( None None O
FRTL None None I-Cell-line-name
- None None I-Cell-line-name
5 None None I-Cell-line-name
- None None O
RhoA None None O
QL None None O
cells None None O
) None None O
exhibited None None O
a None None O
fibroblast None None O
- None None O
like None None O
phenotype None None O
with None None O
organized None None O
actin None None O
fibers None None O
, None None O
whereas None None O
cells None None O
expressing None None O
the None None O
RhoA None None O
negative None None O
dominant None None O
phenotype None None O
( None None O
FRTL None None I-Cell-line-name
- None None I-Cell-line-name
5 None None I-Cell-line-name
- None None O
RhoA None None O
N19 None None O
cells None None O
) None None O
present None None O
a None None O
rounded None None O
morphology None None O
and None None O
lose None None O
normal None None O
cytoskeletal None None O
architecture None None O
. None None O

In None None O
addition None None O
, None None O
expression None None O
of None None O
the None None O
constitutively None None O
active None None O
form None None O
of None None O
RhoA None None O
results None None O
in None None O
TSH None None O
- None None O
independent None None O
proliferation None None O
and None None O
anchorage None None O
- None None O
independent None None O
growth None None O
and None None O
induces None None O
tumors None None O
when None None O
inoculated None None O
in None None O
nude None None O
mice None None O
. None None O

Interestingly None None O
, None None O
FRTL None None I-Cell-line-name
- None None I-Cell-line-name
5 None None I-Cell-line-name
- None None O
RhoA None None O
QL None None O
cells None None O
express None None O
less None None O
Tg None None O
and None None O
TTF None None O
- None None O
1 None None O
than None None O
wild None None O
- None None O
type None None O
FRTL None None I-Cell-line-name
- None None I-Cell-line-name
5 None None I-Cell-line-name
( None None O
FRTL None None I-Cell-line-name
- None None I-Cell-line-name
5 None None I-Cell-line-name
- None None O
vector None None O
) None None O
or None None O
FRTL None None I-Cell-line-name
- None None I-Cell-line-name
5 None None I-Cell-line-name
- None None O
RhoA None None O
N19 None None O
, None None O
suggesting None None O
a None None O
loss None None O
at None None O
the None None O
differentiation None None O
stage None None O
. None None O

This None None O
effect None None O
is None None O
mediated None None O
, None None O
at None None O
least None None O
in None None O
part None None O
, None None O
by None None O
a None None O
decrease None None O
in None None O
TTF None None O
- None None O
1 None None O
activity None None O
, None None O
since None None O
transient None None O
or None None O
stable None None O
expression None None O
of None None O
RhoA None None O
QL None None O
results None None O
in None None O
a None None O
reduction None None O
in None None O
the None None O
activity None None O
of None None O
the None None O
wild None None O
- None None O
type None None O
Tg None None O
promoter None None O
as None None O
well None None O
as None None O
an None None O
artificial None None O
promoter None None O
the None None O
activation None None O
of None None O
which None None O
depends None None O
exclusively None None O
on None None O
TTF None None O
- None None O
1 None None O
. None None O

The None None O
similarity None None O
between None None O
RhoA None None O
effects None None O
and None None O
thyroid None None O
transformation None None O
by None None O
Ras None None O
suggests None None O
that None None O
RhoA None None O
may None None O
act None None O
as None None O
a None None O
downstream None None O
effector None None O
of None None O
Ras None None O
; None None O
in None None O
fact None None O
, None None O
the None None O
dominant None None O
negative None None O
RhoA None None O
N19 None None O
abolished None None O
the None None O
down None None O
- None None O
regulatory None None O
effect None None O
of None None O
Ras None None O
V12 None None O
over None None O
the None None O
Tg None None O
promoter None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
results None None O
show None None O
for None None O
the None None O
first None None O
time None None O
that None None O
active None None O
RhoA None None O
is None None O
able None None O
to None None O
transform None None O
FRTL None None I-Cell-line-name
- None None I-Cell-line-name
5 None None I-Cell-line-name
cells None None O
and None None O
that None None O
this None None O
effect None None O
is None None O
coupled None None O
to None None O
a None None O
loss None None O
of None None O
thyroid None None O
differentiation None None O
due None None O
to None None O
impaired None None O
TTF None None O
- None None O
1 None None O
activity None None O
. None None O

Abnormal None None O
expression None None O
of None None O
E None None O
- None None O
cadherin None None O
and None None O
beta None None O
- None None O
catenin None None O
may None None O
be None None O
a None None O
molecular None None O
marker None None O
of None None O
submucosal None None O
invasion None None O
and None None O
lymph None None O
node None None O
metastasis None None O
in None None O
early None None O
gastric None None O
cancer None None O
. None None O

BACKGROUND None None O
: None None O
Impaired None None O
expression None None O
of None None O
E None None O
- None None O
cadherin None None O
and None None O
alpha None None O
- None None O
and None None O
beta None None O
- None None O
catenin None None O
is None None O
frequently None None O
observed None None O
in None None O
several None None O
human None None O
cancers None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
examine None None O
immunohistochemical None None O
expression None None O
of None None O
these None None O
adhesion None None O
molecules None None O
, None None O
focusing None None O
on None None O
early None None O
gastric None None O
carcinomas None None O
, None None O
and None None O
to None None O
investigate None None O
differences None None O
between None None O
differentiated None None O
and None None O
undifferentiated None None O
gastric None None O
cancer None None O
at None None O
the None None O
early None None O
phase None None O
of None None O
carcinogenesis None None O
. None None O

METHODS None None O
: None None O
Immunohistochemical None None O
staining None None O
of None None O
E None None O
- None None O
cadherin None None O
and None None O
alpha None None O
- None None O
and None None O
beta None None O
- None None O
catenin None None O
was None None O
performed None None O
using None None O
specimens None None O
from None None O
143 None None O
patients None None O
with None None O
early None None O
gastric None None O
cancer None None O
. None None O

RESULTS None None O
: None None O
Abnormal None None O
E None None O
- None None O
cadherin None None O
and None None O
beta None None O
- None None O
catenin None None O
staining None None O
correlated None None O
with None None O
depth None None O
of None None O
tumour None None O
invasion None None O
in None None O
differentiated None None O
- None None O
type None None O
tumours None None O
. None None O

In None None O
contrast None None O
, None None O
abnormal None None O
staining None None O
was None None O
frequently None None O
found None None O
even None None O
in None None O
intramucosal None None O
carcinoma None None O
of None None O
undifferentiated None None O
- None None O
type None None O
tumours None None O
, None None O
suggesting None None O
an None None O
apparent None None O
difference None None O
in None None O
the None None O
onset None None O
of None None O
E None None O
- None None O
cadherin None None O
- None None O
catenin None None O
complex None None O
abnormality None None O
between None None O
the None None O
two None None O
cancer None None O
types None None O
. None None O

Absent None None O
staining None None O
of None None O
beta None None O
- None None O
catenin None None O
was None None O
associated None None O
with None None O
lymph None None O
node None None O
metastasis None None O
. None None O

Multivariate None None O
analysis None None O
revealed None None O
abnormal None None O
E None None O
- None None O
cadherin None None O
expression None None O
as None None O
an None None O
independent None None O
factor None None O
that None None O
correlated None None O
with None None O
submucosal None None O
invasion None None O
in None None O
early None None O
gastric None None O
cancer None None O
. None None O

CONCLUSION None None O
: None None O
Abnormal None None O
E None None O
- None None O
cadherin None None O
expression None None O
is None None O
a None None O
possible None None O
marker None None O
of None None O
submucosal None None O
invasion None None O
in None None O
differentiated None None O
- None None O
type None None O
early None None O
gastric None None O
cancer None None O
and None None O
absent None None O
beta None None O
- None None O
catenin None None O
staining None None O
could None None O
be None None O
used None None O
as None None O
a None None O
predictor None None O
of None None O
lymph None None O
node None None O
metastasis None None O
in None None O
both None None O
types None None O
. None None O

Renormalization None None O
group None None O
analysis None None O
of None None O
autoregressive None None O
processes None None O
and None None O
fractional None None O
noise None None O
. None None O

A None None O
renormalization None None O
group None None O
analysis None None O
is None None O
applied None None O
to None None O
autoregressive None None O
processes None None O
with None None O
an None None O
infinite None None O
series None None O
of None None O
coefficients None None O
. None None O

A None None O
simple None None O
fixed None None O
point None None O
is None None O
given None None O
by None None O
a None None O
random None None O
walk None None O
, None None O
and None None O
a None None O
second None None O
class None None O
is None None O
found None None O
that None None O
is None None O
proportional None None O
to None None O
the None None O
high None None O
order None None O
coefficients None None O
of None None O
fractional None None O
autoregressive None None O
integrated None None O
moving None None O
average None None O
( None None O
ARIMA None None O
) None None O
processes None None O
. None None O

The None None O
approach None None O
might None None O
be None None O
useful None None O
to None None O
detect None None O
nonstationarity None None O
in None None O
autoregressive None None O
processes None None O
. None None O

Epstein None None O
- None None O
Barr None None O
virus None None O
- None None O
associated None None O
nonsmall None None O
cell None None O
lung None None O
carcinoma None None O
: None None O
undifferentiated None None O
" None None O
lymphoepithelioma None None O
- None None O
like None None O
" None None O
carcinoma None None O
as None None O
a None None O
distinct None None O
entity None None O
with None None O
better None None O
prognosis None None O
. None None O

BACKGROUND None None O
: None None O

Epstein None None O
- None None O
Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
infection None None O
in None None O
nonsmall None None O
cell None None O
lung None None O
carcinoma None None O
( None None O
NSCLC None None O
) None None O
has None None O
been None None O
demonstrated None None O
in None None O
some None None O
ethnic None None O
groups None None O
. None None O

The None None O
pathobiology None None O
and None None O
the None None O
role None None O
of None None O
EBV None None O
and None None O
oncoprotein None None O
expression None None O
in None None O
these None None O
tumors None None O
have None None O
not None None O
been None None O
studied None None O
extensively None None O
. None None O

In None None O
this None None O
study None None O
, None None O
the None None O
authors None None O
investigated None None O
EBV None None O
- None None O
encoded None None O
RNA None None O
- None None O
1 None None O
( None None O
EBER1 None None O
) None None O
transcripts None None O
by None None O
in None None O
situ None None O
hybridization None None O
and None None O
the None None O
expression None None O
of None None O
latent None None O
membrane None None O
protein None None O
- None None O
1 None None O
( None None O
LMP None None O
- None None O
1 None None O
) None None O
and None None O
bcl None None O
- None None O
2 None None O
protein None None O
by None None O
immunohistochemistry None None O
in None None O
NSCLC None None O
patients None None O
from None None O
Taiwan None None O
, None None O
where None None O
nasopharyngeal None None O
carcinoma None None O
is None None O
endemic None None O
. None None O

METHODS None None O
: None None O

A None None O
total None None O
of None None O
127 None None O
cases None None O
of None None O
NSCLC None None O
( None None O
43 None None O
cases None None O
of None None O
squamous None None O
cell None None O
carcinoma None None O
[ None None O
SCC None None O
] None None O
, None None O
67 None None O
cases None None O
of None None O
adenocarcinoma None None O
[ None None O
AD None None O
] None None O
, None None O
12 None None O
cases None None O
of None None O
large None None O
cell None None O
carcinoma None None O
[ None None O
LCC None None O
] None None O
, None None O
and None None O
5 None None O
cases None None O
of None None O
lymphoepithelioma None None O
- None None O
like None None O
carcinoma None None O
[ None None O
LE None None O
] None None O
) None None O
were None None O
included None None O
. None None O

A None None O
sensitive None None O
polymerase None None O
chain None None O
reaction None None O
- None None O
derived None None O
, None None O
digoxigenin None None O
- None None O
labeled None None O
DNA None None O
probe None None O
for None None O
in None None O
situ None None O
detection None None O
of None None O
EBER1 None None O
transcripts None None O
was None None O
performed None None O
for None None O
the None None O
detection None None O
of None None O
EBV None None O
. None None O

Immunohistochemistry None None O
using None None O
the None None O
avidin None None O
- None None O
biotin None None O
- None None O
immunoperoxidase None None O
method None None O
was None None O
also None None O
performed None None O
to None None O
evaluate None None O
the None None O
expression None None O
of None None O
bcl None None O
- None None O
2 None None O
and None None O
LMP None None O
- None None O
1 None None O
. None None O

RESULTS None None O
: None None O

EBER1 None None O
was None None O
detected None None O
in None None O
11 None None O
of None None O
the None None O
127 None None O
NSCLC None None O
cases None None O
( None None O
8 None None O
. None None O
7 None None O
% None None O
; None None O
6 None None O
SCC None None O
cases None None O
and None None O
5 None None O
LE None None O
cases None None O
) None None O
. None None O

All None None O
5 None None O
LE None None O
cases None None O
were None None O
EBV None None O
- None None O
positive None None O
, None None O
whereas None None O
only None None O
6 None None O
of None None O
the None None O
43 None None O
SCC None None O
cases None None O
( None None O
14 None None O
% None None O
) None None O
, None None O
0 None None O
of None None O
67 None None O
AD None None O
cases None None O
, None None O
and None None O
12 None None O
LCC None None O
cases None None O
were None None O
EBV None None O
- None None O
positive None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

All None None O
five None None O
LE None None O
cases None None O
showed None None O
diffuse None None O
, None None O
strong None None O
, None None O
positive None None O
staining None None O
of None None O
tumor None None O
cells None None O
; None None O
five None None O
of None None O
the None None O
six None None O
SCC None None O
cases None None O
showed None None O
diffuse None None O
but None None O
weak None None O
staining None None O
. None None O

Among None None O
the None None O
nontumor None None O
epithelial None None O
cells None None O
, None None O
there None None O
was None None O
no None None O
EBER1 None None O
staining None None O
of None None O
any None None O
of None None O
the None None O
11 None None O
EBER1 None None O
- None None O
positive None None O
cases None None O
. None None O

The None None O
mean None None O
age None None O
of None None O
the None None O
LE None None O
patients None None O
was None None O
10 None None O
years None None O
younger None None O
than None None O
that None None O
of None None O
the None None O
patients None None O
with None None O
other None None O
histological None None O
types None None O
. None None O

All None None O
5 None None O
LE None None O
patients None None O
were None None O
nonsmokers None None O
, None None O
whereas None None O
3 None None O
of None None O
the None None O
6 None None O
patients None None O
with None None O
EBER1 None None O
- None None O
positive None None O
SCC None None O
( None None O
50 None None O
% None None O
) None None O
were None None O
smokers None None O
. None None O

EBER1 None None O
expression None None O
did None None O
not None None O
correlate None None O
with None None O
the None None O
2 None None O
- None None O
year None None O
survival None None O
rate None None O
of None None O
overall None None O
cases None None O
, None None O
but None None O
all None None O
5 None None O
LE None None O
patients None None O
were None None O
alive None None O
without None None O
clinical None None O
evidence None None O
of None None O
disease None None O
at None None O
last None None O
follow None None O
- None None O
up None None O
. None None O

Gender None None O
, None None O
lymph None None O
node None None O
or None None O
distant None None O
metastasis None None O
, None None O
and None None O
clinical None None O
stage None None O
were None None O
not None None O
found None None O
to None None O
have None None O
any None None O
correlation None None O
with None None O
EBER1 None None O
expression None None O
( None None O
P None None O
> None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

All None None O
LE None None O
cases None None O
had None None O
bcl None None O
- None None O
2 None None O
oncoprotein None None O
expression None None O
( None None O
100 None None O
% None None O
) None None O
. None None O

This None None O
frequency None None O
was None None O
significantly None None O
different None None O
from None None O
other None None O
histologic None None O
types None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
LMP None None O
- None None O
1 None None O
detection None None O
rate None None O
was None None O
low None None O
and None None O
demonstrated None None O
no None None O
correlation None None O
with None None O
bcl None None O
- None None O
2 None None O
expression None None O
. None None O

CONCLUSIONS None None O
: None None O

In None None O
this None None O
study None None O
, None None O
the None None O
authors None None O
found None None O
that None None O
the None None O
primary None None O
LE None None O
of None None O
the None None O
lung None None O
is None None O
associated None None O
with None None O
young None None O
age None None O
, None None O
a None None O
history None None O
of None None O
not None None O
smoking None None O
, None None O
high None None O
bcl None None O
- None None O
2 None None O
immunoreactivity None None O
, None None O
and None None O
better None None O
survival None None O
rate None None O
. None None O

These None None O
characteristics None None O
demonstrate None None O
that None None O
EBV None None O
- None None O
associated None None O
LE None None O
of None None O
the None None O
lung None None O
is None None O
a None None O
unique None None O
entity None None O
. None None O

The None None O
findings None None O
of None None O
the None None O
current None None O
study None None O
suggest None None O
that None None O
EBV None None O
infection None None O
may None None O
play None None O
a None None O
different None None O
role None None O
in None None O
the None None O
tumorigenesis None None O
of None None O
primary None None O
LE None None O
of None None O
the None None O
lung None None O
than None None O
it None None O
does None None O
in None None O
other None None O
EBER1 None None O
- None None O
positive None None O
NSCLCs None None O
. None None O

Sickle None None O
cell None None O
disease None None O
: None None O
continuous None None O
arterial None None O
spin None None O
- None None O
labeling None None O
perfusion None None O
MR None None O
imaging None None O
in None None O
children None None O
. None None O

Cerebral None None O
blood None None O
flow None None O
( None None O
CBF None None O
) None None O
was None None O
measured None None O
with None None O
continuous None None O
arterial None None O
spin None None O
- None None O
labeling None None O
perfusion None None O
magnetic None None O
resonance None None O
( None None O
MR None None O
) None None O
imaging None None O
in None None O
14 None None O
children None None O
with None None O
sickle None None O
cell None None O
disease None None O
and None None O
seven None None O
control None None O
subjects None None O
. None None O

Mean None None O
CBF None None O
values None None O
were None None O
higher None None O
in None None O
patients None None O
( None None O
P None None O
< None None O
. None None O
005 None None O
) None None O
than None None O
in None None O
control None None O
subjects None None O
in None None O
all None None O
cerebral None None O
artery None None O
territories None None O
. None None O

Three None None O
patients None None O
had None None O
decreased None None O
CBF None None O
in None None O
right None None O
anterior None None O
and None None O
middle None None O
cerebral None None O
artery None None O
territories None None O
compared None None O
with None None O
CBF None None O
on None None O
the None None O
left None None O
, None None O
and None None O
one None None O
patient None None O
had None None O
a None None O
profound None None O
decrease None None O
in None None O
CBF None None O
in None None O
all None None O
three None None O
territories None None O
in None None O
the None None O
right None None O
hemisphere None None O
. None None O

Baseline None None O
CBF None None O
was None None O
significantly None None O
decreased None None O
in None None O
territories None None O
seen None None O
as None None O
unaffected None None O
on None None O
conventional None None O
MR None None O
images None None O
and None None O
MR None None O
angiograms None None O
in None None O
four None None O
children None None O
with None None O
sickle None None O
cell None None O
disease None None O
. None None O

The None None O
role None None O
of None None O
syndecans None None O
in None None O
disease None None O
and None None O
wound None None O
healing None None O
. None None O

Syndecans None None O
are None None O
a None None O
family None None O
of None None O
transmembrane None None O
heparan None None O
sulfate None None O
proteoglycans None None O
widely None None O
expressed None None O
in None None O
both None None O
developing None None O
and None None O
adult None None O
tissues None None O
. None None O

Until None None O
recently None None O
, None None O
their None None O
role None None O
in None None O
pathogenesis None None O
was None None O
largely None None O
unexplored None None O
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
discuss None None O
the None None O
reported None None O
involvement None None O
of None None O
syndecans None None O
in None None O
human None None O
cancers None None O
, None None O
infectious None None O
diseases None None O
, None None O
obesity None None O
, None None O
wound None None O
healing None None O
and None None O
angiogenesis None None O
. None None O

In None None O
some None None O
cancers None None O
, None None O
syndecan None None O
expression None None O
has None None O
been None None O
shown None None O
to None None O
regulate None None O
tumor None None O
cell None None O
function None None O
( None None O
e None None O
. None None O
g None None O
. None None O
proliferation None None O
, None None O
adhesion None None O
, None None O
and None None O
motility None None O
) None None O
and None None O
serve None None O
as None None O
a None None O
prognostic None None O
marker None None O
for None None O
tumor None None O
progression None None O
and None None O
patient None None O
survival None None O
. None None O

The None None O
ectodomains None None O
and None None O
heparan None None O
sulfate None None O
glycosaminoglycan None None O
chains None None O
of None None O
syndecans None None O
can None None O
also None None O
act None None O
as None None O
receptors None None O
/ None None O
co None None O
- None None O
receptors None None O
for None None O
some None None O
bacterial None None O
and None None O
viral None None O
pathogens None None O
, None None O
mediating None None O
infection None None O
. None None O

In None None O
addition None None O
, None None O
syndecans None None O
bind None None O
to None None O
obesity None None O
- None None O
related None None O
factors None None O
and None None O
regulate None None O
their None None O
signaling None None O
, None None O
in None None O
turn None None O
modulating None None O
food None None O
consumption None None O
and None None O
weight None None O
balance None None O
. None None O

In None None O
vivo None None O
animal None None O
models None None O
of None None O
tissue None None O
injury None None O
and None None O
in None None O
vitro None None O
data None None O
also None None O
implicate None None O
syndecans None None O
in None None O
processes None None O
necessary None None O
for None None O
wound None None O
healing None None O
, None None O
including None None O
fibroblast None None O
and None None O
endothelial None None O
proliferation None None O
, None None O
cell None None O
motility None None O
, None None O
angiogenesis None None O
, None None O
and None None O
extracellular None None O
matrix None None O
organization None None O
. None None O

These None None O
new None None O
insights None None O
into None None O
the None None O
involvement None None O
of None None O
syndecans None None O
in None None O
disease None None O
and None None O
tissue None None O
repair None None O
coupled None None O
with None None O
the None None O
emergence None None O
of None None O
syndecan None None O
- None None O
specific None None O
molecular None None O
tools None None O
may None None O
lead None None O
to None None O
novel None None O
therapies None None O
for None None O
a None None O
variety None None O
of None None O
human None None O
diseases None None O
. None None O

Investigating None None O
the None None O
causes None None O
of None None O
low None None O
birth None None O
weight None None O
in None None O
contrasting None None O
ovine None None O
paradigms None None O
. None None O

Intrauterine None None O
growth None None O
restriction None None O
( None None O
IUGR None None O
) None None O
still None None O
accounts None None O
for None None O
a None None O
large None None O
incidence None None O
of None None O
infant None None O
mortality None None O
and None None O
morbidity None None O
worldwide None None O
. None None O

Many None None O
of None None O
the None None O
circulatory None None O
and None None O
transport None None O
properties None None O
of None None O
the None None O
sheep None None O
placenta None None O
are None None O
similar None None O
to None None O
those None None O
of None None O
the None None O
human None None O
placenta None None O
and None None O
as None None O
such None None O
, None None O
the None None O
pregnant None None O
sheep None None O
offers None None O
an None None O
excellent None None O
model None None O
in None None O
which None None O
to None None O
study None None O
the None None O
development None None O
of None None O
IUGR None None O
. None None O

Two None None O
natural None None O
models None None O
of None None O
ovine None None O
IUGR None None O
are None None O
those None None O
of None None O
hyperthermic None None O
exposure None None O
during None None O
pregnancy None None O
, None None O
and None None O
adolescent None None O
overfeeding None None O
, None None O
also None None O
during None None O
pregnancy None None O
. None None O

Both None None O
models None None O
yield None None O
significantly None None O
reduced None None O
placental None None O
weights None None O
and None None O
an None None O
asymmetrically None None O
growth None None O
- None None O
restricted None None O
fetus None None O
, None None O
and None None O
display None None O
altered None None O
maternal None None O
hormone None None O
concentrations None None O
, None None O
indicative None None O
of None None O
an None None O
impaired None None O
trophoblast None None O
capacity None None O
. None None O

Additionally None None O
, None None O
impaired None None O
placental None None O
angiogenesis None None O
and None None O
uteroplacental None None O
blood None None O
flow None None O
appears None None O
to None None O
be None None O
an None None O
early None None O
defect None None O
in None None O
both None None O
the None None O
hyperthermic None None O
and None None O
adolescent None None O
paradigms None None O
. None None O

The None None O
effects None None O
of None None O
these None None O
alterations None None O
in None None O
placental None None O
functional None None O
development None None O
appear None None O
to None None O
be None None O
irreversible None None O
. None None O

IUGR None None O
fetuses None None O
are None None O
both None None O
hypoxic None None O
and None None O
hypoglycaemic None None O
, None None O
and None None O
have None None O
reduced None None O
insulin None None O
and None None O
insulin None None O
- None None O
like None None O
growth None None O
factor None None O
- None None O
1 None None O
( None None O
IGF None None O
- None None O
1 None None O
) None None O
, None None O
and None None O
elevated None None O
concentrations None None O
of None None O
lactate None None O
. None None O

However None None O
, None None O
fetal None None O
utilization None None O
of None None O
oxygen None None O
and None None O
glucose None None O
, None None O
on None None O
a None None O
weight None None O
basis None None O
, None None O
remain None None O
constant None None O
compared None None O
with None None O
control None None O
pregnancies None None O
. None None O

Maintained None None O
utilization None None O
of None None O
these None None O
substrates None None O
, None None O
in None None O
a None None O
substrate None None O
- None None O
deficient None None O
environment None None O
, None None O
suggests None None O
increased None None O
sensitivities None None O
to None None O
metabolic None None O
signals None None O
, None None O
which None None O
may None None O
play None None O
a None None O
role None None O
in None None O
the None None O
development None None O
of None None O
metabolic None None O
diseases None None O
in None None O
later None None O
adult None None O
life None None O
. None None O

Immune None None O
consequences None None O
of None None O
burn None None O
injury None None O
. None None O

The None None O
purpose None None O
of None None O
the None None O
immune None None O
system None None O
is None None O
to None None O
protect None None O
cells None None O
from None None O
invasion None None O
by None None O
microorganisms None None O
. None None O

The None None O
body None None O
has None None O
three None None O
equally None None O
important None None O
interactive None None O
immune None None O
defense None None O
systems None None O
, None None O
all None None O
of None None O
which None None O
are None None O
profoundly None None O
disrupted None None O
with None None O
major None None O
burn None None O
injury None None O
. None None O

The None None O
immune None None O
response None None O
to None None O
burn None None O
injury None None O
is None None O
immediate None None O
, None None O
prolonged None None O
, None None O
and None None O
severe None None O
. None None O

The None None O
end None None O
result None None O
in None None O
individuals None None O
surviving None None O
burn None None O
shock None None O
is None None O
immunosuppression None None O
, None None O
with None None O
increased None None O
susceptibility None None O
to None None O
potentially None None O
fatal None None O
systemic None None O
burn None None O
wound None None O
or None None O
pulmonary None None O
sepsis None None O
. None None O

Nursing None None O
actions None None O
to None None O
support None None O
the None None O
humoral None None O
and None None O
cell None None O
- None None O
mediated None None O
immune None None O
system None None O
of None None O
the None None O
burned None None O
patient None None O
include None None O
providing None None O
nutritional None None O
support None None O
to None None O
maintain None None O
serum None None O
protein None None O
levels None None O
at None None O
optimal None None O
levels None None O
; None None O
measures None None O
to None None O
decrease None None O
edema None None O
and None None O
promote None None O
angiogenesis None None O
in None None O
areas None None O
of None None O
partial None None O
- None None O
thickness None None O
injury None None O
; None None O
meticulous None None O
treatment None None O
of None None O
the None None O
wound None None O
to None None O
prevent None None O
infection None None O
and None None O
promote None None O
healing None None O
; None None O
monitoring None None O
of None None O
antibiotic None None O
use None None O
; None None O
conservative None None O
use None None O
of None None O
invasive None None O
techniques None None O
, None None O
including None None O
intubation None None O
and None None O
vascular None None O
access None None O
devices None None O
; None None O
maintenance None None O
of None None O
fluid None None O
and None None O
electrolyte None None O
balance None None O
and None None O
body None None O
temperature None None O
; None None O
and None None O
energy None None O
conservation None None O
measures None None O
. None None O

Desensitization None None O
of None None O
prostaglandin None None O
F2 None None O
alpha None None O
- None None O
stimulated None None O
inositol None None O
phosphate None None O
generation None None O
in None None O
NIH None None I-Cell-line-name
- None None I-Cell-line-name
3T3 None None I-Cell-line-name
fibroblasts None None O
transformed None None O
by None None O
overexpression None None O
of None None O
normal None None O
c None None O
- None None O
Ha None None O
- None None O
ras None None O
- None None O
1 None None O
, None None O
c None None O
- None None O
Ki None None O
- None None O
ras None None O
- None None O
2 None None O
and None None O
c None None O
- None None O
N None None O
- None None O
ras None None O
genes None None O
. None None O

The None None O
stimulation None None O
of None None O
inositol None None O
phosphate None None O
generation None None O
in None None O
control None None O
and None None O
ras None None O
- None None O
gene None None O
- None None O
transformed None None O
NIH None None I-Cell-line-name
- None None I-Cell-line-name
3T3 None None I-Cell-line-name
cells None None O
by None None O
prostaglandin None None O
F2 None None O
alpha None None O
( None None O
PGF2 None None O
alpha None None O
) None None O
was None None O
investigated None None O
. None None O

Compared None None O
with None None O
the None None O
control None None O
cells None None O
, None None O
a None None O
desensitization None None O
of None None O
the None None O
response None None O
was None None O
observed None None O
in None None O
cells None None O
transformed None None O
by None None O
the None None O
overexpression None None O
of None None O
N None None O
- None None O
, None None O
Ha None None O
- None None O
, None None O
or None None O
Ki None None O
- None None O
ras None None O
genes None None O
. None None O

This None None O
desensitization None None O
was None None O
without None None O
effect None None O
upon None None O
the None None O
concentration None None O
causing None None O
half None None O
- None None O
maximal None None O
effect None None O
( None None O
EC50 None None O
) None None O
, None None O
dissociation None None O
constant None None O
( None None O
Kd None None O
) None None O
or None None O
number None None O
of None None O
PGF2 None None O
alpha None None O
receptors None None O
. None None O

Inhibition None None O
of None None O
PG None None O
synthesis None None O
was None None O
without None None O
effect None None O
upon None None O
desensitization None None O
, None None O
demonstrating None None O
that None None O
the None None O
effect None None O
was None None O
not None None O
agonist None None O
- None None O
induced None None O
. None None O

Desensitization None None O
could None None O
be None None O
induced None None O
in None None O
NIH None None I-Cell-line-name
- None None I-Cell-line-name
3T3 None None I-Cell-line-name
cells None None O
by None None O
culturing None None O
under None None O
conditions None None O
where None None O
the None None O
cells None None O
were None None O
all None None O
in None None O
the None None O
exponential None None O
growth None None O
phase None None O
, None None O
or None None O
by None None O
a None None O
12 None None O
h None None O
exposure None None O
to None None O
a None None O
C None None O
- None None O
kinase None None O
- None None O
activating None None O
phorbol None None O
ester None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
desensitization None None O
of None None O
certain None None O
agonist None None O
- None None O
induced None None O
inositol None None O
phospholipid None None O
responses None None O
in None None O
ras None None O
- None None O
transformed None None O
cells None None O
is None None O
a None None O
consequence None None O
of None None O
increased None None O
cell None None O
proliferation None None O
and None None O
associated None None O
amplification None None O
in None None O
C None None O
- None None O
kinase None None O
activity None None O
and None None O
is None None O
an None None O
indirect None None O
consequence None None O
of None None O
transformation None None O
by None None O
ras None None O
. None None O

Women None None O
' None None O
s None None O
attitudes None None O
, None None O
preferences None None O
, None None O
and None None O
perceived None None O
barriers None None O
to None None O
treatment None None O
for None None O
perinatal None None O
depression None None O
. None None O

BACKGROUND None None O
: None None O

Perinatal None None O
depression None None O
is None None O
associated None None O
with None None O
potential None None O
negative None None O
consequences None None O
for None None O
the None None O
mother None None O
and None None O
infant None None O
, None None O
and None None O
therefore None None O
efforts None None O
to None None O
improve None None O
treatment None None O
access None None O
and None None O
efficacy None None O
are None None O
warranted None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
examine None None O
pregnant None None O
women None None O
' None None O
s None None O
preferences None None O
and None None O
attitudes None None O
about None None O
treatment None None O
for None None O
depression None None O
, None None O
and None None O
perceived None None O
potential None None O
barriers None None O
to None None O
accessing None None O
treatment None None O
. None None O

METHODS None None O
: None None O

Data None None O
were None None O
collected None None O
by None None O
means None None O
of None None O
a None None O
questionnaire None None O
from None None O
a None None O
convenience None None O
sample None None O
of None None O
509 None None O
predominantly None None O
well None None O
- None None O
educated None None O
, None None O
high None None O
- None None O
income None None O
, None None O
married None None O
women None None O
in None None O
the None None O
northeastern None None O
United None None O
States None None O
during None None O
the None None O
last None None O
trimester None None O
of None None O
pregnancy None None O
. None None O

Participants None None O
were None None O
queried None None O
as None None O
to None None O
treatment None None O
modalities None None O
in None None O
which None None O
they None None O
would None None O
most None None O
likely None None O
participate None None O
if None None O
they None None O
wanted None None O
help None None O
for None None O
depression None None O
, None None O
their None None O
attitudes None None O
toward None None O
psychotherapeutic None None O
and None None O
pharmacological None None O
treatments None None O
, None None O
and None None O
perceived None None O
barriers None None O
to None None O
receiving None None O
help None None O
. None None O

RESULTS None None O
: None None O

Most None None O
women None None O
( None None O
92 None None O
% None None O
) None None O
indicated None None O
that None None O
would None None O
likely None None O
participate None None O
in None None O
individual None None O
therapy None None O
if None None O
help None None O
was None None O
needed None None O
. None None O

Only None None O
35 None None O
percent None None O
stated None None O
that None None O
they None None O
would None None O
likely None None O
take None None O
medication None None O
if None None O
recommended None None O
, None None O
and None None O
14 None None O
percent None None O
indicated None None O
that None None O
they None None O
would None None O
participate None None O
in None None O
group None None O
therapy None None O
. None None O

The None None O
greatest None None O
perceived None None O
potential None None O
barriers None None O
to None None O
treatment None None O
were None None O
lack None None O
of None None O
time None None O
( None None O
65 None None O
% None None O
) None None O
, None None O
stigma None None O
( None None O
43 None None O
% None None O
) None None O
, None None O
and None None O
childcare None None O
issues None None O
( None None O
33 None None O
% None None O
) None None O
. None None O

Most None None O
women None None O
indicated None None O
a None None O
preference None None O
to None None O
receive None None O
mental None None O
health None None O
care None None O
at None None O
the None None O
obstetrics None None O
clinic None None O
, None None O
either None None O
from None None O
their None None O
obstetrics None None O
practitioner None None O
or None None O
from None None O
a None None O
mental None None O
health None None O
practitioner None None O
located None None O
at None None O
the None None O
clinic None None O
. None None O

Factors None None O
associated None None O
with None None O
acceptability None None O
of None None O
various None None O
depression None None O
treatments None None O
are None None O
presented None None O
. None None O

CONCLUSIONS None None O
: None None O

Understanding None None O
what None None O
prevents None None O
women None None O
from None None O
seeking None None O
or None None O
obtaining None None O
help None None O
for None None O
depression None None O
and None None O
determining None None O
what None None O
they None None O
prefer None None O
in None None O
the None None O
way None None O
of None None O
treatment None None O
may None None O
lead None None O
to None None O
improved None None O
depression None None O
treatment None None O
rates None None O
and None None O
hold None None O
promise None None O
for None None O
improving None None O
the None None O
overall None None O
health None None O
of None None O
childbearing None None O
women None None O
. None None O

Methotrexate None None O
osteopathy None None O
in None None O
rheumatic None None O
disease None None O
. None None O

OBJECTIVE None None O
: None None O

To None None O
determine None None O
whether None None O
two None None O
adults None None O
with None None O
stress None None O
fractures None None O
receiving None None O
low None None O
weekly None None O
doses None None O
of None None O
methotrexate None None O
had None None O
methotrexate None None O
osteopathy None None O
. None None O

CASE None None O
REPORTS None None O
: None None O

Two None None O
adult None None O
patients None None O
developed None None O
features None None O
consistent None None O
with None None O
methotrexate None None O
osteopathy None None O
while None None O
receiving None None O
low None None O
weekly None None O
doses None None O
of None None O
methotrexate None None O
. None None O

METHODS None None O
: None None O

Iliac None None O
crest None None O
biopsy None None O
samples None None O
were None None O
taken None None O
and None None O
bone None None O
histomorphometry None None O
carried None None O
out None None O
. None None O

RESULTS None None O
: None None O

Symptoms None None O
resolved None None O
when None None O
the None None O
methotrexate None None O
was None None O
discontinued None None O
. None None O

Bone None None O
histology None None O
showed None None O
changes None None O
consistent None None O
with None None O
osteoblast None None O
inhibition None None O
by None None O
methotrexate None None O
. None None O

CONCLUSIONS None None O
: None None O

When None None O
given None None O
in None None O
low None None O
doses None None O
for None None O
prolonged None None O
periods None None O
, None None O
methotrexate None None O
may None None O
have None None O
adverse None None O
effects None None O
on None None O
bone None None O
, None None O
particularly None None O
in None None O
post None None O
- None None O
menopausal None None O
women None None O
. None None O

Simvastatin None None O
induces None None O
apoptosis None None O
of None None O
B None None O
- None None O
CLL None None O
cells None None O
by None None O
activation None None O
of None None O
mitochondrial None None O
caspase None None O
9 None None O
. None None O

BACKGROUND None None O
AND None None O
OBJECTIVES None None O
: None None O
Chronic None None O
lymphocytic None None O
leukemia None None O
( None None O
CLL None None O
) None None O
is None None O
the None None O
most None None O
common None None O
leukemia None None O
in None None O
the None None O
western None None O
world None None O
. None None O

Despite None None O
several None None O
advances None None O
in None None O
therapeutic None None O
options None None O
, None None O
the None None O
disease None None O
remains None None O
incurable None None O
. None None O

Recently None None O
, None None O
it None None O
was None None O
repeatedly None None O
demonstrated None None O
that None None O
statins None None O
, None None O
competitive None None O
inhibitors None None O
of None None O
3 None None O
- None None O
hydroxy None None O
- None None O
3 None None O
- None None O
methyl None None O
glutaryl None None O
coenzyme None None O
A None None O
( None None O
HMG None None O
- None None O
CoA None None O
) None None O
reductase None None O
, None None O
have None None O
antineoplastic None None O
effects None None O
. None None O

Therefore None None O
we None None O
aimed None None O
to None None O
study None None O
the None None O
effects None None O
of None None O
simvastatin None None O
( None None O
Sim None None O
) None None O
on None None O
malignant None None O
B None None O
cells None None O
derived None None O
from None None O
patients None None O
with None None O
CLL None None O
and None None O
mechanisms None None O
of None None O
action None None O
of None None O
the None None O
drug None None O
. None None O

METHODS None None O
AND None None O
RESULTS None None O
: None None O
Purified None None O
B None None O
- None None O
CLL None None O
cells None None O
from None None O
15 None None O
patients None None O
were None None O
cultured None None O
either None None O
alone None None O
or None None O
with None None O
Sim None None O
at None None O
concentrations None None O
of None None O
10 None None O
, None None O
50 None None O
, None None O
and None None O
100 None None O
microM None None O
. None None O

Viability None None O
, None None O
measured None None O
by None None O
the None None O
activity None None O
of None None O
mitochondrial None None O
dehydrogenases None None O
, None None O
was None None O
reduced None None O
significantly None None O
in None None O
the None None O
cells None None O
treated None None O
with None None O
Sim None None O
at None None O
50 None None O
and None None O
100 None None O
microM None None O
for None None O
24 None None O
hours None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
005 None None O
) None None O
. None None O

The None None O
level None None O
of None None O
apoptosis None None O
, None None O
as None None O
measured None None O
by None None O
annexin None None O
binding None None O
to None None O
exposed None None O
phosphatidylserine None None O
moieties None None O
, None None O
increased None None O
significantly None None O
in None None O
the None None O
treated None None O
cells None None O
at None None O
concentrations None None O
higher None None O
than None None O
50 None None O
microM None None O
for None None O
24 None None O
hours None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
003 None None O
) None None O
. None None O

The None None O
level None None O
of None None O
necrosis None None O
, None None O
as None None O
measured None None O
by None None O
propidium None None O
iodide None None O
internalization None None O
, None None O
increased None None O
significantly None None O
after None None O
24 None None O
hours None None O
exposure None None O
to None None O
Sim None None O
at None None O
50 None None O
microM None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

The None None O
apoptotic None None O
cascade None None O
was None None O
studied None None O
by None None O
immunoblot None None O
analysis None None O
of None None O
caspases None None O
following None None O
Sim None None O
treatment None None O
. None None O

These None None O
showed None None O
cleavage None None O
of None None O
caspases None None O
9 None None O
, None None O
8 None None O
, None None O
and None None O
3 None None O
. None None O

Addition None None O
of None None O
the None None O
caspase None None O
inhibitor None None O
Z None None O
- None None O
VAD None None O
. None None O
fmk None None O
inhibited None None O
caspase None None O
8 None None O
and None None O
3 None None O
significantly None None O
but None None O
did None None O
not None None O
affect None None O
caspase None None O
9 None None O
. None None O

CONCLUSION None None O
: None None O
Exposure None None O
of None None O
clonal None None O
B None None O
lymphocytes None None O
from None None O
patients None None O
with None None O
CLL None None O
to None None O
simvastatin None None O
decreases None None O
viability None None O
significantly None None O
by None None O
the None None O
induction None None O
of None None O
apoptosis None None O
. None None O

The None None O
apoptosis None None O
induced None None O
by None None O
Sim None None O
is None None O
probably None None O
initiated None None O
by None None O
the None None O
mitochondrial None None O
caspase None None O
9 None None O
, None None O
which None None O
indirectly None None O
leads None None O
to None None O
activation None None O
of None None O
caspase None None O
3 None None O
and None None O
8 None None O
. None None O

Inhibition None None O
of None None O
autophagy None None O
potentiates None None O
the None None O
antitumor None None O
effect None None O
of None None O
the None None O
multikinase None None O
inhibitor None None O
sorafenib None None O
in None None O
hepatocellular None None O
carcinoma None None O
. None None O

Multikinase None None O
inhibitor None None O
sorafenib None None O
inhibits None None O
proliferation None None O
and None None O
angiogenesis None None O
of None None O
tumors None None O
by None None O
suppressing None None O
the None None O
Raf None None O
/ None None O
MEK None None O
/ None None O
ERK None None O
signaling None None O
pathway None None O
and None None O
VEGF None None O
receptor None None O
tyrosine None None O
kinase None None O
. None None O

It None None O
significantly None None O
prolongs None None O
median None None O
survival None None O
of None None O
patients None None O
with None None O
advanced None None O
hepatocellular None None O
carcinoma None None O
( None None O
HCC None None O
) None None O
but None None O
the None None O
response None None O
is None None O
disease None None O
- None None O
stabilizing None None O
and None None O
cytostatic None None O
rather None None O
than None None O
one None None O
of None None O
tumor None None O
regression None None O
. None None O

To None None O
examine None None O
the None None O
mechanisms None None O
underlying None None O
the None None O
relative None None O
resistance None None O
in None None O
HCC None None O
, None None O
we None None O
investigated None None O
the None None O
role None None O
of None None O
autophagy None None O
, None None O
an None None O
evolutionarily None None O
conserved None None O
self None None O
- None None O
digestion None None O
pathway None None O
, None None O
in None None O
hepatoma None None O
cells None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

Sorafenib None None O
treatment None None O
led None None O
to None None O
accumulation None None O
of None None O
autophagosomes None None O
as None None O
evidenced None None O
by None None O
conversion None None O
from None None O
LC3 None None O
- None None O
I None None O
to None None O
LC3 None None O
- None None O
II None None O
observed None None O
by None None O
immunoblot None None O
in None None O
Huh7 None None I-Cell-line-name
, None None O
HLF None None I-Cell-line-name
and None None O
PLC None None I-Cell-line-name
/ None None I-Cell-line-name
PRF None None I-Cell-line-name
/ None None I-Cell-line-name
5 None None I-Cell-line-name
cells None None O
. None None O

This None None O
induction None None O
was None None O
due None None O
to None None O
activation None None O
of None None O
autophagic None None O
flux None None O
, None None O
as None None O
there None None O
was None None O
further None None O
increase None None O
in None None O
LC3 None None O
- None None O
II None None O
expression None None O
upon None None O
treatment None None O
with None None O
lysosomal None None O
inhibitors None None O
, None None O
clear None None O
decline None None O
of None None O
the None None O
autophagy None None O
substrate None None O
p62 None None O
, None None O
and None None O
an None None O
mRFP None None O
- None None O
GFP None None O
- None None O
LC3 None None O
fluorescence None None O
change None None O
in None None O
sorafenib None None O
- None None O
treated None None O
hepatoma None None O
cells None None O
. None None O

Sorafenib None None O
inhibited None None O
the None None O
mammalian None None O
target None None O
of None None O
rapamycin None None O
complex None None O
1 None None O
and None None O
its None None O
inhibition None None O
led None None O
to None None O
accumulation None None O
of None None O
LC3 None None O
- None None O
II None None O
. None None O

Pharmacological None None O
inhibition None None O
of None None O
autophagic None None O
flux None None O
by None None O
chloroquine None None O
increased None None O
apoptosis None None O
and None None O
decreased None None O
cell None None O
viability None None O
in None None O
hepatoma None None O
cells None None O
. None None O

siRNA None None O
- None None O
mediated None None O
knockdown None None O
of None None O
the None None O
ATG7 None None O
gene None None O
also None None O
sensitized None None O
hepatoma None None O
cells None None O
to None None O
sorafenib None None O
. None None O

Finally None None O
, None None O
sorafenib None None O
induced None None O
autophagy None None O
in None None O
Huh7 None None I-Cell-line-name
xenograft None None O
tumors None None O
in None None O
nude None None O
mice None None O
and None None O
coadministration None None O
with None None O
chloroquine None None O
significantly None None O
suppressed None None O
tumor None None O
growth None None O
compared None None O
with None None O
sorafenib None None O
alone None None O
. None None O

In None None O
conclusion None None O
, None None O
sorafenib None None O
administration None None O
induced None None O
autophagosome None None O
formation None None O
and None None O
enhanced None None O
autophagic None None O
activity None None O
, None None O
which None None O
conferred None None O
a None None O
survival None None O
advantage None None O
to None None O
hepatoma None None O
cells None None O
. None None O

Concomitant None None O
inhibition None None O
of None None O
autophagy None None O
may None None O
be None None O
an None None O
attractive None None O
strategy None None O
for None None O
unlocking None None O
the None None O
antitumor None None O
potential None None O
of None None O
sorafenib None None O
in None None O
HCC None None O
. None None O

Breeding None None O
of None None O
p53 None None O
mice None None O
with None None O
BCCIP None None O
conditional None None O
knockdown None None O
mice None None O

The None None O
heterozygous None None O
p53 None None O
knockout None None O
mice None None O
[ None None O
36 None None O
] None None O
were None None O
crossed None None O
with None None O
LoxPshBCCIP None None O
+ None None O
/ None None O
+ None None O
- None None O
4 None None O
mouse None None O
and None None O
EIIaCre None None O
+ None None O
/ None None O
+ None None O
mouse None None O
respectively None None O
to None None O
generate None None O
p53 None None O
+ None None O
/ None None O
- None None O
; None None O
LoxPshBCCIP None None O
+ None None O
/ None None O
- None None O
, None None O
and None None O
p53 None None O
+ None None O
/ None None O
- None None O
; None None O
EIIaCre None None O
+ None None O
/ None None O
- None None O
mice None None O
. None None O

The None None O
PCR None None O
primers None None O
used None None O
to None None O
genotype None None O
p53 None None O
are None None O
: None None O
p53ex6F None None O
: None None O
5 None None O
' None None O
- None None O
GTATCCCGAGTATCTGGAAGACAG None None O
- None None O
3 None None O
' None None O
, None None O
p53neoF None None O
: None None O
5 None None O
' None None O
- None None O
GCCTTCTATCGCCTTCTTGACG None None O
- None None O
3 None None O
' None None O
, None None O
p53ex7RN None None O
: None None O
5 None None O
' None None O
- None None O
AAGGATAGGTCGGCGGTTCATGC None None O
- None None O
3 None None O
' None None O
. None None O

The None None O
same None None O
PCR None None O
primer None None O
pairs None None O
as None None O
described None None O
earlier None None O
in None None O
this None None O
report None None O
were None None O
used None None O
for None None O
BCCIPshRNA None None O
and None None O
EIIaCre None None O
genotyping None None O
. None None O

The None None O
p53 None None O
+ None None O
/ None None O
- None None O
; None None O
LoxPshBCCIP None None O
+ None None O
/ None None O
+ None None O
mice None None O
were None None O
obtained None None O
by None None O
crossing None None O
p53 None None O
+ None None O
/ None None O
- None None O
; None None O
LoxPshBCCIP None None O
+ None None O
/ None None O
- None None O
females None None O
with None None O
p53 None None O
+ None None O
/ None None O
- None None O
; None None O
LoxPshBCCIP None None O
+ None None O
/ None None O
- None None O
males None None O
. None None O

The None None O
p53 None None O
+ None None O
/ None None O
- None None O
; None None O
LoxPshBCCIP None None O
+ None None O
/ None None O
+ None None O
or None None O
p53 None None O
+ None None O
/ None None O
- None None O
; None None O
LoxPshBCCIP None None O
+ None None O
/ None None O
- None None O
mice None None O
were None None O
crossed None None O
with None None O
p53 None None O
+ None None O
/ None None O
- None None O
; None None O
EIIaCre None None O
+ None None O
/ None None O
- None None O
mice None None O
respectively None None O
. None None O

Prognostic None None O
value None None O
of None None O
HLA None None O
- None None O
DR None None O
expression None None O
and None None O
dendritic None None O
cell None None O
infiltration None None O
in None None O
gastric None None O
cancer None None O
. None None O

We None None O
attempted None None O
to None None O
correlate None None O
the None None O
expression None None O
of None None O
human None None O
leukocyte None None O
antigen None None O
DR None None O
( None None O
HLA None None O
- None None O
DR None None O
) None None O
and None None O
tumor None None O
infiltration None None O
by None None O
S None None O
- None None O
100 None None O
- None None O
protein None None O
- None None O
positive None None O
dendritic None None O
cells None None O
with None None O
clinicopathologic None None O
features None None O
in None None O
165 None None O
patients None None O
with None None O
gastric None None O
cancer None None O
. None None O

The None None O
expression None None O
of None None O
HLA None None O
- None None O
DR None None O
was None None O
correlated None None O
with None None O
the None None O
histologic None None O
type None None O
. None None O

Infiltration None None O
of None None O
dendritic None None O
cells None None O
correlated None None O
negatively None None O
with None None O
distant None None O
lymph None None O
node None None O
metastases None None O
, None None O
clinical None None O
stage None None O
, None None O
and None None O
peritoneal None None O
invasion None None O
. None None O

There None None O
was None None O
no None None O
correlation None None O
between None None O
the None None O
expression None None O
of None None O
HLA None None O
- None None O
DR None None O
and None None O
infiltration None None O
by None None O
dendritic None None O
cells None None O
. None None O

In None None O
patients None None O
with None None O
resectable None None O
gastric None None O
cancer None None O
, None None O
the None None O
grade None None O
of None None O
infiltrating None None O
dendritic None None O
cells None None O
may None None O
be None None O
a None None O
suitable None None O
predictor None None O
of None None O
prognosis None None O
. None None O

Modulation None None O
of None None O
angiogenesis None None O
and None None O
progelatinase None None O
a None None O
by None None O
thrombin None None O
receptor None None O
mimetics None None O
and None None O
antagonists None None O
. None None O

The None None O
angiogenic None None O
action None None O
of None None O
thrombin None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
mediated None None O
by None None O
activation None None O
of None None O
the None None O
thrombin None None O
receptor None None O
. None None O

In None None O
this None None O
report None None O
we None None O
studied None None O
the None None O
effects None None O
of None None O
SFLLR None None O
, None None O
an None None O
agonist None None O
of None None O
the None None O
activated None None O
thrombin None None O
receptor None None O
and None None O
thrombin None None O
receptor None None O
peptide None None O
and None None O
non None None O
peptide None None O
antagonists None None O
on None None O
angiogenesis None None O
in None None O
the None None O
chick None None O
chorioallantoic None None O
membrane None None O
( None None O
CAM None None O
) None None O
system None None O
. None None O

As None None O
antagonists None None O
were None None O
used None None O
the None None O
tripeptide None None O
FPR None None O
and None None O
non None None O
- None None O
peptide None None O
1 None None O
, None None O
4 None None O
- None None O
disubstituted None None O
piperazine None None O
derivatives None None O
. None None O

The None None O
pentapeptide None None O
SFLLR None None O
, None None O
like None None O
thrombin None None O
, None None O
caused None None O
a None None O
marked None None O
stimulation None None O
of None None O
angiogenesis None None O
in None None O
the None None O
CAM None None O
. None None O

FPR None None O
and None None O
the None None O
piperazine None None O
derivatives None None O
caused None None O
suppression None None O
of None None O
angiogenesis None None O
and None None O
in None None O
combination None None O
with None None O
thrombin None None O
antagonized None None O
its None None O
angiogenic None None O
effect None None O
. None None O

Thrombin None None O
and None None O
SFLLR None None O
activated None None O
progelatinase None None O
A None None O
( None None O
MMP None None O
- None None O
2 None None O
) None None O
in None None O
the None None O
culture None None O
medium None None O
of None None O
human None None O
umbilical None None O
cord None None O
endothelial None None O
cells None None O
( None None O
HUVECs None None O
) None None O
. None None O

MMP None None O
- None None O
2 None None O
is None None O
involved None None O
in None None O
the None None O
early None None O
steps None None O
of None None O
angiogenesis None None O
leading None None O
to None None O
local None None O
dissolution None None O
of None None O
basement None None O
membrane None None O
collagen None None O
and None None O
migration None None O
of None None O
the None None O
activated None None O
endothelial None None O
cells None None O
. None None O

FPR None None O
and None None O
the None None O
piperazine None None O
derivatives None None O
inhibited None None O
the None None O
activation None None O
of None None O
this None None O
enzyme None None O
. None None O

They None None O
also None None O
antagonised None None O
the None None O
effects None None O
of None None O
both None None O
thrombin None None O
and None None O
SFLLR None None O
on None None O
MMP None None O
- None None O
2 None None O
activation None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
non None None O
- None None O
thrombogenic None None O
agonists None None O
or None None O
antagonists None None O
of None None O
the None None O
activated None None O
thrombin None None O
receptor None None O
can None None O
be None None O
used None None O
as None None O
modulators None None O
of None None O
angiogenesis None None O
. None None O

Inhibition None None O
of None None O
energy None None O
- None None O
producing None None O
pathways None None O
of None None O
HepG2 None None I-Cell-line-name
cells None None O
by None None O
3 None None O
- None None O
bromopyruvate None None O
. None None O

3 None None O
- None None O
BrPA None None O
( None None O
3 None None O
- None None O
bromopyruvate None None O
) None None O
is None None O
an None None O
alkylating None None O
agent None None O
with None None O
anti None None O
- None None O
tumoral None None O
activity None None O
on None None O
hepatocellular None None O
carcinoma None None O
. None None O

This None None O
compound None None O
inhibits None None O
cellular None None O
ATP None None O
production None None O
owing None None O
to None None O
its None None O
action None None O
on None None O
glycolysis None None O
and None None O
oxidative None None O
phosphorylation None None O
; None None O
however None None O
, None None O
the None None O
specific None None O
metabolic None None O
steps None None O
and None None O
mechanisms None None O
of None None O
3 None None O
- None None O
BrPA None None O
action None None O
in None None O
human None None O
hepatocellular None None O
carcinomas None None O
, None None O
particularly None None O
its None None O
effects None None O
on None None O
mitochondrial None None O
energetics None None O
, None None O
are None None O
poorly None None O
understood None None O
. None None O

In None None O
the None None O
present None None O
study None None O
it None None O
was None None O
found None None O
that None None O
incubation None None O
of None None O
HepG2 None None I-Cell-line-name
cells None None O
with None None O
a None None O
low None None O
concentration None None O
of None None O
3 None None O
- None None O
BrPA None None O
for None None O
a None None O
short None None O
period None None O
( None None O
150 None None O
microM None None O
for None None O
30 None None O
min None None O
) None None O
significantly None None O
affected None None O
both None None O
glycolysis None None O
and None None O
mitochondrial None None O
respiratory None None O
functions None None O
. None None O

The None None O
activity None None O
of None None O
mitochondrial None None O
hexokinase None None O
was None None O
not None None O
inhibited None None O
by None None O
150 None None O
microM None None O
3 None None O
- None None O
BrPA None None O
, None None O
but None None O
this None None O
concentration None None O
caused None None O
more None None O
than None None O
70 None None O
% None None O
inhibition None None O
of None None O
GAPDH None None O
( None None O
glyceraldehyde None None O
- None None O
3 None None O
- None None O
phosphate None None O
dehydrogenase None None O
) None None O
and None None O
3 None None O
- None None O
phosphoglycerate None None O
kinase None None O
activities None None O
. None None O

Additionally None None O
, None None O
3 None None O
- None None O
BrPA None None O
treatment None None O
significantly None None O
impaired None None O
lactate None None O
production None None O
by None None O
HepG2 None None I-Cell-line-name
cells None None O
, None None O
even None None O
when None None O
glucose None None O
was None None O
withdrawn None None O
from None None O
the None None O
incubation None None O
medium None None O
. None None O

Oxygen None None O
consumption None None O
of None None O
HepG2 None None I-Cell-line-name
cells None None O
supported None None O
by None None O
either None None O
pyruvate None None O
/ None None O
malate None None O
or None None O
succinate None None O
was None None O
inhibited None None O
when None None O
cells None None O
were None None O
pre None None O
- None None O
incubated None None O
with None None O
3 None None O
- None None O
BrPA None None O
in None None O
glucose None None O
- None None O
free None None O
medium None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
when None None O
cells None None O
were None None O
pre None None O
- None None O
incubated None None O
in None None O
glucose None None O
- None None O
supplemented None None O
medium None None O
, None None O
oxygen None None O
consumption None None O
was None None O
affected None None O
only None None O
when None None O
succinate None None O
was None None O
used None None O
as None None O
the None None O
oxidizable None None O
substrate None None O
. None None O

An None None O
increase None None O
in None None O
oligomycin None None O
- None None O
independent None None O
respiration None None O
was None None O
observed None None O
in None None O
HepG2 None None I-Cell-line-name
cells None None O
treated None None O
with None None O
3 None None O
- None None O
BrPA None None O
only None None O
when None None O
incubated None None O
in None None O
glucose None None O
- None None O
supplemented None None O
medium None None O
, None None O
indicating None None O
that None None O
3 None None O
- None None O
BrPA None None O
induces None None O
mitochondrial None None O
proton None None O
leakage None None O
as None None O
well None None O
as None None O
blocking None None O
the None None O
electron None None O
transport None None O
system None None O
. None None O

The None None O
activity None None O
of None None O
succinate None None O
dehydrogenase None None O
was None None O
inhibited None None O
by None None O
70 None None O
% None None O
by None None O
3 None None O
- None None O
BrPA None None O
treatment None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
combined None None O
action None None O
of None None O
3 None None O
- None None O
BrPA None None O
on None None O
succinate None None O
dehydrogenase None None O
and None None O
on None None O
glycolysis None None O
, None None O
inhibiting None None O
steps None None O
downstream None None O
of None None O
the None None O
phosphorylation None None O
of None None O
glucose None None O
, None None O
play None None O
an None None O
important None None O
role None None O
in None None O
HepG2 None None I-Cell-line-name
cell None None O
death None None O
. None None O

c None None O
- None None O
Ski None None O
overexpression None None O
promotes None None O
tumor None None O
growth None None O
and None None O
angiogenesis None None O
through None None O
inhibition None None O
of None None O
transforming None None O
growth None None O
factor None None O
- None None O
beta None None O
signaling None None O
in None None O
diffuse None None O
- None None O
type None None O
gastric None None O
carcinoma None None O
. None None O

c None None O
- None None O
Ski None None O
, None None O
originally None None O
identified None None O
as None None O
a None None O
proto None None O
- None None O
oncogene None None O
product None None O
, None None O
is None None O
an None None O
important None None O
negative None None O
regulator None None O
of None None O
transforming None None O
growth None None O
factor None None O
( None None O
TGF None None O
) None None O
- None None O
beta None None O
family None None O
signaling None None O
through None None O
interaction None None O
with None None O
Smad2 None None O
, None None O
Smad3 None None O
, None None O
and None None O
Smad4 None None O
. None None O

High None None O
expression None None O
of None None O
c None None O
- None None O
Ski None None O
has None None O
been None None O
found None None O
in None None O
some None None O
cancers None None O
, None None O
including None None O
gastric None None O
cancer None None O
. None None O

We None None O
previously None None O
showed None None O
that None None O
disruption None None O
of None None O
TGF None None O
- None None O
beta None None O
signaling None None O
by None None O
dominant None None O
- None None O
negative None None O
TGF None None O
- None None O
beta None None O
type None None O
II None None O
receptor None None O
in None None O
a None None O
diffuse None None O
- None None O
type None None O
gastric None None O
carcinoma None None O
model None None O
accelerated None None O
tumor None None O
growth None None O
through None None O
induction None None O
of None None O
tumor None None O
angiogenesis None None O
by None None O
decreased None None O
expression None None O
of None None O
the None None O
anti None None O
- None None O
angiogenic None None O
factor None None O
thrombospondin None None O
( None None O
TSP None None O
) None None O
- None None O
1 None None O
. None None O

Here None None O
, None None O
we None None O
examined None None O
the None None O
function None None O
of None None O
c None None O
- None None O
Ski None None O
in None None O
human None None O
diffuse None None O
- None None O
type None None O
gastric None None O
carcinoma None None O
OCUM None None I-Cell-line-name
- None None I-Cell-line-name
2MLN None None I-Cell-line-name
cells None None O
. None None O

Overexpression None None O
of None None O
c None None O
- None None O
Ski None None O
inhibited None None O
TGF None None O
- None None O
beta None None O
signaling None None O
in None None O
OCUM None None I-Cell-line-name
- None None I-Cell-line-name
2MLN None None I-Cell-line-name
cells None None O
. None None O

Interestingly None None O
, None None O
c None None O
- None None O
Ski None None O
overexpression None None O
resulted None None O
in None None O
extensive None None O
acceleration None None O
of None None O
the None None O
growth None None O
of None None O
subcutaneous None None O
xenografts None None O
in None None O
BALB None None O
/ None None O
c None None O
nu None None O
/ None None O
nu None None O
female None None O
mice None None O
( None None O
6 None None O
weeks None None O
of None None O
age None None O
) None None O
. None None O

Similar None None O
to None None O
tumors None None O
expressing None None O
dominant None None O
- None None O
negative None None O
TGF None None O
- None None O
beta None None O
type None None O
II None None O
receptor None None O
, None None O
histochemical None None O
studies None None O
revealed None None O
less None None O
fibrosis None None O
and None None O
increased None None O
angiogenesis None None O
in None None O
xenografted None None O
tumors None None O
expressing None None O
c None None O
- None None O
Ski None None O
compared None None O
to None None O
control None None O
tumors None None O
. None None O

Induction None None O
of None None O
TSP None None O
- None None O
1 None None O
mRNA None None O
by None None O
TGF None None O
- None None O
beta None None O
was None None O
attenuated None None O
by None None O
c None None O
- None None O
Ski None None O
in None None O
vitro None None O
, None None O
and None None O
expression None None O
of None None O
TSP None None O
- None None O
1 None None O
mRNA None None O
was None None O
decreased None None O
in None None O
tumors None None O
expressing None None O
c None None O
- None None O
Ski None None O
in None None O
vivo None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
c None None O
- None None O
Ski None None O
overexpression None None O
promotes None None O
the None None O
growth None None O
of None None O
diffuse None None O
- None None O
type None None O
gastric None None O
carcinoma None None O
through None None O
induction None None O
of None None O
angiogenesis None None O
. None None O

Prostate None None O
- None None O
specific None None O
membrane None None O
antigen None None O
regulates None None O
angiogenesis None None O
by None None O
modulating None None O
integrin None None O
signal None None O
transduction None None O
. None None O

The None None O
transmembrane None None O
peptidase None None O
prostate None None O
- None None O
specific None None O
membrane None None O
antigen None None O
( None None O
PSMA None None O
) None None O
is None None O
universally None None O
upregulated None None O
in None None O
the None None O
vasculature None None O
of None None O
solid None None O
tumors None None O
, None None O
but None None O
its None None O
functional None None O
role None None O
in None None O
tumor None None O
angiogenesis None None O
has None None O
not None None O
been None None O
investigated None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
angiogenesis None None O
is None None O
severely None None O
impaired None None O
in None None O
PSMA None None O
- None None O
null None None O
animals None None O
and None None O
that None None O
this None None O
angiogenic None None O
defect None None O
occurs None None O
at None None O
the None None O
level None None O
of None None O
endothelial None None O
cell None None O
invasion None None O
through None None O
the None None O
extracellular None None O
matrix None None O
barrier None None O
. None None O

Because None None O
proteolytic None None O
degradation None None O
of None None O
the None None O
extracellular None None O
matrix None None O
is None None O
a None None O
critical None None O
component None None O
of None None O
endothelial None None O
invasion None None O
in None None O
angiogenesis None None O
, None None O
it None None O
is None None O
logical None None O
to None None O
assume None None O
that None None O
PSMA None None O
participates None None O
in None None O
matrix None None O
degradation None None O
. None None O

However None None O
, None None O
we None None O
demonstrate None None O
a None None O
novel None None O
and None None O
more None None O
complex None None O
role None None O
for None None O
PSMA None None O
in None None O
angiogenesis None None O
, None None O
where None None O
it None None O
is None None O
a None None O
principal None None O
component None None O
of None None O
a None None O
regulatory None None O
loop None None O
that None None O
is None None O
tightly None None O
modulating None None O
laminin None None O
- None None O
specific None None O
integrin None None O
signaling None None O
and None None O
GTPase None None O
- None None O
dependent None None O
, None None O
p21 None None O
- None None O
activated None None O
kinase None None O
1 None None O
( None None O
PAK None None O
- None None O
1 None None O
) None None O
activity None None O
. None None O

We None None O
show None None O
that None None O
PSMA None None O
inhibition None None O
, None None O
knockdown None None O
, None None O
or None None O
deficiency None None O
decreases None None O
endothelial None None O
cell None None O
invasion None None O
in None None O
vitro None None O
via None None O
integrin None None O
and None None O
PAK None None O
, None None O
thus None None O
abrogating None None O
angiogenesis None None O
. None None O

Interestingly None None O
, None None O
the None None O
neutralization None None O
of None None O
beta None None O
( None None O
1 None None O
) None None O
or None None O
the None None O
inactivation None None O
of None None O
PAK None None O
increases None None O
PSMA None None O
activity None None O
, None None O
suggesting None None O
that None None O
they None None O
negatively None None O
regulate None None O
PSMA None None O
. None None O

This None None O
negative None None O
regulation None None O
is None None O
mediated None None O
by None None O
the None None O
cytoskeleton None None O
as None None O
the None None O
disruption None None O
of None None O
interactions None None O
between None None O
the None None O
PSMA None None O
cytoplasmic None None O
tail None None O
and None None O
the None None O
anchor None None O
protein None None O
filamin None None O
A None None O
decreases None None O
PSMA None None O
activity None None O
, None None O
integrin None None O
function None None O
, None None O
and None None O
PAK None None O
activation None None O
. None None O

Finally None None O
, None None O
the None None O
inhibition None None O
of None None O
PAK None None O
activation None None O
enhances None None O
the None None O
PSMA None None O
/ None None O
filamin None None O
A None None O
interaction None None O
and None None O
, None None O
thus None None O
, None None O
boosts None None O
PSMA None None O
activity None None O
. None None O

These None None O
data None None O
imply None None O
that None None O
PSMA None None O
participates None None O
in None None O
an None None O
autoregulatory None None O
loop None None O
, None None O
wherein None None O
active None None O
PSMA None None O
facilitates None None O
integrin None None O
signaling None None O
and None None O
PAK None None O
activation None None O
, None None O
leading None None O
to None None O
both None None O
productive None None O
invasion None None O
and None None O
downregulation None None O
of None None O
integrin None None O
beta None None O
( None None O
1 None None O
) None None O
signaling None None O
via None None O
reduced None None O
PSMA None None O
activity None None O
. None None O

Therefore None None O
, None None O
we None None O
have None None O
identified None None O
a None None O
novel None None O
role None None O
for None None O
PSMA None None O
as None None O
a None None O
true None None O
molecular None None O
interface None None O
, None None O
integrating None None O
both None None O
extracellular None None O
and None None O
intracellular None None O
signals None None O
during None None O
angiogenesis None None O
. None None O

Heparin None None O
immobilized None None O
porous None None O
PLGA None None O
microspheres None None O
for None None O
angiogenic None None O
growth None None O
factor None None O
delivery None None O
. None None O

PURPOSE None None O
: None None O
Heparin None None O
immobilized None None O
porous None None O
poly None None O
( None None O
D None None O
, None None O
L None None O
- None None O
lactic None None O
- None None O
co None None O
- None None O
glycolic None None O
acid None None O
) None None O
( None None O
PLGA None None O
) None None O
microspheres None None O
were None None O
prepared None None O
for None None O
sustained None None O
release None None O
of None None O
basic None None O
fibroblast None None O
growth None None O
factor None None O
( None None O
bFGF None None O
) None None O
to None None O
induce None None O
angiogenesis None None O
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O
Porous None None O
PLGA None None O
microspheres None None O
having None None O
primary None None O
amine None None O
groups None None O
on None None O
the None None O
surface None None O
were None None O
prepared None None O
using None None O
an None None O
oil None None O
- None None O
in None None O
- None None O
water None None O
( None None O
O None None O
/ None None O
W None None O
) None None O
single None None O
emulsion None None O
method None None O
using None None O
Pluronic None None O
F None None O
- None None O
127 None None O
as None None O
an None None O
extractable None None O
porogen None None O
. None None O

Heparin None None O
was None None O
surface None None O
immobilized None None O
via None None O
covalent None None O
conjugation None None O
. None None O

bFGF None None O
was None None O
loaded None None O
into None None O
the None None O
heparin None None O
functionalized None None O
( None None O
PLGA None None O
- None None O
heparin None None O
) None None O
microspheres None None O
by None None O
a None None O
simple None None O
dipping None None O
method None None O
. None None O

The None None O
bFGF None None O
loaded None None O
PLGA None None O
- None None O
heparin None None O
microspheres None None O
were None None O
tested None None O
for None None O
in None None O
vitro None None O
release None None O
and None None O
in None None O
vivo None None O
angiogenic None None O
activity None None O
. None None O

RESULTS None None O
: None None O
PLGA None None O
microspheres None None O
with None None O
an None None O
open None None O
- None None O
porous None None O
structure None None O
were None None O
formed None None O
. None None O

The None None O
amount None None O
of None None O
conjugated None None O
amine None None O
group None None O
onto None None O
the None None O
microspheres None None O
was None None O
1 None None O
. None None O
93 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
01 None None O
nmol None None O
/ None None O
mg None None O
- None None O
microspheres None None O
, None None O
while None None O
the None None O
amount None None O
of None None O
heparin None None O
was None None O
95 None None O
. None None O
8 None None O
pmol None None O
/ None None O
mg None None O
- None None O
microspheres None None O
. None None O

PLGA None None O
- None None O
heparin None None O
microspheres None None O
released None None O
out None None O
bFGF None None O
in None None O
a None None O
more None None O
sustained None None O
manner None None O
with None None O
a None None O
smaller None None O
extent None None O
of None None O
initial None None O
burst None None O
than None None O
PLGA None None O
microspheres None None O
, None None O
indicating None None O
that None None O
surface None None O
immobilized None None O
heparin None None O
controlled None None O
the None None O
release None None O
rate None None O
of None None O
bFGF None None O
. None None O

Subcutaneous None None O
implantation None None O
of None None O
bFGF None None O
loaded None None O
PLGA None None O
- None None O
heparin None None O
microspheres None None O
in None None O
mice None None O
significantly None None O
induced None None O
the None None O
formation None None O
of None None O
new None None O
vascular None None O
microvessels None None O
. None None O

CONCLUSIONS None None O
: None None O
PLGA None None O
microspheres None None O
with None None O
an None None O
open None None O
porous None None O
structure None None O
allowed None None O
significant None None O
amount None None O
of None None O
heparin None None O
immobilization None None O
and None None O
bFGF None None O
loading None None O
. None None O

bFGF None None O
loaded None None O
PLGA None None O
- None None O
HP None None O
microspheres None None O
showed None None O
sustained None None O
release None None O
profiles None None O
of None None O
bFGF None None O
in None None O
vitro None None O
, None None O
demonstrating None None O
reversible None None O
and None None O
specific None None O
binding None None O
of None None O
bFGF None None O
to None None O
immobilized None None O
heparin None None O
. None None O

They None None O
also None None O
induced None None O
local None None O
angiogenesis None None O
in None None O
vivo None None O
in None None O
an None None O
animal None None O
model None None O
. None None O

The None None O
cancer None None O
cell None None O
' None None O
s None None O
" None None O
power None None O
plants None None O
" None None O
as None None O
promising None None O
therapeutic None None O
targets None None O
: None None O
an None None O
overview None None O
. None None O

This None None O
introductory None None O
article None None O
to None None O
the None None O
review None None O
series None None O
entitled None None O
" None None O
The None None O
Cancer None None O
Cell None None O
' None None O
s None None O
Power None None O
Plants None None O
as None None O
Promising None None O
Therapeutic None None O
Targets None None O
" None None O
is None None O
written None None O
while None None O
more None None O
than None None O
20 None None O
million None None O
people None None O
suffer None None O
from None None O
cancer None None O
. None None O

It None None O
summarizes None None O
strategies None None O
to None None O
destroy None None O
or None None O
prevent None None O
cancers None None O
by None None O
targeting None None O
their None None O
energy None None O
production None None O
factories None None O
, None None O
i None None O
. None None O
e None None O
. None None O
, None None O
" None None O
power None None O
plants None None O
. None None O
" None None O
All None None O
nucleated None None O
animal None None O
/ None None O
human None None O
cells None None O
have None None O
two None None O
types None None O
of None None O
power None None O
plants None None O
, None None O
i None None O
. None None O
e None None O
. None None O
, None None O
systems None None O
that None None O
make None None O
the None None O
" None None O
high None None O
energy None None O
" None None O
compound None None O
ATP None None O
from None None O
ADP None None O
and None None O
P None None O
( None None O
i None None O
) None None O
. None None O

One None None O
type None None O
is None None O
" None None O
glycolysis None None O
, None None O
" None None O
the None None O
other None None O
the None None O
" None None O
mitochondria None None O
. None None O
" None None O
In None None O
contrast None None O
to None None O
most None None O
normal None None O
cells None None O
where None None O
the None None O
mitochondria None None O
are None None O
the None None O
major None None O
ATP None None O
producers None None O
( None None O
> None None O
90 None None O
% None None O
) None None O
in None None O
fueling None None O
growth None None O
, None None O
human None None O
cancers None None O
detected None None O
via None None O
Positron None None O
Emission None None O
Tomography None None O
( None None O
PET None None O
) None None O
rely None None O
on None None O
both None None O
types None None O
of None None O
power None None O
plants None None O
. None None O

In None None O
such None None O
cancers None None O
, None None O
glycolysis None None O
may None None O
contribute None None O
nearly None None O
half None None O
the None None O
ATP None None O
even None None O
in None None O
the None None O
presence None None O
of None None O
oxygen None None O
( None None O
" None None O
Warburg None None O
effect None None O
" None None O
) None None O
. None None O

Based None None O
solely None None O
on None None O
cell None None O
energetics None None O
, None None O
this None None O
presents None None O
a None None O
challenge None None O
to None None O
identify None None O
curative None None O
agents None None O
that None None O
destroy None None O
only None None O
cancer None None O
cells None None O
as None None O
they None None O
must None None O
destroy None None O
both None None O
of None None O
their None None O
power None None O
plants None None O
causing None None O
" None None O
necrotic None None O
cell None None O
death None None O
" None None O
and None None O
leave None None O
normal None None O
cells None None O
alone None None O
. None None O

One None None O
such None None O
agent None None O
, None None O
3 None None O
- None None O
bromopyruvate None None O
( None None O
3 None None O
- None None O
BrPA None None O
) None None O
, None None O
a None None O
lactic None None O
acid None None O
analog None None O
, None None O
has None None O
been None None O
shown None None O
to None None O
inhibit None None O
both None None O
glycolytic None None O
and None None O
mitochondrial None None O
ATP None None O
production None None O
in None None O
rapidly None None O
growing None None O
cancers None None O
( None None O
Ko None None O
et None None O
al None None O
. None None O
, None None O
Cancer None None O
Letts None None O
. None None O
, None None O
173 None None O
, None None O
83 None None O
- None None O
91 None None O
, None None O
2001 None None O
) None None O
, None None O
leave None None O
normal None None O
cells None None O
alone None None O
, None None O
and None None O
eradicate None None O
advanced None None O
cancers None None O
( None None O
19 None None O
of None None O
19 None None O
) None None O
in None None O
a None None O
rodent None None O
model None None O
( None None O
Ko None None O
et None None O
al None None O
. None None O
, None None O
Biochem None None O
. None None O
Biophys None None O
. None None O
Res None None O
. None None O
Commun None None O
. None None O
, None None O
324 None None O
, None None O
269 None None O
- None None O
275 None None O
, None None O
2004 None None O
) None None O
. None None O

A None None O
second None None O
approach None None O
is None None O
to None None O
induce None None O
only None None O
cancer None None O
cells None None O
to None None O
undergo None None O
" None None O
apoptotic None None O
cell None None O
death None None O
. None None O
" None None O
Here None None O
, None None O
mitochondria None None O
release None None O
cell None None O
death None None O
inducing None None O
factors None None O
( None None O
e None None O
. None None O
g None None O
. None None O
, None None O
cytochrome None None O
c None None O
) None None O
. None None O

In None None O
a None None O
third None None O
approach None None O
, None None O
cancer None None O
cells None None O
are None None O
induced None None O
to None None O
die None None O
by None None O
both None None O
apoptotic None None O
and None None O
necrotic None None O
events None None O
. None None O

In None None O
summary None None O
, None None O
much None None O
effort None None O
is None None O
being None None O
focused None None O
on None None O
identifying None None O
agents None None O
that None None O
induce None None O
" None None O
necrotic None None O
, None None O
" None None O
" None None O
apoptotic None None O
" None None O
or None None O
apoptotic None None O
plus None None O
necrotic None None O
cell None None O
death None None O
only None None O
in None None O
cancer None None O
cells None None O
. None None O

Regardless None None O
how None None O
death None None O
is None None O
inflicted None None O
, None None O
every None None O
cancer None None O
cell None None O
must None None O
die None None O
, None None O
be None None O
it None None O
fast None None O
or None None O
slow None None O
. None None O

Targeting None None O
wide None None O
- None None O
range None None O
oncogenic None None O
transformation None None O
via None None O
PU24FCl None None O
, None None O
a None None O
specific None None O
inhibitor None None O
of None None O
tumor None None O
Hsp90 None None O
. None None O

Agents None None O
that None None O
inhibit None None O
Hsp90 None None O
function None None O
hold None None O
significant None None O
promise None None O
in None None O
cancer None None O
therapy None None O
. None None O

Here None None O
we None None O
present None None O
PU24FCl None None O
, None None O
a None None O
representative None None O
of None None O
the None None O
first None None O
class None None O
of None None O
designed None None O
Hsp90 None None O
inhibitors None None O
. None None O

By None None O
specifically None None O
and None None O
potently None None O
inhibiting None None O
tumor None None O
Hsp90 None None O
, None None O
PU24FCl None None O
exhibits None None O
wide None None O
- None None O
ranging None None O
anti None None O
- None None O
cancer None None O
activities None None O
that None None O
occur None None O
at None None O
similar None None O
doses None None O
in None None O
all None None O
tested None None O
tumor None None O
types None None O
. None None O

Normal None None O
cells None None O
are None None O
10 None None O
- None None O
to None None O
50 None None O
- None None O
fold None None O
more None None O
resistant None None O
to None None O
these None None O
effects None None O
. None None O

Its None None O
Hsp90 None None O
inhibition None None O
results None None O
in None None O
multiple None None O
anti None None O
- None None O
tumor None None O
- None None O
specific None None O
effects None None O
, None None O
such None None O
as None None O
degradation None None O
of None None O
Hsp90 None None O
- None None O
client None None O
proteins None None O
involved None None O
in None None O
cell None None O
growth None None O
, None None O
survival None None O
, None None O
and None None O
specific None None O
transformation None None O
, None None O
inhibition None None O
of None None O
cancer None None O
cell None None O
growth None None O
, None None O
delay None None O
of None None O
cell None None O
cycle None None O
progression None None O
, None None O
induction None None O
of None None O
morphological None None O
and None None O
functional None None O
changes None None O
, None None O
and None None O
apoptosis None None O
. None None O

In None None O
concordance None None O
with None None O
its None None O
higher None None O
affinity None None O
for None None O
tumor None None O
Hsp90 None None O
, None None O
in None None O
vivo None None O
PU24FCl None None O
accumulates None None O
in None None O
tumors None None O
while None None O
being None None O
rapidly None None O
cleared None None O
from None None O
normal None None O
tissue None None O
. None None O

Concentrations None None O
achieved None None O
in None None O
vivo None None O
in None None O
tumors None None O
lead None None O
to None None O
single None None O
- None None O
agent None None O
anti None None O
- None None O
tumor None None O
activity None None O
at None None O
non None None O
- None None O
toxic None None O
doses None None O
. None None O

Comparison None None O
of None None O
tissue None None O
integration None None O
between None None O
polyester None None O
and None None O
polypropylene None None O
prostheses None None O
in None None O
the None None O
preperitoneal None None O
space None None O
. None None O

Tissue None None O
integration None None O
and None None O
implant None None O
characteristics None None O
of None None O
various None None O
biomaterials None None O
commonly None None O
used None None O
for None None O
inguinal None None O
hernia None None O
repair None None O
have None None O
not None None O
been None None O
studied None None O
extensively None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
is None None O
to None None O
compare None None O
behavior None None O
and None None O
tissue None None O
response None None O
between None None O
two None None O
new None None O
polyester None None O
prostheses None None O
and None None O
a None None O
commonly None None O
used None None O
polypropylene None None O
( None None O
PP None None O
) None None O
mesh None None O
. None None O

The None None O
polyester None None O
prostheses None None O
utilized None None O
were None None O
polyester None None O
flat None None O
( None None O
PF None None O
) None None O
and None None O
polyester None None O
soft None None O
three None None O
- None None O
dimensional None None O
( None None O
PS None None O
) None None O
; None None O
the None None O
PP None None O
mesh None None O
utilized None None O
was None None O
Marlex None None O
. None None O

Eight None None O
randomly None None O
assigned None None O
4 None None O
x None None O
4 None None O
- None None O
cm2 None None O
pieces None None O
of None None O
two None None O
different None None O
meshes None None O
were None None O
fixed None None O
in None None O
the None None O
preperitoneal None None O
space None None O
with None None O
a None None O
centrally None None O
placed None None O
single None None O
suture None None O
. None None O

Gross None None O
evaluation None None O
included None None O
shrinkage None None O
and None None O
stiffness None None O
. None None O

Histological None None O
evaluation None None O
included None None O
amount None None O
of None None O
fibrous None None O
and None None O
fat None None O
encapsulation None None O
, None None O
connective None None O
tissue None None O
, None None O
foreign None None O
- None None O
body None None O
reaction None None O
, None None O
neovascularization None None O
, None None O
hemorrhage None None O
, None None O
necrosis None None O
, None None O
and None None O
exudate None None O
. None None O

Evaluations None None O
were None None O
graded None None O
on None None O
a None None O
zero None None O
to None None O
four None None O
scale None None O
. None None O

The None None O
area None None O
and None None O
the None None O
area None None O
ratio None None O
were None None O
measured None None O
using None None O
a None None O
calibrated None None O
micrometer None None O
. None None O

PP None None O
mesh None None O
resulted None None O
in None None O
more None None O
fibrous None None O
encapsulation None None O
and None None O
stiffness None None O
than None None O
PF None None O
and None None O
PS None None O
prostheses None None O
. None None O

PP None None O
also None None O
resulted None None O
in None None O
less None None O
connective None None O
tissue None None O
formation None None O
and None None O
foreign None None O
- None None O
body None None O
reaction None None O
than None None O
PF None None O
and None None O
PS None None O
prostheses None None O
. None None O

There None None O
was None None O
no None None O
difference None None O
in None None O
fat None None O
encapsulation None None O
, None None O
necrosis None None O
, None None O
hemorrhage None None O
, None None O
or None None O
exudate None None O
between None None O
prostheses None None O
. None None O

Both None None O
polyester None None O
prostheses None None O
( None None O
PF None None O
and None None O
PS None None O
) None None O
have None None O
better None None O
tissue None None O
integration None None O
than None None O
the None None O
PP None None O
mesh None None O
, None None O
as None None O
evidenced None None O
by None None O
the None None O
higher None None O
amount None None O
of None None O
connective None None O
tissue None None O
and None None O
lower None None O
extent None None O
of None None O
fibrous None None O
encapsulation None None O
. None None O

The None None O
role None None O
of None None O
p53 None None O
in None None O
glucose None None O
metabolism None None O
. None None O

The None None O
p53 None None O
protein None None O
functions None None O
to None None O
prevent None None O
tumour None None O
development None None O
by None None O
inhibiting None None O
the None None O
outgrowth None None O
of None None O
stressed None None O
or None None O
damaged None None O
cells None None O
. None None O

In None None O
addition None None O
to None None O
well None None O
established None None O
functions None None O
to None None O
block None None O
cell None None O
proliferation None None O
, None None O
recent None None O
studies None None O
have None None O
revealed None None O
a None None O
role None None O
for None None O
p53 None None O
in None None O
the None None O
regulation None None O
of None None O
pathways None None O
involved None None O
in None None O
glucose None None O
metabolism None None O
. None None O

The None None O
metabolic None None O
functions None None O
of None None O
p53 None None O
resist None None O
the None None O
shift None None O
to None None O
glycolysis None None O
that None None O
is None None O
characteristically None None O
seen None None O
in None None O
cancers None None O
, None None O
and None None O
also None None O
help None None O
cells None None O
adapt None None O
to None None O
and None None O
survive None None O
limited None None O
periods None None O
of None None O
metabolic None None O
stress None None O
. None None O

Such None None O
activities None None O
of None None O
p53 None None O
would None None O
not None None O
only None None O
help None None O
to None None O
prevent None None O
cancer None None O
development None None O
, None None O
but None None O
might None None O
also None None O
contribute None None O
to None None O
non None None O
- None None O
tumour None None O
related None None O
roles None None O
for None None O
p53 None None O
, None None O
such None None O
as None None O
in None None O
the None None O
regulation None None O
of None None O
longevity None None O
. None None O

These None None O
new None None O
functions None None O
of None None O
p53 None None O
are None None O
providing None None O
interesting None None O
possibilities None None O
for None None O
the None None O
development None None O
of None None O
novel None None O
therapies None None O
. None None O

Results None None O

Study None None O
of None None O
freeze None None O
- None None O
thaw None None O
effects None None O
and None None O
CSF None None O
pH None None O
on None None O
tissue None None O
RNA None None O
integrity None None O

We None None O
have None None O
long None None O
suspected None None O
, None None O
on None None O
the None None O
basis None None O
of None None O
our None None O
tissue None None O
banking None None O
experience None None O
, None None O
that None None O
most None None O
of None None O
the None None O
molecular None None O
degradation None None O
that None None O
occurs None None O
in None None O
banked None None O
tissue None None O
is None None O
due None None O
to None None O
repeated None None O
freeze None None O
- None None O
thaw None None O
cycles None None O
, None None O
which None None O
occur None None O
due None None O
to None None O
improper None None O
handling None None O
during None None O
dissection None None O
for None None O
tissue None None O
retrieval None None O
or None None O
due None None O
to None None O
freezer None None O
malfunctions None None O
. None None O

Our None None O
freezers None None O
are None None O
currently None None O
protected None None O
by None None O
temperature None None O
- None None O
sensitive None None O
alarms None None O
that None None O
automatically None None O
telephone None None O
maintenance None None O
and None None O
tissue None None O
banking None None O
personnel None None O
when None None O
the None None O
temperature None None O
reaches None None O
a None None O
certain None None O
level None None O
. None None O

More None None O
protection None None O
is None None O
preferable None None O
, None None O
with None None O
CO2 None None O
tanks None None O
for None None O
backup None None O
cooling None None O
the None None O
optimum None None O
( None None O
but None None O
expensive None None O
) None None O
approach None None O
. None None O

We None None O
plan None None O
to None None O
systematically None None O
investigate None None O
the None None O
effects None None O
of None None O
thawing None None O
and None None O
refreezing None None O
on None None O
RNA None None O
integrity None None O
, None None O
by None None O
deliberately None None O
thawing None None O
and None None O
freezing None None O
small None None O
samples None None O
of None None O
brain None None O
tissue None None O
over None None O
varying None None O
time None None O
intervals None None O
and None None O
temperatures None None O
. None None O

Glucocorticoid None None O
receptor None None O
- None None O
induced None None O
MAPK None None O
phosphatase None None O
- None None O
1 None None O
( None None O
MPK None None O
- None None O
1 None None O
) None None O
expression None None O
inhibits None None O
paclitaxel None None O
- None None O
associated None None O
MAPK None None O
activation None None O
and None None O
contributes None None O
to None None O
breast None None O
cancer None None O
cell None None O
survival None None O
. None None O

Glucocorticoid None None O
receptor None None O
( None None O
GR None None O
) None None O
activation None None O
has None None O
recently None None O
been None None O
shown None None O
to None None O
inhibit None None O
apoptosis None None O
in None None O
breast None None O
epithelial None None O
cells None None O
. None None O

We None None O
have None None O
previously None None O
described None None O
a None None O
group None None O
of None None O
genes None None O
that None None O
is None None O
rapidly None None O
up None None O
- None None O
regulated None None O
in None None O
these None None O
cells None None O
following None None O
dexamethasone None None O
( None None O
Dex None None O
) None None O
treatment None None O
. None None O

In None None O
an None None O
effort None None O
to None None O
dissect None None O
the None None O
mechanisms None None O
of None None O
GR None None O
- None None O
mediated None None O
breast None None O
epithelial None None O
cell None None O
survival None None O
, None None O
we None None O
now None None O
examine None None O
the None None O
molecular None None O
events None None O
downstream None None O
of None None O
GR None None O
activation None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
GR None None O
activation None None O
leads None None O
to None None O
both None None O
the None None O
rapid None None O
induction None None O
of None None O
MAPK None None O
phosphatase None None O
- None None O
1 None None O
( None None O
MKP None None O
- None None O
1 None None O
) None None O
mRNA None None O
and None None O
its None None O
sustained None None O
expression None None O
. None None O

Induction None None O
of None None O
the None None O
MKP None None O
- None None O
1 None None O
protein None None O
in None None O
the None None O
MCF10A None None I-Cell-line-name
- None None O
Myc None None O
and None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
breast None None O
epithelial None None O
cell None None O
lines None None O
was None None O
also None None O
seen None None O
. None None O

Paclitaxel None None O
treatment None None O
resulted None None O
in None None O
MAPK None None O
activation None None O
and None None O
apoptosis None None O
of None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
breast None None O
cancer None None O
cells None None O
, None None O
and None None O
both None None O
processes None None O
were None None O
inhibited None None O
by None None O
Dex None None O
pretreatment None None O
. None None O

Furthermore None None O
, None None O
induction None None O
of None None O
MKP None None O
- None None O
1 None None O
correlated None None O
with None None O
the None None O
inhibition None None O
of None None O
extracellular None None O
signal None None O
- None None O
regulated None None O
kinase None None O
( None None O
ERK1 None None O
/ None None O
2 None None O
) None None O
and None None O
c None None O
- None None O
Jun None None O
N None None O
- None None O
terminal None None O
kinase None None O
( None None O
JNK None None O
) None None O
activity None None O
, None None O
whereas None None O
p38 None None O
activity None None O
was None None O
minimally None None O
affected None None O
. None None O

Blocking None None O
Dex None None O
- None None O
induced None None O
MKP None None O
- None None O
1 None None O
induction None None O
using None None O
small None None O
interfering None None O
RNA None None O
increased None None O
ERK1 None None O
/ None None O
2 None None O
and None None O
JNK None None O
phosphorylation None None O
and None None O
decreased None None O
cell None None O
survival None None O
. None None O

ERK1 None None O
/ None None O
2 None None O
and None None O
JNK None None O
inactivation None None O
was None None O
associated None None O
with None None O
Ets None None O
- None None O
like None None O
transcription None None O
factor None None O
- None None O
1 None None O
( None None O
ELK None None O
- None None O
1 None None O
) None None O
dephosphorylation None None O
. None None O

To None None O
explore None None O
the None None O
gene None None O
expression None None O
changes None None O
that None None O
occur None None O
downstream None None O
of None None O
ELK None None O
- None None O
1 None None O
dephosphorylation None None O
, None None O
we None None O
used None None O
a None None O
combination None None O
of None None O
temporal None None O
gene None None O
expression None None O
data None None O
and None None O
promoter None None O
element None None O
analyses None None O
. None None O

This None None O
approach None None O
revealed None None O
a None None O
previously None None O
unrecognized None None O
transcriptional None None O
target None None O
of None None O
ELK None None O
- None None O
1 None None O
, None None O
the None None O
human None None O
tissue None None O
plasminogen None None O
activator None None O
( None None O
tPA None None O
) None None O
. None None O

We None None O
verified None None O
the None None O
predicted None None O
ELK None None O
- None None O
1 None None O
- None None O
- None None O
> None None O
tPA None None O
transcriptional None None O
regulatory None None O
relationship None None O
using None None O
a None None O
luciferase None None O
reporter None None O
assay None None O
. None None O

We None None O
conclude None None O
that None None O
GR None None O
- None None O
mediated None None O
MAPK None None O
inactivation None None O
contributes None None O
to None None O
cell None None O
survival None None O
and None None O
that None None O
the None None O
potential None None O
transcriptional None None O
targets None None O
of None None O
this None None O
inhibition None None O
can None None O
be None None O
identified None None O
from None None O
large None None O
scale None None O
gene None None O
array None None O
analysis None None O
. None None O

Hypoxic None None O
induction None None O
of None None O
HIF None None O
- None None O
1alpha None None O
and None None O
VEGF None None O
expression None None O
in None None O
head None None O
and None None O
neck None None O
squamous None None O
cell None None O
carcinoma None None O
lines None None O
is None None O
mediated None None O
by None None O
stress None None O
activated None None O
protein None None O
kinases None None O
. None None O

Solid None None O
tumors None None O
must None None O
establish None None O
a None None O
blood None None O
supply None None O
in None None O
order None None O
to None None O
proliferate None None O
and None None O
grow None None O
. None None O

Cancer None None O
cells None None O
secrete None None O
soluble None None O
factors None None O
which None None O
can None None O
induce None None O
proliferation None None O
and None None O
migration None None O
of None None O
capillary None None O
endothelial None None O
cells None None O
. None None O

Among None None O
the None None O
most None None O
potent None None O
of None None O
the None None O
angiogenic None None O
factors None None O
is None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
. None None O

Increased None None O
VEGF None None O
expression None None O
by None None O
malignant None None O
tumors None None O
has None None O
been None None O
associated None None O
with None None O
high None None O
vascularity None None O
, None None O
increased None None O
cancer None None O
cell None None O
growth None None O
, None None O
and None None O
lymph None None O
node None None O
metastasis None None O
. None None O

Reduced None None O
oxygen None None O
tension None None O
has None None O
been None None O
shown None None O
to None None O
increase None None O
VEGF None None O
production None None O
by None None O
induction None None O
of None None O
the None None O
transcription None None O
factor None None O
hypoxia None None O
inducible None None O
factor None None O
1 None None O
alpha None None O
( None None O
HIF None None O
- None None O
1alpha None None O
) None None O
. None None O

The None None O
mechanisms None None O
by None None O
which None None O
hypoxic None None O
tumor None None O
environments None None O
induce None None O
HIF None None O
- None None O
1alpha None None O
and None None O
VEGF None None O
expression None None O
are None None O
largely None None O
unknown None None O
. None None O

Jun None None O
N None None O
terminal None None O
kinase None None O
( None None O
JNK1 None None O
) None None O
and None None O
p38 None None O
kinase None None O
are None None O
activated None None O
by None None O
a None None O
variety None None O
of None None O
stress None None O
stimuli None None O
. None None O

To None None O
determine None None O
if None None O
hypoxic None None O
activation None None O
of None None O
these None None O
stress None None O
activated None None O
protein None None O
kinases None None O
regulated None None O
HIF None None O
- None None O
1alpha None None O
and None None O
VEGF None None O
expression None None O
, None None O
we None None O
assayed None None O
JNK1 None None O
and None None O
p38 None None O
activity None None O
in None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
SCC None None O
) None None O
lines None None O
grown None None O
under None None O
normoxic None None O
or None None O
hypoxic None None O
conditions None None O
. None None O

Hypoxia None None O
rapidly None None O
induced None None O
both None None O
JNK1 None None O
and None None O
p38 None None O
activity None None O
in None None O
these None None O
cells None None O
. None None O

This None None O
activation None None O
correlated None None O
with None None O
induction None None O
of None None O
HIF None None O
- None None O
1alpha None None O
expression None None O
and None None O
DNA None None O
binding None None O
activity None None O
which None None O
was None None O
blocked None None O
by None None O
the None None O
p38 None None O
inhibitor None None O
SB203580 None None O
. None None O

Hypoxia None None O
also None None O
increased None None O
VEGF None None O
production None None O
by None None O
SCC None None O
lines None None O
, None None O
which None None O
was None None O
inhibited None None O
by None None O
treatment None None O
with None None O
SB203580 None None O
. None None O

Overexpression None None O
of None None O
JNK1 None None O
or None None O
p38 None None O
was None None O
sufficient None None O
to None None O
induce None None O
HIF None None O
- None None O
1alpha None None O
and None None O
VEGF None None O
expression None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
induction None None O
of None None O
SAPKs None None O
by None None O
hypoxia None None O
regulates None None O
HIF None None O
- None None O
1alpha None None O
and None None O
VEGF None None O
expression None None O
in None None O
head None None O
and None None O
neck None None O
carcinoma None None O
cell None None O
lines None None O
. None None O

Additional None None O
file None None O
3 None None O

Primers None None O
used None None O
in None None O
this None None O
study None None O
. None None O

All None None O
of None None O
the None None O
primers None None O
used None None O
for None None O
generating None None O
PCR None None O
products None None O
for None None O
microinjection None None O
and None None O
site None None O
- None None O
direct None None O
mutagenesis None None O
are None None O
listed None None O
. None None O

Inactivation None None O
of None None O
androgen None None O
- None None O
induced None None O
regulator None None O
ARD1 None None O
inhibits None None O
androgen None None O
receptor None None O
acetylation None None O
and None None O
prostate None None O
tumorigenesis None None O
. None None O

Androgen None None O
signaling None None O
through None None O
androgen None None O
receptor None None O
( None None O
AR None None O
) None None O
is None None O
critical None None O
for None None O
prostate None None O
tumorigenesis None None O
. None None O

Given None None O
that None None O
AR None None O
- None None O
mediated None None O
gene None None O
regulation None None O
is None None O
enhanced None None O
by None None O
AR None None O
coregulators None None O
, None None O
inactivation None None O
of None None O
those None None O
coregulators None None O
is None None O
emerging None None O
as None None O
a None None O
promising None None O
therapy None None O
for None None O
prostate None None O
cancer None None O
( None None O
PCa None None O
) None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
the None None O
N None None O
- None None O
acetyltransferase None None O
arrest None None O
- None None O
defect None None O
1 None None O
protein None None O
( None None O
ARD1 None None O
) None None O
functions None None O
as None None O
a None None O
unique None None O
AR None None O
regulator None None O
in None None O
PCa None None O
cells None None O
. None None O

ARD1 None None O
is None None O
up None None O
- None None O
regulated None None O
in None None O
human None None O
PCa None None O
cell None None O
lines None None O
and None None O
primary None None O
tumor None None O
biopsies None None O
. None None O

The None None O
expression None None O
of None None O
ARD1 None None O
was None None O
augmented None None O
by None None O
treatment None None O
with None None O
synthetic None None O
androgen None None O
( None None O
R1881 None None O
) None None O
unless None None O
AR None None O
is None None O
deficient None None O
or None None O
is None None O
inhibited None None O
by None None O
AR None None O
- None None O
specific None None O
siRNA None None O
or None None O
androgen None None O
inhibitor None None O
bicalutamide None None O
( None None O
Casodex None None O
) None None O
. None None O

Depletion None None O
of None None O
ARD1 None None O
by None None O
shRNA None None O
suppressed None None O
PCa None None O
cell None None O
proliferation None None O
, None None O
anchorage None None O
- None None O
independent None None O
growth None None O
, None None O
and None None O
xenograft None None O
tumor None None O
formation None None O
in None None O
SCID None None O
mice None None O
, None None O
suggesting None None O
that None None O
AR None None O
- None None O
dependent None None O
ARD1 None None O
expression None None O
is None None O
biologically None None O
germane None None O
. None None O

Notably None None O
, None None O
ARD1 None None O
was None None O
critical None None O
for None None O
transcriptionally None None O
regulating None None O
a None None O
number None None O
of None None O
AR None None O
target None None O
genes None None O
that None None O
are None None O
involved None None O
in None None O
prostate None None O
tumorigenesis None None O
. None None O

Furthermore None None O
, None None O
ARD1 None None O
interacted None None O
physically None None O
with None None O
and None None O
acetylated None None O
the None None O
AR None None O
protein None None O
in None None O
vivo None None O
and None None O
in None None O
vitro None None O
. None None O

Because None None O
AR None None O
- None None O
ARD1 None None O
interaction None None O
facilitated None None O
the None None O
AR None None O
binding None None O
to None None O
its None None O
targeted None None O
promoters None None O
for None None O
gene None None O
transcription None None O
, None None O
we None None O
propose None None O
that None None O
ARD1 None None O
functions None None O
as None None O
a None None O
unique None None O
AR None None O
regulator None None O
and None None O
forms None None O
a None None O
positive None None O
feedback None None O
loop None None O
for None None O
AR None None O
- None None O
dependent None None O
prostate None None O
tumorigenesis None None O
. None None O

Disruption None None O
of None None O
AR None None O
- None None O
ARD1 None None O
interactions None None O
may None None O
be None None O
a None None O
potent None None O
intervention None None O
for None None O
androgen None None O
- None None O
dependent None None O
PCa None None O
therapy None None O
. None None O

Crystal None None O
data None None O

C15H12ClN3O2S2 None None O
F None None O
( None None O
000 None None O
) None None O
= None None O
752 None None O

Mr None None O
= None None O
365 None None O
. None None O
85 None None O
Dx None None O
= None None O
1 None None O
. None None O
507 None None O
Mg None None O
m None None O
- None None O
3 None None O

Monoclinic None None O
, None None O
P21 None None O
/ None None O
n None None O
Mo None None O
Kalpha None None O
radiation None None O
, None None O
lambda None None O
= None None O
0 None None O
. None None O
71073 None None O
A None None O

Hall None None O
symbol None None O
: None None O
- None None O
P None None O
2yn None None O
Cell None None O
parameters None None O
from None None O
25 None None O
reflections None None O

a None None O
= None None O
10 None None O
. None None O
175 None None O
( None None O
2 None None O
) None None O
A None None O
theta None None O
= None None O
9 None None O
- None None O
12degrees None None O

b None None O
= None None O
8 None None O
. None None O
4958 None None O
( None None O
17 None None O
) None None O
A None None O
micro None None O
= None None O
0 None None O
. None None O
51 None None O
mm None None O
- None None O
1 None None O

c None None O
= None None O
19 None None O
. None None O
318 None None O
( None None O
4 None None O
) None None O
A None None O
T None None O
= None None O
293 None None O
K None None O

beta None None O
= None None O
105 None None O
. None None O
01 None None O
( None None O
3 None None O
) None None O
degrees None None O
Block None None O
, None None O
yellow None None O

V None None O
= None None O
1613 None None O
. None None O
0 None None O
( None None O
6 None None O
) None None O
A3 None None O
0 None None O
. None None O
25 None None O
x None None O
0 None None O
. None None O
15 None None O
x None None O
0 None None O
. None None O
15 None None O
mm None None O

Z None None O
= None None O
4 None None O

Differential None None O
proteomic None None O
analysis None None O
of None None O
human None None O
hepatocellular None None O
carcinoma None None O
cell None None O
line None None O
metastasis None None O
- None None O
associated None None O
proteins None None O
. None None O

PURPOSE None None O
: None None O
The None None O
comparative None None O
study None None O
of None None O
differentially None None O
expression None None O
of None None O
protein None None O
profiles None None O
of None None O
hepatocellular None None O
carcinoma None None O
cell None None O
lines None None O
with None None O
various None None O
metastasic None None O
potential None None O
and None None O
screening None None O
key None None O
molecules None None O
related None None O
to None None O
hepatocellular None None O
carcinoma None None O
metastasis None None O
and None None O
recurrence None None O
. None None O

METHODS None None O
: None None O
Using None None O
two None None O
- None None O
dimensional None None O
electrophoresis None None O
and None None O
liquid None None O
chromatography None None O
- None None O
electrospray None None O
ionization None None O
- None None O
tandem None None O
mass None None O
spectrometry None None O
( None None O
LC None None O
- None None O
ESI None None O
- None None O
MS None None O
/ None None O
MS None None O
) None None O
, None None O
we None None O
analyzed None None O
differentially None None O
displayed None None O
proteomics None None O
of None None O
human None None O
hepatocellular None None O
carcinoma None None O
cell None None O
lines None None O
Hep3B None None I-Cell-line-name
, None None O
MHCC97L None None I-Cell-line-name
, None None O
MHCC97H None None I-Cell-line-name
with None None O
different None None O
metastasic None None O
potential None None O
. None None O

RESULTS None None O
: None None O
Approximate None None O
1 None None O
, None None O
000 None None O
protein None None O
spots None None O
were None None O
detected None None O
on None None O
silver None None O
- None None O
stained None None O
gel None None O
by None None O
ImageMaster None None O
( None None O
977 None None O
+ None None O
/ None None O
- None None O
113 None None O
spots None None O
in None None O
Hep3B None None I-Cell-line-name
, None None O
1092 None None O
+ None None O
/ None None O
- None None O
40 None None O
in None None O
MHCC97L None None I-Cell-line-name
, None None O
and None None O
889 None None O
+ None None O
/ None None O
- None None O
14 None None O
in None None O
MHCC97H None None I-Cell-line-name
) None None O
. None None O

Fifty None None O
distinct None None O
different None None O
protein None None O
spots None None O
were None None O
analyzed None None O
with None None O
online None None O
LC None None O
- None None O
ESI None None O
- None None O
MS None None O
/ None None O
MS None None O
. None None O

Only None None O
26 None None O
protein None None O
spots None None O
had None None O
a None None O
positive None None O
result None None O
, None None O
including None None O
annexin1 None None O
, None None O
S100A4 None None O
, None None O
and None None O
so None None O
on None None O
. None None O

In None None O
comparison None None O
with None None O
nonmetastasis None None O
Hep3B None None I-Cell-line-name
cell None None O
lines None None O
, None None O
there None None O
were None None O
16 None None O
proteins None None O
overexpressed None None O
in None None O
MHCC97H None None I-Cell-line-name
and None None O
MHCC97L None None I-Cell-line-name
, None None O
10 None None O
proteins None None O
underexpressed None None O
in None None O
MHCC97H None None I-Cell-line-name
and None None O
MHCC97L None None I-Cell-line-name
. None None O

Applying None None O
cell None None O
immunohistochemistry None None O
and None None O
RT None None O
- None None O
PCR None None O
, None None O
we None None O
further None None O
validated None None O
two None None O
interesting None None O
and None None O
different None None O
proteins None None O
, None None O
annexin1 None None O
and None None O
S100A4 None None O
. None None O

CONCLUSION None None O
: None None O
The None None O
protein None None O
profile None None O
of None None O
metastatic None None O
hepatocellular None None O
carcinoma None None O
cell None None O
lines None None O
displayed None None O
obvious None None O
differences None None O
compared None None O
with None None O
non None None O
- None None O
metastatic None None O
liver None None O
cancer None None O
cell None None O
lines None None O
. None None O

The None None O
results None None O
imply None None O
that None None O
various None None O
different None None O
proteins None None O
may None None O
lead None None O
to None None O
HCC None None O
metastasis None None O
together None None O
. None None O

RNA None None O
extraction None None O
and None None O
reverse None None O
transcription None None O

Total None None O
RNA None None O
were None None O
extracted None None O
from None None O
cells None None O
using None None O
either None None O
Trizol None None O
reagent None None O
( None None O
Invitrogen None None O
) None None O
or None None O
RNeasy None None O
kit None None O
( None None O
Qiagen None None O
) None None O
and None None O
treated None None O
with None None O
DNaseI None None O
reagent None None O
( None None O
Macherey None None O
- None None O
Nagel None None O
) None None O
for None None O
30 None None O
min None None O
at None None O
room None None O
temperature None None O
. None None O

Reverse None None O
transcriptions None None O
were None None O
performed None None O
using None None O
1microg None None O
total None None O
RNA None None O
and None None O
the None None O
High None None O
capacity None None O
cDNA None None O
reverse None None O
transcription None None O
kit None None O
with None None O
RNase None None O
Inhibitor None None O
( None None O
Applied None None O
Biosystems None None O
) None None O
. None None O

Background None None O

HIV None None O
- None None O
1 None None O
infectivity None None O
depends None None O
on None None O
free None None O
cholesterol None None O
incorporated None None O
into None None O
the None None O
viral None None O
envelope None None O
. None None O

Here None None O
, None None O
we None None O
analyze None None O
HIV None None O
infectivity None None O
in None None O
the None None O
presence None None O
of None None O
drugs None None O
that None None O
stimulate None None O
cholesterol None None O
efflux None None O
. None None O

Differential None None O
expression None None O
and None None O
mutation None None O
of None None O
NME None None O
genes None None O
in None None O
autologous None None O
cultured None None O
human None None O
melanoma None None O
cells None None O
with None None O
different None None O
metastatic None None O
potentials None None O
. None None O

The None None O
putative None None O
metastasis None None O
suppressor None None O
genes None None O
, None None O
NME1 None None O
( None None O
nm23 None None O
- None None O
1 None None O
) None None O
and None None O
NME2 None None O
( None None O
nm23 None None O
- None None O
2 None None O
) None None O
, None None O
were None None O
examined None None O
in None None O
a None None O
model None None O
system None None O
we None None O
developed None None O
to None None O
approximate None None O
the None None O
dissemination None None O
of None None O
melanoma None None O
from None None O
a None None O
primary None None O
skin None None O
tumor None None O
. None None O

We None None O
utilized None None O
two None None O
autologous None None O
human None None O
melanoma None None O
cell None None O
lines None None O
, None None O
IV None None I-Cell-line-name
Cl None None I-Cell-line-name
1 None None I-Cell-line-name
and None None O
IV None None I-Cell-line-name
Cl None None I-Cell-line-name
3 None None I-Cell-line-name
, None None O
which None None O
displayed None None O
qualitatively None None O
different None None O
metastatic None None O
phenotypes None None O
following None None O
subdermal None None O
inoculation None None O
into None None O
nude None None O
mice None None O
. None None O

Highly None None O
metastatic None None O
IV None None I-Cell-line-name
Cl None None I-Cell-line-name
1 None None I-Cell-line-name
cells None None O
expressed None None O
approximately None None O
5 None None O
fold None None O
lower None None O
levels None None O
of None None O
protein None None O
encoded None None O
by None None O
NME None None O
genes None None O
than None None O
non None None O
- None None O
metastatic None None O
IV None None I-Cell-line-name
Cl None None I-Cell-line-name
3 None None I-Cell-line-name
cells None None O
. None None O

Similar None None O
differences None None O
in None None O
NME None None O
protein None None O
levels None None O
were None None O
observed None None O
in None None O
tumors None None O
induced None None O
by None None O
the None None O
two None None O
cell None None O
lines None None O
in None None O
nude None None O
mice None None O
. None None O

There None None O
were None None O
no None None O
differences None None O
in None None O
NME None None O
mRNA None None O
levels None None O
between None None O
these None None O
two None None O
cell None None O
lines None None O
, None None O
suggesting None None O
that None None O
expression None None O
of None None O
these None None O
proteins None None O
is None None O
regulated None None O
at None None O
a None None O
post None None O
- None None O
transcriptional None None O
level None None O
. None None O

We None None O
found None None O
a None None O
ser122 None None O
- None None O
pro None None O
mutation None None O
in None None O
the None None O
NME2 None None O
gene None None O
of None None O
metastatic None None O
IV None None I-Cell-line-name
Cl None None I-Cell-line-name
1 None None I-Cell-line-name
cells None None O
. None None O

A None None O
similar None None O
ser120 None None O
- None None O
gly None None O
mutation None None O
in None None O
NME1 None None O
has None None O
been None None O
found None None O
in None None O
human None None O
neuroblastoma None None O
, None None O
suggesting None None O
that None None O
mutation None None O
in None None O
this None None O
region None None O
may None None O
be None None O
a None None O
general None None O
phenomenon None None O
related None None O
to None None O
tumor None None O
progression None None O
. None None O

These None None O
mutations None None O
may None None O
have None None O
functional None None O
consequences None None O
since None None O
they None None O
eliminate None None O
potential None None O
phosphorylation None None O
sites None None O
and None None O
may None None O
affect None None O
the None None O
tertiary None None O
structure None None O
of None None O
mature None None O
protein None None O
complexes None None O
. None None O

Solid None None O
tumor None None O
therapy None None O
: None None O
manipulation None None O
of None None O
the None None O
vasculature None None O
with None None O
TNF None None O
. None None O

Drug None None O
delivery None None O
to None None O
solid None None O
tumors None None O
is None None O
one None None O
of None None O
the None None O
most None None O
challenging None None O
aspects None None O
in None None O
cancer None None O
therapy None None O
. None None O

Whereas None None O
agents None None O
seem None None O
promising None None O
in None None O
the None None O
test None None O
tube None None O
, None None O
clinical None None O
trials None None O
often None None O
fail None None O
due None None O
to None None O
unfavorable None None O
pharmacokinetics None None O
, None None O
poor None None O
delivery None None O
, None None O
low None None O
local None None O
concentrations None None O
, None None O
and None None O
limited None None O
accumulation None None O
in None None O
the None None O
target None None O
cell None None O
. None None O

A None None O
major None None O
step None None O
forwards None None O
in None None O
the None None O
treatment None None O
of None None O
solid None None O
tumors None None O
is None None O
the None None O
recognition None None O
of None None O
the None None O
tumor None None O
- None None O
associated None None O
vasculature None None O
as None None O
an None None O
important None None O
target None None O
for None None O
therapy None None O
. None None O

Inhibition None None O
of None None O
tumor None None O
vascular None None O
development None None O
has None None O
a None None O
direct None None O
effect None None O
on None None O
the None None O
growth None None O
and None None O
progression None None O
of None None O
the None None O
tumor None None O
. None None O

Destruction None None O
of None None O
an None None O
existing None None O
vasculature None None O
also None None O
directly None None O
inflicts None None O
serious None None O
damage None None O
to None None O
the None None O
tumor None None O
cell None None O
. None None O

Moreover None None O
, None None O
the None None O
tumor None None O
vascular None None O
bed None None O
can None None O
be None None O
manipulated None None O
facilitating None None O
enhanced None None O
permissiveness None None O
of None None O
the None None O
tumor None None O
for None None O
administered None None O
chemotherapeutics None None O
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
focus None None O
on None None O
the None None O
use None None O
of None None O
tumor None None O
necrosis None None O
factor None None O
alpha None None O
( None None O
TNF None None O
) None None O
in None None O
local None None O
and None None O
systemic None None O
therapy None None O
in None None O
conjunction None None O
with None None O
chemotherapy None None O
. None None O

In None None O
these None None O
settings None None O
TNF None None O
demonstrates None None O
potent None None O
and None None O
selective None None O
activity None None O
on None None O
the None None O
tumor None None O
vascular None None O
bed None None O
, None None O
which None None O
strongly None None O
improves None None O
tumor None None O
response None None O
. None None O

Activation None None O
- None None O
induced None None O
cytidine None None O
deaminase None None O
in None None O
antibody None None O
diversification None None O
and None None O
chromosome None None O
translocation None None O
. None None O

DNA None None O
damage None None O
, None None O
rearrangement None None O
, None None O
and None None O
mutation None None O
of None None O
the None None O
human None None O
genome None None O
are None None O
the None None O
basis None None O
of None None O
carcinogenesis None None O
and None None O
thought None None O
to None None O
be None None O
avoided None None O
at None None O
all None None O
costs None None O
. None None O

An None None O
exception None None O
is None None O
the None None O
adaptive None None O
immune None None O
system None None O
where None None O
lymphocytes None None O
utilize None None O
programmed None None O
DNA None None O
damage None None O
to None None O
effect None None O
antigen None None O
receptor None None O
diversification None None O
. None None O

Both None None O
B None None O
and None None O
T None None O
lymphocytes None None O
diversify None None O
their None None O
antigen None None O
receptors None None O
through None None O
RAG1 None None O
/ None None O
2 None None O
mediated None None O
recombination None None O
, None None O
but None None O
B None None O
cells None None O
undergo None None O
two None None O
additional None None O
processes None None O
- None None O
- None None O
somatic None None O
hypermutation None None O
( None None O
SHM None None O
) None None O
and None None O
class None None O
- None None O
switch None None O
recombination None None O
( None None O
CSR None None O
) None None O
, None None O
both None None O
initiated None None O
by None None O
activation None None O
- None None O
induced None None O
cytidine None None O
deaminase None None O
( None None O
AID None None O
) None None O
. None None O

AID None None O
deaminates None None O
cytidines None None O
in None None O
DNA None None O
resulting None None O
in None None O
U None None O
: None None O
G None None O
mismatches None None O
that None None O
are None None O
processed None None O
into None None O
point None None O
mutations None None O
in None None O
SHM None None O
or None None O
double None None O
- None None O
strand None None O
breaks None None O
in None None O
CSR None None O
. None None O

Although None None O
AID None None O
activity None None O
is None None O
focused None None O
at None None O
Immunoglobulin None None O
( None None O
Ig None None O
) None None O
gene None None O
loci None None O
, None None O
it None None O
also None None O
targets None None O
a None None O
wide None None O
array None None O
of None None O
non None None O
- None None O
Ig None None O
genes None None O
including None None O
oncogenes None None O
associated None None O
with None None O
lymphomas None None O
. None None O

Here None None O
, None None O
we None None O
review None None O
the None None O
molecular None None O
basis None None O
of None None O
AID None None O
regulation None None O
, None None O
targeting None None O
, None None O
and None None O
initiation None None O
of None None O
CSR None None O
and None None O
SHM None None O
, None None O
as None None O
well None None O
as None None O
AID None None O
' None None O
s None None O
role None None O
in None None O
generating None None O
chromosome None None O
translocations None None O
that None None O
contribute None None O
to None None O
lymphomagenesis None None O
. None None O

DNA None None O
damage None None O
induces None None O
a None None O
novel None None O
p53 None None O
- None None O
survivin None None O
signaling None None O
pathway None None O
regulating None None O
cell None None O
cycle None None O
and None None O
apoptosis None None O
in None None O
acute None None O
lymphoblastic None None O
leukemia None None O
cells None None O
. None None O

Survivin None None O
is None None O
a None None O
novel None None O
member None None O
of None None O
the None None O
inhibitor None None O
of None None O
apoptosis None None O
protein None None O
( None None O
IAP None None O
) None None O
family None None O
. None None O

Here None None O
we None None O
report None None O
that None None O
the None None O
chemotherapeutic None None O
drug None None O
doxorubicin None None O
, None None O
a None None O
DNA None None O
- None None O
damaging None None O
agent None None O
, None None O
activates None None O
a None None O
p53 None None O
- None None O
survivin None None O
signaling None None O
pathway None None O
inducing None None O
cell None None O
cycle None None O
arrest None None O
and None None O
apoptosis None None O
in None None O
childhood None None O
acute None None O
lymphoblastic None None O
leukemia None None O
( None None O
ALL None None O
) None None O
. None None O

Treatment None None O
of None None O
wild None None O
- None None O
type None None O
( None None O
wt None None O
) None None O
p53 None None O
ALL None None O
cells None None O
( None None O
EU None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
cell None None O
line None None O
) None None O
with None None O
doxorubicin None None O
caused None None O
accumulation None None O
of None None O
p53 None None O
, None None O
resulting None None O
in None None O
dramatic None None O
down None None O
- None None O
regulation None None O
of None None O
survivin None None O
, None None O
depletion None None O
of None None O
cells None None O
in None None O
G None None O
( None None O
2 None None O
) None None O
/ None None O
M None None O
, None None O
and None None O
apoptosis None None O
( None None O
increased None None O
sub None None O
- None None O
G None None O
( None None O
1 None None O
) None None O
compartment None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
doxorubicin None None O
treatment None None O
of None None O
mutant None None O
( None None O
mut None None O
) None None O
p53 None None O
cells None None O
( None None O
EU None None I-Cell-line-name
- None None I-Cell-line-name
6 None None I-Cell-line-name
/ None None O
ALL None None O
line None None O
) None None O
up None None O
- None None O
regulated None None O
survivin None None O
and None None O
induced None None O
G None None O
( None None O
2 None None O
) None None O
/ None None O
M None None O
arrest None None O
without None None O
inducing None None O
apoptosis None None O
. None None O

However None None O
, None None O
treating None None O
EU None None I-Cell-line-name
- None None I-Cell-line-name
6 None None I-Cell-line-name
with None None O
anti None None O
- None None O
survivin None None O
antisense None None O
resensitized None None O
these None None O
cells None None O
to None None O
doxorubicin None None O
, None None O
resulting None None O
in None None O
apoptosis None None O
. None None O

With None None O
a None None O
p53 None None O
- None None O
null None None O
cell None None O
line None None O
( None None O
EU None None I-Cell-line-name
- None None I-Cell-line-name
4 None None I-Cell-line-name
) None None O
, None None O
although None None O
doxorubicin None None O
treatment None None O
arrested None None O
cells None None O
in None None O
G None None O
( None None O
2 None None O
) None None O
/ None None O
M None None O
, None None O
survivin None None O
expression None None O
was None None O
unchanged None None O
, None None O
and None None O
cells None None O
underwent None None O
only None None O
limited None None O
apoptosis None None O
. None None O

However None None O
, None None O
re None None O
- None None O
expression None None O
of None None O
wt None None O
- None None O
p53 None None O
in None None O
EU None None I-Cell-line-name
- None None I-Cell-line-name
4 None None I-Cell-line-name
cells None None O
could None None O
restore None None O
the None None O
doxorubicin None None O
- None None O
p53 None None O
- None None O
survivin None None O
pathway None None O
, None None O
resulting None None O
in None None O
significantly None None O
decreased None None O
survivin None None O
expression None None O
and None None O
increased None None O
apoptosis None None O
in None None O
these None None O
cells None None O
after None None O
doxorubicin None None O
treatment None None O
. None None O

Following None None O
cotransfection None None O
of None None O
p53 None None O
- None None O
null None None O
EU None None I-Cell-line-name
- None None I-Cell-line-name
4 None None I-Cell-line-name
cells None None O
with None None O
survivin None None O
promoter None None O
- None None O
luciferase None None O
constructs None None O
and None None O
either None None O
wt None None O
- None None O
p53 None None O
or None None O
different None None O
mut None None O
- None None O
p53 None None O
expression None None O
vectors None None O
, None None O
wt None None O
- None None O
p53 None None O
inhibited None None O
survivin None None O
promoter None None O
activity None None O
; None None O
p53 None None O
- None None O
mediated None None O
inhibition None None O
could None None O
be None None O
abrogated None None O
by None None O
overexpression None None O
of None None O
murine None None O
double None None O
minute2 None None O
( None None O
MDM2 None None O
) None None O
protein None None O
. None None O

Together None None O
, None None O
these None None O
studies None None O
define None None O
a None None O
novel None None O
p53 None None O
- None None O
survivin None None O
signaling None None O
pathway None None O
activated None None O
by None None O
DNA None None O
damage None None O
that None None O
results None None O
in None None O
down None None O
- None None O
regulation None None O
of None None O
survivin None None O
, None None O
cell None None O
cycle None None O
arrest None None O
, None None O
and None None O
apoptosis None None O
. None None O

Furthermore None None O
, None None O
our None None O
data None None O
indicate None None O
that None None O
loss None None O
of None None O
wt None None O
- None None O
p53 None None O
function None None O
in None None O
tumor None None O
cells None None O
may None None O
contribute None None O
to None None O
up None None O
- None None O
regulation None None O
of None None O
survivin None None O
and None None O
resistance None None O
to None None O
DNA None None O
- None None O
damaging None None O
agents None None O
. None None O

Genetic None None O
heterogeneity None None O
evidenced None None O
by None None O
low None None O
incidence None None O
of None None O
KAL None None O
- None None O
1 None None O
gene None None O
mutations None None O
in None None O
sporadic None None O
cases None None O
of None None O
gonadotropin None None O
- None None O
releasing None None O
hormone None None O
deficiency None None O
. None None O

Isolated None None O
GnRH None None O
deficiency None None O
is None None O
a None None O
heritable None None O
condition None None O
characterized None None O
by None None O
a None None O
functional None None O
deficit None None O
in None None O
GnRH None None O
secretion None None O
. None None O

Familial None None O
cases None None O
with None None O
different None None O
modes None None O
of None None O
inheritance None None O
have None None O
been None None O
described None None O
, None None O
and None None O
the None None O
gene None None O
responsible None None O
for None None O
the None None O
X None None O
- None None O
linked None None O
form None None O
( None None O
KAL None None O
- None None O
1 None None O
) None None O
has None None O
been None None O
identified None None O
. None None O

However None None O
, None None O
sporadic None None O
cases None None O
with None None O
no None None O
documented None None O
family None None O
history None None O
of None None O
GnRH None None O
deficiency None None O
account None None O
for None None O
the None None O
majority None None O
of None None O
the None None O
affected None None O
patients None None O
. None None O

For None None O
this None None O
reason None None O
, None None O
we None None O
sought None None O
to None None O
determine None None O
the None None O
frequency None None O
with None None O
which None None O
KAL None None O
- None None O
1 None None O
gene None None O
mutations None None O
occur None None O
in None None O
patients None None O
with None None O
sporadic None None O
GnRH None None O
deficiency None None O
. None None O

Only None None O
1 None None O
of None None O
21 None None O
patients None None O
with None None O
sporadic None None O
GnRH None None O
deficiency None None O
was None None O
found None None O
to None None O
bear None None O
a None None O
defect None None O
in None None O
the None None O
KAL None None O
- None None O
1 None None O
gene None None O
( None None O
a None None O
deletion None None O
of None None O
14 None None O
bases None None O
starting None None O
at None None O
codon None None O
464 None None O
) None None O
. None None O

Three None None O
types None None O
of None None O
polymorphic None None O
single None None O
base None None O
substitutions None None O
with None None O
no None None O
apparent None None O
correlation None None O
with None None O
GnRH None None O
deficiency None None O
were None None O
also None None O
detected None None O
in None None O
several None None O
patients None None O
. None None O

In None None O
each None None O
of None None O
3 None None O
different None None O
patients None None O
with None None O
an None None O
X None None O
- None None O
linked None None O
mode None None O
of None None O
inheritance None None O
, None None O
3 None None O
genetic None None O
defects None None O
, None None O
2 None None O
point None None O
mutations None None O
and None None O
a None None O
small None None O
intragenic None None O
deletion None None O
, None None O
were None None O
detected None None O
. None None O

These None None O
defects None None O
consist None None O
of None None O
a None None O
single None None O
base None None O
mutation None None O
introducing None None O
a None None O
stop None None O
codon None None O
at None None O
position None None O
328 None None O
, None None O
a None None O
single None None O
base None None O
mutation None None O
resulting None None O
in None None O
a None None O
phenylalanine None None O
to None None O
leucine None None O
substitution None None O
at None None O
position None None O
517 None None O
, None None O
and None None O
a None None O
9 None None O
- None None O
base None None O
deletion None None O
at None None O
the None None O
3 None None O
' None None O
- None None O
exon None None O
- None None O
intron None None O
splice None None O
site None None O
of None None O
exon None None O
8 None None O
, None None O
respectively None None O
. None None O

All None None O
identified None None O
genetic None None O
defects None None O
occur None None O
within None None O
the None None O
fibronectin None None O
type None None O
III None None O
repeats None None O
of None None O
the None None O
predicted None None O
protein None None O
encoded None None O
by None None O
the None None O
KAL None None O
- None None O
1 None None O
gene None None O
. None None O

In None None O
conclusion None None O
, None None O
our None None O
study None None O
indicates None None O
that None None O
the None None O
incidence None None O
of None None O
genetic None None O
defects None None O
within None None O
the None None O
coding None None O
region None None O
of None None O
the None None O
KAL None None O
- None None O
1 None None O
gene None None O
in None None O
patients None None O
with None None O
sporadic None None O
GnRH None None O
deficiency None None O
is None None O
low None None O
( None None O
5 None None O
- None None O
8 None None O
% None None O
) None None O
, None None O
thus None None O
supporting None None O
the None None O
idea None None O
that None None O
the None None O
X None None O
- None None O
linked None None O
form None None O
of None None O
inheritance None None O
represents None None O
the None None O
least None None O
common None None O
form None None O
of None None O
the None None O
disease None None O
. None None O

INTRODUCTION None None O

Comparing None None O
genomic None None O
sequences None None O
across None None O
related None None O
species None None O
is None None O
a None None O
fruitful None None O
source None None O
of None None O
biological None None O
insight None None O
. None None O

Functional None None O
elements None None O
such None None O
as None None O
exons None None O
tend None None O
to None None O
exhibit None None O
significant None None O
sequence None None O
similarity None None O
due None None O
to None None O
purifying None None O
selection None None O
, None None O
whereas None None O
regions None None O
that None None O
are None None O
not None None O
functional None None O
tend None None O
to None None O
be None None O
neutrally None None O
evolving None None O
and None None O
thus None None O
less None None O
conserved None None O
. None None O

The None None O
first None None O
step None None O
in None None O
comparing None None O
genomic None None O
sequences None None O
is None None O
to None None O
align None None O
them None None O
- None None O
- None None O
to None None O
map None None O
the None None O
letters None None O
of None None O
the None None O
sequences None None O
to None None O
each None None O
other None None O
. None None O

After None None O
an None None O
alignment None None O
is None None O
computed None None O
, None None O
visualization None None O
frameworks None None O
become None None O
essential None None O
to None None O
enable None None O
users None None O
to None None O
interact None None O
with None None O
the None None O
sequence None None O
and None None O
conservation None None O
data None None O
, None None O
especially None None O
in None None O
the None None O
context None None O
of None None O
longer None None O
DNA None None O
sequences None None O
or None None O
whole None None O
genomes None None O
. None None O

Visualization None None O
frameworks None None O
should None None O
be None None O
easy None None O
to None None O
understand None None O
by None None O
a None None O
biologist None None O
and None None O
provide None None O
insight None None O
into None None O
the None None O
mutations None None O
that None None O
a None None O
particular None None O
genomic None None O
locus None None O
has None None O
undergone None None O
. None None O

The None None O
VISTA None None O
portal None None O
is None None O
a None None O
comprehensive None None O
comparative None None O
genomics None None O
resource None None O
that None None O
provides None None O
biomedical None None O
scientists None None O
with None None O
a None None O
single None None O
unified None None O
framework None None O
to None None O
generate None None O
and None None O
download None None O
multiple None None O
sequence None None O
alignments None None O
, None None O
visualize None None O
the None None O
results None None O
in None None O
the None None O
context None None O
of None None O
existing None None O
annotations None None O
and None None O
analyze None None O
comparative None None O
results None None O
in None None O
search None None O
for None None O
important None None O
sequence None None O
signals None None O
in None None O
alignments None None O
. None None O

The None None O
VISTA None None O
suite None None O
of None None O
programs None None O
has None None O
been None None O
in None None O
development None None O
and None None O
continued None None O
use None None O
since None None O
2000 None None O
( None None O
1 None None O
- None None O
4 None None O
) None None O
. None None O

It None None O
was None None O
originally None None O
developed None None O
for None None O
the None None O
alignment None None O
and None None O
comparative None None O
analysis None None O
of None None O
long None None O
genomic None None O
sequences None None O
and None None O
later None None O
was None None O
expanded None None O
to None None O
pair None None O
- None None O
wise None None O
and None None O
multiple None None O
alignment None None O
of None None O
vertebrate None None O
genomes None None O
. None None O

VISTA None None O
has None None O
popularized None None O
the None None O
visualization None None O
of None None O
the None None O
level None None O
of None None O
conservation None None O
in None None O
the None None O
format None None O
of None None O
a None None O
continuous None None O
curve None None O
based None None O
on None None O
the None None O
conservation None None O
in None None O
a None None O
sliding None None O
window None None O
. None None O

This None None O
concept None None O
proved None None O
to None None O
be None None O
extremely None None O
successful None None O
due None None O
to None None O
the None None O
easy None None O
interpretation None None O
of None None O
the None None O
resulting None None O
plots None None O
. None None O

VISTA None None O
was None None O
built None None O
through None None O
a None None O
close None None O
collaboration None None O
between None None O
computational None None O
and None None O
biological None None O
scientists None None O
, None None O
resulting None None O
in None None O
a None None O
product None None O
that None None O
is None None O
robust None None O
, None None O
efficient None None O
and None None O
powerful None None O
, None None O
yet None None O
simple None None O
to None None O
use None None O
for None None O
a None None O
person None None O
without None None O
extensive None None O
computer None None O
experience None None O
, None None O
as None None O
is None None O
illustrated None None O
by None None O
more None None O
than None None O
1000 None None O
citations None None O
to None None O
the None None O
various None None O
VISTA None None O
- None None O
associated None None O
tools None None O
( None None O
according None None O
to None None O
http None None O
: None None O
/ None None O
/ None None O
scholar None None O
. None None O
google None None O
. None None O
com None None O
) None None O
. None None O

In None None O
the None None O
last None None O
2 None None O
years None None O
the None None O
VISTA None None O
portal None None O
has None None O
seen None None O
many None None O
significant None None O
improvements None None O
. None None O

In None None O
addition None None O
to None None O
updating None None O
the None None O
whole None None O
genome None None O
alignments None None O
, None None O
computed None None O
using None None O
recent None None O
assemblies None None O
of None None O
vertebrate None None O
, None None O
insect None None O
, None None O
plant None None O
and None None O
microbial None None O
genomes None None O
, None None O
we None None O
have None None O
added None None O
significant None None O
new None None O
functionality None None O
and None None O
resources None None O
to None None O
the None None O
Genome None None O
Browser None None O
and None None O
other None None O
tools None None O
, None None O
including None None O
: None None O

A None None O
novel None None O
multiple None None O
whole None None O
genome None None O
alignment None None O
algorithm None None O
. None None O

A None None O
new None None O
server None None O
for None None O
whole None None O
- None None O
genome None None O
alignment None None O
of None None O
bacterial None None O
genomes None None O
. None None O

Base None None O
- None None O
pair None None O
level None None O
visualization None None O
ability None None O
within None None O
the None None O
VISTA None None O
browser None None O
. None None O

Visual None None O
access None None O
to None None O
the None None O
results None None O
of None None O
the None None O
prediction None None O
of None None O
potential None None O
deleteriousness None None O
of None None O
non None None O
- None None O
synonymous None None O
Single None None O
Nucleotide None None O
Polymorphisms None None O
( None None O
SNPs None None O
) None None O
by None None O
the None None O
algorithm None None O
PolyPhen None None O
( None None O
5 None None O
) None None O
. None None O

A None None O
novel None None O
conservation None None O
track None None O
, None None O
Rank None None O
- None None O
VISTA None None O
, None None O
to None None O
show None None O
the None None O
statistical None None O
significance None None O
of None None O
conserved None None O
regions None None O
computed None None O
by None None O
the None None O
Gumby None None O
algorithm None None O
( None None O
6 None None O
) None None O
. None None O

Whole None None O
- None None O
genome None None O
rVISTA None None O
, None None O
that None None O
allows None None O
for None None O
evaluation None None O
of None None O
which None None O
conserved None None O
transcription None None O
factor None None O
binding None None O
sites None None O
( None None O
TFBS None None O
) None None O
are None None O
over None None O
- None None O
represented None None O
in None None O
a None None O
group None None O
of None None O
genes None None O
. None None O

Pbx1 None None O
is None None O
a None None O
downstream None None O
target None None O
of None None O
Evi None None O
- None None O
1 None None O
in None None O
hematopoietic None None O
stem None None O
/ None None O
progenitors None None O
and None None O
leukemic None None O
cells None None O
. None None O

Ecotropic None None O
viral None None O
integration None None O
site None None O
- None None O
1 None None O
( None None O
Evi None None O
- None None O
1 None None O
) None None O
is None None O
a None None O
nuclear None None O
transcription None None O
factor None None O
, None None O
which None None O
is None None O
essential None None O
for None None O
the None None O
proliferation None None O
/ None None O
maintenance None None O
of None None O
hematopoietic None None O
stem None None O
cells None None O
( None None O
HSCs None None O
) None None O
. None None O

Aberrant None None O
expression None None O
of None None O
Evi None None O
- None None O
1 None None O
has None None O
been None None O
frequently None None O
found None None O
in None None O
myeloid None None O
leukemia None None O
, None None O
and None None O
is None None O
associated None None O
with None None O
a None None O
poor None None O
patient None None O
survival None None O
. None None O

Recently None None O
, None None O
we None None O
reported None None O
candidate None None O
target None None O
genes None None O
of None None O
Evi None None O
- None None O
1 None None O
shared None None O
in None None O
HSCs None None O
and None None O
leukemic None None O
cells None None O
using None None O
gene None None O
expression None None O
profiling None None O
analysis None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
identified None None O
Pbx1 None None O
, None None O
a None None O
proto None None O
- None None O
oncogene None None O
in None None O
hematopoietic None None O
malignancy None None O
, None None O
as None None O
a None None O
target None None O
gene None None O
of None None O
Evi None None O
- None None O
1 None None O
. None None O

Overexpression None None O
of None None O
Evi None None O
- None None O
1 None None O
increased None None O
Pbx1 None None O
expression None None O
in None None O
hematopoietic None None O
stem None None O
/ None None O
progenitor None None O
cells None None O
. None None O

An None None O
analysis None None O
of None None O
the None None O
Pbx1 None None O
promoter None None O
region None None O
revealed None None O
that None None O
Evi None None O
- None None O
1 None None O
upregulates None None O
Pbx1 None None O
transcription None None O
. None None O

Furthermore None None O
, None None O
reduction None None O
of None None O
Pbx1 None None O
levels None None O
through None None O
RNAi None None O
- None None O
mediated None None O
knockdown None None O
significantly None None O
inhibited None None O
Evi None None O
- None None O
1 None None O
- None None O
induced None None O
transformation None None O
. None None O

In None None O
contrast None None O
, None None O
knockdown None None O
of None None O
Pbx1 None None O
did None None O
not None None O
impair None None O
bone None None O
marrow None None O
transformation None None O
by None None O
E2A None None O
/ None None O
HLF None None O
or None None O
AML1 None None O
/ None None O
ETO None None O
, None None O
suggesting None None O
that None None O
Pbx1 None None O
is None None O
specifically None None O
required None None O
for None None O
the None None O
maintenance None None O
of None None O
bone None None O
marrow None None O
transformation None None O
mediated None None O
by None None O
Evi None None O
- None None O
1 None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
Pbx1 None None O
is None None O
a None None O
target None None O
gene None None O
of None None O
Evi None None O
- None None O
1 None None O
involved None None O
in None None O
Evi None None O
- None None O
1 None None O
- None None O
mediated None None O
leukemogenesis None None O
. None None O

Fibroblast None None O
growth None None O
factor None None O
2 None None O
promotes None None O
microvessel None None O
formation None None O
from None None O
mouse None None O
embryonic None None O
aorta None None O
. None None O

To None None O
delineate None None O
the None None O
roles None None O
that None None O
oxygen None None O
and None None O
fibroblast None None O
growth None None O
factors None None O
( None None O
FGFs None None O
) None None O
play None None O
in None None O
the None None O
process None None O
of None None O
angiogenesis None None O
from None None O
the None None O
embryonic None None O
aorta None None O
, None None O
we None None O
cultured None None O
mouse None None O
embryonic None None O
aorta None None O
explants None None O
( None None O
thoracic None None O
level None None O
to None None O
lateral None None O
vessels None None O
supplying None None O
the None None O
mesonephros None None O
and None None O
metanephros None None O
) None None O
in None None O
a None None O
three None None O
- None None O
dimensional None None O
type None None O
I None None O
collagen None None O
gel None None O
matrix None None O
. None None O

During None None O
8 None None O
days None None O
of None None O
culture None None O
under None None O
5 None None O
% None None O
O None None O
( None None O
2 None None O
) None None O
, None None O
but None None O
not None None O
room None None O
air None None O
, None None O
the None None O
addition None None O
of None None O
FGF2 None None O
to None None O
explants None None O
stimulated None None O
the None None O
formation None None O
of None None O
Gs None None O
- None None O
IB None None O
( None None O
4 None None O
- None None O
) None None O
positive None None O
, None None O
CD31 None None O
- None None O
positive None None O
, None None O
and None None O
Flk None None O
- None None O
1 None None O
- None None O
positive None None O
microvessels None None O
in None None O
a None None O
concentration None None O
- None None O
dependent None None O
manner None None O
. None None O

FGF2 None None O
- None None O
stimulated None None O
microvessel None None O
formation None None O
was None None O
inhibited None None O
by None None O
sequestration None None O
of None None O
FGF2 None None O
via None None O
addition None None O
of None None O
soluble None None O
FGF None None O
receptor None None O
( None None O
FGFR None None O
) None None O
chimera None None O
protein None None O
or None None O
anti None None O
- None None O
FGF2 None None O
antibodies None None O
. None None O

FGFR1 None None O
and None None O
FGFR2 None None O
were None None O
present None None O
on None None O
explants None None O
. None None O

Levels None None O
of None None O
FGFR1 None None O
, None None O
but None None O
not None None O
FGFR2 None None O
, None None O
were None None O
increased None None O
in None None O
embryonic None None O
aorta None None O
cultured None None O
under None None O
5 None None O
% None None O
O None None O
( None None O
2 None None O
) None None O
relative None None O
to None None O
room None None O
air None None O
. None None O

Our None None O
data None None O
suggest None None O
that None None O
low None None O
oxygen None None O
upregulates None None O
FGFR1 None None O
expression None None O
in None None O
embryonic None None O
aorta None None O
in None None O
vitro None None O
and None None O
renders None None O
it None None O
more None None O
responsive None None O
to None None O
FGF2 None None O
. None None O

Randomized None None O
, None None O
open None None O
label None None O
, None None O
prospective None None O
study None None O
on None None O
the None None O
effect None None O
of None None O
zoledronic None None O
acid None None O
on None None O
the None None O
prevention None None O
of None None O
bone None None O
metastases None None O
in None None O
patients None None O
with None None O
recurrent None None O
solid None None O
tumors None None O
that None None O
did None None O
not None None O
present None None O
with None None O
bone None None O
metastases None None O
at None None O
baseline None None O
. None None O

OBJECTIVES None None O
: None None O
Bisphosphonates None None O
have None None O
been None None O
used None None O
successfully None None O
in None None O
the None None O
treatment None None O
of None None O
hypercalcemia None None O
and None None O
to None None O
reduce None None O
skeletal None None O
- None None O
related None None O
complications None None O
of None None O
bone None None O
metastases None None O
. None None O

Recent None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
evidence None None O
suggest None None O
that None None O
they None None O
may None None O
also None None O
have None None O
direct None None O
antitumor None None O
effects None None O
via None None O
induction None None O
of None None O
apoptosis None None O
, None None O
inhibition None None O
of None None O
the None None O
invasive None None O
potential None None O
of None None O
tumor None None O
cell None None O
lines None None O
in None None O
vitro None None O
, None None O
inhibition None None O
of None None O
angiogenesis None None O
, None None O
and None None O
reduction None None O
in None None O
tumor None None O
growth None None O
indirectly None None O
via None None O
effects None None O
on None None O
accessory None None O
cells None None O
. None None O

This None None O
is None None O
a None None O
randomized None None O
, None None O
open None None O
label None None O
, None None O
prospective None None O
study None None O
that None None O
examined None None O
the None None O
effect None None O
of None None O
preventive None None O
zoledronic None None O
acid None None O
treatment None None O
on None None O
the None None O
development None None O
of None None O
bone None None O
metastases None None O
in None None O
patients None None O
with None None O
recurrent None None O
solid None None O
tumors None None O
, None None O
without None None O
bone None None O
metastases None None O
at None None O
the None None O
time None None O
of None None O
randomization None None O
. None None O

METHODS None None O
: None None O
Forty None None O
patients None None O
with None None O
recurrent None None O
or None None O
metastatic None None O
advanced None None O
cancer None None O
, None None O
without None None O
bone None None O
metastases None None O
, None None O
were None None O
randomized None None O
into None None O
the None None O
trial None None O
to None None O
either None None O
receive None None O
zoledronic None None O
acid None None O
or None None O
no None None O
treatment None None O
. None None O

Patients None None O
were None None O
followed None None O
up None None O
until None None O
bone None None O
metastases None None O
were None None O
established None None O
. None None O

RESULTS None None O
: None None O
The None None O
percentage None None O
of None None O
patients None None O
being None None O
bone None None O
metastases None None O
free None None O
at None None O
12 None None O
mo None None O
was None None O
60 None None O
% None None O
in None None O
the None None O
zoledronic None None O
acid None None O
and None None O
10 None None O
% None None O
in None None O
the None None O
control None None O
group None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
0005 None None O
) None None O
, None None O
while None None O
the None None O
percentages None None O
at None None O
18 None None O
mo None None O
were None None O
20 None None O
% None None O
and None None O
5 None None O
% None None O
respectively None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
0002 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O
The None None O
results None None O
have None None O
shown None None O
that None None O
bisphosphonates None None O
as None None O
adjuvant None None O
treatment None None O
might None None O
be None None O
useful None None O
for None None O
the None None O
prevention None None O
of None None O
bone None None O
metastases None None O
; None None O
however None None O
, None None O
there None None O
is None None O
need None None O
for None None O
blinded None None O
randomized None None O
data None None O
before None None O
such None None O
an None None O
approach None None O
would None None O
be None None O
confirmed None None O
. None None O

In None None O
the None None O
meantime None None O
preventive None None O
use None None O
of None None O
bisphosphonates None None O
in None None O
patients None None O
without None None O
any None None O
bone None None O
metastases None None O
should None None O
not None None O
be None None O
used None None O
outside None None O
the None None O
scope None None O
of None None O
a None None O
clinical None None O
trial None None O
. None None O

Genes None None O
associated None None O
with None None O
nonsegmental None None O
vitiligo None None O
. None None O

Low None None O
- None None O
level None None O
X None None O
- None None O
radiation None None O
effects None None O
on None None O
functional None None O
vascular None None O
changes None None O
in None None O
Syrian None None O
hamster None None O
cheek None None O
pouch None None O
epithelium None None O
during None None O
hydrocarbon None None O
carcinogenesis None None O
. None None O

Effects None None O
of None None O
repeated None None O
low None None O
- None None O
level None None O
X None None O
radiation None None O
on None None O
functional None None O
microvascular None None O
changes None None O
in None None O
hamster None None O
cheek None None O
pouch None None O
epithelium None None O
during None None O
and None None O
following None None O
carcinogenesis None None O
by None None O
7 None None O
, None None O
12 None None O
- None None O
dimethylbenz None None O
[ None None O
a None None O
] None None O
anthracene None None O
( None None O
DMBA None None O
) None None O
were None None O
studied None None O
. None None O

Prior None None O
studies None None O
showed None None O
enhancement None None O
of None None O
such None None O
carcinogenesis None None O
by None None O
repeated None None O
20 None None O
rad None None O
head None None O
and None None O
neck None None O
X None None O
- None None O
radiation None None O
exposures None None O
, None None O
and None None O
it None None O
was None None O
proposed None None O
that None None O
one None None O
possible None None O
mechanism None None O
was None None O
radiogenic None None O
alteration None None O
of None None O
the None None O
functional None None O
microvasculature None None O
in None None O
a None None O
manner None None O
which None None O
favored None None O
subsequent None None O
tumor None None O
development None None O
. None None O

Hamsters None None O
were None None O
treated None None O
with None None O
either None None O
radiation None None O
, None None O
DMBA None None O
, None None O
radiation None None O
+ None None O
DMBA None None O
, None None O
or None None O
no None None O
treatment None None O
. None None O

Animals None None O
were None None O
sacrificed None None O
at None None O
3 None None O
- None None O
week None None O
intervals None None O
from None None O
0 None None O
to None None O
39 None None O
weeks None None O
after None None O
treatments None None O
began None None O
. None None O

Pouch None None O
vascular None None O
volume None None O
and None None O
permeability None None O
changes None None O
were None None O
studied None None O
by None None O
fractional None None O
distributions None None O
of None None O
radiotracers None None O
and None None O
were None None O
analyzed None None O
by None None O
a None None O
variety None None O
of None None O
statistical None None O
methods None None O
which None None O
explored None None O
the None None O
vascular None None O
parameters None None O
, None None O
treatment None None O
types None None O
, None None O
elapsed None None O
time None None O
, None None O
presence None None O
of None None O
the None None O
carcinogen None None O
, None None O
and None None O
histopathologic None None O
changes None None O
. None None O

All None None O
treatments None None O
resulted None None O
in None None O
significant None None O
changes None None O
in None None O
vascular None None O
volume None None O
with None None O
time None None O
, None None O
while None None O
only None None O
DMBA None None O
treatments None None O
alone None None O
resulted None None O
in None None O
significant None None O
changes None None O
in None None O
vascular None None O
permeability None None O
with None None O
time None None O
. None None O

Prior None None O
to None None O
the None None O
appearances None None O
of None None O
frank None None O
neoplasms None None O
, None None O
volumetric None None O
changes None None O
in None None O
DMBA None None O
only None None O
and None None O
radiation None None O
only None None O
groups None None O
were None None O
similar None None O
, None None O
while None None O
volume None None O
changes None None O
in None None O
DMBA None None O
+ None None O
radiation None None O
groups None None O
increased None None O
slowly None None O
to None None O
a None None O
peak None None O
later None None O
than None None O
in None None O
other None None O
groups None None O
and None None O
then None None O
declined None None O
steadily None None O
to None None O
levels None None O
similar None None O
to None None O
the None None O
radiation None None O
only None None O
group None None O
. None None O

As None None O
in None None O
prior None None O
studies None None O
, None None O
there None None O
were None None O
significant None None O
vascular None None O
volume None None O
differences None None O
between None None O
DMBA None None O
and None None O
DMBA None None O
+ None None O
radiation None None O
groups None None O
of None None O
tumor None None O
- None None O
bearing None None O
cheek None None O
pouches None None O
. None None O

DMBA None None O
maxima None None O
were None None O
significantly None None O
higher None None O
than None None O
those None None O
of None None O
DMBA None None O
+ None None O
radiation None None O
. None None O

Radiation None None O
significantly None None O
affected None None O
DMBA None None O
- None None O
associated None None O
vascular None None O
volume None None O
and None None O
permeability None None O
changes None None O
during None None O
carcinogenesis None None O
. None None O

Several None None O
possible None None O
explanations None None O
for None None O
the None None O
relationship None None O
of None None O
these None None O
changes None None O
to None None O
the None None O
enhancement None None O
of None None O
DMBA None None O
carcinogenesis None None O
include None None O
: None None O
radiation None None O
blocking None None O
normal None None O
capillary None None O
proliferative None None O
and None None O
/ None None O
or None None O
dilatory None None O
responses None None O
to None None O
inflammation None None O
secondary None None O
to None None O
neoplastic None None O
changes None None O
; None None O
radiation None None O
- None None O
induced None None O
focal None None O
increases None None O
in None None O
the None None O
pericapillary None None O
connective None None O
tissue None None O
histohematic None None O
barrier None None O
, None None O
stimulating None None O
angiogenesis None None O
but None None O
reducing None None O
nutrient None None O
diffusion None None O
; None None O
radiation None None O
exposures None None O
sensitizing None None O
vascular None None O
endothelium None None O
to None None O
subsequent None None O
angiogenic None None O
stimulation None None O
from None None O
premalignant None None O
tissues None None O
; None None O
DMBA None None O
vascular None None O
and None None O
epithelial None None O
effects None None O
partially None None O
or None None O
completely None None O
blocking None None O
radiation None None O
effects None None O
on None None O
epithelial None None O
and None None O
/ None None O
or None None O
endothelial None None O
cells None None O
; None None O
and None None O
radiation None None O
damage None None O
to None None O
vessel None None O
walls None None O
partially None None O
or None None O
fully None None O
inhibiting None None O
normal None None O
physiologic None None O
mechanisms None None O
of None None O
repairing None None O
DMBA None None O
damage None None O
to None None O
the None None O
vessels None None O
. None None O

Heart None None O
sound None None O
and None None O
electrocardiogram None None O
recording None None O
devices None None O
for None None O
telemedicine None None O
environments None None O
. None None O

There None None O
is None None O
currently None None O
a None None O
worldwide None None O
trend None None O
to None None O
bring None None O
healthcare None None O
services None None O
as None None O
close None None O
as None None O
possible None None O
to None None O
the None None O
patient None None O
, None None O
either None None O
through None None O
home None None O
healthcare None None O
systems None None O
, None None O
or None None O
telemedicine None None O
. None None O

There None None O
is None None O
thus None None O
a None None O
general None None O
need None None O
for None None O
equipment None None O
that None None O
can None None O
capture None None O
patient None None O
data None None O
electronically None None O
for None None O
automated None None O
review None None O
or None None O
analysis None None O
by None None O
a None None O
medical None None O
practitioner None None O
. None None O

This None None O
paper None None O
presents None None O
prototype None None O
systems None None O
that None None O
were None None O
developed None None O
with None None O
the None None O
ultimate None None O
aim None None O
for None None O
use None None O
in None None O
telemedicine None None O
settings None None O
in None None O
rural None None O
Africa None None O
. None None O

These None None O
devices None None O
can None None O
be None None O
used None None O
to None None O
electronically None None O
capture None None O
data None None O
on None None O
patients None None O
from None None O
several None None O
sensors None None O
in None None O
a None None O
quick None None O
an None None O
easy None None O
manner None None O
. None None O

In None None O
our None None O
presented None None O
cases None None O
we None None O
focus None None O
on None None O
cardiovascular None None O
information None None O
. None None O

One None None O
of None None O
the None None O
main None None O
advantages None None O
of None None O
the None None O
proposed None None O
systems None None O
is None None O
that None None O
the None None O
data None None O
are None None O
captured None None O
simultaneously None None O
from None None O
multiple None None O
sensors None None O
. None None O

The None None O
data None None O
can None None O
be None None O
stored None None O
and None None O
sent None None O
electronically None None O
for None None O
review None None O
and None None O
analysis None None O
, None None O
and None None O
knowledge None None O
- None None O
based None None O
systems None None O
or None None O
neural None None O
network None None O
type None None O
models None None O
can None None O
be None None O
used None None O
in None None O
the None None O
future None None O
for None None O
semi None None O
- None None O
autonomous None None O
screening None None O
of None None O
the None None O
recordings None None O
, None None O
before None None O
a None None O
patient None None O
is None None O
referred None None O
to None None O
a None None O
specialist None None O
. None None O

Autocrine None None O
angiotensin None None O
system None None O
regulation None None O
of None None O
bovine None None O
aortic None None O
endothelial None None O
cell None None O
migration None None O
and None None O
plasminogen None None O
activator None None O
involves None None O
modulation None None O
of None None O
proto None None O
- None None O
oncogene None None O
pp60c None None O
- None None O
src None None O
expression None None O
. None None O

Rapid None None O
endothelial None None O
cell None None O
migration None None O
and None None O
inhibition None None O
of None None O
thrombosis None None O
are None None O
critical None None O
for None None O
the None None O
resolution None None O
of None None O
denudation None None O
injuries None None O
to None None O
the None None O
vessel None None O
wall None None O
. None None O

Inhibition None None O
of None None O
the None None O
endothelial None None O
cell None None O
autocrine None None O
angiotensin None None O
system None None O
, None None O
with None None O
either None None O
the None None O
angiotensin None None O
- None None O
converting None None O
enzyme None None O
inhibitor None None O
lisinopril None None O
or None None O
the None None O
angiotensin None None O
II None None O
receptor None None O
antagonist None None O
sar1 None None O
, None None O
ile8 None None O
- None None O
angiotensin None None O
II None None O
, None None O
leads None None O
to None None O
increased None None O
endothelial None None O
cell None None O
migration None None O
and None None O
urokinase None None O
- None None O
like None None O
plasminogen None None O
activator None None O
( None None O
u None None O
- None None O
PA None None O
) None None O
activity None None O
( None None O
Bell None None O
, None None O
L None None O
. None None O
, None None O
and None None O
J None None O
. None None O
A None None O
. None None O
Madri None None O
. None None O
1990 None None O
. None None O
Am None None O
. None None O
J None None O
. None None O
Pathol None None O
. None None O
137 None None O
: None None O
7 None None O
- None None O
12 None None O
) None None O
. None None O

Inhibition None None O
of None None O
the None None O
autocrine None None O
angiotensin None None O
system None None O
with None None O
the None None O
converting None None O
- None None O
enzyme None None O
inhibitor None None O
or None None O
the None None O
receptor None None O
antagonist None None O
also None None O
leads None None O
to None None O
increased None None O
expression None None O
of None None O
the None None O
proto None None O
- None None O
oncogene None None O
c None None O
- None None O
src None None O
: None None O
pp60c None None O
- None None O
src None None O
mRNA None None O
increased None None O
7 None None O
- None None O
11 None None O
- None None O
fold None None O
, None None O
c None None O
- None None O
src None None O
protein None None O
3 None None O
- None None O
fold None None O
, None None O
and None None O
c None None O
- None None O
src None None O
kinase None None O
activity None None O
2 None None O
- None None O
3 None None O
- None None O
fold None None O
. None None O

Endothelial None None O
cell None None O
expression None None O
of None None O
c None None O
- None None O
src None None O
was None None O
constitutively None None O
elevated None None O
after None None O
stable None None O
infection None None O
with None None O
a None None O
retroviral None None O
vector None None O
containing None None O
the None None O
c None None O
- None None O
src None None O
coding None None O
sequence None None O
. None None O

Constitutively None None O
increased None None O
c None None O
- None None O
src None None O
kinase None None O
activity None None O
reconstituted None None O
the None None O
increases None None O
in None None O
migration None None O
and None None O
u None None O
- None None O
PA None None O
observed None None O
with None None O
angiotensin None None O
system None None O
interruption None None O
. None None O

Antisera None None O
to None None O
bovine None None O
u None None O
- None None O
PA None None O
blocked None None O
the None None O
increase None None O
in None None O
migration None None O
associated None None O
with None None O
increased None None O
c None None O
- None None O
src None None O
expression None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
increases None None O
in None None O
endothelial None None O
cell None None O
migration None None O
and None None O
plasminogen None None O
activator None None O
after None None O
angiotensin None None O
system None None O
inhibition None None O
are None None O
at None None O
least None None O
partially None None O
pp60c None None O
- None None O
src None None O
mediated None None O
. None None O

Elevated None None O
c None None O
- None None O
src None None O
expression None None O
with None None O
angiotensin None None O
system None None O
inhibition None None O
may None None O
act None None O
to None None O
enhance None None O
intimal None None O
wound None None O
closure None None O
and None None O
to None None O
reduce None None O
luminal None None O
thrombogenicity None None O
in None None O
vivo None None O
. None None O

Effect None None O
of None None O
Trail None None O
on None None O
the None None O
expression None None O
of None None O
endogenous None None O
M2 None None O
. None None O

( None None O
A None None O
) None None O
Effect None None O
of None None O
Trail None None O
on None None O
the None None O
level None None O
of None None O
endogenous None None O
M2 None None O
protein None None O
. None None O

The None None O
expression None None O
level None None O
of None None O
endogenous None None O
M2 None None O
protein None None O
in None None O
HeLa None None I-Cell-line-name
cells None None O
was None None O
determined None None O
using None None O
western None None O
blot None None O
4 None None O
h None None O
following None None O
Trail None None O
( None None O
250 None None O
mug None None O
/ None None O
ml None None O
) None None O
treatment None None O
. None None O

( None None O
B None None O
) None None O
Effect None None O
of None None O
Trail None None O
on None None O
the None None O
endogenous None None O
M2 None None O
mRNA None None O
. None None O

The None None O
expression None None O
level None None O
of None None O
endogenous None None O
M2 None None O
mRNA None None O
in None None O
HeLa None None I-Cell-line-name
cells None None O
was None None O
detected None None O
using None None O
RNase None None O
protection None None O
assay None None O
4 None None O
h None None O
following None None O
Trail None None O
( None None O
250 None None O
mug None None O
/ None None O
ml None None O
) None None O
treatment None None O
. None None O

( None None O
C None None O
) None None O
Effect None None O
of None None O
Trail None None O
on None None O
the None None O
synthesis None None O
of None None O
endogenous None None O
M2 None None O
protein None None O
. None None O

HeLa None None I-Cell-line-name
cells None None O
were None None O
first None None O
treated None None O
with None None O
250 None None O
mug None None O
/ None None O
ml None None O
Trail None None O
followed None None O
by None None O
pulse None None O
labeling None None O
of None None O
newly None None O
synthesized None None O
proteins None None O
with None None O
[ None None O
35S None None O
] None None O
methionine None None O
. None None O

M2 None None O
protein None None O
was None None O
then None None O
immunoprecipitated None None O
and None None O
separated None None O
by None None O
SDS None None O
- None None O
PAGE None None O
for None None O
autoradiography None None O
as None None O
described None None O
in None None O
Materials None None O
and None None O
Methods None None O
. None None O

Sox9 None None O
neural None None O
crest None None O
determinant None None O
gene None None O
controls None None O
patterning None None O
and None None O
closure None None O
of None None O
the None None O
posterior None None O
frontal None None O
cranial None None O
suture None None O
. None None O

Cranial None None O
suture None None O
development None None O
involves None None O
a None None O
complex None None O
interaction None None O
of None None O
genes None None O
and None None O
tissues None None O
derived None None O
from None None O
neural None None O
crest None None O
cells None None O
( None None O
NCC None None O
) None None O
and None None O
paraxial None None O
mesoderm None None O
. None None O

In None None O
mice None None O
, None None O
the None None O
posterior None None O
frontal None None O
( None None O
PF None None O
) None None O
suture None None O
closes None None O
during None None O
the None None O
first None None O
month None None O
of None None O
life None None O
while None None O
other None None O
sutures None None O
remain None None O
patent None None O
throughout None None O
the None None O
life None None O
of None None O
the None None O
animal None None O
. None None O

Given None None O
the None None O
unique None None O
NCC None None O
origin None None O
of None None O
PF None None O
suture None None O
complex None None O
( None None O
analogous None None O
to None None O
metopic None None O
suture None None O
in None None O
humans None None O
) None None O
, None None O
we None None O
performed None None O
quantitative None None O
real None None O
- None None O
time None None O
PCR None None O
and None None O
immunohistochemistry None None O
to None None O
study None None O
the None None O
expression None None O
pattern None None O
of None None O
the None None O
NCC None None O
determinant None None O
gene None None O
Sox9 None None O
and None None O
select None None O
markers None None O
of None None O
extracellular None None O
matrix None None O
. None None O

Our None None O
results None None O
indicated None None O
a None None O
unique None None O
up None None O
- None None O
regulated None None O
expression None None O
of None None O
Sox9 None None O
, None None O
a None None O
regulator None None O
of None None O
chondrogenesis None None O
, None None O
during None None O
initiation None None O
of None None O
PF None None O
suture None None O
closure None None O
, None None O
along None None O
with None None O
the None None O
expression None None O
of None None O
specific None None O
cartilage None None O
markers None None O
( None None O
Type None None O
II None None O
Collagen None None O
and None None O
Type None None O
X None None O
Collagen None None O
) None None O
, None None O
as None None O
well None None O
as None None O
cartilage None None O
tissue None None O
formation None None O
in None None O
the None None O
PF None None O
suture None None O
. None None O

This None None O
process None None O
was None None O
followed None None O
by None None O
expression None None O
of None None O
bone None None O
markers None None O
( None None O
Type None None O
I None None O
Collagen None None O
and None None O
Osteocalcin None None O
) None None O
, None None O
suggesting None None O
endochondral None None O
ossification None None O
. None None O

Moreover None None O
, None None O
we None None O
studied None None O
the None None O
effect None None O
of None None O
haploinsufficiency None None O
of None None O
the None None O
NCC None None O
determinant None None O
gene None None O
Sox9 None None O
in None None O
the None None O
NCC None None O
derived None None O
PF None None O
suture None None O
complex None None O
. None None O

A None None O
decrease None None O
in None None O
dosage None None O
of None None O
Sox9 None None O
by None None O
haploinsufficiency None None O
in None None O
NCC None None O
- None None O
derived None None O
tissues None None O
resulted None None O
in None None O
delayed None None O
PF None None O
suture None None O
closure None None O
. None None O

These None None O
results None None O
demonstrate None None O
a None None O
unique None None O
development None None O
of None None O
the None None O
PF None None O
suture None None O
complex None None O
and None None O
the None None O
role None None O
of None None O
Sox9 None None O
as None None O
an None None O
important None None O
contributor None None O
to None None O
timely None None O
and None None O
proper None None O
closure None None O
of None None O
the None None O
PF None None O
suture None None O
through None None O
endochondral None None O
ossification None None O
. None None O

Host None None O
- None None O
derived None None O
angiopoietin None None O
- None None O
2 None None O
affects None None O
early None None O
stages None None O
of None None O
tumor None None O
development None None O
and None None O
vessel None None O
maturation None None O
but None None O
is None None O
dispensable None None O
for None None O
later None None O
stages None None O
of None None O
tumor None None O
growth None None O
. None None O

The None None O
angiopoietin None None O
/ None None O
Tie2 None None O
system None None O
has None None O
been None None O
identified None None O
as None None O
the None None O
second None None O
vascular None None O
- None None O
specific None None O
receptor None None O
tyrosine None None O
kinase None None O
system None None O
controlling None None O
vessel None None O
assembly None None O
, None None O
maturation None None O
, None None O
and None None O
quiescence None None O
. None None O

Angiopoietin None None O
- None None O
2 None None O
( None None O
Ang None None O
- None None O
2 None None O
) None None O
is None None O
prominently None None O
up None None O
- None None O
regulated None None O
in None None O
the None None O
host None None O
- None None O
derived None None O
vasculature None None O
of None None O
most None None O
tumors None None O
, None None O
making None None O
it None None O
an None None O
attractive None None O
candidate None None O
for None None O
antiangiogenic None None O
intervention None None O
. None None O

Yet None None O
, None None O
the None None O
net None None O
outcome None None O
of None None O
Ang None None O
- None None O
2 None None O
functions None None O
on None None O
tumor None None O
angiogenesis None None O
is None None O
believed None None O
to None None O
be None None O
contextual None None O
depending None None O
on None None O
the None None O
local None None O
cytokine None None O
milieu None None O
. None None O

Correspondingly None None O
, None None O
Ang None None O
- None None O
2 None None O
manipulatory None None O
therapies None None O
have None None O
been None None O
shown None None O
to None None O
exert None None O
protumorigenic None None O
as None None O
well None None O
as None None O
antitumorigenic None None O
effects None None O
. None None O

To None None O
clarify None None O
the None None O
role None None O
of None None O
Ang None None O
- None None O
2 None None O
for None None O
angiogenesis None None O
and None None O
tumor None None O
growth None None O
in None None O
a None None O
definite None None O
genetic None None O
experimental None None O
setting None None O
, None None O
the None None O
present None None O
study None None O
was None None O
aimed None None O
at None None O
comparatively None None O
studying None None O
the None None O
growth None None O
of None None O
different None None O
tumors None None O
in None None O
wild None None O
- None None O
type None None O
and None None O
Ang None None O
- None None O
2 None None O
- None None O
deficient None None O
mice None None O
. None None O

Lewis None None O
lung None None O
carcinomas None None O
, None None O
MT None None O
- None None O
ret None None O
melanomas None None O
, None None O
and None None O
B16F10 None None I-Cell-line-name
melanomas None None O
all None None O
grew None None O
slower None None O
in None None O
Ang None None O
- None None O
2 None None O
- None None O
deficient None None O
mice None None O
. None None O

Yet None None O
, None None O
tumor None None O
growth None None O
in None None O
wild None None O
- None None O
type None None O
and None None O
Ang None None O
- None None O
2 None None O
- None None O
deficient None None O
mice None None O
dissociated None None O
during None None O
early None None O
stages None None O
of None None O
tumor None None O
development None None O
, None None O
whereas None None O
tumor None None O
growth None None O
rates None None O
during None None O
later None None O
stages None None O
of None None O
primary None None O
tumor None None O
progression None None O
were None None O
similar None None O
. None None O

Analysis None None O
of None None O
the None None O
intratumoral None None O
vascular None None O
architecture None None O
revealed None None O
no None None O
major None None O
differences None None O
in None None O
microvessel None None O
density None None O
and None None O
perfusion None None O
characteristics None None O
. None None O

However None None O
, None None O
diameters None None O
of None None O
intratumoral None None O
microvessels None None O
were None None O
smaller None None O
in None None O
tumors None None O
grown None None O
in None None O
Ang None None O
- None None O
2 None None O
- None None O
deficient None None O
mice None None O
, None None O
and None None O
the None None O
vasculature None None O
had None None O
an None None O
altered None None O
pattern None None O
of None None O
pericyte None None O
recruitment None None O
and None None O
maturation None None O
. None None O

Ang None None O
- None None O
2 None None O
- None None O
deficient None None O
tumor None None O
vessels None None O
had None None O
higher None None O
pericyte None None O
coverage None None O
indices None None O
. None None O

Recruited None None O
pericytes None None O
were None None O
desmin None None O
and None None O
NG2 None None O
positive None None O
and None None O
predominately None None O
alpha None None O
- None None O
smooth None None O
muscle None None O
actin None None O
negative None None O
, None None O
indicative None None O
of None None O
a None None O
more None None O
mature None None O
pericyte None None O
phenotype None None O
. None None O

Collectively None None O
, None None O
the None None O
experiments None None O
define None None O
the None None O
role None None O
of None None O
Ang None None O
- None None O
2 None None O
during None None O
tumor None None O
angiogenesis None None O
and None None O
establish None None O
a None None O
better None None O
rationale None None O
for None None O
combination None None O
therapies None None O
involving None None O
Ang None None O
- None None O
2 None None O
manipulatory None None O
therapies None None O
. None None O

Protective None None O
function None None O
of None None O
von None None O
Hippel None None O
- None None O
Lindau None None O
protein None None O
against None None O
impaired None None O
protein None None O
processing None None O
in None None O
renal None None O
carcinoma None None O
cells None None O
. None None O

The None None O
absence None None O
of None None O
functional None None O
von None None O
Hippel None None O
- None None O
Lindau None None O
( None None O
VHL None None O
) None None O
tumor None None O
suppressor None None O
gene None None O
leads None None O
to None None O
the None None O
development None None O
of None None O
neoplasias None None O
characteristic None None O
of None None O
VHL None None O
disease None None O
, None None O
including None None O
renal None None O
cell None None O
carcinoma None None O
( None None O
RCC None None O
) None None O
. None None O

Here None None O
, None None O
we None None O
compared None None O
the None None O
sensitivity None None O
of None None O
RCC None None O
cells None None O
lacking None None O
VHL None None O
gene None None O
function None None O
with None None O
that None None O
of None None O
RCC None None O
cells None None O
expressing None None O
the None None O
wild None None O
- None None O
type None None O
VHL None None O
gene None None O
( None None O
wtVHL None None O
) None None O
after None None O
exposure None None O
to None None O
various None None O
stresses None None O
. None None O

While None None O
the None None O
response None None O
to None None O
most None None O
treatments None None O
was None None O
not None None O
affected None None O
by None None O
the None None O
VHL None None O
gene None None O
status None None O
, None None O
glucose None None O
deprivation None None O
was None None O
found None None O
to None None O
be None None O
much None None O
more None None O
cytotoxic None None O
for None None O
RCC None None O
cells None None O
lacking None None O
VHL None None O
gene None None O
function None None O
than None None O
for None None O
wtVHL None None O
- None None O
expressing None None O
cells None None O
. None None O

The None None O
heightened None None O
sensitivity None None O
of None None O
VHL None None O
- None None O
deficient None None O
cells None None O
was None None O
not None None O
attributed None None O
to None None O
dissimilar None None O
energy None None O
requirements None None O
or None None O
to None None O
differences None None O
in None None O
glucose None None O
uptake None None O
, None None O
but None None O
more None None O
likely None None O
reflects None None O
a None None O
lesser None None O
ability None None O
of None None O
VHL None None O
- None None O
deficient None None O
cells None None O
to None None O
handle None None O
abnormally None None O
processed None None O
proteins None None O
arising None None O
from None None O
impaired None None O
glycosylation None None O
. None None O

In None None O
support None None O
of None None O
this None None O
hypothesis None None O
, None None O
other None None O
treatments None None O
which None None O
act None None O
through None None O
different None None O
mechanisms None None O
to None None O
interfere None None O
with None None O
protein None None O
processing None None O
( None None O
i None None O
. None None O
e None None O
. None None O
, None None O
tunicamycin None None O
, None None O
brefeldin None None O
A None None O
, None None O
and None None O
azetidine None None O
) None None O
were None None O
also None None O
found None None O
to None None O
be None None O
much None None O
more None None O
toxic None None O
for None None O
VHL None None O
- None None O
deficient None None O
cells None None O
. None None O

Furthermore None None O
, None None O
ubiquitination None None O
of None None O
cellular None None O
proteins None None O
was None None O
elevated None None O
in None None O
VHL None None O
- None None O
deficient None None O
cells None None O
, None None O
particularly None None O
after None None O
glucose None None O
deprivation None None O
, None None O
supporting None None O
a None None O
role None None O
for None None O
the None None O
VHL None None O
gene None None O
in None None O
ubiquitin None None O
- None None O
mediated None None O
proteolysis None None O
. None None O

Accordingly None None O
, None None O
the None None O
rate None None O
of None None O
elimination None None O
of None None O
abnormal None None O
proteins None None O
was None None O
lower None None O
in None None O
cells None None O
lacking None None O
a None None O
functional None None O
VHL None None O
gene None None O
than None None O
in None None O
wtVHL None None O
- None None O
expressing None None O
cells None None O
. None None O

Thus None None O
, None None O
pVHL None None O
appears None None O
to None None O
participate None None O
in None None O
the None None O
elimination None None O
of None None O
misprocessed None None O
proteins None None O
, None None O
such None None O
as None None O
those None None O
arising None None O
in None None O
the None None O
cell None None O
due None None O
to None None O
the None None O
unavailability None None O
of None None O
glucose None None O
or None None O
to None None O
other None None O
stresses None None O
. None None O

The None None O
detection None None O
of None None O
macrosomia None None O
at None None O
a None None O
teaching None None O
hospital None None O
. None None O

We None None O
sought None None O
to None None O
determine None None O
the None None O
detection None None O
( None None O
clinical None None O
or None None O
sonographic None None O
) None None O
rate None None O
of None None O
macrosomic None None O
newborns None None O
( None None O
at None None O
least None None O
4000 None None O
g None None O
) None None O
and None None O
the None None O
peripartum None None O
factors None None O
among None None O
those None None O
who None None O
were None None O
or None None O
were None None O
not None None O
identified None None O
accurately None None O
. None None O

We None None O
retrospectively None None O
reviewed None None O
all None None O
deliveries None None O
over None None O
1 None None O
year None None O
and None None O
all None None O
maternal None None O
and None None O
neonatal None None O
charts None None O
of None None O
macrosomic None None O
newborns None None O
delivered None None O
during None None O
that None None O
year None None O
. None None O

Odds None None O
ratio None None O
( None None O
ORs None None O
) None None O
and None None O
95 None None O
% None None O
confidence None None O
intervals None None O
( None None O
CIs None None O
) None None O
were None None O
calculated None None O
. None None O

Over None None O
a None None O
12 None None O
- None None O
month None None O
period None None O
, None None O
the None None O
rate None None O
of None None O
macrosomia None None O
was None None O
10 None None O
% None None O
( None None O
421 None None O
/ None None O
4194 None None O
) None None O
and None None O
of None None O
those None None O
, None None O
only None None O
11 None None O
% None None O
( None None O
95 None None O
% None None O
CI None None O
8 None None O
to None None O
14 None None O
% None None O
) None None O
were None None O
suspected None None O
clinically None None O
or None None O
sonographically None None O
. None None O

None None None O
of None None O
the None None O
newborns None None O
weighing None None O
4500 None None O
g None None O
or None None O
more None None O
were None None O
recognized None None O
before None None O
birth None None O
( None None O
0 None None O
/ None None O
57 None None O
; None None O
95 None None O
% None None O
CI None None O
0 None None O
to None None O
6 None None O
% None None O
) None None O
. None None O

The None None O
rate None None O
of None None O
cesarean None None O
delivery None None O
was None None O
significantly None None O
higher None None O
among None None O
newborns None None O
correctly None None O
identified None None O
as None None O
macrosomic None None O
( None None O
58 None None O
% None None O
) None None O
versus None None O
those None None O
missed None None O
( None None O
36 None None O
% None None O
; None None O
OR None None O
2 None None O
. None None O
76 None None O
, None None O
95 None None O
% None None O
CI None None O
1 None None O
. None None O
46 None None O
, None None O
5 None None O
. None None O
16 None None O
) None None O
. None None O

The None None O
incidence None None O
of None None O
newborns None None O
weighing None None O
in None None O
excess None None O
of None None O
4000 None None O
g None None O
is None None O
10 None None O
% None None O
, None None O
and None None O
approximately None None O
90 None None O
% None None O
of None None O
these None None O
macrosomic None None O
newborns None None O
were None None O
unsuspected None None O
before None None O
birth None None O
. None None O

Angiogenesis None None O
- None None O
a None None O
novel None None O
therapeutic None None O
approach None None O
for None None O
ischemic None None O
heart None None O
disease None None O
. None None O

Angiogenesis None None O
is None None O
the None None O
biologic None None O
process None None O
of None None O
forming None None O
new None None O
blood None None O
vessels None None O
. None None O

Undoubtedly None None O
, None None O
blood None None O
vessels None None O
growth None None O
regulation None None O
is None None O
a None None O
vital None None O
aspect None None O
in None None O
health None None O
and None None O
disease None None O
. None None O

Under None None O
physiological None None O
conditions None None O
, None None O
angiogenesis None None O
is None None O
regulated None None O
by None None O
local None None O
balance None None O
between None None O
endogenous None None O
stimulators None None O
and None None O
inhibitors None None O
of None None O
this None None O
process None None O
. None None O

In None None O
many None None O
diseases None None O
state None None O
body None None O
loses None None O
control None None O
over None None O
angiogenesis None None O
. None None O

Angiogenesis None None O
- None None O
dependent None None O
diseases None None O
result None None O
when None None O
new None None O
blood None None O
vessels None None O
either None None O
grow None None O
excessively None None O
or None None O
insufficiently None None O
. None None O

Insufficient None None O
angiogenesis None None O
occurs None None O
in None None O
diseases None None O
such None None O
as None None O
coronary None None O
artery None None O
disease None None O
, None None O
stroke None None O
and None None O
chronic None None O
wounds None None O
. None None O

Myocardial None None O
ischemia None None O
both None None O
acute None None O
and None None O
chronic None None O
has None None O
been None None O
clearly None None O
shown None None O
to None None O
stimulate None None O
angiogenesis None None O
in None None O
many None None O
experimental None None O
models None None O
. None None O

Therapeutic None None O
angiogenesis None None O
is None None O
the None None O
biological None None O
agents None None O
or None None O
bioactive None None O
material None None O
to None None O
stimulate None None O
the None None O
growth None None O
of None None O
new None None O
blood None None O
vessels None None O
. None None O

Traditional None None O
coronary None None O
revascularization None None O
therapies None None O
such None None O
as None None O
coronary None None O
angioplasty None None O
or None None O
bypass None None O
graft None None O
surgery None None O
, None None O
act None None O
by None None O
restoring None None O
blood None None O
flow None None O
through None None O
the None None O
preexisting None None O
coronary None None O
vessels None None O
. None None O

One None None O
limitation None None O
of None None O
these None None O
approaches None None O
, None None O
however None None O
, None None O
may None None O
be None None O
the None None O
failure None None O
to None None O
normalize None None O
myocardial None None O
perfusion None None O
, None None O
due None None O
to None None O
the None None O
concomitant None None O
presence None None O
or None None O
small None None O
of None None O
resistance None None O
vessel None None O
disease None None O
. None None O

In None None O
contrast None None O
, None None O
therapeutic None None O
angiogenesis None None O
is None None O
based None None O
on None None O
the None None O
concept None None O
that None None O
coronary None None O
collateral None None O
development None None O
may None None O
be None None O
stimulated None None O
by None None O
pharmacological None None O
or None None O
molecular None None O
means None None O
and None None O
can None None O
limit None None O
myocardial None None O
ischemia None None O
. None None O

Studies None None O
, None None O
both None None O
in None None O
human None None O
and None None O
animal None None O
models None None O
support None None O
the None None O
notion None None O
that None None O
, None None O
various None None O
angiogenic None None O
growth None None O
factors None None O
and None None O
progenitor None None O
cells None None O
can None None O
enhance None None O
new None None O
blood None None O
vessels None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
, None None O
fibroblast None None O
growth None None O
factor None None O
( None None O
FGF None None O
) None None O
, None None O
recombinant None None O
proteins None None O
and None None O
bone None None O
marrow None None O
stem None None O
cells None None O
are None None O
currently None None O
used None None O
therapeutic None None O
stimulators None None O
for None None O
angiogenesis None None O
. None None O

As None None O
coronary None None O
artery None None O
disease None None O
is None None O
the None None O
major None None O
cause None None O
of None None O
death None None O
in None None O
the None None O
developed None None O
societies None None O
and None None O
also None None O
an None None O
emerging None None O
health None None O
problem None None O
in None None O
developing None None O
countries None None O
like None None O
Bangladesh None None O
therapeutic None None O
angiogenesis None None O
may None None O
provide None None O
hope None None O
as None None O
a None None O
new None None O
treatment None None O
modality None None O
for None None O
ischemic None None O
heart None None O
disease None None O
with None None O
or None None O
in None None O
place None None O
of None None O
current None None O
therapies None None O
. None None O

Abdominal None None O
approach None None O
for None None O
the None None O
ligation None None O
of None None O
bleeding None None O
oesophageal None None O
varices None None O
. None None O

The None None O
conventional None None O
surgical None None O
treatment None None O
of None None O
bleeding None None O
oesophageal None None O
varices None None O
in None None O
the None None O
emergency None None O
situation None None O
is None None O
based None None O
upon None None O
the None None O
Boerema None None O
- None None O
Crile None None O
operation None None O
of None None O
transthoracic None None O
oesophagotomy None None O
and None None O
ligation None None O
of None None O
the None None O
varices None None O
. None None O

This None None O
and None None O
the None None O
other None None O
methods None None O
of None None O
treatment None None O
of None None O
this None None O
condition None None O
in None None O
current None None O
practice None None O
are None None O
discussed None None O
. None None O

Two None None O
cases None None O
are None None O
reported None None O
in None None O
which None None O
a None None O
transabdominal None None O
oesophagogastrotomy None None O
was None None O
used None None O
to None None O
approach None None O
the None None O
site None None O
of None None O
bleeding None None O
. None None O

This None None O
operation None None O
is None None O
described None None O
and None None O
the None None O
theoretical None None O
and None None O
practical None None O
advantages None None O
it None None O
appears None None O
to None None O
offer None None O
over None None O
the None None O
standard None None O
approach None None O
are None None O
considered None None O
. None None O

[ None None O
Prognostic None None O
significance None None O
of None None O
cellular None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
expression None None O
in None None O
the None None O
course None None O
of None None O
chronic None None O
myeloid None None O
leukaemia None None O
] None None O

INTRODUCTION None None O
: None None O
Increased None None O
angiogenesis None None O
in None None O
bone None None O
marrow None None O
is None None O
one None None O
of None None O
the None None O
characteristics None None O
of None None O
chronic None None O
myeloid None None O
leukaemia None None O
( None None O
CML None None O
) None None O
, None None O
a None None O
clonal None None O
myeloproliferative None None O
disorder None None O
that None None O
expresses None None O
a None None O
chimeric None None O
bcr None None O
/ None None O
abl None None O
protein None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
is None None O
one None None O
of None None O
the None None O
most None None O
potent None None O
and None None O
a None None O
specific None None O
regulator None None O
of None None O
angiogenesis None None O
which None None O
principally None None O
targets None None O
endothelial None None O
cells None None O
and None None O
regulates None None O
several None None O
of None None O
their None None O
functions None None O
, None None O
including None None O
mitogenesis None None O
, None None O
permeability None None O
and None None O
migration None None O
. None None O

The None None O
impact None None O
of None None O
elevated None None O
VEGF None None O
expression None None O
on None None O
the None None O
course None None O
of None None O
chronic None None O
myeloid None None O
leukaemia None None O
is None None O
unknown None None O
. None None O

OBJECTIVE None None O
: None None O
The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
the None None O
follow None None O
- None None O
up None None O
of None None O
VEGF None None O
expression None None O
during None None O
the None None O
course None None O
of None None O
CML None None O
. None None O

METHODS None None O
: None None O
We None None O
studied None None O
VEGF None None O
expression None None O
of None None O
85 None None O
CML None None O
patients None None O
( None None O
median None None O
age None None O
50 None None O
years None None O
, None None O
range None None O
16 None None O
- None None O
75 None None O
years None None O
) None None O
. None None O

At None None O
the None None O
commencement None None O
of None None O
the None None O
study None None O
, None None O
29 None None O
patients None None O
were None None O
in None None O
chronic None None O
phase None None O
( None None O
CP None None O
) None None O
, None None O
25 None None O
in None None O
an None None O
accelerated None None O
phase None None O
( None None O
AP None None O
) None None O
, None None O
and None None O
31 None None O
in None None O
the None None O
blast None None O
crisis None None O
( None None O
BC None None O
) None None O
. None None O

The None None O
temporal None None O
expression None None O
( None None O
percentage None None O
positivity None None O
per None None O
1000 None None O
analysed None None O
cells None None O
) None None O
VEGF None None O
proteins None None O
over None None O
the None None O
course None None O
of None None O
CML None None O
were None None O
studied None None O
using None None O
the None None O
immunohistochemical None None O
technique None None O
utilizing None None O
relevant None None O
monoclonal None None O
antibodies None None O
. None None O

It None None O
was None None O
correlated None None O
with None None O
the None None O
laboratory None None O
( None None O
Hb None None O
, None None O
WBC None None O
and None None O
platelet None None O
counts None None O
, None None O
and None None O
the None None O
percentage None None O
of None None O
blasts None None O
) None None O
and None None O
clinical None None O
parameters None None O
( None None O
organomegaly None None O
, None None O
duration None None O
of None None O
CP None None O
, None None O
AP None None O
, None None O
and None None O
BC None None O
) None None O
of None None O
disease None None O
progression None None O
. None None O

RESULTS None None O
: None None O
The None None O
expression None None O
ofVEGF None None O
protein None None O
was None None O
most None None O
pronounced None None O
in None None O
AP None None O
( None None O
ANOVA None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
033 None None O
) None None O
. None None O

The None None O
level None None O
of None None O
VEGF None None O
expression None None O
correlated None None O
inversely None None O
with None None O
the None None O
degree None None O
of None None O
splenomegaly None None O
( None None O
Pearson None None O
, None None O
r None None O
= None None O
- None None O
0 None None O
. None None O
400 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
011 None None O
) None None O
. None None O

High None None O
expression None None O
of None None O
VEGF None None O
correlated None None O
with None None O
a None None O
shorter None None O
overall None None O
survival None None O
( None None O
log None None O
rank None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
042 None None O
) None None O
. None None O

CONCLUSION None None O
: None None O
Immunohistochemically None None O
confirmed None None O
significance None None O
of None None O
the None None O
expression None None O
of None None O
VEGF None None O
in None None O
dependence None None O
of None None O
the None None O
CML None None O
stage None None O
could None None O
be None None O
of None None O
clinical None None O
importance None None O
in None None O
deciding None None O
on None None O
the None None O
timing None None O
therapy None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
VEGF None None O
plays None None O
a None None O
role None None O
in None None O
the None None O
biology None None O
of None None O
CML None None O
and None None O
that None None O
VEGF None None O
inhibitors None None O
should None None O
be None None O
investigated None None O
in None None O
CML None None O
. None None O

Image None None O
- None None O
directed None None O
and None None O
color None None O
Doppler None None O
studies None None O
of None None O
gallbladder None None O
tumors None None O
. None None O

Thirteen None None O
cases None None O
of None None O
primary None None O
adenocarcinoma None None O
of None None O
the None None O
gallbladder None None O
( None None O
GB None None O
) None None O
, None None O
1 None None O
of None None O
malignant None None O
fibrous None None O
histocytoma None None O
, None None O
3 None None O
of None None O
metastatic None None O
adenocarcinoma None None O
, None None O
5 None None O
of None None O
adenoma None None O
, None None O
5 None None O
of None None O
polypus None None O
, None None O
2 None None O
of None None O
xanthogranuloma None None O
, None None O
6 None None O
of None None O
chronic None None O
cholecystitis None None O
, None None O
4 None None O
of None None O
acute None None O
cholecystitis None None O
, None None O
and None None O
8 None None O
of None None O
subacute None None O
cholecystitis None None O
were None None O
studied None None O
by None None O
image None None O
- None None O
directed None None O
and None None O
color None None O
Doppler None None O
ultrasonography None None O
( None None O
CDUS None None O
) None None O
. None None O

All None None O
of None None O
the None None O
14 None None O
cases None None O
of None None O
primary None None O
GB None None O
cancer None None O
( None None O
10 None None O
masses None None O
, None None O
4 None None O
thickening None None O
wall None None O
) None None O
were None None O
found None None O
to None None O
have None None O
a None None O
high None None O
velocity None None O
arterial None None O
blood None None O
flow None None O
signal None None O
in None None O
the None None O
wall None None O
of None None O
the None None O
GB None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
3 None None O
cases None None O
of None None O
metastatic None None O
cancer None None O
of None None O
the None None O
GB None None O
had None None O
no None None O
blood None None O
flow None None O
signal None None O
in None None O
the None None O
wall None None O
of None None O
the None None O
GB None None O
. None None O

For None None O
the None None O
30 None None O
cases None None O
of None None O
benign None None O
lesions None None O
of None None O
the None None O
GB None None O
, None None O
only None None O
in None None O
12 None None O
cases None None O
was None None O
a None None O
low None None O
velocity None None O
blood None None O
flow None None O
signal None None O
found None None O
. None None O

Nine None None O
of None None O
10 None None O
cases None None O
of None None O
primary None None O
GB None None O
malignancy None None O
were None None O
found None None O
to None None O
have None None O
high None None O
velocity None None O
arterial None None O
blood None None O
flow None None O
signals None None O
in None None O
the None None O
tumor None None O
masses None None O
. None None O

No None None O
blood None None O
flow None None O
signal None None O
was None None O
observed None None O
in None None O
the None None O
masses None None O
of None None O
13 None None O
cases None None O
( None None O
3 None None O
of None None O
metastatic None None O
adenocarcinoma None None O
, None None O
5 None None O
of None None O
adenoma None None O
, None None O
5 None None O
of None None O
polypus None None O
) None None O
. None None O

An None None O
abnormal None None O
high None None O
velocity None None O
arterial None None O
blood None None O
flow None None O
signal None None O
observed None None O
within None None O
masses None None O
in None None O
the None None O
GB None None O
or None None O
in None None O
the None None O
GB None None O
wall None None O
is None None O
a None None O
significant None None O
feature None None O
of None None O
primary None None O
GB None None O
cancer None None O
and None None O
thus None None O
helps None None O
to None None O
differentiate None None O
primary None None O
GB None None O
cancer None None O
from None None O
metastatic None None O
and None None O
benign None None O
lesions None None O
of None None O
the None None O
GB None None O
. None None O

Cancer None None O
metastasis None None O
: None None O
negative None None O
regulation None None O
by None None O
an None None O
invasion None None O
- None None O
suppressor None None O
complex None None O
. None None O

Invasion None None O
is None None O
the None None O
hallmark None None O
of None None O
tumor None None O
malignancy None None O
. None None O

We None None O
situate None None O
invasion None None O
within None None O
microecosystems None None O
comprising None None O
neoplastic None None O
cells None None O
as None None O
well None None O
as None None O
host None None O
cells None None O
. None None O

Modulation None None O
of None None O
invasion None None O
within None None O
such None None O
systems None None O
is None None O
ascribed None None O
to None None O
balances None None O
between None None O
promoter None None O
and None None O
suppressor None None O
pathways None None O
. None None O

The None None O
E None None O
- None None O
cadherin None None O
/ None None O
alpha None None O
- None None O
, None None O
beta None None O
- None None O
, None None O
gamma None None O
- None None O
catenin None None O
complex None None O
has None None O
an None None O
invasion None None O
- None None O
suppressor None None O
function None None O
as None None O
evidenced None None O
by None None O
transfections None None O
either None None O
with None None O
sense None None O
cDNA None None O
encoding None None O
these None None O
molecules None None O
or None None O
with None None O
antisense None None O
cDNA None None O
inhibiting None None O
their None None O
expression None None O
. None None O

Loss None None O
of None None O
heterozygosity None None O
at None None O
the None None O
E None None O
- None None O
Cadherin None None O
( None None O
uvo None None O
) None None O
locus None None O
has None None O
been None None O
reported None None O
, None None O
but None None O
mutations None None O
in None None O
the None None O
E None None O
- None None O
cadherin None None O
gene None None O
seem None None O
to None None O
be None None O
rare None None O
. None None O

Downregulation None None O
of None None O
E None None O
- None None O
cadherin None None O
occurred None None O
at None None O
the None None O
level None None O
of None None O
transcription None None O
or None None O
of None None O
mRNA None None O
stability None None O
. None None O

Ex None None O
vivo None None O
cultures None None O
from None None O
invasive None None O
tumors None None O
or None None O
metastases None None O
produced None None O
cells None None O
that None None O
were None None O
homogeneously None None O
E None None O
- None None O
cadherin None None O
- None None O
positive None None O
and None None O
noninvasive None None O
in None None O
vitro None None O
. None None O

These None None O
observations None None O
have None None O
led None None O
to None None O
the None None O
idea None None O
that None None O
factors None None O
in None None O
the None None O
host None None O
downmodulate None None O
the None None O
E None None O
- None None O
cadherin None None O
complex None None O
and None None O
promote None None O
invasion None None O
most None None O
probably None None O
in None None O
a None None O
transient None None O
way None None O
. None None O

2 None None O
. None None O
2 None None O
. None None O

Iris None None O
and None None O
Ciliary None None O
Body None None O

Serotonin None None O
is None None O
present None None O
in None None O
mammalian None None O
iris None None O
- None None O
ciliary None None O
body None None O
complex None None O
( None None O
ICB None None O
) None None O
at None None O
higher None None O
concentration None None O
that None None O
in None None O
non None None O
- None None O
mammalian None None O
species None None O
[ None None O
5 None None O
, None None O
45 None None O
, None None O
73 None None O
, None None O
129 None None O
, None None O
137 None None O
] None None O
. None None O

Moreover None None O
, None None O
the None None O
presence None None O
of None None O
serotonergic None None O
nerves None None O
has None None O
been None None O
demonstrated None None O
in None None O
studies None None O
conducted None None O
on None None O
the None None O
ICB None None O
of None None O
various None None O
species None None O
[ None None O
102 None None O
, None None O
137 None None O
, None None O
138 None None O
] None None O
. None None O

Experimental None None O
evidence None None O
and None None O
radioligand None None O
analyses None None O
have None None O
defined None None O
the None None O
presence None None O
at None None O
this None None O
level None None O
of None None O
three None None O
different None None O
types None None O
of None None O
serotonin None None O
receptors None None O
[ None None O
10 None None O
, None None O
28 None None O
, None None O
85 None None O
, None None O
136 None None O
, None None O
137 None None O
] None None O
, None None O
i None None O
. None None O
e None None O
. None None O
5 None None O
- None None O
HT1A None None O
, None None O
5 None None O
- None None O
HT2A None None O
/ None None O
2C None None O
and None None O
5 None None O
- None None O
HT7 None None O
[ None None O
98 None None O
] None None O
, None None O
one None None O
linked None None O
to None None O
a None None O
stimulation None None O
of None None O
inositol None None O
phosphates None None O
( None None O
5 None None O
- None None O
HT2 None None O
subtype None None O
) None None O
, None None O
while None None O
the None None O
others None None O
two None None O
are None None O
linked None None O
to None None O
cAMP None None O
activity None None O
. None None O

The None None O
plausibility None None O
of None None O
the None None O
existence None None O
of None None O
more None None O
than None None O
one None None O
5 None None O
- None None O
HT None None O
receptor None None O
type None None O
in None None O
the None None O
ciliary None None O
body None None O
is None None O
confirmed None None O
by None None O
intraocular None None O
pressure None None O
( None None O
IOP None None O
) None None O
experiments None None O
. None None O

Topical None None O
application None None O
of None None O
serotonin None None O
has None None O
been None None O
reported None None O
to None None O
both None None O
elevate None None O
[ None None O
84 None None O
] None None O
and None None O
lower None None O
[ None None O
88 None None O
] None None O
IOP None None O
in None None O
rabbit None None O
. None None O

A None None O
large None None O
number None None O
of None None O
reports None None O
have None None O
shown None None O
that None None O
serotonin None None O
agonists None None O
and None None O
antagonists None None O
can None None O
produce None None O
increases None None O
and None None O
decreases None None O
in None None O
IOP None None O
when None None O
given None None O
orally None None O
, None None O
topically None None O
to None None O
the None None O
eye None None O
or None None O
when None None O
they None None O
are None None O
directly None None O
injected None None O
in None None O
the None None O
anterior None None O
chamber None None O
[ None None O
10 None None O
, None None O
26 None None O
, None None O
34 None None O
, None None O
35 None None O
, None None O
64 None None O
, None None O
75 None None O
, None None O
84 None None O
, None None O
87 None None O
, None None O
88 None None O
, None None O
112 None None O
, None None O
113 None None O
, None None O
126 None None O
, None None O
136 None None O
, None None O
137 None None O
] None None O
. None None O

A None None O
rationale None None O
for None None O
such None None O
apparently None None O
contradictory None None O
results None None O
may None None O
be None None O
due None None O
to None None O
the None None O
different None None O
sites None None O
of None None O
action None None O
, None None O
i None None O
. None None O
e None None O
. None None O
which None None O
class None None O
of None None O
serotonin None None O
receptor None None O
is None None O
activated None None O
. None None O

In None None O
fact None None O
, None None O
in None None O
rabbit None None O
the None None O
administration None None O
of None None O
5 None None O
- None None O
methyl None None O
- None None O
urapidil None None O
( None None O
a None None O
combined None None O
5 None None O
- None None O
HT1A None None O
agonist None None O
/ None None O
alpha1 None None O
adrenoreceptor None None O
antagonist None None O
) None None O
and None None O
8 None None O
- None None O
OH None None O
- None None O
DPAT None None O
( None None O
8 None None O
- None None O
hydroxydypropylaminotetralin None None O
, None None O
a None None O
5HT1A None None O
agonist None None O
) None None O
reduces None None O
IOP None None O
, None None O
while None None O
the None None O
administration None None O
of None None O
5 None None O
- None None O
CT None None O
( None None O
5 None None O
- None None O
carboxamidotryptamine None None O
, None None O
a None None O
5 None None O
- None None O
HT1A None None O
and None None O
5 None None O
- None None O
HT7 None None O
agonist None None O
) None None O
increases None None O
IOP None None O
[ None None O
36 None None O
, None None O
84 None None O
, None None O
99 None None O
] None None O
. None None O

Chidlow None None O
, None None O
Le None None O
Corre None None O
and None None O
Osborne None None O
[ None None O
28 None None O
] None None O
have None None O
recently None None O
demonstrated None None O
that None None O
, None None O
in None None O
section None None O
taken None None O
through None None O
the None None O
whole None None O
eye None None O
and None None O
ciliary None None O
body None None O
, None None O
prominent None None O
5 None None O
- None None O
HT1A None None O
and None None O
5 None None O
- None None O
HT7 None None O
receptor None None O
messenger None None O
ribonucleic None None O
acid None None O
signals None None O
were None None O
obtained None None O
. None None O

These None None O
signals None None O
were None None O
evident None None O
in None None O
both None None O
the None None O
pigmented None None O
and None None O
non None None O
- None None O
pigmented None None O
epithelial None None O
cell None None O
layers None None O
of None None O
the None None O
pars None None O
plicata None None O
region None None O
of None None O
the None None O
ciliary None None O
processes None None O
, None None O
but None None O
not None None O
in None None O
the None None O
pars None None O
plana None None O
or None None O
in None None O
the None None O
ciliary None None O
musculature None None O
. None None O

5 None None O
- None None O
HT1A None None O
and None None O
5 None None O
- None None O
HT7 None None O
signals None None O
were None None O
apparent None None O
in None None O
the None None O
posterior None None O
processes None None O
but None None O
not None None O
in None None O
the None None O
iris None None O
processes None None O
. None None O

The None None O
presence None None O
of None None O
both None None O
receptors None None O
in None None O
the None None O
ciliary None None O
body None None O
would None None O
certainly None None O
provide None None O
an None None O
explanation None None O
for None None O
the None None O
shallow None None O
displacement None None O
curves None None O
observed None None O
in None None O
[ None None O
3H None None O
] None None O
5 None None O
- None None O
HT None None O
binding None None O
studies None None O
with None None O
the None None O
tissue None None O
[ None None O
110 None None O
] None None O
, None None O
since None None O
this None None O
ligand None None O
can None None O
be None None O
used None None O
to None None O
label None None O
both None None O
receptors None None O
. None None O

Because None None O
the None None O
ciliary None None O
epithelium None None O
of None None O
the None None O
pars None None O
plicata None None O
is None None O
responsible None None O
for None None O
the None None O
secretion None None O
of None None O
aqueous None None O
humor None None O
, None None O
an None None O
obvious None None O
function None None O
for None None O
these None None O
two None None O
receptors None None O
would None None O
be None None O
an None None O
involvement None None O
in None None O
the None None O
control None None O
of None None O
aqueous None None O
production None None O
and None None O
, None None O
consequently None None O
, None None O
of None None O
the None None O
IOP None None O
level None None O
. None None O

Further None None O
, None None O
the None None O
almost None None O
identical None None O
distribution None None O
of None None O
the None None O
5 None None O
- None None O
HT1A None None O
and None None O
5 None None O
- None None O
HT7 None None O
messengers None None O
ribonucleic None None O
acid None None O
indicate None None O
that None None O
the None None O
receptors None None O
may None None O
be None None O
co None None O
- None None O
localized None None O
in None None O
epithelial None None O
cells None None O
. None None O

The None None O
presence None None O
of None None O
two None None O
serotonin None None O
receptors None None O
with None None O
opposing None None O
effects None None O
on None None O
cAMP None None O
in None None O
the None None O
same None None O
cell None None O
layer None None O
prompts None None O
the None None O
suggestion None None O
that None None O
they None None O
could None None O
act None None O
antagonistically None None O
. None None O

The None None O
agonism None None O
of None None O
5 None None O
- None None O
HT1A None None O
receptors None None O
, None None O
negatively None None O
coupled None None O
to None None O
cAMP None None O
, None None O
reduces None None O
IOP None None O
by None None O
decreasing None None O
the None None O
production None None O
of None None O
aqueous None None O
humor None None O
, None None O
like None None O
beta None None O
- None None O
receptor None None O
antagonists None None O
which None None O
, None None O
diminishing None None O
the None None O
content None None O
of None None O
cAMP None None O
at None None O
the None None O
postjunctional None None O
site None None O
, None None O
lowers None None O
the None None O
aqueous None None O
humor None None O
secretion None None O
with None None O
a None None O
consequent None None O
decrease None None O
in None None O
IOP None None O
[ None None O
98 None None O
] None None O
. None None O

On None None O
the None None O
contrary None None O
, None None O
the None None O
administration None None O
of None None O
5 None None O
- None None O
CT None None O
induces None None O
a None None O
rise None None O
in None None O
IOP None None O
, None None O
which None None O
is None None O
partly None None O
or None None O
entirely None None O
caused None None O
by None None O
an None None O
increase None None O
in None None O
aqueous None None O
humor None None O
secretion None None O
mediated None None O
by None None O
5 None None O
- None None O
HT7 None None O
receptors None None O
[ None None O
84 None None O
] None None O
. None None O

The None None O
other None None O
type None None O
of None None O
serotonin None None O
receptor None None O
present None None O
in None None O
the None None O
ICB None None O
is None None O
a None None O
5 None None O
- None None O
HT2 None None O
type None None O
. None None O

Serotonin None None O
stimulates None None O
the None None O
accumulation None None O
of None None O
inositol None None O
phosphates None None O
in None None O
the None None O
ICB None None O
and None None O
this None None O
effect None None O
is None None O
partially None None O
counteracted None None O
by None None O
the None None O
5 None None O
- None None O
HT2 None None O
antagonists None None O
ketanserin None None O
, None None O
methysergide None None O
and None None O
mianserin None None O
[ None None O
98 None None O
] None None O
. None None O

Studies None None O
with None None O
ketanserin None None O
have None None O
demonstrated None None O
that None None O
, None None O
when None None O
orally None None O
or None None O
topically None None O
applied None None O
, None None O
it None None O
lowers None None O
IOP None None O
in None None O
animals None None O
, None None O
healthy None None O
volunteers None None O
and None None O
in None None O
glaucomatous None None O
patients None None O
[ None None O
26 None None O
, None None O
34 None None O
, None None O
37 None None O
, None None O
64 None None O
, None None O
75 None None O
, None None O
88 None None O
, None None O
113 None None O
, None None O
126 None None O
] None None O
. None None O

It None None O
has None None O
been None None O
emphasized None None O
that None None O
ketanserin None None O
also None None O
possesses None None O
an None None O
affinity None None O
for None None O
alpha1 None None O
- None None O
adrenoreceptors None None O
[ None None O
27 None None O
, None None O
36 None None O
, None None O
139 None None O
] None None O
, None None O
and None None O
for None None O
this None None O
reason None None O
the None None O
effects None None O
of None None O
ketanserin None None O
on None None O
IOP None None O
may None None O
not None None O
be None None O
entirely None None O
caused None None O
by None None O
its None None O
action None None O
on None None O
5 None None O
- None None O
HT2 None None O
receptors None None O
. None None O

However None None O
, None None O
data None None O
from None None O
human None None O
studies None None O
conducted None None O
after None None O
oral None None O
or None None O
topical None None O
administration None None O
of None None O
ketanserin None None O
, None None O
in None None O
which None None O
were None None O
determined None None O
the None None O
variations None None O
of None None O
IOP None None O
, None None O
total None None O
outflow None None O
facility None None O
and None None O
pupil None None O
diameter None None O
, None None O
demonstrated None None O
that None None O
the None None O
alpha1 None None O
- None None O
adrenoreceptor None None O
blocking None None O
effect None None O
exerted None None O
by None None O
ketanserin None None O
should None None O
represent None None O
a None None O
further None None O
aspect None None O
of None None O
its None None O
mechanism None None O
of None None O
action None None O
, None None O
probably None None O
due None None O
to None None O
a None None O
functional None None O
sharing None None O
of None None O
these None None O
receptors None None O
[ None None O
64 None None O
, None None O
87 None None O
] None None O
. None None O

Lastly None None O
, None None O
already None None O
in None None O
1992 None None O
Martin None None O
and None None O
co None None O
- None None O
workers None None O
showed None None O
the None None O
occurrence None None O
of None None O
a None None O
significant None None O
correlation None None O
between None None O
the None None O
content None None O
of None None O
serotonin None None O
in None None O
the None None O
aqueous None None O
humor None None O
and None None O
IOP None None O
in None None O
the None None O
human None None O
eye None None O
[ None None O
85 None None O
] None None O
. None None O

In None None O
1981 None None O
, None None O
Moro None None O
and None None O
his None None O
collaborators None None O
found None None O
that None None O
intravitreal None None O
injection None None O
of None None O
5 None None O
, None None O
6 None None O
- None None O
dihydroxytryptamine None None O
, None None O
a None None O
serotonergic None None O
neurotoxin None None O
, None None O
causes None None O
miosis None None O
[ None None O
91 None None O
] None None O
. None None O

The None None O
identification None None O
of None None O
5 None None O
- None None O
HT7 None None O
, None None O
but None None O
not None None O
of None None O
5 None None O
- None None O
HT1 None None O
receptors None None O
in None None O
the None None O
rabbit None None O
iris None None O
, None None O
suggests None None O
that None None O
this None None O
population None None O
of None None O
serotonergic None None O
receptors None None O
is None None O
involved None None O
in None None O
the None None O
relaxation None None O
of None None O
the None None O
sphincter None None O
of None None O
the None None O
pupil None None O
. None None O

In None None O
fact None None O
, None None O
one None None O
of None None O
the None None O
function None None O
correlate None None O
to None None O
5 None None O
- None None O
HT7 None None O
receptor None None O
activation None None O
includes None None O
smooth None None O
muscle None None O
relaxation None None O
observed None None O
in None None O
a None None O
variety None None O
of None None O
isolated None None O
tissue None None O
preparations None None O
, None None O
in None None O
which None None O
elevation None None O
of None None O
cAMP None None O
concentration None None O
was None None O
also None None O
detected None None O
[ None None O
3 None None O
, None None O
44 None None O
] None None O
. None None O

Further None None O
evidence None None O
for None None O
the None None O
mediation None None O
of None None O
the None None O
relaxant None None O
response None None O
via None None O
the None None O
5 None None O
- None None O
HT7 None None O
receptor None None O
is None None O
provided None None O
by None None O
the None None O
localization None None O
of None None O
messenger None None O
ribonucleic None None O
acid None None O
transcripts None None O
encoding None None O
the None None O
5 None None O
- None None O
HT7 None None O
receptor None None O
in None None O
many None None O
blood None None O
vessels None None O
[ None None O
67 None None O
] None None O
. None None O

This None None O
hypothesized None None O
mechanism None None O
of None None O
action None None O
is None None O
also None None O
supported None None O
by None None O
the None None O
fact None None O
that None None O
various None None O
other None None O
receptor None None O
types None None O
, None None O
also None None O
positively None None O
coupled None None O
to None None O
cAMP None None O
, None None O
in None None O
the None None O
iris None None O
cause None None O
relaxation None None O
of None None O
the None None O
sphincter None None O
muscle None None O
[ None None O
1 None None O
, None None O
28 None None O
] None None O
. None None O

FUNDING None None O

National None None O
Institutes None None O
of None None O
Health None None O
grants None None O
, None None O
National None None O
Institute None None O
of None None O
Environmental None None O
Health None None O
Sciences None None O
and None None O
the None None O
National None None O
Library None None O
of None None O
Medicine None None O
( None None O
R01 None None O
ES014065 None None O
and None None O
R01 None None O
ES014065 None None O
- None None O
04S1 None None O
to None None O
CTD None None O
) None None O
; None None O
INBRE None None O
program None None O
of None None O
the None None O
National None None O
Center None None O
for None None O
Research None None O
Resources None None O
( None None O
P20 None None O
RR016463 None None O
) None None O
. None None O

Funding None None O
for None None O
open None None O
access None None O
charge None None O
: None None O
NIEHS None None O
grant None None O
( None None O
R01 None None O
ES014065 None None O
) None None O
. None None O

Conflict None None O
of None None O
interest None None O
statement None None O
. None None O

None None None O
declared None None O
. None None O

Melissoidesin None None O
G None None O
, None None O
a None None O
diterpenoid None None O
purified None None O
from None None O
Isodon None None O
melissoides None None O
, None None O
induces None None O
leukemic None None O
- None None O
cell None None O
apoptosis None None O
through None None O
induction None None O
of None None O
redox None None O
imbalance None None O
and None None O
exhibits None None O
synergy None None O
with None None O
other None None O
anticancer None None O
agents None None O
. None None O

Melissoidesin None None O
G None None O
( None None O
MOG None None O
) None None O
is None None O
a None None O
new None None O
diterpenoid None None O
purified None None O
from None None O
Isodon None None O
melissoides None None O
, None None O
a None None O
plant None None O
used None None O
in None None O
Chinese None None O
traditional None None O
medicine None None O
as None None O
antitumor None None O
and None None O
anti None None O
- None None O
inflammatory None None O
agents None None O
. None None O

In None None O
our None None O
study None None O
, None None O
MOG None None O
was None None O
shown None None O
to None None O
specifically None None O
inhibit None None O
the None None O
growth None None O
of None None O
human None None O
leukemia None None O
cell None None O
lines None None O
and None None O
primary None None O
acute None None O
myeloid None None O
leukemia None None O
( None None O
AML None None O
) None None O
blasts None None O
via None None O
induction None None O
of None None O
apoptosis None None O
, None None O
with None None O
the None None O
evidence None None O
of None None O
mitochondrial None None O
DeltaPsim None None O
loss None None O
, None None O
reactive None None O
oxygen None None O
species None None O
production None None O
, None None O
caspases None None O
activation None None O
and None None O
nuclear None None O
fragmentation None None O
. None None O

Furthermore None None O
, None None O
it None None O
was None None O
shown None None O
that None None O
thiol None None O
- None None O
containing None None O
antioxidants None None O
completely None None O
blocked None None O
MOG None None O
- None None O
induced None None O
mitochondrial None None O
DeltaPsim None None O
loss None None O
and None None O
subsequent None None O
cell None None O
apoptosis None None O
, None None O
while None None O
the None None O
inhibition None None O
of None None O
apoptosis None None O
by None None O
benzyloxy None None O
- None None O
carbonyl None None O
- None None O
Val None None O
- None None O
Ala None None O
- None None O
Asp None None O
- None None O
fluoromethylketone None None O
only None None O
partially None None O
attenuated None None O
mitochondrial None None O
DeltaPsim None None O
loss None None O
, None None O
indicating None None O
that None None O
MOG None None O
- None None O
induced None None O
redox None None O
imbalance None None O
is None None O
an None None O
early None None O
event None None O
upstream None None O
to None None O
mitochondrial None None O
DeltaPsim None None O
loss None None O
and None None O
caspase None None O
- None None O
3 None None O
activation None None O
. None None O

Consistently None None O
, None None O
it None None O
was None None O
found None None O
that None None O
MOG None None O
rapidly None None O
decreased None None O
the None None O
intracellular None None O
glutathione None None O
( None None O
GSH None None O
) None None O
content None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
and None None O
the None None O
significance None None O
of None None O
GSH None None O
depletion None None O
in None None O
MOG None None O
- None None O
induced None None O
apoptosis None None O
was None None O
further None None O
supported None None O
by None None O
the None None O
protective None None O
effects None None O
of None None O
tert None None O
- None None O
butylhydroquinone None None O
( None None O
tBHQ None None O
) None None O
and None None O
the None None O
facilitative None None O
effects None None O
of None None O
DL None None O
- None None O
buthionine None None O
( None None O
S None None O
, None None O
R None None O
) None None O
- None None O
sulfoximine None None O
( None None O
BSO None None O
) None None O
. None None O

Furthermore None None O
, None None O
it None None O
was None None O
showed None None O
that None None O
GSH None None O
depletion None None O
induced None None O
by None None O
MOG None None O
rendered None None O
some None None O
leukemia None None O
cell None None O
lines None None O
more None None O
sensitive None None O
to None None O
arsenic None None O
trioxide None None O
( None None O
As2O3 None None O
) None None O
, None None O
doxorubicin None None O
or None None O
cisplatin None None O
. None None O

Additionally None None O
, None None O
the None None O
synergistic None None O
apoptotic None None O
effects None None O
of None None O
MOG None None O
with None None O
As2O3 None None O
were None None O
detected None None O
in None None O
HL None None I-Cell-line-name
- None None I-Cell-line-name
60 None None I-Cell-line-name
and None None O
primary None None O
AML None None O
cells None None O
, None None O
but None None O
not None None O
in None None O
normal None None O
cells None None O
, None None O
suggesting None None O
the None None O
selective None None O
toxicity None None O
of None None O
their None None O
combination None None O
to None None O
the None None O
malignant None None O
cells None None O
. None None O

Together None None O
, None None O
we None None O
proposed None None O
that None None O
MOG None None O
alone None None O
or None None O
administered None None O
with None None O
other None None O
anticancer None None O
agents None None O
may None None O
provide None None O
a None None O
novel None None O
therapeutic None None O
strategy None None O
for None None O
leukemia None None O
. None None O

Experimental None None O
drug None None O
therapy None None O
of None None O
peritumoral None None O
brain None None O
edema None None O
. None None O

Four None None O
drugs None None O
with None None O
potential None None O
anti None None O
- None None O
peritumoral None None O
brain None None O
edema None None O
activity None None O
were None None O
studied None None O
using None None O
the None None O
VX2 None None O
rabbit None None O
brain None None O
tumor None None O
model None None O
. None None O

Meclofenamate None None O
and None None O
indomethacin None None O
were None None O
tested None None O
in None None O
an None None O
attempt None None O
to None None O
confirm None None O
recent None None O
reports None None O
of None None O
anti None None O
- None None O
edema None None O
activity None None O
in None None O
non None None O
steroidal None None O
anti None None O
- None None O
inflammatory None None O
drugs None None O
( None None O
NSAID None None O
' None None O
s None None O
) None None O
. None None O

The None None O
' None None O
angiostatic None None O
' None None O
steroids None None O
17 None None O
hydroxyprogesterone None None O
and None None O
epicortisol None None O
were None None O
tested None None O
because None None O
of None None O
their None None O
lack None None O
of None None O
glucocorticoid None None O
and None None O
mineralocorticoid None None O
effects None None O
and None None O
their None None O
structural None None O
similarity None None O
to None None O
glucocorticoids None None O
. None None O

The None None O
protein None None O
and None None O
water None None O
component None None O
of None None O
brain None None O
edema None None O
were None None O
indirectly None None O
quantitated None None O
. None None O

None None None O
of None None O
the None None O
test None None O
drugs None None O
demonstrated None None O
significant None None O
anti None None O
- None None O
edema None None O
activity None None O
. None None O

This None None O
work None None O
does None None O
not None None O
confirm None None O
reports None None O
that None None O
NSAID None None O
' None None O
s None None O
have None None O
anti None None O
- None None O
edema None None O
activity None None O
and None None O
suggests None None O
that None None O
there None None O
may None None O
be None None O
no None None O
correlation None None O
between None None O
' None None O
angiostatic None None O
' None None O
and None None O
anti None None O
- None None O
edema None None O
activity None None O
in None None O
certain None None O
steroid None None O
compounds None None O
. None None O

( None None O
a None None O
) None None O
The None None O
Tn6087 None None O
target None None O
site None None O
within None None O
S None None O
. None None O
oralis None None O
F None None O
. None None O
MI None None O
. None None O
5 None None O
. None None O

( None None O
b None None O
) None None O
The None None O
left None None O
end None None O
and None None O
( None None O
c None None O
) None None O
right None None O
end None None O
of None None O
Tn6087 None None O
are None None O
shown None None O
in None None O
bold None None O
. None None O

( None None O
d None None O
) None None O
The None None O
joint None None O
of None None O
the None None O
circular None None O
intermediate None None O
of None None O
Tn6087 None None O
is None None O
shown None None O
. None None O

The None None O
transposon None None O
' None None O
s None None O
coupling None None O
sequences None None O
are None None O
shown None None O
in None None O
bold None None O
italics None None O
. None None O

As None None O
can None None O
be None None O
seen None None O
in None None O
( None None O
d None None O
) None None O
, None None O
the None None O
coupling None None O
sequence None None O
at None None O
the None None O
joint None None O
of None None O
the None None O
circular None None O
form None None O
is None None O
a None None O
heteroduplex None None O
. None None O

[ None None O
Biotechnological None None O
and None None O
biomedical None None O
aspects None None O
of None None O
production None None O
and None None O
study None None O
of None None O
metal None None O
cation None None O
- None None O
phospholipid None None O
complexes None None O
] None None O
. None None O

Problems None None O
relating None None O
to None None O
the None None O
technology None None O
of None None O
a None None O
phospholipid None None O
preparation None None O
from None None O
natural None None O
materials None None O
, None None O
liposome None None O
production None None O
, None None O
and None None O
studies None None O
into None None O
the None None O
mechanisms None None O
of None None O
interaction None None O
between None None O
metal None None O
( None None O
trace None None O
elements None None O
) None None O
cations None None O
and None None O
model None None O
bilayer None None O
lipid None None O
membranes None None O
are None None O
discussed None None O
. None None O

The None None O
proposed None None O
technology None None O
of None None O
extraction None None O
allows None None O
for None None O
preparation None None O
of None None O
phospholipids None None O
utilizable None None O
for None None O
liposome None None O
formation None None O
. None None O

The None None O
cation None None O
specificity None None O
of None None O
lipid None None O
bilayers None None O
is None None O
found None None O
to None None O
be None None O
determined None None O
by None None O
the None None O
presence None None O
of None None O
anionic None None O
phosphate None None O
adsorption None None O
sites None None O
on None None O
their None None O
surface None None O
. None None O

The None None O
role None None O
of None None O
hypoxia None None O
in None None O
2 None None O
- None None O
butoxyethanol None None O
- None None O
induced None None O
hemangiosarcoma None None O
. None None O

To None None O
understand None None O
the None None O
molecular None None O
mechanisms None None O
underlying None None O
compound None None O
- None None O
induced None None O
hemangiosarcomas None None O
in None None O
mice None None O
, None None O
and None None O
therefore None None O
, None None O
their None None O
human None None O
relevance None None O
, None None O
a None None O
systems None None O
biology None None O
approach None None O
was None None O
undertaken None None O
using None None O
transcriptomics None None O
and None None O
Causal None None O
Network None None O
Modeling None None O
from None None O
mice None None O
treated None None O
with None None O
2 None None O
- None None O
butoxyethanol None None O
( None None O
2 None None O
- None None O
BE None None O
) None None O
. None None O

2 None None O
- None None O
BE None None O
is None None O
a None None O
hemolytic None None O
agent None None O
that None None O
induces None None O
hemangiosarcomas None None O
in None None O
mice None None O
. None None O

We None None O
hypothesized None None O
that None None O
the None None O
hemolysis None None O
induced None None O
by None None O
2 None None O
- None None O
BE None None O
would None None O
result None None O
in None None O
local None None O
tissue None None O
hypoxia None None O
, None None O
a None None O
well None None O
- None None O
documented None None O
trigger None None O
for None None O
endothelial None None O
cell None None O
proliferation None None O
leading None None O
to None None O
hemangiosarcoma None None O
. None None O

Gene None None O
expression None None O
data None None O
from None None O
bone None None O
marrow None None O
( None None O
BM None None O
) None None O
, None None O
liver None None O
, None None O
and None None O
spleen None None O
of None None O
mice None None O
exposed None None O
to None None O
a None None O
single None None O
dose None None O
( None None O
4 None None O
h None None O
) None None O
or None None O
seven None None O
daily None None O
doses None None O
of None None O
2 None None O
- None None O
BE None None O
were None None O
used None None O
to None None O
develop None None O
a None None O
mechanistic None None O
model None None O
of None None O
hemangiosarcoma None None O
. None None O

The None None O
resulting None None O
mechanistic None None O
model None None O
confirms None None O
previous None None O
work None None O
proposing None None O
that None None O
2 None None O
- None None O
BE None None O
induces None None O
macrophage None None O
activation None None O
and None None O
inflammation None None O
in None None O
the None None O
liver None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
model None None O
supports None None O
local None None O
tissue None None O
hypoxia None None O
in None None O
the None None O
liver None None O
and None None O
spleen None None O
, None None O
coupled None None O
with None None O
increased None None O
erythropoeitin None None O
signaling None None O
and None None O
erythropoiesis None None O
in None None O
the None None O
spleen None None O
and None None O
BM None None O
, None None O
and None None O
suppression None None O
of None None O
mechanisms None None O
that None None O
contribute None None O
to None None O
genomic None None O
stability None None O
, None None O
events None None O
that None None O
could None None O
be None None O
contributing None None O
factors None None O
to None None O
hemangiosarcoma None None O
formation None None O
. None None O

Finally None None O
, None None O
an None None O
immunohistochemistry None None O
method None None O
( None None O
Hypoxyprobe None None O
) None None O
demonstrated None None O
that None None O
tissue None None O
hypoxia None None O
was None None O
present None None O
in None None O
the None None O
spleen None None O
and None None O
BM None None O
. None None O

Together None None O
, None None O
the None None O
results None None O
of None None O
this None None O
study None None O
identify None None O
molecular None None O
mechanisms None None O
that None None O
initiate None None O
hemangiosarcoma None None O
, None None O
a None None O
key None None O
step None None O
in None None O
understanding None None O
safety None None O
concerns None None O
that None None O
can None None O
impact None None O
drug None None O
decision None None O
processes None None O
, None None O
and None None O
identified None None O
hypoxia None None O
as None None O
a None None O
possible None None O
contributing None None O
factor None None O
for None None O
2 None None O
- None None O
BE None None O
- None None O
induced None None O
hemangiosarcoma None None O
in None None O
mice None None O
. None None O

Spacing None None O
effects None None O
on None None O
the None None O
memory None None O
for None None O
faces None None O
. None None O

25 None None O
undergraduate None None O
women None None O
studied None None O
12 None None O
stimulus None None O
pictures None None O
of None None O
female None None O
faces None None O
successively None None O
presented None None O
in None None O
spaced None None O
or None None O
massed None None O
conditions None None O
and None None O
made None None O
affective None None O
judgments None None O
for None None O
the None None O
pictures None None O
along None None O
a None None O
dimension None None O
of None None O
like None None O
to None None O
dislike None None O
. None None O

One None None O
week None None O
after None None O
the None None O
exposure None None O
( None None O
study None None O
) None None O
period None None O
, None None O
subjects None None O
were None None O
given None None O
an None None O
identification None None O
test None None O
comprised None None O
of None None O
photographs None None O
of None None O
the None None O
same None None O
female None None O
faces None None O
with None None O
different None None O
expressions None None O
. None None O

Analysis None None O
showed None None O
that None None O
the None None O
pictures None None O
presented None None O
in None None O
the None None O
spaced None None O
condition None None O
were None None O
more None None O
frequently None None O
and None None O
accurately None None O
identified None None O
than None None O
those None None O
presented None None O
under None None O
the None None O
massed None None O
condition None None O
and None None O
that None None O
affective None None O
judgment None None O
was None None O
unrelated None None O
to None None O
conditions None None O
of None None O
presentation None None O
. None None O

[ None None O
Interleukin None None O
- None None O
18 None None O
and None None O
new None None O
drugs None None O
. None None O
Protective None None O
effect None None O
against None None O
tumor None None O
growth None None O
and None None O
infections None None O
] None None O
. None None O

IL None None O
- None None O
18 None None O
, None None O
originally None None O
identified None None O
as None None O
interferon None None O
- None None O
gamma None None O
inducing None None O
factor None None O
( None None O
IGIF None None O
) None None O
, None None O
is None None O
related None None O
to None None O
the None None O
IL None None O
- None None O
1 None None O
family None None O
in None None O
terms None None O
of None None O
its None None O
structure None None O
as None None O
well None None O
as None None O
its None None O
processing None None O
, None None O
receptor None None O
, None None O
signal None None O
transduction None None O
pathway None None O
and None None O
pro None None O
- None None O
inflammatory None None O
properties None None O
. None None O

IL None None O
- None None O
18 None None O
is None None O
also None None O
functionally None None O
related None None O
to None None O
IL None None O
- None None O
12 None None O
, None None O
as None None O
it None None O
induces None None O
the None None O
production None None O
of None None O
Th1 None None O
cytokines None None O
and None None O
participates None None O
in None None O
cell None None O
- None None O
mediated None None O
immune None None O
cytotoxicity None None O
. None None O

A None None O
summary None None O
is None None O
made None None O
of None None O
recent None None O
advances None None O
in None None O
the None None O
understanding None None O
of None None O
IL None None O
- None None O
18 None None O
structure None None O
, None None O
processing None None O
, None None O
receptor None None O
expression None None O
and None None O
immunoregulatory None None O
functions None None O
. None None O

It None None O
focuses None None O
on None None O
the None None O
role None None O
of None None O
IL None None O
- None None O
18 None None O
modulation None None O
in None None O
tumours None None O
, None None O
infections None None O
and None None O
autoimmune None None O
and None None O
inflammatory None None O
diseases None None O
. None None O

Cardiac None None O
gap None None O
junction None None O
configuration None None O
after None None O
an None None O
uncoupling None None O
treatment None None O
as None None O
a None None O
function None None O
of None None O
time None None O
. None None O

Rabbit None None O
ventricle None None O
either None None O
was None None O
fixed None None O
in None None O
glutaraldehyde None None O
without None None O
injury None None O
( None None O
control None None O
) None None O
or None None O
was None None O
injured None None O
before None None O
fixation None None O
, None None O
presumably None None O
causing None None O
electrical None None O
uncoupling None None O
of None None O
the None None O
gap None None O
junctions None None O
. None None O

All None None O
tissue None None O
was None None O
then None None O
processed None None O
for None None O
freeze None None O
- None None O
fracture None None O
. None None O

Replicas None None O
of None None O
control None None O
gap None None O
junctions None None O
exhibited None None O
irregular None None O
packing None None O
of None None O
the None None O
P None None O
- None None O
face None None O
particles None None O
and None None O
E None None O
- None None O
face None None O
pits None None O
. None None O

Average None None O
center None None O
- None None O
to None None O
- None None O
center None None O
spacing None None O
of None None O
the None None O
particles None None O
was None None O
10 None None O
. None None O
5 None None O
nm None None O
. None None O

Tissue None None O
fixed None None O
1 None None O
- None None O
5 None None O
min None None O
after None None O
injury None None O
showed None None O
clumping None None O
of None None O
gap None None O
junctional None None O
particles None None O
and None None O
pits None None O
. None None O

Within None None O
the None None O
clumps None None O
, None None O
the None None O
particles None None O
and None None O
pits None None O
were None None O
hexagonally None None O
packed None None O
and None None O
the None None O
center None None O
- None None O
to None None O
- None None O
center None None O
spacing None None O
of None None O
the None None O
particles None None O
averaged None None O
9 None None O
. None None O
5 None None O
nm None None O
. None None O

In None None O
tissue None None O
fixed None None O
15 None None O
- None None O
30 None None O
min None None O
after None None O
injury None None O
, None None O
the None None O
clumps None None O
of None None O
gap None None O
junctional None None O
particles None None O
had None None O
coalesced None None O
into None None O
a None None O
homogeneous None None O
structure None None O
in None None O
most None None O
junctions None None O
. None None O

The None None O
packing None None O
of None None O
the None None O
particles None None O
and None None O
pits None None O
was None None O
hexagonal None None O
and None None O
the None None O
spacing None None O
of None None O
the None None O
particles None None O
averaged None None O
9 None None O
. None None O
5 None None O
nm None None O
. None None O

A None None O
few None None O
pieces None None O
of None None O
rabbit None None O
atrium None None O
were None None O
frozen None None O
without None None O
prior None None O
fixation None None O
or None None O
cryoprotection None None O
to None None O
try None None O
to None None O
assess None None O
the None None O
effect None None O
of None None O
glutarldehyde None None O
fixation None None O
on None None O
gap None None O
junction None None O
structure None None O
. None None O

In None None O
this None None O
tissue None None O
the None None O
gap None None O
junctional None None O
particles None None O
were None None O
irregularly None None O
packed None None O
and None None O
their None None O
spacing None None O
averaged None None O
10 None None O
. None None O
0 None None O
nm None None O
. None None O

Short None None O
pigment None None O
epithelial None None O
- None None O
derived None None O
factor None None O
- None None O
derived None None O
peptide None None O
inhibits None None O
angiogenesis None None O
and None None O
tumor None None O
growth None None O
. None None O

PURPOSE None None O
: None None O
Pigment None None O
epithelial None None O
- None None O
derived None None O
factor None None O
( None None O
PEDF None None O
) None None O
is None None O
a None None O
potent None None O
angiogenesis None None O
inhibitor None None O
with None None O
multiple None None O
other None None O
functions None None O
, None None O
some None None O
of None None O
which None None O
enhance None None O
tumor None None O
growth None None O
. None None O

Our None None O
previous None None O
studies None None O
mapped None None O
PEDF None None O
antiangiogenic None None O
and None None O
prosurvival None None O
activities None None O
to None None O
distinct None None O
epitopes None None O
. None None O

This None None O
study None None O
was None None O
aimed None None O
to None None O
determine None None O
the None None O
minimal None None O
fragment None None O
of None None O
PEDF None None O
, None None O
which None None O
maintains None None O
antiangiogenic None None O
and None None O
antitumor None None O
efficacy None None O
. None None O

EXPERIMENTAL None None O
DESIGN None None O
: None None O
We None None O
analyzed None None O
antigenicity None None O
, None None O
hydrophilicity None None O
, None None O
and None None O
charge None None O
distribution None None O
of None None O
the None None O
angioinhibitory None None O
epitope None None O
( None None O
the None None O
34 None None O
- None None O
mer None None O
) None None O
and None None O
designed None None O
three None None O
peptides None None O
covering None None O
its None None O
COOH None None O
terminus None None O
, None None O
P14 None None O
, None None O
P18 None None O
, None None O
and None None O
P23 None None O
. None None O

We None None O
analyzed None None O
their None None O
ability None None O
to None None O
block None None O
endothelial None None O
cell None None O
chemotaxis None None O
and None None O
induce None None O
apoptosis None None O
in None None O
vitro None None O
and None None O
their None None O
antiangiogenic None None O
activity None None O
in None None O
vivo None None O
. None None O

The None None O
selected None None O
peptide None None O
was None None O
tested None None O
for None None O
the None None O
antitumor None None O
activity None None O
against None None O
mildly None None O
aggressive None None O
xenografted None None O
prostate None None O
carcinoma None None O
and None None O
highly None None O
aggressive None None O
renal None None O
cell None None O
carcinoma None None O
. None None O

To None None O
verify None None O
that None None O
P18 None None O
acts None None O
in None None O
the None None O
same None None O
manner None None O
as None None O
PEDF None None O
, None None O
we None None O
used None None O
immunohistochemistry None None O
to None None O
measure None None O
PEDF None None O
targets None None O
, None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
2 None None O
, None None O
and None None O
CD95 None None O
ligand None None O
expression None None O
in None None O
P18 None None O
- None None O
treated None None O
vasculature None None O
. None None O

RESULTS None None O
: None None O
P14 None None O
and None None O
P18 None None O
blocked None None O
endothelial None None O
cell None None O
chemotaxis None None O
; None None O
P18 None None O
and None None O
P23 None None O
induced None None O
apoptosis None None O
. None None O

P18 None None O
showed None None O
the None None O
highest None None O
IC50 None None O
and None None O
blocked None None O
angiogenesis None None O
in None None O
vivo None None O
: None None O
P23 None None O
was None None O
inactive None None O
and None None O
P14 None None O
was None None O
proangiogenic None None O
. None None O

P18 None None O
increased None None O
the None None O
production None None O
of None None O
CD95 None None O
ligand None None O
and None None O
reduced None None O
the None None O
expression None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
2 None None O
by None None O
the None None O
endothelial None None O
cells None None O
in None None O
vivo None None O
. None None O

In None None O
tumor None None O
studies None None O
, None None O
P18 None None O
was None None O
more None None O
effective None None O
in None None O
blocking None None O
the None None O
angiogenesis None None O
and None None O
growth None None O
of None None O
the None None O
prostate None None O
cancer None None O
than None None O
parental None None O
34 None None O
- None None O
mer None None O
; None None O
in None None O
the None None O
renal None None O
cell None None O
carcinoma None None O
, None None O
P18 None None O
strongly None None O
decreased None None O
angiogenesis None None O
and None None O
halted None None O
the None None O
progression None None O
of None None O
established None None O
tumors None None O
. None None O

CONCLUSIONS None None O
: None None O
P18 None None O
is None None O
a None None O
novel None None O
and None None O
potent None None O
antiangiogenic None None O
biotherapeutic None None O
agent None None O
that None None O
has None None O
potential None None O
to None None O
be None None O
developed None None O
for None None O
the None None O
treatment None None O
of None None O
prostate None None O
and None None O
renal None None O
cancer None None O
. None None O

Observed None None O
type None None O
I None None O
error None None O
for None None O
datasets None None O
simulated None None O
under None None O
the None None O
null None None O
hypothesis None None O

[ None None O
Study None None O
on None None O
the None None O
expression None None O
of None None O
angiogenesis None None O
and None None O
spontaneous None None O
apoptosis None None O
and None None O
their None None O
relevance None None O
in None None O
laryngeal None None O
squamous None None O
cell None None O
carcinoma None None O
] None None O

OBJECTIVE None None O
: None None O
To None None O
investigate None None O
the None None O
relationship None None O
among None None O
angiogenesis None None O
, None None O
spontaneous None None O
apoptosis None None O
and None None O
clinicopathological None None O
parameters None None O
in None None O
laryngeal None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
LSCC None None O
) None None O
. None None O

METHOD None None O
: None None O
The None None O
intratumor None None O
microvessel None None O
density None None O
( None None O
IMVD None None O
) None None O
, None None O
apoptotic None None O
index None None O
( None None O
AI None None O
) None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
expression None None O
were None None O
detected None None O
by None None O
immunohistochemistry None None O
SABC None None O
and None None O
terminal None None O
uridine None None O
deoxynucleotidyl None None O
transferase None None O
mediated None None O
nick None None O
end None None O
labeling None None O
( None None O
TUNEL None None O
) None None O
methods None None O
in34 None None O
LSCC None None O
patients None None O
. None None O

RESULT None None O
: None None O
The None None O
average None None O
IMVD None None O
was None None O
( None None O
21 None None O
. None None O
50 None None O
+ None None O
/ None None O
- None None O
8 None None O
. None None O
87 None None O
) None None O
, None None O
and None None O
median None None O
of None None O
AI None None O
was None None O
1 None None O
. None None O
15 None None O
% None None O
. None None O

The None None O
average None None O
IMVD None None O
in None None O
positive None None O
and None None O
negative None None O
cervical None None O
lymphatic None None O
metastasis None None O
was None None O
( None None O
26 None None O
. None None O
33 None None O
+ None None O
/ None None O
- None None O
9 None None O
. None None O
70 None None O
) None None O
and None None O
( None None O
17 None None O
. None None O
68 None None O
+ None None O
/ None None O
- None None O
6 None None O
. None None O
06 None None O
) None None O
respectively None None O
, None None O
and None None O
the None None O
IMVD None None O
with None None O
positive None None O
lymphatic None None O
metastasis None None O
tumors None None O
was None None O
statistical None None O
significantly None None O
higher None None O
than None None O
those None None O
with None None O
negative None None O
cervical None None O
lymphatic None None O
metastasis None None O
tumors None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

The None None O
average None None O
IMVD None None O
had None None O
statistical None None O
difference None None O
in None None O
histological None None O
grading None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
) None None O
, None None O
and None None O
analysis None None O
by None None O
one None None O
to None None O
one None None O
, None None O
the None None O
average None None O
IMVD None None O
had None None O
statistical None None O
difference None None O
between None None O
high None None O
and None None O
median None None O
grading None None O
. None None O

Expression None None O
of None None O
VEGF None None O
had None None O
a None None O
significantly None None O
positive None None O
correlation None None O
with None None O
IMVD None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
51 None None O
, None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

Statistical None None O
analysis None None O
revealed None None O
a None None O
significantly None None O
inverse None None O
correlation None None O
between None None O
AI None None O
and None None O
IMVD None None O
( None None O
r None None O
= None None O
- None None O
0 None None O
. None None O
53 None None O
, None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

We None None O
failed None None O
to None None O
find None None O
the None None O
statistical None None O
difference None None O
between None None O
IMVD None None O
and None None O
tumor None None O
T None None O
- None None O
stage None None O
in None None O
LSCC None None O
. None None O

CONCLUSION None None O
: None None O
IMVD None None O
may None None O
be None None O
an None None O
important None None O
indicator None None O
to None None O
predict None None O
cervical None None O
lymphatic None None O
metastasis None None O
in None None O
LSCC None None O
. None None O

VEGF None None O
might None None O
be None None O
an None None O
important None None O
angiogenic None None O
factor None None O
, None None O
and None None O
could None None O
promote None None O
tumor None None O
angiogenesis None None O
in None None O
LSCC None None O
. None None O

Tumor None None O
angiogenesis None None O
might None None O
contribute None None O
to None None O
tumor None None O
malignant None None O
progression None None O
by None None O
inhibiting None None O
spontaneous None None O
apoptosis None None O
in None None O
LSCC None None O
. None None O

ERK None None O
signaling None None O
is None None O
involved None None O
in None None O
decreasing None None O
BDNF None None O
- None None O
induced None None O
gene None None O
activity None None O
via None None O
Eph None None O
receptors None None O

Data None None O
provided None None O
so None None O
far None None O
suggest None None O
that None None O
ephrin None None O
- None None O
A5 None None O
might None None O
counteract None None O
BDNF None None O
- None None O
mediated None None O
gene None None O
expression None None O
and None None O
growth None None O
cone None None O
responses None None O
via None None O
decreasing None None O
ERK None None O
activity None None O
and None None O
nuclear None None O
localization None None O
( None None O
Figs None None O
. None None O
2 None None O
and None None O
3 None None O
) None None O
. None None O

To None None O
test None None O
this None None O
hypothesis None None O
more None None O
directly None None O
, None None O
we None None O
analyzed None None O
whether None None O
Eph None None O
forward None None O
signaling None None O
can None None O
still None None O
suppress None None O
BDNF None None O
- None None O
stimulated None None O
IEG None None O
induction None None O
and None None O
growth None None O
cone None None O
collapse None None O
when None None O
ERK None None O
kinase None None O
activity None None O
was None None O
experimentally None None O
raised None None O
. None None O

For None None O
this None None O
, None None O
ERK None None O
activity None None O
was None None O
elevated None None O
by None None O
expressing None None O
constitutively None None O
- None None O
active None None O
MEK1 None None O
( None None O
CA None None O
- None None O
MEK1 None None O
) None None O
, None None O
an None None O
ERK None None O
upstream None None O
activator None None O
, None None O
in None None O
cortical None None O
neurons None None O
( None None O
Fig None None O
. None None O
S3 None None O
) None None O
. None None O

Subsequently None None O
, None None O
neurons None None O
were None None O
subjected None None O
to None None O
either None None O
an None None O
ephrin None None O
- None None O
A5 None None O
mediated None None O
growth None None O
cone None None O
collapse None None O
assay None None O
( None None O
Fig None None O
. None None O
5 None None O
) None None O
or None None O
stimulated None None O
with None None O
guidance None None O
cues None None O
for None None O
20 None None O
minutes None None O
and None None O
IEG None None O
mRNA None None O
levels None None O
were None None O
quantified None None O
via None None O
qRT None None O
- None None O
PCR None None O
( None None O
Fig None None O
. None None O
6 None None O
) None None O
. None None O

10 None None O
. None None O
1371 None None O
/ None None O
journal None None O
. None None O
pone None None O
. None None O
0026089 None None O
. None None O
g005 None None O
Figure None None O
5 None None O

Constitutively None None O
- None None O
active None None O
MEK1 None None O
blocks None None O
ephrin None None O
- None None O
A5 None None O
mediated None None O
growth None None O
cone None None O
collapse None None O
. None None O

Wild None None O
- None None O
type None None O
neurons None None O
were None None O
electroporated None None O
with None None O
vectors None None O
expressing None None O
GFP None None O
( None None O
control None None O
; None None O
A None None O
, None None O
C None None O
, None None O
E None None O
) None None O
or None None O
expressing None None O
a None None O
FLAG None None O
- None None O
tagged None None O
constitutively None None O
- None None O
active None None O
MEK1 None None O
( None None O
CA None None O
- None None O
MEK1 None None O
; None None O
B None None O
, None None O
D None None O
, None None O
F None None O
) None None O
. None None O

Neurons None None O
were None None O
treated None None O
with None None O
ephrin None None O
- None None O
A5 None None O
- None None O
Fc None None O
for None None O
30 None None O
min None None O
followed None None O
by None None O
visualization None None O
of None None O
GFP None None O
( None None O
A None None O
, None None O
C None None O
, None None O
E None None O
) None None O
or None None O
CA None None O
- None None O
MEK None None O
- None None O
1 None None O
( None None O
green None None O
in None None O
B None None O
, None None O
D None None O
, None None O
F None None O
) None None O
, None None O
F None None O
- None None O
actin None None O
and None None O
betaIII None None O
tubulin None None O
. None None O

( None None O
A None None O
, None None O
B None None O
) None None O
Overexpression None None O
of None None O
CA None None O
- None None O
MEK1 None None O
( None None O
B None None O
) None None O
reduces None None O
mean None None O
neurite None None O
length None None O
compared None None O
to None None O
a None None O
control None None O
GFP None None O
- None None O
expressing None None O
neuron None None O
( None None O
A None None O
) None None O
. None None O

( None None O
C None None O
- None None O
F None None O
) None None O
A None None O
control None None O
growth None None O
cone None None O
without None None O
ephrin None None O
- None None O
A5 None None O
application None None O
( None None O
C None None O
) None None O
typically None None O
protrudes None None O
multiple None None O
filopodia None None O
( None None O
arrow None None O
) None None O
. None None O

CA None None O
- None None O
MEK None None O
- None None O
1 None None O
expressing None None O
growth None None O
cones None None O
( None None O
D None None O
) None None O
were None None O
indistinguishable None None O
from None None O
a None None O
GFP None None O
- None None O
expressing None None O
growth None None O
cone None None O
. None None O

Note None None O
that None None O
CA None None O
- None None O
MEK1 None None O
was None None O
expressed None None O
in None None O
a None None O
dot None None O
- None None O
like None None O
pattern None None O
in None None O
the None None O
growth None None O
cone None None O
( None None O
arrowheads None None O
in None None O
D None None O
and None None O
F None None O
) None None O
. None None O

Upon None None O
ephrin None None O
- None None O
A5 None None O
application None None O
, None None O
a None None O
control None None O
growth None None O
cone None None O
( None None O
E None None O
) None None O
collapsed None None O
resulting None None O
in None None O
only None None O
few None None O
filopodia None None O
. None None O

In None None O
contrast None None O
, None None O
a None None O
CA None None O
- None None O
MEK1 None None O
expressing None None O
growth None None O
cone None None O
( None None O
F None None O
) None None O
was None None O
only None None O
partially None None O
collapsed None None O
and None None O
many None None O
filopodia None None O
structures None None O
were None None O
preserved None None O
after None None O
ephrin None None O
- None None O
A5 None None O
induction None None O
. None None O

( None None O
G None None O
) None None O
Quantification None None O
of None None O
average None None O
neurite None None O
length None None O
. None None O

( None None O
H None None O
, None None O
I None None O
) None None O
Quantification None None O
of None None O
growth None None O
cone None None O
area None None O
( None None O
H None None O
) None None O
and None None O
filopodia None None O
number None None O
/ None None O
growth None None O
cone None None O
( None None O
I None None O
) None None O
in None None O
the None None O
four None None O
conditions None None O
. None None O

Ephrin None None O
- None None O
A5 None None O
induces None None O
a None None O
growth None None O
cone None None O
collapse None None O
, None None O
resulting None None O
in None None O
reduced None None O
growth None None O
cone None None O
area None None O
and None None O
filopodia None None O
number None None O
in None None O
GFP None None O
but None None O
not None None O
CA None None O
- None None O
MEK1 None None O
expressing None None O
neurons None None O
. None None O

Scale None None O
- None None O
bar None None O
( None None O
A None None O
, None None O
B None None O
) None None O
= None None O
10 None None O
microm None None O
; None None O
( None None O
C None None O
- None None O
F None None O
) None None O
= None None O
2 None None O
microm None None O
. None None O

10 None None O
. None None O
1371 None None O
/ None None O
journal None None O
. None None O
pone None None O
. None None O
0026089 None None O
. None None O
g006 None None O
Figure None None O
6 None None O

Ephrin None None O
- None None O
A5 None None O
suppresses None None O
BDNF None None O
- None None O
induced None None O
IEG None None O
responses None None O
via None None O
MAP None None O
kinase None None O
signaling None None O
. None None O

Wild None None O
- None None O
type None None O
cortical None None O
neurons None None O
, None None O
mock None None O
- None None O
electroporated None None O
( None None O
black None None O
bars None None O
) None None O
or None None O
with None None O
a None None O
vector None None O
expressing None None O
constitutively None None O
- None None O
active None None O
MEK1 None None O
( None None O
white None None O
bars None None O
) None None O
, None None O
were None None O
treated None None O
with None None O
guidance None None O
cues None None O
for None None O
20 None None O
minutes None None O
as None None O
depicted None None O
, None None O
followed None None O
by None None O
mRNA None None O
quantification None None O
. None None O

In None None O
mock None None O
- None None O
electroporated None None O
neurons None None O
, None None O
BDNF None None O
induced None None O
an None None O
IEG None None O
response None None O
of None None O
c None None O
- None None O
fos None None O
( None None O
A None None O
) None None O
, None None O
Egr1 None None O
( None None O
B None None O
) None None O
, None None O
Egr2 None None O
( None None O
C None None O
) None None O
and None None O
Arc None None O
( None None O
D None None O
) None None O
. None None O

Co None None O
- None None O
application None None O
of None None O
ephrin None None O
- None None O
A5 None None O
and None None O
BDNF None None O
reduced None None O
mRNA None None O
levels None None O
of None None O
all None None O
four None None O
IEGs None None O
in None None O
mock None None O
- None None O
electroporated None None O
neurons None None O
( None None O
A None None O
- None None O
D None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
expression None None O
of None None O
constitutively None None O
- None None O
active None None O
MEK1 None None O
prevented None None O
Eph None None O
forward None None O
signaling None None O
from None None O
suppressing None None O
BDNF None None O
- None None O
evoked None None O
IEG None None O
responses None None O
. None None O

This None None O
was None None O
most None None O
evident None None O
for None None O
the None None O
IEGs None None O
Egr1 None None O
( None None O
B None None O
) None None O
and None None O
Egr2 None None O
( None None O
C None None O
) None None O
. None None O

First None None O
of None None O
all None None O
, None None O
we None None O
analyzed None None O
the None None O
impact None None O
of None None O
CA None None O
- None None O
MEK1 None None O
on None None O
neurite None None O
outgrowth None None O
and None None O
ephrin None None O
- None None O
A5 None None O
mediated None None O
growth None None O
cone None None O
responses None None O
( None None O
Fig None None O
. None None O
5 None None O
) None None O
. None None O

The None None O
average None None O
neurite None None O
length None None O
of None None O
neurons None None O
overexpressing None None O
CA None None O
- None None O
MEK1 None None O
( None None O
Fig None None O
. None None O
5B None None O
) None None O
was None None O
clearly None None O
reduced None None O
compared None None O
to None None O
control None None O
GFP None None O
expressing None None O
neurons None None O
( None None O
Fig None None O
. None None O
5A None None O
; None None O
see None None O
quantification None None O
in None None O
( None None O
G None None O
) None None O
) None None O
. None None O

Growth None None O
cones None None O
of None None O
GFP None None O
( None None O
C None None O
) None None O
and None None O
CA None None O
- None None O
MEK1 None None O
expressing None None O
neurons None None O
were None None O
similar None None O
and None None O
protruded None None O
many None None O
filopodia None None O
( None None O
arrows None None O
in None None O
Fig None None O
. None None O
5C None None O
- None None O
F None None O
) None None O
. None None O

CA None None O
- None None O
MEK1 None None O
expression None None O
in None None O
growth None None O
cones None None O
was None None O
confined None None O
to None None O
individual None None O
dot None None O
- None None O
like None None O
structures None None O
( None None O
arrowheads None None O
in None None O
Fig None None O
. None None O
5D None None O
, None None O
F None None O
) None None O
. None None O

Ephrin None None O
- None None O
A5 None None O
application None None O
on None None O
a None None O
GFP None None O
expressing None None O
control None None O
growth None None O
cone None None O
( None None O
Fig None None O
. None None O
5E None None O
) None None O
resulted None None O
in None None O
a None None O
growth None None O
cone None None O
collapse None None O
as None None O
revealed None None O
by None None O
reduced None None O
overall None None O
growth None None O
cone None None O
area None None O
and None None O
filopodia None None O
number None None O
( None None O
quantified None None O
in None None O
Fig None None O
. None None O
5H None None O
, None None O
I None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
in None None O
neurons None None O
overexpressing None None O
CA None None O
- None None O
MEK1 None None O
( None None O
Fig None None O
. None None O
5F None None O
) None None O
, None None O
ephrin None None O
- None None O
A5 None None O
induced None None O
only None None O
a None None O
partial None None O
growth None None O
cone None None O
collapse None None O
. None None O

Thus None None O
, None None O
growth None None O
cone None None O
area None None O
and None None O
filopodia None None O
number None None O
were None None O
not None None O
reduced None None O
( None None O
see None None O
Fig None None O
. None None O
5H None None O
, None None O
I None None O
) None None O
. None None O

This None None O
result None None O
suggests None None O
that None None O
an None None O
ephrin None None O
- None None O
A5 None None O
induced None None O
signaling None None O
cascade None None O
targets None None O
MAP None None O
kinase None None O
signaling None None O
to None None O
exert None None O
a None None O
full None None O
growth None None O
cone None None O
collapse None None O
. None None O

This None None O
result None None O
is None None O
in None None O
contrast None None O
to None None O
a None None O
recent None None O
report None None O
[ None None O
46 None None O
] None None O
which None None O
excluded None None O
ERK None None O
signaling None None O
downstream None None O
of None None O
an None None O
ephrin None None O
- None None O
A5 None None O
mediated None None O
growth None None O
cone None None O
collapse None None O
. None None O

Next None None O
, None None O
we None None O
tested None None O
whether None None O
ephrin None None O
- None None O
A5 None None O
signaling None None O
suppresses None None O
ERK None None O
kinase None None O
signaling None None O
also None None O
to None None O
interfere None None O
with None None O
BDNF None None O
- None None O
mediated None None O
gene None None O
expression None None O
( None None O
Fig None None O
. None None O
6 None None O
) None None O
. None None O

In None None O
agreement None None O
with None None O
previous None None O
results None None O
( None None O
Fig None None O
. None None O
4 None None O
) None None O
, None None O
in None None O
mock None None O
- None None O
electroporated None None O
neurons None None O
, None None O
ephrin None None O
- None None O
A5 None None O
incubation None None O
reduced None None O
the None None O
BDNF None None O
- None None O
mediated None None O
up None None O
- None None O
regulation None None O
of None None O
c None None O
- None None O
fos None None O
( None None O
Fig None None O
. None None O
6A None None O
) None None O
, None None O
Egr1 None None O
( None None O
Fig None None O
. None None O
6B None None O
) None None O
, None None O
Egr2 None None O
( None None O
Fig None None O
. None None O
6C None None O
) None None O
and None None O
Arc None None O
( None None O
Fig None None O
. None None O
6D None None O
) None None O
mRNA None None O
. None None O

In None None O
contrast None None O
, None None O
in None None O
neurons None None O
over None None O
- None None O
expressing None None O
CA None None O
- None None O
MEK1 None None O
, None None O
ephrin None None O
- None None O
A5 None None O
could None None O
not None None O
suppress None None O
BDNF None None O
- None None O
induced None None O
IEG None None O
responses None None O
to None None O
the None None O
same None None O
degree None None O
. None None O

Particularly None None O
Egr1 None None O
( None None O
Fig None None O
. None None O
6B None None O
) None None O
and None None O
Egr2 None None O
( None None O
Fig None None O
. None None O
6C None None O
) None None O
mRNA None None O
levels None None O
were None None O
almost None None O
identical None None O
when None None O
comparing None None O
neurons None None O
treated None None O
with None None O
BDNF None None O
alone None None O
and None None O
neurons None None O
with None None O
BDNF None None O
and None None O
ephrin None None O
- None None O
A5 None None O
together None None O
. None None O

Thus None None O
, None None O
ephrin None None O
- None None O
A5 None None O
represses None None O
gene None None O
activity None None O
elicited None None O
by None None O
BDNF None None O
at None None O
least None None O
in None None O
part None None O
via None None O
MAP None None O
kinases None None O
. None None O

Besides None None O
IEGs None None O
, None None O
we None None O
inspected None None O
the None None O
influence None None O
of None None O
both None None O
guidance None None O
cues None None O
on None None O
cytoskeletal None None O
genes None None O
, None None O
whose None None O
gene None None O
products None None O
might None None O
modulate None None O
cytoskeletal None None O
dynamics None None O
evoked None None O
by None None O
ephrin None None O
- None None O
As None None O
and None None O
/ None None O
or None None O
neurotrophins None None O
( None None O
Fig None None O
. None None O
S4 None None O
) None None O
. None None O

Therefore None None O
, None None O
the None None O
filamentous None None O
actin None None O
( None None O
F None None O
- None None O
actin None None O
) None None O
stabilizing None None O
tropomyosins None None O
( None None O
Tpm1 None None O
and None None O
Tpm2 None None O
) None None O
, None None O
the None None O
F None None O
- None None O
actin None None O
cross None None O
- None None O
linker None None O
alpha None None O
- None None O
actinin None None O
1 None None O
( None None O
Actn1 None None O
) None None O
and None None O
the None None O
motor None None O
protein None None O
dynein None None O
light None None O
chain None None O
1 None None O
( None None O
Dnal1 None None O
) None None O
were None None O
analyzed None None O
. None None O

mRNA None None O
levels None None O
of None None O
other None None O
cytoskeletal None None O
genes None None O
were None None O
not None None O
altered None None O
by None None O
any None None O
of None None O
the None None O
guidance None None O
cues None None O
( None None O
i None None O
. None None O
e None None O
. None None O
cofilin None None O
, None None O
filamin None None O
A None None O
, None None O
mena None None O
, None None O
vinculin None None O
and None None O
smooth None None O
muscle None None O
actin None None O
; None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

Short None None O
- None None O
term None None O
stimulation None None O
with None None O
guidance None None O
cues None None O
did None None O
not None None O
result None None O
in None None O
major None None O
alterations None None O
of None None O
cytoskeletal None None O
mRNA None None O
levels None None O
except None None O
for None None O
upregulation None None O
of None None O
Tpm1 None None O
by None None O
ephrin None None O
- None None O
A5 None None O
( None None O
Fig None None O
. None None O
S4A None None O
) None None O
. None None O

At None None O
16h None None O
of None None O
incubation None None O
, None None O
both None None O
tropomyosin None None O
genes None None O
were None None O
induced None None O
by None None O
BDNF None None O
and None None O
ephrin None None O
- None None O
A5 None None O
alone None None O
and None None O
both None None O
together None None O
( None None O
Fig None None O
. None None O
S4B None None O
, None None O
D None None O
) None None O
. None None O

Actn1 None None O
levels None None O
were None None O
induced None None O
by None None O
individual None None O
application None None O
of None None O
ephrin None None O
- None None O
A5 None None O
and None None O
BDNF None None O
and None None O
by None None O
co None None O
- None None O
application None None O
of None None O
both None None O
( None None O
Fig None None O
. None None O
S4F None None O
) None None O
. None None O

A None None O
similar None None O
profile None None O
was None None O
observed None None O
for None None O
the None None O
dynein None None O
light None None O
chain None None O
( None None O
Fig None None O
. None None O
S4H None None O
) None None O
. None None O

Taken None None O
together None None O
, None None O
cytoskeletal None None O
gene None None O
expression None None O
was None None O
modulated None None O
by None None O
ephrin None None O
- None None O
A5 None None O
and None None O
BDNF None None O
. None None O

In None None O
contrast None None O
to None None O
the None None O
antagonistic None None O
impact None None O
on None None O
the None None O
IEG None None O
gene None None O
response None None O
( None None O
Figs None None O
. None None O
4 None None O
and None None O
6 None None O
) None None O
, None None O
ephrin None None O
- None None O
A5 None None O
and None None O
BDNF None None O
resulted None None O
in None None O
rather None None O
synergistic None None O
action None None O
on None None O
cytoskeletal None None O
gene None None O
expression None None O
. None None O

This None None O
difference None None O
might None None O
be None None O
due None None O
to None None O
short None None O
- None None O
term None None O
( None None O
i None None O
. None None O
e None None O
. None None O
20 None None O
minutes None None O
) None None O
vs None None O
. None None O
long None None O
- None None O
term None None O
( None None O
i None None O
. None None O
e None None O
. None None O
16h None None O
) None None O
exposure None None O
of None None O
both None None O
guidance None None O
cues None None O
in None None O
the None None O
IEG None None O
and None None O
cytoskeletal None None O
gene None None O
response None None O
, None None O
respectively None None O
. None None O

Results None None O

Long None None O
- None None O
term None None O
immunosuppression None None O
in None None O
burned None None O
patients None None O
assessed None None O
by None None O
in None None O
vitro None None O
neutrophil None None O
oxidative None None O
burst None None O
( None None O
Phagoburst None None O
) None None O
. None None O

OBJECTIVE None None O
: None None O

To None None O
assess None None O
the None None O
duration None None O
and None None O
magnitude None None O
of None None O
immunosuppression None None O
induced None None O
by None None O
burns None None O
as None None O
measured None None O
by None None O
the None None O
neutrophil None None O
oxidative None None O
burst None None O
in None None O
vitro None None O
. None None O

DESIGN None None O
: None None O

Prospective None None O
exploratory None None O
cohort None None O
study None None O
. None None O

SETTING None None O
: None None O

Tertiary None None O
referral None None O
unit None None O
, None None O
University None None O
Hospital None None O
, None None O
Linkoping None None O
, None None O
Sweden None None O
( None None O
National None None O
Burn None None O
Unit None None O
) None None O
. None None O

PATIENTS None None O
AND None None O
HEALTHY None None O
VOLUNTEERS None None O
( None None O
CONTROLS None None O
) None None O
: None None O
Twenty None None O
- None None O
eight None None O
subjects None None O
consecutively None None O
admitted None None O
to None None O
the None None O
Burn None None O
Unit None None O
. None None O

The None None O
mean None None O
total None None O
burn None None O
surface None None O
area None None O
( None None O
TBSA None None O
% None None O
) None None O
was None None O
36 None None O
( None None O
range None None O
13 None None O
- None None O
87 None None O
) None None O
and None None O
mean None None O
age None None O
44 None None O
years None None O
( None None O
range None None O
14 None None O
- None None O
89 None None O
) None None O
. None None O

Patients None None O
' None None O
data None None O
were None None O
collected None None O
prospectively None None O
in None None O
the None None O
burn None None O
unit None None O
, None None O
which None None O
also None None O
included None None O
sequential None None O
organ None None O
failure None None O
assessment None None O
( None None O
SOFA None None O
) None None O
score None None O
. None None O

INTERVENTIONS None None O
: None None O

None None None O
. None None O

MEASUREMENTS None None O
AND None None O
RESULTS None None O
: None None O

To None None O
assess None None O
the None None O
changes None None O
in None None O
the None None O
oxidative None None O
capacity None None O
of None None O
neutrophils None None O
after None None O
the None None O
burn None None O
, None None O
blood None None O
samples None None O
for None None O
the None None O
Phagoburst None None O
analysis None None O
were None None O
taken None None O
on None None O
admission None None O
and None None O
at None None O
least None None O
once None None O
every None None O
second None None O
week None None O
for None None O
the None None O
duration None None O
of None None O
stay None None O
in None None O
hospital None None O
and None None O
thereafter None None O
monthly None None O
up None None O
to None None O
12 None None O
months None None O
after None None O
the None None O
burn None None O
. None None O

Neutrophils None None O
were None None O
stimulated None None O
in None None O
vitro None None O
by None None O
Escherichia None None O
coli None None O
, None None O
phorbol None None O
12 None None O
- None None O
phorbol None None O
myristate None None O
13 None None O
- None None O
acetate None None O
( None None O
PMA None None O
) None None O
, None None O
and None None O
peptide None None O
N None None O
- None None O
formyl None None O
- None None O
Met None None O
- None None O
Leu None None O
- None None O
Phe None None O
( None None O
fMLP None None O
) None None O
. None None O

Oxidative None None O
burst None None O
was None None O
measured None None O
by None None O
flow None None O
cytometry None None O
. None None O

Oxidative None None O
capacity None None O
of None None O
the None None O
neutrophils None None O
decreased None None O
similarly None None O
for None None O
all None None O
three None None O
stimulants None None O
: None None O
there None None O
was None None O
a None None O
pathological None None O
decrease None None O
shortly None None O
after None None O
admission None None O
, None None O
with None None O
the None None O
lowest None None O
value None None O
occurring None None O
between None None O
days None None O
7 None None O
and None None O
10 None None O
, None None O
followed None None O
by None None O
a None None O
gradual None None O
recovery None None O
during None None O
the None None O
ensuing None None O
months None None O
. None None O

Full None None O
recovery None None O
( None None O
to None None O
the None None O
values None None O
of None None O
the None None O
controls None None O
) None None O
was None None O
seen None None O
first None None O
3 None None O
. None None O
5 None None O
months None None O
after None None O
the None None O
burn None None O
. None None O

Using None None O
multiple None None O
regression None None O
, None None O
we None None O
found None None O
that None None O
only None None O
age None None O
and None None O
time None None O
since None None O
the None None O
burn None None O
significantly None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
affected None None O
the None None O
oxidative None None O
burst None None O
. None None O

White None None O
cell None None O
count None None O
( None None O
WCC None None O
) None None O
and None None O
C None None O
- None None O
reactive None None O
protein None None O
( None None O
CRP None None O
) None None O
values None None O
returned None None O
to None None O
reference None None O
ranges None None O
long None None O
before None None O
the None None O
oxidative None None O
burst None None O
. None None O

CONCLUSIONS None None O
: None None O

This None None O
study None None O
provides None None O
evidence None None O
that None None O
immunosuppression None None O
in None None O
those None None O
injured None None O
by None None O
burns None None O
, None None O
as None None O
assessed None None O
by None None O
the None None O
in None None O
vitro None None O
oxidative None None O
burst None None O
of None None O
neutrophils None None O
, None None O
remains None None O
long None None O
after None None O
the None None O
event None None O
of None None O
the None None O
burn None None O
( None None O
up None None O
to None None O
3 None None O
. None None O
5 None None O
months None None O
after None None O
burn None None O
) None None O
. None None O

Absence None None O
of None None O
correlations None None O
to None None O
TBSA None None O
% None None O
, None None O
FTB None None O
% None None O
, None None O
blood None None O
transfusion None None O
, None None O
opiates None None O
provided None None O
, None None O
and None None O
multiple None None O
organ None None O
failure None None O
score None None O
and None None O
laboratory None None O
infection None None O
variables None None O
together None None O
with None None O
the None None O
finding None None O
that None None O
decreased None None O
oxidative None None O
burst None None O
was None None O
uniform None None O
after None None O
the None None O
injury None None O
, None None O
suggesting None None O
that None None O
this None None O
immunosuppression None None O
is None None O
primarily None None O
due None None O
to None None O
the None None O
general None None O
metabolic None None O
response None None O
rather None None O
than None None O
recurring None None O
infections None None O
. None None O

[ None None O
A None None O
case None None O
report None None O
of None None O
advanced None None O
gastric None None O
cancer None None O
responding None None O
to None None O
TS None None O
- None None O
1 None None O
, None None O
a None None O
novel None None O
oral None None O
fluorouracil None None O
derivative None None O
] None None O
. None None O

TS None None O
- None None O
1 None None O
is None None O
a None None O
new None None O
, None None O
oral None None O
anticancer None None O
agent None None O
composed None None O
of None None O
two None None O
modulators None None O
, None None O
gimeracil None None O
( None None O
CDHP None None O
) None None O
and None None O
oteracil None None O
potassium None None O
( None None O
Oxo None None O
) None None O
are None None O
mixed None None O
with None None O
tegafur None None O
in None None O
a None None O
ratio None None O
of None None O
1 None None O
: None None O
0 None None O
. None None O
4 None None O
: None None O
1 None None O
. None None O

We None None O
report None None O
one None None O
case None None O
of None None O
advanced None None O
gastric None None O
cancer None None O
with None None O
lung None None O
and None None O
lymph None None O
node None None O
metastases None None O
that None None O
completely None None O
responded None None O
to None None O
TS None None O
- None None O
1 None None O
. None None O

A None None O
71 None None O
- None None O
year None None O
- None None O
old None None O
woman None None O
was None None O
admitted None None O
to None None O
our None None O
hospital None None O
because None None O
of None None O
breathlessness None None O
. None None O

A None None O
diagnosis None None O
of None None O
advanced None None O
gastric None None O
cancer None None O
with None None O
extensive None None O
lymph None None O
node None None O
metastases None None O
and None None O
multiple None None O
pulmonary None None O
metastases None None O
was None None O
made None None O
. None None O

One None None O
hundred None None O
mg None None O
/ None None O
body None None O
/ None None O
day None None O
of None None O
TS None None O
- None None O
1 None None O
was None None O
orally None None O
administrated None None O
for None None O
4 None None O
weeks None None O
. None None O

A None None O
partial None None O
response None None O
( None None O
PR None None O
) None None O
was None None O
obtained None None O
after None None O
the None None O
first None None O
course None None O
with None None O
regression None None O
of None None O
multiple None None O
pulmonary None None O
metastases None None O
. None None O

After None None O
1 None None O
drug None None O
- None None O
free None None O
week None None O
, None None O
the None None O
second None None O
course None None O
was None None O
administered None None O
with None None O
120 None None O
mg None None O
/ None None O
body None None O
/ None None O
day None None O
of None None O
TS None None O
- None None O
1 None None O
for None None O
4 None None O
weeks None None O
. None None O

After None None O
two None None O
courses None None O
, None None O
the None None O
primary None None O
tumor None None O
was None None O
reduced None None O
to None None O
an None None O
ulcer None None O
scar None None O
with None None O
pathological None None O
confirmation None None O
of None None O
a None None O
complete None None O
disappearance None None O
of None None O
the None None O
cancer None None O
tissue None None O
. None None O

Moreover None None O
, None None O
computed None None O
tomography None None O
( None None O
CT None None O
) None None O
showed None None O
a None None O
complete None None O
regression None None O
of None None O
the None None O
extensive None None O
lymph None None O
node None None O
and None None O
diffuse None None O
lung None None O
metastases None None O
, None None O
for None None O
a None None O
complete None None O
response None None O
( None None O
CR None None O
) None None O
. None None O

The None None O
serum None None O
level None None O
of None None O
CEA None None O
was None None O
reduced None None O
from None None O
172 None None O
. None None O
7 None None O
ng None None O
/ None None O
ml None None O
to None None O
8 None None O
. None None O
1 None None O
ng None None O
/ None None O
ml None None O
after None None O
TS None None O
- None None O
1 None None O
treatment None None O
. None None O

As None None O
for None None O
adverse None None O
events None None O
, None None O
only None None O
pigmentation None None O
of None None O
the None None O
skin None None O
and None None O
Grade None None O
2 None None O
oral None None O
aphta None None O
were None None O
observed None None O
. None None O

T140 None None O
analogs None None O
as None None O
CXCR4 None None O
antagonists None None O
identified None None O
as None None O
anti None None O
- None None O
metastatic None None O
agents None None O
in None None O
the None None O
treatment None None O
of None None O
breast None None O
cancer None None O
. None None O

A None None O
chemokine None None O
receptor None None O
, None None O
CXCR4 None None O
, None None O
and None None O
its None None O
endogenous None None O
ligand None None O
, None None O
stromal None None O
cell None None O
- None None O
derived None None O
factor None None O
- None None O
1 None None O
( None None O
SDF None None O
- None None O
1 None None O
) None None O
, None None O
have None None O
been None None O
recognized None None O
to None None O
be None None O
involved None None O
in None None O
the None None O
metastasis None None O
of None None O
several None None O
types None None O
of None None O
cancers None None O
. None None O

T140 None None O
analogs None None O
are None None O
peptidic None None O
CXCR4 None None O
antagonists None None O
composed None None O
of None None O
14 None None O
amino None None O
acid None None O
residues None None O
that None None O
were None None O
previously None None O
developed None None O
as None None O
anti None None O
- None None O
HIV None None O
agents None None O
having None None O
inhibitory None None O
activity None None O
against None None O
HIV None None O
- None None O
entry None None O
through None None O
its None None O
co None None O
- None None O
receptor None None O
, None None O
CXCR4 None None O
. None None O

Herein None None O
, None None O
we None None O
report None None O
that None None O
these None None O
compounds None None O
effectively None None O
inhibited None None O
SDF None None O
- None None O
1 None None O
- None None O
induced None None O
migration None None O
of None None O
human None None O
breast None None O
cancer None None O
cells None None O
( None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
) None None O
, None None O
human None None O
leukemia None None O
T None None O
cells None None O
( None None O
Sup None None I-Cell-line-name
- None None I-Cell-line-name
T1 None None I-Cell-line-name
) None None O
and None None O
human None None O
umbilical None None O
vein None None O
endothelial None None O
cells None None O
at None None O
concentrations None None O
of None None O
10 None None O
- None None O
100 None None O
nM None None O
in None None O
vitro None None O
. None None O

Furthermore None None O
, None None O
slow None None O
release None None O
administration None None O
by None None O
subcutaneous None None O
injection None None O
using None None O
an None None O
Alzet None None O
osmotic None None O
pump None None O
of None None O
a None None O
potent None None O
and None None O
bio None None O
- None None O
stable None None O
T140 None None O
analog None None O
, None None O
4F None None O
- None None O
benzoyl None None O
- None None O
TN14003 None None O
, None None O
gave None None O
a None None O
partial None None O
, None None O
but None None O
statistically None None O
significant None None O
( None None O
P None None O
< None None O
/ None None O
= None None O
0 None None O
. None None O
05 None None O
( None None O
t None None O
- None None O
test None None O
) None None O
) None None O
reduction None None O
in None None O
pulmonary None None O
metastasis None None O
of None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
in None None O
SCID None None O
mice None None O
, None None O
even None None O
though None None O
no None None O
attempt None None O
was None None O
made None None O
to None None O
inhibit None None O
other None None O
important None None O
targets None None O
such None None O
as None None O
CCR7 None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
T140 None None O
analogs None None O
have None None O
potential None None O
use None None O
for None None O
cancer None None O
therapy None None O
, None None O
and None None O
that None None O
small None None O
molecular None None O
CXCR4 None None O
antagonists None None O
could None None O
potentially None None O
replace None None O
neutralizing None None O
antibodies None None O
as None None O
anti None None O
- None None O
metastatic None None O
agents None None O
for None None O
breast None None O
cancer None None O
. None None O

Pten None None O
signaling None None O
in None None O
gliomas None None O
. None None O

In None None O
1997 None None O
, None None O
the None None O
PTEN None None O
gene None None O
( None None O
phosphatase None None O
and None None O
tensin None None O
homolog None None O
deleted None None O
on None None O
chromosome None None O
10 None None O
) None None O
was None None O
identified None None O
as None None O
a None None O
tumor None None O
suppressor None None O
gene None None O
on None None O
the None None O
long None None O
arm None None O
of None None O
chromosome None None O
10 None None O
. None None O

Since None None O
then None None O
, None None O
important None None O
progress None None O
has None None O
been None None O
made None None O
with None None O
respect None None O
to None None O
the None None O
understanding None None O
of None None O
the None None O
role None None O
of None None O
the None None O
Pten None None O
protein None None O
in None None O
the None None O
normal None None O
development None None O
of None None O
the None None O
brain None None O
as None None O
well None None O
as None None O
in None None O
the None None O
molecular None None O
pathogenesis None None O
of None None O
human None None O
gliomas None None O
. None None O

This None None O
review None None O
summarizes None None O
the None None O
current None None O
state None None O
of None None O
the None None O
art None None O
concerning None None O
the None None O
involvement None None O
of None None O
aberrant None None O
Pten None None O
function None None O
in None None O
the None None O
development None None O
of None None O
different None None O
biologic None None O
features None None O
of None None O
malignant None None O
gliomas None None O
, None None O
such None None O
as None None O
loss None None O
of None None O
cell None None O
- None None O
cycle None None O
control None None O
and None None O
uncontrolled None None O
cell None None O
proliferation None None O
, None None O
escape None None O
from None None O
apoptosis None None O
, None None O
brain None None O
invasion None None O
, None None O
and None None O
aberrant None None O
neoangiogenesis None None O
. None None O

Most None None O
of None None O
the None None O
tumor None None O
- None None O
suppressive None None O
properties None None O
of None None O
Pten None None O
are None None O
dependent None None O
on None None O
its None None O
lipid None None O
phosphatase None None O
activity None None O
, None None O
which None None O
inhibits None None O
the None None O
phosphatidylinositol None None O
- None None O
3 None None O
' None None O
- None None O
kinase None None O
( None None O
PI3K None None O
) None None O
/ None None O
Akt None None O
signaling None None O
pathway None None O
through None None O
dephosphorylation None None O
of None None O
phosphatidylinositol None None O
- None None O
( None None O
3 None None O
, None None O
4 None None O
, None None O
5 None None O
) None None O
- None None O
triphosphate None None O
. None None O

The None None O
additional None None O
function None None O
of None None O
Pten None None O
as None None O
a None None O
dual None None O
- None None O
specificity None None O
protein None None O
phosphatase None None O
may None None O
also None None O
play None None O
a None None O
role None None O
in None None O
glioma None None O
pathogenesis None None O
. None None O

Besides None None O
the None None O
wealth None None O
of None None O
data None None O
elucidating None None O
the None None O
functional None None O
roles None None O
of None None O
Pten None None O
, None None O
recent None None O
studies None None O
suggest None None O
a None None O
diagnostic None None O
significance None None O
of None None O
PTEN None None O
gene None None O
alterations None None O
as None None O
a None None O
molecular None None O
marker None None O
for None None O
poor None None O
prognosis None None O
in None None O
anaplastic None None O
astrocytomas None None O
and None None O
anaplastic None None O
oligodendrogliomas None None O
. None None O

Furthermore None None O
, None None O
the None None O
possibility None None O
of None None O
selective None None O
targeting None None O
of None None O
PTEN None None O
mutant None None O
tumor None None O
cells None None O
by None None O
specific None None O
pharmacologic None None O
inhibitors None None O
of None None O
members None None O
of None None O
the None None O
Pten None None O
/ None None O
PI3K None None O
/ None None O
Akt None None O
pathway None None O
opens None None O
up None None O
new None None O
perspectives None None O
for None None O
a None None O
targeted None None O
molecular None None O
therapy None None O
of None None O
malignant None None O
gliomas None None O
. None None O

Antiangiogenic None None O
and None None O
antitumor None None O
effects None None O
of None None O
a None None O
protein None None O
kinase None None O
Cbeta None None O
inhibitor None None O
in None None O
human None None O
breast None None O
cancer None None O
and None None O
ovarian None None O
cancer None None O
xenografts None None O
. None None O

In None None O
cell None None O
culture None None O
, None None O
the None None O
compound None None O
317615 None None O
2HCl None None O
, None None O
a None None O
potent None None O
inhibitor None None O
of None None O
VEGF None None O
- None None O
stimulated None None O
HUVEC None None O
proliferation None None O
, None None O
was None None O
not None None O
very None None O
effective None None O
against None None O
MX None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
breast None None O
cancer None None O
cells None None O
( None None O
IC50 None None O
= None None O
8 None None O
. None None O
1 None None O
microM None None O
) None None O
or None None O
SKOV None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
ovarian None None O
carcinoma None None O
cells None None O
( None None O
IC50 None None O
= None None O
9 None None O
. None None O
5 None None O
microM None None O
) None None O
. None None O

Exposure None None O
to None None O
combinations None None O
of None None O
paclitaxel None None O
or None None O
carboplatin None None O
and None None O
317615 None None O
x None None O
2HCl None None O
with None None O
MX None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
cells None None O
in None None O
culture None None O
resulted None None O
in None None O
cell None None O
survival None None O
that None None O
reflected None None O
primarily None None O
additivity None None O
of None None O
the None None O
two None None O
agents None None O
. None None O

Exposure None None O
of None None O
SKOV None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
cells None None O
to None None O
paclitaxel None None O
or None None O
carboplatin None None O
along None None O
with None None O
317615 None None O
2HCl None None O
resulted None None O
in None None O
cell None None O
survivals None None O
that None None O
reflected None None O
additivity None None O
of None None O
317615 None None O
x None None O
2HCl None None O
with None None O
paclitaxel None None O
and None None O
greater None None O
- None None O
than None None O
- None None O
additive None None O
cytotoxicity None None O
with None None O
carboplatin None None O
. None None O

Administration None None O
of None None O
317615 None None O
x None None O
2HCI None None O
orally None None O
twice None None O
daily None None O
to None None O
nude None None O
mice None None O
bearing None None O
subcutaneous None None O
MX None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
tumors None None O
or None None O
SKOV None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
tumors None None O
resulted None None O
in None None O
a None None O
decreased None None O
number None None O
of None None O
intratumoral None None O
vessels None None O
as None None O
determined None None O
by None None O
CD31 None None O
and None None O
CD105 None None O
staining None None O
with None None O
decreases None None O
of None None O
35 None None O
% None None O
and None None O
43 None None O
% None None O
in None None O
MX None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
tumors None None O
and None None O
60 None None O
% None None O
and None None O
75 None None O
% None None O
in None None O
SKOV None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
tumors None None O
, None None O
respectively None None O
. None None O

317615 None None O
x None None O
2HCl None None O
was None None O
an None None O
active None None O
antitumor None None O
agent None None O
against None None O
the None None O
MX None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
xenograft None None O
and None None O
increased None None O
the None None O
tumor None None O
growth None None O
delay None None O
produced None None O
by None None O
paclitaxel None None O
by None None O
1 None None O
. None None O
7 None None O
- None None O
fold None None O
and None None O
the None None O
tumor None None O
growth None None O
delay None None O
produced None None O
by None None O
carboplatin None None O
by None None O
3 None None O
. None None O
8 None None O
- None None O
fold None None O
. None None O

Administration None None O
of None None O
317615 None None O
x None None O
2HCl None None O
also None None O
increased None None O
the None None O
tumor None None O
growth None None O
delay None None O
produced None None O
by None None O
fractionated None None O
radiation None None O
therapy None None O
in None None O
the None None O
MX None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
tumor None None O
. None None O

Treatment None None O
with None None O
317615 None None O
x None None O
2HCl None None O
alone None None O
increased None None O
the None None O
lifespan None None O
of None None O
animals None None O
bearing None None O
intraperitoneal None None O
SKOV None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
xenografts None None O
by None None O
1 None None O
. None None O
9 None None O
fold None None O
compared None None O
with None None O
untreated None None O
control None None O
animals None None O
. None None O

The None None O
combination None None O
of None None O
paclitaxel None None O
and None None O
317615 None None O
x None None O
2HCl None None O
resulted None None O
in None None O
100 None None O
% None None O
120 None None O
- None None O
day None None O
survival None None O
of None None O
SKOV None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
bearing None None O
animals None None O
. None None O

Administration None None O
of None None O
317615 None None O
x None None O
2HCl None None O
along None None O
with None None O
carboplatin None None O
to None None O
animals None None O
bearing None None O
the None None O
SKOV None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
tumor None None O
produced None None O
a None None O
1 None None O
. None None O
8 None None O
- None None O
fold None None O
increase None None O
in None None O
lifespan None None O
compared None None O
with None None O
carboplatin None None O
alone None None O
. None None O

317615 None None O
x None None O
2HCl None None O
is None None O
a None None O
promising None None O
new None None O
antiangiogenic None None O
agent None None O
that None None O
is None None O
in None None O
early None None O
phase None None O
clinical None None O
testing None None O
. None None O

[ None None O
Reactive None None O
states None None O
among None None O
psychopathic None None O
personalities None None O
of None None O
different None None O
clinical None None O
groups None None O
] None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
a None None O
clinical None None O
follow None None O
- None None O
up None None O
of None None O
71 None None O
psychopaths None None O
with None None O
manifestations None None O
of None None O
reactive None None O
psychosis None None O
, None None O
the None None O
authors None None O
established None None O
the None None O
clinico None None O
- None None O
typological None None O
characteristics None None O
of None None O
both None None O
groups None None O
of None None O
pathology None None O
and None None O
the None None O
system None None O
of None None O
correlations None None O
between None None O
them None None O
. None None O

They None None O
also None None O
described None None O
the None None O
structure None None O
of None None O
the None None O
psychopathic None None O
and None None O
psychogenic None None O
syndromes None None O
, None None O
the None None O
type None None O
of None None O
psychopathic None None O
personality None None O
reaction None None O
and None None O
the None None O
form None None O
of None None O
psychogenic None None O
responses None None O
and None None O
proved None None O
statistically None None O
their None None O
close None None O
interrelationship None None O
. None None O

Data None None O
were None None O
obtained None None O
on None None O
some None None O
general None None O
regularities None None O
of None None O
interrelations None None O
of None None O
reactive None None O
psychoses None None O
with None None O
a None None O
psychopathic None None O
background None None O
which None None O
are None None O
important None None O
for None None O
the None None O
prognosis None None O
, None None O
prophylaxis None None O
and None None O
therapy None None O
of None None O
reactive None None O
states None None O
. None None O

Thyrotropin None None O
receptor None None O
: None None O
a None None O
role None None O
for None None O
thyroid None None O
tumourigenesis None None O
? None None O

Human None None O
thyroid None None O
tumours None None O
represent None None O
an None None O
example None None O
of None None O
the None None O
interplay None None O
of None None O
genetic None None O
and None None O
non None None O
genetic None None O
carcinogenesis None None O
. None None O

Recently None None O
, None None O
genetic None None O
abnormalities None None O
in None None O
the None None O
elements None None O
of None None O
the None None O
Thyrotropin None None O
receptor None None O
( None None O
TSH None None O
- None None O
R None None O
) None None O
dependent None None O
cAMP None None O
regulatory None None O
cascade None None O
have None None O
been None None O
found None None O
to None None O
be None None O
involved None None O
both None None O
in None None O
benign None None O
and None None O
malignant None None O
thyroid None None O
tumours None None O
. None None O

The None None O
presence None None O
of None None O
activating None None O
mutations None None O
has None None O
been None None O
demonstrated None None O
in None None O
the None None O
TSH None None O
- None None O
R None None O
gene None None O
as None None O
well None None O
as None None O
in None None O
the None None O
Gs None None O
alpha None None O
protein None None O
gene None None O
in None None O
thyroid None None O
toxic None None O
adenoma None None O
resulting None None O
in None None O
the None None O
constitutive None None O
activation None None O
of None None O
the None None O
cAMP None None O
pathway None None O
and None None O
it None None O
has None None O
been None None O
hypothesised None None O
that None None O
these None None O
genetic None None O
alterations None None O
may None None O
play None None O
a None None O
causative None None O
role None None O
in None None O
the None None O
disease None None O
. None None O

However None None O
, None None O
recent None None O
observations None None O
suggest None None O
more None None O
caution None None O
in None None O
accepting None None O
such None None O
a None None O
hypothesis None None O
. None None O

The None None O
presence None None O
of None None O
activating None None O
TSH None None O
- None None O
R None None O
mutations None None O
has None None O
also None None O
been None None O
demonstrated None None O
in None None O
differentiated None None O
thyroid None None O
carcinomas None None O
. None None O

At None None O
present None None O
, None None O
the None None O
percentage None None O
of None None O
such None None O
a None None O
modification None None O
is None None O
low None None O
, None None O
unless None None O
referred None None O
to None None O
selected None None O
series None None O
of None None O
tumours None None O
. None None O

Activating None None O
mutations None None O
of None None O
the None None O
TSH None None O
- None None O
R None None O
gene None None O
have None None O
been None None O
detected None None O
in None None O
a None None O
group None None O
of None None O
differentiated None None O
carcinomas None None O
with None None O
high None None O
basal None None O
adenylyl None None O
cyclase None None O
activity None None O
, None None O
and None None O
in None None O
a None None O
few None None O
cases None None O
of None None O
hyperfunctioning None None O
thyroid None None O
carcinoma None None O
. None None O

However None None O
, None None O
the None None O
role None None O
of None None O
the None None O
TSH None None O
- None None O
R None None O
- None None O
related None None O
cAMP None None O
pathway None None O
alterations None None O
in None None O
thyroid None None O
transformation None None O
remains None None O
to None None O
be None None O
elucidated None None O
. None None O

In None None O
this None None O
review None None O
, None None O
the None None O
role None None O
of None None O
TSH None None O
- None None O
R None None O
gene None None O
alterations None None O
in None None O
benign None None O
and None None O
malignant None None O
thyroid None None O
neoplasia None None O
is None None O
examined None None O
. None None O

View None None O
of None None O
the None None O
structure None None O
of None None O
the None None O
title None None O
compound None None O
along None None O
the None None O
a None None O
axis None None O
displaying None None O
chains None None O
alternating None None O
with None None O
amine None None O
groups None None O
. None None O

Calculation None None O
of None None O
male None None O
mating None None O
success None None O

In None None O
order None None O
to None None O
compare None None O
whether None None O
males None None O
' None None O
access None None O
to None None O
receptive None None O
females None None O
followed None None O
the None None O
predictions None None O
of None None O
the None None O
PoA None None O
model None None O
, None None O
we None None O
calculated None None O
mating None None O
success None None O
as None None O
follows None None O
. None None O

For None None O
all None None O
the None None O
mating None None O
partners None None O
a None None O
female None None O
had None None O
during None None O
the None None O
receptive None None O
period None None O
of None None O
her None None O
conceptive None None O
cycle None None O
, None None O
mating None None O
success None None O
of None None O
each None None O
mating None None O
partner None None O
was None None O
calculated None None O
as None None O
the None None O
number None None O
of None None O
mating None None O
series None None O
a None None O
male None None O
was None None O
involved None None O
in None None O
divided None None O
by None None O
the None None O
total None None O
number None None O
of None None O
mating None None O
series None None O
the None None O
female None None O
was None None O
involved None None O
in None None O
. None None O

Overall None None O
mating None None O
success None None O
of None None O
each None None O
male None None O
was None None O
calculated None None O
as None None O
the None None O
sum None None O
of None None O
all None None O
mating None None O
successes None None O
calculated None None O
for None None O
this None None O
male None None O
as None None O
described None None O
above None None O
. None None O

Malate None None O
- None None O
citrate None None O
cycle None None O
during None None O
glycolysis None None O
and None None O
glutaminolysis None None O
in None None O
Ehrlich None None O
ascites None None O
tumor None None O
cells None None O
. None None O

The None None O
malate None None O
- None None O
citrate None None O
cycle None None O
was None None O
studied None None O
during None None O
aerobic None None O
glycolysis None None O
and None None O
glutaminolysis None None O
in None None O
a None None O
strain None None O
of None None O
Ehrlich None None O
ascites None None O
tumor None None O
cells None None O
which None None O
showed None None O
a None None O
very None None O
low None None O
malate None None O
- None None O
aspartate None None O
shuttle None None O
system None None O
activity None None O
. None None O

The None None O
experimental None None O
approach None None O
includes None None O
: None None O
estimation None None O
of None None O
mitochondrial None None O
NAD None None O
[ None None O
P None None O
] None None O
+ None None O
- None None O
dependent None None O
malic None None O
enzyme None None O
activity None None O
; None None O
respiratory None None O
activity None None O
of None None O
freshly None None O
harvested None None O
or None None O
fasted None None O
cells None None O
, None None O
and None None O
of None None O
isolated None None O
mitochondria None None O
; None None O
and None None O
determination None None O
of None None O
the None None O
metabolites None None O
involved None None O
in None None O
the None None O
glycolytic None None O
and None None O
glutaminolytic None None O
pathways None None O
. None None O

The None None O
results None None O
suggest None None O
that None None O
in None None O
this None None O
strain None None O
, None None O
the None None O
malate None None O
- None None O
citrate None None O
shuttle None None O
is None None O
not None None O
an None None O
effective None None O
pathway None None O
for None None O
transferring None None O
glycolytic None None O
reducing None None O
equivalents None None O
from None None O
cytosol None None O
to None None O
mitochondria None None O
. None None O

Less None None O
than None None O
15 None None O
% None None O
of None None O
the None None O
glucose None None O
uptake None None O
was None None O
affected None None O
by None None O
the None None O
1 None None O
, None None O
2 None None O
, None None O
3 None None O
- None None O
benzenetricarboxylate None None O
inhibition None None O
of None None O
the None None O
malate None None O
- None None O
citrate None None O
shuttle None None O
. None None O

Moreover None None O
, None None O
in None None O
the None None O
presence None None O
of None None O
glucose None None O
, None None O
the None None O
malate None None O
- None None O
citrate None None O
cycle None None O
did None None O
not None None O
appear None None O
to None None O
play None None O
an None None O
important None None O
role None None O
in None None O
the None None O
glutaminolytic None None O
process None None O
. None None O

The None None O
present None None O
work None None O
supports None None O
and None None O
extends None None O
the None None O
finding None None O
of None None O
previous None None O
studies None None O
, None None O
since None None O
the None None O
results None None O
showed None None O
that None None O
the None None O
glucose None None O
metabolism None None O
depressed None None O
the None None O
oxidative None None O
processes None None O
in None None O
Ehrlich None None O
ascites None None O
tumor None None O
mitochondria None None O
, None None O
not None None O
only None None O
alone None None O
, None None O
but None None O
also None None O
in None None O
the None None O
presence None None O
of None None O
glutamine None None O
. None None O

Interestingly None None O
, None None O
the None None O
high None None O
glutamine None None O
uptake None None O
was None None O
maintained None None O
in None None O
the None None O
presence None None O
of None None O
glucose None None O
. None None O

Images None None O

FIGURE None None O
2 None None O
. None None O

A None None O

FIGURE None None O
2 None None O
. None None O

B None None O

FIGURE None None O
3 None None O
. None None O

An None None O
introduction None None O
to None None O
evidence None None O
- None None O
based None None O
practice None None O
for None None O
hand None None O
surgeons None None O
and None None O
therapists None None O
. None None O

Evidence None None O
- None None O
based None None O
practice None None O
is None None O
a None None O
methodical None None O
approach None None O
to None None O
clinical None None O
practice None None O
where None None O
experience None None O
, None None O
best None None O
research None None O
evidence None None O
, None None O
and None None O
patient None None O
goals None None O
and None None O
values None None O
are None None O
integrated None None O
to None None O
make None None O
optimal None None O
decisions None None O
when None None O
making None None O
a None None O
diagnosis None None O
, None None O
selecting None None O
a None None O
diagnostic None None O
test None None O
, None None O
picking None None O
an None None O
intervention None None O
or None None O
determining None None O
prognosis None None O
. None None O

There None None O
are None None O
five None None O
steps None None O
in None None O
this None None O
process None None O
. None None O

Hand None None O
surgeons None None O
and None None O
therapists None None O
can None None O
use None None O
the None None O
evidence None None O
- None None O
based None None O
process None None O
to None None O
attain None None O
optimal None None O
management None None O
of None None O
individual None None O
patients None None O
, None None O
manage None None O
their None None O
overall None None O
practice None None O
, None None O
guide None None O
the None None O
ongoing None None O
professional None None O
development None None O
, None None O
and None None O
deal None None O
with None None O
funding None None O
and None None O
policy None None O
makers None None O
. None None O

Classification None None O
result None None O
. None None O

Results None None O
and None None O
Discussion None None O

Figure None None O
4 None None O
shows None None O
the None None O
frequency None None O
response None None O
of None None O
the None None O
device None None O
before None None O
and None None O
after None None O
plating None None O
cells None None O
. None None O

In None None O
the None None O
frequency None None O
range None None O
measured None None O
( None None O
4 None None O
- None None O
600 None None O
Hz None None O
) None None O
, None None O
only None None O
two None None O
clear None None O
peaks None None O
can None None O
be None None O
seen None None O
in None None O
the None None O
bare None None O
device None None O
. None None O

After None None O
cells None None O
had None None O
adhered None None O
to None None O
the None None O
surface None None O
, None None O
there None None O
is None None O
a None None O
shift None None O
in None None O
both None None O
the None None O
resonant None None O
frequency None None O
and None None O
the None None O
height None None O
of None None O
these None None O
peaks None None O
. None None O

Table None None O
1 None None O
shows None None O
the None None O
results None None O
for None None O
this None None O
trial None None O
and None None O
a None None O
second None None O
trial None None O
where None None O
the None None O
experiment None None O
was None None O
repeated None None O
to None None O
confirm None None O
the None None O
initial None None O
results None None O
. None None O

At None None O
a None None O
plating None None O
density None None O
of None None O
1300 None None O
cells None None O
/ None None O
mm2 None None O
, None None O
there None None O
were None None O
approximately None None O
140 None None O
cells None None O
on None None O
the None None O
portion None None O
of None None O
the None None O
cantilever None None O
free None None O
to None None O
vibrate None None O
( None None O
dimensions None None O
shown None None O
in None None O
Figure None None O
1 None None O
) None None O
. None None O

Table None None O
1 None None O

Cantilever None None O
response None None O
data None None O
from None None O
two None None O
trials None None O

Experiment None None O
# None None O
1 None None O
Experiment None None O
# None None O
2 None None O

Freq None None O
. None None O

1 None None O
( None None O
kHz None None O
) None None O
Amp None None O
. None None O

1 None None O
( None None O
deg None None O
) None None O
Freq None None O
. None None O

2 None None O
( None None O
kHz None None O
) None None O
Amp None None O
. None None O

2 None None O
( None None O
deg None None O
) None None O
Freq None None O
. None None O

1 None None O
( None None O
kHz None None O
) None None O
Amp None None O
. None None O

1 None None O
( None None O
deg None None O
) None None O
Freq None None O
. None None O

2 None None O
( None None O
kHz None None O
) None None O
Amp None None O
. None None O

2 None None O
( None None O
deg None None O
) None None O

Initial None None O
313 None None O
. None None O
0 None None O
. None None O
086 None None O
375 None None O
. None None O
5 None None O
. None None O
055 None None O
313 None None O
. None None O
9 None None O
. None None O
091 None None O
376 None None O
. None None O
5 None None O
. None None O
071 None None O

With None None O
cells None None O
307 None None O
. None None O
5 None None O
. None None O
031 None None O
371 None None O
. None None O
0 None None O
. None None O
018 None None O
308 None None O
. None None O
052 None None O
370 None None O
. None None O
5 None None O
. None None O
043 None None O

Change None None O
5 None None O
. None None O
5 None None O
. None None O
055 None None O
4 None None O
. None None O
5 None None O
. None None O
037 None None O
5 None None O
. None None O
9 None None O
. None None O
039 None None O
6 None None O
. None None O
0 None None O
. None None O
028 None None O

Figure None None O
4 None None O

Phase None None O
angle None None O
vs None None O
. None None O
frequency None None O
. None None O

( None None O
left None None O
) None None O
Phase None None O
angle None None O
of None None O
impedance None None O
with None None O
linear None None O
regression None None O
line None None O
. None None O

( None None O
right None None O
) None None O
To None None O
provide None None O
an None None O
easier None None O
comparison None None O
, None None O
phase None None O
angles None None O
have None None O
been None None O
levelled None None O
with None None O
respect None None O
to None None O
the None None O
linear None None O
regression None None O
line None None O
that None None O
passes None None O
through None None O
each None None O
set None None O
of None None O
data None None O
. None None O

The None None O
addition None None O
of None None O
cells None None O
causes None None O
the None None O
peaks None None O
to None None O
shift None None O
to None None O
lower None None O
frequencies None None O
and None None O
decrease None None O
in None None O
amplitude None None O
. None None O

The None None O
two None None O
peaks None None O
shown None None O
were None None O
the None None O
only None None O
detectable None None O
resonances None None O
despite None None O
the None None O
relatively None None O
wide None None O
frequency None None O
range None None O
measured None None O
. None None O

The None None O
electrical None None O
detection None None O
of None None O
resonances None None O
is None None O
critically None None O
compromised None None O
by None None O
the None None O
strong None None O
damping None None O
imposed None None O
by None None O
the None None O
cell None None O
media None None O
, None None O
making None None O
these None None O
measurements None None O
more None None O
challenging None None O
than None None O
those None None O
carried None None O
out None None O
in None None O
air None None O
or None None O
in None None O
a None None O
vacuum None None O
where None None O
resonance None None O
peaks None None O
show None None O
much None None O
larger None None O
amplitude None None O
[ None None O
18 None None O
] None None O
. None None O

In None None O
the None None O
desired None None O
in None None O
vivo None None O
application None None O
for None None O
this None None O
work None None O
, None None O
as None None O
a None None O
sensor None None O
for None None O
stent None None O
healing None None O
, None None O
it None None O
can None None O
be None None O
expected None None O
that None None O
in None None O
the None None O
course None None O
of None None O
normal None None O
healing None None O
the None None O
stent None None O
will None None O
be None None O
fully None None O
populated None None O
with None None O
a None None O
significantly None None O
thicker None None O
layer None None O
of None None O
endothelial None None O
cells None None O
. None None O

In None None O
the None None O
case None None O
of None None O
restenosis None None O
, None None O
this None None O
lining None None O
would None None O
be None None O
even None None O
thicker None None O
. None None O

This None None O
may None None O
hamper None None O
any None None O
movement None None O
of None None O
the None None O
cantilever None None O
and None None O
cause None None O
the None None O
peaks None None O
to None None O
eventually None None O
become None None O
undetectable None None O
. None None O

Frequent None None O
measurements None None O
of None None O
the None None O
resonant None None O
frequencies None None O
will None None O
differentiate None None O
this None None O
end None None O
state None None O
with None None O
the None None O
possibility None None O
of None None O
device None None O
failure None None O
. None None O

The None None O
noninvasive None None O
nature None None O
of None None O
these None None O
measurements None None O
that None None O
can None None O
be None None O
transmitted None None O
wirelessly None None O
to None None O
an None None O
external None None O
device None None O
make None None O
this None None O
an None None O
attractive None None O
and None None O
low None None O
risk None None O
option None None O
for None None O
monitoring None None O
healing None None O
. None None O

Dissecting None None O
genetic None None O
networks None None O
underlying None None O
complex None None O
phenotypes None None O
: None None O
the None None O
theoretical None None O
framework None None O
. None None O

Great None None O
progress None None O
has None None O
been None None O
made None None O
in None None O
genetic None None O
dissection None None O
of None None O
quantitative None None O
trait None None O
variation None None O
during None None O
the None None O
past None None O
two None None O
decades None None O
, None None O
but None None O
many None None O
studies None None O
still None None O
reveal None None O
only None None O
a None None O
small None None O
fraction None None O
of None None O
quantitative None None O
trait None None O
loci None None O
( None None O
QTLs None None O
) None None O
, None None O
and None None O
epistasis None None O
remains None None O
elusive None None O
. None None O

We None None O
integrate None None O
contemporary None None O
knowledge None None O
of None None O
signal None None O
transduction None None O
pathways None None O
with None None O
principles None None O
of None None O
quantitative None None O
and None None O
population None None O
genetics None None O
to None None O
characterize None None O
genetic None None O
networks None None O
underlying None None O
complex None None O
traits None None O
, None None O
using None None O
a None None O
model None None O
founded None None O
upon None None O
one None None O
- None None O
way None None O
functional None None O
dependency None None O
of None None O
downstream None None O
genes None None O
on None None O
upstream None None O
regulators None None O
( None None O
the None None O
principle None None O
of None None O
hierarchy None None O
) None None O
and None None O
mutual None None O
functional None None O
dependency None None O
among None None O
related None None O
genes None None O
( None None O
functional None None O
genetic None None O
units None None O
, None None O
FGU None None O
) None None O
. None None O

Both None None O
simulated None None O
and None None O
real None None O
data None None O
suggest None None O
that None None O
complementary None None O
epistasis None None O
contributes None None O
greatly None None O
to None None O
quantitative None None O
trait None None O
variation None None O
, None None O
and None None O
obscures None None O
the None None O
phenotypic None None O
effects None None O
of None None O
many None None O
' None None O
downstream None None O
' None None O
loci None None O
in None None O
pathways None None O
. None None O

The None None O
mathematical None None O
relationships None None O
between None None O
the None None O
main None None O
effects None None O
and None None O
epistatic None None O
effects None None O
of None None O
genes None None O
acting None None O
at None None O
different None None O
levels None None O
of None None O
signaling None None O
pathways None None O
were None None O
established None None O
using None None O
the None None O
quantitative None None O
and None None O
population None None O
genetic None None O
parameters None None O
. None None O

Both None None O
loss None None O
of None None O
function None None O
and None None O
" None None O
co None None O
- None None O
adapted None None O
" None None O
gene None None O
complexes None None O
formed None None O
by None None O
multiple None None O
alleles None None O
with None None O
differentiated None None O
functions None None O
( None None O
effects None None O
) None None O
are None None O
predicted None None O
to None None O
be None None O
frequent None None O
types None None O
of None None O
allelic None None O
diversity None None O
at None None O
loci None None O
that None None O
contribute None None O
to None None O
the None None O
genetic None None O
variation None None O
of None None O
complex None None O
traits None None O
in None None O
populations None None O
. None None O

Downstream None None O
FGUs None None O
appear None None O
to None None O
be None None O
more None None O
vulnerable None None O
to None None O
loss None None O
of None None O
function None None O
than None None O
their None None O
upstream None None O
regulators None None O
, None None O
but None None O
this None None O
vulnerability None None O
is None None O
apparently None None O
compensated None None O
by None None O
different None None O
FGUs None None O
of None None O
similar None None O
functions None None O
. None None O

Other None None O
predictions None None O
from None None O
the None None O
model None None O
may None None O
account None None O
for None None O
puzzling None None O
results None None O
regarding None None O
responses None None O
to None None O
selection None None O
, None None O
genotype None None O
by None None O
environment None None O
interaction None None O
, None None O
and None None O
the None None O
genetic None None O
basis None None O
of None None O
heterosis None None O
. None None O

p53 None None O
hot None None O
- None None O
spot None None O
mutants None None O
increase None None O
tumor None None O
vascularization None None O
via None None O
ROS None None O
- None None O
mediated None None O
activation None None O
of None None O
the None None O
HIF1 None None O
/ None None O
VEGF None None O
- None None O
A None None O
pathway None None O
. None None O

The None None O
function None None O
of None None O
p53 None None O
tumor None None O
suppressor None None O
is None None O
often None None O
altered None None O
in None None O
various None None O
human None None O
tumors None None O
predominantly None None O
through None None O
missense None None O
- None None O
mutations None None O
resulting None None O
in None None O
accumulation None None O
of None None O
mutant None None O
proteins None None O
. None None O

We None None O
revealed None None O
that None None O
expression None None O
of None None O
p53 None None O
proteins None None O
with None None O
amino None None O
- None None O
acid None None O
substitutions None None O
at None None O
codons None None O
175 None None O
( None None O
R175H None None O
) None None O
, None None O
248 None None O
( None None O
R248W None None O
) None None O
, None None O
and None None O
273 None None O
( None None O
R273H None None O
) None None O
, None None O
representing None None O
the None None O
hot None None O
- None None O
spots None None O
of None None O
mutations None None O
in None None O
various None None O
human None None O
tumors None None O
, None None O
increased None None O
the None None O
number None None O
of None None O
vessels None None O
in None None O
HCT116 None None I-Cell-line-name
human None None O
colon None None O
carcinoma None None O
xenografts None None O
and None None O
, None None O
as None None O
a None None O
result None None O
, None None O
accelerated None None O
their None None O
growth None None O
. None None O

Stimulation None None O
of None None O
tumor None None O
angiogenesis None None O
was None None O
connected None None O
with None None O
about None None O
2 None None O
- None None O
fold None None O
increase None None O
in None None O
intracellular None None O
level None None O
of None None O
reactive None None O
oxygen None None O
species None None O
( None None O
ROS None None O
) None None O
. None None O

Antioxidant None None O
N None None O
- None None O
acetyl None None O
- None None O
l None None O
- None None O
aspartate None None O
( None None O
NAC None None O
) None None O
decreased None None O
vessels None None O
number None None O
in None None O
tumors None None O
formed None None O
by None None O
cells None None O
with None None O
inactivated None None O
p53 None None O
and None None O
inhibited None None O
their None None O
growth None None O
. None None O

Effect None None O
of None None O
ROS None None O
on None None O
angiogenesis None None O
in None None O
tumors None None O
expressing None None O
hot None None O
- None None O
spot None None O
p53 None None O
mutants None None O
was None None O
correlated None None O
with None None O
their None None O
ability None None O
to None None O
increase None None O
a None None O
content None None O
of None None O
HIF1 None None O
transcriptional None None O
factor None None O
responsible None None O
for None None O
up None None O
- None None O
regulation None None O
of None None O
VEGF None None O
- None None O
A None None O
mRNAs None None O
. None None O

Neural None None O
network None None O
analysis None None O
of None None O
spectroscopic None None O
data None None O
of None None O
lycopene None None O
and None None O
beta None None O
- None None O
carotene None None O
content None None O
in None None O
food None None O
samples None None O
compared None None O
to None None O
HPLC None None O
- None None O
UV None None O
- None None O
vis None None O
. None None O

In None None O
this None None O
study None None O
a None None O
neural None None O
network None None O
( None None O
NN None None O
) None None O
model None None O
was None None O
designed None None O
to None None O
predict None None O
lycopene None None O
and None None O
beta None None O
- None None O
carotene None None O
concentrations None None O
in None None O
food None None O
samples None None O
, None None O
combined None None O
with None None O
a None None O
simple None None O
and None None O
fast None None O
technique None None O
, None None O
such None None O
as None None O
UV None None O
- None None O
vis None None O
spectroscopy None None O
. None None O

The None None O
measurement None None O
of None None O
the None None O
absorbance None None O
at None None O
446 None None O
and None None O
502 None None O
nm None None O
of None None O
different None None O
beta None None O
- None None O
carotene None None O
and None None O
lycopene None None O
standard None None O
mixtures None None O
was None None O
used None None O
to None None O
optimize None None O
a None None O
neural None None O
network None None O
based None None O
on None None O
a None None O
multilayer None None O
perceptron None None O
( None None O
MLP None None O
) None None O
( None None O
learning None None O
and None None O
verification None None O
process None None O
) None None O
. None None O

Then None None O
, None None O
for None None O
validation None None O
purposes None None O
, None None O
the None None O
optimized None None O
NN None None O
has None None O
been None None O
applied None None O
to None None O
determine None None O
the None None O
concentration None None O
of None None O
both None None O
compounds None None O
in None None O
food None None O
samples None None O
( None None O
fresh None None O
tomato None None O
, None None O
tomato None None O
concentrate None None O
, None None O
tomato None None O
sauce None None O
, None None O
ketchup None None O
, None None O
tomato None None O
juice None None O
, None None O
watermelon None None O
, None None O
medlar None None O
, None None O
green None None O
pepper None None O
, None None O
and None None O
carrots None None O
) None None O
, None None O
comparing None None O
the None None O
NN None None O
results None None O
with None None O
the None None O
known None None O
values None None O
of None None O
these None None O
compounds None None O
obtained None None O
by None None O
analytical None None O
techniques None None O
( None None O
UV None None O
- None None O
vis None None O
and None None O
HPLC None None O
) None None O
. None None O

It None None O
was None None O
concluded None None O
that None None O
when None None O
the None None O
MLP None None O
- None None O
NN None None O
is None None O
used None None O
within None None O
the None None O
range None None O
studied None None O
, None None O
the None None O
optimized None None O
NN None None O
is None None O
able None None O
to None None O
estimate None None O
the None None O
beta None None O
- None None O
carotene None None O
and None None O
lycopene None None O
concentrations None None O
in None None O
food None None O
samples None None O
with None None O
an None None O
adequate None None O
accuracy None None O
, None None O
solving None None O
the None None O
UV None None O
- None None O
vis None None O
interference None None O
of None None O
beta None None O
- None None O
carotene None None O
and None None O
lycopene None None O
. None None O

Neoplastic None None O
transformation None None O
and None None O
tumorigenesis None None O
associated None None O
with None None O
overexpression None None O
of None None O
phospholipase None None O
D None None O
isozymes None None O
in None None O
cultured None None O
murine None None O
fibroblasts None None O
. None None O

Phospholipase None None O
D None None O
( None None O
PLD None None O
) None None O
has None None O
been None None O
suggested None None O
to None None O
play None None O
an None None O
important None None O
role None None O
in None None O
a None None O
variety None None O
of None None O
cellular None None O
functions None None O
. None None O

PLD None None O
activity None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
significantly None None O
elevated None None O
in None None O
many None None O
tumours None None O
and None None O
transformed None None O
cells None None O
, None None O
suggesting None None O
the None None O
possibility None None O
that None None O
PLD None None O
might None None O
be None None O
involved None None O
in None None O
tumorigenesis None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
have None None O
established None None O
stable None None O
cell None None O
lines None None O
overexpressing None None O
PLD1 None None O
and None None O
PLD2 None None O
from None None O
fibroblast None None O
cells None None O
. None None O

These None None O
cells None None O
, None None O
but None None O
not None None O
control None None O
cells None None O
, None None O
showed None None O
altered None None O
growth None None O
properties None None O
and None None O
anchorage None None O
- None None O
independent None None O
growth None None O
in None None O
soft None None O
agar None None O
. None None O

Both None None O
PLD1 None None O
and None None O
PLD2 None None O
also None None O
induced None None O
an None None O
up None None O
- None None O
regulation None None O
of None None O
the None None O
activity None None O
of None None O
matrix None None O
metalloprotease None None O
- None None O
9 None None O
as None None O
detected None None O
by None None O
zymograms None None O
. None None O

Furthermore None None O
, None None O
both None None O
PLD1 None None O
and None None O
PLD2 None None O
transformants None None O
, None None O
but None None O
not None None O
vector None None O
- None None O
transfectants None None O
, None None O
induced None None O
undifferentiated None None O
sarcoma None None O
when None None O
transplanted None None O
into None None O
nude None None O
mice None None O
. None None O

Both None None O
PLD1 None None O
- None None O
and None None O
PLD2 None None O
- None None O
mediated None None O
cell None None O
cycle None None O
distributions None None O
in None None O
stable None None O
cell None None O
lines None None O
revealed None None O
an None None O
increased None None O
fraction None None O
of None None O
cells None None O
in None None O
the None None O
S None None O
phase None None O
compared None None O
with None None O
control None None O
cells None None O
. None None O

Interestingly None None O
, None None O
the None None O
level None None O
of None None O
cyclin None None O
D3 None None O
protein None None O
, None None O
known None None O
as None None O
an None None O
activator None None O
of None None O
G None None O
( None None O
1 None None O
) None None O
to None None O
S None None O
phase None None O
transition None None O
in None None O
the None None O
cell None None O
cycle None None O
, None None O
was None None O
aberrantly None None O
high None None O
in None None O
cells None None O
overexpressing None None O
PLD1 None None O
and None None O
PLD2 None None O
compared None None O
with None None O
control None None O
cells None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
overexpression None None O
of None None O
PLD None None O
isozymes None None O
may None None O
play None None O
an None None O
important None None O
role None None O
in None None O
neoplastic None None O
transformation None None O
. None None O

[ None None O
Retinochoroidopathy None None O
after None None O
intravitreal None None O
anti None None O
- None None O
VEGF None None O
treatment None None O
] None None O

A None None O
74 None None O
- None None O
year None None O
- None None O
old None None O
man None None O
presented None None O
with None None O
persistent None None O
metamorphopsias None None O
of None None O
the None None O
right None None O
eye None None O
2 None None O
weeks None None O
after None None O
intravitreal None None O
injection None None O
of None None O
bevacizumab None None O
to None None O
treat None None O
choroidal None None O
neovascularization None None O
due None None O
to None None O
exudative None None O
age None None O
- None None O
related None None O
macular None None O
degeneration None None O
. None None O

The None None O
diagnosis None None O
reached None None O
was None None O
retinochoroiditis None None O
as None None O
an None None O
occult None None O
manifestation None None O
of None None O
sarcoidosis None None O
, None None O
possibly None None O
resulting None None O
from None None O
an None None O
intravitreal None None O
injection None None O
of None None O
bevacizumab None None O
. None None O

The None None O
patient None None O
received None None O
a None None O
prescription None None O
for None None O
100 None None O
mg None None O
Ultralan None None O
to None None O
be None None O
taken None None O
daily None None O
for None None O
3 None None O
days None None O
and None None O
then None None O
tapered None None O
in None None O
3 None None O
day None None O
steps None None O
. None None O

During None None O
the None None O
further None None O
course None None O
no None None O
deterioration None None O
of None None O
the None None O
condition None None O
was None None O
observed None None O
. None None O

Serum None None O
and None None O
urine None None O
levels None None O
of None None O
interleukin None None O
- None None O
8 None None O
in None None O
patients None None O
with None None O
non None None O
- None None O
Hodgkin None None O
' None None O
s None None O
lymphoma None None O
. None None O

Angiogenesis None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
many None None O
types None None O
of None None O
cancer None None O
. None None O

Interleukin None None O
- None None O
8 None None O
( None None O
IL None None O
- None None O
8 None None O
) None None O
is None None O
known None None O
to None None O
be None None O
a None None O
pro None None O
- None None O
inflammatory None None O
and None None O
pro None None O
- None None O
angiogenic None None O
cytokine None None O
, None None O
and None None O
IL None None O
- None None O
8 None None O
has None None O
been None None O
reported None None O
to None None O
be None None O
associated None None O
with None None O
tumor None None O
progression None None O
, None None O
prognosis None None O
and None None O
survival None None O
in None None O
several None None O
types None None O
of None None O
cancers None None O
. None None O

However None None O
, None None O
the None None O
role None None O
of None None O
IL None None O
- None None O
8 None None O
in None None O
non None None O
- None None O
Hodgkin None None O
' None None O
s None None O
lymphoma None None O
( None None O
NHL None None O
) None None O
has None None O
not None None O
been None None O
fully None None O
determined None None O
. None None O

Here None None O
, None None O
we None None O
evaluated None None O
the None None O
usefulness None None O
of None None O
measuring None None O
serum None None O
and None None O
urine None None O
IL None None O
- None None O
8 None None O
levels None None O
in None None O
patients None None O
with None None O
NHL None None O
. None None O

We None None O
developed None None O
reference None None O
intervals None None O
for None None O
serum None None O
and None None O
urine None None O
IL None None O
- None None O
8 None None O
level None None O
in None None O
131 None None O
control None None O
individuals None None O
. None None O

We None None O
measured None None O
serum None None O
IL None None O
- None None O
8 None None O
and None None O
urine None None O
IL None None O
- None None O
8 None None O
levels None None O
in None None O
patients None None O
with None None O
NHL None None O
, None None O
and None None O
we None None O
compared None None O
the None None O
concentrations None None O
with None None O
those None None O
of None None O
control None None O
individuals None None O
. None None O

The None None O
reference None None O
intervals None None O
for None None O
serum None None O
IL None None O
- None None O
8 None None O
and None None O
urine None None O
IL None None O
- None None O
8 None None O
corrected None None O
by None None O
creatinine None None O
( None None O
Cr None None O
) None None O
were None None O
15 None None O
. None None O
9 None None O
- None None O
430 None None O
. None None O
3 None None O
pg None None O
/ None None O
mL None None O
and None None O
0 None None O
. None None O
0 None None O
- None None O
28 None None O
. None None O
4 None None O
pg None None O
/ None None O
mg None None O
Cr None None O
, None None O
respectively None None O
. None None O

The None None O
concentrations None None O
of None None O
urine None None O
IL None None O
- None None O
8 None None O
/ None None O
Cr None None O
were None None O
significantly None None O
higher None None O
in None None O
patients None None O
than None None O
in None None O
controls None None O
( None None O
48 None None O
. None None O
9 None None O
+ None None O
/ None None O
- None None O
194 None None O
. None None O
4 None None O
vs None None O
. None None O
5 None None O
. None None O
2 None None O
+ None None O
/ None None O
- None None O
13 None None O
. None None O
8 None None O
pg None None O
/ None None O
mg None None O
Cr None None O
, None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

However None None O
, None None O
there None None O
were None None O
no None None O
significant None None O
differences None None O
in None None O
serum None None O
IL None None O
- None None O
8 None None O
concentrations None None O
between None None O
NHL None None O
patients None None O
and None None O
controls None None O
( None None O
159 None None O
. None None O
2 None None O
+ None None O
/ None None O
- None None O
40 None None O
. None None O
4 None None O
vs None None O
. None None O
99 None None O
. None None O
6 None None O
+ None None O
/ None None O
- None None O
107 None None O
. None None O
1 None None O
pg None None O
/ None None O
mL None None O
; None None O
P None None O
= None None O
0 None None O
. None None O
099 None None O
) None None O
. None None O

Receiver None None O
operating None None O
characteristic None None O
( None None O
ROC None None O
) None None O
analysis None None O
gave None None O
0 None None O
. None None O
83 None None O
and None None O
0 None None O
. None None O
43 None None O
ROC None None O
area None None O
values None None O
for None None O
urine None None O
IL None None O
- None None O
8 None None O
/ None None O
Cr None None O
and None None O
serum None None O
IL None None O
- None None O
8 None None O
, None None O
respectively None None O
. None None O

There None None O
was None None O
no None None O
correlation None None O
between None None O
the None None O
serum None None O
and None None O
urine None None O
concentrations None None O
of None None O
IL None None O
- None None O
8 None None O
and None None O
clinical None None O
variables None None O
, None None O
the None None O
only None None O
exception None None O
being None None O
the None None O
international None None O
prognostic None None O
index None None O
( None None O
IPI None None O
) None None O
, None None O
which None None O
showed None None O
a None None O
marginal None None O
correlation None None O
with None None O
urine None None O
IL None None O
- None None O
8 None None O
/ None None O
Cr None None O
levels None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
07 None None O
) None None O
. None None O

This None None O
study None None O
indicated None None O
that None None O
urine None None O
IL None None O
- None None O
8 None None O
/ None None O
Cr None None O
levels None None O
might None None O
be None None O
useful None None O
as None None O
a None None O
diagnostic None None O
marker None None O
of None None O
NHL None None O
. None None O

Figures None None O
and None None O
Tables None None O

Stages None None O
in None None O
the None None O
life None None O
cycle None None O
of None None O
Plasmodium None None O
falciparum None None O

( None None O
Illustration None None O
: None None O
Coatney None None O
GR None None O
, None None O
Collins None None O
WE None None O
, None None O
Warren None None O
M None None O
, None None O
Contacos None None O
PG None None O
( None None O
1971 None None O
) None None O

The None None O
primate None None O
malarias None None O
. None None O
( None None O
Bethesda None None O
) None None O
: None None O
U None None O
. None None O
S None None O
. None None O
Department None None O
of None None O
Health None None O
, None None O
Education None None O
and None None O
Welfare None None O
. None None O
) None None O

Tail None None O
flick None None O
test None None O

CSLE None None O
did None None O
not None None O
show None None O
any None None O
difference None None O
compared None None O
with None None O
control None None O
, None None O
at None None O
all None None O
the None None O
tested None None O
doses None None O
[ None None O
Figure None None O
4 None None O
] None None O
. None None O

Morphine None None O
showed None None O
a None None O
significant None None O
increase None None O
of None None O
latency None None O
time None None O
at None None O
45 None None O
, None None O
60 None None O
and None None O
75 None None O
min None None O
. None None O

Figure None None O
4 None None O

Effect None None O
of None None O
CSLE None None O
( None None O
100 None None O
, None None O
200 None None O
and None None O
500 None None O
mg None None O
/ None None O
kg None None O
) None None O
and None None O
morphine None None O
on None None O
the None None O
latency None None O
response None None O
of None None O
mice None None O
in None None O
the None None O
tail None None O
flick None None O
test None None O
. None None O

Values None None O
are None None O
presented None None O
as None None O
the None None O
mean None None O
+ None None O
/ None None O
- None None O
SEM None None O
( None None O
n None None O
= None None O
5 None None O
) None None O
* None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
, None None O
significant None None O
increase None None O
from None None O
control None None O

Molecular None None O
biology None None O
of None None O
cervical None None O
cancer None None O
and None None O
its None None O
precursors None None O
. None None O

Cervical None None O
cancer None None O
develops None None O
from None None O
well None None O
- None None O
defined None None O
precursor None None O
lesions None None O
referred None None O
to None None O
as None None O
either None None O
cervical None None O
intraepithelial None None O
neoplasia None None O
or None None O
squamous None None O
intraepithelial None None O
lesions None None O
. None None O

It None None O
is None None O
now None None O
known None None O
that None None O
specific None None O
types None None O
of None None O
human None None O
papillomaviruses None None O
( None None O
HPV None None O
) None None O
are None None O
the None None O
principal None None O
etiologic None None O
agents None None O
for None None O
both None None O
cervical None None O
cancer None None O
and None None O
its None None O
precursors None None O
. None None O

The None None O
high None None O
- None None O
oncogenic None None O
- None None O
risk None None O
HPV None None O
types None None O
associated None None O
with None None O
invasive None None O
cervical None None O
cancer None None O
produce None None O
two None None O
oncoproteins None None O
, None None O
designated None None O
E6 None None O
and None None O
E7 None None O
, None None O
which None None O
interact None None O
with None None O
endogenous None None O
cell None None O
cycle None None O
regulatory None None O
proteins None None O
, None None O
including None None O
p53 None None O
and None None O
Rb None None O
. None None O

The None None O
interaction None None O
of None None O
virally None None O
derived None None O
and None None O
endogenous None None O
cellular None None O
proteins None None O
converges None None O
in None None O
deregulation None None O
of None None O
cell None None O
cycle None None O
progression None None O
and None None O
appears None None O
to None None O
be None None O
critical None None O
for None None O
the None None O
development None None O
of None None O
cervical None None O
cancers None None O
. None None O

However None None O
, None None O
the None None O
development None None O
of None None O
cervical None None O
cancer None None O
is None None O
a None None O
multistep None None O
process None None O
that None None O
cannot None None O
be None None O
explained None None O
simply None None O
by None None O
infection None None O
with None None O
specific None None O
types None None O
of None None O
HPV None None O
. None None O

One None None O
additional None None O
event None None O
that None None O
appears None None O
to None None O
play None None O
a None None O
role None None O
in None None O
tumor None None O
progression None None O
is None None O
integration None None O
of None None O
HPV None None O
DNA None None O
into None None O
the None None O
host None None O
genome None None O
. None None O

Integration None None O
of None None O
HPV None None O
DNA None None O
frequently None None O
disrupts None None O
the None None O
E2 None None O
open None None O
reading None None O
frames None None O
, None None O
resulting None None O
in None None O
overexpression None None O
of None None O
the None None O
E6 None None O
and None None O
E7 None None O
oncoproteins None None O
and None None O
possibly None None O
causing None None O
genomic None None O
instability None None O
. None None O

Additional None None O
cofactors None None O
and None None O
mutational None None O
events None None O
may None None O
be None None O
important None None O
in None None O
the None None O
pathogenesis None None O
of None None O
invasive None None O
cervical None None O
cancers None None O
and None None O
may None None O
include None None O
chromosomal None None O
rearrangements None None O
, None None O
loss None None O
of None None O
constitutional None None O
heterozygosity None None O
, None None O
and None None O
proto None None O
- None None O
oncogene None None O
activation None None O
. None None O

A None None O
small None None O
peptide None None O
derived None None O
from None None O
Flt None None O
- None None O
1 None None O
( None None O
VEGFR None None O
- None None O
1 None None O
) None None O
functions None None O
as None None O
an None None O
angiogenic None None O
inhibitor None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
is None None O
an None None O
angiogenic None None O
stimulator None None O
which None None O
functions None None O
through None None O
two None None O
endothelial None None O
specific None None O
tyrosine None None O
kinase None None O
receptors None None O
, None None O
Flt None None O
- None None O
1 None None O
and None None O
Flk None None O
- None None O
1 None None O
. None None O

In None None O
this None None O
work None None O
, None None O
we None None O
show None None O
that None None O
an None None O
11 None None O
- None None O
amino None None O
acid None None O
peptide None None O
derived None None O
from None None O
the None None O
second None None O
immunoglobulin None None O
- None None O
like None None O
domain None None O
of None None O
Flt None None O
- None None O
1 None None O
functions None None O
as None None O
an None None O
angiogenic None None O
inhibitor None None O
in None None O
chick None None O
chorioallantoic None None O
membrane None None O
and None None O
inhibited None None O
VEGF None None O
- None None O
induced None None O
vascular None None O
permeability None None O
in None None O
Miles None None O
' None None O
assay None None O
without None None O
binding None None O
to None None O
VEGF None None O
directly None None O
. None None O

Circular None None O
dichroism None None O
and None None O
nuclear None None O
magnetic None None O
resonance None None O
analyses None None O
indicate None None O
that None None O
this None None O
peptide None None O
forms None None O
a None None O
stable None None O
extended None None O
structure None None O
in None None O
solution None None O
, None None O
presumably None None O
beta None None O
- None None O
sheet None None O
structure None None O
and None None O
is None None O
most None None O
likely None None O
existing None None O
as None None O
a None None O
dimer None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
this None None O
small None None O
peptide None None O
functions None None O
as None None O
an None None O
angiogenic None None O
inhibitor None None O
by None None O
inhibiting None None O
VEGF None None O
function None None O
through None None O
a None None O
non None None O
- None None O
VEGF None None O
binding None None O
mechanism None None O
. None None O

Appearance None None O
of None None O
tumorous None None O
phenotypes None None O
in None None O
goldfish None None O
erythrophores None None O
transfected None None O
with None None O
ras None None O
, None None O
src None None O
, None None O
and None None O
myc None None O
oncogenes None None O
and None None O
spontaneous None None O
differentiation None None O
of None None O
the None None O
transformants None None O
in None None O
vitro None None O
. None None O

When None None O
goldfish None None O
erythrophores None None O
isolated None None O
from None None O
the None None O
skin None None O
by None None O
tissue None None O
digestion None None O
and None None O
centrifugation None None O
in None None O
a None None O
Percoll None None O
density None None O
gradient None None O
were None None O
transfected None None O
in None None O
a None None O
monolayer None None O
- None None O
culture None None O
with None None O
v None None O
- None None O
Ha None None O
- None None O
ras None None O
or None None O
v None None O
- None None O
src None None O
oncogene None None O
either None None O
singly None None O
or None None O
in None None O
combination None None O
with None None O
v None None O
- None None O
myc None None O
by None None O
means None None O
of None None O
calcium None None O
phosphate None None O
- None None O
DNA None None O
co None None O
- None None O
precipitation None None O
, None None O
there None None O
appeared None None O
a None None O
certain None None O
number None None O
of None None O
transformants None None O
manifesting None None O
a None None O
chromatoblast None None O
- None None O
like None None O
profile None None O
and None None O
tumorous None None O
phenotypes None None O
as None None O
seen None None O
in None None O
the None None O
capability None None O
for None None O
unlimited None None O
growth None None O
, None None O
and None None O
piling None None O
- None None O
up None None O
in None None O
a None None O
monolayer None None O
- None None O
culture None None O
or None None O
colony None None O
formation None None O
in None None O
semi None None O
- None None O
solid None None O
soft None None O
agar None None O
. None None O

After None None O
successive None None O
growth None None O
in None None O
vitro None None O
for None None O
longer None None O
than None None O
one None None O
month None None O
which None None O
was None None O
scarcely None None O
observed None None O
with None None O
the None None O
erythrophores None None O
, None None O
the None None O
vast None None O
majority None None O
of None None O
such None None O
transformants None None O
began None None O
to None None O
differentiate None None O
into None None O
erythrophores None None O
and None None O
ceased None None O
proliferation None None O
spontaneously None None O
. None None O

The None None O
onset None None O
of None None O
their None None O
differentiation None None O
was None None O
ascertained None None O
by None None O
the None None O
deposition None None O
of None None O
marker None None O
pteridine None None O
pigments None None O
. None None O

None None None O
of None None O
the None None O
transformants None None O
differentiated None None O
into None None O
melanophores None None O
or None None O
iridophores None None O
or None None O
other None None O
neural None None O
crest None None O
derivatives None None O
as None None O
seen None None O
in None None O
goldfish None None O
erythrophoroma None None O
cells None None O
. None None O

Little None None O
difference None None O
was None None O
observed None None O
in None None O
their None None O
transforming None None O
efficiency None None O
( None None O
0 None None O
. None None O
2 None None O
- None None O
0 None None O
. None None O
3 None None O
transformants None None O
/ None None O
micrograms None None O
DNA None None O
) None None O
between None None O
the None None O
combinations None None O
of None None O
oncogenes None None O
applied None None O
but None None O
a None None O
tendency None None O
was None None O
noted None None O
that None None O
cells None None O
transfected None None O
with None None O
ras None None O
or None None O
src None None O
in None None O
combination None None O
with None None O
myc None None O
developed None None O
the None None O
capacity None None O
to None None O
grow None None O
for None None O
a None None O
longer None None O
period None None O
and None None O
differentiated None None O
at None None O
a None None O
later None None O
stage None None O
than None None O
those None None O
transfected None None O
solely None None O
with None None O
ras None None O
or None None O
src None None O
. None None O

One None None O
cell None None O
line None None O
( None None O
ESM None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
) None None O
derived None None O
from None None O
the None None O
erythrophores None None O
transfected None None O
with None None O
src None None O
/ None None O
myc None None O
grew None None O
successively None None O
over None None O
nine None None O
months None None O
, None None O
indicating None None O
its None None O
acquisition None None O
of None None O
immortality None None O
. None None O

The None None O
expression None None O
of None None O
the None None O
transfected None None O
oncogenes None None O
in None None O
this None None O
cell None None O
line None None O
was None None O
examined None None O
in None None O
comparison None None O
with None None O
the None None O
erythrophoroma None None O
cells None None O
by None None O
Western None None O
and None None O
Northern None None O
blot None None O
analyses None None O
. None None O

Collaxa None None O
BPEL None None O
Server None None O
Screenshot None None O
of None None O
Collaxa None None O
' None None O
s None None O
bpelz None None O
design None None O
tool None None O
, None None O
building None None O
a None None O
choreography None None O
of None None O
GetHAPI None None O
and None None O
GetUMLS None None O
web None None O
services None None O

[ None None O
Suppurated None None O
acute None None O
obstructive None None O
cholangitis None None O
. None None O
Anatomoclinical None None O
and None None O
therapeutic None None O
aspects None None O
] None None O
. None None O

A None None O
total None None O
of None None O
134 None None O
cases None None O
are None None O
discussed None None O
, None None O
with None None O
suppurated None None O
acute None None O
obstructive None None O
angiocholitis None None O
, None None O
that None None O
underwent None None O
surgical None None O
treatment None None O
over None None O
a None None O
period None None O
of None None O
10 None None O
years None None O
, None None O
representing None None O
12 None None O
, None None O
8 None None O
% None None O
of None None O
the None None O
total None None O
number None None O
of None None O
organic None None O
obstructions None None O
of None None O
the None None O
hepato None None O
- None None O
choledocus None None O
. None None O

From None None O
the None None O
standpoint None None O
of None None O
the None None O
etiopathogenic None None O
mechanisms None None O
the None None O
angiocholitis None None O
was None None O
determined None None O
by None None O
biliary None None O
lithiasis None None O
in None None O
59 None None O
cases None None O
, None None O
by None None O
sclerosis None None O
of None None O
the None None O
Oddi None None O
sphincter None None O
in None None O
5 None None O
cases None None O
, None None O
by None None O
postoperative None None O
cicatriceal None None O
stenosis None None O
of None None O
the None None O
main None None O
biliary None None O
pathway None None O
in None None O
2 None None O
cases None None O
, None None O
by None None O
hepatic None None O
hydatitosis None None O
in None None O
16 None None O
cases None None O
, None None O
by None None O
Vater None None O
ampuloma None None O
in None None O
10 None None O
cases None None O
by None None O
cancers None None O
of None None O
the None None O
main None None O
biliary None None O
pathway None None O
in None None O
40 None None O
cases None None O
and None None O
by None None O
the None None O
congenital None None O
cyst None None O
of None None O
the None None O
choledocus None None O
in None None O
one None None O
case None None O
. None None O

The None None O
high None None O
frequency None None O
was None None O
noted None None O
, None None O
of None None O
the None None O
severe None None O
forms None None O
of None None O
ictero None None O
- None None O
uremigenic None None O
angiocholitis None None O
( None None O
representing None None O
68 None None O
cases None None O
, None None O
or None None O
50 None None O
, None None O
7 None None O
% None None O
of None None O
the None None O
total None None O
, None None O
with None None O
a None None O
death None None O
rate None None O
of None None O
34 None None O
% None None O
) None None O
. None None O

Medico None None O
- None None O
surgical None None O
treatment None None O
should None None O
be None None O
performed None None O
as None None O
early None None O
as None None O
possible None None O
, None None O
and None None O
it None None O
must None None O
be None None O
intensive None None O
, None None O
complex None None O
, None None O
and None None O
adapted None None O
to None None O
the None None O
anatomo None None O
- None None O
clinical None None O
forms None None O
. None None O

The None None O
authors None None O
performed None None O
evacuation None None O
choledocotomy None None O
with None None O
external None None O
draining None None O
in None None O
22 None None O
cases None None O
( None None O
3 None None O
deaths None None O
) None None O
, None None O
and None None O
choledoco None None O
- None None O
duodenal None None O
anastomosis None None O
in None None O
46 None None O
cases None None O
( None None O
10 None None O
deaths None None O
) None None O
, None None O
choledoco None None O
- None None O
jejunostomia None None O
in None None O
3 None None O
cases None None O
, None None O
Oddi None None O
sphincterotomia None None O
in None None O
12 None None O
cases None None O
( None None O
2 None None O
deaths None None O
) None None O
ampulectomia None None O
in None None O
5 None None O
cases None None O
( None None O
2 None None O
deaths None None O
) None None O
. None None O

Peripheral None None O
bilio None None O
- None None O
hepatodigestive None None O
anastomoses None None O
were None None O
performed None None O
in None None O
40 None None O
cases None None O
with None None O
5 None None O
deaths None None O
. None None O

Outcomes None None O

The None None O
primary None None O
outcomes None None O
of None None O
this None None O
study None None O
are None None O
smoking None None O
abstinence None None O
rates None None O
post None None O
release None None O
as None None O
well None None O
as None None O
number None None O
of None None O
days None None O
to None None O
first None None O
cigarette None None O
after None None O
release None None O
. None None O

Seven None None O
day None None O
point None None O
- None None O
prevalence None None O
abstinence None None O
will None None O
be None None O
determined None None O
by None None O
combining None None O
self None None O
- None None O
reported None None O
tobacco None None O
use None None O
over None None O
the None None O
prior None None O
seven None None O
days None None O
and None None O
urine None None O
cotinine None None O
assays None None O
( None None O
below None None O
200 None None O
ng None None O
/ None None O
ml None None O
versus None None O
200 None None O
or None None O
above None None O
) None None O
. None None O

Participants None None O
with None None O
self None None O
- None None O
reported None None O
abstinence None None O
and None None O
cotinine None None O
levels None None O
below None None O
the None None O
cut None None O
- None None O
off None None O
will None None O
be None None O
classified None None O
as None None O
abstinent None None O
. None None O

Participants None None O
lost None None O
to None None O
follow None None O
- None None O
up None None O
will None None O
be None None O
considered None None O
non None None O
- None None O
abstinent None None O
. None None O

A None None O
secondary None None O
analysis None None O
will None None O
examine None None O
the None None O
effect None None O
of None None O
length None None O
of None None O
forced None None O
abstinence None None O
on None None O
quit None None O
rates None None O
. None None O

The None None O
Akt None None O
/ None None O
mTOR None None O
pathway None None O
assures None None O
the None None O
synthesis None None O
of None None O
HIF None None O
- None None O
1alpha None None O
protein None None O
in None None O
a None None O
glucose None None O
- None None O
and None None O
reoxygenation None None O
- None None O
dependent None None O
manner None None O
in None None O
irradiated None None O
tumors None None O
. None None O

Transcriptional None None O
activity None None O
of None None O
HIF None None O
- None None O
1 None None O
( None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
- None None O
1 None None O
) None None O
has None None O
been None None O
reported None None O
to None None O
be None None O
up None None O
- None None O
regulated None None O
in None None O
solid None None O
tumors None None O
after None None O
ionizing None None O
radiation None None O
; None None O
however None None O
, None None O
the None None O
molecular None None O
mechanism None None O
underlying None None O
the None None O
response None None O
remains None None O
to None None O
be None None O
elucidated None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
performed None None O
a None None O
series None None O
of None None O
molecular None None O
imaging None None O
experiments None None O
using None None O
a None None O
HIF None None O
- None None O
1 None None O
- None None O
dependent None None O
reporter None None O
gene None None O
, None None O
5HREp None None O
- None None O
ODD None None O
- None None O
luc None None O
, None None O
and None None O
found None None O
an None None O
essential None None O
role None None O
of None None O
the None None O
Akt None None O
/ None None O
mTOR None None O
pathway None None O
. None None O

Hypoxic None None O
tumor None None O
cells None None O
distant None None O
from None None O
blood None None O
vessels None None O
were None None O
dramatically None None O
reoxygenated None None O
at None None O
24 None None O
h None None O
postirradiation None None O
, None None O
and None None O
HIF None None O
- None None O
1 None None O
activity None None O
increased None None O
as None None O
HIF None None O
- None None O
1alpha None None O
accumulated None None O
in None None O
the None None O
reoxygenated None None O
regions None None O
. None None O

The None None O
accumulation None None O
was None None O
inhibited None None O
with None None O
a None None O
nonmetabolizable None None O
glucose None None O
analog None None O
, None None O
2 None None O
- None None O
deoxy None None O
- None None O
d None None O
- None None O
glucose None None O
, None None O
through None None O
the None None O
suppression None None O
of None None O
radiation None None O
- None None O
induced None None O
phosphorylation None None O
of None None O
Akt None None O
in None None O
the None None O
reoxygenated None None O
regions None None O
. None None O

Akt None None O
knockdown None None O
and None None O
an None None O
mTOR None None O
inhibitor None None O
revealed None None O
the None None O
importance None None O
of None None O
the None None O
Akt None None O
/ None None O
mTOR None None O
pathway None None O
in None None O
the None None O
postirradiation None None O
accumulation None None O
of None None O
HIF None None O
- None None O
1alpha None None O
. None None O

In None None O
vitro None None O
experiments None None O
confirmed None None O
that None None O
an None None O
increase None None O
in None None O
glucose None None O
availability None None O
induced None None O
Akt None None O
phosphorylation None None O
under None None O
reoxygenated None None O
conditions None None O
and None None O
consequently None None O
up None None O
- None None O
regulated None None O
HIF None None O
- None None O
1alpha None None O
translation None None O
. None None O

Moreover None None O
, None None O
both None None O
the None None O
accelerated None None O
translation None None O
and None None O
the None None O
previously None None O
reported None None O
reactive None None O
oxygen None None O
species None None O
- None None O
mediated None None O
stabilization None None O
of None None O
HIF None None O
- None None O
1alpha None None O
protein None None O
were None None O
essential None None O
to None None O
the None None O
activation None None O
of None None O
HIF None None O
- None None O
1 None None O
. None None O

All None None O
of None None O
these None None O
results None None O
indicate None None O
that None None O
Akt None None O
/ None None O
mTOR None None O
- None None O
dependent None None O
translation None None O
of None None O
HIF None None O
- None None O
1alpha None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
the None None O
postirradiation None None O
up None None O
- None None O
regulation None None O
of None None O
intratumoral None None O
HIF None None O
- None None O
1 None None O
activity None None O
in None None O
response None None O
to None None O
radiation None None O
- None None O
induced None None O
alterations None None O
of None None O
glucose None None O
and None None O
oxygen None None O
availability None None O
in None None O
a None None O
solid None None O
tumor None None O
. None None O

Miscellaneous None None O
Proteins None None O

Apart None None O
from None None O
the None None O
above None None O
- None None O
described None None O
proteins None None O
, None None O
several None None O
other None None O
molecules None None O
are None None O
also None None O
associated None None O
with None None O
the None None O
pathological None None O
lesions None None O
of None None O
AD None None O
, None None O
and None None O
some None None O
of None None O
these None None O
can None None O
be None None O
regarded None None O
as None None O
amateur None None O
chaperones None None O
. None None O

Acute None None O
phase None None O
proteins None None O
, None None O
such None None O
as None None O
alpha1 None None O
- None None O
antichymotrypsin None None O
( None None O
ACT None None O
) None None O
, None None O
alpha2 None None O
- None None O
macroglobulin None None O
( None None O
alpha2M None None O
) None None O
, None None O
and None None O
SAP None None O
, None None O
are None None O
all None None O
associated None None O
with None None O
Abeta None None O
deposition None None O
[ None None O
129 None None O
- None None O
132 None None O
] None None O
. None None O

ACT None None O
is None None O
a None None O
serine None None O
protease None None O
inhibitor None None O
of None None O
the None None O
serpin None None O
family None None O
, None None O
and None None O
in None None O
AD None None O
, None None O
ACT None None O
levels None None O
are None None O
upregulated None None O
, None None O
and None None O
binding None None O
of None None O
ACT None None O
with None None O
Abeta None None O
induces None None O
Abeta None None O
fibrillogenesis None None O
[ None None O
133 None None O
- None None O
135 None None O
] None None O
. None None O

Furthermore None None O
, None None O
when None None O
ACT None None O
is None None O
overexpressed None None O
in None None O
transgenic None None O
mice None None O
, None None O
an None None O
increased None None O
plaque None None O
load None None O
in None None O
the None None O
brains None None O
of None None O
these None None O
mice None None O
and None None O
impaired None None O
spatial None None O
learning None None O
is None None O
observed None None O
[ None None O
134 None None O
, None None O
135 None None O
] None None O
. None None O

alpha2M None None O
also None None O
binds None None O
Abeta None None O
, None None O
although None None O
in None None O
contrast None None O
to None None O
ACT None None O
, None None O
this None None O
binding None None O
prevents None None O
Abeta None None O
fibril None None O
formation None None O
and None None O
fibril None None O
- None None O
associated None None O
neurotoxicity None None O
[ None None O
136 None None O
, None None O
137 None None O
] None None O
. None None O

alpha2M None None O
promotes None None O
the None None O
protease None None O
- None None O
mediated None None O
degradation None None O
of None None O
alpha2M None None O
/ None None O
Abeta None None O
complexes None None O
and None None O
contributes None None O
to None None O
clearance None None O
of None None O
Abeta None None O
from None None O
the None None O
brain None None O
( None None O
discussed None None O
in None None O
paragraph None None O
4 None None O
) None None O
[ None None O
138 None None O
, None None O
139 None None O
] None None O
. None None O

The None None O
glycoprotein None None O
SAP None None O
belongs None None O
to None None O
the None None O
pentraxin None None O
family None None O
and None None O
is None None O
a None None O
common None None O
component None None O
of None None O
all None None O
known None None O
types None None O
of None None O
amyloid None None O
fibrils None None O
. None None O

SAP None None O
is None None O
upregulated None None O
in None None O
AD None None O
and None None O
protects None None O
amyloid None None O
fibrils None None O
from None None O
proteolysis None None O
in None None O
vitro None None O
[ None None O
140 None None O
, None None O
141 None None O
] None None O
. None None O

SAP None None O
not None None O
only None None O
colocalizes None None O
with None None O
SPs None None O
and None None O
interacts None None O
with None None O
aggregated None None O
Abeta None None O
; None None O
SAP None None O
oligomers None None O
also None None O
bind None None O
and None None O
activate None None O
C1 None None O
[ None None O
142 None None O
] None None O
. None None O

Both None None O
C1 None None O
and None None O
SAP None None O
may None None O
bind None None O
to None None O
fibrillar None None O
Abeta None None O
deposits None None O
in None None O
vivo None None O
and None None O
induce None None O
microglial None None O
activation None None O
, None None O
as None None O
cultured None None O
human None None O
microglial None None O
cells None None O
show None None O
an None None O
increase None None O
in None None O
cytokine None None O
production None None O
after None None O
co None None O
- None None O
stimulation None None O
of None None O
Abeta None None O
with None None O
C1q None None O
and None None O
SAP None None O
[ None None O
104 None None O
] None None O
. None None O

These None None O
observations None None O
further None None O
strengthen None None O
the None None O
above None None O
- None None O
noted None None O
suggestion None None O
that None None O
not None None O
only None None O
Abeta None None O
, None None O
but None None O
also None None O
several None None O
Abeta None None O
- None None O
binding None None O
proteins None None O
, None None O
are None None O
capable None None O
of None None O
activating None None O
the None None O
complement None None O
system None None O
, None None O
and None None O
thus None None O
, None None O
contribute None None O
to None None O
neuroinflammation None None O
in None None O
AD None None O
. None None O

In None None O
addition None None O
, None None O
both None None O
alpha2M None None O
and None None O
ACT None None O
, None None O
in None None O
contrast None None O
to None None O
SAP None None O
, None None O
can None None O
be None None O
regarded None None O
as None None O
amateur None None O
chaperones None None O
, None None O
as None None O
they None None O
regulate None None O
conformational None None O
changes None None O
of None None O
Abeta None None O
. None None O

Tissue None None O
- None None O
type None None O
plasminogen None None O
activator None None O
( None None O
tPA None None O
) None None O
regulates None None O
activation None None O
of None None O
plasminogen None None O
into None None O
plasmin None None O
and None None O
is None None O
expressed None None O
in None None O
various None None O
regions None None O
of None None O
the None None O
brain None None O
especially None None O
in None None O
the None None O
hippocampus None None O
[ None None O
143 None None O
] None None O
. None None O

Several None None O
reports None None O
suggested None None O
an None None O
important None None O
role None None O
for None None O
tPA None None O
in None None O
AD None None O
, None None O
as None None O
the None None O
tPA None None O
system None None O
is None None O
involved None None O
in None None O
Abeta None None O
turnover None None O
[ None None O
144 None None O
, None None O
145 None None O
] None None O
. None None O

Fibrillar None None O
forms None None O
of None None O
Abeta None None O
stimulate None None O
tPA None None O
activity None None O
in None None O
vitro None None O
, None None O
whereas None None O
in None None O
AD None None O
patients None None O
, None None O
a None None O
reduction None None O
of None None O
tPA None None O
activity None None O
is None None O
observed None None O
in None None O
the None None O
affected None None O
areas None None O
[ None None O
144 None None O
, None None O
146 None None O
] None None O
. None None O

Although None None O
tPA None None O
has None None O
no None None O
effect None None O
on None None O
conformational None None O
changes None None O
of None None O
Abeta None None O
, None None O
it None None O
might None None O
play None None O
a None None O
role None None O
in None None O
the None None O
clearance None None O
of None None O
Abeta None None O
from None None O
the None None O
brain None None O
( None None O
paragraph None None O
4 None None O
] None None O
. None None O

The None None O
actin None None O
- None None O
regulatory None None O
protein None None O
gelsolin None None O
is None None O
found None None O
both None None O
intracellularly None None O
and None None O
in None None O
plasma None None O
[ None None O
147 None None O
, None None O
148 None None O
] None None O
. None None O

Plasma None None O
gelsolin None None O
can None None O
be None None O
considered None None O
an None None O
amateur None None O
chaperone None None O
, None None O
as None None O
it None None O
binds None None O
Abeta None None O
and None None O
not None None O
only None None O
inhibits None None O
its None None O
Abeta None None O
fibrillization None None O
but None None O
is None None O
also None None O
capable None None O
of None None O
degrading None None O
preformed None None O
Abeta None None O
fibrils None None O
[ None None O
149 None None O
, None None O
150 None None O
] None None O
. None None O

Furthermore None None O
, None None O
gelsolin None None O
inhibits None None O
Abeta None None O
- None None O
mediated None None O
neurotoxicity None None O
[ None None O
151 None None O
] None None O
. None None O

One None None O
of None None O
the None None O
major None None O
gangliosides None None O
in None None O
the None None O
brain None None O
is None None O
GM1 None None O
. None None O

Soluble None None O
Abeta None None O
binds None None O
GM1 None None O
and None None O
the None None O
formed None None O
complexes None None O
accelerate None None O
Abeta None None O
fibrillogenesis None None O
by None None O
acting None None O
as None None O
a None None O
seed None None O
for None None O
Abeta None None O
[ None None O
152 None None O
] None None O
. None None O

In None None O
the None None O
presence None None O
of None None O
GM1 None None O
, None None O
Abeta None None O
is None None O
more None None O
neurotoxic None None O
than None None O
Abeta None None O
alone None None O
, None None O
and None None O
cholesterol None None O
- None None O
rich None None O
membranes None None O
demonstrate None None O
accelerated None None O
Abeta None None O
binding None None O
due None None O
to None None O
the None None O
formation None None O
of None None O
GM1 None None O
clusters None None O
[ None None O
153 None None O
, None None O
154 None None O
] None None O
. None None O

As None None O
GM1 None None O
is None None O
a None None O
major None None O
component None None O
of None None O
lipid None None O
rafts None None O
and None None O
recent None None O
studies None None O
suggest None None O
that None None O
Abeta None None O
accumulation None None O
in None None O
these None None O
lipid None None O
rafts None None O
is None None O
an None None O
early None None O
event None None O
in None None O
AD None None O
development None None O
, None None O
GM1 None None O
might None None O
play None None O
an None None O
important None None O
role None None O
in None None O
the None None O
early None None O
steps None None O
in None None O
AD None None O
pathogenesis None None O
[ None None O
155 None None O
, None None O
156 None None O
] None None O
. None None O

In None None O
summary None None O
, None None O
several None None O
proteins None None O
are None None O
associated None None O
with None None O
Abeta None None O
aggregates None None O
in None None O
the None None O
AD None None O
brain None None O
and None None O
contribute None None O
to None None O
the None None O
aggregation None None O
of None None O
Abeta None None O
and None None O
should None None O
, None None O
therefore None None O
, None None O
be None None O
considered None None O
as None None O
amateur None None O
chaperones None None O
. None None O

In None None O
addition None None O
, None None O
they None None O
might None None O
play None None O
a None None O
role None None O
in None None O
triggering None None O
inflammation None None O
. None None O

14 None None O
- None None O
3 None None O
- None None O
3zeta None None O
Overexpression None None O
and None None O
abnormal None None O
beta None None O
- None None O
catenin None None O
expression None None O
are None None O
associated None None O
with None None O
poor None None O
differentiation None None O
and None None O
progression None None O
in None None O
stage None None O
I None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
cancer None None O
. None None O

Recent None None O
studies None None O
have None None O
shown None None O
that None None O
14 None None O
- None None O
3 None None O
- None None O
3zeta None None O
interacted None None O
with None None O
other None None O
key None None O
cellular None None O
proteins None None O
involved None None O
in None None O
the None None O
tumor None None O
development None None O
and None None O
progression None None O
. None None O

Knowledge None None O
of None None O
14 None None O
- None None O
3 None None O
- None None O
3zeta None None O
and None None O
beta None None O
- None None O
catenin None None O
expression None None O
and None None O
clinical None None O
significance None None O
in None None O
the None None O
same None None O
tumor None None O
tissues None None O
is None None O
limited None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
expression None None O
and None None O
significance None None O
of None None O
14 None None O
- None None O
3 None None O
- None None O
3zeta None None O
and None None O
beta None None O
- None None O
catenin None None O
in None None O
stage None None O
I None None O
non None None O
- None None O
small None None O
- None None O
cell None None O
lung None None O
cancer None None O
( None None O
NSCLC None None O
) None None O
. None None O

Specimens None None O
of None None O
NSCLC None None O
and None None O
adjacent None None O
normal None None O
lung None None O
tissues None None O
were None None O
collected None None O
from None None O
110 None None O
patients None None O
. None None O

The None None O
expressions None None O
of None None O
14 None None O
- None None O
3 None None O
- None None O
3zeta None None O
and None None O
beta None None O
- None None O
catenin None None O
were None None O
detected None None O
by None None O
western None None O
blotting None None O
, None None O
double None None O
labeling None None O
immunofluorescence None None O
, None None O
confocal None None O
laser None None O
scanning None None O
microscopy None None O
and None None O
immunohistochemistry None None O
. None None O

The None None O
expression None None O
of None None O
14 None None O
- None None O
3 None None O
- None None O
3zeta None None O
was None None O
upregulated None None O
in None None O
stage None None O
I None None O
NSCLC None None O
. None None O

Further None None O
, None None O
the None None O
overexpression None None O
of None None O
14 None None O
- None None O
3 None None O
- None None O
3zeta None None O
correlated None None O
with None None O
histological None None O
grades None None O
, None None O
lymph None None O
node None None O
metastasis None None O
and None None O
poor None None O
clinical None None O
outcome None None O
. None None O

Abnormal None None O
expression None None O
of None None O
beta None None O
- None None O
catenin None None O
was None None O
significantly None None O
correlated None None O
with None None O
poor None None O
differentiation None None O
and None None O
lymph None None O
node None None O
metastasis None None O
. None None O

Abnormal None None O
beta None None O
- None None O
catenin None None O
expression None None O
was None None O
associated None None O
significantly None None O
with None None O
positive None None O
14 None None O
- None None O
3 None None O
- None None O
3zeta None None O
expression None None O
. None None O

In None None O
conclusion None None O
, None None O
14 None None O
- None None O
3 None None O
- None None O
3zeta None None O
and None None O
beta None None O
- None None O
catenin None None O
might None None O
have None None O
an None None O
important None None O
role None None O
in None None O
development None None O
, None None O
progression None None O
and None None O
metastatic None None O
process None None O
of None None O
NSCLC None None O
. None None O

14 None None O
- None None O
3 None None O
- None None O
3zeta None None O
might None None O
be None None O
used None None O
as None None O
prognostic None None O
biomarkers None None O
for None None O
NSCLC None None O
. None None O

Recombinant None None O
human None None O
prothrombin None None O
kringle None None O
- None None O
2 None None O
inhibits None None O
B16F10 None None I-Cell-line-name
melanoma None None O
metastasis None None O
through None None O
inhibition None None O
of None None O
neovascularization None None O
and None None O
reduction None None O
of None None O
matrix None None O
metalloproteinase None None O
expression None None O
. None None O

Angiogenesis None None O
, None None O
a None None O
multi None None O
- None None O
step None None O
process None None O
which None None O
involves None None O
endothelial None None O
cell None None O
proliferation None None O
, None None O
adhesion None None O
, None None O
migration None None O
, None None O
and None None O
basement None None O
membrane None None O
( None None O
BM None None O
) None None O
degradation None None O
, None None O
is None None O
essential None None O
for None None O
tumor None None O
metastasis None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
recombinant None None O
human None None O
prothrombin None None O
kringle None None O
- None None O
2 None None O
( None None O
rk None None O
- None None O
2 None None O
) None None O
inhibited None None O
bovine None None O
capillary None None O
endothelial None None O
cell None None O
migration None None O
with None None O
an None None O
IC None None O
( None None O
50 None None O
) None None O
( None None O
concentration None None O
for None None O
half None None O
maximal None None O
inhibition None None O
) None None O
of None None O
38 None None O
nM None None O
and None None O
inhibited None None O
adhesion None None O
to None None O
extracellular None None O
matrix None None O
( None None O
ECM None None O
) None None O
proteins None None O
. None None O

Because None None O
tumor None None O
metastasis None None O
requires None None O
angiogenesis None None O
, None None O
we None None O
examined None None O
whether None None O
rk None None O
- None None O
2 None None O
could None None O
inhibit None None O
metastases None None O
induced None None O
by None None O
injection None None O
of None None O
B16F10 None None I-Cell-line-name
melanoma None None O
cells None None O
into None None O
mice None None O
. None None O

The None None O
results None None O
revealed None None O
that None None O
the None None O
metastatic None None O
tumors None None O
in None None O
mouse None None O
lung None None O
were None None O
markedly None None O
decreased None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
and None None O
acute None None O
lung None None O
injury None None O
induced None None O
by None None O
B16F10 None None I-Cell-line-name
melanoma None None O
metastasis None None O
was None None O
diminished None None O
by None None O
systemic None None O
rk None None O
- None None O
2 None None O
treatment None None O
. None None O

In None None O
immunohistochemical None None O
analysis None None O
, None None O
rk None None O
- None None O
2 None None O
reduced None None O
expression None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
, None None O
which None None O
is None None O
a None None O
potent None None O
angiogenic None None O
activator None None O
and None None O
neovascularization None None O
in None None O
the None None O
mouse None None O
lung None None O
. None None O

Also None None O
, None None O
rk None None O
- None None O
2 None None O
diminished None None O
the None None O
expression None None O
of None None O
matrix None None O
metalloproteinase None None O
- None None O
2 None None O
and None None O
- None None O
9 None None O
in None None O
the None None O
mouse None None O
lung None None O
which None None O
induces None None O
tumor None None O
metastasis None None O
and None None O
angiogenesis None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
inhibition None None O
of None None O
B16F10 None None I-Cell-line-name
melanoma None None O
metastasis None None O
by None None O
rk None None O
- None None O
2 None None O
was None None O
caused None None O
by None None O
inhibition None None O
of None None O
neovascularization None None O
and None None O
reduction None None O
of None None O
matrix None None O
metalloproteinase None None O
expression None None O
. None None O

Determination None None O
of None None O
eprosartan None None O
in None None O
human None None O
plasma None None O
and None None O
urine None None O
by None None O
LC None None O
/ None None O
MS None None O
/ None None O
MS None None O
. None None O

A None None O
protein None None O
precipitation None None O
, None None O
liquid None None O
chromatography None None O
/ None None O
tandem None None O
mass None None O
spectrometry None None O
( None None O
LC None None O
/ None None O
MS None None O
/ None None O
MS None None O
) None None O
method None None O
has None None O
been None None O
developed None None O
and None None O
validated None None O
for None None O
the None None O
determination None None O
of None None O
eprosartan None None O
in None None O
human None None O
plasma None None O
and None None O
urine None None O
. None None O

The None None O
solvent None None O
system None None O
also None None O
served None None O
as None None O
a None None O
protein None None O
precipitation None None O
reagent None None O
. None None O

The None None O
chromatographic None None O
separation None None O
was None None O
achieved None None O
on None None O
a None None O
CAPCELL None None O
PAK None None O
C18 None None O
column None None O
( None None O
50 None None O
mmx2 None None O
. None None O
0 None None O
mm None None O
, None None O
5 None None O
microm None None O
, None None O
Shiseido None None O
) None None O
. None None O

A None None O
mobile None None O
phase None None O
was None None O
consisted None None O
of None None O
0 None None O
. None None O
5 None None O
% None None O
formic None None O
acid None None O
in None None O
water None None O
and None None O
0 None None O
. None None O
5 None None O
% None None O
formic None None O
acid None None O
in None None O
acetonitrile None None O
( None None O
72 None None O
: None None O
28 None None O
) None None O
. None None O

Detection None None O
was None None O
by None None O
positive None None O
ion None None O
electrospray None None O
tandem None None O
mass None None O
spectrometry None None O
on None None O
a None None O
Sciex None None O
API3000 None None O
. None None O

The None None O
standard None None O
curves None None O
, None None O
which None None O
ranged None None O
from None None O
5 None None O
to None None O
2000 None None O
ng None None O
/ None None O
mL None None O
in None None O
human None None O
plasma None None O
and None None O
from None None O
0 None None O
. None None O
25 None None O
to None None O
50 None None O
microg None None O
/ None None O
mL None None O
in None None O
urine None None O
, None None O
were None None O
fitted None None O
to None None O
a None None O
1 None None O
/ None None O
x None None O
weighted None None O
quadratic None None O
regression None None O
model None None O
. None None O

The None None O
method None None O
proved None None O
to None None O
be None None O
accurate None None O
, None None O
specific None None O
and None None O
sensitive None None O
enough None None O
to None None O
be None None O
successfully None None O
applied None None O
to None None O
a None None O
pharmacokinetic None None O
study None None O
. None None O

No None None O
evidence None None O
for None None O
an None None O
influence None None O
of None None O
the None None O
human None None O
platelet None None O
antigen None None O
- None None O
1 None None O
polymorphism None None O
on None None O
the None None O
antiplatelet None None O
effects None None O
of None None O
glycoprotein None None O
IIb None None O
/ None None O
IIIa None None O
inhibitors None None O
. None None O

This None None O
study None None O
investigated None None O
the None None O
hypothesis None None O
that None None O
the None None O
human None None O
platelet None None O
antigen None None O
- None None O
1 None None O
( None None O
HPA None None O
- None None O
1 None None O
) None None O
polymorphism None None O
may None None O
influence None None O
the None None O
antiplatelet None None O
effects None None O
of None None O
glycoprotein None None O
( None None O
GP None None O
) None None O
IIb None None O
/ None None O
IIIa None None O
inhibitors None None O
. None None O

Adenosine None None O
diphosphate None None O
( None None O
30 None None O
micro None None O
mol None None O
) None None O
- None None O
induced None None O
fibrinogen None None O
binding None None O
was None None O
measured None None O
by None None O
flow None None O
cytometry None None O
. None None O

Abciximab None None O
( None None O
0 None None O
. None None O
03 None None O
- None None O
3 None None O
micro None None O
g None None O
/ None None O
ml None None O
) None None O
, None None O
tirofiban None None O
( None None O
0 None None O
. None None O
3 None None O
- None None O
30 None None O
nmol None None O
/ None None O
l None None O
) None None O
or None None O
eptifibatide None None O
( None None O
0 None None O
. None None O
01 None None O
- None None O
1 None None O
micro None None O
g None None O
/ None None O
ml None None O
) None None O
were None None O
incubated None None O
for None None O
15 None None O
min None None O
with None None O
the None None O
samples None None O
prior None None O
to None None O
stimulation None None O
. None None O

IC None None O
( None None O
50 None None O
) None None O
values None None O
for None None O
the None None O
inhibition None None O
of None None O
fibrinogen None None O
binding None None O
were None None O
determined None None O
from None None O
each None None O
experiment None None O
. None None O

All None None O
subjects None None O
were None None O
genotyped None None O
by None None O
GALIOS None None O
and None None O
automated None None O
fluorescence None None O
correlation None None O
spectroscopy None None O
. None None O

Although None None O
a None None O
marked None None O
variability None None O
in None None O
the None None O
inhibitory None None O
effects None None O
of None None O
all None None O
three None None O
GPIIb None None O
/ None None O
IIIa None None O
inhibitors None None O
was None None O
confirmed None None O
, None None O
there None None O
were None None O
no None None O
significant None None O
differences None None O
between None None O
the None None O
genotypes None None O
with None None O
respect None None O
to None None O
the None None O
inhibition None None O
of None None O
fibrinogen None None O
binding None None O
. None None O

Thus None None O
, None None O
the None None O
present None None O
study None None O
does None None O
not None None O
provide None None O
evidence None None O
for None None O
an None None O
effect None None O
of None None O
HPA None None O
- None None O
1 None None O
polymorphism None None O
on None None O
the None None O
inter None None O
- None None O
individual None None O
variability None None O
in None None O
the None None O
platelet None None O
inhibitory None None O
effects None None O
of None None O
the None None O
three None None O
GPIIb None None O
/ None None O
IIIa None None O
inhibitors None None O
approved None None O
for None None O
clinical None None O
use None None O
. None None O

MoClo None None O
cloning None None O
protocol None None O

Restriction None None O
- None None O
ligations None None O
were None None O
set None None O
up None None O
by None None O
pipetting None None O
in None None O
one None None O
tube None None O
approximately None None O
40 None None O
fmol None None O
( None None O
~ None None O
100 None None O
ng None None O
of None None O
DNA None None O
for None None O
a None None O
4 None None O
kb None None O
plasmid None None O
) None None O
of None None O
each None None O
DNA None None O
component None None O
( None None O
PCR None None O
product None None O
or None None O
plasmid None None O
) None None O
, None None O
10 None None O
U None None O
of None None O
the None None O
required None None O
restriction None None O
enzyme None None O
( None None O
BsaI None None O
or None None O
BpiI None None O
) None None O
and None None O
10 None None O
U None None O
T4 None None O
DNA None None O
ligase None None O
( None None O
using None None O
high None None O
concentration None None O
ligase None None O
, None None O
20 None None O
U None None O
/ None None O
microl None None O
) None None O
in None None O
Promega None None O
ligation None None O
buffer None None O
in None None O
a None None O
final None None O
reaction None None O
volume None None O
of None None O
20 None None O
microl None None O
. None None O

The None None O
reaction None None O
was None None O
incubated None None O
in None None O
a None None O
thermocycler None None O
for None None O
5 None None O
hours None None O
at None None O
37degreesC None None O
, None None O
5 None None O
min None None O
at None None O
50degreesC None None O
and None None O
10 None None O
min None None O
at None None O
80degreesC None None O
. None None O

The None None O
reaction None None O
mix None None O
was None None O
then None None O
added None None O
to None None O
100 None None O
microl None None O
chemically None None O
competent None None O
DH10b None None I-Cell-line-name
cells None None O
, None None O
incubated None None O
for None None O
15 None None O
- None None O
30 None None O
min None None O
on None None O
ice None None O
and None None O
transformed None None O
by None None O
heat None None O
shock None None O
. None None O

800 None None O
microl None None O
of None None O
liquid None None O
LB None None O
was None None O
then None None O
added None None O
to None None O
the None None O
transformation None None O
, None None O
and None None O
the None None O
cells None None O
were None None O
let None None O
to None None O
recover None None O
45 None None O
min None None O
at None None O
37degreesC None None O
. None None O

Different None None O
aliquots None None O
of None None O
the None None O
transformation None None O
were None None O
plated None None O
on None None O
LB None None O
plates None None O
containing None None O
the None None O
appropriate None None O
antibiotic None None O
. None None O

The None None O
number None None O
of None None O
colonies None None O
was None None O
counted None None O
for None None O
one None None O
or None None O
two None None O
selected None None O
plates None None O
( None None O
containing None None O
countable None None O
number None None O
of None None O
colonies None None O
) None None O
, None None O
or None None O
from None None O
a None None O
section None None O
of None None O
the None None O
plates None None O
when None None O
very None None O
high None None O
number None None O
of None None O
colonies None None O
were None None O
obtained None None O
even None None O
for None None O
the None None O
lowest None None O
volume None None O
plated None None O
. None None O

The None None O
number None None O
of None None O
colonies None None O
was None None O
then None None O
extrapolated None None O
for None None O
the None None O
entire None None O
transformation None None O
. None None O

For None None O
level None None O
2 None None O
- None None O
2 None None O
cloning None None O
, None None O
two None None O
type None None O
IIS None None O
enzymes None None O
were None None O
required None None O
, None None O
BpiI None None O
and None None O
BsaI None None O
. None None O

The None None O
same None None O
protocol None None O
was None None O
used None None O
as None None O
described None None O
above None None O
except None None O
that None None O
10 None None O
U None None O
and None None O
2 None None O
. None None O
5 None None O
U None None O
were None None O
used None None O
for None None O
the None None O
enzymes None None O
BpiI None None O
and None None O
BsaI None None O
, None None O
respectively None None O
. None None O

To None None O
optimize None None O
efficiency None None O
of None None O
the None None O
restriction None None O
- None None O
ligation None None O
for None None O
the None None O
final None None O
construct None None O
containing None None O
11 None None O
transcription None None O
units None None O
( None None O
cL2 None None O
- None None O
13 None None O
* None None O
) None None O
, None None O
a None None O
variation None None O
of None None O
this None None O
protocol None None O
was None None O
used None None O
as None None O
follows None None O
. None None O

The None None O
reaction None None O
mix None None O
was None None O
set None None O
up None None O
containing None None O
20 None None O
U None None O
ligase None None O
, None None O
5 None None O
U None None O
BpiI None None O
and None None O
5 None None O
U None None O
BsaI None None O
, None None O
in None None O
a None None O
total None None O
reaction None None O
volume None None O
of None None O
20 None None O
microl None None O
. None None O

The None None O
mix None None O
was None None O
incubated None None O
in None None O
a None None O
thermocycler None None O
with None None O
the None None O
following None None O
parameters None None O
: None None O
incubation None None O
for None None O
2 None None O
minutes None None O
at None None O
37degreesC None None O
, None None O
5 None None O
minutes None None O
at None None O
16degreesC None None O
, None None O
both None None O
steps None None O
repeated None None O
45 None None O
times None None O
, None None O
followed None None O
by None None O
incubation None None O
for None None O
5 None None O
minutes None None O
at None None O
50degreesC None None O
and None None O
10 None None O
minutes None None O
at None None O
80degreesC None None O
. None None O

The None None O
reaction None None O
mix None None O
was None None O
transformed None None O
in None None O
E None None O
. None None O
coli None None O
chemically None None O
competent None None O
cells None None O
as None None O
described None None O
above None None O
. None None O

Cyclin None None O
D1 None None O
/ None None O
bcl None None O
- None None O
1 None None O
cooperates None None O
with None None O
myc None None O
genes None None O
in None None O
the None None O
generation None None O
of None None O
B None None O
- None None O
cell None None O
lymphoma None None O
in None None O
transgenic None None O
mice None None O
. None None O

The None None O
chromosomal None None O
translocation None None O
t None None O
( None None O
11 None None O
: None None O
14 None None O
) None None O
is None None O
associated None None O
with None None O
human None None O
lymphoid None None O
neoplasia None None O
affecting None None O
centrocytic None None O
B None None O
- None None O
cells None None O
of None None O
intermediate None None O
differentiation None None O
. None None O

As None None O
a None None O
consequence None None O
the None None O
cyclin None None O
D1 None None O
( None None O
bcl None None O
- None None O
1 None None O
) None None O
gene None None O
is None None O
juxtaposed None None O
to None None O
the None None O
immunoglobulin None None O
heavy None None O
chain None None O
enhancer None None O
E None None O
mu None None O
. None None O

To None None O
show None None O
that None None O
transcriptional None None O
activation None None O
of None None O
cyclin None None O
D1 None None O
is None None O
causally None None O
involved None None O
in None None O
the None None O
generation None None O
of None None O
B None None O
- None None O
cell None None O
neoplasia None None O
we None None O
have None None O
generated None None O
transgenic None None O
mice None None O
that None None O
carry None None O
a None None O
cyclin None None O
D1 None None O
gene None None O
under None None O
the None None O
transcriptional None None O
control None None O
of None None O
the None None O
E None None O
mu None None O
element None None O
. None None O

E None None O
mu None None O
cyclin None None O
D1 None None O
transgenic None None O
mice None None O
show None None O
only None None O
very None None O
subtle None None O
alterations None None O
in None None O
the None None O
cycling None None O
behaviour None None O
of None None O
B None None O
- None None O
cell None None O
populations None None O
in None None O
the None None O
bone None None O
marrow None None O
compared None None O
with None None O
normal None None O
mice None None O
and None None O
do None None O
not None None O
develop None None O
lymphoid None None O
tumours None None O
. None None O

However None None O
, None None O
E None None O
mu None None O
- None None O
directed None None O
coexpression None None O
of None None O
cyclin None None O
D1 None None O
and None None O
N None None O
- None None O
MYC None None O
or None None O
L None None O
- None None O
MYC None None O
in None None O
double None None O
transgenic None None O
mice None None O
reveals None None O
a None None O
strong None None O
cooperative None None O
effect None None O
between None None O
MYC None None O
and None None O
cyclin None None O
D1 None None O
provoking None None O
the None None O
rapid None None O
development None None O
of None None O
clonal None None O
pre None None O
- None None O
B None None O
and None None O
B None None O
- None None O
cell None None O
lymphomas None None O
. None None O

Interestingly None None O
, None None O
crossing None None O
of None None O
cyclin None None O
D1 None None O
transgenic None None O
mice None None O
with None None O
E None None O
mu None None O
L None None O
- None None O
myc None None O
transgenics None None O
that None None O
express None None O
their None None O
transgene None None O
in None None O
both None None O
B None None O
- None None O
and None None O
T None None O
- None None O
cells None None O
but None None O
predominantly None None O
develop None None O
T None None O
- None None O
cell None None O
tumours None None O
leads None None O
in None None O
double None None O
transgenics None None O
exclusively None None O
to None None O
B None None O
- None None O
cell None None O
neoplasia None None O
. None None O

The None None O
data None None O
presented None None O
here None None O
demonstrate None None O
that None None O
transcriptional None None O
activation None None O
of None None O
cyclin None None O
D1 None None O
can None None O
oncogenically None None O
transform None None O
B None None O
- None None O
cells None None O
in None None O
concert None None O
with None None O
a None None O
myc None None O
gene None None O
. None None O

They None None O
establish None None O
cyclin None None O
D1 None None O
as None None O
a None None O
proto None None O
- None None O
oncogene None None O
whose None None O
activity None None O
appears None None O
to None None O
depend None None O
on None None O
a None None O
specific None None O
cell None None O
type None None O
as None None O
well None None O
as None None O
on None None O
a None None O
specific None None O
cooperating None None O
partner None None O
and None None O
link None None O
disturbances None None O
in None None O
the None None O
regulation None None O
of None None O
cell None None O
cycle None None O
progression None None O
to None None O
the None None O
development None None O
of None None O
human None None O
malignancies None None O
. None None O

Relative None None O
phage None None O
haplotype None None O
frequencies None None O
in None None O
PAO1 None None O
samples None None O
, None None O
( None None O
A None None O
) None None O
planktonic None None O
, None None O
( None None O
B None None O
) None None O
biofilm None None O
4 None None O
days None None O
, None None O
( None None O
C None None O
) None None O
biofilm None None O
11 None None O
days None None O
. None None O

Human None None O
papillomavirus None None O
oncoprotein None None O
E6 None None O
inactivates None None O
the None None O
transcriptional None None O
coactivator None None O
human None None O
ADA3 None None O
. None None O

High None None O
- None None O
risk None None O
human None None O
papillomaviruses None None O
( None None O
HPVs None None O
) None None O
are None None O
associated None None O
with None None O
carcinomas None None O
of None None O
the None None O
cervix None None O
and None None O
other None None O
genital None None O
tumors None None O
. None None O

The None None O
HPV None None O
oncoprotein None None O
E6 None None O
is None None O
essential None None O
for None None O
oncogenic None None O
transformation None None O
. None None O

We None None O
identify None None O
here None None O
hADA3 None None O
, None None O
human None None O
homologue None None O
of None None O
the None None O
yeast None None O
transcriptional None None O
coactivator None None O
yADA3 None None O
, None None O
as None None O
a None None O
novel None None O
E6 None None O
- None None O
interacting None None O
protein None None O
and None None O
a None None O
target None None O
of None None O
E6 None None O
- None None O
induced None None O
degradation None None O
. None None O

hADA3 None None O
binds None None O
selectively None None O
to None None O
the None None O
high None None O
- None None O
risk None None O
HPV None None O
E6 None None O
proteins None None O
and None None O
only None None O
to None None O
immortalization None None O
- None None O
competent None None O
E6 None None O
mutants None None O
. None None O

hADA3 None None O
functions None None O
as None None O
a None None O
coactivator None None O
for None None O
p53 None None O
- None None O
mediated None None O
transactivation None None O
by None None O
stabilizing None None O
p53 None None O
protein None None O
. None None O

Notably None None O
, None None O
three None None O
immortalizing None None O
E6 None None O
mutants None None O
that None None O
do None None O
not None None O
induce None None O
direct None None O
p53 None None O
degradation None None O
but None None O
do None None O
interact None None O
with None None O
hADA3 None None O
induced None None O
the None None O
abrogation None None O
of None None O
p53 None None O
- None None O
mediated None None O
transactivation None None O
and None None O
G None None O
( None None O
1 None None O
) None None O
cell None None O
cycle None None O
arrest None None O
after None None O
DNA None None O
damage None None O
, None None O
comparable None None O
to None None O
wild None None O
- None None O
type None None O
E6 None None O
. None None O

These None None O
findings None None O
reveal None None O
a None None O
novel None None O
strategy None None O
of None None O
HPV None None O
E6 None None O
- None None O
induced None None O
loss None None O
of None None O
p53 None None O
function None None O
that None None O
is None None O
independent None None O
of None None O
direct None None O
p53 None None O
degradation None None O
. None None O

Given None None O
the None None O
likely None None O
role None None O
of None None O
the None None O
evolutionarily None None O
conserved None None O
hADA3 None None O
in None None O
multiple None None O
coactivator None None O
complexes None None O
, None None O
inactivation None None O
of None None O
its None None O
function None None O
may None None O
allow None None O
E6 None None O
to None None O
perturb None None O
numerous None None O
cellular None None O
pathways None None O
during None None O
HPV None None O
oncogenesis None None O
. None None O

Targeting None None O
PIM None None O
kinases None None O
impairs None None O
survival None None O
of None None O
hematopoietic None None O
cells None None O
transformed None None O
by None None O
kinase None None O
inhibitor None None O
- None None O
sensitive None None O
and None None O
kinase None None O
inhibitor None None O
- None None O
resistant None None O
forms None None O
of None None O
Fms None None O
- None None O
like None None O
tyrosine None None O
kinase None None O
3 None None O
and None None O
BCR None None O
/ None None O
ABL None None O
. None None O

Previous None None O
studies None None O
have None None O
shown None None O
that None None O
activation None None O
of None None O
the None None O
signal None None O
transducer None None O
and None None O
activator None None O
of None None O
transcription None None O
5 None None O
( None None O
STAT5 None None O
) None None O
plays None None O
an None None O
essential None None O
role None None O
in None None O
leukemogenesis None None O
mediated None None O
through None None O
constitutive None None O
activated None None O
protein None None O
tyrosine None None O
kinases None None O
( None None O
PTK None None O
) None None O
. None None O

Because None None O
PIM None None O
- None None O
1 None None O
is None None O
a None None O
STAT5 None None O
target None None O
gene None None O
, None None O
we None None O
analyzed None None O
the None None O
role None None O
of None None O
the None None O
family None None O
of None None O
PIM None None O
serine None None O
/ None None O
threonine None None O
kinases None None O
( None None O
PIM None None O
- None None O
1 None None O
to None None O
PIM None None O
- None None O
3 None None O
) None None O
in None None O
PTK None None O
- None None O
mediated None None O
transformation None None O
of None None O
hematopoietic None None O
cells None None O
. None None O

Ba None None I-Cell-line-name
/ None None I-Cell-line-name
F3 None None I-Cell-line-name
cells None None O
transformed None None O
to None None O
growth None None O
factor None None O
independence None None O
by None None O
various None None O
oncogenic None None O
PTKs None None O
( None None O
TEL None None O
/ None None O
JAK2 None None O
, None None O
TEL None None O
/ None None O
TRKC None None O
, None None O
TEL None None O
/ None None O
ABL None None O
, None None O
BCR None None O
/ None None O
ABL None None O
, None None O
FLT3 None None O
- None None O
ITD None None O
, None None O
and None None O
H4 None None O
/ None None O
PDGFbetaR None None O
) None None O
show None None O
abundant None None O
expression None None O
of None None O
PIM None None O
- None None O
1 None None O
and None None O
PIM None None O
- None None O
2 None None O
. None None O

Suppression None None O
of None None O
PIM None None O
- None None O
1 None None O
activity None None O
had None None O
a None None O
negligible None None O
effect None None O
on None None O
transformation None None O
. None None O

In None None O
contrast None None O
, None None O
expression None None O
of None None O
kinase None None O
- None None O
dead None None O
PIM None None O
- None None O
2 None None O
mutant None None O
( None None O
PIM None None O
- None None O
2KD None None O
) None None O
led None None O
to None None O
a None None O
rapid None None O
decline None None O
of None None O
survival None None O
in None None O
Ba None None I-Cell-line-name
/ None None I-Cell-line-name
F3 None None I-Cell-line-name
cells None None O
transformed None None O
by None None O
FLT3 None None O
- None None O
ITD None None O
but None None O
not None None O
by None None O
other None None O
oncogenic None None O
PTKs None None O
tested None None O
. None None O

Coexpression None None O
of None None O
PIM None None O
- None None O
1KD None None O
and None None O
PIM None None O
- None None O
2KD None None O
abrogated None None O
growth None None O
factor None None O
- None None O
independent None None O
growth None None O
of None None O
Ba None None I-Cell-line-name
/ None None I-Cell-line-name
F3 None None I-Cell-line-name
transformed None None O
by None None O
several None None O
PTKs None None O
, None None O
including None None O
BCR None None O
/ None None O
ABL None None O
. None None O

Targeted None None O
down None None O
- None None O
regulation None None O
of None None O
PIM None None O
- None None O
2 None None O
by None None O
RNA None None O
interference None None O
( None None O
RNAi None None O
) None None O
selectively None None O
abrogated None None O
survival None None O
of None None O
Ba None None I-Cell-line-name
/ None None I-Cell-line-name
F3 None None I-Cell-line-name
cells None None O
transformed None None O
by None None O
various None None O
Fms None None O
- None None O
like None None O
tyrosine None None O
kinase None None O
3 None None O
( None None O
FLT3 None None O
) None None O
- None None O
activating None None O
mutants None None O
[ None None O
internal None None O
tandem None None O
duplication None None O
( None None O
ITD None None O
) None None O
and None None O
kinase None None O
domain None None O
] None None O
and None None O
attenuated None None O
growth None None O
of None None O
human None None O
cell None None O
lines None None O
containing None None O
FLT3 None None O
mutations None None O
. None None O

Interestingly None None O
, None None O
cells None None O
transformed None None O
by None None O
FLT3 None None O
and None None O
BCR None None O
/ None None O
ABL None None O
mutations None None O
that None None O
confer None None O
resistance None None O
to None None O
small None None O
- None None O
molecule None None O
tyrosine None None O
kinase None None O
inhibitors None None O
were None None O
still None None O
sensitive None None O
to None None O
knockdown None None O
of None None O
PIM None None O
- None None O
2 None None O
, None None O
or None None O
PIM None None O
- None None O
1 None None O
and None None O
PIM None None O
- None None O
2 None None O
by None None O
RNAi None None O
. None None O

Our None None O
observations None None O
indicate None None O
that None None O
combined None None O
inactivation None None O
of None None O
PIM None None O
- None None O
1 None None O
and None None O
PIM None None O
- None None O
2 None None O
interferes None None O
with None None O
oncogenic None None O
PTKs None None O
and None None O
suggest None None O
that None None O
PIMs None None O
are None None O
alternative None None O
therapeutic None None O
targets None None O
in None None O
PTK None None O
- None None O
mediated None None O
leukemia None None O
. None None O

Targeting None None O
the None None O
PIM None None O
kinase None None O
family None None O
could None None O
provide None None O
a None None O
new None None O
avenue None None O
to None None O
overcome None None O
resistance None None O
against None None O
small None None O
- None None O
molecule None None O
tyrosine None None O
kinase None None O
inhibitors None None O
. None None O

Survivin None None O
expression None None O
in None None O
breast None None O
carcinoma None None O
: None None O
correlation None None O
with None None O
apoptosis None None O
and None None O
prognosis None None O
. None None O

BACKGROUND None None O
: None None O
Survivin None None O
is None None O
a None None O
novel None None O
inhibitor None None O
of None None O
apoptosis None None O
commonly None None O
detected None None O
in None None O
tissues None None O
during None None O
fetal None None O
development None None O
and None None O
in None None O
cancer None None O
, None None O
but None None O
not None None O
usually None None O
in None None O
normal None None O
tissues None None O
. None None O

It None None O
has None None O
been None None O
suggested None None O
that None None O
the None None O
expression None None O
of None None O
this None None O
protein None None O
may None None O
be None None O
of None None O
prognostic None None O
significance None None O
in None None O
gastric None None O
, None None O
colorectal None None O
, None None O
and None None O
bladder None None O
carcinomas None None O
. None None O

We None None O
assessed None None O
survivin None None O
expression None None O
in None None O
breast None None O
carcinomas None None O
correlating None None O
results None None O
with None None O
expression None None O
of None None O
other None None O
antiapoptotic None None O
( None None O
bcl None None O
- None None O
2 None None O
, None None O
bcl None None O
- None None O
x None None O
) None None O
and None None O
proapoptotic None None O
( None None O
bax None None O
) None None O
markers None None O
, None None O
with None None O
prognostic None None O
parameters None None O
, None None O
and None None O
with None None O
prognosis None None O
. None None O

DESIGN None None O
: None None O
Paraffin None None O
- None None O
embedded None None O
sections None None O
of None None O
37 None None O
breast None None O
carcinomas None None O
were None None O
immunostained None None O
for None None O
survivin None None O
, None None O
bcl None None O
- None None O
2 None None O
, None None O
bcl None None O
- None None O
x None None O
, None None O
and None None O
bax None None O
. None None O

Expression None None O
was None None O
evaluated None None O
in None None O
normal None None O
breast None None O
tissue None None O
and None None O
carcinoma None None O
, None None O
nuclei None None O
and None None O
cytoplasm None None O
, None None O
as None None O
intensity None None O
( None None O
0 None None O
to None None O
3 None None O
+ None None O
) None None O
, None None O
and None None O
percentage None None O
of None None O
positive None None O
cells None None O
. None None O

RESULTS None None O
: None None O
Survivin None None O
expression None None O
was None None O
noted None None O
in None None O
30 None None O
( None None O
81 None None O
% None None O
) None None O
of None None O
breast None None O
carcinomas None None O
, None None O
and None None O
in None None O
normal None None O
breast None None O
tissue None None O
, None None O
in None None O
nuclei None None O
, None None O
and None None O
cytoplasm None None O
. None None O

There None None O
was None None O
a None None O
significant None None O
correlation None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
022 None None O
) None None O
between None None O
survivin None None O
and None None O
bcl None None O
- None None O
x None None O
expression None None O
; None None O
survivin None None O
and None None O
bcl None None O
- None None O
x None None O
tended None None O
to None None O
correlate None None O
with None None O
overall None None O
survival None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
072 None None O
and None None O
0 None None O
. None None O
075 None None O
, None None O
respectively None None O
) None None O
, None None O
but None None O
not None None O
with None None O
disease None None O
- None None O
free None None O
survival None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
19 None None O
and None None O
0 None None O
. None None O
18 None None O
, None None O
respectively None None O
) None None O
. None None O

There None None O
was None None O
no None None O
correlation None None O
of None None O
survivin None None O
with None None O
bcl None None O
- None None O
2 None None O
or None None O
bax None None O
expression None None O
, None None O
or None None O
with None None O
other None None O
prognostic None None O
parameters None None O
( None None O
age None None O
, None None O
tumor None None O
size None None O
, None None O
histologic None None O
type None None O
, None None O
histologic None None O
grade None None O
, None None O
nodal None None O
status None None O
, None None O
and None None O
tumor None None O
stage None None O
) None None O
( None None O
P None None O
> None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

CONCLUSION None None O
: None None O
The None None O
majority None None O
( None None O
81 None None O
% None None O
) None None O
of None None O
breast None None O
carcinomas None None O
show None None O
survivin None None O
expression None None O
which None None O
correlates None None O
with None None O
bcl None None O
- None None O
x None None O
, None None O
another None None O
antiapoptotic None None O
marker None None O
, None None O
and None None O
both None None O
markers None None O
tend None None O
to None None O
correlate None None O
with None None O
prognosis None None O
. None None O

Curcumin None None O
induces None None O
apoptosis None None O
in None None O
immortalized None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
and None None O
malignant None None O
cancer None None O
cell None None O
lines None None O
. None None O

Curcumin None None O
, None None O
which None None O
is None None O
a None None O
widely None None O
used None None O
dietary None None O
pigment None None O
and None None O
spice None None O
, None None O
has None None O
been None None O
demonstrated None None O
to None None O
be None None O
an None None O
effective None None O
inhibitor None None O
of None None O
tumor None None O
promotion None None O
in None None O
mouse None None O
skin None None O
carcinogenesis None None O
. None None O

We None None O
report None None O
that None None O
curcumin None None O
induces None None O
cell None None O
shrinkage None None O
, None None O
chromatin None None O
condensation None None O
, None None O
and None None O
DNA None None O
fragmentation None None O
, None None O
characteristics None None O
of None None O
apoptosis None None O
, None None O
in None None O
immortalized None None O
mouse None None O
embryo None None O
fibroblast None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
erb None None O
B2 None None O
oncogene None None O
- None None O
transformed None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
, None None O
mouse None None O
sarcoma None None O
S180 None None I-Cell-line-name
, None None O
human None None O
colon None None O
cancer None None O
cell None None O
HT None None I-Cell-line-name
- None None I-Cell-line-name
29 None None I-Cell-line-name
, None None O
human None None O
kidney None None O
cancer None None O
cell None None O
293 None None I-Cell-line-name
, None None O
and None None O
human None None O
hepatocellular None None O
carcinoma None None O
Hep None None I-Cell-line-name
G2 None None I-Cell-line-name
cells None None O
, None None O
but None None O
not None None O
in None None O
primary None None O
culture None None O
of None None O
mouse None None O
embryonic None None O
fibroblast None None O
C3H None None I-Cell-line-name
10T1 None None I-Cell-line-name
/ None None I-Cell-line-name
2 None None I-Cell-line-name
, None None O
rat None None O
embryonic None None O
fibroblast None None O
, None None O
and None None O
human None None O
foreskin None None O
fibroblast None None O
cells None None O
in None None O
a None None O
concentration None None O
- None None O
and None None O
time None None O
- None None O
dependent None None O
manner None None O
. None None O

Many None None O
cellular None None O
and None None O
biochemical None None O
effects None None O
of None None O
curcumin None None O
in None None O
mouse None None O
fibroblast None None O
cells None None O
have None None O
been None None O
reported None None O
, None None O
such None None O
as None None O
inhibition None None O
of None None O
protein None None O
kinase None None O
C None None O
( None None O
PKC None None O
) None None O
activity None None O
induced None None O
by None None O
phorbol None None O
12 None None O
- None None O
myristate None None O
13 None None O
- None None O
acetate None None O
treatment None None O
, None None O
inhibition None None O
of None None O
tyrosine None None O
protein None None O
kinase None None O
activity None None O
, None None O
and None None O
inhibition None None O
of None None O
arachidonic None None O
acid None None O
( None None O
AA None None O
) None None O
metabolism None None O
. None None O

Treatment None None O
of None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
cells None None O
with None None O
the None None O
PKC None None O
inhibitor None None O
staurosporine None None O
, None None O
the None None O
tyrosine None None O
kinase None None O
inhibitor None None O
herbimycin None None O
A None None O
, None None O
and None None O
the None None O
AA None None O
metabolism None None O
inhibitor None None O
quinacrine None None O
induces None None O
apoptotic None None O
cell None None O
death None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
, None None O
in None None O
some None None O
immortalized None None O
and None None O
transformed None None O
cells None None O
, None None O
blocking None None O
the None None O
cellular None None O
signal None None O
transduction None None O
might None None O
trigger None None O
the None None O
induction None None O
of None None O
apoptosis None None O
. None None O

An None None O
unusual None None O
case None None O
of None None O
benign None None O
mucous None None O
membrane None None O
pemphigoid None None O
. None None O

This None None O
case None None O
of None None O
benign None None O
mucous None None O
membrane None None O
pemphigoid None None O
( None None O
BMMP None None O
) None None O
is None None O
unusual None None O
in None None O
that None None O
blistering None None O
, None None O
scarring None None O
lesions None None O
were None None O
confined None None O
to None None O
the None None O
skin None None O
for None None O
15 None None O
years None None O
before None None O
mucous None None O
membranes None None O
were None None O
involved None None O
. None None O

The None None O
onset None None O
of None None O
this None None O
disorder None None O
at None None O
the None None O
age None None O
of None None O
38 None None O
is None None O
also None None O
unusual None None O
. None None O

Detailed None None O
immunological None None O
investigation None None O
was None None O
performed None None O
on None None O
this None None O
patient None None O
but None None O
the None None O
results None None O
in None None O
no None None O
way None None O
clarify None None O
the None None O
present None None O
confusion None None O
regarding None None O
the None None O
immunopathological None None O
processes None None O
in None None O
BMMP None None O
related None None O
to None None O
those None None O
operative None None O
in None None O
bullous None None O
pemphigoid None None O
. None None O

Multicentre None None O
study None None O
on None None O
peri None None O
- None None O
and None None O
postoperative None None O
central None None O
venous None None O
oxygen None None O
saturation None None O
in None None O
high None None O
- None None O
risk None None O
surgical None None O
patients None None O
. None None O

INTRODUCTION None None O
: None None O

Low None None O
central None None O
venous None None O
oxygen None None O
saturation None None O
( None None O
ScvO2 None None O
) None None O
has None None O
been None None O
associated None None O
with None None O
increased None None O
risk None None O
of None None O
postoperative None None O
complications None None O
in None None O
high None None O
- None None O
risk None None O
surgery None None O
. None None O

Whether None None O
this None None O
association None None O
is None None O
centre None None O
- None None O
specific None None O
or None None O
more None None O
generalisable None None O
is None None O
not None None O
known None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
assess None None O
the None None O
association None None O
between None None O
peri None None O
- None None O
and None None O
postoperative None None O
ScvO2 None None O
and None None O
outcome None None O
in None None O
high None None O
- None None O
risk None None O
surgical None None O
patients None None O
in None None O
a None None O
multicentre None None O
setting None None O
. None None O

METHODS None None O
: None None O

Three None None O
large None None O
European None None O
university None None O
hospitals None None O
( None None O
two None None O
in None None O
Finland None None O
, None None O
one None None O
in None None O
Switzerland None None O
) None None O
participated None None O
. None None O

In None None O
60 None None O
patients None None O
with None None O
intra None None O
- None None O
abdominal None None O
surgery None None O
lasting None None O
more None None O
than None None O
90 None None O
minutes None None O
, None None O
the None None O
presence None None O
of None None O
at None None O
least None None O
two None None O
of None None O
Shoemaker None None O
' None None O
s None None O
criteria None None O
, None None O
and None None O
ASA None None O
( None None O
American None None O
Society None None O
of None None O
Anesthesiologists None None O
) None None O
class None None O
greater None None O
than None None O
2 None None O
, None None O
ScvO2 None None O
was None None O
determined None None O
preoperatively None None O
and None None O
at None None O
two None None O
hour None None O
intervals None None O
during None None O
the None None O
operation None None O
until None None O
12 None None O
hours None None O
postoperatively None None O
. None None O

Hospital None None O
length None None O
of None None O
stay None None O
( None None O
LOS None None O
) None None O
mortality None None O
, None None O
and None None O
predefined None None O
postoperative None None O
complications None None O
were None None O
recorded None None O
. None None O

RESULTS None None O
: None None O

The None None O
age None None O
of None None O
the None None O
patients None None O
was None None O
72 None None O
+ None None O
/ None None O
- None None O
10 None None O
years None None O
( None None O
mean None None O
+ None None O
/ None None O
- None None O
standard None None O
deviation None None O
) None None O
, None None O
and None None O
simplified None None O
acute None None O
physiology None None O
score None None O
( None None O
SAPS None None O
II None None O
) None None O
was None None O
32 None None O
+ None None O
/ None None O
- None None O
12 None None O
. None None O

Hospital None None O
LOS None None O
was None None O
10 None None O
. None None O
5 None None O
( None None O
8 None None O
to None None O
14 None None O
) None None O
days None None O
, None None O
and None None O
28 None None O
- None None O
day None None O
hospital None None O
mortality None None O
was None None O
10 None None O
. None None O
0 None None O
% None None O
. None None O

Preoperative None None O
ScvO2 None None O
decreased None None O
from None None O
77 None None O
% None None O
+ None None O
/ None None O
- None None O
10 None None O
% None None O
to None None O
70 None None O
% None None O
+ None None O
/ None None O
- None None O
11 None None O
% None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
immediately None None O
after None None O
surgery None None O
and None None O
remained None None O
unchanged None None O
12 None None O
hours None None O
later None None O
. None None O

A None None O
total None None O
of None None O
67 None None O
postoperative None None O
complications None None O
were None None O
recorded None None O
in None None O
32 None None O
patients None None O
. None None O

After None None O
multivariate None None O
analysis None None O
, None None O
mean None None O
ScvO2 None None O
value None None O
( None None O
odds None None O
ratio None None O
[ None None O
OR None None O
] None None O
1 None None O
. None None O
23 None None O
[ None None O
95 None None O
% None None O
confidence None None O
interval None None O
( None None O
CI None None O
) None None O
1 None None O
. None None O
01 None None O
to None None O
1 None None O
. None None O
50 None None O
] None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
037 None None O
) None None O
, None None O
hospital None None O
LOS None None O
( None None O
OR None None O
0 None None O
. None None O
75 None None O
[ None None O
95 None None O
% None None O
CI None None O
0 None None O
. None None O
59 None None O
to None None O
0 None None O
. None None O
94 None None O
] None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
012 None None O
) None None O
, None None O
and None None O
SAPS None None O
II None None O
( None None O
OR None None O
0 None None O
. None None O
90 None None O
[ None None O
95 None None O
% None None O
CI None None O
0 None None O
. None None O
82 None None O
to None None O
0 None None O
. None None O
99 None None O
] None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
029 None None O
) None None O
were None None O
independently None None O
associated None None O
with None None O
postoperative None None O
complications None None O
. None None O

The None None O
optimal None None O
value None None O
of None None O
mean None None O
ScvO2 None None O
to None None O
discriminate None None O
between None None O
patients None None O
who None None O
did None None O
or None None O
did None None O
not None None O
develop None None O
complications None None O
was None None O
73 None None O
% None None O
( None None O
sensitivity None None O
72 None None O
% None None O
, None None O
specificity None None O
61 None None O
% None None O
) None None O
. None None O

CONCLUSION None None O
: None None O

Low None None O
ScvO2 None None O
perioperatively None None O
is None None O
related None None O
to None None O
increased None None O
risk None None O
of None None O
postoperative None None O
complications None None O
in None None O
high None None O
- None None O
risk None None O
surgery None None O
. None None O

This None None O
warrants None None O
trials None None O
with None None O
goal None None O
- None None O
directed None None O
therapy None None O
using None None O
ScvO2 None None O
as None None O
a None None O
target None None O
in None None O
high None None O
- None None O
risk None None O
surgery None None O
patients None None O
. None None O

Newly None None O
recognized None None O
syndrome None None O
with None None O
heminasal None None O
aplasia None None O
and None None O
ocular None None O
anomalies None None O
or None None O
wider None None O
spectrum None None O
of None None O
heminasal None None O
aplasia None None O
/ None None O
atypical None None O
clefting None None O
syndrome None None O
? None None O

We None None O
report None None O
on None None O
five None None O
unrelated None None O
Brazilian None None O
patients None None O
with None None O
heminasal None None O
aplasia None None O
associated None None O
with None None O
diverses None None O
anomalies None None O
, None None O
including None None O
lateral None None O
proboscis None None O
, None None O
and None None O
anomalies None None O
of None None O
the None None O
eye None None O
and None None O
first None None O
branchial None None O
arch None None O
. None None O

We None None O
suggest None None O
that None None O
these None None O
patients None None O
represent None None O
different None None O
conditions None None O
within None None O
the None None O
spectrum None None O
of None None O
the None None O
heminasal None None O
aplasia None None O
malformation None None O
. None None O

Clinical None None O
, None None O
genetic None None O
, None None O
and None None O
differential None None O
diagnosis None None O
are None None O
discussed None None O
. None None O

N None None O
- None None O
methyl None None O
- None None O
N None None O
- None None O
nitrosourea None None O
- None None O
induced None None O
transformation None None O
of None None O
rat None None O
urothelial None None O
cells None None O
in None None O
vitro None None O
is None None O
not None None O
mediated None None O
by None None O
activation None None O
of None None O
ras None None O
oncogenes None None O
. None None O

Adult None None O
rat None None O
urothelial None None O
cells None None O
were None None O
transformed None None O
in None None O
vitro None None O
following None None O
treatment None None O
with None None O
a None None O
single None None O
dose None None O
of None None O
N None None O
- None None O
methyl None None O
- None None O
N None None O
- None None O
nitrosourea None None O
( None None O
MNU None None O
) None None O
or None None O
MNU None None O
treatment None None O
followed None None O
by None None O
promotion None None O
with None None O
sodium None None O
saccharin None None O
. None None O

This None None O
in None None O
vitro None None O
transformation None None O
process None None O
involves None None O
multiple None None O
steps None None O
: None None O
slow None None O
- None None O
growing None None O
' None None O
pre None None O
- None None O
neoplastic None None O
' None None O
epithelial None None O
foci None None O
are None None O
induced None None O
70 None None O
- None None O
100 None None O
days None None O
after None None O
MNU None None O
treatment None None O
and None None O
from None None O
such None None O
foci None None O
rapidly None None O
proliferating None None O
immortal None None O
cell None None O
lines None None O
were None None O
established None None O
, None None O
some None None O
of None None O
which None None O
became None None O
tumorigenic None None O
after None None O
a None None O
further None None O
latent None None O
period None None O
. None None O

A None None O
series None None O
of None None O
epithelial None None O
cell None None O
lines None None O
and None None O
a None None O
single None None O
fibroblast None None O
cell None None O
line None None O
established None None O
in None None O
this None None O
way None None O
were None None O
analysed None None O
for None None O
the None None O
presence None None O
of None None O
transforming None None O
genes None None O
by None None O
DNA None None O
transfection None None O
into None None O
NIH3T3 None None I-Cell-line-name
cells None None O
. None None O

None None None O
of None None O
the None None O
epithelial None None O
cell None None O
lines None None O
induced None None O
foci None None O
in None None O
a None None O
focus None None O
formation None None O
assay None None O
. None None O

The None None O
single None None O
non None None O
- None None O
epithelial None None O
line None None O
induced None None O
foci None None O
and None None O
was None None O
found None None O
to None None O
contain None None O
an None None O
activated None None O
c None None O
- None None O
Ki None None O
- None None O
ras None None O
gene None None O
with None None O
a None None O
G None None O
- None None O
- None None O
- None None O
- None None O
A None None O
transition None None O
in None None O
codon None None O
12 None None O
. None None O

To None None O
assay None None O
for None None O
the None None O
possible None None O
presence None None O
of None None O
transforming None None O
genes None None O
which None None O
were None None O
not None None O
active None None O
in None None O
a None None O
focus None None O
formation None None O
assay None None O
, None None O
two None None O
of None None O
the None None O
epithelial None None O
lines None None O
were None None O
analysed None None O
further None None O
by None None O
co None None O
- None None O
transfection None None O
with None None O
a None None O
dominant None None O
selectable None None O
marker None None O
, None None O
followed None None O
by None None O
selection None None O
and None None O
inoculation None None O
into None None O
nude None None O
mice None None O
. None None O

No None None O
tumours None None O
were None None O
induced None None O
within None None O
the None None O
latent None None O
period None None O
for None None O
tumour None None O
production None None O
by None None O
control None None O
cells None None O
transfected None None O
with None None O
NIH3T3 None None I-Cell-line-name
cell None None O
DNA None None O
( None None O
40 None None O
- None None O
60 None None O
days None None O
) None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
there None None O
is None None O
cell None None O
type None None O
specificity None None O
for None None O
oncogene None None O
activation None None O
during None None O
in None None O
vitro None None O
rat None None O
bladder None None O
transformation None None O
initiated None None O
by None None O
a None None O
single None None O
carcinogen None None O
and None None O
that None None O
ras None None O
gene None None O
activation None None O
is None None O
not None None O
a None None O
necessary None None O
step None None O
in None None O
urothelial None None O
transformation None None O
in None None O
vitro None None O
. None None O

Differential None None O
regulation None None O
of None None O
in None None O
vivo None None O
angiogenesis None None O
by None None O
angiotensin None None O
II None None O
receptors None None O
. None None O

Angiotensin None None O
II None None O
( None None O
ANG None None O
II None None O
) None None O
, None None O
a None None O
key None None O
regulator None None O
of None None O
blood None None O
pressure None None O
and None None O
body None None O
fluid None None O
homeostasis None None O
, None None O
exerts None None O
mitogenic None None O
effects None None O
on None None O
endothelial None None O
cells None None O
. None None O

We None None O
therefore None None O
hypothesized None None O
that None None O
ANG None None O
II None None O
could None None O
be None None O
a None None O
mediator None None O
between None None O
homeostatic None None O
changes None None O
within None None O
the None None O
vascular None None O
perfusion None None O
bed None None O
and None None O
growth None None O
factor None None O
- None None O
driven None None O
angiogenesis None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
applied None None O
the None None O
alginate None None O
implant None None O
angiogenesis None None O
model None None O
in None None O
mice None None O
with None None O
normal None None O
ANG None None O
II None None O
levels None None O
, None None O
elevated None None O
ANG None None O
II None None O
levels None None O
by None None O
transgenic None None O
overexpression None None O
of None None O
angiotensinogen None None O
( None None O
AOGEN None None O
) None None O
, None None O
or None None O
in None None O
AT2 None None O
receptor None None O
- None None O
deficient None None O
mice None None O
. None None O

We None None O
demonstrate None None O
that None None O
a None None O
decrease None None O
in None None O
the None None O
amount None None O
of None None O
circulating None None O
ANG None None O
II None None O
by None None O
the None None O
angiotensin None None O
- None None O
converting None None O
enzyme None None O
( None None O
ACE None None O
) None None O
inhibitor None None O
enalapril None None O
or None None O
the None None O
AT1 None None O
receptor None None O
antagonist None None O
losartan None None O
induced None None O
a None None O
stimulation None None O
of None None O
in None None O
vivo None None O
angiogenesis None None O
implying None None O
an None None O
inhibitory None None O
function None None O
of None None O
ANG None None O
II None None O
through None None O
the None None O
AT1 None None O
receptor None None O
. None None O

However None None O
, None None O
the None None O
strong None None O
increase None None O
of None None O
angiogenesis None None O
in None None O
AOGEN None None O
- None None O
transgenic None None O
mice None None O
compared None None O
with None None O
mice None None O
with None None O
normal None None O
ANG None None O
II None None O
levels None None O
suggests None None O
additional None None O
stimulatory None None O
activity None None O
. None None O

We None None O
showed None None O
that None None O
the None None O
ANG None None O
II None None O
- None None O
induced None None O
stimulation None None O
of None None O
angiogenesis None None O
is None None O
linked None None O
to None None O
the None None O
AT2 None None O
receptor None None O
as None None O
an None None O
impaired None None O
induction None None O
of None None O
angiogenesis None None O
was None None O
obtained None None O
in None None O
AT2 None None O
receptor None None O
knockout None None O
mice None None O
. None None O

These None None O
findings None None O
provide None None O
the None None O
first None None O
evidence None None O
that None None O
the None None O
AT2 None None O
receptor None None O
mediates None None O
a None None O
stimulation None None O
of None None O
in None None O
vivo None None O
angiogenesis None None O
and None None O
indicate None None O
that None None O
ANG None None O
II None None O
is None None O
a None None O
humoral None None O
regulator None None O
of None None O
peripheral None None O
angiogenesis None None O
involving None None O
two None None O
receptor None None O
subtypes None None O
with None None O
opposing None None O
actions None None O
. None None O

Summary None None O

Kindt None None O
et None None O
al None None O
. None None O
1 None None O
published None None O
a None None O
report None None O
entitled None None O
" None None O
Intestinal None None O
immune None None O
activation None None O
in None None O
presumed None None O
post None None O
- None None O
infectious None None O
functional None None O
syspepsia None None O
" None None O
in None None O
the None None O
August None None O
issue None None O
of None None O
Neurogastroenterology None None O
and None None O
Motility None None O
in None None O
2009 None None O
. None None O

By None None O
comparing None None O
the None None O
signs None None O
of None None O
inflammation None None O
and None None O
the None None O
degree None None O
of None None O
hyperplasia None None O
of None None O
the None None O
enterochromaffin None None O
cells None None O
( None None O
EC None None O
) None None O
in None None O
duodenal None None O
biopsies None None O
obtained None None O
from None None O
patients None None O
with None None O
presumed None None O
post None None O
- None None O
infectious None None O
functional None None O
dyspepsia None None O
( None None O
PI None None O
- None None O
FD None None O
) None None O
and None None O
unspecified None None O
- None None O
onset None None O
functional None None O
dyspepsia None None O
( None None O
U None None O
- None None O
FD None None O
) None None O
, None None O
they None None O
showed None None O
that None None O
PI None None O
- None None O
FD None None O
is None None O
associated None None O
with None None O
persistence None None O
of None None O
focal None None O
T None None O
- None None O
cell None None O
aggregates None None O
, None None O
decrease None None O
in None None O
CD4 None None O
+ None None O
cells None None O
and None None O
increased None None O
macrophage None None O
counts None None O
surrounding None None O
the None None O
crypts None None O
, None None O
without None None O
any None None O
significant None None O
differences None None O
in None None O
the None None O
numbers None None O
of None None O
EC None None O
or None None O
chromogranin None None O
A None None O
( None None O
CA None None O
) None None O
- None None O
positive None None O
cells None None O
( None None O
mast None None O
cells None None O
) None None O
. None None O

This None None O
finding None None O
may None None O
indicate None None O
impaired None None O
ability None None O
of None None O
the None None O
immune None None O
system None None O
in None None O
these None None O
cases None None O
to None None O
terminate None None O
the None None O
inflammatory None None O
response None None O
after None None O
an None None O
acute None None O
insult None None O
. None None O

Luciferase None None O
Assay None None O

For None None O
Fig None None O
. None None O

1 None None O
, None None O
10 None None O
ng None None O
of None None O
TORC1 None None O
, None None O
5 None None O
ng None None O
of None None O
TORC2 None None O
, None None O
and None None O
15 None None O
ng None None O
of None None O
PKAalpha None None O
expression None None O
plasmids None None O
were None None O
transfected None None O
into None None O
HEK293 None None I-Cell-line-name
cells None None O
. None None O

For None None O
Fig None None O
. None None O

2 None None O
, None None O
800 None None O
ng None None O
of None None O
total None None O
DNA None None O
consisted None None O
of None None O
200 None None O
ng None None O
of None None O
the None None O
pMLHoxb1ARE None None O
luciferase None None O
reporter None None O
and None None O
100 None None O
ng None None O
of None None O
each None None O
expression None None O
plasmid None None O
. None None O

A None None O
lacZ None None O
reporter None None O
was None None O
co None None O
- None None O
transfected None None O
to None None O
normalize None None O
transfection None None O
efficiency None None O
. None None O

For None None O
Fig None None O
. None None O

3A None None O
, None None O
the None None O
amounts None None O
of None None O
pENTR None None O
T2i None None O
shRNA None None O
( None None O
TORC2 None None O
shRNA None None O
) None None O
are None None O
given None None O
within None None O
the None None O
panel None None O
. None None O

For None None O
Fig None None O
. None None O

3B None None O
, None None O
25 None None O
, None None O
000 None None O
cells None None O
per None None O
well None None O
were None None O
plated None None O
in None None O
48 None None O
- None None O
well None None O
plates None None O
and None None O
transfected None None O
using None None O
Lipofectamine None None O
2000 None None O
with None None O
the None None O
following None None O
vectors None None O
: None None O
40 None None O
ng None None O
of None None O
pML5xUAS None None O
, None None O
40 None None O
ng None None O
of None None O
pGAL None None O
- None None O
DBD None None O
or None None O
pGAL None None O
- None None O
MEIS1A None None O
( None None O
335 None None O
- None None O
390 None None O
) None None O
, None None O
40 None None O
ng None None O
of None None O
pRSV None None O
- None None O
PBS None None O
or None None O
pRSV None None O
- None None O
PKA None None O
, None None O
40 None None O
ng None None O
of None None O
pENTR None None O
U6 None None O
( None None O
control None None O
shRNA None None O
) None None O
or None None O
pENTR None None O
T2i None None O
shRNA None None O
( None None O
TORC2 None None O
shRNA None None O
) None None O
, None None O
and None None O
100 None None O
ng None None O
of None None O
pRSV None None O
- None None O
beta None None O
- None None O
galactosidase None None O
. None None O

At None None O
48 None None O
h None None O
post None None O
- None None O
transfection None None O
, None None O
cell None None O
lysates None None O
were None None O
prepared None None O
using None None O
100 None None O
mul None None O
per None None O
well None None O
of None None O
lysis None None O
buffer None None O
( None None O
1 None None O
% None None O
Triton None None O
X None None O
- None None O
100 None None O
, None None O
1 None None O
mm None None O
dithiothreitol None None O
, None None O
92 None None O
. None None O
8 None None O
mm None None O
K2HPO4 None None O
, None None O
pH None None O
7 None None O
. None None O
8 None None O
, None None O
9 None None O
. None None O
2 None None O
mm None None O
KH2PO4 None None O
, None None O
pH None None O
7 None None O
. None None O
8 None None O
) None None O
and None None O
centrifuged None None O
for None None O
5 None None O
min None None O
at None None O
4 None None O
degreesC None None O
. None None O

A None None O
20 None None O
- None None O
mul None None O
aliquot None None O
of None None O
the None None O
supernatant None None O
was None None O
added None None O
to None None O
12 None None O
. None None O
5 None None O
mul None None O
of None None O
assay None None O
buffer None None O
( None None O
20 None None O
mm None None O
ATP None None O
, None None O
40 None None O
mm None None O
MgCl2 None None O
, None None O
0 None None O
. None None O
4 None None O
m None None O
Tris None None O
- None None O
Cl None None O
, None None O
pH None None O
7 None None O
. None None O
8 None None O
) None None O
. None None O

The None None O
mixture None None O
was None None O
immediately None None O
quantified None None O
for None None O
luciferase None None O
activity None None O
using None None O
a None None O
Lumat None None O
LB None None O
9507 None None O
luminometer None None O
( None None O
EG None None O
& None None O
G None None O
Berthold None None O
) None None O
that None None O
dispensed None None O
100 None None O
mul None None O
per None None O
reaction None None O
of None None O
luciferin None None O
solution None None O
, None None O
which None None O
contains None None O
1 None None O
mm None None O
d None None O
- None None O
( None None O
- None None O
) None None O
- None None O
luciferin None None O
( None None O
catalogue None None O
number None None O
11626353001 None None O
, None None O
Roche None None O
) None None O
and None None O
0 None None O
. None None O
1 None None O
m None None O
Tris None None O
- None None O
Cl None None O
, None None O
pH None None O
7 None None O
. None None O
8 None None O
. None None O

Methods None None O

We None None O
studied None None O
3 None None O
, None None O
574 None None O
Canadian None None O
children None None O
, None None O
aged None None O
7 None None O
- None None O
8 None None O
yr None None O
, None None O
enrolled None None O
in None None O
a None None O
population None None O
- None None O
based None None O
birth None None O
cohort None None O
. None None O

Standardized None None O
questionnaires None None O
were None None O
completed None None O
by None None O
the None None O
children None None O
' None None O
s None None O
parents None None O
, None None O
and None None O
data None None O
were None None O
analyzed None None O
by None None O
multivariate None None O
logistic None None O
regression None None O
. None None O

Sensitivity None None O
analysis None None O
of None None O
the None None O
influence None None O
of None None O
source None None O
- None None O
term None None O
and None None O
environmental None None O
parameters None None O
on None None O
the None None O
radiological None None O
risk None None O
of None None O
coal None None O
- None None O
fired None None O
plants None None O
. None None O

A None None O
sensitivity None None O
analysis None None O
was None None O
undertaken None None O
to None None O
determine None None O
the None None O
influence None None O
of None None O
different None None O
source None None O
- None None O
term None None O
and None None O
environmental None None O
parameters None None O
on None None O
the None None O
radiological None None O
risks None None O
from None None O
a None None O
coal None None O
- None None O
fired None None O
plant None None O
( None None O
CFP None None O
) None None O
. None None O

It None None O
was None None O
found None None O
that None None O
the None None O
release None None O
rate None None O
of None None O
radionuclides None None O
and None None O
the None None O
effective None None O
release None None O
height None None O
most None None O
significantly None None O
influence None None O
radiological None None O
risk None None O
. None None O

Site None None O
characteristics None None O
, None None O
such None None O
as None None O
rain None None O
scavenging None None O
coefficients None None O
and None None O
food None None O
acquirement None None O
habits None None O
, None None O
have None None O
a None None O
lesser None None O
influence None None O
, None None O
and None None O
some None None O
parameters None None O
, None None O
such None None O
as None None O
time None None O
delay None None O
before None None O
ingestion None None O
of None None O
contaminated None None O
food None None O
, None None O
have None None O
practically None None O
no None None O
influence None None O
on None None O
the None None O
radiological None None O
impact None None O
of None None O
a None None O
CFP None None O
. None None O

The None None O
contribution None None O
to None None O
radiation None None O
risks None None O
of None None O
different None None O
exposure None None O
modes None None O
( None None O
i None None O
. None None O
e None None O
. None None O
inhalation None None O
, None None O
ingestion None None O
and None None O
contact None None O
with None None O
ground None None O
surface None None O
) None None O
were None None O
also None None O
analyzed None None O
, None None O
as None None O
well None None O
as None None O
of None None O
specific None None O
radionuclides None None O
and None None O
human None None O
body None None O
organs None None O
. None None O

Results None None O
of None None O
the None None O
sensitivity None None O
analysis None None O
were None None O
interpreted None None O
in None None O
terms None None O
of None None O
the None None O
characteristics None None O
of None None O
the None None O
fuel None None O
, None None O
facilities None None O
and None None O
site None None O
of None None O
a None None O
CFP None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
by None None O
proper None None O
choice None None O
of None None O
coal None None O
, None None O
furnace None None O
, None None O
ash None None O
filtration None None O
and None None O
stack None None O
height None None O
, None None O
as None None O
well None None O
as None None O
by None None O
proper None None O
siting None None O
, None None O
the None None O
radiological None None O
impact None None O
of None None O
a None None O
CFP None None O
can None None O
be None None O
drastically None None O
reduced None None O
. None None O

Additional None None O
File None None O
1 None None O

Appendix None None O
1 None None O
. None None O

Indications None None O
for None None O
liver None None O
function None None O
tests None None O
with None None O
no None None O
obvious None None O
liver None None O
disease None None O
, None None O
and None None O
consequent None None O
investigations None None O

Competing None None O
interests None None O

The None None O
authors None None O
declare None None O
that None None O
they None None O
have None None O
no None None O
competing None None O
interests None None O
. None None O

3 None None O
. None None O
2 None None O
. None None O

Molecular None None O
Mechanisms None None O
Mediating None None O
the None None O
Perinatal None None O
Beta None None O
- None None O
Cell None None O
Adaptive None None O
Response None None O
to None None O
Early None None O
- None None O
Life None None O
Stressors None None O

Molecular None None O
mechanisms None None O
responsible None None O
for None None O
impaired None None O
beta None None O
- None None O
cell None None O
mass None None O
formation None None O
after None None O
IUCR None None O
or None None O
IUPR None None O
have None None O
come None None O
under None None O
investigation None None O
. None None O

First None None O
, None None O
it None None O
has None None O
been None None O
proposed None None O
that None None O
IUCR None None O
can None None O
result None None O
in None None O
a None None O
reduction None None O
of None None O
the None None O
embryonic None None O
beta None None O
- None None O
cell None None O
progenitor None None O
pool None None O
leading None None O
to None None O
inappropriate None None O
postnatal None None O
beta None None O
- None None O
cell None None O
formation None None O
. None None O

Stanger None None O
et None None O
al None None O
. None None O

[ None None O
108 None None O
] None None O
demonstrated None None O
that None None O
selective None None O
genetic None None O
reduction None None O
in None None O
the None None O
size None None O
of None None O
PDX None None O
- None None O
1 None None O
+ None None O
pancreatic None None O
progenitors None None O
during None None O
the None None O
fetal None None O
period None None O
results None None O
in None None O
impaired None None O
beta None None O
- None None O
cell None None O
formation None None O
during None None O
the None None O
postnatal None None O
period None None O
with None None O
consequent None None O
development None None O
of None None O
glucose None None O
intolerance None None O
during None None O
adulthood None None O
. None None O

Consistent None None O
with None None O
this None None O
, None None O
maternal None None O
food None None O
restriction None None O
leads None None O
to None None O
significant None None O
reduction None None O
in None None O
PDX None None O
- None None O
1 None None O
+ None None O
and None None O
neurogenin None None O
- None None O
3 None None O
+ None None O
pancreatic None None O
precursors None None O
during None None O
embryonic None None O
development None None O
in None None O
rats None None O
, None None O
diminished None None O
postnatal None None O
beta None None O
- None None O
cell None None O
formation None None O
, None None O
and None None O
inability None None O
to None None O
expand None None O
beta None None O
- None None O
cell None None O
mass None None O
in None None O
response None None O
to None None O
pregnancy None None O
[ None None O
47 None None O
, None None O
94 None None O
] None None O
. None None O

The None None O
UPI None None O
model None None O
is None None O
also None None O
characterized None None O
by None None O
a None None O
permanent None None O
decrease None None O
in None None O
islet None None O
PDX None None O
- None None O
1 None None O
mRNA None None O
expression None None O
. None None O

This None None O
decrease None None O
has None None O
recently None None O
been None None O
shown None None O
to None None O
be None None O
due None None O
to None None O
progressive None None O
epigenetic None None O
silencing None None O
of None None O
the None None O
Pdx1 None None O
gene None None O
locus None None O
secondary None None O
to None None O
proximal None None O
promoter None None O
methylation None None O
[ None None O
69 None None O
, None None O
109 None None O
] None None O
, None None O
and None None O
it None None O
may None None O
be None None O
responsible None None O
for None None O
the None None O
decreased None None O
rate None None O
of None None O
beta None None O
- None None O
cell None None O
replication None None O
and None None O
inappropriate None None O
postnatal None None O
beta None None O
- None None O
cell None None O
mass None None O
development None None O
[ None None O
69 None None O
, None None O
110 None None O
] None None O
. None None O

In None None O
the None None O
same None None O
way None None O
of None None O
thinking None None O
, None None O
studies None None O
have None None O
demonstrated None None O
that None None O
the None None O
maintenance None None O
of None None O
methylated None None O
histone None None O
H3 None None O
Lys4 None None O
by None None O
Set7 None None O
/ None None O
9 None None O
, None None O
a None None O
member None None O
of None None O
the None None O
SET None None O
methyltransferase None None O
family None None O
, None None O
is None None O
crucial None None O
to None None O
Pdx1 None None O
activity None None O
in None None O
beta None None O
- None None O
cell None None O
lines None None O
[ None None O
111 None None O
- None None O
113 None None O
] None None O
. None None O

This None None O
led None None O
to None None O
the None None O
hypothesis None None O
that None None O
Set7 None None O
/ None None O
9 None None O
may None None O
represent None None O
a None None O
novel None None O
chromatin None None O
- None None O
modifying None None O
protein None None O
that None None O
functions None None O
in None None O
part None None O
through None None O
its None None O
recruitment None None O
to None None O
target None None O
genes None None O
by None None O
cell None None O
- None None O
specific None None O
transcription None None O
factors None None O
such None None O
as None None O
Pdx1 None None O
. None None O

Since None None O
then None None O
, None None O
a None None O
role None None O
of None None O
histone None None O
methyl None None O
transferases None None O
, None None O
particularly None None O
set7 None None O
, None None O
has None None O
also None None O
been None None O
demonstrated None None O
in None None O
the None None O
sustained None None O
deleterious None None O
effects None None O
of None None O
chronic None None O
hyperglycemia None None O
on None None O
human None None O
microvascular None None O
endothelial None None O
cells None None O
[ None None O
114 None None O
] None None O
. None None O

Such None None O
an None None O
epigenetic None None O
change None None O
could None None O
potentially None None O
be None None O
involved None None O
in None None O
the None None O
deleterious None None O
effect None None O
of None None O
high None None O
glucose None None O
upon None None O
the None None O
fetal None None O
pancreas None None O
in None None O
the None None O
IUED None None O
models None None O
. None None O

Another None None O
mechanism None None O
proposed None None O
to None None O
explain None None O
reduced None None O
beta None None O
- None None O
cell None None O
formation None None O
after None None O
IUCR None None O
is None None O
related None None O
to None None O
prenatal None None O
glucocorticoid None None O
exposure None None O
. None None O

Administration None None O
of None None O
either None None O
dexamethasone None None O
or None None O
carbenoxolone None None O
( None None O
to None None O
inhibit None None O
11 None None O
beta None None O
- None None O
hydroxysteroid None None O
dehydrogenase None None O
type None None O
2 None None O
) None None O
to None None O
normal None None O
pregnant None None O
rats None None O
also None None O
causes None None O
fetal None None O
growth None None O
retardation None None O
and None None O
the None None O
adult None None O
offspring None None O
are None None O
hypertensive None None O
and None None O
hyperglycemic None None O
, None None O
with None None O
hyperactive None None O
hypothalamic None None O
- None None O
pituitary None None O
- None None O
adrenal None None O
axis None None O
[ None None O
115 None None O
] None None O
. None None O

Maternal None None O
undernutrition None None O
significantly None None O
increased None None O
both None None O
fetal None None O
and None None O
maternal None None O
corticosterone None None O
concentrations None None O
in None None O
rats None None O
[ None None O
116 None None O
] None None O
. None None O

Subsequently None None O
, None None O
maternal None None O
and None None O
/ None None O
or None None O
fetal None None O
overexposure None None O
to None None O
glucocorticoids None None O
( None None O
via None None O
administration None None O
of None None O
dexamethasone None None O
) None None O
impairs None None O
both None None O
fetal None None O
and None None O
postnatal None None O
beta None None O
- None None O
cell None None O
formation None None O
in None None O
rodents None None O
and None None O
nonhuman None None O
primates None None O
[ None None O
94 None None O
, None None O
117 None None O
- None None O
119 None None O
] None None O
. None None O

Seckl None None O
et None None O
al None None O
. None None O

[ None None O
115 None None O
] None None O
have None None O
shown None None O
that None None O
fetal None None O
corticosterone None None O
concentrations None None O
are None None O
inversely None None O
correlated None None O
with None None O
fetal None None O
insulin None None O
content None None O
and None None O
postnatal None None O
beta None None O
- None None O
cell None None O
formation None None O
in None None O
rats None None O
. None None O

Evidence None None O
suggests None None O
that None None O
glucocorticoids None None O
can None None O
exert None None O
a None None O
direct None None O
effect None None O
on None None O
the None None O
developing None None O
fetal None None O
pancreas None None O
via None None O
transcriptional None None O
modulation None None O
of None None O
transcription None None O
factors None None O
involved None None O
in None None O
beta None None O
- None None O
cell None None O
formation None None O
and None None O
differentiation None None O
[ None None O
117 None None O
] None None O
. None None O

Glucocorticoid None None O
receptors None None O
are None None O
present None None O
in None None O
the None None O
pancreas None None O
during None None O
embryonic None None O
development None None O
of None None O
rodents None None O
and None None O
humans None None O
[ None None O
117 None None O
] None None O
, None None O
and None None O
glucocorticoids None None O
can None None O
bind None None O
to None None O
the None None O
Pdx1 None None O
promoter None None O
and None None O
thus None None O
suppress None None O
fetal None None O
endocrine None None O
cell None None O
differentiation None None O
[ None None O
117 None None O
] None None O
. None None O

Glucocorticoid None None O
treatment None None O
has None None O
been None None O
shown None None O
to None None O
significantly None None O
reduce None None O
fetal None None O
expression None None O
of None None O
key None None O
endocrine None None O
transcription None None O
factors None None O
such None None O
as None None O
Pdx1 None None O
and None None O
Pax6 None None O
but None None O
simultaneously None None O
increase None None O
expression None None O
of None None O
transcription None None O
factors None None O
that None None O
regulate None None O
development None None O
of None None O
the None None O
exocrine None None O
pancreas None None O
[ None None O
119 None None O
] None None O
. None None O

It None None O
has None None O
also None None O
been None None O
demonstrated None None O
that None None O
the None None O
UPI None None O
or None None O
the None None O
low None None O
- None None O
protein None None O
IUPR None None O
offspring None None O
experience None None O
increased None None O
oxidative None None O
stress None None O
and None None O
impaired None None O
mitochondrial None None O
function None None O
[ None None O
96 None None O
, None None O
120 None None O
] None None O
. None None O

The None None O
mitochondrial None None O
dysfunction None None O
was None None O
not None None O
limited None None O
to None None O
just None None O
the None None O
beta None None O
cell None None O
, None None O
as None None O
mitochondria None None O
from None None O
both None None O
the None None O
liver None None O
and None None O
skeletal None None O
muscle None None O
exhibit None None O
decreased None None O
oxidation None None O
of None None O
pyruvate None None O
, None None O
subsequently None None O
leading None None O
to None None O
the None None O
development None None O
of None None O
features None None O
commonly None None O
found None None O
in None None O
T2D None None O
[ None None O
100 None None O
, None None O
121 None None O
] None None O
. None None O

Also None None O
exposure None None O
to None None O
a None None O
Western None None O
- None None O
style None None O
diet None None O
before None None O
and None None O
during None None O
pregnancy None None O
( None None O
an None None O
IUEO None None O
model None None O
) None None O
alters None None O
the None None O
redox None None O
state None None O
as None None O
early None None O
as None None O
preimplantation None None O
development None None O
, None None O
leading None None O
to None None O
mild None None O
oxidative None None O
stress None None O
associated None None O
with None None O
inflammation None None O
. None None O

The None None O
finding None None O
that None None O
administration None None O
of None None O
antioxidants None None O
to None None O
the None None O
dam None None O
reverses None None O
oxidative None None O
stress None None O
and None None O
completely None None O
prevents None None O
the None None O
development None None O
of None None O
glucose None None O
intolerance None None O
and None None O
increased None None O
adiposity None None O
in None None O
the None None O
adult None None O
offspring None None O
suggests None None O
that None None O
oxidative None None O
stress None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
the None None O
development None None O
of None None O
adiposity None None O
in None None O
this None None O
case None None O
[ None None O
122 None None O
] None None O
. None None O

Some None None O
studies None None O
in None None O
the None None O
low None None O
- None None O
protein None None O
IUPR None None O
model None None O
have None None O
demonstrated None None O
that None None O
oxidative None None O
stress None None O
is None None O
not None None O
limited None None O
to None None O
just None None O
mitochondrial None None O
DNA None None O
damage None None O
, None None O
but None None O
also None None O
to None None O
genomic None None O
DNA None None O
, None None O
impacting None None O
cell None None O
- None None O
cycle None None O
regulation None None O
and None None O
gene None None O
expression None None O
[ None None O
123 None None O
] None None O
. None None O

While None None O
DNA None None O
is None None O
being None None O
targeted None None O
throughout None None O
by None None O
ROS None None O
, None None O
there None None O
are None None O
particular None None O
regions None None O
that None None O
are None None O
known None None O
to None None O
be None None O
more None None O
sensitive None None O
to None None O
ROS None None O
- None None O
mediated None None O
damage None None O
, None None O
for None None O
example None None O
, None None O
telomeres None None O
. None None O

Telomeres None None O
comprise None None O
GC None None O
- None None O
rich None None O
repeats None None O
and None None O
are None None O
found None None O
at None None O
the None None O
ends None None O
of None None O
each None None O
chromosome None None O
. None None O

They None None O
are None None O
known None None O
to None None O
shorten None None O
with None None O
each None None O
cellular None None O
division None None O
and None None O
, None None O
hence None None O
, None None O
can None None O
act None None O
as None None O
a None None O
mitotic None None O
clock None None O
, None None O
registering None None O
the None None O
number None None O
of None None O
replicative None None O
divisions None None O
to None None O
have None None O
taken None None O
place None None O
within None None O
the None None O
cell None None O
. None None O

Investigations None None O
using None None O
an None None O
IUPR None None O
model None None O
have None None O
indeed None None O
reported None None O
a None None O
decrease None None O
in None None O
longevity None None O
in None None O
the None None O
offspring None None O
[ None None O
123 None None O
, None None O
124 None None O
] None None O
accompanied None None O
by None None O
reduction None None O
in None None O
mitochondrial None None O
antioxidant None None O
defences None None O
[ None None O
96 None None O
, None None O
125 None None O
] None None O
and None None O
telomere None None O
length None None O
in None None O
islets None None O
[ None None O
125 None None O
] None None O
. None None O

Pancreatic None None O
islet None None O
development None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
influenced None None O
by None None O
a None None O
number None None O
of None None O
growth None None O
factors None None O
including None None O
the None None O
insulin None None O
- None None O
like None None O
growth None None O
factors None None O
, None None O
IGF None None O
- None None O
I None None O
and None None O
IGF None None O
- None None O
II None None O
whose None None O
expression None None O
in None None O
utero None None O
is None None O
regulated None None O
by None None O
nutrient None None O
and None None O
hormone None None O
concentrations None None O
. None None O

IUPR None None O
modifies None None O
expression None None O
of None None O
both None None O
IGF None None O
genes None None O
in None None O
a None None O
variety None None O
of None None O
fetal None None O
tissues None None O
. None None O

In None None O
an None None O
IUPR None None O
rat None None O
model None None O
with None None O
a None None O
decreased None None O
beta None None O
- None None O
cell None None O
mass None None O
and None None O
beta None None O
- None None O
cell None None O
replication None None O
and None None O
an None None O
increased None None O
rate None None O
of None None O
beta None None O
- None None O
cell None None O
apoptosis None None O
, None None O
gene None None O
expression None None O
for None None O
IGF None None O
- None None O
II None None O
but None None O
not None None O
IGF None None O
- None None O
I None None O
was None None O
found None None O
reduced None None O
in None None O
the None None O
fetal None None O
pancreas None None O
[ None None O
126 None None O
] None None O
. None None O

In None None O
a None None O
different None None O
IUPR None None O
model None None O
with None None O
more None None O
severe None None O
global None None O
food None None O
restriction None None O
which None None O
induced None None O
hyperinsulinemia None None O
and None None O
an None None O
increase None None O
in None None O
beta None None O
- None None O
cell None None O
mass None None O
in None None O
their None None O
fetuses None None O
[ None None O
90 None None O
] None None O
, None None O
the None None O
fetal None None O
phenotype None None O
was None None O
unexpectedly None None O
associated None None O
with None None O
an None None O
increase None None O
in None None O
pancreatic None None O
IGF None None O
- None None O
I None None O
expression None None O
, None None O
islet None None O
IGF None None O
- None None O
1R None None O
[ None None O
91 None None O
] None None O
, None None O
and None None O
IRS None None O
- None None O
2 None None O
[ None None O
92 None None O
] None None O
. None None O

In None None O
the None None O
fetal None None O
GK None None O
/ None None O
Par None None O
rat None None O
exposed None None O
to None None O
mild None None O
hyperglycemia None None O
during None None O
gestation None None O
( None None O
a None None O
model None None O
of None None O
IUED None None O
) None None O
, None None O
data None None O
from None None O
our None None O
group None None O
suggest None None O
that None None O
the None None O
beta None None O
- None None O
cell None None O
deficit None None O
( None None O
reduced None None O
by None None O
more None None O
than None None O
50 None None O
% None None O
) None None O
starts None None O
as None None O
early None None O
as None None O
fetal None None O
age None None O
E16 None None O
and None None O
reflects None None O
decreased None None O
beta None None O
- None None O
cell None None O
proliferation None None O
, None None O
a None None O
limitation None None O
of None None O
beta None None O
- None None O
cell None None O
neogenesis None None O
from None None O
precursors None None O
, None None O
and None None O
increased None None O
apoptosis None None O
of None None O
both None None O
beta None None O
cells None None O
and None None O
their None None O
precursors None None O
[ None None O
86 None None O
] None None O
. None None O

Notably None None O
, None None O
Pdx1 None None O
and None None O
Neurogenin3 None None O
expression None None O
were None None O
decreased None None O
on None None O
E18 None None O
but None None O
normally None None O
expressed None None O
on None None O
E13 None None O
[ None None O
86 None None O
] None None O
. None None O

Defective None None O
signalling None None O
through None None O
the None None O
Igf2 None None O
/ None None O
Igf1 None None O
- None None O
R None None O
pathway None None O
may None None O
represent None None O
the None None O
primary None None O
instrumental None None O
anomaly None None O
since None None O
Igf2 None None O
and None None O
Igf1 None None O
- None None O
R None None O
protein None None O
expressions None None O
are None None O
already None None O
decreased None None O
within None None O
the None None O
GK None None O
/ None None O
Par None None O
pancreatic None None O
rudiment None None O
at None None O
E13 None None O
, None None O
at None None O
a None None O
time None None O
when None None O
beta None None O
- None None O
cell None None O
mass None None O
( None None O
first None None O
wave None None O
of None None O
beta None None O
- None None O
cell None None O
expansion None None O
) None None O
is None None O
in None None O
fact None None O
normal None None O
[ None None O
31 None None O
] None None O
. None None O

Low None None O
levels None None O
of None None O
pancreatic None None O
Igf2 None None O
associated None None O
with None None O
beta None None O
- None None O
cell None None O
mass None None O
deficiency None None O
are None None O
maintained None None O
thereafter None None O
within None None O
the None None O
fetal None None O
pancreas None None O
[ None None O
87 None None O
] None None O
. None None O

Crossbreeding None None O
protocols None None O
between None None O
nondiabetic None None O
W None None O
and None None O
diabetic None None O
GK None None O
rats None None O
showed None None O
that None None O
, None None O
in None None O
late None None O
gestation None None O
( None None O
E18 None None O
) None None O
, None None O
pancreatic None None O
Igf2 None None O
protein None None O
expression None None O
was None None O
as None None O
low None None O
in None None O
GKmother None None O
/ None None O
GKfather None None O
and None None O
Wmother None None O
/ None None O
GKfather None None O
crosses None None O
as None None O
in None None O
GKmother None None O
/ None None O
GKfather None None O
crosses None None O
[ None None O
87 None None O
] None None O
. None None O

These None None O
findings None None O
rather None None O
support None None O
the None None O
hypothesis None None O
that None None O
the None None O
pancreatic None None O
Igf2 None None O
anomaly None None O
in None None O
the None None O
GK None None O
diabetic None None O
model None None O
is None None O
linked None None O
to None None O
a None None O
genetic None None O
determinism None None O
. None None O

This None None O
view None None O
is None None O
also None None O
consistent None None O
with None None O
the None None O
results None None O
of None None O
genetic None None O
analyses None None O
that None None O
linked None None O
a None None O
locus None None O
containing None None O
the None None O
gene None None O
encoding None None O
Igf2 None None O
to None None O
diabetes None None O
in None None O
the None None O
GK None None O
rat None None O
[ None None O
127 None None O
] None None O
. None None O

The None None O
Igf2 None None O
gene None None O
is None None O
subjected None None O
to None None O
paternal None None O
genomic None None O
imprinting None None O
. None None O

However None None O
, None None O
because None None O
the None None O
Igf2 None None O
expression None None O
is None None O
similarly None None O
affected None None O
in None None O
fetuses None None O
, None None O
regardless None None O
of None None O
whether None None O
the None None O
father None None O
is None None O
W None None O
or None None O
GK None None O
[ None None O
87 None None O
] None None O
, None None O
we None None O
cannot None None O
conclude None None O
with None None O
a None None O
simple None None O
change None None O
of None None O
Igf2 None None O
gene None None O
imprinting None None O
in None None O
the None None O
GK None None O
rat None None O
. None None O

Finally None None O
, None None O
our None None O
understanding None None O
of None None O
the None None O
underlying None None O
mechanisms None None O
for None None O
reduced None None O
BCM None None O
in None None O
response None None O
to None None O
inappropriate None None O
perinatal None None O
nutrition None None O
is None None O
growing None None O
rapidly None None O
. None None O

However None None O
, None None O
the None None O
relative None None O
contribution None None O
of None None O
the None None O
many None None O
intrinsic None None O
and None None O
extrinsic None None O
factors None None O
which None None O
contribute None None O
to None None O
the None None O
adaptive None None O
response None None O
of None None O
the None None O
developing None None O
endocrine None None O
pancreas None None O
is None None O
still None None O
to None None O
be None None O
established None None O
. None None O

A None None O
potential None None O
role None None O
for None None O
the None None O
Src None None O
- None None O
like None None O
adapter None None O
protein None None O
SLAP None None O
- None None O
2 None None O
in None None O
signaling None None O
by None None O
the None None O
colony None None O
stimulating None None O
factor None None O
- None None O
1 None None O
receptor None None O
. None None O

The None None O
development None None O
of None None O
macrophages None None O
from None None O
myeloid None None O
progenitor None None O
cells None None O
is None None O
primarily None None O
controlled None None O
by None None O
the None None O
growth None None O
factor None None O
colony None None O
stimulating None None O
factor None None O
- None None O
1 None None O
( None None O
CSF None None O
- None None O
1 None None O
) None None O
and None None O
its None None O
cognate None None O
receptor None None O
, None None O
a None None O
transmembrane None None O
tyrosine None None O
kinase None None O
encoded None None O
by None None O
the None None O
c None None O
- None None O
Fms None None O
proto None None O
- None None O
oncogene None None O
. None None O

The None None O
CSF None None O
- None None O
1 None None O
receptor None None O
exerts None None O
its None None O
biological None None O
effects None None O
on None None O
cells None None O
via None None O
a None None O
range None None O
of None None O
signaling None None O
proteins None None O
including None None O
Erk1 None None O
/ None None O
2 None None O
and None None O
Akt None None O
. None None O

Here None None O
we None None O
have None None O
investigated None None O
the None None O
potential None None O
involvement None None O
of None None O
the None None O
Src None None O
- None None O
like None None O
adapter None None O
protein None None O
( None None O
SLAP None None O
- None None O
2 None None O
) None None O
in None None O
signaling None None O
by None None O
the None None O
CSF None None O
- None None O
1 None None O
receptor None None O
in None None O
mouse None None O
bone None None O
marrow None None O
- None None O
derived None None O
macrophages None None O
. None None O

RT None None O
- None None O
PCR None None O
analysis None None O
revealed None None O
constitutive None None O
expression None None O
of None None O
the None None O
SLAP None None O
- None None O
2 None None O
gene None None O
in None None O
bone None None O
marrow None None O
macrophages None None O
. None None O

Surprisingly None None O
, None None O
co None None O
- None None O
immunoprecipitation None None O
and None None O
GST None None O
binding None None O
experiments None None O
demonstrated None None O
that None None O
the None None O
CSF None None O
- None None O
1 None None O
receptor None None O
could None None O
bind None None O
to None None O
SLAP None None O
- None None O
2 None None O
in None None O
a None None O
ligand None None O
- None None O
independent None None O
manner None None O
. None None O

Furthermore None None O
, None None O
the None None O
binding None None O
of None None O
SLAP None None O
- None None O
2 None None O
to None None O
the None None O
CSF None None O
- None None O
1 None None O
receptor None None O
involved None None O
multiple None None O
domains None None O
of None None O
SLAP None None O
- None None O
2 None None O
. None None O

SLAP None None O
- None None O
2 None None O
also None None O
bound None None O
c None None O
- None None O
Cbl None None O
, None None O
with None None O
the None None O
interaction None None O
being None None O
mediated None None O
, None None O
at None None O
least None None O
in None None O
part None None O
, None None O
by None None O
the None None O
unique None None O
C None None O
- None None O
terminal None None O
domain None None O
of None None O
SLAP None None O
- None None O
2 None None O
. None None O

Overexpression None None O
of None None O
SLAP None None O
- None None O
2 None None O
in None None O
bone None None O
marrow None None O
macrophages None None O
partially None None O
suppressed None None O
the None None O
CSF None None O
- None None O
1 None None O
- None None O
induced None None O
tyrosine None None O
phosphorylation None None O
and None None O
/ None None O
or None None O
expression None None O
level None None O
of None None O
a None None O
approximately None None O
80 None None O
kDa None None O
protein None None O
without None None O
affecting None None O
CSF None None O
- None None O
1 None None O
- None None O
induced None None O
global None None O
tyrosine None None O
phosphorylation None None O
, None None O
or None None O
activation None None O
of None None O
Akt None None O
or None None O
Erk1 None None O
/ None None O
2 None None O
. None None O

Significantly None None O
, None None O
CSF None None O
- None None O
1 None None O
stimulation None None O
induced None None O
serine None None O
phosphorylation None None O
of None None O
SLAP None None O
- None None O
2 None None O
. None None O

Pharmacologic None None O
inhibition None None O
of None None O
specific None None O
protein None None O
kinases None None O
revealed None None O
that None None O
CSF None None O
- None None O
1 None None O
- None None O
induced None None O
phosphorylation None None O
of None None O
SLAP None None O
- None None O
2 None None O
was None None O
dependent None None O
on None None O
JNK None None O
activity None None O
. None None O

Taken None None O
together None None O
, None None O
our None None O
results None None O
suggest None None O
that None None O
SLAP None None O
- None None O
2 None None O
could None None O
potentially None None O
be None None O
involved None None O
in None None O
signaling None None O
by None None O
the None None O
CSF None None O
- None None O
1 None None O
receptor None None O
. None None O

[ None None O
Clinical None None O
significance None None O
of None None O
interleukin None None O
- None None O
6 None None O
( None None O
IL None None O
- None None O
6 None None O
) None None O
as None None O
a None None O
prognostic None None O
factor None None O
of None None O
cancer None None O
disease None None O
] None None O

Interleukin None None O
- None None O
6 None None O
( None None O
IL None None O
- None None O
6 None None O
) None None O
is None None O
proinflammatory None None O
cytokine None None O
that None None O
produces None None O
multifunctional None None O
effects None None O
. None None O

It None None O
is None None O
also None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
immune None None O
reactions None None O
, None None O
hematopoiesis None None O
and None None O
inflammatory None None O
state None None O
. None None O

Interleukin None None O
- None None O
6 None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
associated None None O
with None None O
tumor None None O
progression None None O
including None None O
inhibition None None O
of None None O
cancer None None O
cells None None O
apoptosis None None O
and None None O
stimulation None None O
of None None O
angiogenesis None None O
. None None O

Anti None None O
- None None O
IL None None O
- None None O
6 None None O
therapy None None O
is None None O
a None None O
new None None O
strategy None None O
in None None O
the None None O
inflammatory None None O
autoimmune None None O
diseases None None O
and None None O
cancer None None O
. None None O

Clinical None None O
studies None None O
have None None O
shown None None O
elevated None None O
serum None None O
IL None None O
- None None O
6 None None O
concentrations None None O
in None None O
patients None None O
with None None O
endometrial None None O
cancer None None O
, None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
carcinoma None None O
, None None O
colorectal None None O
cancer None None O
, None None O
renal None None O
cell None None O
carcinoma None None O
, None None O
breast None None O
and None None O
ovarian None None O
cancer None None O
. None None O

Serum None None O
IL None None O
- None None O
6 None None O
levels None None O
correlate None None O
with None None O
tumor None None O
stage None None O
, None None O
and None None O
survival None None O
of None None O
patients None None O
. None None O

In None None O
this None None O
article None None O
we None None O
have None None O
focused None None O
on None None O
a None None O
role None None O
of None None O
IL None None O
- None None O
6 None None O
as None None O
a None None O
prognostic None None O
factor None None O
in None None O
several None None O
malignancies None None O
such None None O
as None None O
colorectal None None O
cancer None None O
, None None O
breast None None O
cancer None None O
, None None O
gastric None None O
cancer None None O
and None None O
pancreatic None None O
cancer None None O
. None None O

Pancreatic None None O
endocrine None None O
tumors None None O
: None None O
expression None None O
profiling None None O
evidences None None O
a None None O
role None None O
for None None O
AKT None None O
- None None O
mTOR None None O
pathway None None O
. None None O

PURPOSE None None O
: None None O
We None None O
investigated None None O
the None None O
global None None O
gene None None O
expression None None O
in None None O
a None None O
large None None O
panel None None O
of None None O
pancreatic None None O
endocrine None None O
tumors None None O
( None None O
PETs None None O
) None None O
aimed None None O
at None None O
identifying None None O
new None None O
potential None None O
targets None None O
for None None O
therapy None None O
and None None O
biomarkers None None O
to None None O
predict None None O
patient None None O
outcome None None O
. None None O

PATIENTS None None O
AND None None O
METHODS None None O
: None None O
Using None None O
a None None O
custom None None O
microarray None None O
, None None O
we None None O
analyzed None None O
72 None None O
primary None None O
PETs None None O
, None None O
seven None None O
matched None None O
metastases None None O
, None None O
and None None O
10 None None O
normal None None O
pancreatic None None O
samples None None O
. None None O

Relevant None None O
differentially None None O
expressed None None O
genes None None O
were None None O
validated None None O
by None None O
either None None O
quantitative None None O
real None None O
- None None O
time None None O
polymerase None None O
chain None None O
reaction None None O
or None None O
immunohistochemistry None None O
on None None O
tissue None None O
microarrays None None O
. None None O

RESULTS None None O
: None None O
Our None None O
data None None O
showed None None O
that None None O
: None None O
tuberous None None O
sclerosis None None O
2 None None O
( None None O
TSC2 None None O
) None None O
and None None O
phosphatase None None O
and None None O
tensin None None O
homolog None None O
( None None O
PTEN None None O
) None None O
were None None O
downregulated None None O
in None None O
most None None O
of None None O
the None None O
primary None None O
tumors None None O
, None None O
and None None O
their None None O
low None None O
expression None None O
was None None O
significantly None None O
associated None None O
with None None O
shorter None None O
disease None None O
- None None O
free None None O
and None None O
overall None None O
survival None None O
; None None O
somatostatin None None O
receptor None None O
2 None None O
( None None O
SSTR2 None None O
) None None O
was None None O
absent None None O
or None None O
very None None O
low None None O
in None None O
insulinomas None None O
compared None None O
with None None O
nonfunctioning None None O
tumors None None O
; None None O
and None None O
expression None None O
of None None O
fibroblast None None O
growth None None O
factor None None O
13 None None O
( None None O
FGF13 None None O
) None None O
gene None None O
was None None O
significantly None None O
associated None None O
with None None O
the None None O
occurrence None None O
of None None O
liver None None O
metastasis None None O
and None None O
shorter None None O
disease None None O
- None None O
free None None O
survival None None O
. None None O

TSC2 None None O
and None None O
PTEN None None O
are None None O
two None None O
key None None O
inhibitors None None O
of None None O
the None None O
Akt None None O
/ None None O
mammalian None None O
target None None O
of None None O
rapamycin None None O
( None None O
mTOR None None O
) None None O
pathway None None O
and None None O
the None None O
specific None None O
inhibition None None O
of None None O
mTOR None None O
with None None O
rapamycin None None O
or None None O
RAD001 None None O
inhibited None None O
cell None None O
proliferation None None O
of None None O
PET None None O
cell None None O
lines None None O
. None None O

CONCLUSION None None O
: None None O
Our None None O
results None None O
strongly None None O
support None None O
a None None O
role None None O
for None None O
PI3K None None O
/ None None O
Akt None None O
/ None None O
mTOR None None O
pathway None None O
in None None O
PET None None O
, None None O
which None None O
ties None None O
in None None O
with None None O
the None None O
fact None None O
that None None O
mTOR None None O
inhibitors None None O
have None None O
reached None None O
phase None None O
III None None O
trials None None O
in None None O
neuroendocrine None None O
tumors None None O
. None None O

The None None O
finding None None O
of None None O
differential None None O
SSTR None None O
expression None None O
raises None None O
the None None O
potential None None O
for None None O
SSTR None None O
expression None None O
to None None O
be None None O
evaluated None None O
as None None O
a None None O
marker None None O
of None None O
response None None O
to None None O
somatostatin None None O
analogs None None O
. None None O

Finally None None O
, None None O
we None None O
identified None None O
FGF13 None None O
as None None O
a None None O
new None None O
prognostic None None O
marker None None O
that None None O
predicted None None O
poorer None None O
outcome None None O
in None None O
patients None None O
who None None O
were None None O
clinically None None O
considered None None O
free None None O
from None None O
disease None None O
. None None O

Details None None O
of None None O
treatment None None O
programs None None O
A None None O
and None None O
B None None O
in None None O
respect None None O
to None None O
visits None None O
to None None O
different None None O
health None None O
care None None O
professionals None None O
and None None O
treatment None None O
activities None None O

Proto None None O
- None None O
oncogene None None O
N None None O
- None None O
myc None None O
promoter None None O
is None None O
down None None O
regulated None None O
by None None O
the None None O
Wilms None None O
' None None O
tumor None None O
suppressor None None O
gene None None O
WT1 None None O
. None None O

The None None O
Wilms None None O
' None None O
tumor None None O
1 None None O
( None None O
WT1 None None O
) None None O
gene None None O
is None None O
a None None O
tumor None None O
suppressor None None O
gene None None O
that None None O
encodes None None O
a None None O
zinc None None O
- None None O
finger None None O
transcription None None O
factor None None O
. None None O

WT1 None None O
represses None None O
transcription None None O
of None None O
several None None O
growth None None O
factors None None O
and None None O
growth None None O
factor None None O
receptors None None O
. None None O

The None None O
N None None O
- None None O
myc None None O
proto None None O
- None None O
oncogene None None O
encodes None None O
a None None O
transcription None None O
factor None None O
which None None O
regulates None None O
cell None None O
growth None None O
and None None O
differentiation None None O
. None None O

N None None O
- None None O
myc None None O
is None None O
coexpressed None None O
with None None O
WT1 None None O
in None None O
the None None O
developing None None O
kidney None None O
and None None O
is None None O
overexpressed None None O
in None None O
many None None O
Wilms None None O
' None None O
tumors None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
the None None O
proto None None O
- None None O
oncogene None None O
N None None O
- None None O
myc None None O
promoter None None O
was None None O
down None None O
- None None O
regulated None None O
by None None O
WT1 None None O
in None None O
transient None None O
transfection None None O
assays None None O
. None None O

However None None O
, None None O
mutant None None O
WT1 None None O
( None None O
R394W None None O
) None None O
which None None O
has None None O
a None None O
mutation None None O
in None None O
the None None O
DNA None None O
binding None None O
domain None None O
could None None O
not None None O
repress None None O
the None None O
N None None O
- None None O
myc None None O
promoter None None O
. None None O

Electrophoretic None None O
mobility None None O
shift None None O
assays None None O
showed None None O
that None None O
the None None O
oligonucleotides None None O
containing None None O
the None None O
WT1 None None O
motifs None None O
could None None O
bind None None O
recombinant None None O
WT1 None None O
proteins None None O
. None None O

This None None O
suggests None None O
that None None O
the None None O
repression None None O
of None None O
the None None O
N None None O
- None None O
myc None None O
promoter None None O
is None None O
mediated None None O
through None None O
the None None O
WT1 None None O
binding None None O
sites None None O
. None None O

This None None O
finding None None O
may None None O
help None None O
to None None O
elucidate None None O
the None None O
relationship None None O
of None None O
WT1 None None O
and None None O
N None None O
- None None O
myc None None O
in None None O
tumorigenesis None None O
and None None O
renal None None O
development None None O
. None None O

Deletion None None O
of None None O
Tip30 None None O
leads None None O
to None None O
rapid None None O
immortalization None None O
of None None O
murine None None O
mammary None None O
epithelial None None O
cells None None O
and None None O
ductal None None O
hyperplasia None None O
in None None O
the None None O
mammary None None O
gland None None O
. None None O

Transformation None None O
of None None O
mammary None None O
epithelial None None O
cells None None O
( None None O
MECs None None O
) None None O
from None None O
the None None O
normal None None O
to None None O
the None None O
neoplastic None None O
stage None None O
requires None None O
the None None O
dysregulation None None O
of None None O
tumor None None O
suppressor None None O
genes None None O
and None None O
proto None None O
- None None O
oncogenes None None O
. None None O

Tip30 None None O
is None None O
a None None O
tumor None None O
suppressor None None O
that None None O
can None None O
inhibit None None O
estrogen None None O
receptor None None O
- None None O
mediated None None O
transcription None None O
in None None O
MECs None None O
, None None O
but None None O
its None None O
role None None O
in None None O
MEC None None O
proliferation None None O
remains None None O
unknown None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
deleting None None O
the None None O
Tip30 None None O
gene None None O
leads None None O
to None None O
ductal None None O
hyperplasia None None O
in None None O
mouse None None O
mammary None None O
glands None None O
early None None O
in None None O
life None None O
and None None O
extensive None None O
mammary None None O
hyperplasia None None O
with None None O
age None None O
. None None O

Tip30 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
mammary None None O
glands None None O
transplanted None None O
into None None O
wild None None O
- None None O
type None None O
mammary None None O
fat None None O
pads None None O
also None None O
display None None O
mammary None None O
trees None None O
with None None O
extensive None None O
ductal None None O
hyperplasia None None O
. None None O

Strikingly None None O
, None None O
Tip30 None None O
deletion None None O
promotes None None O
proliferation None None O
of None None O
primary None None O
MECs None None O
and None None O
results None None O
in None None O
rapid None None O
immortalization None None O
of None None O
MECs None None O
in None None O
vitro None None O
relative None None O
to None None O
wild None None O
- None None O
type None None O
cells None None O
. None None O

Gene None None O
array None None O
analysis None None O
identified None None O
significant None None O
increases None None O
in None None O
the None None O
expression None None O
of None None O
mammary None None O
epithelial None None O
growth None None O
factors None None O
Wisp2 None None O
and None None O
Igf None None O
- None None O
1 None None O
in None None O
Tip30 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
cells None None O
. None None O

Knockdown None None O
of None None O
either None None O
Wisp2 None None O
or None None O
Igf None None O
- None None O
1 None None O
using None None O
short None None O
interfering None None O
RNA None None O
dramatically None None O
inhibited None None O
proliferation None None O
of None None O
Tip30 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
cells None None O
. None None O

Together None None O
, None None O
these None None O
results None None O
suggest None None O
that None None O
Tip30 None None O
is None None O
an None None O
intrinsic None None O
and None None O
negative None None O
regulator None None O
of None None O
MEC None None O
proliferation None None O
partly None None O
through None None O
the None None O
inhibition None None O
of None None O
Wisp2 None None O
and None None O
Igf None None O
- None None O
1 None None O
expression None None O
, None None O
and None None O
its None None O
absence None None O
in None None O
the None None O
mammary None None O
gland None None O
may None None O
predispose None None O
MECs None None O
to None None O
neoplastic None None O
transformation None None O
. None None O

Cancer None None O
progression None None O
and None None O
p53 None None O
. None None O

In None None O
a None None O
complex None None O
organism None None O
, None None O
somatic None None O
cells None None O
are None None O
under None None O
intermittent None None O
selection None None O
pressure None None O
for None None O
the None None O
emergence None None O
of None None O
mutants None None O
that None None O
can None None O
survive None None O
environmental None None O
insults None None O
and None None O
that None None O
can None None O
grow None None O
autonomously None None O
despite None None O
adverse None None O
conditions None None O
. None None O

Repeated None None O
rounds None None O
of None None O
mutation None None O
, None None O
selection None None O
, None None O
and None None O
proliferation None None O
may None None O
lead None None O
to None None O
cancer None None O
. None None O

The None None O
organism None None O
prevents None None O
malignant None None O
transformation None None O
by None None O
assuring None None O
accurate None None O
DNA None None O
repair None None O
before None None O
cell None None O
division None None O
, None None O
by None None O
forcing None None O
the None None O
death None None O
of None None O
cells None None O
with None None O
excessive None None O
DNA None None O
damage None None O
, None None O
and None None O
by None None O
placing None None O
limits None None O
on None None O
the None None O
replicative None None O
lifespans None None O
of None None O
most None None O
somatic None None O
cells None None O
. None None O

The None None O
p53 None None O
gene None None O
is None None O
a None None O
" None None O
guardian None None O
of None None O
the None None O
genome None None O
" None None O
- None None O
- None None O
it None None O
regulates None None O
multiple None None O
components None None O
of None None O
the None None O
DNA None None O
damage None None O
control None None O
response None None O
and None None O
promotes None None O
cellular None None O
senescence None None O
. None None O

Disabling None None O
mutations None None O
and None None O
deletions None None O
of None None O
p53 None None O
occur None None O
in None None O
50 None None O
% None None O
of None None O
human None None O
tumours None None O
. None None O

p53 None None O
- None None O
deficient None None O
cancers None None O
are None None O
often None None O
unstable None None O
, None None O
aggressive None None O
, None None O
and None None O
resistant None None O
to None None O
therapy None None O
. None None O

Prolonged None None O
control None None O
of None None O
patterned None None O
biofilm None None O
formation None None O
by None None O
bio None None O
- None None O
inert None None O
surface None None O
chemistry None None O
. None None O

A None None O
bio None None O
- None None O
inert None None O
surface None None O
chemistry None None O
was None None O
developed None None O
that None None O
can None None O
confine None None O
biofilm None None O
formation None None O
in None None O
designed None None O
patterns None None O
for None None O
at None None O
least None None O
26 None None O
days None None O
. None None O

Methodologies None None O
for None None O
measuring None None O
carcinogen None None O
adducts None None O
in None None O
humans None None O
. None None O

In None None O
summary None None O
, None None O
although None None O
some None None O
of None None O
the None None O
more None None O
optimistic None None O
aspirations None None O
for None None O
human None None O
biomonitoring None None O
studies None None O
envisaged None None O
a None None O
decade None None O
ago None None O
have None None O
not None None O
been None None O
realized None None O
thus None None O
far None None O
, None None O
some None None O
considerable None None O
advances None None O
have None None O
been None None O
made None None O
. None None O

The None None O
examples None None O
cited None None O
above None None O
indicate None None O
that None None O
the None None O
feasibility None None O
of None None O
biomonitoring None None O
has None None O
been None None O
clearly None None O
established None None O
. None None O

In None None O
addition None None O
, None None O
they None None O
demonstrate None None O
the None None O
need None None O
for None None O
preliminary None None O
biomarker None None O
testing None None O
and None None O
validation None None O
through None None O
transitional None None O
studies None None O
prior None None O
to None None O
their None None O
field None None O
application None None O
. None None O

In None None O
the None None O
next None None O
decade None None O
of None None O
research None None O
into None None O
carcinogen None None O
adducts None None O
in None None O
humans None None O
, None None O
continued None None O
improvements None None O
in None None O
the None None O
reproducibility None None O
and None None O
specificity None None O
of None None O
assays None None O
for None None O
DNA None None O
adducts None None O
will None None O
be None None O
needed None None O
. None None O

Perhaps None None O
the None None O
increasing None None O
use None None O
of None None O
hybrid None None O
methodologies None None O
to None None O
concentrate None None O
adducts None None O
followed None None O
by None None O
specific None None O
chemical None None O
analyses None None O
will None None O
allow None None O
such None None O
adducts None None O
to None None O
be None None O
monitored None None O
more None None O
precisely None None O
. None None O

Of None None O
course None None O
, None None O
further None None O
basic None None O
research None None O
into None None O
the None None O
mechanisms None None O
of None None O
carcinogenesis None None O
will None None O
allow None None O
the None None O
measurement None None O
of None None O
specific None None O
novel None None O
markers None None O
which None None O
are None None O
more None None O
closely None None O
tied None None O
to None None O
the None None O
disease None None O
endpoint None None O
than None None O
adducts None None O
. None None O

The None None O
development None None O
of None None O
new None None O
assays None None O
for None None O
determining None None O
metabolic None None O
phenotypes None None O
and None None O
genotypes None None O
relevant None None O
to None None O
carcinogenesis None None O
should None None O
improve None None O
our None None O
estimates None None O
of None None O
susceptibility None None O
( None None O
46 None None O
- None None O
48 None None O
) None None O
. None None O

Such None None O
new None None O
approaches None None O
along None None O
with None None O
the None None O
sustained None None O
improvement None None O
of None None O
current None None O
assays None None O
will None None O
allow None None O
molecular None None O
approaches None None O
to None None O
continue None None O
to None None O
enrich None None O
cancer None None O
epidemiology None None O
in None None O
the None None O
future None None O
. None None O

Mineralization None None O
( None None O
red None None O
) None None O
of None None O
the None None O
aorta None None O
is None None O
prevented None None O
by None None O
local None None O
( None None O
left None None O
) None None O
, None None O
but None None O
not None None O
global None None O
( None None O
right None None O
) None None O
, None None O
Mgp None None O
expression None None O
. None None O

Induction None None O
of None None O
apoptosis None None O
in None None O
skeletal None None O
tissues None None O
: None None O
phosphate None None O
- None None O
mediated None None O
chick None None O
chondrocyte None None O
apoptosis None None O
is None None O
calcium None None O
dependent None None O
. None None O

In None None O
an None None O
earlier None None O
study None None O
, None None O
we None None O
have None None O
shown None None O
that None None O
Pi None None O
induced None None O
apoptosis None None O
of None None O
terminally None None O
differentiated None None O
hypertrophic None None O
chondrocytes None None O
. None None O

To None None O
ascertain None None O
whether None None O
Ca2 None None O
+ None None O
modulates None None O
Pi None None O
- None None O
induced None None O
cell None None O
death None None O
, None None O
we None None O
asked None None O
the None None O
following None None O
two None None O
questions None None O
: None None O
First None None O
, None None O
can None None O
we None None O
prevent None None O
Pi None None O
- None None O
induced None None O
apoptosis None None O
by None None O
removing None None O
Ca2 None None O
+ None None O
from None None O
the None None O
culture None None O
medium None None O
; None None O
alternatively None None O
, None None O
can None None O
we None None O
potentiate None None O
cell None None O
death None None O
by None None O
increasing None None O
the None None O
Ca2 None None O
+ None None O
concentration None None O
? None None O

Second None None O
, None None O
can None None O
we None None O
inhibit None None O
chondrocyte None None O
apoptosis None None O
by None None O
blocking None None O
Pi None None O
transport None None O
? None None O

We None None O
also None None O
explored None None O
the None None O
mechanism None None O
of None None O
apoptosis None None O
by None None O
evaluating None None O
mitochondrial None None O
activity None None O
and None None O
reactive None None O
oxygen None None O
species None None O
( None None O
ROS None None O
) None None O
generation None None O
in None None O
cells None None O
treated None None O
with None None O
the None None O
ion None None O
pair None None O
. None None O

We None None O
noted None None O
that None None O
EDTA None None O
and None None O
EGTA None None O
blocked None None O
Pi None None O
- None None O
induced None None O
apoptosis None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
. None None O

While None None O
high None None O
levels None None O
of None None O
Ca2 None None O
+ None None O
alone None None O
had None None O
little None None O
effect None None O
on None None O
chondrocyte None None O
viability None None O
, None None O
the None None O
cation None None O
enhanced None None O
Pi None None O
- None None O
dependent None None O
cell None None O
death None None O
and None None O
greatly None None O
increased None None O
Pi None None O
uptake None None O
. None None O

When None None O
Pi None None O
transport None None O
was None None O
blocked None None O
, None None O
there None None O
was None None O
complete None None O
inhibition None None O
of None None O
cell None None O
killing None None O
. None None O

The None None O
process None None O
of None None O
cell None None O
death None None O
was None None O
characterized None None O
by None None O
mitochondrial None None O
hyperpolarization None None O
; None None O
two None None O
hours None None O
following None None O
apoptogen None None O
treatment None None O
, None None O
there None None O
was None None O
a None None O
significant None None O
decrease None None O
in None None O
the None None O
mitochondrial None None O
membrane None None O
potential None None O
. None None O

Coincident None None O
with None None O
the None None O
changes None None O
in None None O
mitochondrial None None O
function None None O
, None None O
there None None O
was None None O
an None None O
increase None None O
in None None O
intracellular None None O
Ca2 None None O
+ None None O
that None None O
was None None O
maintained None None O
throughout None None O
the None None O
experimental None None O
period None None O
. None None O

A None None O
raised None None O
Ca2 None None O
+ None None O
signal None None O
was None None O
observed None None O
in None None O
blebs None None O
at None None O
the None None O
cell None None O
membrane None None O
. None None O

Finally None None O
, None None O
we None None O
noted None None O
that None None O
, None None O
75 None None O
minutes None None O
after None None O
treatment None None O
with None None O
the None None O
ion None None O
pair None None O
, None None O
there None None O
was None None O
a None None O
six None None O
- None None O
fold None None O
elevation None None O
in None None O
ROS None None O
levels None None O
. None None O

This None None O
increase None None O
declined None None O
to None None O
baseline None None O
values None None O
after None None O
three None None O
hours None None O
. None None O

Based None None O
on None None O
these None None O
observations None None O
, None None O
we None None O
suggest None None O
that None None O
, None None O
at None None O
the None None O
cartilage None None O
mineralization None None O
front None None O
, None None O
an None None O
elevation None None O
in None None O
local None None O
environmental None None O
Ca2 None None O
+ None None O
and None None O
Pi None None O
concentrations None None O
modulates None None O
oxidative None None O
metabolism None None O
, None None O
and None None O
triggers None None O
apoptosis None None O
of None None O
terminally None None O
differentiated None None O
chondrocytes None None O
. None None O

MOR1K None None O
expression None None O
and None None O
binding None None O
pattern None None O
. None None O

( None None O
A None None O
) None None O
The None None O
schematic None None O
diagram None None O
illustrates None None O
the None None O
exonic None None O
composition None None O
and None None O
relative None None O
positions None None O
of None None O
PCR None None O
primers None None O
designed None None O
to None None O
amplify None None O
the None None O
major None None O
MOR1 None None O
isoform None None O
and None None O
the None None O
newly None None O
identified None None O
alternative None None O
MOR1K None None O
isoform None None O
. None None O

The None None O
relative None None O
positions None None O
of None None O
translation None None O
initiation None None O
start None None O
and None None O
stop None None O
codons None None O
are None None O
designated None None O
by None None O
ATG None None O
and None None O
TGA None None O
, None None O
respectively None None O
. None None O

The None None O
predicted None None O
protein None None O
structure None None O
of None None O
MOR1 None None O
and None None O
MOR1K None None O
isoforms None None O
is None None O
schematically None None O
presented None None O
. None None O

Translation None None O
of None None O
the None None O
MOR1K None None O
variant None None O
results None None O
in None None O
a None None O
6TM None None O
receptor None None O
, None None O
truncated None None O
at None None O
the None None O
N None None O
- None None O
terminus None None O
. None None O

( None None O
B None None O
) None None O
Real None None O
- None None O
time None None O
PCR None None O
was None None O
performed None None O
on None None O
total None None O
RNA None None O
samples None None O
from None None O
the None None O
human None None O
brain None None O
regions None None O
known None None O
to None None O
express None None O
MOR1 None None O
. None None O

Primers None None O
specific None None O
for None None O
exons None None O
1 None None O
and None None O
2 None None O
were None None O
used None None O
to None None O
measure None None O
MOR1 None None O
and None None O
primers None None O
specific None None O
for None None O
exons None None O
13 None None O
and None None O
exon None None O
2 None None O
were None None O
used None None O
to None None O
measure None None O
MOR1K None None O
[ None None O
32 None None O
] None None O
. None None O

GAP3DH None None O
was None None O
used None None O
as None None O
a None None O
control None None O
for None None O
cDNA None None O
loading None None O
and None None O
PCR None None O
efficiency None None O
. None None O

( None None O
C None None O
) None None O
Confocal None None O
images None None O
of None None O
C None None O
- None None O
terminally None None O
MYC None None O
- None None O
tagged None None O
MOR1 None None O
or None None O
FLAG None None O
- None None O
tagged None None O
MOR1K None None O
overexpressed None None O
in None None O
HEK293 None None I-Cell-line-name
cells None None O
and None None O
stained None None O
with None None O
either None None O
Anti None None O
- None None O
MYC None None O
- None None O
Tag None None O
Antibody None None O
( None None O
Alexa None None O
Fluor None None O
647 None None O
Conjugate None None O
) None None O
or None None O
Anti None None O
- None None O
DYKDDDDK None None O
Tag None None O
Antibody None None O
( None None O
Alexa None None O
Fluor None None O
555 None None O
conjugate None None O
) None None O
. None None O

Cells None None O
transfected None None O
with None None O
MOR1 None None O
showed None None O
membrane None None O
expression None None O
of None None O
receptor None None O
, None None O
while None None O
cell None None O
transfected None None O
with None None O
MOR1K None None O
express None None O
receptor None None O
only None None O
intracellular None None O
. None None O

( None None O
D None None O
) None None O
Confocal None None O
images None None O
of None None O
C None None O
- None None O
terminally None None O
FLAG None None O
- None None O
tagged None None O
MOR1K None None O
overexpressed None None O
in None None O
Be2C None None I-Cell-line-name
cells None None O
and None None O
stained None None O
with None None O
either None None O
Anti None None O
- None None O
FLAG None None O
M2 None None O
Antibody None None O
Alexa None None O
Fluor None None O
Conjugate None None O
or None None O
fluorescent None None O
- None None O
labeled None None O
naloxone None None O
( None None O
FNAL None None O
) None None O
. None None O

Cells None None O
transfected None None O
with None None O
MOR1K None None O
showed None None O
intracellular None None O
retention None None O
of None None O
FNAL None None O
that None None O
co None None O
- None None O
localized None None O
with None None O
antibody None None O
- None None O
labeled None None O
receptor None None O
. None None O

( None None O
E None None O
) None None O
The None None O
binding None None O
of None None O
naloxone None None O
to None None O
MOR1K None None O
was None None O
assessed None None O
using None None O
flow None None O
cytometry None None O
to None None O
measure None None O
FNAL None None O
retention None None O
. None None O

Be2C None None I-Cell-line-name
cells None None O
transfected None None O
with None None O
either None None O
MOR1 None None O
or None None O
MOR1K None None O
isoforms None None O
showed None None O
increased None None O
retention None None O
of None None O
FNAL None None O
at None None O
concentrations None None O
of None None O
0 None None O
. None None O
1 None None O
and None None O
1 None None O
muM None None O
. None None O

FNAL None None O
retention None None O
was None None O
abolished None None O
in None None O
the None None O
presence None None O
of None None O
10 None None O
muM None None O
unlabelled None None O
naloxone None None O
( None None O
Nal None None O
) None None O
. None None O

In None None O
panel None None O
E None None O
, None None O
data None None O
are None None O
presented None None O
as None None O
mean None None O
+ None None O
SEM None None O
. None None O

* None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
different None None O
from None None O
controls None None O
) None None O
. None None O

Introduction None None O

Hip None None O
fractures None None O
in None None O
the None None O
aged None None O
constitute None None O
a None None O
major None None O
health None None O
problem None None O
with None None O
substantial None None O
morbidity None None O
[ None None O
1 None None O
] None None O
, None None O
mortality None None O
[ None None O
2 None None O
, None None O
3 None None O
] None None O
, None None O
and None None O
, None None O
as None None O
the None None O
ageing None None O
population None None O
increases None None O
, None None O
an None None O
increasing None None O
burden None None O
on None None O
the None None O
health None None O
care None None O
system None None O
[ None None O
4 None None O
] None None O
. None None O

Fracture None None O
risk None None O
varies None None O
markedly None None O
between None None O
countries None None O
[ None None O
5 None None O
] None None O
. None None O

In None None O
a None None O
study None None O
by None None O
Kanis None None O
et None None O
al None None O
. None None O

[ None None O
6 None None O
] None None O
, None None O
comparing None None O
10 None None O
- None None O
year None None O
probability None None O
of None None O
hip None None O
fracture None None O
, None None O
all None None O
countries None None O
except None None O
Norway None None O
had None None O
lower None None O
risk None None O
than None None O
Sweden None None O
. None None O

Other None None O
countries None None O
categorized None None O
at None None O
very None None O
high None None O
risk None None O
( None None O
> None None O
75 None None O
% None None O
of None None O
the None None O
risk None None O
of None None O
Sweden None None O
) None None O
were None None O
Iceland None None O
, None None O
Denmark None None O
and None None O
the None None O
US None None O
. None None O

At None None O
the None None O
age None None O
of None None O
80 None None O
, None None O
the None None O
estimated None None O
probability None None O
of None None O
sustaining None None O
a None None O
hip None None O
fracture None None O
the None None O
next None None O
10 None None O
years None None O
is None None O
8 None None O
. None None O
6 None None O
% None None O
and None None O
17 None None O
. None None O
7 None None O
% None None O
in None None O
Norwegian None None O
men None None O
and None None O
women None None O
, None None O
respectively None None O
[ None None O
7 None None O
] None None O
, None None O
and None None O
a None None O
report None None O
from None None O
the None None O
Norwegian None None O
capital None None O
Oslo None None O
calculated None None O
an None None O
overall None None O
annual None None O
fracture None None O
rate None None O
of None None O
118 None None O
. None None O
0 None None O
in None None O
women None None O
and None None O
44 None None O
. None None O
0 None None O
in None None O
men None None O
per None None O
10 None None O
, None None O
000 None None O
[ None None O
8 None None O
] None None O
. None None O

Several None None O
recent None None O
studies None None O
are None None O
reporting None None O
declining None None O
fracture None None O
incidence None None O
[ None None O
9 None None O
- None None O
14 None None O
] None None O
. None None O

Although None None O
the None None O
Norwegian None None O
hip None None O
fracture None None O
rates None None O
remain None None O
the None None O
highest None None O
reported None None O
in None None O
the None None O
world None None O
, None None O
data None None O
from None None O
Oslo None None O
in None None O
1996 None None O
- None None O
1997 None None O
indicated None None O
no None None O
increasing None None O
incidence None None O
rates None None O
compared None None O
to None None O
the None None O
1988 None None O
- None None O
1989 None None O
[ None None O
8 None None O
] None None O
. None None O
Within None None O
Norway None None O
, None None O
considerable None None O
geographic None None O
differences None None O
have None None O
been None None O
reported None None O
, None None O
with None None O
substantially None None O
lower None None O
rates None None O
in None None O
smaller None None O
cities None None O
and None None O
rural None None O
areas None None O
compared None None O
to None None O
Oslo None None O
[ None None O
7 None None O
, None None O
15 None None O
] None None O
. None None O

However None None O
, None None O
these None None O
are None None O
reports None None O
based None None O
on None None O
sporadic None None O
studies None None O
in None None O
few None None O
regions None None O
and None None O
in None None O
limited None None O
time None None O
periods None None O
[ None None O
16 None None O
, None None O
17 None None O
] None None O
. None None O

From None None O
1985 None None O
to None None O
2003 None None O
, None None O
the None None O
Norwegian None None O
Institute None None O
of None None O
Public None None O
Health None None O
commissioned None None O
four None None O
Norwegian None None O
hospitals None None O
, None None O
representing None None O
10 None None O
% None None O
of None None O
the None None O
population None None O
, None None O
to None None O
run None None O
a None None O
national None None O
injury None None O
registry None None O
[ None None O
18 None None O
] None None O
. None None O

The None None O
registry None None O
collected None None O
a None None O
variety None None O
of None None O
data None None O
connected None None O
to None None O
the None None O
actual None None O
injury None None O
itself None None O
and None None O
the None None O
event None None O
leading None None O
to None None O
the None None O
injury None None O
. None None O

In None None O
the None None O
city None None O
of None None O
Harstad None None O
in None None O
Northern None None O
Norway None None O
, None None O
the None None O
registration None None O
continued None None O
and None None O
has None None O
been None None O
running None None O
for None None O
more None None O
than None None O
23 None None O
years None None O
. None None O

Throughout None None O
the None None O
years None None O
of None None O
the None None O
National None None O
Injury None None O
Registry None None O
, None None O
the None None O
injury None None O
rates None None O
in None None O
Harstad None None O
closely None None O
resembled None None O
the None None O
rates None None O
of None None O
the None None O
national None None O
registry None None O
[ None None O
18 None None O
] None None O
. None None O

With None None O
reference None None O
to None None O
the None None O
recent None None O
reports None None O
suggesting None None O
stabilizing None None O
hip None None O
fracture None None O
incidence None None O
internationally None None O
as None None O
well None None O
as None None O
nationally None None O
, None None O
and None None O
regional None None O
differences None None O
within None None O
Norway None None O
, None None O
we None None O
have None None O
used None None O
the None None O
hip None None O
fracture None None O
data None None O
in None None O
the None None O
Harstad None None O
Injury None None O
Registry None None O
to None None O
: None None O

Describe None None O
age None None O
- None None O
and None None O
sex None None O
- None None O
specific None None O
incidence None None O
of None None O
hip None None O
fractures None None O
in None None O
Harstad None None O
, None None O
Northern None None O
Norway None None O
and None None O
make None None O
comparison None None O
with None None O
rates None None O
from None None O
the None None O
Norwegian None None O
capital None None O
Oslo None None O

Describe None None O
time None None O
trends None None O
in None None O
hip None None O
fracture None None O
incidence None None O
in None None O
Harstad None None O
from None None O
1994 None None O
to None None O
2008 None None O

Describe None None O
place None None O
of None None O
injury None None O
and None None O
seasonal None None O
variations None None O
in None None O
hip None None O
fracture None None O
incidence None None O
in None None O
Harstad None None O

Compare None None O
3 None None O
- None None O
month None None O
, None None O
6 None None O
- None None O
month None None O
, None None O
and None None O
1 None None O
- None None O
year None None O
mortality None None O
after None None O
hip None None O
fracture None None O
between None None O
women None None O
and None None O
men None None O
in None None O
Harstad None None O

Representative None None O
PCR None None O
/ None None O
LDR None None O
results None None O
for None None O
HPTs None None O
in None None O
fimX None None O
, None None O
BP0059 None None O
, None None O
BP0880 None None O
, None None O
sphB2 None None O
, None None O
ptxA None None O
, None None O
and None None O
bhuR None None O
. None None O

Raw None None O
capillary None None O
electrophoresis None None O
data None None O
for None None O
ligation None None O
products None None O
( None None O
green None None O
) None None O
and None None O
molecular None None O
weight None None O
standards None None O
( None None O
red None None O
) None None O
displayed None None O
as None None O
if None None O
an None None O
electrophoretic None None O
gel None None O
image None None O
. None None O

Assayed None None O
locus None None O
is None None O
indicated None None O
at None None O
the None None O
top None None O
of None None O
each None None O
panel None None O
; None None O
strain None None O
and None None O
length None None O
of None None O
its None None O
HPT None None O
allele None None O
are None None O
noted None None O
above None None O
each None None O
lane None None O
. None None O

Representative None None O
LDR None None O
results None None O
are None None O
depicted None None O
here None None O
; None None O
for None None O
complete None None O
data None None O
from None None O
all None None O
strains None None O
see None None O
Additional None None O
files None None O
8 None None O
, None None O
9 None None O
, None None O
10 None None O
, None None O
11 None None O
, None None O
12 None None O
, None None O
and None None O
13 None None O
. None None O

BP0880 None None O
, None None O
BP0059 None None O
, None None O
fimX None None O
, None None O
and None None O
sphB2 None None O
HPTs None None O
were None None O
screened None None O
by None None O
uniplex None None O
LDR None None O
reactions None None O
containing None None O
only None None O
the None None O
discriminating None None O
oligonucleotide None None O
that None None O
targets None None O
the None None O
Tohama None None O
I None None O
sequence None None O
. None None O

The None None O
ptxA None None O
and None None O
bhuR None None O
HPTs None None O
were None None O
screened None None O
by None None O
multiplex None None O
reactions None None O
that None None O
contain None None O
all None None O
three None None O
discriminating None None O
oligonucleotides None None O
. None None O

Letters None None O
in None None O
teal None None O
indicate None None O
molecular None None O
weight None None O
standards None None O
as None None O
labeled None None O
in None None O
the None None O
corresponding None None O
supplementary None None O
figures None None O
. None None O

Ligation None None O
products None None O
( None None O
arrows None None O
) None None O
are None None O
labeled None None O
using None None O
the None None O
notation None None O
described None None O
in None None O
the None None O
legend None None O
to None None O
Figure None None O
1 None None O
. None None O

The None None O
open None None O
arrowhead None None O
indicates None None O
a None None O
synthesis None None O
artifact None None O
in None None O
the None None O
BP0059 None None O
common None None O
oligonucleotide None None O
preparation None None O
. None None O

Alterations None None O
in None None O
carbohydrate None None O
metabolism None None O
in None None O
canine None None O
lymphoma None None O
. None None O

Following None None O
an None None O
overnight None None O
fast None None O
, None None O
blood None None O
samples None None O
were None None O
obtained None None O
from None None O
14 None None O
dogs None None O
with None None O
previously None None O
untreated None None O
lymphoma None None O
before None None O
and None None O
5 None None O
, None None O
15 None None O
, None None O
30 None None O
, None None O
45 None None O
, None None O
60 None None O
, None None O
and None None O
90 None None O
minutes None None O
following None None O
an None None O
intravenous None None O
challenge None None O
with None None O
500 None None O
mg None None O
/ None None O
kg None None O
dextrose None None O
. None None O

Samples None None O
were None None O
assayed None None O
for None None O
glucose None None O
, None None O
lactate None None O
, None None O
and None None O
insulin None None O
concentrations None None O
and None None O
compared None None O
statistically None None O
with None None O
ten None None O
control None None O
dogs None None O
of None None O
similar None None O
weight None None O
and None None O
age None None O
undergoing None None O
an None None O
identical None None O
dextrose None None O
challenge None None O
. None None O

Dogs None None O
with None None O
lymphoma None None O
had None None O
similar None None O
glucose None None O
tolerance None None O
curves None None O
when None None O
compared None None O
with None None O
controls None None O
. None None O

Lactate None None O
concentrations None None O
were None None O
significantly None None O
higher None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
at None None O
baseline None None O
and None None O
all None None O
time None None O
periods None None O
of None None O
the None None O
glucose None None O
tolerance None None O
test None None O
in None None O
dogs None None O
with None None O
lymphoma None None O
when None None O
compared None None O
with None None O
controls None None O
. None None O

Rise None None O
in None None O
lactate None None O
concentrations None None O
over None None O
baseline None None O
levels None None O
in None None O
the None None O
first None None O
30 None None O
minutes None None O
of None None O
the None None O
glucose None None O
tolerance None None O
test None None O
were None None O
significantly None None O
higher None None O
in None None O
dogs None None O
with None None O
lymphoma None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
011 None None O
) None None O
. None None O

Insulin None None O
concentrations None None O
were None None O
significantly None None O
higher None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
at None None O
baseline None None O
and None None O
at None None O
the None None O
5 None None O
- None None O
, None None O
45 None None O
- None None O
, None None O
60 None None O
- None None O
, None None O
and None None O
90 None None O
- None None O
minute None None O
time None None O
periods None None O
of None None O
the None None O
glucose None None O
tolerance None None O
test None None O
in None None O
dogs None None O
with None None O
lymphoma None None O
. None None O

Rise None None O
in None None O
insulin None None O
concentrations None None O
over None None O
baseline None None O
in None None O
the None None O
first None None O
5 None None O
minutes None None O
of None None O
the None None O
glucose None None O
tolerance None None O
test None None O
were None None O
also None None O
significantly None None O
greater None None O
in None None O
dogs None None O
with None None O
lymphoma None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
021 None None O
) None None O
. None None O

These None None O
results None None O
indicate None None O
carbohydrate None None O
metabolism None None O
is None None O
altered None None O
in None None O
dogs None None O
with None None O
lymphoma None None O
. None None O

Many None None O
of None None O
these None None O
alterations None None O
parallel None None O
those None None O
observed None None O
in None None O
human None None O
patients None None O
suffering None None O
from None None O
cancer None None O
cachexia None None O
making None None O
canine None None O
lymphoma None None O
a None None O
potential None None O
model None None O
for None None O
further None None O
study None None O
of None None O
the None None O
pathogenesis None None O
and None None O
therapy None None O
of None None O
cancer None None O
cachexia None None O
. None None O

Correlation None None O
of None None O
lymphatic None None O
vessel None None O
density None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
with None None O
nodal None None O
metastasis None None O
in None None O
papillary None None O
thyroid None None O
microcarcinoma None None O
. None None O

BACKGROUND None None O
: None None O
The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
not None None O
only None None O
the None None O
intratumoral None None O
and None None O
peritumoral None None O
lymphatic None None O
vessel None None O
density None None O
( None None O
ILD None None O
and None None O
PLD None None O
) None None O
but None None O
also None None O
the None None O
expression None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factors None None O
( None None O
VEGFs None None O
) None None O
and None None O
to None None O
test None None O
their None None O
correlation None None O
with None None O
regional None None O
lymph None None O
nodal None None O
metastases None None O
in None None O
papillary None None O
thyroid None None O
microcarcinoma None None O
( None None O
PTMC None None O
) None None O
. None None O

METHODS None None O
: None None O
A None None O
clinicopathologic None None O
data None None O
review None None O
was None None O
performed None None O
in None None O
60 None None O
patients None None O
with None None O
PTMC None None O
treated None None O
with None None O
total None None O
thyroidectomies None None O
involving None None O
neck None None O
dissections None None O
. None None O

The None None O
patterns None None O
of None None O
lymphatic None None O
vessels None None O
, None None O
the None None O
expression None None O
of None None O
VEGFs None None O
, None None O
and None None O
their None None O
correlation None None O
with None None O
neck None None O
metastases None None O
were None None O
assessed None None O
. None None O

RESULTS None None O
: None None O
PLD None None O
was None None O
significantly None None O
higher None None O
than None None O
ILD None None O
( None None O
p None None O
< None None O
. None None O
001 None None O
) None None O
. None None O

Patients None None O
with None None O
high None None O
PLD None None O
( None None O
> None None O
8 None None O
. None None O
0 None None O
) None None O
showed None None O
higher None None O
rates None None O
of None None O
neck None None O
metastases None None O
than None None O
low None None O
PLD None None O
( None None O
< None None O
= None None O
8 None None O
. None None O
0 None None O
) None None O
( None None O
74 None None O
. None None O
0 None None O
% None None O
vs None None O
46 None None O
. None None O
8 None None O
% None None O
, None None O
p None None O
= None None O
. None None O
03 None None O
) None None O
. None None O

Univariate None None O
and None None O
multivariate None None O
analyses None None O
revealed None None O
high None None O
PLD None None O
as None None O
the None None O
only None None O
independent None None O
variable None None O
predictive None None O
of None None O
neck None None O
metastasis None None O
. None None O

The None None O
expression None None O
of None None O
VEGFs None None O
did None None O
not None None O
correlate None None O
with None None O
either None None O
lymphatic None None O
density None None O
or None None O
neck None None O
metastasis None None O
. None None O

CONCLUSIONS None None O
: None None O
PLD None None O
may None None O
be None None O
of None None O
potential None None O
benefit None None O
in None None O
the None None O
prediction None None O
of None None O
neck None None O
metastasis None None O
in None None O
PTMC None None O
. None None O

Neurologic None None O
diagnosis None None O
and None None O
treatment None None O
in None None O
patients None None O
with None None O
computed None None O
tomography None None O
and None None O
nasal None None O
endoscopy None None O
negative None None O
facial None None O
pain None None O
. None None O

OBJECTIVE None None O
: None None O

To None None O
determine None None O
the None None O
helpfulness None None O
of None None O
specialist None None O
neurology None None O
referral None None O
for None None O
patients None None O
with None None O
facial None None O
pain None None O
, None None O
a None None O
normal None None O
sinus None None O
computed None None O
tomography None None O
( None None O
CT None None O
) None None O
scan None None O
, None None O
and None None O
normal None None O
nasal None None O
endoscopy None None O
findings None None O
. None None O

STUDY None None O
DESIGN None None O
: None None O

Prospective None None O
identification None None O
of None None O
patients None None O
and None None O
analysis None None O
of None None O
data None None O
approved None None O
by None None O
the None None O
Institutional None None O
Review None None O
Board None None O
. None None O

METHODS None None O
: None None O

The None None O
data None None O
of None None O
104 None None O
consecutive None None O
patients None None O
presenting None None O
with None None O
facial None None O
pain None None O
, None None O
a None None O
normal None None O
sinus None None O
CT None None O
scan None None O
, None None O
and None None O
normal None None O
nasal None None O
endoscopy None None O
findings None None O
were None None O
reviewed None None O
. None None O

The None None O
patients None None O
presented None None O
to None None O
a None None O
single None None O
rhinologist None None O
in None None O
a None None O
tertiary None None O
care None None O
institution None None O
. None None O

All None None O
patients None None O
were None None O
referred None None O
for None None O
specialist None None O
neurologic None None O
evaluation None None O
and None None O
potential None None O
treatment None None O
. None None O

Further None None O
information None None O
was None None O
obtained None None O
from None None O
a None None O
patient None None O
survey None None O
. None None O

RESULTS None None O
: None None O

Of None None O
the None None O
104 None None O
patients None None O
, None None O
81 None None O
were None None O
women None None O
and None None O
23 None None O
were None None O
men None None O
. None None O

The None None O
average None None O
age None None O
was None None O
46 None None O
years None None O
( None None O
range None None O
, None None O
22 None None O
- None None O
85 None None O
) None None O
. None None O

Fifty None None O
- None None O
six None None O
had None None O
clear None None O
CT None None O
scans None None O
, None None O
48 None None O
had None None O
minimal None None O
change None None O
, None None O
and None None O
all None None O
had None None O
negative None None O
endoscopies None None O
. None None O

Twenty None None O
- None None O
nine None None O
had None None O
previous None None O
unsuccessful None None O
sinus None None O
surgery None None O
. None None O

The None None O
average None None O
follow None None O
- None None O
up None None O
period None None O
was None None O
10 None None O
. None None O
5 None None O
months None None O
. None None O

Forty None None O
of None None O
75 None None O
patients None None O
seeing None None O
a None None O
neurologist None None O
were None None O
seen None None O
on None None O
multiple None None O
occasions None None O
. None None O

Four None None O
percent None None O
of None None O
patients None None O
seen None None O
by None None O
a None None O
neurologist None None O
had None None O
an None None O
unsuspected None None O
serious None None O
intracranial None None O
diagnosis None None O
. None None O

The None None O
most None None O
common None None O
diagnoses None None O
were None None O
migraine None None O
( None None O
37 None None O
% None None O
) None None O
, None None O
rebound None None O
headache None None O
( None None O
17 None None O
% None None O
) None None O
, None None O
chronic None None O
daily None None O
headache None None O
( None None O
17 None None O
% None None O
) None None O
, None None O
and None None O
obstructive None None O
sleep None None O
apnea None None O
( None None O
16 None None O
% None None O
) None None O
. None None O

Overall None None O
, None None O
58 None None O
% None None O
improved None None O
on None None O
medical None None O
therapy None None O
; None None O
60 None None O
% None None O
of None None O
those None None O
with None None O
a None None O
clear None None O
CT None None O
scan None None O
improved None None O
, None None O
and None None O
53 None None O
% None None O
of None None O
those None None O
with None None O
minimal None None O
change None None O
on None None O
CT None None O
scan None None O
improved None None O
( None None O
P None None O
= None None O
. None None O
749 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O

Facial None None O
pain None None O
remains None None O
a None None O
difficult None None O
symptom None None O
to None None O
diagnose None None O
and None None O
treat None None O
in None None O
rhinologic None None O
practice None None O
. None None O

Patients None None O
often None None O
undergo None None O
surgery None None O
without None None O
help None None O
. None None O

Most None None O
patients None None O
with None None O
facial None None O
pain None None O
, None None O
a None None O
normal None None O
sinus None None O
CT None None O
scan None None O
, None None O
and None None O
normal None None O
endoscopy None None O
findings None None O
benefit None None O
from None None O
neurologic None None O
consultation None None O
. None None O

Serious None None O
intracranial None None O
pathologic None None O
conditions None None O
can None None O
be None None O
excluded None None O
and None None O
diagnosis None None O
- None None O
specific None None O
pharmacogenetic None None O
therapy None None O
instituted None None O
with None None O
improvement None None O
in None None O
more None None O
than None None O
50 None None O
% None None O
. None None O

Basilar None None O
papilla None None O

The None None O
basilar None None O
papilla None None O
is None None O
found None None O
in None None O
a None None O
recess None None O
that None None O
opens None None O
into None None O
the None None O
saccular None None O
space None None O
at None None O
one None None O
end None None O
, None None O
and None None O
is None None O
limited None None O
by None None O
a None None O
thin None None O
contact None None O
membrane None None O
at None None O
the None None O
other None None O
. None None O

The None None O
contact None None O
membrane None None O
separates None None O
the None None O
endolymphatic None None O
fluid None None O
in None None O
the None None O
papillar None None O
recess None None O
from None None O
the None None O
perilymphatic None None O
fluid None None O
at None None O
the None None O
round None None O
window None None O
( None None O
Lewis None None O
and None None O
Narins None None O
1999 None None O
; None None O
Wever None None O
1985 None None O
) None None O
. None None O

The None None O
recess None None O
perimeter None None O
is None None O
roughly None None O
oval None None O
in None None O
shape None None O
; None None O
in None None O
the None None O
bullfrog None None O
, None None O
Rana None None O
catesbeiana None None O
, None None O
its None None O
major None None O
axis None None O
is None None O
approximately None None O
200 None None O
mum None None O
long None None O
, None None O
while None None O
the None None O
minor None None O
axis None None O
measures None None O
approximately None None O
150 None None O
mum None None O
( None None O
Van None None O
Bergeijk None None O
1957 None None O
) None None O
. None None O

In None None O
the None None O
leopard None None O
frog None None O
, None None O
Rana None None O
pipiens None None O
pipiens None None O
, None None O
it None None O
is None None O
of None None O
similar None None O
size None None O
( None None O
personal None None O
observation None None O
, None None O
RLMS None None O
& None None O
JMS None None O
) None None O
. None None O

The None None O
oval None None O
perimeter None None O
of None None O
the None None O
lumen None None O
is None None O
formed None None O
from None None O
limbic None None O
tissue None None O
; None None O
a None None O
substance None None O
unique None None O
to None None O
the None None O
inner None None O
ear None None O
, None None O
and None None O
similar None None O
to None None O
cartilage None None O
( None None O
Wever None None O
1985 None None O
) None None O
. None None O

The None None O
sensory None None O
epithelium None None O
is None None O
approximately None None O
100 None None O
mum None None O
long None None O
. None None O

It None None O
occupies None None O
a None None O
curved None None O
area None None O
that None None O
is None None O
symmetrical None None O
in None None O
the None None O
major None None O
axis None None O
of None None O
the None None O
elliptical None None O
lumen None None O
. None None O

It None None O
contains None None O
approximately None None O
60 None None O
hair None None O
cells None None O
( None None O
measured None None O
in None None O
Rana None None O
catesbeiana None None O
) None None O
, None None O
from None None O
which None None O
the None None O
stereovilli None None O
protrude None None O
into None None O
the None None O
lumen None None O
and None None O
connect None None O
to None None O
the None None O
tectorial None None O
membrane None None O
( None None O
Frishkopf None None O
and None None O
Flock None None O
1974 None None O
) None None O
. None None O

Typically None None O
the None None O
orientation None None O
of None None O
the None None O
hair None None O
cells None None O
, None None O
as None None O
defined None None O
by None None O
the None None O
direction None None O
to None None O
which None None O
the None None O
v None None O
- None None O
shape None None O
of None None O
the None None O
stereovilli None None O
bundle None None O
points None None O
( None None O
Lewis None None O
et None None O
al None None O
. None None O
1985 None None O
) None None O
, None None O
is None None O
away None None O
from None None O
the None None O
sacculus None None O
in None None O
Ranidae None None O
. None None O

The None None O
tectorial None None O
membrane None None O
spans None None O
the None None O
lumen None None O
of None None O
the None None O
papillar None None O
recess None None O
. None None O

It None None O
occludes None None O
about None None O
half None None O
the None None O
lumen None None O
, None None O
and None None O
consequently None None O
takes None None O
an None None O
approximately None None O
semi None None O
- None None O
circular None None O
shape None None O
when None None O
viewed None None O
from None None O
the None None O
saccular None None O
side None None O
( None None O
Frishkopf None None O
and None None O
Flock None None O
1974 None None O
; None None O
Wever None None O
1985 None None O
) None None O
. None None O

The None None O
membrane None None O
has None None O
pores None None O
at None None O
the None None O
surface None None O
closest None None O
to None None O
the None None O
epithelium None None O
, None None O
into None None O
which None None O
the None None O
tips None None O
of None None O
the None None O
hair None None O
bundles None None O
project None None O
( None None O
Lewis None None O
and None None O
Narins None None O
1999 None None O
) None None O
. None None O
4 None None O

Listerine None None O
: None None O
past None None O
, None None O
present None None O
and None None O
future None None O
- None None O
- None None O
a None None O
test None None O
of None None O
thyme None None O
. None None O

Listerine None None O
, None None O
a None None O
mouthrinse None None O
composed None None O
of None None O
a None None O
mixture None None O
of None None O
essential None None O
oils None None O
, None None O
was None None O
created None None O
in None None O
1879 None None O
and None None O
was None None O
originally None None O
formulated None None O
as None None O
a None None O
surgical None None O
antiseptic None None O
. None None O

In None None O
spite None None O
of None None O
its None None O
known None None O
antimicrobial None None O
properties None None O
it None None O
was None None O
thought None None O
of None None O
as None None O
a None None O
product None None O
in None None O
search None None O
of None None O
a None None O
use None None O
and None None O
promoted None None O
as None None O
a None None O
deterrent None None O
for None None O
halitosis None None O
and None None O
as None None O
a None None O
floor None None O
cleaner None None O
. None None O

In None None O
the None None O
last None None O
several None None O
years None None O
Listerine None None O
has None None O
emerged None None O
as None None O
a None None O
bona None None O
fide None None O
therapeutic None None O
agent None None O
for None None O
reduction None None O
of None None O
plaque None None O
induced None None O
oral None None O
diseases None None O
. None None O

In None None O
contrast None None O
to None None O
the None None O
inconsistent None None O
history None None O
of None None O
Listerine None None O
, None None O
systemic None None O
antibiotics None None O
discovered None None O
in None None O
the None None O
1940 None None O
' None None O
s None None O
were None None O
heralded None None O
as None None O
miracle None None O
drugs None None O
. None None O

However None None O
, None None O
the None None O
value None None O
of None None O
prophylactic None None O
usage None None O
of None None O
antibiotics None None O
has None None O
come None None O
under None None O
scrutiny None None O
as None None O
a None None O
result None None O
of None None O
increasing None None O
resistance None None O
and None None O
adverse None None O
reactions None None O
. None None O

Moreover None None O
, None None O
reports None None O
by None None O
both None None O
American None None O
and None None O
British None None O
professional None None O
societies None None O
have None None O
led None None O
to None None O
a None None O
re None None O
- None None O
evaluation None None O
of None None O
the None None O
relative None None O
risks None None O
associated None None O
with None None O
plaque None None O
induced None None O
bacteremia None None O
when None None O
twice None None O
- None None O
yearly None None O
visits None None O
to None None O
dental None None O
professionals None None O
are None None O
compared None None O
to None None O
daily None None O
activities None None O
. None None O

These None None O
new None None O
recommendations None None O
and None None O
revelations None None O
open None None O
the None None O
door None None O
for None None O
local None None O
antimicrobial None None O
approaches None None O
to None None O
reduce None None O
the None None O
challenge None None O
of None None O
plaque None None O
- None None O
induced None None O
bacteremias None None O
. None None O

These None None O
issues None None O
will None None O
be None None O
discussed None None O
in None None O
the None None O
context None None O
of None None O
Listerine None None O
, None None O
its None None O
intricate None None O
and None None O
complicated None None O
past None None O
, None None O
and None None O
its None None O
connection None None O
to None None O
current None None O
uses None None O
in None None O
oral None None O
health None None O
and None None O
beyond None None O
. None None O

Heparin None None O
- None None O
steroid None None O
conjugates None None O
: None None O
new None None O
angiogenesis None None O
inhibitors None None O
with None None O
antitumor None None O
activity None None O
in None None O
mice None None O
. None None O

Inhibitors None None O
of None None O
angiogenesis None None O
hold None None O
potential None None O
in None None O
the None None O
treatment None None O
of None None O
cancer None None O
and None None O
other None None O
diseases None None O
where None None O
the None None O
disease None None O
is None None O
caused None None O
or None None O
maintained None None O
by None None O
the None None O
inappropriate None None O
growth None None O
of None None O
blood None None O
vessels None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
a None None O
novel None None O
inhibitor None None O
of None None O
angiogenesis None None O
was None None O
synthesized None None O
by None None O
covalently None None O
linking None None O
a None None O
nonanticoagulating None None O
derivative None None O
of None None O
heparin None None O
, None None O
heparin None None O
adipic None None O
hydrazide None None O
( None None O
HAH None None O
) None None O
, None None O
by None None O
an None None O
acid None None O
- None None O
labile None None O
bond None None O
to None None O
the None None O
antiangiogenic None None O
steroid None None O
, None None O
cortisol None None O
. None None O

The None None O
rationale None None O
was None None O
that None None O
the None None O
heparin None None O
derivative None None O
, None None O
which None None O
binds None None O
to None None O
sulfated None None O
polyanion None None O
receptors None None O
on None None O
endothelial None None O
cells None None O
, None None O
should None None O
concentrate None None O
the None None O
steroid None None O
on None None O
the None None O
surface None None O
of None None O
vascular None None O
endothelial None None O
cells None None O
. None None O

Endocytosis None None O
of None None O
the None None O
conjugate None None O
and None None O
decomposition None None O
of None None O
the None None O
acid None None O
- None None O
labile None None O
linkage None None O
inside None None O
lysosomes None None O
and None None O
other None None O
acidic None None O
intracellular None None O
compartments None None O
should None None O
then None None O
lead None None O
to None None O
release None None O
of None None O
the None None O
cortisol None None O
and None None O
expression None None O
of None None O
its None None O
antiproliferative None None O
activity None None O
. None None O

Analysis None None O
of None None O
the None None O
stability None None O
of None None O
HAH None None O
- None None O
cortisol None None O
showed None None O
that None None O
it None None O
was None None O
stable None None O
at None None O
pH None None O
7 None None O
. None None O
4 None None O
and None None O
broke None None O
down None None O
rapidly None None O
( None None O
t1 None None O
/ None None O
2 None None O
15 None None O
min None None O
) None None O
at None None O
pH None None O
4 None None O
. None None O
8 None None O
at None None O
37 None None O
degrees None None O
C None None O
. None None O

Treatment None None O
of None None O
murine None None O
pulmonary None None O
capillary None None O
endothelial None None O
cells None None O
with None None O
HAH None None O
- None None O
cortisol None None O
at None None O
10 None None O
( None None O
- None None O
5 None None O
) None None O
M None None O
( None None O
with None None O
respect None None O
to None None O
cortisol None None O
) None None O
suppressed None None O
their None None O
DNA None None O
synthesis None None O
by None None O
50 None None O
% None None O
and None None O
inhibited None None O
their None None O
migration None None O
into None None O
wounded None None O
areas None None O
of None None O
confluent None None O
monolayers None None O
. None None O

HAH None None O
- None None O
cortisol None None O
at None None O
10 None None O
( None None O
- None None O
4 None None O
) None None O
M None None O
( None None O
with None None O
respect None None O
to None None O
cortisol None None O
) None None O
did None None O
not None None O
suppress None None O
the None None O
DNA None None O
synthesis None None O
of None None O
Lewis None None O
lung None None O
carcinoma None None O
cells None None O
. None None O

Daily None None O
i None None O
. None None O
p None None O
. None None O
injections None None O
of None None O
HAH None None O
- None None O
cortisol None None O
into None None O
mice None None O
bearing None None O
s None None O
. None None O
c None None O
. None None O
sponge None None O
implants None None O
retarded None None O
vascularization None None O
of None None O
the None None O
sponge None None O
, None None O
and None None O
injections None None O
directly None None O
into None None O
the None None O
sponge None None O
abolished None None O
vascularization None None O
for None None O
as None None O
long None None O
as None None O
the None None O
injections None None O
were None None O
continued None None O
. None None O

Daily None None O
i None None O
. None None O
v None None O
. None None O
injections None None O
of None None O
HAH None None O
- None None O
cortisol None None O
at None None O
doses None None O
causing None None O
no None None O
apparent None None O
toxicity None None O
retarded None None O
the None None O
growth None None O
of None None O
solid None None O
s None None O
. None None O
c None None O
. None None O

Lewis None None O
lung None None O
carcinomas None None O
in None None O
mice None None O
by None None O
up None None O
to None None O
65 None None O
% None None O
. None None O

In None None O
all None None O
of None None O
these None None O
assays None None O
, None None O
equivalent None None O
treatments None None O
with None None O
a None None O
mixture None None O
of None None O
the None None O
HAH None None O
plus None None O
cortisol None None O
was None None O
significantly None None O
less None None O
effective None None O
. None None O

The None None O
antiproliferative None None O
effect None None O
of None None O
HAH None None O
- None None O
cortisol None None O
on None None O
endothelial None None O
cells None None O
appeared None None O
independent None None O
of None None O
the None None O
glucocorticoid None None O
activity None None O
of None None O
the None None O
steroid None None O
since None None O
HAH None None O
conjugated None None O
to None None O
5 None None O
beta None None O
- None None O
pregnane None None O
- None None O
3 None None O
alpha None None O
, None None O
17 None None O
alpha None None O
, None None O
21 None None O
- None None O
triol None None O
- None None O
20 None None O
- None None O
one None None O
, None None O
a None None O
steroid None None O
lacking None None O
glucocorticoid None None O
or None None O
mineralocorticoid None None O
activity None None O
, None None O
was None None O
even None None O
more None None O
effective None None O
at None None O
inhibiting None None O
DNA None None O
synthesis None None O
by None None O
murine None None O
pulmonary None None O
capillary None None O
endothelial None None O
cells None None O
than None None O
was None None O
HAH None None O
- None None O
cortisol None None O
. None None O

In None None O
conclusion None None O
, None None O
HAH None None O
- None None O
cortisol None None O
represents None None O
the None None O
prototype None None O
of None None O
a None None O
new None None O
class None None O
of None None O
angiogenesis None None O
inhibitors None None O
for None None O
the None None O
treatment None None O
of None None O
cancer None None O
and None None O
other None None O
angiogenic None None O
diseases None None O
. None None O

Mapping None None O
of None None O
the None None O
L None None O
- None None O
methylmalonyl None None O
- None None O
CoA None None O
mutase None None O
gene None None O
to None None O
mouse None None O
chromosome None None O
17 None None O
. None None O

In None None O
humans None None O
, None None O
methylmalonyl None None O
acidemia None None O
is None None O
caused None None O
by None None O
a None None O
deficiency None None O
of None None O
L None None O
- None None O
methylmalonyl None None O
- None None O
CoA None None O
mutase None None O
( None None O
MUT None None O
) None None O
controlled None None O
by None None O
a None None O
gene None None O
that None None O
has None None O
been None None O
mapped None None O
to None None O
chromosome None None O
6 None None O
. None None O

The None None O
mouse None None O
homolog None None O
of None None O
this None None O
gene None None O
has None None O
now None None O
been None None O
mapped None None O
to None None O
mouse None None O
chromosome None None O
17 None None O
. None None O

Recombinant None None O
inbred None None O
and None None O
congenic None None O
strains None None O
place None None O
the None None O
mouse None None O
Mut None None O
locus None None O
1 None None O
. None None O
06 None None O
cM None None O
distal None None O
to None None O
H None None O
- None None O
2 None None O
, None None O
between None None O
Pgk None None O
- None None O
2 None None O
and None None O
Ce None None O
- None None O
2 None None O
. None None O

The None None O
relative None None O
order None None O
of None None O
syntenic None None O
probes None None O
flanking None None O
H None None O
- None None O
2 None None O
on None None O
mouse None None O
chromosome None None O
17 None None O
and None None O
HLA None None O
on None None O
human None None O
chromosome None None O
6 None None O
is None None O
shown None None O
to None None O
be None None O
different None None O
. None None O

Mechanisms None None O
of None None O
pericyte None None O
recruitment None None O
in None None O
tumour None None O
angiogenesis None None O
: None None O
a None None O
new None None O
role None None O
for None None O
metalloproteinases None None O
. None None O

Pericytes None None O
occur None None O
in None None O
tumour None None O
blood None None O
vessels None None O
and None None O
are None None O
critical None None O
for None None O
the None None O
development None None O
of None None O
a None None O
functional None None O
vascular None None O
network None None O
. None None O

Targeting None None O
tumour None None O
pericytes None None O
is None None O
a None None O
promising None None O
anti None None O
- None None O
angiogenic None None O
therapy None None O
but None None O
requires None None O
identifying None None O
the None None O
mechanisms None None O
of None None O
their None None O
recruitment None None O
in None None O
tumour None None O
and None None O
addressing None None O
whether None None O
these None None O
mechanisms None None O
can None None O
be None None O
selectively None None O
harnessed None None O
. None None O

Among None None O
the None None O
pathways None None O
involved None None O
in None None O
pericyte None None O
recruitment None None O
during None None O
embryonic None None O
development None None O
, None None O
the None None O
contribution None None O
of None None O
platelet None None O
- None None O
derived None None O
growth None None O
factor None None O
B None None O
and None None O
sphingosine None None O
1 None None O
- None None O
phosphate None None O
is None None O
confirmed None None O
in None None O
tumour None None O
angiogenesis None None O
. None None O

The None None O
effect None None O
of None None O
angiopoietin None None O
1 None None O
depends None None O
on None None O
the None None O
tumour None None O
model None None O
. None None O

Transforming None None O
growth None None O
factor None None O
- None None O
beta1 None None O
enhances None None O
tumour None None O
vascularization None None O
and None None O
microvessel None None O
maturation None None O
. None None O

Recent None None O
reports None None O
suggest None None O
a None None O
participation None None O
of None None O
matrix None None O
metalloproteinases None None O
( None None O
MMP None None O
) None None O
in None None O
tumour None None O
pericyte None None O
recruitment None None O
that None None O
is None None O
consistent None None O
with None None O
the None None O
effect None None O
of None None O
certain None None O
MMPs None None O
in None None O
the None None O
development None None O
of None None O
microvasculature None None O
in None None O
embryonic None None O
development None None O
and None None O
in None None O
in None None O
vitro None None O
models None None O
of None None O
vascular None None O
remodelling None None O
. None None O

Here None None O
, None None O
we None None O
discuss None None O
the None None O
possibility None None O
for None None O
MMPs None None O
to None None O
contribute None None O
to None None O
pericyte None None O
recruitment None None O
at None None O
six None None O
levels None None O
: None None O
( None None O
1 None None O
) None None O
direct None None O
promotion None None O
of None None O
pericyte None None O
invasion None None O
by None None O
extracellular None None O
matrix None None O
degradation None None O
; None None O
( None None O
2 None None O
) None None O
stimulation None None O
of None None O
pericyte None None O
proliferation None None O
and None None O
protection None None O
against None None O
apoptosis None None O
by None None O
modification None None O
of None None O
the None None O
ECM None None O
; None None O
( None None O
3 None None O
) None None O
activation None None O
of None None O
pericytes None None O
through None None O
the None None O
release None None O
of None None O
growth None None O
factor None None O
bound None None O
to None None O
the None None O
ECM None None O
; None None O
( None None O
4 None None O
) None None O
transactivation None None O
of None None O
angiogenic None None O
cell None None O
surface None None O
receptor None None O
; None None O
( None None O
5 None None O
) None None O
propagation None None O
of None None O
angiogenic None None O
signalling None None O
as None None O
cofactor None None O
; None None O
and None None O
( None None O
6 None None O
) None None O
recruitment None None O
of None None O
bone None None O
marrow None None O
- None None O
derived None None O
stem None None O
cells None None O
. None None O

All None None O
- None None O
cause None None O
mortality None None O
in None None O
RALES None None O
and None None O
EPHESUS None None O
( None None O
adapted None None O
from None None O
[ None None O
4 None None O
] None None O
and None None O
[ None None O
5 None None O
] None None O
) None None O
. None None O

Mean None None O
follow None None O
- None None O
up None None O
period None None O
is None None O
24 None None O
months None None O
in None None O
RALES None None O
and None None O
16 None None O
months None None O
in None None O
EPHESUS None None O

Antivascular None None O
actions None None O
of None None O
microtubule None None O
- None None O
binding None None O
drugs None None O
. None None O

Microtubule None None O
- None None O
binding None None O
drugs None None O
( None None O
MBD None None O
) None None O
are None None O
widely None None O
used None None O
in None None O
cancer None None O
chemotherapy None None O
and None None O
also None None O
have None None O
clinically None None O
relevant None None O
antiangiogenic None None O
and None None O
vascular None None O
- None None O
disrupting None None O
properties None None O
. None None O

These None None O
antivascular None None O
actions None None O
are None None O
due None None O
in None None O
part None None O
to None None O
direct None None O
effects None None O
on None None O
endothelial None None O
cells None None O
, None None O
and None None O
all None None O
MBDs None None O
( None None O
both None None O
microtubule None None O
- None None O
stabilizing None None O
and None None O
microtubule None None O
- None None O
destabilizing None None O
) None None O
inhibit None None O
endothelial None None O
cell None None O
proliferation None None O
, None None O
migration None None O
, None None O
and None None O
tube None None O
formation None None O
in None None O
vitro None None O
, None None O
actions None None O
that None None O
are None None O
thought None None O
to None None O
correspond None None O
to None None O
therapeutic None None O
antiangiogenic None None O
actions None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
microtubule None None O
- None None O
destabilizing None None O
agents None None O
cause None None O
prominent None None O
changes None None O
in None None O
endothelial None None O
cell None None O
morphology None None O
, None None O
an None None O
action None None O
associated None None O
with None None O
rapid None None O
vascular None None O
collapse None None O
in None None O
vivo None None O
. None None O

The None None O
effects None None O
on None None O
endothelial None None O
cells None None O
occur None None O
in None None O
vitro None None O
at None None O
low None None O
drug None None O
concentrations None None O
, None None O
which None None O
do None None O
not None None O
affect None None O
microtubule None None O
gross None None O
morphology None None O
, None None O
do None None O
not None None O
cause None None O
microtubule None None O
bundling None None O
or None None O
microtubule None None O
loss None None O
and None None O
do None None O
not None None O
induce None None O
cell None None O
cycle None None O
arrest None None O
, None None O
apoptosis None None O
, None None O
or None None O
cell None None O
death None None O
. None None O

Rather None None O
, None None O
it None None O
has None None O
been None None O
hypothesized None None O
that None None O
, None None O
at None None O
low None None O
concentrations None None O
, None None O
MBDs None None O
produce None None O
more None None O
subtle None None O
effects None None O
on None None O
microtubule None None O
dynamics None None O
, None None O
block None None O
critical None None O
cell None None O
signaling None None O
pathways None None O
, None None O
and None None O
prevent None None O
the None None O
microtubules None None O
from None None O
properly None None O
interacting None None O
with None None O
transient None None O
subcellular None None O
assemblies None None O
( None None O
focal None None O
adhesions None None O
and None None O
adherens None None O
junctions None None O
) None None O
whose None None O
subsequent None None O
stabilization None None O
and None None O
/ None None O
or None None O
maturation None None O
are None None O
required None None O
for None None O
cell None None O
motility None None O
and None None O
cell None None O
- None None O
cell None None O
interactions None None O
. None None O

This None None O
review None None O
will None None O
focus None None O
on None None O
recent None None O
studies None None O
to None None O
define None None O
the None None O
molecular None None O
mechanisms None None O
for None None O
the None None O
antivascular None None O
actions None None O
of None None O
the None None O
MBDs None None O
, None None O
information None None O
that None None O
could None None O
be None None O
useful None None O
in None None O
the None None O
identification None None O
or None None O
design None None O
of None None O
agents None None O
whose None None O
actions None None O
more None None O
selectively None None O
target None None O
the None None O
tumor None None O
vasculature None None O
. None None O

Adenovirus None None O
- None None O
mediated None None O
gene None None O
transfer None None O
of None None O
endostatin None None O
in None None O
vivo None None O
results None None O
in None None O
high None None O
level None None O
of None None O
transgene None None O
expression None None O
and None None O
inhibition None None O
of None None O
tumor None None O
growth None None O
and None None O
metastases None None O
. None None O

Inhibition None None O
of None None O
angiogenesis None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
an None None O
effective None None O
strategy None None O
in None None O
cancer None None O
therapy None None O
in None None O
mice None None O
. None None O

However None None O
, None None O
its None None O
widespread None None O
application None None O
has None None O
been None None O
hampered None None O
by None None O
difficulties None None O
in None None O
the None None O
large None None O
- None None O
scale None None O
production None None O
of None None O
the None None O
antiangiogenic None None O
proteins None None O
. None None O

This None None O
limitation None None O
may None None O
be None None O
resolved None None O
by None None O
in None None O
vivo None None O
delivery None None O
and None None O
expression None None O
of None None O
the None None O
antiangiogenic None None O
genes None None O
. None None O

We None None O
have None None O
constructed None None O
a None None O
recombinant None None O
adenovirus None None O
that None None O
expresses None None O
murine None None O
endostatin None None O
that None None O
is None None O
biologically None None O
active None None O
both None None O
in None None O
vitro None None O
, None None O
as None None O
determined None None O
in None None O
endothelial None None O
cell None None O
proliferation None None O
assays None None O
, None None O
and None None O
in None None O
vivo None None O
, None None O
by None None O
suppression None None O
of None None O
angiogenesis None None O
induced None None O
by None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
165 None None O
. None None O

Persistent None None O
high None None O
serum None None O
levels None None O
of None None O
endostatin None None O
( None None O
605 None None O
- None None O
1740 None None O
ng None None O
/ None None O
ml None None O
; None None O
mean None None O
, None None O
936 None None O
ng None None O
/ None None O
ml None None O
) None None O
were None None O
achieved None None O
after None None O
systemic None None O
administration None None O
of None None O
the None None O
vector None None O
to None None O
nude None None O
mice None None O
, None None O
which None None O
resulted None None O
in None None O
significant None None O
reduction None None O
of None None O
the None None O
growth None None O
rates None None O
and None None O
the None None O
volumes None None O
of None None O
JC None None O
breast None None O
carcinoma None None O
and None None O
Lewis None None O
lung None None O
carcinoma None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
and None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
, None None O
respectively None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
endostatin None None O
vector None None O
treatment None None O
completely None None O
prevented None None O
the None None O
formation None None O
of None None O
pulmonary None None O
micrometastases None None O
in None None O
Lewis None None O
lung None None O
carcinoma None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
0001 None None O
) None None O
. None None O

Immunohistochemical None None O
staining None None O
of None None O
the None None O
tumors None None O
demonstrated None None O
a None None O
decreased None None O
number None None O
of None None O
blood None None O
vessels None None O
in None None O
the None None O
treatment None None O
group None None O
versus None None O
the None None O
controls None None O
. None None O

In None None O
conclusion None None O
, None None O
the None None O
present None None O
study None None O
clearly None None O
demonstrates None None O
the None None O
potential None None O
of None None O
vector None None O
- None None O
mediated None None O
antiangiogenic None None O
gene None None O
therapy None None O
as None None O
a None None O
component None None O
in None None O
cancer None None O
therapy None None O
. None None O

p24 None None O
family None None O
type None None O
1 None None O
transmembrane None None O
proteins None None O
are None None O
required None None O
for None None O
insulin None None O
biosynthesis None None O
and None None O
secretion None None O
in None None O
pancreatic None None O
beta None None O
- None None O
cells None None O
. None None O

The None None O
p24 None None O
protein None None O
family None None O
have None None O
multiple None None O
functions None None O
in None None O
protein None None O
transport None None O
in None None O
the None None O
early None None O
secretory None None O
pathway None None O
. None None O

In None None O
this None None O
study None None O
we None None O
examined None None O
the None None O
role None None O
of None None O
p24 None None O
proteins None None O
in None None O
insulin None None O
transport None None O
. None None O

Several None None O
members None None O
were None None O
detected None None O
in None None O
insulinoma None None O
cell None None O
lines None None O
and None None O
rat None None O
islets None None O
and None None O
expression None None O
levels None None O
positively None None O
correlated None None O
with None None O
insulin None None O
abundance None None O
, None None O
particularly None None O
for None None O
p24delta1 None None O
and None None O
p24beta1 None None O
. None None O

Knocking None None O
down None None O
p24delta1 None None O
in None None O
insulinoma None None O
cell None None O
lines None None O
, None None O
which None None O
also None None O
resulted None None O
in None None O
the None None O
concomitant None None O
knock None None O
- None None O
down None None O
of None None O
other None None O
family None None O
members None None O
, None None O
impaired None None O
glucose None None O
- None None O
stimulated None None O
insulin None None O
secretion None None O
, None None O
decreased None None O
total None None O
cellular None None O
insulin None None O
content None None O
and None None O
reduced None None O
proinsulin None None O
biosynthesis None None O
. None None O

There None None O
was None None O
no None None O
effect None None O
on None None O
overall None None O
protein None None O
biosynthesis None None O
or None None O
ER None None O
stress None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
p24delta1 None None O
and None None O
possibly None None O
other None None O
p24 None None O
family None None O
proteins None None O
are None None O
required None None O
for None None O
normal None None O
insulin None None O
biosynthesis None None O
and None None O
subsequent None None O
secretion None None O
in None None O
pancreatic None None O
beta None None O
- None None O
cells None None O
. None None O

Lactotransferrin None None O
binding None None O
to None None O
its None None O
platelet None None O
receptor None None O
inhibits None None O
platelet None None O
aggregation None None O
. None None O

A None None O
fluorescent None None O
lactotransferrin None None O
probe None None O
was None None O
prepared None None O
by None None O
coupling None None O
5 None None O
- None None O
( None None O
( None None O
[ None None O
2 None None O
- None None O
( None None O
carbhydrazino None None O
) None None O
methyl None None O
] None None O
- None None O
thio None None O
) None None O
acetyl None None O
) None None O
amino None None O
fluorescein None None O
to None None O
aldehyde None None O
groups None None O
that None None O
were None None O
produced None None O
by None None O
a None None O
mild None None O
periodic None None O
- None None O
acid None None O
oxidation None None O
of None None O
the None None O
glycan None None O
moieties None None O
of None None O
lactotransferrin None None O
. None None O

In None None O
this None None O
manner None None O
, None None O
the None None O
receptor None None O
- None None O
binding None None O
site None None O
of None None O
the None None O
lactotransferrin None None O
remains None None O
active None None O
in None None O
contrast None None O
to None None O
the None None O
binding None None O
site None None O
of None None O
the None None O
lactotransferrin None None O
derivatized None None O
with None None O
fluorescein None None O
isothiocyanate None None O
. None None O

The None None O
fluorescent None None O
probe None None O
allowed None None O
us None None O
to None None O
characterize None None O
, None None O
by None None O
flow None None O
cytometry None None O
, None None O
the None None O
binding None None O
of None None O
lactotransferrin None None O
to None None O
non None None O
- None None O
activated None None O
human None None O
platelets None None O
. None None O

The None None O
putative None None O
lactotransferrin None None O
platelet None None O
receptor None None O
was None None O
purified None None O
and None None O
its None None O
immunological None None O
and None None O
physico None None O
- None None O
chemical None None O
properties None None O
were None None O
found None None O
to None None O
be None None O
very None None O
similar None None O
to None None O
those None None O
of None None O
the None None O
receptor None None O
previously None None O
isolated None None O
from None None O
activated None None O
human None None O
lymphocytes None None O
. None None O

Lactotransferrin None None O
inhibits None None O
ADP None None O
- None None O
induced None None O
platelet None None O
aggregation None None O
at None None O
concentrations None None O
down None None O
to None None O
5 None None O
nM None None O
, None None O
which None None O
can None None O
be None None O
reached None None O
in None None O
the None None O
plasma None None O
after None None O
leukocyte None None O
degranulation None None O
. None None O

Inhibition None None O
of None None O
platelet None None O
aggregation None None O
was None None O
also None None O
observed None None O
with None None O
the None None O
N None None O
- None None O
terminal None None O
fragment None None O
of None None O
lactotransferrin None None O
( None None O
residues None None O
3 None None O
- None None O
281 None None O
; None None O
50 None None O
% None None O
inhibition None None O
= None None O
2 None None O
microM None None O
) None None O
and None None O
with None None O
CFQWQRNMRKVRGPPVSC None None O
synthetic None None O
octodecapeptide None None O
( None None O
residues None None O
20 None None O
- None None O
37 None None O
; None None O
50 None None O
% None None O
inhibition None None O
= None None O
20 None None O
microM None None O
) None None O
corresponding None None O
to None None O
one None None O
of None None O
the None None O
two None None O
external None None O
loops None None O
( None None O
residues None None O
28 None None O
- None None O
34 None None O
and None None O
39 None None O
- None None O
42 None None O
) None None O
where None None O
we None None O
recently None None O
located None None O
the None None O
receptor None None O
- None None O
binding None None O
site None None O
. None None O

The None None O
activity None None O
( None None O
50 None None O
% None None O
inhibition None None O
= None None O
500 None None O
microM None None O
) None None O
of None None O
the None None O
tetrapeptide None None O
KRDS None None O
( None None O
residues None None O
39 None None O
- None None O
42 None None O
) None None O
, None None O
which None None O
has None None O
already None None O
been None None O
described None None O
, None None O
was None None O
at None None O
least None None O
25 None None O
- None None O
times None None O
and None None O
16000 None None O
- None None O
times None None O
lower None None O
than None None O
the None None O
activity None None O
of None None O
the None None O
octodecapeptide None None O
and None None O
of None None O
the None None O
lactotransferrin None None O
molecules None None O
, None None O
respectively None None O
. None None O

Finally None None O
, None None O
the None None O
inhibition None None O
was None None O
demonstrated None None O
to None None O
be None None O
mediated None None O
by None None O
a None None O
mechanism None None O
which None None O
requires None None O
the None None O
binding None None O
of None None O
lactotransferrin None None O
to None None O
its None None O
putative None None O
receptor None None O
and None None O
not None None O
to None None O
platelet None None O
glycoprotein None None O
IIb None None O
- None None O
IIIa None None O
. None None O

The None None O
LHRH None None O
pulse None None O
generator None None O
: None None O
a None None O
mediobasal None None O
hypothalamic None None O
location None None O
. None None O

The None None O
location None None O
and None None O
mechanism None None O
of None None O
LHRH None None O
pulse None None O
generator None None O
are None None O
discussed None None O
based None None O
on None None O
our None None O
series None None O
of None None O
experiments None None O
. None None O

Suckling None None O
stimulus None None O
is None None O
a None None O
novel None None O
stimulus None None O
that None None O
inhibits None None O
LH None None O
pulses None None O
without None None O
any None None O
cooperation None None O
from None None O
ovarian None None O
steroids None None O
, None None O
unlike None None O
other None None O
stimuli None None O
such None None O
as None None O
stress None None O
, None None O
photoperiod None None O
etc None None O
. None None O

It None None O
is None None O
directly None None O
involved None None O
in None None O
suppressing None None O
the None None O
activity None None O
of None None O
the None None O
LHRH None None O
pulse None None O
generator None None O
. None None O

The None None O
information None None O
from None None O
teats None None O
suckled None None O
by None None O
pups None None O
or None None O
babies None None O
is None None O
conveyed None None O
dorsally None None O
to None None O
the None None O
mediobasal None None O
hypothalamus None None O
( None None O
MBH None None O
) None None O
, None None O
where None None O
the None None O
LHRH None None O
pulse None None O
generator None None O
may None None O
be None None O
located None None O
. None None O

Experiments None None O
using None None O
various None None O
types None None O
of None None O
deafferentation None None O
and None None O
fetal None None O
brain None None O
tissue None None O
transplantation None None O
confirmed None None O
that None None O
the None None O
LHRH None None O
pulse None None O
generator None None O
is None None O
located None None O
in None None O
the None None O
MBH None None O
and None None O
suggested None None O
that None None O
LHRH None None O
pulse None None O
generator None None O
consists None None O
of None None O
nonLHRH None None O
neurons None None O
. None None O

Endogenous None None O
excitatory None None O
amino None None O
acid None None O
is None None O
one None None O
of None None O
the None None O
possible None None O
neurotransmitters None None O
that None None O
regulate None None O
LHRH None None O
release None None O
at None None O
the None None O
nerve None None O
terminal None None O
in None None O
ME None None O
. None None O

Allergic None None O
pulmonary None None O
inflammation None None O
promotes None None O
the None None O
recruitment None None O
of None None O
circulating None None O
tumor None None O
cells None None O
to None None O
the None None O
lung None None O
. None None O

Allergen None None O
- None None O
induced None None O
respiratory None None O
inflammation None None O
facilitates None None O
and None None O
/ None None O
or None None O
elicits None None O
the None None O
extravasation None None O
of None None O
proinflammatory None None O
leukocytes None None O
by None None O
well None None O
- None None O
understood None None O
mechanisms None None O
that None None O
mediate None None O
the None None O
movement None None O
of None None O
multiple None None O
cell None None O
types None None O
. None None O

The None None O
nonspecific None None O
character None None O
of None None O
these None None O
pathways None None O
led None None O
us None None O
to None None O
hypothesize None None O
that None None O
circulating None None O
cancer None None O
cells None None O
use None None O
similar None None O
mechanisms None None O
, None None O
promoting None None O
secondary None None O
tumor None None O
formation None None O
at None None O
distal None None O
sites None None O
. None None O

To None None O
test None None O
this None None O
hypothesis None None O
, None None O
the None None O
frequency None None O
of None None O
metastasis None None O
to None None O
the None None O
lung None None O
as None None O
a None None O
function None None O
of None None O
allergic None None O
pulmonary None None O
inflammation None None O
was None None O
assessed None None O
following None None O
the None None O
i None None O
. None None O
v None None O
. None None O
injection None None O
of None None O
B16 None None I-Cell-line-name
- None None I-Cell-line-name
F10 None None I-Cell-line-name
melanoma None None O
cells None None O
in None None O
mice None None O
. None None O

These None None O
studies None None O
showed None None O
that None None O
allergen None None O
- None None O
induced None None O
pulmonary None None O
inflammation None None O
resulted None None O
in None None O
a None None O
> None None O
3 None None O
- None None O
fold None None O
increase None None O
in None None O
lung None None O
metastases None None O
. None None O

This None None O
increase None None O
was None None O
dependent None None O
on None None O
CD4 None None O
( None None O
+ None None O
) None None O
T None None O
- None None O
cell None None O
activities None None O
; None None O
however None None O
, None None O
it None None O
occurred None None O
independent None None O
of None None O
the None None O
induced None None O
eosinophilia None None O
associated None None O
with None None O
allergen None None O
provocation None None O
. None None O

Interventional None None O
strategies None None O
showed None None O
that None None O
existing None None O
therapeutic None None O
modalities None None O
for None None O
asthma None None O
, None None O
such None None O
as None None O
inhaled None None O
corticosteroids None None O
, None None O
were None None O
sufficient None None O
to None None O
block None None O
the None None O
enhanced None None O
pulmonary None None O
recruitment None None O
of None None O
cancer None None O
cells None None O
from None None O
circulation None None O
. None None O

Additional None None O
mechanistic None None O
studies None None O
further None None O
suggested None None O
that None None O
the None None O
ability None None O
of None None O
circulating None None O
cancer None None O
cells None None O
to None None O
extravasate None None O
to None None O
surrounding None None O
lung None None O
tissues None None O
was None None O
linked None None O
to None None O
the None None O
activation None None O
of None None O
the None None O
vascular None None O
endothelium None None O
via None None O
one None None O
or None None O
more None None O
Galpha None None O
( None None O
i None None O
) None None O
- None None O
coupled None None O
receptors None None O
. None None O

Interestingly None None O
, None None O
a None None O
survey None None O
of None None O
a None None O
clinical None None O
breast None None O
cancer None None O
surgical None None O
database None None O
showed None None O
that None None O
the None None O
incidence None None O
of None None O
asthma None None O
was None None O
higher None None O
among None None O
patients None None O
with None None O
lung None None O
metastases None None O
. None None O

Thus None None O
, None None O
our None None O
data None None O
show None None O
that None None O
allergic None None O
respiratory None None O
inflammation None None O
may None None O
represent None None O
a None None O
risk None None O
factor None None O
for None None O
the None None O
development None None O
of None None O
lung None None O
metastases None None O
and None None O
suggest None None O
that None None O
amelioration None None O
of None None O
the None None O
pulmonary None None O
inflammation None None O
associated None None O
with None None O
asthma None None O
will None None O
have None None O
a None None O
direct None None O
and None None O
immediate None None O
benefit None None O
to None None O
the None None O
7 None None O
% None None O
to None None O
8 None None O
% None None O
of None None O
breast None None O
cancer None None O
patients None None O
with None None O
this None None O
lung None None O
disease None None O
. None None O

WNT None None O
/ None None O
TCF None None O
signaling None None O
through None None O
LEF1 None None O
and None None O
HOXB9 None None O
mediates None None O
lung None None O
adenocarcinoma None None O
metastasis None None O
. None None O

Metastasis None None O
from None None O
lung None None O
adenocarcinoma None None O
can None None O
occur None None O
swiftly None None O
to None None O
multiple None None O
organs None None O
within None None O
months None None O
of None None O
diagnosis None None O
. None None O

The None None O
mechanisms None None O
that None None O
confer None None O
this None None O
rapid None None O
metastatic None None O
capacity None None O
to None None O
lung None None O
tumors None None O
are None None O
unknown None None O
. None None O

Activation None None O
of None None O
the None None O
canonical None None O
WNT None None O
/ None None O
TCF None None O
pathway None None O
is None None O
identified None None O
here None None O
as None None O
a None None O
determinant None None O
of None None O
metastasis None None O
to None None O
brain None None O
and None None O
bone None None O
during None None O
lung None None O
adenocarcinoma None None O
progression None None O
. None None O

Gene None None O
expression None None O
signatures None None O
denoting None None O
WNT None None O
/ None None O
TCF None None O
activation None None O
are None None O
associated None None O
with None None O
relapse None None O
to None None O
multiple None None O
organs None None O
in None None O
primary None None O
lung None None O
adenocarcinoma None None O
. None None O

Metastatic None None O
subpopulations None None O
isolated None None O
from None None O
independent None None O
lymph None None O
node None None O
- None None O
derived None None O
lung None None O
adenocarcinoma None None O
cell None None O
lines None None O
harbor None None O
a None None O
hyperactive None None O
WNT None None O
/ None None O
TCF None None O
pathway None None O
. None None O

Reduction None None O
of None None O
TCF None None O
activity None None O
in None None O
these None None O
cells None None O
attenuates None None O
their None None O
ability None None O
to None None O
form None None O
brain None None O
and None None O
bone None None O
metastases None None O
in None None O
mice None None O
, None None O
independently None None O
of None None O
effects None None O
on None None O
tumor None None O
growth None None O
in None None O
the None None O
lungs None None O
. None None O

The None None O
WNT None None O
/ None None O
TCF None None O
target None None O
genes None None O
HOXB9 None None O
and None None O
LEF1 None None O
are None None O
identified None None O
as None None O
mediators None None O
of None None O
chemotactic None None O
invasion None None O
and None None O
colony None None O
outgrowth None None O
. None None O

Thus None None O
, None None O
a None None O
distinct None None O
WNT None None O
/ None None O
TCF None None O
signaling None None O
program None None O
through None None O
LEF1 None None O
and None None O
HOXB9 None None O
enhances None None O
the None None O
competence None None O
of None None O
lung None None O
adenocarcinoma None None O
cells None None O
to None None O
colonize None None O
the None None O
bones None None O
and None None O
the None None O
brain None None O
. None None O

For None None O
a None None O
video None None O
summary None None O
of None None O
this None None O
article None None O
, None None O
see None None O
the None None O
PaperFlick None None O
file None None O
available None None O
with None None O
the None None O
online None None O
Supplemental None None O
Data None None O
. None None O

Breast None None O
cancer None None O

The None None O
incidence None None O
of None None O
breast None None O
cancer None None O
is None None O
no None None O
higher None None O
than None None O
in None None O
the None None O
rest None None O
of None None O
the None None O
population None None O
. None None O

Tamoxifen None None O
should None None O
not None None O
be None None O
used None None O
as None None O
it None None O
may None None O
worsen None None O
symptoms None None O
[ None None O
43 None None O
] None None O
. None None O

Women None None O
need None None O
also None None O
specific None None O
management None None O
for None None O
treatment None None O
of None None O
HAE None None O
. None None O

Short None None O
term None None O
prophylaxis None None O
: None None O
three None None O
options None None O
are None None O
available None None O
: None None O
attenuated None None O
androgens None None O
, None None O
tranexamic None None O
acid None None O
or None None O
C1Inh None None O
concentrate None None O
. None None O

There None None O
is None None O
no None None O
specific None None O
problem None None O
for None None O
the None None O
use None None O
of None None O
theses None None O
drugs None None O
for None None O
short None None O
course None None O
in None None O
female None None O
patients None None O
. None None O

In None None O
case None None O
of None None O
short None None O
term None None O
prophylaxis None None O
with None None O
attenuated None None O
androgens None None O
, None None O
no None None O
virilisation None None O
has None None O
been None None O
observed None None O
[ None None O
44 None None O
, None None O
45 None None O
] None None O
. None None O

Acute None None O
attack None None O
treatment None None O
: None None O
there None None O
is None None O
no None None O
specific None None O
problem None None O
for None None O
the None None O
use None None O
of None None O
C1inh None None O
concentrate None None O
, None None O
tranexamic None None O
acid None None O
, None None O
icatibant None None O
; None None O
or None None O
ecallantide None None O
in None None O
female None None O
patients None None O
. None None O

Gene None None O
therapy None None O
for None None O
gliomas None None O
: None None O
p53 None None O
and None None O
E2F None None O
- None None O
1 None None O
proteins None None O
and None None O
the None None O
target None None O
of None None O
apoptosis None None O
. None None O

Current None None O
therapy None None O
for None None O
glioma None None O
is None None O
suboptimal None None O
. None None O

The None None O
transfer None None O
of None None O
apoptosis None None O
genes None None O
to None None O
tumors None None O
constitutes None None O
one None None O
of None None O
the None None O
most None None O
promising None None O
strategies None None O
for None None O
cancer None None O
gene None None O
therapy None None O
. None None O

We None None O
have None None O
previously None None O
shown None None O
that None None O
massive None None O
apoptosis None None O
occurs None None O
when None None O
wild None None O
- None None O
type None None O
p53 None None O
or None None O
E2F None None O
- None None O
1 None None O
expression None None O
is None None O
induced None None O
in None None O
glioma None None O
. None None O

However None None O
, None None O
the None None O
mechanism None None O
of None None O
action None None O
and None None O
the None None O
efficiency None None O
in None None O
inducing None None O
apoptosis None None O
of None None O
these None None O
two None None O
proteins None None O
are None None O
not None None O
similar None None O
. None None O

Adenovirus None None O
- None None O
mediated None None O
p53 None None O
gene None None O
transfer None None O
is None None O
ineffective None None O
in None None O
causing None None O
apoptosis None None O
in None None O
glioma None None O
cells None None O
that None None O
retain None None O
wild None None O
- None None O
type None None O
p53 None None O
genotype None None O
or None None O
overexpress None None O
the None None O
p21 None None O
protein None None O
. None None O

The None None O
p16 None None O
/ None None O
Rb None None O
/ None None O
E2F None None O
pathway None None O
is None None O
the None None O
most None None O
frequent None None O
target None None O
of None None O
genetic None None O
alterations None None O
in None None O
gliomas None None O
, None None O
and None None O
therefore None None O
constitutes None None O
a None None O
suitable None None O
target None None O
for None None O
gene None None O
therapy None None O
strategies None None O
. None None O

However None None O
, None None O
the None None O
transfer None None O
of None None O
either None None O
the None None O
p16 None None O
or None None O
Rb None None O
gene None None O
to None None O
glioma None None O
cells None None O
results None None O
in None None O
cytostatic None None O
effect None None O
. None None O

The None None O
E2F None None O
- None None O
1 None None O
protein None None O
is None None O
able None None O
to None None O
induce None None O
generalized None None O
apoptosis None None O
in None None O
gliomas None None O
independently None None O
of None None O
the None None O
p53 None None O
, None None O
p16 None None O
or None None O
Rb None None O
status None None O
. None None O

In None None O
addition None None O
, None None O
p21 None None O
- None None O
or None None O
p16 None None O
- None None O
mediated None None O
growth None None O
arrest None None O
did None None O
not None None O
protect None None O
glioma None None O
cells None None O
from None None O
E2F None None O
- None None O
1 None None O
- None None O
mediated None None O
apoptosis None None O
. None None O

The None None O
apoptotic None None O
molecule None None O
bax None None O
is None None O
induced None None O
in None None O
p53 None None O
- None None O
mediated None None O
apoptosis None None O
, None None O
but None None O
bax None None O
is None None O
not None None O
induced None None O
in None None O
E2F None None O
- None None O
1 None None O
- None None O
mediated None None O
apoptosis None None O
in None None O
glioma None None O
cells None None O
. None None O

Careful None None O
selection None None O
of None None O
patients None None O
may None None O
be None None O
necessary None None O
before None None O
designing None None O
therapeutic None None O
strategies None None O
using None None O
either None None O
p53 None None O
or None None O
E2F None None O
- None None O
1 None None O
as None None O
a None None O
therapeutic None None O
tools None None O
for None None O
glioma None None O
patients None None O
. None None O

Enhancement None None O
of None None O
docetaxel None None O
- None None O
induced None None O
cytotoxicity None None O
and None None O
apoptosis None None O
by None None O
all None None O
- None None O
trans None None O
retinoic None None O
acid None None O
( None None O
ATRA None None O
) None None O
through None None O
downregulation None None O
of None None O
survivin None None O
( None None O
BIRC5 None None O
) None None O
, None None O
MCL None None O
- None None O
1 None None O
and None None O
LTbeta None None O
- None None O
R None None O
in None None O
hormone None None O
- None None O
and None None O
drug None None O
resistant None None O
prostate None None O
cancer None None O
cell None None O
line None None O
, None None O
DU None None I-Cell-line-name
- None None I-Cell-line-name
145 None None I-Cell-line-name
. None None O

BACKGROUND None None O
: None None O
The None None O
management None None O
of None None O
hormone None None O
- None None O
refractory None None O
prostate None None O
cancer None None O
( None None O
HRPC None None O
) None None O
still None None O
remains None None O
as None None O
an None None O
important None None O
challenge None None O
of None None O
daily None None O
oncology None None O
practice None None O
. None None O

Docetaxel None None O
has None None O
proved None None O
to None None O
be None None O
a None None O
first None None O
line None None O
treatment None None O
choice None None O
. None None O

All None None O
- None None O
trans None None O
retinoic None None O
acid None None O
( None None O
ATRA None None O
) None None O
could None None O
potently None None O
inhibit None None O
the None None O
growth None None O
of None None O
prostate None None O
cancer None None O
cells None None O
in None None O
vitro None None O
and None None O
its None None O
combination None None O
with None None O
various None None O
anticancer None None O
agents None None O
results None None O
in None None O
increased None None O
cytotoxicity None None O
. None None O

Based None None O
on None None O
these None None O
data None None O
, None None O
our None None O
aim None None O
was None None O
to None None O
examine None None O
the None None O
synergistic None None O
/ None None O
additive None None O
cytotoxic None None O
and None None O
apoptotic None None O
effects None None O
of None None O
combination None None O
of None None O
docetaxel None None O
and None None O
ATRA None None O
, None None O
in None None O
hormone None None O
- None None O
and None None O
drug None None O
refractory None None O
human None None O
DU None None I-Cell-line-name
- None None I-Cell-line-name
145 None None I-Cell-line-name
prostate None None O
cancer None None O
cells None None O
. None None O

Furthermore None None O
, None None O
we None None O
have None None O
searched None None O
for None None O
the None None O
underlying None None O
mechanisms None None O
of None None O
apoptosis None None O
by None None O
demonstrating None None O
apoptosis None None O
- None None O
related None None O
genes None None O
. None None O

METHODS None None O
: None None O
XTT None None O
cell None None O
proliferation None None O
assay None None O
was None None O
used None None O
for None None O
showing None None O
cytotoxicity None None O
. None None O

For None None O
verifying None None O
apoptosis None None O
, None None O
both None None O
DNA None None O
Fragmentation None None O
by None None O
ELISA None None O
assay None None O
and None None O
caspase None None O
3 None None O
/ None None O
7 None None O
activity None None O
measurement None None O
were None None O
used None None O
. None None O

For None None O
detecting None None O
the None None O
mechanism None None O
of None None O
apoptosis None None O
induced None None O
by None None O
docetaxel None None O
- None None O
ATRA None None O
combination None None O
, None None O
OligoGeArray None None O
which None None O
consists None None O
of None None O
112 None None O
apoptosis None None O
related None None O
genes None None O
was None None O
used None None O
. None None O

RESULTS None None O
: None None O
Our None None O
results None None O
revealed None None O
that None None O
docetaxel None None O
and None None O
ATRA None None O
were None None O
synergistically None None O
cytotoxic None None O
and None None O
apoptotic None None O
in None None O
DU None None I-Cell-line-name
- None None I-Cell-line-name
145 None None I-Cell-line-name
cells None None O
, None None O
in None None O
a None None O
dose None None O
- None None O
and None None O
time None None O
dependent None None O
manner None None O
. None None O

It None None O
was None None O
also None None O
shown None None O
by None None O
our None None O
studies None None O
that None None O
apoptosis None None O
was None None O
induced None None O
in None None O
DU None None I-Cell-line-name
- None None I-Cell-line-name
145 None None I-Cell-line-name
prostate None None O
carcinoma None None O
cells None None O
with None None O
significant None None O
cytotoxicity None None O
, None None O
no None None O
matter None None O
which None None O
agent None None O
applied None None O
first None None O
. None None O

We None None O
have None None O
found None None O
out None None O
that None None O
docetaxel None None O
- None None O
ATRA None None O
combination None None O
significantly None None O
downregulates None None O
survivin None None O
( None None O
BIRC5 None None O
) None None O
, None None O
myeloid None None O
cell None None O
leukemia None None O
- None None O
1 None None O
( None None O
MCL None None O
- None None O
1 None None O
) None None O
and None None O
lymphotoxin None None O
beta None None O
- None None O
receptor None None O
( None None O
LTbetaR None None O
) None None O
genes None None O
, None None O
which None None O
all None None O
three None None O
have None None O
pivotal None None O
roles None None O
in None None O
regulation None None O
of None None O
apoptosis None None O
and None None O
cell None None O
cycle None None O
progression None None O
. None None O

CONCLUSION None None O
: None None O
In None None O
conclusion None None O
, None None O
we None None O
strongly None None O
suggest None None O
that None None O
docetaxel None None O
and None None O
ATRA None None O
combination None None O
is None None O
a None None O
good None None O
candidate None None O
for None None O
this None None O
challenging None None O
era None None O
of None None O
daily None None O
oncologic None None O
practice None None O
. None None O

Also None None O
, None None O
the None None O
combination None None O
of None None O
docetaxel None None O
and None None O
ATRA None None O
might None None O
allow None None O
a None None O
reduction None None O
in None None O
docetaxel None None O
doses None None O
and None None O
by None None O
this None None O
way None None O
may None None O
diminish None None O
docetaxel None None O
adverse None None O
effects None None O
while None None O
maintaining None None O
the None None O
therapeutic None None O
effect None None O
in None None O
patients None None O
with None None O
HRPC None None O
. None None O

NF None None O
- None None O
kappaB None None O
/ None None O
Rel None None O
transcriptional None None O
pathway None None O
: None None O
implications None None O
in None None O
pancreatic None None O
cancer None None O
. None None O

Despite None None O
considerable None None O
efforts None None O
in None None O
understanding None None O
the None None O
cellular None None O
mechanisms None None O
contributing None None O
to None None O
pancreatic None None O
cancer None None O
, None None O
the None None O
prognosis None None O
of None None O
this None None O
malignant None None O
disease None None O
is None None O
still None None O
extremely None None O
poor None None O
. None None O

Although None None O
pancreatic None None O
cancer None None O
is None None O
the None None O
fifth None None O
common None None O
cause None None O
of None None O
cancer None None O
death None None O
in None None O
Western None None O
countries None None O
, None None O
current None None O
options None None O
in None None O
treatment None None O
enable None None O
a None None O
5 None None O
- None None O
yr None None O
survival None None O
rate None None O
for None None O
all None None O
stages None None O
of None None O
less None None O
than None None O
5 None None O
% None None O
. None None O

In None None O
the None None O
face None None O
fo None None O
the None None O
fatal None None O
outcome None None O
, None None O
new None None O
approaches None None O
to None None O
the None None O
therapy None None O
have None None O
been None None O
established None None O
. None None O

Based None None O
on None None O
its None None O
role None None O
in None None O
malignant None None O
transformation None None O
, None None O
apoptosis None None O
, None None O
and None None O
cell None None O
proliferation None None O
, None None O
the None None O
transcription None None O
factor None None O
NF None None O
- None None O
kappaB None None O
/ None None O
Rel None None O
has None None O
gained None None O
the None None O
attention None None O
of None None O
many None None O
laboratories None None O
. None None O

This None None O
review None None O
provides None None O
basic None None O
information None None O
for None None O
the None None O
understanding None None O
of None None O
the None None O
biology None None O
of None None O
NF None None O
- None None O
kappaB None None O
and None None O
aims None None O
at None None O
presenting None None O
experimental None None O
data None None O
illustrating None None O
the None None O
involvement None None O
of None None O
NF None None O
- None None O
kappaB None None O
/ None None O
Rel None None O
in None None O
pancreatic None None O
cancer None None O
. None None O

Tarsoconjunctival None None O
flap None None O
after None None O
division None None O

Liposomal None None O
honokiol None None O
inhibits None None O
VEGF None None O
- None None O
D None None O
- None None O
induced None None O
lymphangiogenesis None None O
and None None O
metastasis None None O
in None None O
xenograft None None O
tumor None None O
model None None O
. None None O

Lymph None None O
nodes None None O
metastasis None None O
of None None O
tumor None None O
could None None O
be None None O
a None None O
crucial None None O
early None None O
step None None O
in None None O
the None None O
metastatic None None O
process None None O
. None None O

Induction None None O
of None None O
tumor None None O
lymphangiogenesis None None O
by None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
- None None O
D None None O
may None None O
play None None O
an None None O
important None None O
role None None O
in None None O
promoting None None O
tumor None None O
metastasis None None O
to None None O
regional None None O
lymph None None O
nodes None None O
and None None O
these None None O
processes None None O
can None None O
be None None O
inhibited None None O
by None None O
inactivation None None O
of None None O
the None None O
VEGFR None None O
- None None O
3 None None O
signaling None None O
pathway None None O
. None None O

Honokiol None None O
has None None O
been None None O
reported None None O
to None None O
possess None None O
potent None None O
antiangiogenesis None None O
and None None O
antitumor None None O
properties None None O
in None None O
several None None O
cell None None O
lines None None O
and None None O
xenograft None None O
tumor None None O
models None None O
. None None O

However None None O
, None None O
its None None O
role None None O
in None None O
tumor None None O
- None None O
associated None None O
lymphangiogenesis None None O
and None None O
lymphatic None None O
metastasis None None O
remains None None O
unclear None None O
. None None O

Here None None O
, None None O
we None None O
established None None O
lymph None None O
node None None O
metastasis None None O
models None None O
by None None O
injecting None None O
overexpressing None None O
VEGF None None O
- None None O
D None None O
Lewis None None O
lung None None O
carcinoma None None O
cells None None O
into None None O
C57BL None None O
/ None None O
6 None None O
mice None None O
to None None O
explore None None O
the None None O
effect None None O
of None None O
honokiol None None O
on None None O
tumor None None O
- None None O
associated None None O
lymphangiogenesis None None O
and None None O
related None None O
lymph None None O
node None None O
metastasis None None O
. None None O

The None None O
underlying None None O
mechanisms None None O
were None None O
systematically None None O
investigated None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

In None None O
in None None O
vivo None None O
study None None O
, None None O
liposomal None None O
honokiol None None O
significantly None None O
inhibited None None O
the None None O
tumor None None O
- None None O
associated None None O
lymphangiogenesis None None O
and None None O
metastasis None None O
in None None O
Lewis None None O
lung None None O
carcinoma None None O
model None None O
. None None O

A None None O
remarkable None None O
delay None None O
of None None O
tumor None None O
growth None None O
and None None O
prolonged None None O
life None None O
span None None O
were None None O
also None None O
observed None None O
. None None O

In None None O
in None None O
vitro None None O
study None None O
, None None O
honokiol None None O
inhibited None None O
VEGF None None O
- None None O
D None None O
- None None O
induced None None O
survival None None O
, None None O
proliferation None None O
and None None O
tube None None O
- None None O
formation None None O
of None None O
both None None O
human None None O
umbilical None None O
vein None None O
endothelial None None O
cells None None O
( None None O
HUVECs None None O
) None None O
and None None O
lymphatic None None O
vascular None None O
endothelial None None O
cells None None O
( None None O
HLECs None None I-Cell-line-name
) None None O
. None None O

Western None None O
blotting None None O
analysis None None O
showed None None O
that None None O
liposomal None None O
honokiol None None O
- None None O
inhibited None None O
Akt None None O
and None None O
MAPK None None O
phosphorylation None None O
in None None O
2 None None O
endothelial None None O
cells None None O
, None None O
and None None O
downregulated None None O
expressions None None O
of None None O
VEGFR None None O
- None None O
2 None None O
of None None O
human None None O
vascular None None O
endothelial None None O
cells None None O
and None None O
VEGFR None None O
- None None O
3 None None O
of None None O
lymphatic None None O
endothelial None None O
cells None None O
. None None O

Thus None None O
, None None O
we None None O
identified None None O
for None None O
the None None O
first None None O
time None None O
that None None O
honokiol None None O
provided None None O
therapeutic None None O
benefit None None O
not None None O
only None None O
by None None O
direct None None O
effects None None O
on None None O
tumor None None O
cells None None O
and None None O
antiangiogenesis None None O
but None None O
also None None O
by None None O
inhibiting None None O
lymphangiogenesis None None O
and None None O
metastasis None None O
via None None O
the None None O
VEGFR None None O
- None None O
3 None None O
pathway None None O
. None None O

The None None O
present None None O
findings None None O
may None None O
be None None O
of None None O
importance None None O
to None None O
investigate None None O
the None None O
molecular None None O
mechanisms None None O
underlying None None O
the None None O
spread None None O
of None None O
cancer None None O
via None None O
the None None O
lymphatics None None O
and None None O
explore None None O
the None None O
therapeutical None None O
strategy None None O
of None None O
honokiol None None O
on None None O
antilymphangiogenesis None None O
and None None O
antimetastasis None None O
. None None O

Identification None None O
of None None O
a None None O
small None None O
region None None O
of None None O
the None None O
v None None O
- None None O
fos None None O
gene None None O
product None None O
that None None O
is None None O
sufficient None None O
for None None O
transforming None None O
potential None None O
and None None O
growth None None O
- None None O
stimulating None None O
activity None None O
. None None O

To None None O
analyze None None O
the None None O
structure None None O
- None None O
function None None O
relationship None None O
for None None O
the None None O
v None None O
- None None O
fos None None O
protein None None O
, None None O
we None None O
constructed None None O
in None None O
- None None O
frame None None O
insertion None None O
and None None O
deletion None None O
mutants None None O
of None None O
the None None O
v None None O
- None None O
fos None None O
gene None None O
carried None None O
by None None O
FBJ None None O
- None None O
MuSV None None O
, None None O
and None None O
expressed None None O
them None None O
in None None O
chicken None None O
primary None None O
cells None None O
using None None O
retrovirus None None O
vectors None None O
. None None O

We None None O
assessed None None O
the None None O
effects None None O
of None None O
these None None O
mutations None None O
on None None O
the None None O
ability None None O
of None None O
the None None O
v None None O
- None None O
fos None None O
protein None None O
to None None O
transform None None O
chicken None None O
embryo None None O
fibroblasts None None O
and None None O
to None None O
stimulate None None O
cellular None None O
proliferation None None O
of None None O
chicken None None O
neuroretinal None None O
cells None None O
. None None O

The None None O
mutant None None O
which None None O
retains None None O
only None None O
the None None O
central None None O
region None None O
of None None O
the None None O
v None None O
- None None O
fos None None O
protein None None O
( None None O
Met111 None None O
- None None O
Ile206 None None O
) None None O
have None None O
both None None O
activities None None O
, None None O
but None None O
the None None O
mutants None None O
which None None O
have None None O
deletions None None O
in None None O
this None None O
region None None O
, None None O
and None None O
one None None O
of None None O
the None None O
mutants None None O
that None None O
has None None O
a None None O
four None None O
amino None None O
acid None None O
insertion None None O
in None None O
it None None O
, None None O
lost None None O
both None None O
activities None None O
. None None O

The None None O
central None None O
region None None O
that None None O
is None None O
sufficient None None O
for None None O
these None None O
activities None None O
includes None None O
the None None O
evolutionarily None None O
highly None None O
conserved None None O
region None None O
among None None O
human None None O
, None None O
mouse None None O
and None None O
chicken None None O
c None None O
- None None O
fos None None O
proteins None None O
. None None O

Additionally None None O
, None None O
this None None O
sequence None None O
shares None None O
some None None O
homology None None O
with None None O
the None None O
DNA None None O
binding None None O
domain None None O
of None None O
GCN4 None None O
and None None O
c None None O
- None None O
jun None None O
protein None None O
. None None O

The None None O
truncated None None O
fos None None O
protein None None O
that None None O
contains None None O
only None None O
part None None O
of None None O
the None None O
central None None O
region None None O
is None None O
not None None O
phosphorylated None None O
in None None O
chicken None None O
embryo None None O
fibroblasts None None O
, None None O
indicating None None O
that None None O
phosphorylation None None O
of None None O
the None None O
fos None None O
protein None None O
is None None O
not None None O
necessary None None O
for None None O
the None None O
transforming None None O
activity None None O
. None None O

Figures None None O
and None None O
Tables None None O

Figure None None O
1 None None O

Allergen None None O
and None None O
particle None None O
dose None None O
- None None O
response None None O
experiments None None O
in None None O
BALB None None O
/ None None O
cA None None O
and None None O
NIH None None O
mice None None O
Levels None None O
of None None O
serum None None O
OVA None None O
- None None O
specific None None O
IgE None None O
( None None O
A None None O
, None None O
D None None O
) None None O
, None None O
IgG1 None None O
( None None O
B None None O
, None None O
E None None O
) None None O
and None None O
IgG2a None None O
( None None O
C None None O
, None None O
F None None O
) None None O
on None None O
day None None O
26 None None O
after None None O
injection None None O
into None None O
one None None O
hind None None O
footpad None None O
of None None O
100 None None O
( None None O
open None None O
columns None None O
) None None O
, None None O
50 None None O
( None None O
gray None None O
) None None O
or None None O
10 None None O
( None None O
black None None O
) None None O
mug None None O
OVA None None O
combined None None O
with None None O
100 None None O
, None None O
40 None None O
, None None O
10 None None O
or None None O
0 None None O
mug None None O
PSP None None O
, None None O
or None None O
buffer None None O
( None None O
HBSS None None O
( None None O
hatched None None O
) None None O
) None None O
, None None O
in None None O
BALB None None O
/ None None O
cA None None O
( None None O
A None None O
, None None O
B None None O
, None None O
C None None O
) None None O
and None None O
NIH None None O
( None None O
D None None O
, None None O
E None None O
, None None O
F None None O
) None None O
mice None None O
. None None O

On None None O
day None None O
21 None None O
the None None O
mice None None O
were None None O
boostered None None O
with None None O
the None None O
same None None O
OVA None None O
dose None None O
in None None O
the None None O
footpad None None O
. None None O

The None None O
PSP None None O
- None None O
control None None O
( None None O
" None None O
PSP None None O
ctr None None O
" None None O
) None None O
group None None O
was None None O
given None None O
100 None None O
mug None None O
PSP None None O
on None None O
day None None O
0 None None O
, None None O
followed None None O
by None None O
HBSS None None O
injection None None O
on None None O
day None None O
21 None None O
( None None O
diamonds None None O
) None None O
. None None O

Values None None O
( None None O
arbitrary None None O
units None None O
, None None O
AU None None O
) None None O
for None None O
individual None None O
mice None None O
( None None O
circles None None O
) None None O
and None None O
median None None O
values None None O
( None None O
columns None None O
) None None O
for None None O
groups None None O
of None None O
eight None None O
mice None None O
are None None O
shown None None O
. None None O

Dotted None None O
lines None None O
indicate None None O
the None None O
lower None None O
or None None O
higher None None O
detection None None O
limits None None O
for None None O
the None None O
ELISA None None O
assays None None O
. None None O

Note None None O
different None None O
scales None None O
for None None O
the None None O
two None None O
strains None None O
of None None O
mice None None O
. None None O

Figure None None O
2 None None O

The None None O
adjuvant None None O
effect None None O
of None None O
PSP None None O
on None None O
OVA None None O
- None None O
specific None None O
IgE None None O
and None None O
IgG2a None None O
responses None None O
in None None O
different None None O
strains None None O
of None None O
mice None None O
Levels None None O
of None None O
serum None None O
OVA None None O
- None None O
specific None None O
IgE None None O
( None None O
A None None O
) None None O
and None None O
IgG2a None None O
( None None O
B None None O
) None None O
on None None O
day None None O
26 None None O
after None None O
injection None None O
into None None O
one None None O
hind None None O
footpad None None O
of None None O
HBSS None None O
( None None O
open None None O
columns None None O
) None None O
, None None O
10 None None O
mug None None O
OVA None None O
( None None O
gray None None O
) None None O
, None None O
40 None None O
mug None None O
PSP None None O
( None None O
hatched None None O
) None None O
or None None O
10 None None O
mug None None O
OVA None None O
+ None None O
40 None None O
mug None None O
PSP None None O
( None None O
black None None O
) None None O
in None None O
different None None O
mouse None None O
strains None None O
. None None O

On None None O
day None None O
21 None None O
all None None O
mice None None O
were None None O
boostered None None O
with None None O
10 None None O
mug None None O
OVA None None O
in None None O
the None None O
footpad None None O
. None None O

Vertical None None O
straight None None O
lines None None O
indicate None None O
separate None None O
experiments None None O
. None None O

Values None None O
( None None O
arbitrary None None O
units None None O
, None None O
AU None None O
) None None O
for None None O
individual None None O
mice None None O
( None None O
circles None None O
) None None O
and None None O
median None None O
values None None O
( None None O
columns None None O
) None None O
for None None O
groups None None O
of None None O
mice None None O
are None None O
shown None None O
. None None O

Dotted None None O
lines None None O
indicate None None O
the None None O
lower None None O
detection None None O
limits None None O
for None None O
the None None O
ELISA None None O
assays None None O
. None None O

Brackets None None O
indicate None None O
statistically None None O
significant None None O
differences None None O
between None None O
groups None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

All None None O
experiments None None O
were None None O
performed None None O
twice None None O
with None None O
similar None None O
results None None O
, None None O
with None None O
eight None None O
mice None None O
per None None O
group None None O
. None None O

Figure None None O
3 None None O

The None None O
primary None None O
cellular None None O
response None None O
in None None O
the None None O
draining None None O
lymph None None O
node None None O
The None None O
primary None None O
cellular None None O
response None None O
in None None O
the None None O
draining None None O
PLN None None O
was None None O
determined None None O
five None None O
days None None O
after None None O
a None None O
single None None O
injection None None O
of None None O
HBSS None None O
( None None O
open None None O
columns None None O
) None None O
, None None O
10 None None O
mug None None O
OVA None None O
( None None O
gray None None O
) None None O
, None None O
40 None None O
mug None None O
PSP None None O
( None None O
hatched None None O
) None None O
or None None O
10 None None O
mug None None O
OVA None None O
+ None None O
40 None None O
mug None None O
PSP None None O
( None None O
black None None O
) None None O
into None None O
both None None O
hind None None O
footpads None None O
of None None O
BALB None None O
/ None None O
cA None None O
, None None O
NIH None None O
and None None O
C3H None None O
/ None None O
HeN None None O
mice None None O
. None None O

The None None O
total None None O
lymph None None O
node None None O
cell None None O
numbers None None O
( None None O
A None None O
) None None O
and None None O
IL None None O
- None None O
4 None None O
( None None O
B None None O
) None None O
, None None O
IFN None None O
- None None O
gamma None None O
( None None O
C None None O
) None None O
and None None O
IL None None O
- None None O
10 None None O
( None None O
D None None O
) None None O
secreted None None O
from None None O
the None None O
PLN None None O
cells None None O
after None None O
ex None None O
vivo None None O
stimulation None None O
with None None O
Con None None O
A None None O
were None None O
determined None None O
. None None O

Values None None O
for None None O
individual None None O
samples None None O
( None None O
circles None None O
) None None O
and None None O
group None None O
median None None O
values None None O
( None None O
columns None None O
) None None O
are None None O
shown None None O
. None None O

Dotted None None O
lines None None O
indicate None None O
the None None O
lower None None O
detection None None O
limits None None O
for None None O
the None None O
cytokine None None O
ELISA None None O
assays None None O
, None None O
and None None O
brackets None None O
indicate None None O
statistically None None O
significant None None O
differences None None O
between None None O
groups None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

TxA2 None None O
, None None O
generated None None O
from None None O
arachidonic None None O
acid None None O
by None None O
cyclooxygenase None None O
1 None None O
( None None O
COX None None O
- None None O
1 None None O
) None None O
and None None O
Tx None None O
synthase None None O
, None None O
further None None O
amplifies None None O
platelet None None O
activation None None O
. None None O

COX None None O
- None None O
1 None None O
converts None None O
arachidonic None None O
acid None None O
into None None O
prostaglandin None None O
endoperoxides None None O
PGG2 None None O
and None None O
PGH2 None None O
, None None O
the None None O
latter None None O
being None None O
, None None O
in None None O
turn None None O
, None None O
transformed None None O
by None None O
Tx None None O
synthase None None O
into None None O
TxA2 None None O
, None None O
a None None O
potent None None O
amplifier None None O
of None None O
platelet None None O
aggregation None None O
with None None O
vasoconstrictive None None O
properties None None O
. None None O

At None None O
the None None O
site None None O
of None None O
the None None O
atheroma None None O
rupture None None O
, None None O
platelet None None O
- None None O
released None None O
TxA2 None None O
leads None None O
to None None O
downstream None None O
micro None None O
- None None O
vessel None None O
contraction None None O
and None None O
thrombus None None O
propagation None None O
( None None O
7 None None O
) None None O
. None None O

In None None O
addition None None O
to None None O
its None None O
role None None O
in None None O
coagulation None None O
, None None O
thrombin None None O
at None None O
extremely None None O
low None None O
concentrations None None O
is None None O
one None None O
of None None O
the None None O
major None None O
platelet None None O
activators None None O
( None None O
8 None None O
) None None O
. None None O

Human None None O
platelets None None O
express None None O
two None None O
cell None None O
surface None None O
G None None O
- None None O
protein None None O
- None None O
coupled None None O
protease None None O
- None None O
activated None None O
receptors None None O
( None None O
PARs None None O
) None None O
for None None O
thrombin None None O
: None None O
PAR None None O
- None None O
1 None None O
and None None O
PAR None None O
- None None O
4 None None O
. None None O

By None None O
binding None None O
the None None O
hirudin None None O
- None None O
like None None O
extracellular None None O
amino None None O
terminal None None O
domain None None O
( None None O
the None None O
so None None O
- None None O
called None None O
thrombin None None O
receptor None None O
) None None O
, None None O
thrombin None None O
activates None None O
platelets None None O
and None None O
smooth None None O
muscle None None O
cells None None O
, None None O
thus None None O
promoting None None O
platelet None None O
pro None None O
- None None O
coagulant None None O
activity None None O
, None None O
shape None None O
change None None O
, None None O
secretion None None O
and None None O
release None None O
of None None O
agonists None None O
( None None O
ADP None None O
and None None O
TxA2 None None O
) None None O
, None None O
expression None None O
of None None O
P None None O
- None None O
selectin None None O
, None None O
activation None None O
of None None O
the None None O
alphaIIbbeta3 None None O
integrin None None O
receptor None None O
, None None O
and None None O
aggregation None None O
. None None O

Thrombin None None O
also None None O
binds None None O
to None None O
GpIbalpha None None O
on None None O
the None None O
surface None None O
of None None O
platelets None None O
, None None O
thought None None O
to None None O
act None None O
as None None O
a None None O
co None None O
- None None O
factor None None O
that None None O
localizes None None O
the None None O
enzyme None None O
on None None O
the None None O
platelet None None O
surface None None O
and None None O
accelerates None None O
the None None O
hydrolysis None None O
of None None O
PAR None None O
- None None O
1 None None O
( None None O
9 None None O
) None None O
. None None O

PAR None None O
- None None O
1 None None O
and None None O
P2Y12 None None O
cross None None O
- None None O
react None None O
in None None O
platelet None None O
activation None None O
, None None O
and None None O
Galphaq None None O
and None None O
Galphai None None O
- None None O
coupled None None O
receptors None None O
are None None O
involved None None O
in None None O
this None None O
process None None O
. None None O

Thrombin None None O
- None None O
dependent None None O
platelet None None O
aggregation None None O
is None None O
mediated None None O
in None None O
part None None O
by None None O
secreted None None O
ADP None None O
, None None O
acting None None O
on None None O
the None None O
Galphai None None O
- None None O
linked None None O
ADP None None O
receptor None None O
. None None O

By None None O
blocking None None O
Galphaq None None O
via None None O
PAR None None O
- None None O
1 None None O
and None None O
Gbetai None None O
via None None O
P2Y12 None None O
, None None O
combined None None O
inhibition None None O
of None None O
thrombin None None O
and None None O
P2Y12 None None O
receptors None None O
leads None None O
to None None O
a None None O
synergistic None None O
inhibitory None None O
effect None None O
on None None O
thrombin None None O
- None None O
induced None None O
platelet None None O
aggregation None None O
( None None O
10 None None O
) None None O
. None None O

5 None None O
- None None O
HT None None O
is None None O
a None None O
vasoconstrictor None None O
agent None None O
that None None O
binds None None O
to None None O
5HT None None O
- None None O
2A None None O
receptors None None O
and None None O
amplifies None None O
the None None O
platelet None None O
response None None O
by None None O
stimulating None None O
shape None None O
change None None O
and None None O
enhancing None None O
platelet None None O
recruitment None None O
at None None O
sites None None O
of None None O
injury None None O
( None None O
3 None None O
) None None O
. None None O

It None None O
may None None O
also None None O
play None None O
a None None O
pro None None O
- None None O
coagulant None None O
role None None O
by None None O
promoting None None O
the None None O
retention None None O
of None None O
fibrinogen None None O
and None None O
thrombospondin None None O
on None None O
the None None O
platelet None None O
surface None None O
. None None O

Intraplatelet None None O
5 None None O
- None None O
HT None None O
stores None None O
are None None O
implicated None None O
in None None O
shear None None O
- None None O
induced None None O
platelet None None O
aggregation None None O
and None None O
thrombus None None O
propagation None None O
( None None O
3 None None O
) None None O
. None None O

Background None None O

Previous None None O
publications None None O
indicate None None O
that None None O
acupuncture None None O
is None None O
efficient None None O
for None None O
the None None O
treatment None None O
of None None O
pelvic None None O
girdle None None O
pain None None O
, None None O
PGP None None O
, None None O
in None None O
pregnant None None O
women None None O
. None None O

However None None O
, None None O
the None None O
use None None O
of None None O
acupuncture None None O
for None None O
PGP None None O
is None None O
rare None None O
due None None O
to None None O
insufficient None None O
documentation None None O
of None None O
adverse None None O
effects None None O
of None None O
this None None O
treatment None None O
in None None O
this None None O
specific None None O
condition None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
work None None O
was None None O
to None None O
assess None None O
adverse None None O
effects None None O
of None None O
acupuncture None None O
on None None O
the None None O
pregnancy None None O
, None None O
mother None None O
, None None O
delivery None None O
and None None O
the None None O
fetus None None O
/ None None O
neonate None None O
in None None O
comparison None None O
with None None O
women None None O
that None None O
received None None O
stabilising None None O
exercises None None O
as None None O
adjunct None None O
to None None O
standard None None O
treatment None None O
or None None O
standard None None O
treatment None None O
alone None None O
. None None O

Variables None None O

Our None None O
study None None O
used None None O
the None None O
following None None O
9 None None O
HRQOL None None O
questions None None O
from None None O
the None None O
2004 None None O
Rhode None None O
Island None None O
BRFSS None None O
: None None O
1 None None O
) None None O
self None None O
- None None O
rated None None O
general None None O
health None None O
status None None O
; None None O
and None None O
self None None O
- None None O
reported None None O
number None None O
of None None O
healthy None None O
and None None O
unhealthy None None O
days None None O
in None None O
the None None O
previous None None O
30 None None O
days None None O
for None None O
2 None None O
) None None O
physical None None O
health None None O
, None None O
3 None None O
) None None O
mental None None O
health None None O
, None None O
4 None None O
) None None O
physical None None O
or None None O
mental None None O
health None None O
- None None O
related None None O
activity None None O
limitation None None O
, None None O
5 None None O
) None None O
pain None None O
- None None O
related None None O
activity None None O
limitation None None O
, None None O
6 None None O
) None None O
sad None None O
, None None O
blue None None O
, None None O
or None None O
depressed None None O
, None None O
7 None None O
) None None O
worried None None O
, None None O
tense None None O
, None None O
or None None O
anxious None None O
, None None O
8 None None O
) None None O
lack None None O
of None None O
rest None None O
or None None O
sleep None None O
, None None O
and None None O
9 None None O
) None None O
lack None None O
of None None O
energy None None O
( None None O
1 None None O
, None None O
2 None None O
, None None O
15 None None O
) None None O
. None None O

We None None O
created None None O
9 None None O
dichotomous None None O
indicator None None O
variables None None O
. None None O

The None None O
responses None None O
to None None O
the None None O
self None None O
- None None O
rated None None O
general None None O
health None None O
status None None O
question None None O
were None None O
dichotomized None None O
into None None O
" None None O
poor None None O
" None None O
( None None O
poor None None O
or None None O
fair None None O
) None None O
health None None O
or None None O
" None None O
good None None O
" None None O
( None None O
good None None O
, None None O
very None None O
good None None O
, None None O
or None None O
excellent None None O
) None None O
health None None O
. None None O

The None None O
indicators None None O
measured None None O
in None None O
days None None O
were None None O
dichotomized None None O
at None None O
a None None O
cutoff None None O
value None None O
of None None O
14 None None O
or None None O
more None None O
days None None O
of None None O
poor None None O
health None None O
in None None O
the None None O
previous None None O
month None None O
compared None None O
to None None O
less None None O
than None None O
14 None None O
days None None O
( None None O
3 None None O
) None None O
. None None O

We None None O
selected None None O
the None None O
14 None None O
- None None O
day None None O
minimum None None O
period None None O
because None None O
most None None O
of None None O
the None None O
publications None None O
we None None O
reviewed None None O
that None None O
use None None O
the None None O
BRFSS None None O
HRQOL None None O
indicators None None O
( None None O
outcomes None None O
) None None O
use None None O
the None None O
cutoff None None O
of None None O
14 None None O
or None None O
more None None O
days None None O
compared None None O
to None None O
13 None None O
or None None O
fewer None None O
days None None O
( None None O
3 None None O
- None None O
5 None None O
, None None O
7 None None O
- None None O
11 None None O
, None None O
16 None None O
, None None O
17 None None O
) None None O
. None None O

Adopting None None O
this None None O
precedent None None O
ensured None None O
comparability None None O
. None None O

In None None O
addition None None O
, None None O
clinicians None None O
and None None O
clinical None None O
researchers None None O
often None None O
use None None O
this None None O
period None None O
as None None O
a None None O
marker None None O
for None None O
clinical None None O
depression None None O
and None None O
anxiety None None O
disorders None None O
, None None O
and None None O
long None None O
symptomatic None None O
durations None None O
are None None O
associated None None O
with None None O
high None None O
levels None None O
of None None O
activity None None O
limitation None None O
( None None O
2 None None O
, None None O
18 None None O
) None None O
. None None O

Detailed None None O
definitions None None O
of None None O
the None None O
9 None None O
indicators None None O
are None None O
available None None O
in None None O
our None None O
previous None None O
article None None O
( None None O
1 None None O
) None None O
or None None O
are None None O
accessible None None O
through None None O
the None None O
Centers None None O
for None None O
Disease None None O
Control None None O
and None None O
Prevention None None O
' None None O
s None None O
HRQOL None None O
Web None None O
site None None O
( None None O
2 None None O
) None None O
. None None O

We None None O
chose None None O
12 None None O
predictors None None O
for None None O
the None None O
analysis None None O
: None None O
5 None None O
standard None None O
demographic None None O
measures None None O
( None None O
age None None O
, None None O
sex None None O
, None None O
race None None O
/ None None O
Hispanic None None O
ethnicity None None O
, None None O
annual None None O
income None None O
, None None O
and None None O
employment None None O
status None None O
) None None O
; None None O
4 None None O
health None None O
conditions None None O
( None None O
asthma None None O
, None None O
diabetes None None O
, None None O
obesity None None O
, None None O
and None None O
physical None None O
disability None None O
) None None O
; None None O
and None None O
3 None None O
health None None O
risk None None O
behaviors None None O
( None None O
smoking None None O
, None None O
chronic None None O
alcohol None None O
use None None O
, None None O
and None None O
no None None O
leisure None None O
- None None O
time None None O
physical None None O
activity None None O
) None None O
. None None O

These None None O
predictors None None O
paralleled None None O
the None None O
results None None O
of None None O
other None None O
studies None None O
that None None O
have None None O
examined None None O
relationships None None O
between None None O
a None None O
specific None None O
HRQOL None None O
indicator None None O
and None None O
various None None O
predictors None None O
( None None O
17 None None O
, None None O
19 None None O
) None None O
, None None O
or None None O
that None None O
have None None O
examined None None O
multiple None None O
HRQOL None None O
indicators None None O
in None None O
relation None None O
to None None O
demographics None None O
( None None O
4 None None O
, None None O
20 None None O
) None None O
, None None O
health None None O
risks None None O
( None None O
5 None None O
, None None O
10 None None O
, None None O
21 None None O
) None None O
, None None O
or None None O
specific None None O
health None None O
conditions None None O
( None None O
6 None None O
- None None O
9 None None O
, None None O
12 None None O
, None None O
22 None None O
) None None O
. None None O

We None None O
dichotomized None None O
some None None O
predictors None None O
for None None O
the None None O
analysis None None O
( None None O
ie None None O
, None None O
sex None None O
, None None O
current None None O
smoking None None O
, None None O
alcohol None None O
use None None O
, None None O
physical None None O
activity None None O
, None None O
asthma None None O
, None None O
diabetes None None O
, None None O
obesity None None O
, None None O
and None None O
disability None None O
) None None O
, None None O
whereas None None O
other None None O
predictors None None O
had None None O
multiple None None O
categories None None O
( None None O
ie None None O
, None None O
age None None O
, None None O
race None None O
/ None None O
Hispanic None None O
ethnicity None None O
, None None O
income None None O
, None None O
and None None O
employment None None O
status None None O
) None None O
. None None O

The None None O
definitions None None O
of None None O
the None None O
12 None None O
predictors None None O
are None None O
available None None O
in None None O
our None None O
previous None None O
article None None O
( None None O
1 None None O
) None None O
. None None O

Reference None None O
groups None None O
chosen None None O
for None None O
the None None O
IRT None None O
model None None O
were None None O
those None None O
having None None O
the None None O
lowest None None O
risk None None O
for None None O
poor None None O
or None None O
fair None None O
general None None O
health None None O
and None None O
usually None None O
the None None O
lowest None None O
risk None None O
for None None O
the None None O
other None None O
HRQOL None None O
variables None None O
as None None O
well None None O
. None None O

Expression None None O
of None None O
CDK4 None None O
or None None O
CDK2 None None O
in None None O
mouse None None O
oral None None O
cavity None None O
is None None O
retained None None O
in None None O
adult None None O
pituitary None None O
with None None O
distinct None None O
effects None None O
on None None O
tumorigenesis None None O
. None None O

The None None O
keratin None None O
5 None None O
( None None O
K5 None None O
) None None O
promoter None None O
drives None None O
transgenic None None O
expression None None O
to None None O
the None None O
basal None None O
cell None None O
layer None None O
of None None O
stratified None None O
epithelia None None O
. None None O

Surprisingly None None O
, None None O
analysis None None O
of None None O
K5CDK4 None None O
and None None O
K5CDK2 None None O
transgenic None None O
mouse None None O
embryos None None O
showed None None O
CDK4 None None O
and None None O
CDK2 None None O
expression None None O
not None None O
only None None O
in None None O
the None None O
expected None None O
tissues None None O
, None None O
but None None O
also None None O
in None None O
the None None O
adenohypophysis None None O
. None None O

This None None O
organ None None O
is None None O
derived None None O
from None None O
an None None O
upwards None None O
growth None None O
of None None O
the None None O
primitive None None O
oropharynx None None O
, None None O
a None None O
K5 None None O
- None None O
expressing None None O
tissue None None O
. None None O

We None None O
show None None O
that None None O
transgenic None None O
expression None None O
of None None O
CDKs None None O
in None None O
the None None O
embryonic None None O
oral None None O
ectoderm None None O
is None None O
specifically None None O
retained None None O
in None None O
undifferentiated None None O
cells None None O
from None None O
the None None O
pars None None O
intermedia None None O
of None None O
the None None O
adenohypophysis None None O
. None None O

Interestingly None None O
, None None O
we None None O
found None None O
that None None O
K5CDK4 None None O
mice None None O
show None None O
a None None O
decreased None None O
number None None O
of None None O
pituitary None None O
stem None None O
cells None None O
, None None O
even None None O
though None None O
CDK4 None None O
is None None O
not None None O
expressed None None O
in None None O
the None None O
stem None None O
cells None None O
but None None O
in None None O
transit None None O
- None None O
amplifying None None O
( None None O
TA None None O
) None None O
- None None O
like None None O
cells None None O
. None None O

Interestingly None None O
, None None O
CDK4 None None O
- None None O
expressing None None O
cells None None O
, None None O
but None None O
not None None O
CDK2 None None O
- None None O
expressing None None O
cells None None O
, None None O
strongly None None O
synergize None None O
with None None O
lack None None O
of None None O
p27 None None O
( None None O
Kip1 None None O
) None None O
to None None O
generate None None O
pituitary None None O
carcinomas None None O
that None None O
appear None None O
with None None O
shortened None None O
latency None None O
and None None O
are None None O
drastically None None O
more None None O
aggressive None None O
than None None O
those None None O
arising None None O
in None None O
p27 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
mice None None O
. None None O

Thus None None O
, None None O
we None None O
show None None O
that None None O
deregulation None None O
of None None O
CDK None None O
expression None None O
in None None O
the None None O
primitive None None O
oral None None O
epithelium None None O
plays None None O
a None None O
unique None None O
function None None O
, None None O
providing None None O
a None None O
selective None None O
advantage None None O
that None None O
gives None None O
rise None None O
to None None O
transgene None None O
- None None O
positive None None O
TA None None O
- None None O
like None None O
pituitary None None O
cells None None O
. None None O

Furthermore None None O
, None None O
retention None None O
of None None O
CDK4 None None O
in None None O
these None None O
TA None None O
- None None O
like None None O
pituitary None None O
cells None None O
synergizes None None O
with None None O
loss None None O
of None None O
p27 None None O
( None None O
Kip1 None None O
) None None O
to None None O
induce None None O
pituitary None None O
adenocarcinomas None None O
. None None O

This None None O
model None None O
suggests None None O
that None None O
forced None None O
expression None None O
of None None O
CDK4 None None O
sensitizes None None O
cells None None O
and None None O
synergizes None None O
with None None O
a None None O
second None None O
change None None O
resulting None None O
in None None O
tumor None None O
development None None O
. None None O

A None None O
STAT3 None None O
- None None O
mediated None None O
metabolic None None O
switch None None O
is None None O
involved None None O
in None None O
tumour None None O
transformation None None O
and None None O
STAT3 None None O
addiction None None O
. None None O

The None None O
pro None None O
- None None O
oncogenic None None O
transcription None None O
factor None None O
STAT3 None None O
is None None O
constitutively None None O
activated None None O
in None None O
a None None O
wide None None O
variety None None O
of None None O
tumours None None O
that None None O
often None None O
become None None O
addicted None None O
to None None O
its None None O
activity None None O
, None None O
but None None O
no None None O
unifying None None O
view None None O
of None None O
a None None O
core None None O
function None None O
determining None None O
this None None O
widespread None None O
STAT3 None None O
- None None O
dependence None None O
has None None O
yet None None O
emerged None None O
. None None O

We None None O
show None None O
here None None O
that None None O
constitutively None None O
active None None O
STAT3 None None O
acts None None O
as None None O
a None None O
master None None O
regulator None None O
of None None O
cell None None O
metabolism None None O
, None None O
inducing None None O
aerobic None None O
glycolysis None None O
and None None O
down None None O
- None None O
regulating None None O
mitochondrial None None O
activity None None O
both None None O
in None None O
primary None None O
fibroblasts None None O
and None None O
in None None O
STAT3 None None O
- None None O
dependent None None O
tumour None None O
cell None None O
lines None None O
. None None O

As None None O
a None None O
result None None O
, None None O
cells None None O
are None None O
protected None None O
from None None O
apoptosis None None O
and None None O
senescence None None O
while None None O
becoming None None O
highly None None O
sensitive None None O
to None None O
glucose None None O
deprivation None None O
. None None O

We None None O
show None None O
that None None O
enhanced None None O
glycolysis None None O
is None None O
dependent None None O
on None None O
HIF None None O
- None None O
1alpha None None O
up None None O
- None None O
regulation None None O
, None None O
while None None O
reduced None None O
mitochondrial None None O
activity None None O
is None None O
HIF None None O
- None None O
1alpha None None O
- None None O
independent None None O
and None None O
likely None None O
caused None None O
by None None O
STAT3 None None O
- None None O
mediated None None O
down None None O
- None None O
regulation None None O
of None None O
mitochondrial None None O
proteins None None O
. None None O

The None None O
induction None None O
of None None O
aerobic None None O
glycolysis None None O
is None None O
an None None O
important None None O
component None None O
of None None O
STAT3 None None O
pro None None O
- None None O
oncogenic None None O
activities None None O
, None None O
since None None O
inhibition None None O
of None None O
STAT3 None None O
tyrosine None None O
phosphorylation None None O
in None None O
the None None O
tumour None None O
cell None None O
lines None None O
down None None O
- None None O
regulates None None O
glycolysis None None O
prior None None O
to None None O
leading None None O
to None None O
growth None None O
arrest None None O
and None None O
cell None None O
death None None O
, None None O
both None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

We None None O
propose None None O
that None None O
this None None O
novel None None O
, None None O
central None None O
metabolic None None O
role None None O
is None None O
at None None O
the None None O
core None None O
of None None O
the None None O
addiction None None O
for None None O
STAT3 None None O
shown None None O
by None None O
so None None O
many None None O
biologically None None O
different None None O
tumours None None O
. None None O

In None None O
situ None None O
alkylation None None O
of None None O
cysteine None None O
residues None None O
in None None O
a None None O
hydrophobic None None O
membrane None None O
protein None None O
immobilized None None O
on None None O
polyvinylidene None None O
difluoride None None O
membranes None None O
by None None O
electroblotting None None O
prior None None O
to None None O
microsequence None None O
and None None O
amino None None O
acid None None O
analysis None None O
. None None O

For None None O
identification None None O
of None None O
cysteine None None O
residues None None O
on None None O
microsequence None None O
analysis None None O
it None None O
is None None O
crucial None None O
to None None O
derivatize None None O
the None None O
sulfhydryl None None O
groups None None O
. None None O

This None None O
reaction None None O
requires None None O
a None None O
desalting None None O
step None None O
which None None O
often None None O
represents None None O
a None None O
major None None O
obstacle None None O
, None None O
especially None None O
if None None O
the None None O
sample None None O
consists None None O
of None None O
limited None None O
amounts None None O
of None None O
a None None O
hydrophobic None None O
membrane None None O
protein None None O
. None None O

An None None O
alkylation None None O
procedure None None O
is None None O
described None None O
, None None O
allowing None None O
efficient None None O
derivatization None None O
( None None O
greater None None O
than None None O
90 None None O
% None None O
) None None O
of None None O
cysteines None None O
and None None O
cystines None None O
even None None O
in None None O
low None None O
microgram None None O
quantities None None O
, None None O
as None None O
revealed None None O
by None None O
test None None O
analyses None None O
with None None O
lysozyme None None O
and None None O
a None None O
hydrophobic None None O
membrane None None O
protein None None O
. None None O

The None None O
modified None None O
protein None None O
is None None O
recovered None None O
in None None O
high None None O
yields None None O
in None None O
a None None O
form None None O
suitable None None O
for None None O
both None None O
microsequence None None O
analysis None None O
and None None O
amino None None O
acid None None O
analysis None None O
. None None O

The None None O
method None None O
involves None None O
electrophoretic None None O
desalting None None O
by None None O
miniaturized None None O
Tricine None None O
- None None O
sodium None None O
dodecyl None None O
sulfate None None O
- None None O
polyacrylamide None None O
gel None None O
electrophoresis None None O
and None None O
in None None O
situ None None O
alkylation None None O
after None None O
electro None None O
- None None O
transfer None None O
onto None None O
polyvinylidene None None O
difluoride None None O
membranes None None O
. None None O

Precautions None None O
against None None O
NH2 None None O
- None None O
terminal None None O
blocking None None O
during None None O
sample None None O
preparations None None O
are None None O
provided None None O
. None None O

The None None O
general None None O
applicability None None O
of None None O
the None None O
method None None O
is None None O
illustrated None None O
by None None O
the None None O
structural None None O
characterization None None O
of None None O
the None None O
low None None O
abundance None None O
membrane None None O
receptor None None O
for None None O
human None None O
urokinase None None O
plasminogen None None O
activator None None O
. None None O

Acute None None O
ablation None None O
of None None O
Langerhans None None O
cells None None O
enhances None None O
skin None None O
immune None None O
responses None None O
. None None O

Understanding None None O
the None None O
function None None O
of None None O
Langerhans None None O
cells None None O
( None None O
LCs None None O
) None None O
in None None O
vivo None None O
has None None O
been None None O
complicated None None O
by None None O
conflicting None None O
results None None O
from None None O
LC None None O
- None None O
deficient None None O
mice None None O
. None None O

Human None None O
Langerin None None O
- None None O
DTA None None O
mice None None O
constitutively None None O
lack None None O
LCs None None O
and None None O
develop None None O
exaggerated None None O
contact None None O
hypersensitivity None None O
( None None O
CHS None None O
) None None O
responses None None O
. None None O

Murine None None O
Langerin None None O
- None None O
diphtheria None None O
toxin None None O
receptor None None O
( None None O
DTR None None O
) None None O
mice None None O
allow None None O
for None None O
the None None O
inducible None None O
elimination None None O
of None None O
LCs None None O
and None None O
Langerin None None O
( None None O
+ None None O
) None None O
dermal None None O
dendritic None None O
cells None None O
( None None O
dDCs None None O
) None None O
after None None O
administration None None O
of None None O
diphtheria None None O
toxin None None O
, None None O
which None None O
results None None O
in None None O
reduced None None O
CHS None None O
. None None O

When None None O
Langerin None None O
( None None O
+ None None O
) None None O
dDCs None None O
have None None O
partially None None O
repopulated None None O
the None None O
skin None None O
but None None O
LCs None None O
are None None O
still None None O
absent None None O
, None None O
CHS None None O
returns None None O
to None None O
normal None None O
. None None O

Thus None None O
, None None O
LCs None None O
appear None None O
to None None O
be None None O
suppressive None None O
in None None O
human None None O
Langerin None None O
- None None O
DTA None None O
mice None None O
and None None O
redundant None None O
in None None O
murine None None O
Langerin None None O
- None None O
DTR None None O
mice None None O
. None None O

To None None O
determine None None O
whether None None O
inducible None None O
versus None None O
constitutive None None O
LC None None O
ablation None None O
explains None None O
these None None O
results None None O
, None None O
we None None O
engineered None None O
human None None O
Langerin None None O
- None None O
DTR None None O
mice None None O
in None None O
which None None O
diphtheria None None O
toxin None None O
ablates None None O
LCs None None O
without None None O
affecting None None O
Langerin None None O
( None None O
+ None None O
) None None O
dDCs None None O
. None None O

The None None O
inducible None None O
ablation None None O
of None None O
LCs None None O
in None None O
human None None O
Langerin None None O
- None None O
DTR None None O
mice None None O
resulted None None O
in None None O
increased None None O
CHS None None O
. None None O

Thus None None O
, None None O
LC None None O
- None None O
mediated None None O
suppression None None O
does None None O
not None None O
require None None O
their None None O
absence None None O
during None None O
ontogeny None None O
or None None O
during None None O
the None None O
steady None None O
- None None O
state None None O
and None None O
is None None O
consistent None None O
with None None O
a None None O
model None None O
in None None O
which None None O
LCs None None O
actively None None O
suppress None None O
Ag None None O
- None None O
specific None None O
CHS None None O
responses None None O
. None None O

Conclusion None None O
: None None O

This None None O
study None None O
demonstrates None None O
that None None O
surgery None None O
plus None None O
chemotherapy None None O
and None None O
radiation None None O
therapy None None O
is None None O
helpful None None O
for None None O
treating None None O
patients None None O
with None None O
pelvic None None O
Ewing None None O
' None None O
s None None O
sarcoma None None O
, None None O
particularly None None O
in None None O
achieving None None O
local None None O
control None None O
. None None O

Integrin None None O
alphavbeta3 None None O
requirement None None O
for None None O
sustained None None O
mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
activity None None O
during None None O
angiogenesis None None O
. None None O

Angiogenesis None None O
depends None None O
on None None O
growth None None O
factors None None O
and None None O
vascular None None O
cell None None O
adhesion None None O
events None None O
. None None O

Integrins None None O
and None None O
growth None None O
factors None None O
are None None O
capable None None O
of None None O
activating None None O
the None None O
ras None None O
/ None None O
MAP None None O
kinase None None O
pathway None None O
in None None O
vitro None None O
, None None O
yet None None O
how None None O
these None None O
signals None None O
influence None None O
endothelial None None O
cells None None O
during None None O
angiogenesis None None O
is None None O
unknown None None O
. None None O

Upon None None O
initiation None None O
of None None O
angiogenesis None None O
with None None O
basic None None O
fibroblast None None O
growth None None O
factor None None O
( None None O
bFGF None None O
) None None O
on None None O
the None None O
chick None None O
chorioallantoic None None O
membrane None None O
( None None O
CAM None None O
) None None O
, None None O
endothelial None None O
cell None None O
mitogen None None O
- None None O
activated None None O
protein None None O
( None None O
MAP None None O
) None None O
kinase None None O
( None None O
ERK None None O
) None None O
activity None None O
was None None O
detected None None O
as None None O
early None None O
as None None O
5 None None O
min None None O
yet None None O
was None None O
sustained None None O
for None None O
at None None O
least None None O
20 None None O
h None None O
. None None O

The None None O
initial None None O
wave None None O
of None None O
ERK None None O
activity None None O
( None None O
5 None None O
- None None O
120 None None O
min None None O
) None None O
was None None O
refractory None None O
to None None O
integrin None None O
antagonists None None O
, None None O
whereas None None O
the None None O
sustained None None O
activity None None O
( None None O
4 None None O
- None None O
20 None None O
h None None O
) None None O
depended None None O
on None None O
integrin None None O
alphavbeta3 None None O
, None None O
but None None O
not None None O
beta1 None None O
integrins None None O
. None None O

Inhibition None None O
of None None O
MAP None None O
kinase None None O
kinase None None O
( None None O
MEK None None O
) None None O
during None None O
this None None O
sustained None None O
alphavbeta3 None None O
- None None O
dependent None None O
ERK None None O
signal None None O
blocked None None O
the None None O
formation None None O
of None None O
new None None O
blood None None O
vessels None None O
while None None O
not None None O
influencing None None O
preexisting None None O
blood None None O
vessels None None O
on None None O
the None None O
CAM None None O
. None None O

Inhibition None None O
of None None O
MEK None None O
also None None O
blocked None None O
growth None None O
factor None None O
induced None None O
migration None None O
but None None O
not None None O
adhesion None None O
of None None O
endothelial None None O
cells None None O
in None None O
vitro None None O
. None None O

Therefore None None O
, None None O
angiogenesis None None O
depends None None O
on None None O
sustained None None O
ERK None None O
activity None None O
regulated None None O
by None None O
the None None O
ligation None None O
state None None O
of None None O
both None None O
a None None O
growth None None O
factor None None O
receptor None None O
and None None O
integrin None None O
alphavbeta3 None None O
. None None O

p53 None None O
mutation None None O
heterogeneity None None O
in None None O
cancer None None O
. None None O

The None None O
p53 None None O
gene None None O
is None None O
inactivated None None O
in None None O
about None None O
50 None None O
% None None O
of None None O
human None None O
cancers None None O
and None None O
the None None O
p53 None None O
protein None None O
is None None O
an None None O
essential None None O
component None None O
of None None O
the None None O
cell None None O
response None None O
induced None None O
by None None O
genotoxic None None O
stresses None None O
such None None O
as None None O
those None None O
generated None None O
by None None O
radiotherapy None None O
or None None O
chemotherapy None None O
. None None O

It None None O
is None None O
therefore None None O
highly None None O
likely None None O
that None None O
these None None O
alterations None None O
are None None O
an None None O
important None None O
component None None O
in None None O
tumor None None O
resistance None None O
to None None O
therapy None None O
. None None O

The None None O
particular None None O
characteristics None None O
of None None O
these None None O
alterations None None O
, None None O
80 None None O
% None None O
of None None O
which None None O
are None None O
missense None None O
mutations None None O
leading None None O
to None None O
functionally None None O
heterogeneous None None O
proteins None None O
, None None O
make None None O
p53 None None O
a None None O
unique None None O
gene None None O
in None None O
the None None O
class None None O
of None None O
tumor None None O
suppressor None None O
genes None None O
. None None O

A None None O
considerable None None O
number None None O
of None None O
mutant None None O
p53 None None O
proteins None None O
probably None None O
have None None O
an None None O
oncogenic None None O
activity None None O
per None None O
se None None O
and None None O
therefore None None O
actively None None O
participate None None O
in None None O
cell None None O
transformation None None O
. None None O

The None None O
fact None None O
that None None O
the None None O
apoptotic None None O
and None None O
antiproliferative None None O
functions None None O
of None None O
p53 None None O
can None None O
be None None O
dissociated None None O
in None None O
certain None None O
mutants None None O
also None None O
suggests None None O
another None None O
level None None O
of None None O
complexity None None O
in None None O
the None None O
relationships None None O
between None None O
p53 None None O
inactivation None None O
and None None O
neoplasia None None O
. None None O

The None None O
role None None O
of None None O
Hes None None O
genes None None O
in None None O
intestinal None None O
development None None O
, None None O
homeostasis None None O
and None None O
tumor None None O
formation None None O
. None None O

Notch None None O
signaling None None O
regulates None None O
intestinal None None O
development None None O
, None None O
homeostasis None None O
and None None O
tumorigenesis None None O
, None None O
but None None O
its None None O
precise None None O
downstream None None O
mechanism None None O
remains None None O
largely None None O
unknown None None O
. None None O

Here None None O
we None None O
found None None O
that None None O
inactivation None None O
of None None O
the None None O
Notch None None O
effectors None None O
Hes1 None None O
, None None O
Hes3 None None O
and None None O
Hes5 None None O
, None None O
but None None O
not None None O
Hes1 None None O
alone None None O
, None None O
led None None O
to None None O
reduced None None O
cell None None O
proliferation None None O
, None None O
increased None None O
secretory None None O
cell None None O
formation None None O
and None None O
altered None None O
intestinal None None O
structures None None O
in None None O
adult None None O
mice None None O
. None None O

However None None O
, None None O
in None None O
Apc None None O
mutation None None O
- None None O
induced None None O
intestinal None None O
tumors None None O
, None None O
inactivation None None O
of None None O
Hes1 None None O
alone None None O
was None None O
sufficient None None O
for None None O
reducing None None O
tumor None None O
cell None None O
proliferation None None O
and None None O
inducing None None O
differentiation None None O
of None None O
tumor None None O
cells None None O
into None None O
all None None O
types None None O
of None None O
intestinal None None O
epithelial None None O
cells None None O
, None None O
but None None O
without None None O
affecting None None O
the None None O
homeostasis None None O
of None None O
normal None None O
crypts None None O
owing None None O
to None None O
genetic None None O
redundancy None None O
. None None O

These None None O
results None None O
indicated None None O
that None None O
Hes None None O
genes None None O
cooperatively None None O
regulate None None O
intestinal None None O
development None None O
and None None O
homeostasis None None O
and None None O
raised None None O
the None None O
possibility None None O
that None None O
Hes1 None None O
is None None O
a None None O
promising None None O
target None None O
to None None O
induce None None O
the None None O
differentiation None None O
of None None O
tumor None None O
cells None None O
. None None O

Fractional None None O
atomic None None O
coordinates None None O
and None None O
isotropic None None O
or None None O
equivalent None None O
isotropic None None O
displacement None None O
parameters None None O
( None None O
A2 None None O
) None None O

x None None O
y None None O
z None None O
Uiso None None O
* None None O
/ None None O
Ueq None None O

C1 None None O
0 None None O
. None None O
3043 None None O
( None None O
3 None None O
) None None O
0 None None O
. None None O
1779 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
79280 None None O
( None None O
13 None None O
) None None O
0 None None O
. None None O
0445 None None O
( None None O
6 None None O
) None None O

C2 None None O
0 None None O
. None None O
4358 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
1697 None None O
( None None O
5 None None O
) None None O
0 None None O
. None None O
84058 None None O
( None None O
17 None None O
) None None O
0 None None O
. None None O
0604 None None O
( None None O
8 None None O
) None None O

H2 None None O
0 None None O
. None None O
4201 None None O
0 None None O
. None None O
1476 None None O
0 None None O
. None None O
8809 None None O
0 None None O
. None None O
072 None None O
* None None O

C3 None None O
0 None None O
. None None O
5911 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
1953 None None O
( None None O
6 None None O
) None None O
0 None None O
. None None O
8269 None None O
( None None O
2 None None O
) None None O
0 None None O
. None None O
0783 None None O
( None None O
12 None None O
) None None O

H3 None None O
0 None None O
. None None O
6811 None None O
0 None None O
. None None O
1914 None None O
0 None None O
. None None O
8584 None None O
0 None None O
. None None O
094 None None O
* None None O

C4 None None O
0 None None O
. None None O
6130 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
2267 None None O
( None None O
6 None None O
) None None O
0 None None O
. None None O
7670 None None O
( None None O
2 None None O
) None None O
0 None None O
. None None O
0773 None None O
( None None O
11 None None O
) None None O

H4 None None O
0 None None O
. None None O
7180 None None O
0 None None O
. None None O
2427 None None O
0 None None O
. None None O
7582 None None O
0 None None O
. None None O
093 None None O
* None None O

C5 None None O
0 None None O
. None None O
4818 None None O
( None None O
5 None None O
) None None O
0 None None O
. None None O
2344 None None O
( None None O
5 None None O
) None None O
0 None None O
. None None O
7202 None None O
( None None O
2 None None O
) None None O
0 None None O
. None None O
0746 None None O
( None None O
10 None None O
) None None O

H5 None None O
0 None None O
. None None O
4980 None None O
0 None None O
. None None O
2547 None None O
0 None None O
. None None O
6798 None None O
0 None None O
. None None O
090 None None O
* None None O

C6 None None O
0 None None O
. None None O
3257 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
2121 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
73293 None None O
( None None O
15 None None O
) None None O
0 None None O
. None None O
0562 None None O
( None None O
7 None None O
) None None O

H6 None None O
0 None None O
. None None O
2360 None None O
0 None None O
. None None O
2200 None None O
0 None None O
. None None O
7015 None None O
0 None None O
. None None O
067 None None O
* None None O

C7 None None O
0 None None O
. None None O
1252 None None O
( None None O
3 None None O
) None None O
0 None None O
. None None O
3838 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
90059 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0400 None None O
( None None O
6 None None O
) None None O

C8 None None O
0 None None O
. None None O
2051 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
5522 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
90920 None None O
( None None O
13 None None O
) None None O
0 None None O
. None None O
0484 None None O
( None None O
6 None None O
) None None O

H8 None None O
0 None None O
. None None O
2132 None None O
0 None None O
. None None O
6288 None None O
0 None None O
. None None O
8758 None None O
0 None None O
. None None O
058 None None O
* None None O

C9 None None O
0 None None O
. None None O
2725 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
6041 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
96827 None None O
( None None O
15 None None O
) None None O
0 None None O
. None None O
0558 None None O
( None None O
7 None None O
) None None O

C10 None None O
0 None None O
. None None O
2645 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
4935 None None O
( None None O
4 None None O
) None None O
1 None None O
. None None O
01861 None None O
( None None O
14 None None O
) None None O
0 None None O
. None None O
0590 None None O
( None None O
8 None None O
) None None O

H10 None None O
0 None None O
. None None O
3122 None None O
0 None None O
. None None O
5293 None None O
1 None None O
. None None O
0582 None None O
0 None None O
. None None O
071 None None O
* None None O

C11 None None O
0 None None O
. None None O
1830 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
3278 None None O
( None None O
4 None None O
) None None O
1 None None O
. None None O
00819 None None O
( None None O
13 None None O
) None None O
0 None None O
. None None O
0534 None None O
( None None O
7 None None O
) None None O

C12 None None O
0 None None O
. None None O
1118 None None O
( None None O
3 None None O
) None None O
0 None None O
. None None O
2699 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
95062 None None O
( None None O
12 None None O
) None None O
0 None None O
. None None O
0480 None None O
( None None O
6 None None O
) None None O

H12 None None O
0 None None O
. None None O
0561 None None O
0 None None O
. None None O
1577 None None O
0 None None O
. None None O
9451 None None O
0 None None O
. None None O
058 None None O
* None None O

N1 None None O
0 None None O
. None None O
0494 None None O
( None None O
3 None None O
) None None O
0 None None O
. None None O
3297 None None O
( None None O
3 None None O
) None None O
0 None None O
. None None O
84009 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0441 None None O
( None None O
5 None None O
) None None O

H1N None None O
0 None None O
. None None O
038 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
418 None None O
( None None O
3 None None O
) None None O
0 None None O
. None None O
8138 None None O
( None None O
12 None None O
) None None O
0 None None O
. None None O
053 None None O
* None None O

O1 None None O
- None None O
0 None None O
. None None O
0021 None None O
( None None O
3 None None O
) None None O
0 None None O
. None None O
1298 None None O
( None None O
3 None None O
) None None O
0 None None O
. None None O
74998 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0527 None None O
( None None O
5 None None O
) None None O

O2 None None O
0 None None O
. None None O
1112 None None O
( None None O
3 None None O
) None None O
- None None O
0 None None O
. None None O
0066 None None O
( None None O
3 None None O
) None None O
0 None None O
. None None O
85135 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0574 None None O
( None None O
6 None None O
) None None O

Cl1 None None O
0 None None O
. None None O
37237 None None O
( None None O
16 None None O
) None None O
0 None None O
. None None O
81541 None None O
( None None O
13 None None O
) None None O
0 None None O
. None None O
97944 None None O
( None None O
5 None None O
) None None O
0 None None O
. None None O
0927 None None O
( None None O
4 None None O
) None None O

Cl2 None None O
0 None None O
. None None O
16462 None None O
( None None O
15 None None O
) None None O
0 None None O
. None None O
18752 None None O
( None None O
15 None None O
) None None O
1 None None O
. None None O
07089 None None O
( None None O
4 None None O
) None None O
0 None None O
. None None O
0834 None None O
( None None O
4 None None O
) None None O

S1 None None O
0 None None O
. None None O
10584 None None O
( None None O
7 None None O
) None None O
0 None None O
. None None O
14095 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
80800 None None O
( None None O
3 None None O
) None None O
0 None None O
. None None O
0412 None None O
( None None O
3 None None O
) None None O

Members None None O
of None None O
the None None O
src None None O
and None None O
ras None None O
oncogene None None O
families None None O
supplant None None O
the None None O
epidermal None None O
growth None None O
factor None None O
requirement None None O
of None None O
BALB None None O
/ None None O
MK None None O
- None None O
2 None None O
keratinocytes None None O
and None None O
induce None None O
distinct None None O
alterations None None O
in None None O
their None None O
terminal None None O
differentiation None None O
program None None O
. None None O

BALB None None O
- None None O
/ None None O
MK None None O
- None None O
2 None None O
mouse None None O
epidermal None None O
keratinocytes None None O
required None None O
epidermal None None O
growth None None O
factor None None O
for None None O
proliferation None None O
and None None O
terminally None None O
differentiated None None O
in None None O
response None None O
to None None O
high None None O
Ca2 None None O
+ None None O
concentration None None O
. None None O

Infection None None O
with None None O
retroviruses None None O
containing None None O
transforming None None O
genes None None O
of None None O
the None None O
src None None O
and None None O
ras None None O
oncogene None None O
families None None O
led None None O
to None None O
rapid None None O
loss None None O
of None None O
epidermal None None O
growth None None O
factor None None O
dependence None None O
, None None O
in None None O
some None None O
cases None None O
, None None O
accompanied None None O
by None None O
alterations None None O
in None None O
cellular None None O
morphology None None O
. None None O

The None None O
virus None None O
- None None O
altered None None O
cells None None O
continued None None O
to None None O
proliferate None None O
in None None O
the None None O
presence None None O
of None None O
high None None O
levels None None O
of None None O
extracellular None None O
calcium None None O
but None None O
exhibited None None O
alterations None None O
in None None O
normal None None O
keratinocyte None None O
terminal None None O
differentiation None None O
that None None O
appear None None O
to None None O
be None None O
specific None None O
to None None O
the None None O
particular None None O
oncogene None None O
. None None O

These None None O
alterations None None O
bore None None O
similarities None None O
to None None O
abnormalities None None O
in None None O
differentiation None None O
observed None None O
in None None O
naturally None None O
occurring None None O
squamous None None O
epithelial None None O
malignancies None None O
. None None O

Application None None O
of None None O
clonal None None O
analysis None None O
. None None O

Differential None None O
diagnosis None None O
for None None O
synchronous None None O
primary None None O
ovarian None None O
and None None O
endometrial None None O
cancers None None O
and None None O
metastatic None None O
cancer None None O
. None None O

Simultaneous None None O
involvement None None O
of None None O
the None None O
endometrium None None O
and None None O
the None None O
ovary None None O
by None None O
carcinoma None None O
is None None O
a None None O
familiar None None O
problem None None O
in None None O
the None None O
routine None None O
practice None None O
of None None O
surgical None None O
pathology None None O
. None None O

Such None None O
cases None None O
may None None O
be None None O
considered None None O
either None None O
examples None None O
of None None O
a None None O
single None None O
primary None None O
carcinoma None None O
with None None O
metastasis None None O
or None None O
as None None O
synchronous None None O
primary None None O
neoplasms None None O
. None None O

The None None O
distinction None None O
between None None O
these None None O
two None None O
possibilities None None O
is None None O
made None None O
based None None O
on None None O
clinicopathologic None None O
observations None None O
, None None O
and None None O
therefore None None O
may None None O
not None None O
be None None O
definitive None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
the None None O
authors None None O
used None None O
molecular None None O
techniques None None O
to None None O
analyze None None O
the None None O
clonal None None O
composition None None O
of None None O
five None None O
cases None None O
of None None O
concurrent None None O
adenocarcinomas None None O
of None None O
the None None O
endometrium None None O
and None None O
ovary None None O
that None None O
were None None O
clinicopathologically None None O
diagnosed None None O
as None None O
synchronous None None O
primary None None O
tumors None None O
. None None O

Patterns None None O
of None None O
X None None O
- None None O
chromosome None None O
inactivation None None O
, None None O
mutations None None O
in None None O
the None None O
K None None O
- None None O
ras None None O
gene None None O
, None None O
mutations None None O
or None None O
allelic None None O
loss None None O
of None None O
the None None O
p53 None None O
gene None None O
, None None O
or None None O
human None None O
papillomavirus None None O
detection None None O
were None None O
identical None None O
in None None O
both None None O
endometrial None None O
and None None O
ovarian None None O
lesions None None O
in None None O
three None None O
of None None O
the None None O
cases None None O
suggesting None None O
that None None O
those None None O
three None None O
cases None None O
represented None None O
single None None O
primary None None O
tumors None None O
with None None O
metastases None None O
. None None O

In None None O
both None None O
of None None O
the None None O
other None None O
two None None O
cases None None O
, None None O
the None None O
patterns None None O
of None None O
X None None O
- None None O
chromosome None None O
inactivation None None O
clearly None None O
demonstrated None None O
the None None O
presence None None O
of None None O
independent None None O
primary None None O
tumors None None O
. None None O

The None None O
application None None O
of None None O
molecular None None O
technology None None O
may None None O
play None None O
an None None O
important None None O
role None None O
for None None O
the None None O
differential None None O
diagnosis None None O
between None None O
synchronous None None O
primary None None O
carcinomas None None O
and None None O
a None None O
single None None O
carcinoma None None O
with None None O
metastasis None None O
. None None O

Building None None O
the None None O
vertebrate None None O
vasculature None None O
: None None O
research None None O
is None None O
going None None O
swimmingly None None O
. None None O

The None None O
vertebrate None None O
vasculature None None O
develops None None O
in None None O
remarkably None None O
similar None None O
fashion None None O
in None None O
all None None O
vertebrates None None O
. None None O

A None None O
cohort None None O
of None None O
unspecified None None O
mesodermal None None O
cells None None O
differentiates None None O
into None None O
primitive None None O
endothelial None None O
cells None None O
, None None O
which None None O
migrate None None O
to None None O
and None None O
occupy None None O
positions None None O
within None None O
the None None O
stereotypical None None O
blueprint None None O
of None None O
the None None O
primitive None None O
vasculature None None O
. None None O

Once None None O
in None None O
position None None O
, None None O
these None None O
cells None None O
coalesce None None O
and None None O
form None None O
cords None None O
, None None O
which None None O
lumenize None None O
and None None O
become None None O
ensheathed None None O
by None None O
supporting None None O
pericytes None None O
and None None O
smooth None None O
muscle None None O
cells None None O
. None None O

This None None O
primitive None None O
vascular None None O
network None None O
is None None O
extensively None None O
remodeled None None O
in None None O
some None None O
places None None O
, None None O
and None None O
expanded None None O
by None None O
sprouting None None O
in None None O
others None None O
. None None O

Various None None O
studies None None O
using None None O
the None None O
mouse None None O
, None None O
quail None None O
/ None None O
chick None None O
, None None O
and None None O
frog None None O
have None None O
uncovered None None O
a None None O
number None None O
of None None O
signals None None O
that None None O
guide None None O
these None None O
complex None None O
processes None None O
but None None O
many None None O
gaps None None O
still None None O
exist None None O
in None None O
our None None O
understanding None None O
of None None O
the None None O
mechanisms None None O
by None None O
which None None O
the None None O
embryonic None None O
vasculature None None O
is None None O
built None None O
. None None O

Because None None O
many None None O
questions None None O
will None None O
require None None O
in None None O
vivo None None O
studies None None O
to None None O
be None None O
properly None None O
addressed None None O
, None None O
the None None O
zebrafish None None O
, None None O
with None None O
its None None O
unique None None O
accessibility None None O
to None None O
analysis None None O
by None None O
combined None None O
embryological None None O
, None None O
molecular None None O
, None None O
and None None O
genetic None None O
methods None None O
, None None O
should None None O
prove None None O
invaluable None None O
in None None O
identifying None None O
new None None O
molecules None None O
involved None None O
in None None O
blood None None O
vessel None None O
development None None O
and None None O
integrating None None O
pathways None None O
that None None O
influence None None O
embryonic None None O
blood None None O
vessel None None O
formation None None O
. None None O

Combined None None O
topical None None O
fluconazole None None O
and None None O
corticosteroid None None O
treatment None None O
for None None O
experimental None None O
Candida None None O
albicans None None O
keratomycosis None None O
. None None O

PURPOSE None None O
: None None O
To None None O
determine None None O
the None None O
most None None O
efficient None None O
time None None O
point None None O
and None None O
concentration None None O
of None None O
topical None None O
corticosteroids None None O
in None None O
Candida None None O
albicans None None O
keratitis None None O
treated None None O
with None None O
fluconazole None None O
. None None O

METHODS None None O
: None None O
Corneas None None O
of None None O
105 None None O
rabbits None None O
were None None O
infected None None O
with None None O
viable None None O
yeast None None O
cells None None O
of None None O
C None None O
. None None O
albicans None None O
( None None O
2 None None O
. None None O
5 None None O
x None None O
10 None None O
( None None O
5 None None O
) None None O
) None None O
. None None O

After None None O
a None None O
48 None None O
- None None O
hour None None O
incubation None None O
period None None O
, None None O
seven None None O
groups None None O
of None None O
animals None None O
were None None O
treated None None O
for None None O
21 None None O
days None None O
with None None O
fluconazole None None O
, None None O
with None None O
group None None O
I None None O
acting None None O
as None None O
a None None O
control None None O
, None None O
and None None O
groups None None O
II None None O
to None None O
VII None None O
receiving None None O
adjunct None None O
therapy None None O
with None None O
the None None O
corticosteroid None None O
prednisolone None None O
( None None O
5 None None O
or None None O
10 None None O
times None None O
daily None None O
; None None O
3 None None O
, None None O
9 None None O
, None None O
or None None O
15 None None O
days None None O
after None None O
infection None None O
) None None O
. None None O

The None None O
degree None None O
of None None O
corneal None None O
infiltration None None O
, None None O
ulceration None None O
, None None O
corneal None None O
clouding None None O
, None None O
hypopyon None None O
, None None O
conjunctivitis None None O
, None None O
neovascularization None None O
, None None O
and None None O
corneal None None O
perforation None None O
was None None O
monitored None None O
over None None O
a None None O
24 None None O
- None None O
day None None O
period None None O
, None None O
as None None O
well None None O
as None None O
recultivation None None O
and None None O
resistance None None O
to None None O
fluconazole None None O
of None None O
the None None O
C None None O
. None None O
albicans None None O
pathogen None None O
. None None O

RESULTS None None O
: None None O
The None None O
control None None O
group None None O
showed None None O
the None None O
highest None None O
level None None O
of None None O
corneal None None O
clouding None None O
and None None O
neovascularization None None O
. None None O

In None None O
comparison None None O
, None None O
by None None O
day None None O
24 None None O
, None None O
the None None O
majority None None O
of None None O
groups None None O
also None None O
treated None None O
with None None O
prednisolone None None O
displayed None None O
significantly None None O
less None None O
corneal None None O
clouding None None O
and None None O
neovascularization None None O
. None None O

An None None O
immediate None None O
decrease None None O
in None None O
corneal None None O
clouding None None O
was None None O
observed None None O
in None None O
groups None None O
treated None None O
with None None O
additional None None O
low None None O
- None None O
or None None O
high None None O
- None None O
dose None None O
prednisolone None None O
from None None O
day None None O
9 None None O
after None None O
inoculation None None O
. None None O

After None None O
additional None None O
prednisolone None None O
treatment None None O
from None None O
day None None O
9 None None O
or None None O
15 None None O
after None None O
inoculation None None O
, None None O
no None None O
significant None None O
difference None None O
was None None O
detected None None O
in None None O
the None None O
recultivation None None O
rate None None O
of None None O
C None None O
. None None O
albicans None None O
compared None None O
with None None O
the None None O
control None None O
. None None O

Early None None O
administration None None O
of None None O
prednisolone None None O
( None None O
day None None O
3 None None O
, None None O
low None None O
and None None O
high None None O
dose None None O
) None None O
resulted None None O
in None None O
the None None O
recultivation None None O
of None None O
significantly None None O
more None None O
C None None O
. None None O
albicans None None O
. None None O

CONCLUSIONS None None O
: None None O
Fluconazole None None O
plus None None O
adjunct None None O
high None None O
- None None O
dose None None O
prednisolone None None O
treatment None None O
was None None O
most None None O
effective None None O
when None None O
administered None None O
9 None None O
days None None O
after None None O
infection None None O
. None None O

The None None O
delayed None None O
application None None O
of None None O
corticosteroids None None O
after None None O
treatment None None O
with None None O
antimycotic None None O
drugs None None O
in None None O
cases None None O
of None None O
fungal None None O
keratitis None None O
is None None O
therefore None None O
not None None O
contraindicated None None O
and None None O
may None None O
be None None O
beneficial None None O
in None None O
patients None None O
. None None O

Correlation None None O
matrix None None O
for None None O
ear None None O
( None None O
E None None O
) None None O
traits None None O
in None None O
2006 None None O
; None None O
data None None O
from None None O
water None None O
stress None None O
plots None None O
( None None O
lower None None O
left None None O
) None None O
and None None O
well None None O
- None None O
watered None None O
plots None None O
( None None O
upper None None O
right None None O
) None None O
of None None O
350 None None O
maize None None O
inbreds None None O

Tonometry None None O
in None None O
normal None None O
and None None O
scarred None None O
corneas None None O
, None None O
and None None O
in None None O
postkeratoplasty None None O
eyes None None O
: None None O
a None None O
comparative None None O
study None None O
of None None O
the None None O
Goldmann None None O
, None None O
the None None O
ProTon None None O
and None None O
the None None O
Schiotz None None O
tonometers None None O
. None None O

PURPOSE None None O
: None None O

Clinical None None O
comparison None None O
of None None O
intraocular None None O
pressure None None O
( None None O
IOP None None O
) None None O
measured None None O
with None None O
the None None O
Goldmann None None O
applanation None None O
tonometer None None O
( None None O
GAT None None O
) None None O
, None None O
the None None O
ProTon None None O
tonometer None None O
( None None O
PT None None O
) None None O
, None None O
and None None O
the None None O
Schiotz None None O
tonometer None None O
( None None O
ST None None O
) None None O
, None None O
in None None O
normal None None O
eyes None None O
, None None O
eyes None None O
with None None O
scarred None None O
corneas None None O
and None None O
postkeratoplasty None None O
eyes None None O
. None None O

MATERIAL None None O
AND None None O
METHODS None None O
: None None O

The None None O
IOP None None O
readings None None O
with None None O
GAT None None O
, None None O
PT None None O
, None None O
and None None O
ST None None O
were None None O
compared None None O
in None None O
125 None None O
eyes None None O
with None None O
normal None None O
corneas None None O
( None None O
Group None None O
A None None O
) None None O
, None None O
17 None None O
eyes None None O
with None None O
scarred None None O
corneas None None O
( None None O
Group None None O
B None None O
) None None O
, None None O
and None None O
in None None O
21 None None O
postkeratoplasty None None O
eyes None None O
( None None O
Group None None O
C None None O
) None None O
. None None O

The None None O
data None None O
were None None O
statistically None None O
analysed None None O
at None None O
95 None None O
% None None O
confidence None None O
interval None None O
; None None O
linear None None O
regression None None O
analysis None None O
and None None O
paired None None O
t None None O
- None None O
test None None O
were None None O
done None None O
. None None O

RESULTS None None O
: None None O

The None None O
mean None None O
differences None None O
and None None O
their None None O
standard None None O
deviation None None O
[ None None O
SD None None O
] None None O
between None None O
GAT None None O
and None None O
PT None None O
readings None None O
, None None O
and None None O
GAT None None O
and None None O
ST None None O
readings None None O
respectively None None O
were None None O
: None None O
[ None None O
1 None None O
] None None O
in None None O
Group None None O
A None None O
: None None O
- None None O
0 None None O
. None None O
23 None None O
[ None None O
SD None None O
2 None None O
. None None O
75 None None O
] None None O
mmHg None None O
and None None O
+ None None O
0 None None O
. None None O
24 None None O
[ None None O
SD None None O
3 None None O
. None None O
18 None None O
] None None O
mmHg None None O
respectively None None O
; None None O
[ None None O
2 None None O
] None None O
in None None O
Group None None O
B None None O
: None None O
- None None O
1 None None O
. None None O
8 None None O
[ None None O
SD None None O
12 None None O
. None None O
67 None None O
] None None O
mmHg None None O
and None None O
- None None O
4 None None O
. None None O
5 None None O
[ None None O
SD None None O
9 None None O
. None None O
95 None None O
mmHg None None O
; None None O
and None None O
[ None None O
3 None None O
] None None O
in None None O
Group None None O
C None None O
: None None O
+ None None O
0 None None O
. None None O
24 None None O
[ None None O
SD None None O
8 None None O
. None None O
72 None None O
] None None O
mmHg None None O
and None None O
- None None O
0 None None O
. None None O
12 None None O
[ None None O
SD None None O
8 None None O
. None None O
7 None None O
] None None O
mmHg None None O
. None None O

They None None O
were None None O
not None None O
statistically None None O
significant None None O
. None None O

In None None O
Group None None O
A None None O
the None None O
95 None None O
% None None O
confidence None None O
interval None None O
between None None O
GAT None None O
and None None O
PT None None O
readings None None O
was None None O
- None None O
5 None None O
. None None O
27 None None O
mmHg None None O
to None None O
5 None None O
. None None O
73 None None O
mmHg None None O
, None None O
and None None O
between None None O
GAT None None O
and None None O
ST None None O
readings None None O
, None None O
- None None O
6 None None O
. None None O
12 None None O
mmHg None None O
to None None O
6 None None O
. None None O
59 None None O
mmHg None None O
. None None O

Ninety None None O
six None None O
[ None None O
77 None None O
% None None O
] None None O
eyes None None O
with None None O
the None None O
PT None None O
and None None O
84 None None O
[ None None O
69 None None O
% None None O
] None None O
eyes None None O
with None None O
ST None None O
measurements None None O
were None None O
within None None O
3 None None O
mmHg None None O
of None None O
GAT None None O
pressure None None O
. None None O

The None None O
correlation None None O
coefficients None None O
[ None None O
r None None O
] None None O
for None None O
PT None None O
and None None O
ST None None O
were None None O
0 None None O
. None None O
93 None None O
[ None None O
P None None O
= None None O
0 None None O
. None None O
0000 None None O
] None None O
and None None O
0 None None O
. None None O
88 None None O
[ None None O
P None None O
= None None O
0 None None O
. None None O
0000 None None O
] None None O
respectively None None O
. None None O

In None None O
Group None None O
B None None O
95 None None O
% None None O
confidence None None O
interval None None O
between None None O
GAT None None O
and None None O
PT None None O
readings None None O
was None None O
- None None O
27 None None O
. None None O
17 None None O
mmHg None None O
to None None O
23 None None O
. None None O
51 None None O
mmHg None None O
, None None O
and None None O
between None None O
GAT None None O
and None None O
ST None None O
measurement None None O
, None None O
- None None O
24 None None O
. None None O
37 None None O
mmHg None None O
to None None O
15 None None O
. None None O
44 None None O
mmHg None None O
. None None O

The None None O
correlation None None O
coefficients None None O
[ None None O
r None None O
] None None O
for None None O
the None None O
PT None None O
and None None O
ST None None O
were None None O
0 None None O
. None None O
112 None None O
[ None None O
P None None O
= None None O
0 None None O
. None None O
660 None None O
] None None O
and None None O
0 None None O
. None None O
630 None None O
[ None None O
P None None O
= None None O
0 None None O
. None None O
006 None None O
] None None O
respectively None None O
. None None O

In None None O
group None None O
C None None O
, None None O
the None None O
95 None None O
% None None O
confidence None None O
interval None None O
between None None O
GAT None None O
and None None O
PT None None O
measurements None None O
was None None O
- None None O
17 None None O
. None None O
20 None None O
mmHg None None O
to None None O
17 None None O
. None None O
67 None None O
mmHg None None O
, None None O
and None None O
between None None O
GAT None None O
and None None O
ST None None O
measurements None None O
, None None O
- None None O
17 None None O
. None None O
51 None None O
mmHg None None O
to None None O
17 None None O
. None None O
27 None None O
mmHg None None O
. None None O

The None None O
correlation None None O
coefficients None None O
[ None None O
r None None O
] None None O
for None None O
the None None O
PT None None O
and None None O
the None None O
ST None None O
were None None O
0 None None O
. None None O
780 None None O
[ None None O
P None None O
= None None O
0 None None O
. None None O
0000 None None O
] None None O
and None None O
0 None None O
. None None O
740 None None O
[ None None O
P None None O
= None None O
0 None None O
. None None O
0001 None None O
] None None O
respectively None None O
. None None O

CONCLUSIONS None None O
: None None O

In None None O
clinical None None O
practice None None O
PT None None O
appears None None O
to None None O
have None None O
a None None O
higher None None O
level None None O
of None None O
accuracy None None O
than None None O
ST None None O
in None None O
normal None None O
corneas None None O
. None None O

In None None O
scarred None None O
corneas None None O
and None None O
post None None O
- None None O
penetrating None None O
keratoplasty None None O
eyes None None O
, None None O
because None None O
of None None O
high None None O
SD None None O
for None None O
mean None None O
differences None None O
and None None O
wide None None O
confidence None None O
interval None None O
of None None O
95 None None O
% None None O
, None None O
both None None O
PT None None O
and None None O
ST None None O
are None None O
inaccurate None None O
in None None O
measuring None None O
IOP None None O
as None None O
compared None None O
to None None O
GAT None None O
in None None O
such None None O
eyes None None O
. None None O

The None None O
Acute None None O
Dialysis None None O
Quality None None O
Initiative None None O
- None None O
- None None O
part None None O
IV None None O
: None None O
membranes None None O
for None None O
CRRT None None O
. None None O

The None None O
extracorporeal None None O
membrane None None O
used None None O
in None None O
a None None O
continuous None None O
renal None None O
replacement None None O
therapy None None O
( None None O
CRRT None None O
) None None O
for None None O
the None None O
treatment None None O
of None None O
a None None O
critically None None O
ill None None O
patient None None O
with None None O
acute None None O
renal None None O
failure None None O
( None None O
ARF None None O
) None None O
is None None O
vitally None None O
important None None O
for None None O
several None None O
reasons None None O
, None None O
including None None O
its None None O
influence None None O
on None None O
biocompatibility None None O
and None None O
filter None None O
performance None None O
. None None O

The None None O
clinical None None O
relevance None None O
of None None O
membrane None None O
- None None O
related None None O
biocompatibility None None O
markers None None O
traditionally None None O
used None None O
in None None O
chronic None None O
hemodialysis None None O
remains None None O
unclear None None O
in None None O
CRRT None None O
. None None O

Numerous None None O
approaches None None O
may None None O
be None None O
used None None O
to None None O
assess None None O
membrane None None O
and None None O
filter None None O
performance None None O
in None None O
CRRT None None O
, None None O
but None None O
no None None O
specific None None O
methodology None None O
is None None O
accepted None None O
widely None None O
at None None O
present None None O
. None None O

Although None None O
a None None O
potential None None O
benefit None None O
of None None O
certain None None O
membranes None None O
used None None O
for None None O
CRRT None None O
is None None O
adsorptive None None O
removal None None O
of None None O
inflammatory None None O
mediators None None O
, None None O
this None None O
issue None None O
has None None O
not None None O
been None None O
assessed None None O
carefully None None O
in None None O
well None None O
- None None O
designed None None O
clinical None None O
trials None None O
. None None O

These None None O
and None None O
other None None O
issues None None O
should None None O
be None None O
the None None O
subject None None O
of None None O
future None None O
clinical None None O
research None None O
efforts None None O
. None None O

2 None None O
. None None O

Methods None None O

We None None O
conducted None None O
a None None O
systematic None None O
study None None O
of None None O
patients None None O
hospitalized None None O
from None None O
August None None O
2006 None None O
until None None O
September None None O
2007 None None O
at None None O
the None None O
Yerevan None None O
City None None O
and None None O
the None None O
Republican None None O
Dispensaries None None O
, None None O
the None None O
two None None O
reference None None O
TB None None O
hospitals None None O
in None None O
Armenia None None O
. None None O

Following None None O
focus None None O
group None None O
discussions None None O
and None None O
pilot None None O
testing None None O
to None None O
refine None None O
the None None O
survey None None O
instrument None None O
, None None O
patient None None O
interviews None None O
began None None O
in None None O
the None None O
fall None None O
of None None O
2006 None None O
and None None O
were None None O
conducted None None O
by None None O
trained None None O
students None None O
in None None O
the None None O
public None None O
health None None O
program None None O
of None None O
the None None O
American None None O
University None None O
of None None O
Armenia None None O
. None None O

Students None None O
received None None O
training None None O
by None None O
the None None O
study None None O
designer None None O
( None None O
SO None None O
) None None O
on None None O
principles None None O
of None None O
interview None None O
ethics None None O
and None None O
interviewing None None O
processes None None O
. None None O

Most None None O
patient None None O
interviews None None O
were None None O
conducted None None O
at None None O
the None None O
Republican None None O
Dispensary None None O
in None None O
Abovian None None O
Marz None None O
, None None O
the None None O
national None None O
TB None None O
diagnostic None None O
and None None O
treatment None None O
facility None None O
to None None O
which None None O
all None None O
suspected None None O
cases None None O
throughout None None O
the None None O
country None None O
are None None O
referred None None O
for None None O
diagnostic None None O
confirmation None None O
. None None O

In None None O
the None None O
past None None O
several None None O
years None None O
, None None O
strong None None O
financial None None O
support None None O
has None None O
been None None O
provided None None O
to None None O
Armenia None None O
by None None O
a None None O
number None None O
of None None O
international None None O
organizations None None O
, None None O
such None None O
as None None O
the None None O
German None None O
Gesellschaft None None O
fur None None O
Technische None None O
Zusammenarbeit None None O
( None None O
GTZ None None O
) None None O
, None None O
the None None O
Global None None O
Fund None None O
to None None O
Fight None None O
AIDS None None O
, None None O
Tuberculosis None None O
and None None O
Malaria None None O
, None None O
and None None O
the None None O
Red None None O
Cross None None O
, None None O
which None None O
has None None O
enabled None None O
both None None O
microscopic None None O
and None None O
culture None None O
examinations None None O
for None None O
each None None O
TB None None O
case None None O
to None None O
be None None O
performed None None O
at None None O
the None None O
National None None O
Reference None None O
Laboratory None None O
located None None O
at None None O
the None None O
Republican None None O
TB None None O
Dispensary None None O
. None None O

All None None O
culture None None O
- None None O
confirmed None None O
TB None None O
cases None None O
are None None O
admitted None None O
as None None O
in None None O
- None None O
patients None None O
while None None O
undergoing None None O
the None None O
initial None None O
phase None None O
of None None O
therapy None None O
. None None O

Because None None O
all None None O
confirmed None None O
TB None None O
patients None None O
in None None O
Armenia None None O
are None None O
referred None None O
to None None O
one None None O
of None None O
these None None O
dispensaries None None O
for None None O
treatment None None O
, None None O
this None None O
population None None O
represents None None O
all None None O
known None None O
TB None None O
cases None None O
in None None O
the None None O
country None None O
. None None O

Therefore None None O
, None None O
all None None O
culture None None O
- None None O
confirmed None None O
TB None None O
in None None O
- None None O
patients None None O
present None None O
at None None O
the None None O
time None None O
of None None O
the None None O
interviewer None None O
visits None None O
were None None O
eligible None None O
for None None O
inclusion None None O
in None None O
the None None O
study None None O
( None None O
the None None O
study None None O
group None None O
included None None O
both None None O
new None None O
and None None O
relapsed None None O
patients None None O
) None None O
. None None O

Our None None O
systematic None None O
sample None None O
of None None O
the None None O
inpatient None None O
TB None None O
population None None O
- None None O
- None None O
in None None O
which None None O
interviewers None None O
visited None None O
every None None O
hospital None None O
room None None O
to None None O
identify None None O
patients None None O
willing None None O
to None None O
participate None None O
- None None O
- None None O
yielded None None O
a None None O
participation None None O
rate None None O
of None None O
approximately None None O
80 None None O
% None None O
( None None O
a None None O
total None None O
of None None O
240 None None O
patients None None O
) None None O
. None None O

Interviewers None None O
collected None None O
demographic None None O
information None None O
and None None O
asked None None O
each None None O
patient None None O
to None None O
recall None None O
when None None O
they None None O
first None None O
began None None O
to None None O
feel None None O
ill None None O
, None None O
what None None O
symptoms None None O
they None None O
experienced None None O
, None None O
how None None O
long None None O
after None None O
symptom None None O
onset None None O
they None None O
waited None None O
to None None O
see None None O
a None None O
doctor None None O
, None None O
their None None O
reasons None None O
for None None O
delaying None None O
medical None None O
evaluation None None O
, None None O
the None None O
type None None O
of None None O
facility None None O
at None None O
which None None O
they None None O
first None None O
sought None None O
care None None O
, None None O
the None None O
initial None None O
diagnosis None None O
, None None O
if None None O
they None None O
had None None O
been None None O
referred None None O
for None None O
further None None O
evaluation None None O
, None None O
and None None O
their None None O
adherence None None O
to None None O
treatment None None O
once None None O
diagnosed None None O
with None None O
TB None None O
. None None O

In None None O
2006 None None O
, None None O
129 None None O
of None None O
the None None O
planned None None O
250 None None O
surveys None None O
were None None O
completed None None O
. None None O

Data None None O
collection None None O
resumed None None O
in None None O
the None None O
fall None None O
of None None O
2007 None None O
and None None O
a None None O
total None None O
of None None O
240 None None O
interviews None None O
were None None O
conducted None None O
. None None O

Ectopic None None O
localization None None O
of None None O
mitochondrial None None O
ATP None None O
synthase None None O
: None None O
a None None O
target None None O
for None None O
anti None None O
- None None O
angiogenesis None None O
intervention None None O
? None None O

A None None O
receptor None None O
for None None O
angiostatin None None O
was None None O
identified None None O
on None None O
the None None O
surface None None O
of None None O
endothelial None None O
cells None None O
as None None O
F None None O
( None None O
1 None None O
) None None O
- None None O
F None None O
( None None O
0 None None O
) None None O
ATP None None O
synthase None None O
( None None O
Moser None None O
et None None O
al None None O
. None None O
, None None O
1999 None None O
) None None O
. None None O

Proc None None O
. None None O

Natl None None O
. None None O

Acad None None O
. None None O

Sci None None O
. None None O

U None None O
. None None O
S None None O
. None None O
A None None O
. None None O

96 None None O
, None None O
2811 None None O
- None None O
2816 None None O
. None None O

This None None O
ectopic None None O
ATP None None O
synthase None None O
catalyzes None None O
ATP None None O
synthesis None None O
and None None O
is None None O
inhibited None None O
by None None O
angiostatin None None O
over None None O
a None None O
wide None None O
pH None None O
range None None O
. None None O

Endothelial None None O
cells None None O
grown None None O
at None None O
normal None None O
pH None None O
suffer None None O
no None None O
ill None None O
effects None None O
from None None O
this None None O
angiostatin None None O
- None None O
mediated None None O
inhibition None None O
of None None O
ATP None None O
synthase None None O
, None None O
whereas None None O
endothelial None None O
cells None None O
grown None None O
at None None O
low None None O
, None None O
tumor None None O
- None None O
like None None O
extracellular None None O
pH None None O
cannot None None O
maintain None None O
a None None O
normal None None O
intracellular None None O
pH None None O
and None None O
die None None O
. None None O

Angiostatin None None O
inhibits None None O
both None None O
ATP None None O
synthesis None None O
and None None O
ATP None None O
hydrolysis None None O
( None None O
Moser None None O
et None None O
al None None O
. None None O
, None None O
2001 None None O
) None None O
and None None O
interferes None None O
with None None O
intracellular None None O
pH None None O
regulation None None O
( None None O
Wahl None None O
and None None O
Grant None None O
, None None O
2002 None None O
; None None O
Wahl None None O
et None None O
al None None O
. None None O
, None None O
2002 None None O
) None None O
. None None O

Although None None O
angiostatin None None O
administered None None O
intravenously None None O
is None None O
cleared None None O
from None None O
the None None O
circulation None None O
in None None O
a None None O
matter None None O
of None None O
minutes None None O
, None None O
angiostatin None None O
- None None O
mimetics None None O
that None None O
are None None O
more None None O
stable None None O
have None None O
potential None None O
for None None O
clinical None None O
application None None O
. None None O

An None None O
angiostatin None None O
- None None O
mimetic None None O
activity None None O
has None None O
recently None None O
been None None O
observed None None O
using None None O
a None None O
polyclonal None None O
antibody None None O
against None None O
the None None O
beta None None O
catalytic None None O
subunit None None O
of None None O
ATP None None O
synthase None None O
. None None O

In None None O
order None None O
to None None O
explore None None O
the None None O
mechanism None None O
of None None O
action None None O
of None None O
angiostatin None None O
and None None O
its None None O
mimetics None None O
, None None O
further None None O
work None None O
needs None None O
to None None O
be None None O
done None None O
to None None O
evaluate None None O
clinical None None O
applicability None None O
, None None O
specificity None None O
, None None O
and None None O
contraindications None None O
for None None O
this None None O
class None None O
of None None O
therapeutics None None O
. None None O

Impaired None None O
coronary None None O
collateral None None O
vessel None None O
development None None O
in None None O
patients None None O
with None None O
proliferative None None O
diabetic None None O
retinopathy None None O
. None None O

BACKGROUND None None O
: None None O
Diabetic None None O
patients None None O
have None None O
been None None O
reported None None O
to None None O
have None None O
impaired None None O
coronary None None O
collateral None None O
vessel None None O
growth None None O
, None None O
although None None O
they None None O
have None None O
excessive None None O
neovascularization None None O
in None None O
the None None O
retina None None O
. None None O

HYPOTHESIS None None O
: None None O
This None None O
study None None O
was None None O
designed None None O
to None None O
compare None None O
coronary None None O
collateral None None O
circulation None None O
( None None O
CCC None None O
) None None O
in None None O
patients None None O
with None None O
proliferative None None O
diabetic None None O
retinopathy None None O
( None None O
PDR None None O
) None None O
with None None O
that None None O
in None None O
patients None None O
without None None O
DR None None O
. None None O

METHODS None None O
: None None O
Ninety None None O
diabetic None None O
patients None None O
with None None O
chronic None None O
total None None O
occlusion None None O
in None None O
at None None O
least None None O
one None None O
major None None O
epicardial None None O
coronary None None O
artery None None O
were None None O
enrolled None None O
in None None O
the None None O
study None None O
. None None O

Groups None None O
1 None None O
and None None O
2 None None O
consisted None None O
of None None O
48 None None O
patients None None O
without None None O
DR None None O
and None None O
42 None None O
patients None None O
with None None O
PDR None None O
, None None O
respectively None None O
. None None O

Coronary None None O
collateral None None O
circulation None None O
( None None O
CCC None None O
) None None O
was None None O
analyzed None None O
according None None O
to None None O
the None None O
Rentrop None None O
system None None O
. None None O

Each None None O
group None None O
was None None O
also None None O
divided None None O
into None None O
two None None O
subgroups None None O
according None None O
to None None O
poor None None O
and None None O
good None None O
CCC None None O
. None None O

Serum None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
levels None None O
were None None O
measured None None O
using None None O
the None None O
enzyme None None O
- None None O
linked None None O
immunosorbent None None O
assay None None O
( None None O
ELISA None None O
) None None O
kit None None O
. None None O

RESULTS None None O
: None None O
The None None O
mean None None O
Rentrop None None O
collateral None None O
score None None O
was None None O
higher None None O
in None None O
Group None None O
1 None None O
than None None O
in None None O
Group None None O
2 None None O
( None None O
2 None None O
. None None O
39 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
07 None None O
vs None None O
. None None O
1 None None O
. None None O
76 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
76 None None O
, None None O
respectively None None O
, None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

When None None O
the None None O
two None None O
groups None None O
were None None O
compared None None O
with None None O
respect None None O
to None None O
poor None None O
and None None O
good None None O
CCC None None O
, None None O
poor None None O
CCC None None O
was None None O
higher None None O
in None None O
patients None None O
with None None O
PDR None None O
( None None O
64 None None O
vs None None O
. None None O
36 None None O
% None None O
, None None O
respectively None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

Serum None None O
VEGF None None O
levels None None O
were None None O
higher None None O
in None None O
patients None None O
with None None O
PDR None None O
than None None O
in None None O
those None None O
without None None O
DR None None O
( None None O
219 None None O
+ None None O
/ None None O
- None None O
99 None None O
vs None None O
. None None O
139 None None O
+ None None O
/ None None O
- None None O
98 None None O
pg None None O
/ None None O
ml None None O
, None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
; None None O
however None None O
, None None O
patients None None O
with None None O
poor None None O
and None None O
good None None O
CCC None None O
had None None O
similar None None O
VEGF None None O
levels None None O
. None None O

CONCLUSIONS None None O
: None None O
We None None O
have None None O
shown None None O
that None None O
patients None None O
with None None O
PDR None None O
have None None O
a None None O
lower None None O
coronary None None O
collateral None None O
score None None O
than None None O
patients None None O
without None None O
DR None None O
. None None O

Also None None O
, None None O
serum None None O
VEGF None None O
was None None O
significantly None None O
higher None None O
in None None O
patients None None O
with None None O
PDR None None O
than None None O
in None None O
those None None O
without None None O
DR None None O
. None None O

These None None O
findings None None O
have None None O
suggested None None O
that None None O
diabetes None None O
mellitus None None O
may None None O
have None None O
a None None O
different None None O
action None None O
on None None O
retinal None None O
and None None O
coronary None None O
circulation None None O
. None None O

Magnetic None None O
resonance None None O
imaging None None O
of None None O
axial None None O
plan None None O
with None None O
intravenous None None O
contrast None None O
gadolinium None None O
- None None O
BOPTA None None O
demonstrating None None O
a None None O
mass None None O
adherent None None O
to None None O
the None None O
right None None O
ventricular None None O
wall None None O
. None None O

Effects None None O
of None None O
hypertension None None O
and None None O
sympathetic None None O
denervation None None O
on None None O
cerebral None None O
blood None None O
flow None None O
in None None O
newborn None None O
pigs None None O
. None None O

To None None O
investigate None None O
the None None O
potential None None O
role None None O
of None None O
sympathetic None None O
nerves None None O
in None None O
preventing None None O
pronounced None None O
increases None None O
in None None O
cerebral None None O
blood None None O
flow None None O
, None None O
we None None O
evaluated None None O
the None None O
effects None None O
of None None O
abrupt None None O
hypertension None None O
on None None O
the None None O
cerebral None None O
circulation None None O
of None None O
newborn None None O
pigs None None O
with None None O
intact None None O
cerebral None None O
sympathetic None None O
innervation None None O
and None None O
after None None O
cerebral None None O
sympathetic None None O
denervation None None O
. None None O

Epinephrine None None O
infusion None None O
was None None O
used None None O
to None None O
induce None None O
abrupt None None O
increases None None O
in None None O
mean None None O
( None None O
+ None None O
/ None None O
- None None O
SEM None None O
) None None O
arterial None None O
pressure None None O
( None None O
innervated None None O
pigs None None O
, None None O
62 None None O
+ None None O
/ None None O
- None None O
3 None None O
mm None None O
of None None O
Hg None None O
to None None O
115 None None O
+ None None O
/ None None O
- None None O
3 None None O
mm None None O
of None None O
Hg None None O
; None None O
denervated None None O
pigs None None O
, None None O
71 None None O
+ None None O
/ None None O
- None None O
4 None None O
mm None None O
of None None O
Hg None None O
to None None O
132 None None O
+ None None O
/ None None O
- None None O
4 None None O
mm None None O
of None None O
Hg None None O
) None None O
that None None O
remained None None O
increased None None O
for None None O
the None None O
3 None None O
minutes None None O
of None None O
the None None O
study None None O
. None None O

Abrupt None None O
hypertension None None O
increased None None O
blood None None O
flow None None O
to None None O
all None None O
brain None None O
regions None None O
. None None O

In None None O
denervated None None O
pigs None None O
, None None O
the None None O
increased None None O
flow None None O
to None None O
the None None O
cerebrum None None O
was None None O
prolonged None None O
, None None O
compared None None O
with None None O
that None None O
in None None O
pigs None None O
with None None O
intact None None O
sympathetic None None O
innervation None None O
. None None O

Differences None None O
between None None O
pigs None None O
of None None O
the None None O
innervated None None O
and None None O
denervated None None O
groups None None O
were None None O
not None None O
apparent None None O
, None None O
with None None O
respect None None O
to None None O
blood None None O
flow None None O
to None None O
any None None O
other None None O
region None None O
( None None O
caudate None None O
region None None O
, None None O
brain None None O
stem None None O
, None None O
cerebellum None None O
) None None O
. None None O

In None None O
newborn None None O
pigs None None O
, None None O
sympathetic None None O
nerves None None O
may None None O
attenuate None None O
hypertension None None O
- None None O
induced None None O
increases None None O
in None None O
blood None None O
flow None None O
to None None O
the None None O
cerebrum None None O
, None None O
but None None O
do None None O
not None None O
appear None None O
to None None O
affect None None O
flow None None O
to None None O
the None None O
rest None None O
of None None O
the None None O
brain None None O
. None None O

Role None None O
of None None O
the None None O
fibrinolytic None None O
and None None O
matrix None None O
metalloproteinase None None O
systems None None O
in None None O
development None None O
of None None O
adipose None None O
tissue None None O
. None None O

Obesity None None O
is None None O
a None None O
common None None O
disorder None None O
and None None O
related None None O
diseases None None O
such None None O
as None None O
diabetes None None O
, None None O
atherosclerosis None None O
, None None O
hypertension None None O
, None None O
cardiovascular None None O
disease None None O
and None None O
cancer None None O
are None None O
a None None O
major None None O
cause None None O
of None None O
mortality None None O
and None None O
morbidity None None O
in None None O
Western None None O
- None None O
type None None O
societies None None O
. None None O

Development None None O
of None None O
obesity None None O
is None None O
associated None None O
with None None O
extensive None None O
modifications None None O
in None None O
adipose None None O
tissue None None O
involving None None O
adipogenesis None None O
, None None O
angiogenesis None None O
and None None O
extracellular None None O
matrix None None O
proteolysis None None O
. None None O

The None None O
fibrinolytic None None O
( None None O
plasminogen None None O
/ None None O
plasmin None None O
) None None O
and None None O
matrix None None O
metalloproteinase None None O
( None None O
MMP None None O
) None None O
systems None None O
cooperate None None O
in None None O
these None None O
processes None None O
. None None O

A None None O
nutritionally None None O
induced None None O
obesity None None O
model None None O
in None None O
transgenic None None O
mice None None O
has None None O
been None None O
used None None O
extensively None None O
to None None O
study None None O
the None None O
role None None O
of None None O
the None None O
fibrinolytic None None O
and None None O
MMP None None O
systems None None O
in None None O
the None None O
development None None O
of None None O
obesity None None O
. None None O

These None None O
studies None None O
support None None O
a None None O
role None None O
of None None O
both None None O
systems None None O
in None None O
adipogenesis None None O
and None None O
obesity None None O
; None None O
the None None O
role None None O
of None None O
specific None None O
members None None O
of None None O
these None None O
families None None O
, None None O
however None None O
, None None O
remains None None O
to None None O
be None None O
determined None None O
. None None O

[ None None O
The None None O
assessment None None O
of None None O
flow None None O
velocity None None O
in None None O
carotid None None O
and None None O
intracranial None None O
arteries None None O
in None None O
three None None O
different None None O
age None None O
groups None None O
] None None O
. None None O

In None None O
this None None O
report None None O
we None None O
assess None None O
the None None O
systolic None None O
maximal None None O
flow None None O
velocity None None O
in None None O
carotid None None O
and None None O
intracranial None None O
arteries None None O
in None None O
191 None None O
subjects None None O
with None None O
no None None O
history None None O
of None None O
cerebral None None O
vascular None None O
disease None None O
in None None O
3 None None O
age None None O
groups None None O
: None None O
20 None None O
- None None O
40 None None O
years None None O
( None None O
1 None None O
group None None O
) None None O
, None None O
41 None None O
- None None O
60 None None O
years None None O
( None None O
2 None None O
group None None O
) None None O
, None None O
and None None O
above None None O
60 None None O
years None None O
( None None O
3 None None O
group None None O
) None None O
. None None O

The None None O
subjects None None O
were None None O
assessed None None O
using None None O
Sonomed None None O
Transcranial None None O
Doppler None None O
Spectrograph None None O
according None None O
to None None O
generally None None O
accepted None None O
principles None None O
. None None O

The None None O
purpose None None O
of None None O
the None None O
study None None O
was None None O
to None None O
establish None None O
the None None O
mean None None O
value None None O
of None None O
maximal None None O
flow None None O
velocity None None O
in None None O
each None None O
particular None None O
artery None None O
in None None O
three None None O
age None None O
groups None None O
, None None O
and None None O
to None None O
observe None None O
the None None O
changes None None O
in None None O
this None None O
parameter None None O
with None None O
age None None O
. None None O

The None None O
results None None O
were None None O
analyzed None None O
using None None O
statistical None None O
methods None None O
and None None O
a None None O
significant None None O
decrease None None O
in None None O
blood None None O
flow None None O
, None None O
Vmax None None O
, None None O
was None None O
found None None O
in None None O
all None None O
investigated None None O
arteries None None O
. None None O

A None None O
mean None None O
decrease None None O
of None None O
8 None None O
. None None O
02 None None O
% None None O
in None None O
flow None None O
velocity None None O
Vmax None None O
was None None O
found None None O
, None None O
when None None O
comparing None None O
groups None None O
2 None None O
and None None O
1 None None O
, None None O
and None None O
difference None None O
15 None None O
. None None O
99 None None O
% None None O
comparing None None O
3 None None O
and None None O
1 None None O
. None None O

CX3CR1 None None O
- None None O
dependent None None O
subretinal None None O
microglia None None O
cell None None O
accumulation None None O
is None None O
associated None None O
with None None O
cardinal None None O
features None None O
of None None O
age None None O
- None None O
related None None O
macular None None O
degeneration None None O
. None None O

The None None O
role None None O
of None None O
retinal None None O
microglial None None O
cells None None O
( None None O
MCs None None O
) None None O
in None None O
age None None O
- None None O
related None None O
macular None None O
degeneration None None O
( None None O
AMD None None O
) None None O
is None None O
unclear None None O
. None None O

Here None None O
we None None O
demonstrated None None O
that None None O
all None None O
retinal None None O
MCs None None O
express None None O
CX3C None None O
chemokine None None O
receptor None None O
1 None None O
( None None O
CX3CR1 None None O
) None None O
and None None O
that None None O
homozygosity None None O
for None None O
the None None O
CX3CR1 None None O
M280 None None O
allele None None O
, None None O
which None None O
is None None O
associated None None O
with None None O
impaired None None O
cell None None O
migration None None O
, None None O
increases None None O
the None None O
risk None None O
of None None O
AMD None None O
. None None O

In None None O
humans None None O
with None None O
AMD None None O
, None None O
MCs None None O
accumulated None None O
in None None O
the None None O
subretinal None None O
space None None O
at None None O
sites None None O
of None None O
retinal None None O
degeneration None None O
and None None O
choroidal None None O
neovascularization None None O
( None None O
CNV None None O
) None None O
. None None O

In None None O
CX3CR1 None None O
- None None O
deficient None None O
mice None None O
, None None O
MCs None None O
accumulated None None O
subretinally None None O
with None None O
age None None O
and None None O
albino None None O
background None None O
and None None O
after None None O
laser None None O
impact None None O
preceding None None O
retinal None None O
degeneration None None O
. None None O

Raising None None O
the None None O
albino None None O
mice None None O
in None None O
the None None O
dark None None O
prevented None None O
both None None O
events None None O
. None None O

The None None O
appearance None None O
of None None O
lipid None None O
- None None O
bloated None None O
subretinal None None O
MCs None None O
was None None O
drusen None None O
- None None O
like None None O
on None None O
funduscopy None None O
of None None O
senescent None None O
mice None None O
, None None O
and None None O
CX3CR1 None None O
- None None O
dependent None None O
MC None None O
accumulation None None O
was None None O
associated None None O
with None None O
an None None O
exacerbation None None O
of None None O
experimental None None O
CNV None None O
. None None O

These None None O
results None None O
show None None O
that None None O
CX3CR1 None None O
- None None O
dependent None None O
accumulation None None O
of None None O
subretinal None None O
MCs None None O
evokes None None O
cardinal None None O
features None None O
of None None O
AMD None None O
. None None O

These None None O
findings None None O
reveal None None O
what None None O
we None None O
believe None None O
to None None O
be None None O
a None None O
novel None None O
pathogenic None None O
process None None O
with None None O
important None None O
implications None None O
for None None O
the None None O
development None None O
of None None O
new None None O
therapies None None O
for None None O
AMD None None O
. None None O

The None None O
neural None None O
stem None None O
cell None None O
fate None None O
determinant None None O
TLX None None O
promotes None None O
tumorigenesis None None O
and None None O
genesis None None O
of None None O
cells None None O
resembling None None O
glioma None None O
stem None None O
cells None None O
. None None O

A None None O
growing None None O
body None None O
of None None O
evidence None None O
indicates None None O
that None None O
deregulation None None O
of None None O
stem None None O
cell None None O
fate None None O
determinants None None O
is None None O
a None None O
hallmark None None O
of None None O
many None None O
types None None O
of None None O
malignancies None None O
. None None O

The None None O
neural None None O
stem None None O
cell None None O
fate None None O
determinant None None O
TLX None None O
plays None None O
a None None O
pivotal None None O
role None None O
in None None O
neurogenesis None None O
in None None O
the None None O
adult None None O
brain None None O
by None None O
maintaining None None O
neural None None O
stem None None O
cells None None O
. None None O

Here None None O
, None None O
we None None O
report None None O
a None None O
tumorigenic None None O
role None None O
of None None O
TLX None None O
in None None O
brain None None O
tumor None None O
initiation None None O
and None None O
progression None None O
. None None O

Increased None None O
TLX None None O
expression None None O
was None None O
observed None None O
in None None O
a None None O
number None None O
of None None O
glioma None None O
cells None None O
and None None O
glioma None None O
stem None None O
cells None None O
, None None O
and None None O
correlated None None O
with None None O
poor None None O
survival None None O
of None None O
patients None None O
with None None O
gliomas None None O
. None None O

Ectopic None None O
expression None None O
of None None O
TLX None None O
in None None O
the None None O
U87MG None None I-Cell-line-name
glioma None None O
cell None None O
line None None O
and None None O
Ink4a None None O
/ None None O
Arf None None O
- None None O
deficient None None O
mouse None None O
astrocytes None None O
( None None O
Ink4a None None O
/ None None O
Arf None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
astrocytes None None O
) None None O
induced None None O
cell None None O
proliferation None None O
with None None O
a None None O
concomitant None None O
increase None None O
in None None O
cyclin None None O
D None None O
expression None None O
, None None O
and None None O
accelerated None None O
foci None None O
formation None None O
in None None O
soft None None O
agar None None O
and None None O
tumor None None O
formation None None O
in None None O
in None None O
vivo None None O
transplantation None None O
assays None None O
. None None O

Furthermore None None O
, None None O
overexpression None None O
of None None O
TLX None None O
in None None O
Ink4a None None O
/ None None O
Arf None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
astrocytes None None O
inhibited None None O
cell None None O
migration None None O
and None None O
invasion None None O
and None None O
promoted None None O
neurosphere None None O
formation None None O
and None None O
Nestin None None O
expression None None O
, None None O
which None None O
are None None O
hallmark None None O
characteristics None None O
of None None O
glioma None None O
stem None None O
cells None None O
, None None O
under None None O
stem None None O
cell None None O
culture None None O
conditions None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
TLX None None O
is None None O
involved None None O
in None None O
glioma None None O
stem None None O
cell None None O
genesis None None O
and None None O
represents None None O
a None None O
potential None None O
therapeutic None None O
target None None O
for None None O
this None None O
type None None O
of None None O
malignancy None None O
. None None O

Candle None None O
wicks None None O

Candles None None O
with None None O
a None None O
lead None None O
metal None None O
core None None O
contribute None None O
to None None O
lead None None O
in None None O
the None None O
home None None O
( None None O
Nriagu None None O
and None None O
Kim None None O
2000 None None O
; None None O
van None None O
Alphen None None O
1999 None None O
) None None O
. None None O

Exposure None None O
occurs None None O
both None None O
from None None O
air None None O
and None None O
from None None O
hand None None O
- None None O
to None None O
- None None O
mouth None None O
activity None None O
. None None O

However None None O
, None None O
to None None O
date None None O
, None None O
no None None O
children None None O
' None None O
s None None O
EBLs None None O
traceable None None O
to None None O
candles None None O
have None None O
been None None O
reported None None O
. None None O

In None None O
2002 None None O
, None None O
the None None O
CPSC None None O
banned None None O
candlewicks None None O
containing None None O
> None None O
0 None None O
. None None O
06 None None O
% None None O
lead None None O
( None None O
CPSC None None O
2003 None None O
) None None O
. None None O

The None None O
most None None O
highly None None O
represented None None O
gene None None O
ontology None None O
themes None None O
in None None O
the None None O
neurosphere None None O
vs None None O
. None None O
differentiated None None O
cells None None O
comparison None None O
( None None O
F None None O
- None None O
G None None O
) None None O
. None None O

Reduced None None O
oncogenicity None None O
of None None O
p190 None None O
Bcr None None O
/ None None O
Abl None None O
F None None O
- None None O
actin None None O
- None None O
binding None None O
domain None None O
mutants None None O
. None None O

The None None O
deregulated None None O
Bcr None None O
/ None None O
Abl None None O
tyrosine None None O
kinase None None O
is None None O
responsible None None O
for None None O
the None None O
development None None O
of None None O
Philadelphia None None O
( None None O
Ph None None O
) None None O
- None None O
positive None None O
leukemia None None O
in None None O
humans None None O
. None None O

To None None O
investigate None None O
the None None O
significance None None O
of None None O
the None None O
C None None O
- None None O
terminal None None O
Abl None None O
actin None None O
- None None O
binding None None O
domain None None O
within None None O
Bcr None None O
/ None None O
Abl None None O
p190 None None O
in None None O
the None None O
development None None O
of None None O
leukemia None None O
/ None None O
lymphoma None None O
in None None O
vivo None None O
, None None O
mutant None None O
p190 None None O
DNA None None O
constructs None None O
were None None O
used None None O
to None None O
generate None None O
transgenic None None O
mice None None O
. None None O

Eight None None O
founder None None O
and None None O
progeny None None O
mice None None O
of None None O
5 None None O
different None None O
lines None None O
were None None O
monitored None None O
for None None O
leukemogenesis None None O
. None None O

Latency None None O
was None None O
markedly None None O
increased None None O
and None None O
occurrence None None O
decreased None None O
in None None O
the None None O
p190 None None O
del None None O
C None None O
lines None None O
as None None O
compared None None O
with None None O
nonmutated None None O
p190 None None O
BCR None None O
/ None None O
ABL None None O
transgenics None None O
. None None O

Western None None O
blot None None O
analysis None None O
of None None O
involved None None O
hematologic None None O
tissues None None O
of None None O
the None None O
p190 None None O
del None None O
C None None O
transgenics None None O
with None None O
end None None O
- None None O
stage None None O
disease None None O
showed None None O
high None None O
- None None O
level None None O
expression None None O
of None None O
the None None O
transgene None None O
and None None O
tyrosine None None O
phosphorylation None None O
of None None O
Cbl None None O
and None None O
Hef1 None None O
/ None None O
Cas None None O
, None None O
proteins None None O
previously None None O
shown None None O
to None None O
be None None O
affected None None O
by None None O
Bcr None None O
/ None None O
Abl None None O
. None None O

These None None O
results None None O
show None None O
that None None O
the None None O
actin None None O
- None None O
binding None None O
domain None None O
of None None O
Abl None None O
enhances None None O
leukemia None None O
development None None O
but None None O
does None None O
not None None O
appear None None O
to None None O
be None None O
an None None O
absolute None None O
requirement None None O
for None None O
leukemogenesis None None O
. None None O

High None None O
- None None O
grade None None O
clear None None O
cell None None O
renal None None O
cell None None O
carcinoma None None O
has None None O
a None None O
higher None None O
angiogenic None None O
activity None None O
than None None O
low None None O
- None None O
grade None None O
renal None None O
cell None None O
carcinoma None None O
based None None O
on None None O
histomorphological None None O
quantification None None O
and None None O
qRT None None O
- None None O
PCR None None O
mRNA None None O
expression None None O
profile None None O
. None None O

Clear None None O
cell None None O
renal None None O
cell None None O
carcinoma None None O
( None None O
CC None None O
- None None O
RCC None None O
) None None O
is None None O
a None None O
highly None None O
vascularised None None O
tumour None None O
and None None O
is None None O
therefore None None O
an None None O
attractive None None O
disease None None O
to None None O
study None None O
angiogenesis None None O
and None None O
to None None O
test None None O
novel None None O
angiogenesis None None O
inhibitors None None O
in None None O
early None None O
clinical None None O
development None None O
. None None O

Endothelial None None O
cell None None O
proliferation None None O
plays None None O
a None None O
pivotal None None O
role None None O
in None None O
the None None O
process None None O
of None None O
angiogenesis None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
compare None None O
angiogenesis None None O
parameters None None O
in None None O
low None None O
nuclear None None O
grade None None O
( None None O
n None None O
= None None O
87 None None O
) None None O
vs None None O
high None None O
nuclear None None O
grade None None O
CC None None O
- None None O
RCC None None O
( None None O
n None None O
= None None O
63 None None O
) None None O
. None None O

A None None O
panel None None O
of None None O
antibodies None None O
was None None O
used None None O
for None None O
immunohistochemistry None None O
: None None O
CD34 None None O
/ None None O
Ki None None O
- None None O
67 None None O
, None None O
carbonic None None O
anhydrase None None O
IX None None O
, None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
- None None O
1alpha None None O
( None None O
HIF None None O
- None None O
1alpha None None O
) None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
. None None O

Vessel None None O
density None None O
( None None O
MVD None None O
- None None O
microvessel None None O
density None None O
) None None O
, None None O
endothelial None None O
cell None None O
proliferation None None O
fraction None None O
( None None O
ECP None None O
% None None O
) None None O
and None None O
tumour None None O
cell None None O
proliferation None None O
fraction None None O
( None None O
TCP None None O
% None None O
) None None O
were None None O
assessed None None O
. None None O

mRNA None None O
expression None None O
levels None None O
of None None O
angiogenesis None None O
stimulators None None O
and None None O
inhibitors None None O
were None None O
determined None None O
by None None O
quantitative None None O
RT None None O
- None None O
PCR None None O
. None None O

High None None O
- None None O
grade None None O
CC None None O
- None None O
RCC None None O
showed None None O
a None None O
higher None None O
ECP None None O
% None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
049 None None O
) None None O
, None None O
a None None O
higher None None O
TCP None None O
% None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
009 None None O
) None None O
, None None O
a None None O
higher None None O
VEGF None None O
protein None None O
expression None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
, None None O
a None None O
lower None None O
MVD None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
and None None O
a None None O
lower None None O
HIF None None O
- None None O
1alpha None None O
protein None None O
expression None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
002 None None O
) None None O
than None None O
low None None O
- None None O
grade None None O
CC None None O
- None None O
RCC None None O
. None None O

Growth None None O
factor None None O
mRNA None None O
expression None None O
analyses None None O
revealed None None O
a None None O
higher None None O
expression None None O
of None None O
angiopoietin None None O
2 None None O
in None None O
low None None O
- None None O
grade None None O
CC None None O
- None None O
RCC None None O
. None None O

Microvessel None None O
density None None O
and None None O
ECP None None O
% None None O
were None None O
inversely None None O
correlated None None O
( None None O
Rho None None O
= None None O
- None None O
0 None None O
. None None O
26 None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

Because None None O
of None None O
the None None O
imperfect None None O
association None None O
of None None O
nuclear None None O
grade None None O
and None None O
ECP None None O
% None None O
or None None O
MVD None None O
, None None O
CC None None O
- None None O
RCC None None O
was None None O
also None None O
grouped None None O
based None None O
on None None O
low None None O
/ None None O
high None None O
MVD None None O
and None None O
ECP None None O
% None None O
. None None O

This None None O
analysis None None O
revealed None None O
a None None O
higher None None O
expression None None O
of None None O
vessel None None O
maturation None None O
and None None O
stabilisation None None O
factors None None O
( None None O
placental None None O
growth None None O
factor None None O
, None None O
PDGFB1 None None O
, None None O
angiopoietin None None O
1 None None O
) None None O
in None None O
CC None None O
- None None O
RCC None None O
with None None O
high None None O
MVD None None O
, None None O
a None None O
group None None O
of None None O
CC None None O
- None None O
RCC None None O
highly None None O
enriched None None O
in None None O
low None None O
nuclear None None O
grade None None O
CC None None O
- None None O
RCC None None O
, None None O
with None None O
low None None O
ECP None None O
% None None O
. None None O

Our None None O
results None None O
suggest None None O
heterogeneity None None O
in None None O
angiogenic None None O
activity None None O
and None None O
vessel None None O
maturation None None O
of None None O
CC None None O
- None None O
RCC None None O
, None None O
to None None O
a None None O
large None None O
extent None None O
linked None None O
to None None O
nuclear None None O
grade None None O
, None None O
and None None O
, None None O
with None None O
probable None None O
therapeutic None None O
implications None None O
. None None O

Extracellular None None O
matrix None None O
as None None O
a None None O
bioactive None None O
material None None O
for None None O
soft None None O
tissue None None O
reconstruction None None O
. None None O

The None None O
extracellular None None O
matrix None None O
( None None O
ECM None None O
) None None O
directs None None O
all None None O
phases None None O
of None None O
healing None None O
following None None O
trauma None None O
or None None O
disease None None O
and None None O
is None None O
therefore None None O
a None None O
natural None None O
source None None O
of None None O
prosthetic None None O
mesh None None O
material None None O
that None None O
can None None O
be None None O
used None None O
strategically None None O
to None None O
induce None None O
the None None O
repair None None O
and None None O
restoration None None O
of None None O
soft None None O
tissues None None O
following None None O
surgery None None O
. None None O

Biomaterials None None O
such None None O
as None None O
Surgisis None None O
( None None O
Cook None None O
Biotech None None O
Incorporated None None O
, None None O
West None None O
Lafayette None None O
, None None O
IN None None O
, None None O
USA None None O
) None None O
, None None O
which None None O
are None None O
derived None None O
from None None O
natural None None O
ECM None None O
, None None O
provide None None O
the None None O
extracellular None None O
components None None O
necessary None None O
to None None O
direct None None O
the None None O
healing None None O
response None None O
, None None O
allow None None O
for None None O
the None None O
proliferation None None O
of None None O
new None None O
, None None O
healthy None None O
tissue None None O
and None None O
restore None None O
tissue None None O
integrity None None O
to None None O
the None None O
damaged None None O
site None None O
. None None O

The None None O
3 None None O
- None None O
D None None O
organization None None O
of None None O
these None None O
extracellular None None O
components None None O
distinguishes None None O
the None None O
Surgisis None None O
mesh None None O
from None None O
synthetic None None O
materials None None O
and None None O
is None None O
associated None None O
with None None O
constructive None None O
tissue None None O
remodelling None None O
instead None None O
of None None O
scar None None O
tissue None None O
. None None O

Common None None O
features None None O
of None None O
this None None O
ECM None None O
- None None O
assisted None None O
tissue None None O
remodelling None None O
include None None O
angiogenesis None None O
, None None O
recruitment None None O
of None None O
circulating None None O
progenitor None None O
cells None None O
and None None O
constructive None None O
remodelling None None O
of None None O
damaged None None O
tissue None None O
structures None None O
. None None O

The None None O
tissue None None O
response None None O
to None None O
this None None O
biologic None None O
mesh None None O
is None None O
discussed None None O
in None None O
the None None O
context None None O
of None None O
recent None None O
reports None None O
on None None O
clinical None None O
hernia None None O
repair None None O
. None None O

Tumour None None O
angiogenesis None None O
: None None O
its None None O
mechanism None None O
and None None O
therapeutic None None O
implications None None O
in None None O
malignant None None O
gliomas None None O
. None None O

Angiogenesis None None O
is None None O
a None None O
key None None O
event None None O
in None None O
the None None O
progression None None O
of None None O
malignant None None O
gliomas None None O
. None None O

The None None O
presence None None O
of None None O
microvascular None None O
proliferation None None O
leads None None O
to None None O
the None None O
histological None None O
diagnosis None None O
of None None O
glioblastoma None None O
multiforme None None O
. None None O

Tumour None None O
angiogenesis None None O
involves None None O
multiple None None O
cellular None None O
processes None None O
including None None O
endothelial None None O
cell None None O
proliferation None None O
, None None O
migration None None O
, None None O
reorganisation None None O
of None None O
extracellular None None O
matrix None None O
and None None O
tube None None O
formation None None O
. None None O

These None None O
processes None None O
are None None O
regulated None None O
by None None O
numerous None None O
pro None None O
- None None O
angiogenic None None O
and None None O
anti None None O
- None None O
angiogenic None None O
growth None None O
factors None None O
. None None O

Angiogenesis None None O
inhibitors None None O
have None None O
been None None O
developed None None O
to None None O
interrupt None None O
the None None O
angiogenic None None O
process None None O
at None None O
the None None O
growth None None O
factor None None O
, None None O
receptor None None O
tyrosine None None O
kinase None None O
and None None O
intracellular None None O
kinase None None O
levels None None O
. None None O

Other None None O
anti None None O
- None None O
angiogenic None None O
therapies None None O
alter None None O
the None None O
immune None None O
response None None O
and None None O
endogeneous None None O
angiogenesis None None O
inhibitor None None O
levels None None O
. None None O

Most None None O
anti None None O
- None None O
angiogenic None None O
therapies None None O
for None None O
malignant None None O
gliomas None None O
are None None O
in None None O
Phase None None O
I None None O
/ None None O
II None None O
trials None None O
and None None O
only None None O
modest None None O
efficacies None None O
are None None O
reported None None O
for None None O
monotherapies None None O
. None None O

The None None O
greatest None None O
potential None None O
for None None O
angiogenesis None None O
inhibitors None None O
may None None O
lie None None O
in None None O
their None None O
ability None None O
to None None O
combine None None O
safely None None O
with None None O
chemotherapy None None O
and None None O
radiotherapy None None O
. None None O

Distinct None None O
role None None O
of None None O
PLCbeta3 None None O
in None None O
VEGF None None O
- None None O
mediated None None O
directional None None O
migration None None O
and None None O
vascular None None O
sprouting None None O
. None None O

Endothelial None None O
cell None None O
proliferation None None O
and None None O
migration None None O
is None None O
essential None None O
to None None O
angiogenesis None None O
. None None O

Typically None None O
, None None O
proliferation None None O
and None None O
chemotaxis None None O
of None None O
endothelial None None O
cells None None O
is None None O
driven None None O
by None None O
growth None None O
factors None None O
such None None O
as None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
and None None O
basic None None O
fibroblast None None O
growth None None O
factor None None O
( None None O
bFGF None None O
) None None O
. None None O

VEGF None None O
activates None None O
phospholipases None None O
( None None O
PLCs None None O
) None None O
- None None O
specifically None None O
PLCgamma1 None None O
- None None O
that None None O
are None None O
important None None O
for None None O
tubulogenesis None None O
, None None O
differentiation None None O
and None None O
DNA None None O
synthesis None None O
. None None O

However None None O
, None None O
we None None O
show None None O
here None None O
that None None O
VEGF None None O
, None None O
specifically None None O
through None None O
VEGFR2 None None O
, None None O
induces None None O
phosphorylation None None O
of None None O
two None None O
serine None None O
residues None None O
on None None O
PLCbeta3 None None O
, None None O
and None None O
this None None O
was None None O
confirmed None None O
in None None O
an None None O
ex None None O
vivo None None O
embryoid None None O
body None None O
model None None O
. None None O

Knockdown None None O
of None None O
PLCbeta3 None None O
in None None O
HUVEC None None O
cells None None O
affects None None O
IP3 None None O
production None None O
, None None O
actin None None O
reorganization None None O
, None None O
migration None None O
and None None O
proliferation None None O
; None None O
whereas None None O
migration None None O
is None None O
inhibited None None O
, None None O
proliferation None None O
is None None O
enhanced None None O
. None None O

Our None None O
data None None O
suggest None None O
that None None O
enhanced None None O
proliferation None None O
is None None O
precipitated None None O
by None None O
an None None O
accelerated None None O
cell None None O
cycle None None O
, None None O
and None None O
decreased None None O
migration None None O
by None None O
an None None O
inability None None O
to None None O
activate None None O
CDC42 None None O
. None None O

Given None None O
that None None O
PLCbeta3 None None O
is None None O
typically None None O
known None None O
as None None O
an None None O
effector None None O
of None None O
heterotrimeric None None O
G None None O
- None None O
proteins None None O
, None None O
our None None O
data None None O
demonstrate None None O
a None None O
unique None None O
crosstalk None None O
between None None O
the None None O
G None None O
- None None O
protein None None O
and None None O
receptor None None O
tyrosine None None O
kinase None None O
( None None O
RTK None None O
) None None O
axes None None O
and None None O
reveal None None O
a None None O
novel None None O
molecular None None O
mechanism None None O
of None None O
VEGF None None O
signaling None None O
and None None O
, None None O
thus None None O
, None None O
angiogenesis None None O
. None None O

[ None None O
Inhibitory None None O
effect None None O
of None None O
adenovirus None None O
- None None O
mediated None None O
endostatin None None O
gene None None O
transfer None None O
on None None O
transplanted None None O
lung None None O
carcinoma None None O
in None None O
mice None None O
] None None O

OBJECTIVE None None O
: None None O
To None None O
investigate None None O
the None None O
effect None None O
of None None O
adenovirus None None O
- None None O
mediated None None O
endostatin None None O
gene None None O
transfer None None O
on None None O
transplanted None None O
lung None None O
cancer None None O
in None None O
mice None None O
and None None O
its None None O
mechanism None None O
of None None O
action None None O
. None None O

METHODS None None O
: None None O
Transplant None None O
tumor None None O
model None None O
was None None O
induced None None O
by None None O
subcutaneous None None O
inoculation None None O
of None None O
2 None None O
x None None O
10 None None O
( None None O
6 None None O
) None None O
Lewis None None O
lung None None O
cancer None None O
( None None O
LLC None None O
) None None O
cells None None O
into None None O
the None None O
back None None O
of None None O
C57BL None None O
/ None None O
6 None None O
mice None None O
. None None O

The None None O
mice None None O
were None None O
treated None None O
by None None O
intratumoral None None O
injection None None O
of None None O
2 None None O
x None None O
10 None None O
( None None O
9 None None O
) None None O
pfu None None O
Ad None None O
- None None O
mEndostatin None None O
. None None O

The None None O
expression None None O
of None None O
endostatin None None O
in None None O
situ None None O
and None None O
its None None O
maintaining None None O
time None None O
were None None O
detected None None O
by None None O
immunohistochemistry None None O
and None None O
Western None None O
Blot None None O
, None None O
respectively None None O
. None None O

The None None O
endostatin None None O
level None None O
in None None O
serum None None O
was None None O
determined None None O
by None None O
ELISA None None O
. None None O

The None None O
inhibition None None O
of None None O
tumor None None O
growth None None O
and None None O
changes None None O
of None None O
survival None None O
were None None O
recorded None None O
and None None O
the None None O
microvessel None None O
density None None O
( None None O
MVD None None O
) None None O
was None None O
determined None None O
by None None O
histochemical None None O
stainingwith None None O
CD31 None None O
and None None O
CD105 None None O
antibodies None None O
. None None O

The None None O
tumor None None O
apoptosis None None O
was None None O
observed None None O
by None None O
electron None None O
microscopy None None O
. None None O

RESULTS None None O
: None None O
In None None O
comparison None None O
with None None O
controls None None O
, None None O
intratumoral None None O
injection None None O
of None None O
Ad None None O
- None None O
mEndostatin None None O
significantly None None O
inhibited None None O
the None None O
tumor None None O
growth None None O
and None None O
metastasis None None O
, None None O
and None None O
prolonged None None O
the None None O
survival None None O
rate None None O
of None None O
mice None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Strong None None O
positive None None O
expression None None O
of None None O
mEndostatin None None O
was None None O
seen None None O
in None None O
the None None O
tumor None None O
tissue None None O
after None None O
injection None None O
of None None O
Ad None None O
- None None O
mEndostatin None None O
, None None O
immunhistochemically None None O
ostained None None O
by None None O
mouse None None O
endostatin None None O
monoclonal None None O
antibody None None O
, None None O
while None None O
the None None O
control None None O
groups None None O
showed None None O
only None None O
very None None O
low None None O
expression None None O
or None None O
absence None None O
. None None O

Serum None None O
endostatin None None O
concentration None None O
was None None O
1540 None None O
+ None None O
/ None None O
- None None O
560 None None O
ng None None O
/ None None O
ml None None O
at None None O
the None None O
second None None O
week None None O
of None None O
administration None None O
, None None O
the None None O
expression None None O
of None None O
endostatin None None O
diminished None None O
a None None O
month None None O
later None None O
. None None O

The None None O
microvessel None None O
density None None O
( None None O
MVD None None O
) None None O
) None None O
decreased None None O
from None None O
42 None None O
. None None O
4 None None O
+ None None O
/ None None O
- None None O
4 None None O
. None None O
8 None None O
to None None O
10 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
3 None None O
. None None O
2 None None O
per None None O
x None None O
200 None None O
magnificetion None None O
microscopic None None O
field None None O
by None None O
CD10 None None O
staining None None O
and None None O
from None None O
68 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
4 None None O
. None None O
5 None None O
to None None O
37 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
4 None None O
. None None O
6 None None O
by None None O
CD31 None None O
staining None None O
, None None O
respectively None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

More None None O
apoptotic None None O
tumor None None O
cells None None O
were None None O
seen None None O
under None None O
the None None O
transmission None None O
electron None None O
microscope None None O
. None None O

CONCLUSION None None O
: None None O
Endostatin None None O
gene None None O
therapy None None O
mediated None None O
by None None O
adenoviral None None O
vector None None O
efficiently None None O
induces None None O
expression None None O
of None None O
endostatin None None O
in None None O
vivo None None O
, None None O
and None None O
inhibits None None O
the None None O
growth None None O
and None None O
metastasis None None O
of None None O
tumor None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
its None None O
action None None O
is None None O
targeted None None O
to None None O
tumor None None O
neovasculature None None O
and None None O
the None None O
mechanism None None O
is None None O
inhibition None None O
of None None O
tumor None None O
angiogenesis None None O
. None None O

DNA None None O
isolation None None O

All None None O
solutions None None O
used None None O
for None None O
DNA None None O
isolation None None O
are None None O
purged None None O
with None None O
nitrogen None None O
( None None O
immediately None None O
prior None None O
to None None O
use None None O
) None None O
and None None O
supplemented None None O
with None None O
50 None None O
muM None None O
phenyl None None O
- None None O
tert None None O
- None None O
butyl None None O
nitrone None None O
to None None O
minimise None None O
oxidative None None O
damage None None O
to None None O
DNA None None O
[ None None O
31 None None O
] None None O
. None None O

Qiagen None None O
DNAeasy None None O
Kit None None O
( None None O
# None None O
69506 None None O
) None None O

includes None None O
: None None O
Proteinase None None O
K None None O
, None None O
AW1 None None O
, None None O
AW2 None None O
, None None O
AE None None O
and None None O
Spin None None O
- None None O
columns None None O

Dithiothreitol None None O
( None None O
DTT None None O
; None None O
Sigma None None O
) None None O

Ethanol None None O
( None None O
Ajax None None O
Finechem None None O
# None None O
214 None None O
- None None O
2 None None O
. None None O
5L None None O
) None None O

Nitrogen None None O
( None None O
for None None O
purging None None O
of None None O
buffers None None O
) None None O

Authors None None O
' None None O
contributions None None O

FR None None O
initiated None None O
and None None O
designed None None O
the None None O
research None None O
, None None O
collected None None O
and None None O
analyzed None None O
the None None O
data None None O
and None None O
wrote None None O
the None None O
paper None None O
. None None O

FO None None O
was None None O
the None None O
main None None O
supervisor None None O
, None None O
helped None None O
in None None O
analysis None None O
, None None O
and None None O
revised None None O
and None None O
edited None None O
the None None O
drafts None None O
. None None O

MN None None O
was None None O
co None None O
- None None O
supervisor None None O
and None None O
revised None None O
the None None O
drafts None None O
. None None O

Planning None None O
for None None O
the None None O
Future None None O
: None None O
Disaster None None O
Preparedness None None O
and None None O
Mitigation None None O

It None None O
is None None O
often None None O
believed None None O
that None None O
casualties None None O
from None None O
natural None None O
disasters None None O
are None None O
unavoidable None None O
, None None O
but None None O
this None None O
belief None None O
is None None O
false None None O
[ None None O
8 None None O
] None None O
. None None O

There None None O
are None None O
many None None O
measures None None O
that None None O
can None None O
reduce None None O
morbidity None None O
and None None O
mortality None None O
following None None O
large None None O
and None None O
potentially None None O
catastrophic None None O
flooding None None O
events None None O
[ None None O
19 None None O
] None None O
. None None O

Early None None O
warning None None O
of None None O
impending None None O
floods None None O
and None None O
natural None None O
events None None O
such None None O
as None None O
hurricanes None None O
allows None None O
sufficient None None O
time None None O
for None None O
communities None None O
to None None O
be None None O
evacuated None None O
to None None O
safe None None O
areas None None O
. None None O

Although None None O
Florida None None O
experienced None None O
one None None O
of None None O
the None None O
worst None None O
hurricane None None O
seasons None None O
on None None O
record None None O
in None None O
2004 None None O
, None None O
the None None O
number None None O
of None None O
fatalities None None O
was None None O
lower None None O
than None None O
expected None None O
because None None O
of None None O
early None None O
warning None None O
and None None O
evacuation None None O
. None None O

Early None None O
warning None None O
also None None O
provides None None O
sufficient None None O
time None None O
to None None O
prepare None None O
when None None O
evacuation None None O
is None None O
not None None O
possible None None O
. None None O

Hurricane None None O
George None None O
in None None O
1998 None None O
caused None None O
widespread None None O
damage None None O
and None None O
several None None O
fatalities None None O
in None None O
the None None O
Dominican None None O
Republic None None O
, None None O
where None None O
residents None None O
were None None O
not None None O
warned None None O
. None None O

In None None O
contrast None None O
, None None O
Cuba None None O
and None None O
Puerto None None O
Rico None None O
experienced None None O
relatively None None O
limited None None O
damage None None O
and None None O
loss None None O
of None None O
life None None O
, None None O
because None None O
preparations None None O
were None None O
made None None O
in None None O
the None None O
hours None None O
before None None O
the None None O
storm None None O
. None None O

Disaster None None O
preparedness None None O
can None None O
also None None O
be None None O
developed None None O
for None None O
communities None None O
that None None O
are None None O
regularly None None O
exposed None None O
to None None O
flooding None None O
disasters None None O
. None None O

Cyclone None None O
shelters None None O
built None None O
by None None O
the None None O
Red None None O
Cross None None O
in None None O
Orissa None None O
, None None O
India None None O
, None None O
saved None None O
many None None O
thousands None None O
of None None O
lives None None O
in None None O
1999 None None O
when None None O
two None None O
cyclones None None O
struck None None O
. None None O

In None None O
the None None O
region None None O
of None None O
the None None O
Americas None None O
, None None O
the None None O
Pan None None O
American None None O
Health None None O
Organization None None O
has None None O
spent None None O
many None None O
years None None O
promoting None None O
and None None O
integrating None None O
disaster None None O
preparedness None None O
into None None O
building None None O
health None None O
facilities None None O
to None None O
ensure None None O
that None None O
medical None None O
services None None O
needed None None O
to None None O
treat None None O
victims None None O
and None None O
maintain None None O
ongoing None None O
care None None O
for None None O
patients None None O
with None None O
chronic None None O
conditions None None O
will None None O
not None None O
be None None O
disrupted None None O
by None None O
disasters None None O
. None None O

A None None O
recent None None O
global None None O
- None None O
scale None None O
review None None O
of None None O
health None None O
risks None None O
from None None O
flooding None None O
highlights None None O
that None None O
in None None O
flood None None O
- None None O
prone None None O
areas None None O
, None None O
disaster None None O
preparedness None None O
within None None O
the None None O
health None None O
system None None O
as None None O
a None None O
whole None None O
is None None O
particularly None None O
important None None O
[ None None O
20 None None O
] None None O
. None None O

In None None O
addition None None O
to None None O
infrastructure None None O
and None None O
early None None O
- None None O
warning None None O
systems None None O
, None None O
another None None O
key None None O
element None None O
in None None O
disaster None None O
preparedness None None O
is None None O
education None None O
and None None O
raising None None O
awareness None None O
about None None O
disaster None None O
risks None None O
and None None O
response None None O
plans None None O
. None None O

Had None None O
there None None O
been None None O
greater None None O
awareness None None O
about None None O
the None None O
risk None None O
of None None O
tsunamis None None O
, None None O
perhaps None None O
many None None O
lives None None O
could None None O
have None None O
been None None O
saved None None O
in None None O
the None None O
South None None O
Asian None None O
disaster None None O
in None None O
December None None O
2004 None None O
. None None O

Hepatitis None None O
B None None O
virus None None O
integration None None O
event None None O
in None None O
human None None O
chromosome None None O
17p None None O
near None None O
the None None O
p53 None None O
gene None None O
identifies None None O
the None None O
region None None O
of None None O
the None None O
chromosome None None O
commonly None None O
deleted None None O
in None None O
virus None None O
- None None O
positive None None O
hepatocellular None None O
carcinomas None None O
. None None O

The None None O
development None None O
of None None O
hepatocellular None None O
carcinoma None None O
( None None O
HCC None None O
) None None O
presumably None None O
occurs None None O
in None None O
multiple None None O
steps None None O
and None None O
is None None O
influenced None None O
by None None O
numerous None None O
factors None None O
. None None O

Hepatitis None None O
B None None O
virus None None O
( None None O
HBV None None O
) None None O
is None None O
strongly None None O
associated None None O
with None None O
the None None O
development None None O
of None None O
HCC None None O
in None None O
people None None O
chronically None None O
infected None None O
with None None O
the None None O
virus None None O
, None None O
but None None O
the None None O
mechanism None None O
of None None O
viral None None O
involvement None None O
remains None None O
unclear None None O
. None None O

One None None O
possibility None None O
is None None O
that None None O
the None None O
gross None None O
chromosomal None None O
alterations None None O
frequently None None O
observed None None O
in None None O
HCC None None O
DNA None None O
at None None O
the None None O
site None None O
of None None O
HBV None None O
integration None None O
may None None O
alter None None O
the None None O
expression None None O
of None None O
important None None O
nearby None None O
cellular None None O
genes None None O
. None None O

We None None O
previously None None O
reported None None O
the None None O
cloning None None O
and None None O
characterization None None O
of None None O
a None None O
HBV None None O
insert None None O
from None None O
a None None O
Chinese None None O
HCC None None O
. None None O

The None None O
viral None None O
insert None None O
mapped None None O
to None None O
chromosome None None O
17p11 None None O
. None None O
2 None None O
- None None O
12 None None O
, None None O
and None None O
cellular None None O
sequences None None O
were None None O
duplicated None None O
at None None O
the None None O
site None None O
of None None O
viral None None O
integration None None O
. None None O

In None None O
the None None O
present None None O
study None None O
a None None O
DNA None None O
probe None None O
derived None None O
from None None O
cellular None None O
DNA None None O
sequences None None O
adjacent None None O
to None None O
the None None O
previously None None O
characterized None None O
HBV None None O
insert None None O
was None None O
used None None O
to None None O
analyze None None O
a None None O
set None None O
of None None O
19 None None O
matched None None O
normal None None O
liver None None O
and None None O
HBV None None O
- None None O
positive None None O
hepatoma None None O
samples None None O
obtained None None O
from None None O
the None None O
same None None O
region None None O
of None None O
China None None O
, None None O
near None None O
Shanghai None None O
. None None O

Tumor None None O
- None None O
specific None None O
DNA None None O
changes None None O
were None None O
detected None None O
in None None O
two None None O
additional None None O
HCCs None None O
, None None O
suggesting None None O
that None None O
the None None O
small None None O
region None None O
of None None O
chromosome None None O
17p None None O
defined None None O
by None None O
the None None O
flanking None None O
cell None None O
DNA None None O
probe None None O
is None None O
commonly None None O
altered None None O
in None None O
hepatomas None None O
. None None O

Restriction None None O
fragment None None O
length None None O
polymorphism None None O
studies None None O
demonstrated None None O
that None None O
the None None O
loss None None O
of None None O
one None None O
copy None None O
of None None O
portions None None O
of None None O
chromosome None None O
17 None None O
occurred None None O
in None None O
10 None None O
( None None O
53 None None O
% None None O
) None None O
of None None O
the None None O
19 None None O
patients None None O
. None None O

The None None O
loss None None O
of None None O
one None None O
allele None None O
of None None O
the None None O
p53 None None O
gene None None O
( None None O
located None None O
on None None O
chromosome None None O
17p13 None None O
) None None O
occurred None None O
in None None O
at None None O
least None None O
6 None None O
( None None O
60 None None O
% None None O
) None None O
of None None O
the None None O
10 None None O
patients None None O
who None None O
were None None O
heterozygous None None O
at None None O
the None None O
p53 None None O
locus None None O
. None None O

As None None O
the None None O
p53 None None O
gene None None O
is None None O
known None None O
to None None O
possess None None O
tumor None None O
suppressor None None O
activity None None O
, None None O
the None None O
functional None None O
loss None None O
of None None O
this None None O
gene None None O
may None None O
be None None O
a None None O
significant None None O
step None None O
in None None O
the None None O
development None None O
of None None O
a None None O
subset None None O
of None None O
HCCs None None O
. None None O

High None None O
levels None None O
of None None O
allele None None O
loss None None O
also None None O
were None None O
detected None None O
for None None O
chromosomes None None O
8q None None O
( None None O
4 None None O
of None None O
9 None None O
; None None O
44 None None O
% None None O
) None None O
and None None O
16p None None O
( None None O
5 None None O
of None None O
6 None None O
; None None O
83 None None O
% None None O
) None None O
and None None O
may None None O
indicate None None O
the None None O
presence None None O
of None None O
additional None None O
cellular None None O
genes None None O
whose None None O
functional None None O
loss None None O
is None None O
important None None O
in None None O
the None None O
development None None O
of None None O
HCCs None None O
. None None O

Hypocholesterolaemic None None O
and None None O
antioxidant None None O
effects None None O
of None None O
Glycyrrhiza None None O
glabra None None O
( None None O
Linn None None O
) None None O
in None None O
rats None None O
. None None O

The None None O
hypocholesterolaemic None None O
and None None O
antioxidant None None O
effects None None O
of None None O
Glycyrrhiza None None O
glabra None None O
( None None O
GG None None O
) None None O
root None None O
powder None None O
were None None O
examined None None O
in None None O
hypercholesterolaemic None None O
male None None O
albino None None O
rats None None O
. None None O

A None None O
4 None None O
- None None O
week None None O
administration None None O
of None None O
GG None None O
root None None O
powder None None O
( None None O
5 None None O
and None None O
10 None None O
gm None None O
% None None O
in None None O
diet None None O
) None None O
to None None O
hypercholesterolaemic None None O
rats None None O
resulted None None O
in None None O
significant None None O
reduction None None O
in None None O
plasma None None O
, None None O
hepatic None None O
total None None O
lipids None None O
, None None O
cholesterol None None O
, None None O
triglycerides None None O
and None None O
plasma None None O
low None None O
- None None O
density None None O
lipoprotein None None O
and None None O
VLDL None None O
- None None O
cholesterol None None O
accompanied None None O
by None None O
significant None None O
increases None None O
in None None O
HDL None None O
- None None O
cholesterol None None O
levels None None O
. None None O

Furthermore None None O
, None None O
significant None None O
increases None None O
in None None O
fecal None None O
cholesterol None None O
, None None O
neutral None None O
sterols None None O
and None None O
bile None None O
acid None None O
excretion None None O
along None None O
with None None O
an None None O
increase None None O
in None None O
hepatic None None O
HMG None None O
- None None O
CoA None None O
reductase None None O
activity None None O
and None None O
bile None None O
acid None None O
production None None O
were None None O
observed None None O
in None None O
these None None O
animals None None O
. None None O

The None None O
root None None O
powder None None O
administration None None O
to None None O
hypercholesterolaemic None None O
rats None None O
also None None O
decreased None None O
hepatic None None O
lipid None None O
peroxidation None None O
with None None O
a None None O
concomitant None None O
increase None None O
in None None O
superoxide None None O
dismutase None None O
( None None O
SOD None None O
) None None O
and None None O
catalase None None O
activities None None O
and None None O
total None None O
ascorbic None None O
acid None None O
content None None O
. None None O

Thus None None O
, None None O
the None None O
hypocholesterolaemic None None O
and None None O
antioxidant None None O
effects None None O
of None None O
GG None None O
root None None O
appeared None None O
to None None O
be None None O
mediated None None O
via None None O
( None None O
i None None O
) None None O
accelerated None None O
cholesterol None None O
, None None O
neutral None None O
sterol None None O
and None None O
bile None None O
acid None None O
elimination None None O
through None None O
fecal None None O
matter None None O
with None None O
an None None O
increased None None O
hepatic None None O
bile None None O
acid None None O
production None None O
and None None O
( None None O
ii None None O
) None None O
improving None None O
the None None O
activities None None O
of None None O
hepatic None None O
SOD None None O
, None None O
catalase None None O
and None None O
increasing None None O
the None None O
ascorbic None None O
acid None None O
content None None O
. None None O

The None None O
normo None None O
- None None O
cholesterolaemic None None O
animals None None O
when None None O
fed None None O
with None None O
GG None None O
root None None O
powder None None O
at None None O
10 None None O
gm None None O
% None None O
level None None O
, None None O
registered None None O
a None None O
significant None None O
decline None None O
in None None O
plasma None None O
lipid None None O
profiles None None O
and None None O
an None None O
increase None None O
in None None O
HDL None None O
- None None O
cholesterol None None O
content None None O
. None None O

The None None O
antioxidant None None O
status None None O
of None None O
these None None O
animals None None O
also None None O
was None None O
improved None None O
upon None None O
treatment None None O
. None None O

Neurovascular None None O
effects None None O
of None None O
CD47 None None O
signaling None None O
: None None O
promotion None None O
of None None O
cell None None O
death None None O
, None None O
inflammation None None O
, None None O
and None None O
suppression None None O
of None None O
angiogenesis None None O
in None None O
brain None None O
endothelial None None O
cells None None O
in None None O
vitro None None O
. None None O

The None None O
concept None None O
of None None O
the None None O
neurovascular None None O
unit None None O
emphasizes None None O
that None None O
common None None O
signals None None O
and None None O
substrates None None O
underlie None None O
the None None O
physiology None None O
and None None O
pathophysiology None None O
of None None O
neuronal None None O
and None None O
endothelial None None O
compartments None None O
in None None O
brain None None O
. None None O

Recent None None O
data None None O
suggest None None O
that None None O
activation None None O
of None None O
the None None O
integrin None None O
- None None O
associated None None O
protein None None O
CD47 None None O
promotes None None O
neuronal None None O
cell None None O
death None None O
. None None O

Is None None O
it None None O
possible None None O
that None None O
CD47 None None O
may None None O
also None None O
negatively None None O
affect None None O
cerebral None None O
endothelial None None O
cells None None O
? None None O

Exposure None None O
of None None O
wild None None O
- None None O
type None None O
primary None None O
mouse None None O
cerebral None None O
endothelial None None O
cells None None O
to None None O
the None None O
CD47 None None O
ligand None None O
thrombospondin None None O
1 None None O
( None None O
TSP None None O
- None None O
1 None None O
) None None O
induced None None O
an None None O
increasing None None O
amount None None O
of None None O
cell None None O
death None None O
, None None O
whereas None None O
cytotoxicity None None O
was None None O
significantly None None O
decreased None None O
in None None O
cerebral None None O
endothelial None None O
cells None None O
derived None None O
from None None O
CD47 None None O
knockout None None O
mice None None O
. None None O

The None None O
specific None None O
CD47 None None O
- None None O
activating None None O
peptide None None O
, None None O
4N1K None None O
, None None O
similarly None None O
induced None None O
cell None None O
death None None O
in None None O
human None None O
brain None None O
microvascular None None O
endothelial None None O
cells None None O
. None None O

Promotion None None O
of None None O
inflammation None None O
was None None O
also None None O
involved None None O
because None None O
lower None None O
TSP None None O
- None None O
1 None None O
was None None O
able None None O
to None None O
up None None O
- None None O
regulate None None O
the None None O
adhesion None None O
molecules None None O
intercellular None None O
adhesion None None O
molecule None None O
- None None O
1 None None O
and None None O
vascular None None O
cell None None O
adhesion None None O
molecule None None O
- None None O
1 None None O
. None None O

Finally None None O
, None None O
CD47 None None O
signaling None None O
may None None O
suppress None None O
angiogenesis None None O
because None None O
4N1K None None O
significantly None None O
inhibited None None O
endothelial None None O
cell None None O
migration None None O
and None None O
tube None None O
formation None None O
in None None O
vitro None None O
. None None O

We None None O
conclude None None O
that None None O
CD47 None None O
signaling None None O
can None None O
negatively None None O
affect None None O
the None None O
viability None None O
and None None O
function None None O
of None None O
cerebral None None O
endothelial None None O
cells None None O
, None None O
further None None O
supporting None None O
the None None O
notion None None O
that None None O
CD47 None None O
may None None O
be None None O
a None None O
potential None None O
neurovascular None None O
target None None O
for None None O
stroke None None O
and None None O
brain None None O
injury None None O
. None None O

Haplotype None None O
block None None O
structure None None O
from None None O
one None None O
replicate None None O
generated None None O
by None None O
the None None O
block None None O
method None None O
( None None O
ALS None None O
) None None O
. None None O

Insulin None None O
- None None O
like None None O
growth None None O
factor None None O
1 None None O
receptor None None O
enhances None None O
invasion None None O
and None None O
induces None None O
resistance None None O
to None None O
apoptosis None None O
of None None O
colon None None O
cancer None None O
cells None None O
through None None O
the None None O
Akt None None O
/ None None O
Bcl None None O
- None None O
x None None O
( None None O
L None None O
) None None O
pathway None None O
. None None O

Colon None None O
cancer None None O
overexpresses None None O
insulin None None O
- None None O
like None None O
growth None None O
factor None None O
1 None None O
( None None O
IGF1 None None O
) None None O
and None None O
insulin None None O
- None None O
like None None O
growth None None O
factor None None O
1 None None O
receptor None None O
( None None O
IGF1 None None O
- None None O
R None None O
) None None O
, None None O
as None None O
compared None None O
with None None O
normal None None O
or None None O
adenomatous None None O
mucosa None None O
, None None O
and None None O
it None None O
has None None O
been None None O
postulated None None O
that None None O
colorectal None None O
cancer None None O
cells None None O
depend None None O
on None None O
the None None O
IGF1 None None O
/ None None O
IGF1 None None O
- None None O
R None None O
pathway None None O
for None None O
their None None O
growth None None O
and None None O
progression None None O
. None None O

In None None O
this None None O
study None None O
, None None O
using None None O
the None None O
human None None O
colon None None O
cancer None None O
cell None None O
line None None O
HCT116 None None I-Cell-line-name
, None None O
we None None O
find None None O
that None None O
established None None O
HCT116 None None I-Cell-line-name
/ None None O
IGF1 None None O
- None None O
R None None O
transfectants None None O
exhibit None None O
a None None O
more None None O
aggressive None None O
transformed None None O
phenotype None None O
than None None O
the None None O
parental None None O
cell None None O
line None None O
, None None O
as None None O
demonstrated None None O
by None None O
their None None O
higher None None O
proliferation None None O
rate None None O
in None None O
response None None O
to None None O
IGF1 None None O
, None None O
higher None None O
degree None None O
of None None O
anchorage None None O
- None None O
independent None None O
growth None None O
, None None O
resistance None None O
to None None O
serum None None O
deprivation None None O
- None None O
induced None None O
apoptosis None None O
, None None O
and None None O
higher None None O
migratory None None O
capability None None O
in None None O
a None None O
monolayer None None O
" None None O
wounding None None O
assay None None O
. None None O
" None None O
When None None O
injected None None O
into None None O
nude None None O
mice None None O
, None None O
HCT116 None None I-Cell-line-name
/ None None O
IGF1 None None O
- None None O
R None None O
transfectants None None O
were None None O
highly None None O
invasive None None O
and None None O
produced None None O
distant None None O
metastases None None O
, None None O
whereas None None O
the None None O
parental None None O
cell None None O
did None None O
not None None O
. None None O

Moreover None None O
, None None O
the None None O
overexpression None None O
of None None O
IGF1 None None O
- None None O
R None None O
in None None O
these None None O
cells None None O
was None None O
associated None None O
with None None O
IGF1 None None O
- None None O
R None None O
- None None O
induced None None O
activation None None O
of None None O
Akt None None O
and None None O
up None None O
- None None O
regulation None None O
of None None O
the None None O
antiapoptotic None None O
protein None None O
Bcl None None O
- None None O
x None None O
( None None O
L None None O
) None None O
. None None O

We None None O
also None None O
show None None O
that None None O
Akt None None O
pathway None None O
mediates None None O
IGF1 None None O
- None None O
R None None O
- None None O
induced None None O
Bcl None None O
- None None O
x None None O
( None None O
L None None O
) None None O
expression None None O
at None None O
transcriptional None None O
level None None O
. None None O

Our None None O
data None None O
demonstrate None None O
, None None O
for None None O
the None None O
first None None O
time None None O
, None None O
that None None O
IGF1 None None O
- None None O
R None None O
/ None None O
Akt None None O
/ None None O
Bcl None None O
- None None O
x None None O
( None None O
L None None O
) None None O
pathway None None O
may None None O
contribute None None O
to None None O
a None None O
more None None O
aggressive None None O
malignant None None O
phenotype None None O
, None None O
in None None O
a None None O
subset None None O
of None None O
colorectal None None O
cancers None None O
. None None O

Neutrophil None None O
function None None O
in None None O
chronic None None O
neutrophilic None None O
leukemia None None O
: None None O
defective None None O
respiratory None None O
burst None None O
in None None O
response None None O
to None None O
phorbol None None O
esters None None O
. None None O

Functional None None O
analyses None None O
were None None O
performed None None O
on None None O
neutrophils None None O
isolated None None O
from None None O
6 None None O
patients None None O
from None None O
two None None O
institutions None None O
who None None O
displayed None None O
features None None O
of None None O
chronic None None O
neutrophilic None None O
leukemia None None O
( None None O
CNL None None O
) None None O
. None None O

These None None O
neutrophils None None O
demonstrated None None O
a None None O
consistent None None O
deficiency None None O
( None None O
44 None None O
+ None None O
/ None None O
- None None O
8 None None O
% None None O
of None None O
control None None O
values None None O
) None None O
in None None O
superoxide None None O
anion None None O
( None None O
O2 None None O
- None None O
) None None O
production None None O
in None None O
response None None O
to None None O
the None None O
phorbol None None O
ester None None O
, None None O
phorbol None None O
myristate None None O
acetate None None O
( None None O
PMA None None O
) None None O
. None None O

O2 None None O
- None None O
production None None O
in None None O
response None None O
to None None O
chemotactic None None O
peptides None None O
was None None O
near None None O
normal None None O
( None None O
82 None None O
. None None O
3 None None O
+ None None O
/ None None O
- None None O
10 None None O
. None None O
7 None None O
% None None O
of None None O
control None None O
values None None O
) None None O
. None None O

Bacterial None None O
killing None None O
was None None O
normal None None O
in None None O
the None None O
two None None O
patients None None O
studied None None O
, None None O
and None None O
chemotaxis None None O
was None None O
diminished None None O
in None None O
response None None O
to None None O
zymosan None None O
- None None O
activated None None O
plasma None None O
and None None O
to None None O
high None None O
concentrations None None O
of None None O
chemotactic None None O
peptides None None O
in None None O
the None None O
patients None None O
studied None None O
. None None O

Cytosolic None None O
C None None O
kinase None None O
activity None None O
was None None O
decreased None None O
in None None O
one None None O
of None None O
the None None O
two None None O
patients None None O
studied None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
a None None O
deficient None None O
O2 None None O
- None None O
release None None O
in None None O
response None None O
to None None O
PMA None None O
is None None O
a None None O
hallmark None None O
of None None O
neutrophils None None O
in None None O
CNL None None O
and None None O
may None None O
provide None None O
a None None O
diagnostic None None O
indicator None None O
of None None O
this None None O
condition None None O
. None None O

Functional None None O
significance None None O
of None None O
VEGF None None O
- None None O
a None None O
in None None O
human None None O
ovarian None None O
carcinoma None None O
: None None O
role None None O
in None None O
vasculogenic None None O
mimicry None None O
. None None O

Ovarian None None O
cancer None None O
is None None O
a None None O
silent None None O
killer None None O
, None None O
and None None O
shows None None O
early None None O
extensive None None O
tumor None None O
invasion None None O
and None None O
peritoneal None None O
metastasis None None O
. None None O

The None None O
microcirculation None None O
of None None O
most None None O
tumors None None O
includes None None O
cooperation None None O
of None None O
pre None None O
- None None O
existing None None O
vessels None None O
, None None O
intussusceptive None None O
microvascular None None O
growth None None O
, None None O
postnatal None None O
vasculogenesis None None O
, None None O
glomeruloid None None O
angiogenesis None None O
and None None O
vasculogenic None None O
mimicry None None O
( None None O
VM None None O
) None None O
. None None O

VM None None O
is None None O
critical None None O
for None None O
a None None O
tumor None None O
blood None None O
supply None None O
and None None O
is None None O
asscociated None None O
with None None O
aggressive None None O
features None None O
and None None O
metastasis None None O
. None None O

Our None None O
studies None None O
highlight None None O
the None None O
plasticity None None O
of None None O
aggressive None None O
human None None O
ovarian None None O
carcinoma None None O
cells None None O
and None None O
call None None O
into None None O
question None None O
the None None O
underlying None None O
significance None None O
of None None O
their None None O
ability None None O
to None None O
form None None O
VM None None O
in None None O
vitro None None O
induced None None O
by None None O
VEGF None None O
- None None O
a None None O
. None None O

These None None O
studies None None O
also None None O
show None None O
their None None O
clinicalpathological None None O
features None None O
of None None O
the None None O
cancers None None O
with None None O
human None None O
Paraffin None None O
- None None O
embedded None None O
tumor None None O
tissue None None O
samples None None O
. None None O

Results None None O
show None None O
that None None O
the None None O
process None None O
: None None O
VEGF None None O
- None None O
a None None O
- None None O
- None None O
greater None None O
than None None O
EphA2 None None O
- None None O
- None None O
greater None None O
than None None O
MMPs None None O
- None None O
- None None O
greater None None O
than None None O
VM None None O
is None None O
the None None O
main None None O
pathway None None O
for None None O
VM None None O
formation None None O
and None None O
VEGF None None O
- None None O
a None None O
appears None None O
to None None O
play None None O
an None None O
important None None O
role None None O
in None None O
the None None O
formation None None O
of None None O
VM None None O
based None None O
on None None O
our None None O
in None None O
vitro None None O
assays None None O
and None None O
clinical None None O
immunohistochemical None None O
analyses None None O
. None None O

VM None None O
- None None O
targeting None None O
strategies None None O
for None None O
ovarian None None O
cancer None None O
include None None O
anti None None O
- None None O
VEGF None None O
- None None O
a None None O
treatment None None O
, None None O
knocking None None O
down None None O
the None None O
EphA2 None None O
gene None None O
and None None O
using None None O
antibodies None None O
against None None O
human None None O
MMPs None None O
if None None O
the None None O
tumor None None O
is None None O
VM None None O
positive None None O
. None None O

This None None O
strategy None None O
may None None O
be None None O
of None None O
significant None None O
value None None O
in None None O
laying None None O
the None None O
foundation None None O
for None None O
a None None O
more None None O
explicit None None O
anti None None O
- None None O
tumor None None O
angiogenesis None None O
therapy None None O
. None None O

Effect None None O
of None None O
estrogen None None O
and None None O
progesterone None None O
on None None O
macrophage None None O
activation None None O
during None None O
wound None None O
healing None None O
. None None O

Age None None O
- None None O
related None None O
impaired None None O
wound None None O
healing None None O
leads None None O
to None None O
substantial None None O
morbidity None None O
and None None O
mortality None None O
along None None O
with None None O
a None None O
large None None O
financial None None O
burden None None O
to None None O
health None None O
services None None O
. None None O

There None None O
is None None O
accumulating None None O
evidence None None O
that None None O
the None None O
tissue None None O
damage None None O
associated None None O
with None None O
chronic None None O
wounds None None O
is None None O
initiated None None O
and None None O
propagated None None O
by None None O
an None None O
inappropriately None None O
excessive None None O
inflammatory None None O
response None None O
. None None O

Research None None O
on None None O
age None None O
- None None O
related None None O
impaired None None O
wound None None O
healing None None O
suggests None None O
that None None O
the None None O
decline None None O
in None None O
sex None None O
steroid None None O
hormones None None O
with None None O
age None None O
may None None O
have None None O
a None None O
substantial None None O
influence None None O
on None None O
the None None O
inflammatory None None O
response None None O
in None None O
vivo None None O
. None None O

Topical None None O
and None None O
systemic None None O
estrogen None None O
treatments None None O
have None None O
shown None None O
an None None O
increased None None O
rate None None O
of None None O
healing None None O
by None None O
reducing None None O
inflammation None None O
, None None O
however None None O
the None None O
underlying None None O
mechanisms None None O
are None None O
little None None O
understood None None O
. None None O

In None None O
vitro None None O
studies None None O
also None None O
suggest None None O
progesterone None None O
may None None O
play None None O
a None None O
role None None O
in None None O
modulating None None O
inflammation None None O
. None None O

Macrophages None None O
are None None O
essential None None O
mediators None None O
of None None O
inflammation None None O
and None None O
wound None None O
healing None None O
. None None O

Macrophages None None O
can None None O
be None None O
activated None None O
in None None O
a None None O
classical None None O
or None None O
alternative None None O
manner None None O
in None None O
parallel None None O
with None None O
the None None O
T None None O
( None None O
H None None O
) None None O
1 None None O
/ None None O
T None None O
( None None O
H None None O
) None None O
2 None None O
dichotomy None None O
, None None O
respectively None None O
. None None O

Using None None O
a None None O
murine None None O
incisional None None O
wound None None O
healing None None O
model None None O
this None None O
study None None O
was None None O
carried None None O
out None None O
to None None O
investigate None None O
the None None O
roles None None O
of None None O
estrogen None None O
and None None O
progesterone None None O
on None None O
macrophage None None O
activation None None O
during None None O
the None None O
wound None None O
healing None None O
response None None O
. None None O

Our None None O
findings None None O
suggest None None O
with None None O
a None None O
reduction None None O
of None None O
steroid None None O
hormones None None O
following None None O
ovariectomy None None O
, None None O
alternatively None None O
activated None None O
macrophage None None O
markers None None O
( None None O
Fizz1 None None O
and None None O
Ym1 None None O
) None None O
were None None O
reduced None None O
, None None O
with None None O
this None None O
effect None None O
being None None O
reversed None None O
with None None O
the None None O
administration None None O
of None None O
estrogen None None O
or None None O
progesterone None None O
; None None O
suggesting None None O
that None None O
with None None O
the None None O
reduction None None O
of None None O
steroid None None O
hormones None None O
macrophages None None O
are None None O
activated None None O
in None None O
a None None O
classical None None O
manner None None O
, None None O
promoting None None O
inflammation None None O
, None None O
whereas None None O
estrogen None None O
or None None O
progesterone None None O
are None None O
contributing None None O
toward None None O
macrophage None None O
activation None None O
in None None O
an None None O
alternative None None O
manner None None O
, None None O
driving None None O
wound None None O
repair None None O
, None None O
angiogenesis None None O
, None None O
and None None O
remodeling None None O
. None None O

Elevated None None O
expression None None O
of None None O
the None None O
junB None None O
proto None None O
- None None O
oncogene None None O
is None None O
essential None None O
for None None O
v None None O
- None None O
fos None None O
induced None None O
transformation None None O
of None None O
Rat None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
cells None None O
. None None O

We None None O
previously None None O
described None None O
the None None O
isolation None None O
of None None O
non None None O
- None None O
tumorigenic None None O
revertants None None O
from None None O
mutagenized None None O
populations None None O
of None None O
v None None O
- None None O
fos None None O
- None None O
transformed None None O
Rat None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
cells None None O
( None None O
Zarbl None None O
et None None O
al None None O
. None None O
, None None O
1987 None None O
) None None O
. None None O

In None None O
the None None O
present None None O
study None None O
we None None O
examined None None O
the None None O
possibility None None O
that None None O
the None None O
revertant None None O
phenotype None None O
resulted None None O
from None None O
mutations None None O
that None None O
altered None None O
the None None O
expression None None O
or None None O
activities None None O
of None None O
the None None O
c None None O
- None None O
jun None None O
or None None O
junB None None O
proto None None O
- None None O
oncogenes None None O
. None None O

The None None O
results None None O
demonstrated None None O
that None None O
levels None None O
of None None O
the None None O
c None None O
- None None O
jun None None O
mRNA None None O
and None None O
protein None None O
were None None O
unchanged None None O
in None None O
the None None O
revertants None None O
when None None O
compared None None O
to None None O
the None None O
transformed None None O
parental None None O
cells None None O
, None None O
and None None O
ectopic None None O
overexpression None None O
of None None O
c None None O
- None None O
jun None None O
failed None None O
to None None O
retransform None None O
the None None O
revertants None None O
. None None O

Although None None O
one None None O
mutant None None O
allele None None O
was None None O
detected None None O
in None None O
revertant None None O
EMS None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
- None None I-Cell-line-name
19 None None I-Cell-line-name
, None None O
overexpression None None O
of None None O
this None None O
mutant None None O
allele None None O
failed None None O
to None None O
inhibit None None O
v None None O
- None None O
fos None None O
induced None None O
cell None None O
transformation None None O
. None None O

Together None None O
these None None O
results None None O
indicated None None O
that None None O
the None None O
revertant None None O
phenotype None None O
did None None O
not None None O
result None None O
from None None O
altered None None O
expression None None O
or None None O
mutations None None O
in None None O
the None None O
c None None O
- None None O
jun None None O
gene None None O
. None None O

In None None O
contrast None None O
to None None O
the None None O
results None None O
obtained None None O
with None None O
c None None O
- None None O
jun None None O
, None None O
the None None O
levels None None O
of None None O
junB None None O
mRNA None None O
and None None O
protein None None O
were None None O
found None None O
to None None O
be None None O
reduced None None O
two None None O
- None None O
or None None O
threefold None None O
in None None O
revertant None None O
EMS None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
- None None I-Cell-line-name
19 None None I-Cell-line-name
. None None O

Ectopic None None O
overexpression None None O
of None None O
junB None None O
induced None None O
transformation None None O
of None None O
revertant None None O
EMS None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
- None None I-Cell-line-name
19 None None I-Cell-line-name
, None None O
but None None O
failed None None O
to None None O
transform None None O
Rat None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
cells None None O
. None None O

Moreover None None O
, None None O
about None None O
10 None None O
% None None O
of None None O
v None None O
- None None O
fos None None O
transformed None None O
cells None None O
transfected None None O
with None None O
vectors None None O
that None None O
express None None O
antisense None None O
junB None None O
mRNA None None O
acquired None None O
a None None O
non None None O
- None None O
transformed None None O
phenotype None None O
. None None O

Together None None O
these None None O
results None None O
indicate None None O
that None None O
expression None None O
of None None O
junB None None O
above None None O
a None None O
threshold None None O
level None None O
is None None O
essential None None O
for None None O
v None None O
- None None O
fos None None O
- None None O
induced None None O
transformation None None O
of None None O
Rat None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
fibroblasts None None O
. None None O

Refinement None None O

R None None O
[ None None O
F None None O
2 None None O
> None None O
2sigma None None O
( None None O
F None None O
2 None None O
) None None O
] None None O
= None None O
0 None None O
. None None O
052 None None O

wR None None O
( None None O
F None None O
2 None None O
) None None O
= None None O
0 None None O
. None None O
132 None None O

S None None O
= None None O
1 None None O
. None None O
02 None None O

3804 None None O
reflections None None O

229 None None O
parameters None None O

67 None None O
restraints None None O

H None None O
- None None O
atom None None O
parameters None None O
constrained None None O

Deltarhomax None None O
= None None O
0 None None O
. None None O
56 None None O
e None None O
A None None O
- None None O
3 None None O

Deltarhomin None None O
= None None O
- None None O
0 None None O
. None None O
38 None None O
e None None O
A None None O
- None None O
3 None None O

[ None None O
Radiologic None None O
- None None O
pathologic None None O
correlations None None O
in None None O
breast None None O
diseases None None O
] None None O

The None None O
objective None None O
of None None O
this None None O
article None None O
is None None O
to None None O
explain None None O
radiologic None None O
patterns None None O
of None None O
benign None None O
and None None O
malignant None None O
breast None None O
lesions None None O
( None None O
masses None None O
, None None O
microcalcifications None None O
) None None O
based None None O
on None None O
histological None None O
correlations None None O
. None None O

The None None O
stromal None None O
fibrous None None O
reaction None None O
associated None None O
to None None O
infiltrating None None O
carcinomas None None O
is None None O
responsible None None O
of None None O
focal None None O
increased None None O
density None None O
, None None O
and None None O
architectural None None O
distorsion None None O
, None None O
ultrasound None None O
acoustic None None O
shadowing None None O
; None None O
abnormal None None O
neoangiogenesis None None O
can None None O
be None None O
detected None None O
by None None O
Doppler None None O
, None None O
CT None None O
or None None O
MR None None O
imaging None None O
. None None O

Invasive None None O
carcinomas None None O
without None None O
spiculated None None O
margins None None O
are None None O
poorly None None O
differentiated None None O
tumors None None O
. None None O

Mammographic None None O
patterns None None O
of None None O
microcalcifications None None O
depend None None O
on None None O
their None None O
physiopathological None None O
process None None O
( None None O
necrosis None None O
, None None O
secretion None None O
) None None O
, None None O
and None None O
the None None O
shape None None O
of None None O
clusters None None O
( None None O
round None None O
, None None O
triangular None None O
) None None O
typifies None None O
their None None O
anatomical None None O
site None None O
of None None O
origin None None O
( None None O
lobular None None O
, None None O
ductal None None O
) None None O
. None None O

Less None None O
frequent None None O
lesions None None O
( None None O
invasive None None O
lobular None None O
, None None O
mucinous None None O
, None None O
and None None O
medullary None None O
carcinomas None None O
, None None O
radial None None O
scar None None O
) None None O
will None None O
be None None O
also None None O
explained None None O
based None None O
on None None O
radiopathological None None O
correlations None None O
. None None O

Knowledge None None O
of None None O
radiopathological None None O
correlations None None O
in None None O
breast None None O
diseases None None O
helps None None O
the None None O
radiologists None None O
to None None O
analyze None None O
and None None O
characterize None None O
breast None None O
lesions None None O
. None None O

Prognostic None None O
value None None O
of None None O
angiogenesis None None O
in None None O
operable None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
cancer None None O
. None None O

Tumour None None O
angiogenesis None None O
is None None O
an None None O
important None None O
factor None None O
for None None O
tumour None None O
growth None None O
and None None O
metastasis None None O
. None None O

Although None None O
some None None O
recent None None O
reports None None O
suggest None None O
that None None O
microvessel None None O
counts None None O
in None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
cancer None None O
are None None O
related None None O
to None None O
a None None O
poor None None O
disease None None O
outcome None None O
, None None O
the None None O
results None None O
were None None O
not None None O
conclusive None None O
and None None O
were None None O
not None None O
compared None None O
with None None O
other None None O
molecular None None O
prognostic None None O
markers None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
the None None O
vascular None None O
grade None None O
was None None O
assessed None None O
in None None O
107 None None O
( None None O
T1 None None O
, None None O
2 None None O
- None None O
N0 None None O
, None None O
1 None None O
) None None O
operable None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
carcinomas None None O
, None None O
using None None O
the None None O
JC70 None None O
monoclonal None None O
antibody None None O
to None None O
CD31 None None O
. None None O

Three None None O
vascular None None O
grades None None O
were None None O
defined None None O
with None None O
appraisal None None O
by None None O
eye None None O
and None None O
by None None O
Chalkley None None O
counting None None O
: None None O
high None None O
( None None O
Chalkley None None O
score None None O
7 None None O
- None None O
12 None None O
) None None O
, None None O
medium None None O
( None None O
5 None None O
- None None O
6 None None O
) None None O
, None None O
and None None O
low None None O
( None None O
2 None None O
- None None O
4 None None O
) None None O
. None None O

There None None O
was None None O
a None None O
significant None None O
correlation None None O
between None None O
eye None None O
appraisal None None O
and None None O
Chalkley None None O
counting None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
0001 None None O
) None None O
. None None O

Vascular None None O
grade None None O
was None None O
not None None O
related None None O
to None None O
histology None None O
, None None O
grade None None O
, None None O
proliferation None None O
index None None O
( None None O
Ki67 None None O
) None None O
, None None O
or None None O
EGFR None None O
or None None O
p53 None None O
expression None None O
. None None O

Tumours None None O
from None None O
younger None None O
patients None None O
had None None O
a None None O
higher None None O
grade None None O
of None None O
angiogenesis None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Apart None None O
from None None O
the None None O
vascular None None O
grade None None O
, None None O
none None None O
of None None O
the None None O
other None None O
factors None None O
examined None None O
was None None O
statistically None None O
related None None O
to None None O
lymph None None O
node None None O
metastasis None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
0001 None None O
) None None O
. None None O

A None None O
univariate None None O
analysis None None O
of None None O
survival None None O
showed None None O
that None None O
vascular None None O
grade None None O
was None None O
the None None O
most None None O
significant None None O
prognostic None None O
factor None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
0004 None None O
) None None O
, None None O
followed None None O
by None None O
N None None O
- None None O
stage None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

In None None O
a None None O
multivariate None None O
analysis None None O
, None None O
N None None O
- None None O
stage None None O
and None None O
vascular None None O
grade None None O
were None None O
not None None O
found None None O
to None None O
be None None O
independent None None O
prognostic None None O
factors None None O
, None None O
since None None O
they None None O
were None None O
strongly None None O
related None None O
to None None O
each None None O
other None None O
. None None O

Excluding None None O
N None None O
- None None O
stage None None O
, None None O
vascular None None O
grade None None O
was None None O
the None None O
only None None O
independent None None O
prognostic None None O
factor None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
007 None None O
) None None O
. None None O

Kaplan None None O
- None None O
Meier None None O
survival None None O
curves None None O
showed None None O
a None None O
statistically None None O
significant None None O
worse None None O
prognosis None None O
for None None O
patients None None O
with None None O
high None None O
vascular None None O
grade None None O
, None None O
but None None O
no None None O
difference None None O
was None None O
observed None None O
between None None O
low None None O
and None None O
medium None None O
vascular None None O
grade None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
angiogenesis None None O
in None None O
operable None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
cancer None None O
is None None O
a None None O
major None None O
prognostic None None O
factor None None O
for None None O
survival None None O
and None None O
, None None O
among None None O
the None None O
parameters None None O
tested None None O
, None None O
is None None O
the None None O
only None None O
factor None None O
related None None O
to None None O
cancer None None O
cell None None O
migration None None O
to None None O
lymph None None O
nodes None None O
. None None O

The None None O
integration None None O
of None None O
vascular None None O
grading None None O
in None None O
clinical None None O
trials None None O
on None None O
adjuvant None None O
chemotherapy None None O
and None None O
/ None None O
or None None O
radiotherapy None None O
could None None O
substantially None None O
contribute None None O
in None None O
defining None None O
groups None None O
of None None O
operable None None O
patients None None O
who None None O
might None None O
benefit None None O
from None None O
cytotoxic None None O
treatment None None O
. None None O

Primary None None O
hyperparathyroidism None None O
and None None O
the None None O
heart None None O
: None None O
cardiac None None O
abnormalities None None O
correlated None None O
to None None O
clinical None None O
and None None O
biochemical None None O
data None None O
. None None O

Comparing None None O
patients None None O
with None None O
primary None None O
hyperparathyroidism None None O
( None None O
PHP None None O
) None None O
to None None O
a None None O
normocalcemic None None O
control None None O
population None None O
, None None O
those None None O
with None None O
PHP None None O
have None None O
a None None O
higher None None O
incidence None None O
of None None O
cardiovascular None None O
disease None None O
and None None O
cardiac None None O
abnormalities None None O
. None None O

This None None O
study None None O
aimed None None O
at None None O
correlating None None O
cardiac None None O
findings None None O
( None None O
valvular None None O
and None None O
myocardial None None O
calcification None None O
, None None O
myocardial None None O
hypertrophy None None O
) None None O
with None None O
clinical None None O
data None None O
( None None O
age None None O
, None None O
sex None None O
, None None O
clinical None None O
manifestation None None O
, None None O
nephrolithiasis None None O
, None None O
nephrocalcinosis None None O
, None None O
hypertension None None O
, None None O
skeletal None None O
abnormalities None None O
, None None O
hypercalcemic None None O
syndrome None None O
) None None O
and None None O
biochemical None None O
data None None O
( None None O
serum None None O
calcium None None O
, None None O
serum None None O
phosphate None None O
, None None O
serum None None O
iPTH None None O
level None None O
, None None O
serum None None O
creatinine None None O
) None None O
. None None O

A None None O
group None None O
of None None O
132 None None O
consecutive None None O
patients None None O
with None None O
surgically None None O
verified None None O
PHP None None O
( None None O
94 None None O
women None None O
, None None O
38 None None O
men None None O
; None None O
ages None None O
15 None None O
- None None O
86 None None O
, None None O
mean None None O
age None None O
57 None None O
+ None None O
/ None None O
- None None O
16 None None O
years None None O
) None None O
were None None O
included None None O
in None None O
this None None O
study None None O
. None None O

Blood None None O
chemistry None None O
, None None O
clinical None None O
presentation None None O
, None None O
radiography None None O
, None None O
and None None O
echocardiography None None O
were None None O
carried None None O
out None None O
in None None O
all None None O
patients None None O
for None None O
univariate None None O
and None None O
multivariate None None O
analyses None None O
of None None O
all None None O
parameters None None O
. None None O

There None None O
was None None O
no None None O
statistical None None O
correlation None None O
between None None O
clinical None None O
symptoms None None O
, None None O
biochemical None None O
data None None O
, None None O
and None None O
cardiac None None O
calcific None None O
alterations None None O
. None None O

Typical None None O
skeletal None None O
manifestations None None O
( None None O
osteolysis None None O
/ None None O
subperiostal None None O
resorption None None O
) None None O
and None None O
valvular None None O
calcifications None None O
were None None O
significantly None None O
correlated None None O
to None None O
left None None O
ventricular None None O
hypertrophy None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
005 None None O
) None None O
. None None O

Cardiac None None O
abnormalities None None O
such None None O
as None None O
calcific None None O
myocardial None None O
deposits None None O
or None None O
mitral None None O
and None None O
aortic None None O
valvular None None O
calcifications None None O
do None None O
not None None O
correlate None None O
with None None O
laboratory None None O
findings None None O
and None None O
clinical None None O
presentation None None O
at None None O
the None None O
time None None O
of None None O
diagnosis None None O
. None None O

There None None O
was None None O
no None None O
biochemical None None O
or None None O
clinical None None O
variable None None O
that None None O
could None None O
predict None None O
the None None O
frequency None None O
or None None O
severity None None O
of None None O
valvular None None O
sclerosis None None O
or None None O
calcific None None O
deposits None None O
in None None O
the None None O
myocardium None None O
. None None O

However None None O
, None None O
PHP None None O
- None None O
related None None O
skeletal None None O
abnormalities None None O
and None None O
valvular None None O
calcification None None O
were None None O
predicting None None O
factors None None O
for None None O
left None None O
ventricular None None O
hypertrophy None None O
, None None O
a None None O
reversible None None O
cardiac None None O
manifestation None None O
of None None O
PHP None None O
. None None O

Myocardial None None O
hypertrophy None None O
is None None O
more None None O
often None None O
found None None O
with None None O
classic None None O
symptomatic None None O
PHP None None O
with None None O
osseous None None O
abnormalities None None O
. None None O

The None None O
effect None None O
of None None O
p None None O
- None None O
chlorophenylalanine None None O
on None None O
the None None O
pethidine None None O
- None None O
or None None O
methadone None None O
- None None O
induced None None O
decrease None None O
in None None O
locomotor None None O
activity None None O
of None None O
rats None None O
. None None O

Either None None O
pethidine None None O
HCl None None O
( None None O
50 None None O
mg None None O
/ None None O
kg None None O
s None None O
. None None O
c None None O
. None None O
) None None O
or None None O
methadone None None O
HCl None None O
( None None O
8 None None O
mg None None O
/ None None O
kg None None O
s None None O
. None None O
c None None O
. None None O
) None None O
produced None None O
a None None O
prominent None None O
decrease None None O
in None None O
locomotor None None O
activity None None O
of None None O
rats None None O
. None None O

Pretreatment None None O
of None None O
rats None None O
with None None O
p None None O
- None None O
chlorophenylalanine None None O
( None None O
p None None O
- None None O
CPA None None O
, None None O
320 None None O
mg None None O
/ None None O
kg None None O
i None None O
. None None O
p None None O
. None None O
) None None O
48 None None O
h None None O
before None None O
the None None O
narcotic None None O
injection None None O
significantly None None O
antagonized None None O
the None None O
activity None None O
- None None O
decreasing None None O
effects None None O
of None None O
narcotics None None O
. None None O

When None None O
rats None None O
pretreated None None O
with None None O
p None None O
- None None O
CPA None None O
were None None O
given None None O
5 None None O
- None None O
hydroxytryptophan None None O
( None None O
75 None None O
mg None None O
/ None None O
kg None None O
s None None O
. None None O
c None None O
. None None O
) None None O
30 None None O
min None None O
before None None O
narcotic None None O
administration None None O
, None None O
the None None O
activity None None O
- None None O
decreasing None None O
response None None O
to None None O
narcotics None None O
was None None O
restored None None O
. None None O

Thus None None O
, None None O
a None None O
decrease None None O
in None None O
locomotor None None O
activity None None O
induced None None O
in None None O
rats None None O
by None None O
either None None O
pethidine None None O
or None None O
methadone None None O
is None None O
probably None None O
mediated None None O
by None None O
serotonergic None None O
mechanisms None None O
. None None O

[ None None O
mRNA None None O
expression None None O
of None None O
metastasis None None O
- None None O
suppressor None None O
gene None None O
nm23 None None O
in None None O
carcinoma None None O
of None None O
buccal None None O
mucosa None None O
. None None O
II None None O
. None None O
Quantitative None None O
reverse None None O
transcription None None O
PCR None None O
amplification None None O
] None None O
. None None O

The None None O
nm23 None None O
gene None None O
is None None O
a None None O
conspicuous None None O
metastasis None None O
- None None O
suppressor None None O
gene None None O
. None None O

The None None O
authors None None O
detected None None O
both None None O
nm23 None None O
- None None O
H1 None None O
and None None O
nm23 None None O
- None None O
H2 None None O
mRNA None None O
levels None None O
in None None O
47 None None O
tissues None None O
samples None None O
of None None O
patients None None O
with None None O
carcinoma None None O
of None None O
buccal None None O
mucosa None None O
( None None O
CBM None None O
) None None O
by None None O
quantitative None None O
reverse None None O
transcription None None O
PCR None None O
amplification None None O
. None None O

The None None O
results None None O
showed None None O
that None None O
expression None None O
levels None None O
of None None O
both None None O
nm23 None None O
- None None O
H1 None None O
and None None O
nm23 None None O
- None None O
H2 None None O
mRNA None None O
varied None None O
in None None O
normal None None O
buccal None None O
mucosa None None O
, None None O
leukoplakia None None O
, None None O
adjacent None None O
nontumorous None None O
mucosa None None O
, None None O
submandibular None None O
gland None None O
, None None O
CBM None None O
and None None O
lymph None None O
nodes None None O
with None None O
or None None O
without None None O
metastasis None None O
. None None O

The None None O
nm23 None None O
- None None O
H1 None None O
mRNA None None O
expression None None O
levels None None O
in None None O
CBM None None O
with None None O
lymph None None O
nodes None None O
metastases None None O
were None None O
lower None None O
than None None O
those None None O
in None None O
CBM None None O
without None None O
metastases None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
, None None O
while None None O
no None None O
significance None None O
of None None O
nm23 None None O
- None None O
H2 None None O
mRNA None None O
expression None None O
levels None None O
was None None O
found None None O
between None None O
CBM None None O
with None None O
and None None O
CBM None None O
without None None O
metastasis None None O
( None None O
P None None O
> None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
results None None O
were None None O
comparative None None O
to None None O
those None None O
of None None O
Northern None None O
blotting None None O
of None None O
the None None O
same None None O
cases None None O
. None None O

The None None O
authors None None O
concluded None None O
that None None O
, None None O
as None None O
also None None O
in None None O
the None None O
study None None O
of None None O
Northern None None O
blotting None None O
, None None O
the None None O
expression None None O
of None None O
nm23 None None O
- None None O
H1 None None O
mRNA None None O
significantly None None O
correlated None None O
inversely None None O
with None None O
lymph None None O
node None None O
metastasis None None O
in None None O
CBM None None O
, None None O
while None None O
the None None O
expression None None O
of None None O
nm23 None None O
- None None O
H2 None None O
mRNA None None O
not None None O
. None None O

Q None None O
- None None O
RT None None O
- None None O
PCR None None O
was None None O
a None None O
useful None None O
method None None O
to None None O
detect None None O
the None None O
mRNA None None O
levels None None O
of None None O
nm23 None None O
gene None None O
in None None O
buccal None None O
carcinoma None None O
. None None O

Tropical None None O
splenomegaly None None O
syndrome None None O
in None None O
Zambia None None O
: None None O
further None None O
observations None None O
and None None O
effects None None O
of None None O
cycloguanil None None O
and None None O
proguanil None None O
. None None O

Nineteen None None O
Zambian None None O
patients None None O
with None None O
the None None O
tropical None None O
splenomegaly None None O
syndrome None None O
and None None O
sinusoidal None None O
lymphocytosis None None O
on None None O
liver None None O
biopsy None None O
were None None O
studied None None O
. None None O

The None None O
association None None O
of None None O
macrobulinaemia None None O
with None None O
the None None O
tropical None None O
splenomegaly None None O
syndrome None None O
has None None O
again None None O
been None None O
confirmed None None O
. None None O

Sixteen None None O
patients None None O
were None None O
treated None None O
with None None O
antimalarials None None O
- None None O
12 None None O
with None None O
cycloguanil None None O
pamoate None None O
alone None None O
, None None O
3 None None O
with None None O
cycloguanil None None O
and None None O
proguanil None None O
, None None O
and None None O
1 None None O
with None None O
proguanil None None O
alone None None O
. None None O

Twelve None None O
patients None None O
were None None O
observed None None O
for None None O
periods None None O
of None None O
sufficient None None O
length None None O
for None None O
the None None O
drug None None O
effect None None O
to None None O
be None None O
assessed None None O
, None None O
and None None O
in None None O
11 None None O
there None None O
was None None O
a None None O
good None None O
response None None O
in None None O
terms None None O
of None None O
decrease None None O
in None None O
spleen None None O
size None None O
. None None O
Cycloguanil None None O
pamoate None None O
may None None O
be None None O
of None None O
value None None O
both None None O
for None None O
prophylaxis None None O
and None None O
treatment None None O
in None None O
areas None None O
where None None O
tropical None None O
splenomegaly None None O
syndrome None None O
is None None O
endemic None None O
. None None O

Effects None None O
of None None O
3 None None O
- None None O
chloromethylthiochromone None None O
- None None O
1 None None O
, None None O
1 None None O
- None None O
dioxide None None O
on None None O
nucleic None None O
acid None None O
, None None O
protein None None O
, None None O
and None None O
aerobic None None O
and None None O
anaerobic None None O
metabolism None None O
of None None O
Ehrlich None None O
ascites None None O
tumor None None O
cells None None O
. None None O

3 None None O
- None None O
Chloromethylthiochromone None None O
- None None O
1 None None O
, None None O
1 None None O
- None None O
dioxide None None O
was None None O
observed None None O
to None None O
be None None O
a None None O
potent None None O
inhibitor None None O
of None None O
Ehrlich None None O
ascites None None O
carcinoma None None O
growth None None O
and None None O
a None None O
moderate None None O
inhibitor None None O
of None None O
P None None I-Cell-line-name
- None None I-Cell-line-name
388 None None I-Cell-line-name
lymphocytic None None O
leukemia None None O
growth None None O
at None None O
10 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
. None None O

Preliminary None None O
in None None O
vitro None None O
studies None None O
showed None None O
that None None O
the None None O
agents None None O
significantly None None O
inhibited None None O
RNA None None O
and None None O
DNA None None O
synthesis None None O
in None None O
Ehrlich None None O
ascites None None O
cells None None O
. None None O

In None None O
vivo None None O
studies None None O
after None None O
dosing None None O
on None None O
Days None None O
6 None None O
, None None O
7 None None O
, None None O
and None None O
8 None None O
demonstrated None None O
the None None O
same None None O
reductions None None O
in None None O
nucleic None None O
acid None None O
synthesis None None O
and None None O
a None None O
moderate None None O
reduction None None O
in None None O
protein None None O
synthesis None None O
. None None O

The None None O
primary None None O
site None None O
of None None O
nucleic None None O
acid None None O
synthesis None None O
, None None O
which None None O
was None None O
blocked None None O
by None None O
3 None None O
- None None O
chloromethylthiochromone None None O
, None None O
was None None O
at None None O
orotidine None None O
monophosphate None None O
decarboxylase None None O
in None None O
the None None O
primidine None None O
pathway None None O
. None None O

Other None None O
enzymes None None O
, None None O
in None None O
anaerobic None None O
and None None O
aerobic None None O
glycolysis None None O
, None None O
which None None O
were None None O
blocked None None O
include None None O
hexokinase None None O
, None None O
phosphofructokinase None None O
, None None O
succinic None None O
and None None O
alpha None None O
- None None O
ketoglutarate None None O
dehydrogenases None None O
, None None O
as None None O
well None None O
as None None O
States None None O
3 None None O
and None None O
4 None None O
of None None O
oxidative None None O
phosphorylation None None O
. None None O

Biochemical None None O
traits None None O

Oscillatory None None O
alpha None None O
- None None O
band None None O
mechanisms None None O
and None None O
the None None O
deployment None None O
of None None O
spatial None None O
attention None None O
to None None O
anticipated None None O
auditory None None O
and None None O
visual None None O
target None None O
locations None None O
: None None O
supramodal None None O
or None None O
sensory None None O
- None None O
specific None None O
control None None O
mechanisms None None O
? None None O

Oscillatory None None O
alpha None None O
- None None O
band None None O
activity None None O
( None None O
8 None None O
- None None O
15 None None O
Hz None None O
) None None O
over None None O
parieto None None O
- None None O
occipital None None O
cortex None None O
in None None O
humans None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
suppression None None O
of None None O
processing None None O
for None None O
inputs None None O
at None None O
to None None O
- None None O
be None None O
- None None O
ignored None None O
regions None None O
of None None O
space None None O
, None None O
with None None O
increased None None O
alpha None None O
- None None O
band None None O
power None None O
observed None None O
over None None O
cortex None None O
contralateral None None O
to None None O
locations None None O
expected None None O
to None None O
contain None None O
distractors None None O
. None None O

It None None O
is None None O
unclear None None O
whether None None O
similar None None O
processes None None O
operate None None O
during None None O
deployment None None O
of None None O
spatial None None O
attention None None O
in None None O
other None None O
sensory None None O
modalities None None O
. None None O

Evidence None None O
from None None O
lesion None None O
patients None None O
suggests None None O
that None None O
parietal None None O
regions None None O
house None None O
supramodal None None O
representations None None O
of None None O
space None None O
. None None O

The None None O
parietal None None O
lobes None None O
are None None O
prominent None None O
generators None None O
of None None O
alpha None None O
oscillations None None O
, None None O
raising None None O
the None None O
possibility None None O
that None None O
alpha None None O
is None None O
a None None O
neural None None O
signature None None O
of None None O
supramodal None None O
spatial None None O
attention None None O
. None None O

Furthermore None None O
, None None O
when None None O
spatial None None O
attention None None O
is None None O
deployed None None O
within None None O
vision None None O
, None None O
processing None None O
of None None O
task None None O
- None None O
irrelevant None None O
auditory None None O
inputs None None O
at None None O
attended None None O
locations None None O
is None None O
also None None O
enhanced None None O
, None None O
pointing None None O
to None None O
automatic None None O
links None None O
between None None O
spatial None None O
deployments None None O
across None None O
senses None None O
. None None O

Here None None O
, None None O
we None None O
asked None None O
whether None None O
lateralized None None O
alpha None None O
- None None O
band None None O
activity None None O
is None None O
also None None O
evident None None O
in None None O
a None None O
purely None None O
auditory None None O
spatial None None O
- None None O
cueing None None O
task None None O
and None None O
whether None None O
it None None O
had None None O
the None None O
same None None O
underlying None None O
generator None None O
configuration None None O
as None None O
in None None O
a None None O
purely None None O
visuospatial None None O
task None None O
. None None O

If None None O
common None None O
to None None O
both None None O
sensory None None O
systems None None O
, None None O
this None None O
would None None O
provide None None O
strong None None O
support None None O
for None None O
" None None O
supramodal None None O
" None None O
attention None None O
theory None None O
. None None O

Alternately None None O
, None None O
alpha None None O
- None None O
band None None O
differences None None O
between None None O
auditory None None O
and None None O
visual None None O
tasks None None O
would None None O
support None None O
a None None O
sensory None None O
- None None O
specific None None O
account None None O
. None None O

Lateralized None None O
shifts None None O
in None None O
alpha None None O
- None None O
band None None O
activity None None O
were None None O
indeed None None O
observed None None O
during None None O
a None None O
purely None None O
auditory None None O
spatial None None O
task None None O
. None None O

Crucially None None O
, None None O
there None None O
were None None O
clear None None O
differences None None O
in None None O
scalp None None O
topographies None None O
of None None O
this None None O
alpha None None O
activity None None O
depending None None O
on None None O
the None None O
sensory None None O
system None None O
within None None O
which None None O
spatial None None O
attention None None O
was None None O
deployed None None O
. None None O

Findings None None O
suggest None None O
that None None O
parietally None None O
generated None None O
alpha None None O
- None None O
band None None O
mechanisms None None O
are None None O
central None None O
to None None O
attentional None None O
deployments None None O
across None None O
modalities None None O
but None None O
that None None O
they None None O
are None None O
invoked None None O
in None None O
a None None O
sensory None None O
- None None O
specific None None O
manner None None O
. None None O

The None None O
data None None O
support None None O
an None None O
" None None O
interactivity None None O
account None None O
, None None O
" None None O
whereby None None O
a None None O
supramodal None None O
system None None O
interacts None None O
with None None O
sensory None None O
- None None O
specific None None O
control None None O
systems None None O
during None None O
deployment None None O
of None None O
spatial None None O
attention None None O
. None None O

Outcomes None None O
of None None O
cefazolin None None O
versus None None O
ceftriaxone None None O
therapy None None O
in None None O
treating None None O
lower None None O
respiratory None None O
tract None None O
infections None None O
in None None O
adults None None O
. None None O

OBJECTIVE None None O
: None None O

To None None O
determine None None O
whether None None O
choice None None O
of None None O
a None None O
first None None O
- None None O
versus None None O
third None None O
- None None O
generation None None O
cephalosporin None None O
as None None O
initial None None O
therapy None None O
for None None O
lower None None O
respiratory None None O
tract None None O
infections None None O
in None None O
hospitalized None None O
adults None None O
affects None None O
the None None O
course None None O
and None None O
duration None None O
of None None O
care None None O
, None None O
both None None O
of None None O
which None None O
may None None O
influence None None O
antimicrobial None None O
treatment None None O
cost None None O
. None None O

DESIGN None None O
: None None O

Retrospective None None O
analysis None None O
of None None O
discharge None None O
abstracts None None O
and None None O
hospital None None O
pharmacy None None O
records None None O
. None None O

SETTING None None O
: None None O

Forty None None O
- None None O
eight None None O
US None None O
acute None None O
- None None O
care None None O
hospitals None None O
. None None O

PATIENTS None None O
: None None O

One None None O
thousand None None O
ninety None None O
- None None O
two None None O
hospitalized None None O
adults None None O
( None None O
aged None None O
> None None O
17 None None O
y None None O
) None None O
with None None O
principal None None O
diagnoses None None O
of None None O
lower None None O
respiratory None None O
tract None None O
infections None None O
( None None O
DRGs None None O
79 None None O
- None None O
80 None None O
, None None O
89 None None O
- None None O
90 None None O
) None None O
. None None O

INTERVENTIONS None None O
: None None O

Cefazolin None None O
or None None O
ceftriaxone None None O
, None None O
given None None O
as None None O
sole None None O
antimicrobial None None O
therapy None None O
for None None O
at None None O
least None None O
one None None O
day None None O
. None None O

MAIN None None O
OUTCOME None None O
MEASURES None None O
: None None O

( None None O
1 None None O
) None None O
The None None O
number None None O
of None None O
patients None None O
who None None O
received None None O
another None None O
parenteral None None O
antibiotic None None O
anytime None None O
prior None None O
to None None O
hospital None None O
discharge None None O
; None None O
( None None O
2 None None O
) None None O
the None None O
number None None O
of None None O
days None None O
during None None O
which None None O
patients None None O
received None None O
any None None O
parenteral None None O
antibiotic None None O
while None None O
in None None O
the None None O
hospital None None O
; None None O
and None None O
( None None O
3 None None O
) None None O
the None None O
number None None O
of None None O
days None None O
patients None None O
remained None None O
hospitalized None None O
following None None O
the None None O
start None None O
of None None O
antibiotic None None O
therapy None None O
. None None O

RESULTS None None O
: None None O

Patients None None O
treated None None O
with None None O
cefazolin None None O
( None None O
n None None O
= None None O
763 None None O
) None None O
were None None O
more None None O
likely None None O
to None None O
receive None None O
another None None O
parenteral None None O
antibiotic None None O
while None None O
in None None O
the None None O
hospital None None O
( None None O
30 None None O
. None None O
3 None None O
vs None None O
. None None O
20 None None O
. None None O
7 None None O
percent None None O
; None None O
p None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
and None None O
received None None O
more None None O
total None None O
days None None O
of None None O
therapy None None O
( None None O
7 None None O
. None None O
2 None None O
vs None None O
. None None O
6 None None O
. None None O
7 None None O
d None None O
; None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
than None None O
those None None O
treated None None O
with None None O
ceftriaxone None None O
( None None O
n None None O
= None None O
329 None None O
) None None O
. None None O

Although None None O
the None None O
time None None O
to None None O
hospital None None O
discharge None None O
did None None O
not None None O
differ None None O
in None None O
the None None O
full None None O
sample None None O
( None None O
9 None None O
. None None O
2 None None O
d None None O
for None None O
both None None O
groups None None O
) None None O
, None None O
it None None O
was None None O
greater None None O
among None None O
those None None O
receiving None None O
cefazolin None None O
( None None O
8 None None O
. None None O
6 None None O
vs None None O
. None None O
8 None None O
. None None O
0 None None O
d None None O
; None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
when None None O
patients None None O
with None None O
lengths None None O
of None None O
stay None None O
exceeding None None O
24 None None O
days None None O
were None None O
excluded None None O
from None None O
both None None O
groups None None O
. None None O

CONCLUSIONS None None O
: None None O

In None None O
addition None None O
to None None O
acquisition None None O
cost None None O
, None None O
differences None None O
in None None O
course None None O
and None None O
duration None None O
of None None O
care None None O
should None None O
be None None O
considered None None O
when None None O
determining None None O
the None None O
most None None O
cost None None O
- None None O
effective None None O
choice None None O
for None None O
antimicrobial None None O
therapy None None O
. None None O

C None None O
/ None None O
EBPbeta None None O
is None None O
over None None O
- None None O
expressed None None O
in None None O
gastric None None O
carcinogenesis None None O
and None None O
is None None O
associated None None O
with None None O
COX None None O
- None None O
2 None None O
expression None None O
. None None O

The None None O
CCAAT None None O
/ None None O
enhancer None None O
- None None O
binding None None O
protein None None O
beta None None O
( None None O
C None None O
/ None None O
EBPbeta None None O
) None None O
transcription None None O
factor None None O
has None None O
been None None O
associated None None O
with None None O
several None None O
cancer None None O
models None None O
. None None O

In None None O
this None None O
study None None O
, None None O
the None None O
expression None None O
of None None O
C None None O
/ None None O
EBPbeta None None O
was None None O
analysed None None O
in None None O
a None None O
series None None O
of None None O
90 None None O
gastric None None O
carcinomas None None O
( None None O
GCs None None O
) None None O
. None None O

We None None O
also None None O
assessed None None O
the None None O
effect None None O
of None None O
C None None O
/ None None O
EBPbeta None None O
on None None O
COX None None O
- None None O
2 None None O
expression None None O
. None None O

In None None O
normal None None O
gastric None None O
mucosa None None O
, None None O
C None None O
/ None None O
EBPbeta None None O
expression None None O
was None None O
restricted None None O
to None None O
cells None None O
in None None O
the None None O
proliferative None None O
zone None None O
. None None O

In None None O
intestinal None None O
metaplasia None None O
, None None O
dysplasia None None O
, None None O
and None None O
GC None None O
of None None O
the None None O
intestinal None None O
and None None O
atypical None None O
subtypes None None O
, None None O
C None None O
/ None None O
EBPbeta None None O
was None None O
over None None O
- None None O
expressed None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
0001 None None O
, None None O
for None None O
the None None O
association None None O
with None None O
histological None None O
type None None O
) None None O
. None None O

C None None O
/ None None O
EBPbeta None None O
and None None O
Ki67 None None O
, None None O
a None None O
marker None None O
of None None O
cell None None O
proliferation None None O
, None None O
were None None O
also None None O
co None None O
- None None O
expressed None None O
in None None O
primary None None O
GC None None O
. None None O

We None None O
also None None O
observed None None O
an None None O
overlap None None O
between None None O
C None None O
/ None None O
EBPbeta None None O
and None None O
COX None None O
- None None O
2 None None O
expression None None O
in None None O
GC None None O
. None None O

Using None None O
GC None None O
cell None None O
lines None None O
we None None O
show None None O
that None None O
C None None O
/ None None O
EBPbeta None None O
can None None O
regulate None None O
the None None O
expression None None O
of None None O
endogenous None None O
COX None None O
- None None O
2 None None O
and None None O
transactivate None None O
the None None O
promoter None None O
of None None O
the None None O
COX None None O
- None None O
2 None None O
gene None None O
, None None O
depending None None O
on None None O
its None None O
methylation None None O
status None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
C None None O
/ None None O
EBPbeta None None O
may None None O
be None None O
a None None O
marker None None O
of None None O
neoplastic None None O
transformation None None O
and None None O
also None None O
play None None O
an None None O
active None None O
role None None O
in None None O
gastric None None O
tumourigenesis None None O
by None None O
regulating None None O
COX None None O
- None None O
2 None None O
expression None None O
. None None O

[ None None O
Treatment None None O
of None None O
the None None O
diabetic None None O
foot None None O
by None None O
hyperbaric None None O
oxygen None None O
] None None O

Diabetic None None O
foot None None O
wounds None None O
are None None O
consequences None None O
of None None O
the None None O
neuropathy None None O
and None None O
the None None O
small None None O
and None None O
large None None O
vessel None None O
disease None None O
that None None O
complicate None None O
diabetes None None O
. None None O

At None None O
the None None O
cellular None None O
level None None O
, None None O
the None None O
result None None O
is None None O
hypoxia None None O
which None None O
impairs None None O
wound None None O
healing None None O
. None None O

Hyperbaric None None O
oxygenation None None O
( None None O
HBO None None O
) None None O
may None None O
be None None O
a None None O
useful None None O
adjuvant None None O
to None None O
wound None None O
care None None O
. None None O

It None None O
leads None None O
to None None O
enhanced None None O
oxygenation None None O
of None None O
the None None O
affected None None O
tissues None None O
, None None O
has None None O
an None None O
antiseptic None None O
effect None None O
, None None O
reduces None None O
edema None None O
, None None O
and None None O
accelerates None None O
collagen None None O
production None None O
and None None O
angiogenesis None None O
, None None O
thus None None O
enhancing None None O
tissue None None O
repair None None O
. None None O

14 None None O
diabetics None None O
with None None O
chronic None None O
nonhealing None None O
wounds None None O
which None None O
did None None O
not None None O
respond None None O
to None None O
treatment None None O
for None None O
at None None O
least None None O
3 None None O
months None None O
were None None O
treated None None O
by None None O
HBO None None O
. None None O

All None None O
had None None O
palpable None None O
pedal None None O
pulses None None O
. None None O

Transcutaneous None None O
measurements None None O
of None None O
tissue None None O
pO2 None None O
showed None None O
elevation None None O
from None None O
20 None None O
+ None None O
/ None None O
- None None O
10 None None O
mm None None O
Hg None None O
during None None O
air None None O
breathing None None O
to None None O
643 None None O
+ None None O
/ None None O
- None None O
242 None None O
mm None None O
Hg None None O
while None None O
breathing None None O
pure None None O
oxygen None None O
at None None O
2 None None O
. None None O
5 None None O
ATA None None O
. None None O

They None None O
were None None O
treated None None O
with None None O
HBO None None O
in None None O
56 None None O
+ None None O
/ None None O
- None None O
10 None None O
consecutive None None O
HBO None None O
sessions None None O
. None None O

In None None O
11 None None O
there None None O
was None None O
complete None None O
wound None None O
healing None None O
, None None O
while None None O
in None None O
1 None None O
there None None O
was None None O
partial None None O
response None None O
, None None O
in None None O
1 None None O
minimal None None O
response None None O
, None None O
and None None O
in None None O
1 None None O
a None None O
transient None None O
response None None O
. None None O

HBO None None O
is None None O
useful None None O
in None None O
chronic None None O
nonhealing None None O
wounds None None O
of None None O
the None None O
diabetic None None O
foot None None O
and None None O
of None None O
the None None O
diabetic None None O
foot None None O
with None None O
impending None None O
amputation None None O
. None None O

It None None O
is None None O
a None None O
safe None None O
mode None None O
of None None O
therapy None None O
, None None O
but None None O
further None None O
studies None None O
are None None O
required None None O
to None None O
establish None None O
its None None O
efficacy None None O
and None None O
to None None O
ascertain None None O
which None None O
diabetic None None O
patients None None O
and None None O
wounds None None O
will None None O
benefit None None O
the None None O
most None None O
from None None O
it None None O
. None None O

Authors None None O
' None None O
contributions None None O

MP None None O
prepared None None O
the None None O
first None None O
draft None None O
with None None O
the None None O
assistance None None O
of None None O
JLdR None None O
. None None O

Other None None O
authors None None O
reviewed None None O
the None None O
manuscript None None O
, None None O
provided None None O
further None None O
contributions None None O
and None None O
suggestions None None O
. None None O

All None None O
of None None O
the None None O
authors None None O
worked None None O
collectively None None O
to None None O
develop None None O
the None None O
algorithms None None O
and None None O
methods None None O
described None None O
in None None O
this None None O
paper None None O
. None None O

TBX21 None None O
: None None O
a None None O
functional None None O
variant None None O
predicts None None O
improvement None None O
in None None O
asthma None None O
with None None O
the None None O
use None None O
of None None O
inhaled None None O
corticosteroids None None O
. None None O

TBX21 None None O
encodes None None O
for None None O
the None None O
transcription None None O
factor None None O
T None None O
- None None O
bet None None O
( None None O
T None None O
- None None O
box None None O
expressed None None O
in None None O
T None None O
cells None None O
) None None O
, None None O
which None None O
influences None None O
naive None None O
T None None O
lymphocyte None None O
development None None O
and None None O
has None None O
been None None O
implicated None None O
in None None O
asthma None None O
pathogenesis None None O
. None None O

Specifically None None O
, None None O
the None None O
T None None O
- None None O
bet None None O
knockout None None O
mouse None None O
spontaneously None None O
develops None None O
airway None None O
hyperresponsiveness None None O
and None None O
other None None O
changes None None O
consistent None None O
with None None O
asthma None None O
. None None O

Because None None O
airway None None O
responsiveness None None O
is None None O
moderated None None O
by None None O
the None None O
use None None O
of None None O
inhaled None None O
corticosteroids None None O
in None None O
asthma None None O
, None None O
it None None O
is None None O
conceivable None None O
that None None O
genetic None None O
variation None None O
in None None O
TBX21 None None O
may None None O
alter None None O
asthma None None O
phenotypes None None O
in None None O
a None None O
treatment None None O
- None None O
specific None None O
fashion None None O
. None None O

Here None None O
we None None O
demonstrate None None O
that None None O
the None None O
nonsynonymous None None O
variation None None O
in None None O
TBX21 None None O
coding None None O
for None None O
replacement None None O
of None None O
histidine None None O
33 None None O
with None None O
glutamine None None O
is None None O
associated None None O
with None None O
significant None None O
improvement None None O
in None None O
the None None O
PC None None O
( None None O
20 None None O
) None None O
( None None O
a None None O
measure None None O
of None None O
airway None None O
responsiveness None None O
) None None O
of None None O
asthmatic None None O
children None None O
in None None O
a None None O
large None None O
clinical None None O
trial None None O
spanning None None O
4 None None O
years None None O
. None None O

We None None O
note None None O
that None None O
this None None O
increase None None O
occurs None None O
only None None O
in None None O
the None None O
children None None O
randomized None None O
to None None O
inhaled None None O
corticosteroids None None O
and None None O
that None None O
it None None O
dramatically None None O
enhances None None O
the None None O
overall None None O
improvement None None O
in None None O
PC None None O
( None None O
20 None None O
) None None O
associated None None O
with None None O
inhaled None None O
corticosteroid None None O
usage None None O
. None None O

The None None O
average None None O
PC None None O
( None None O
20 None None O
) None None O
at None None O
trial None None O
end None None O
for None None O
subjects None None O
on None None O
inhaled None None O
corticosteroids None None O
possessing None None O
a None None O
variant None None O
allele None None O
was None None O
in None None O
the None None O
normal None None O
range None None O
for None None O
nonasthmatics None None O
. None None O

In None None O
cellular None None O
models None None O
, None None O
we None None O
show None None O
that None None O
the None None O
TBX21 None None O
variant None None O
increases None None O
T None None O
helper None None O
1 None None O
and None None O
decreases None None O
T None None O
helper None None O
2 None None O
cytokine None None O
expression None None O
comparably None None O
with None None O
wild None None O
type None None O
. None None O

TBX21 None None O
may None None O
thus None None O
be None None O
an None None O
important None None O
determinant None None O
pharmacogenetic None None O
response None None O
to None None O
the None None O
therapy None None O
of None None O
asthma None None O
with None None O
inhaled None None O
corticosteroids None None O
. None None O

Genes None None O
related None None O
to None None O
signal None None O
transduction None None O

On None None O
day None None O
7 None None O
, None None O
the None None O
up None None O
- None None O
regulated None None O
genes None None O
related None None O
to None None O
signal None None O
transduction None None O
were None None O
PDE1A None None O
, None None O
MYO10 None None O
, None None O
APOB None None O
, None None O
and None None O
so None None O
on None None O
, None None O
and None None O
down None None O
- None None O
regulated None None O
genes None None O
were None None O
CYTL1 None None O
and None None O
IL6 None None O
. None None O

On None None O
day None None O
14 None None O
, None None O
the None None O
up None None O
- None None O
regulated None None O
genes None None O
were None None O
ANGPTL4 None None O
, None None O
EPHA3 None None O
, None None O
RASL10B None None O
, None None O
etc None None O
. None None O
, None None O
and None None O
the None None O
down None None O
- None None O
regulated None None O
genes None None O
were None None O
CXCL12 None None O
, None None O
CCL8 None None O
and None None O
VLDLR None None O
. None None O

The None None O
genes None None O
up None None O
- None None O
regulated None None O
on None None O
both None None O
days None None O
were None None O
LEP None None O
, None None O
RAC3 None None O
, None None O
and None None O
RASL11B None None O
, None None O
and None None O
those None None O
down None None O
- None None O
regulated None None O
both None None O
days None None O
were None None O
MX1 None None O
and None None O
WISP2 None None O
. None None O

Notably None None O
, None None O
up None None O
- None None O
and None None O
down None None O
- None None O
regulated None None O
genes None None O
PDE1A None None O
, None None O
APOB None None O
, None None O
ALCAM None None O
, None None O
PSCD4 None None O
, None None O
CYTL1 None None O
, None None O
and None None O
IL6 None None O
were None None O
more None None O
strongly None None O
expressed None None O
on None None O
day None None O
7 None None O
than None None O
on None None O
day None None O
14 None None O
, None None O
while None None O
ANGPTL4 None None O
, None None O
EPHA3 None None O
, None None O
RAB12 None None O
, None None O
CXCL12 None None O
, None None O
CCL8 None None O
, None None O
and None None O
VLDLR None None O
were None None O
more None None O
strongly None None O
expressed None None O
on None None O
day None None O
14 None None O
than None None O
on None None O
day None None O
7 None None O
. None None O

Estradiol None None O
increases None None O
IL None None O
- None None O
8 None None O
secretion None None O
of None None O
normal None None O
human None None O
breast None None O
tissue None None O
and None None O
breast None None O
cancer None None O
in None None O
vivo None None O
. None None O

IL None None O
- None None O
8 None None O
or None None O
CXCL8 None None O
has None None O
been None None O
associated None None O
with None None O
tumor None None O
angiogenesis None None O
, None None O
metastasis None None O
, None None O
and None None O
poor None None O
prognosis None None O
in None None O
breast None None O
cancer None None O
. None None O

Estrogen None None O
is None None O
crucial None None O
in None None O
breast None None O
carcinogenesis None None O
and None None O
tumor None None O
progression None None O
. None None O

Whether None None O
sex None None O
steroids None None O
affect None None O
IL None None O
- None None O
8 None None O
secretion None None O
of None None O
normal None None O
breast None None O
tissue None None O
or None None O
breast None None O
cancer None None O
is None None O
not None None O
known None None O
. None None O

Several None None O
cell None None O
types None None O
in None None O
a None None O
tissue None None O
secrete None None O
IL None None O
- None None O
8 None None O
. None None O

Hence None None O
, None None O
regulatory None None O
mechanisms None None O
of None None O
IL None None O
- None None O
8 None None O
need None None O
to None None O
be None None O
investigated None None O
in None None O
whole None None O
tissue None None O
. None None O

We None None O
used None None O
microdialysis None None O
to None None O
sample None None O
IL None None O
- None None O
8 None None O
in None None O
normal None None O
human None None O
breast None None O
tissue None None O
in None None O
situ None None O
in None None O
pre None None O
- None None O
and None None O
postmenopausal None None O
women None None O
, None None O
preoperatively None None O
in None None O
breast None None O
cancers None None O
of None None O
women None None O
, None None O
and None None O
in None None O
experimental None None O
breast None None O
cancer None None O
in None None O
mice None None O
. None None O

We None None O
found None None O
a None None O
significant None None O
positive None None O
correlation None None O
between None None O
IL None None O
- None None O
8 None None O
and None None O
estradiol None None O
in None None O
normal None None O
breast None None O
tissue None None O
and None None O
hormone None None O
- None None O
dependent None None O
breast None None O
cancer None None O
in None None O
vivo None None O
. None None O

Ex None None O
vivo None None O
, None None O
estradiol None None O
exposure None None O
increased None None O
the None None O
IL None None O
- None None O
8 None None O
secretion None None O
of None None O
normal None None O
whole None None O
breast None None O
tissue None None O
in None None O
culture None None O
. None None O

In None None O
experimental None None O
breast None None O
cancer None None O
, None None O
estradiol None None O
increased None None O
IL None None O
- None None O
8 None None O
whereas None None O
the None None O
anti None None O
- None None O
estrogen None None O
tamoxifen None None O
inhibited None None O
the None None O
secretion None None O
of None None O
IL None None O
- None None O
8 None None O
both None None O
in None None O
vitro None None O
and None None O
extracellularly None None O
in None None O
vivo None None O
in None None O
tumors None None O
of None None O
nude None None O
mice None None O
. None None O

An None None O
anti None None O
- None None O
IL None None O
- None None O
8 None None O
Ab None None O
inhibited None None O
endothelial None None O
cell None None O
proliferation None None O
induced None None O
by None None O
cancer None None O
cell None None O
produced None None O
IL None None O
- None None O
8 None None O
and None None O
tumors None None O
with None None O
low None None O
IL None None O
- None None O
8 None None O
levels None None O
exhibited None None O
decreased None None O
angiogenesis None None O
. None None O

Our None None O
results None None O
strongly None None O
suggest None None O
that None None O
estradiol None None O
has None None O
a None None O
critical None None O
role None None O
in None None O
the None None O
regulation None None O
of None None O
IL None None O
- None None O
8 None None O
in None None O
normal None None O
human None None O
breast None None O
tissue None None O
and None None O
human None None O
breast None None O
cancer None None O
. None None O

IL None None O
- None None O
8 None None O
may None None O
present None None O
a None None O
novel None None O
therapeutic None None O
target None None O
for None None O
estrogen None None O
driven None None O
breast None None O
carcinogenesis None None O
and None None O
tumor None None O
progression None None O
. None None O

Ultraviolet None None O
B None None O
irradiation None None O
promotes None None O
tumorigenic None None O
and None None O
metastatic None None O
properties None None O
in None None O
primary None None O
cutaneous None None O
melanoma None None O
via None None O
induction None None O
of None None O
interleukin None None O
8 None None O
. None None O

UV None None O
radiation None None O
has None None O
been None None O
shown None None O
to None None O
play None None O
a None None O
role None None O
in None None O
the None None O
initiation None None O
of None None O
human None None O
cutaneous None None O
melanoma None None O
, None None O
but None None O
its None None O
role None None O
in None None O
the None None O
development None None O
of None None O
malignant None None O
melanoma None None O
to None None O
the None None O
metastatic None None O
state None None O
is None None O
not None None O
very None None O
well None None O
defined None None O
. None None O

Although None None O
previous None None O
studies None None O
have None None O
concentrated None None O
on None None O
the None None O
effect None None O
of None None O
UV None None O
- None None O
B None None O
on None None O
the None None O
host None None O
immune None None O
response None None O
, None None O
the None None O
effect None None O
of None None O
UV None None O
- None None O
B None None O
on None None O
the None None O
tumor None None O
cells None None O
was None None O
not None None O
elucidated None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
UV None None O
- None None O
B None None O
can None None O
induce None None O
interleukin None None O
8 None None O
( None None O
IL None None O
- None None O
8 None None O
) None None O
mRNA None None O
and None None O
protein None None O
secretion None None O
in None None O
human None None O
cutaneous None None O
melanoma None None O
with None None O
negligible None None O
expression None None O
of None None O
IL None None O
- None None O
8 None None O
. None None O

UV None None O
- None None O
B None None O
- None None O
induced None None O
IL None None O
- None None O
8 None None O
was None None O
constitutively None None O
expressed None None O
60 None None O
days None None O
after None None O
irradiation None None O
in None None O
tumors None None O
implanted None None O
in None None O
mice None None O
. None None O

Induction None None O
of None None O
IL None None O
- None None O
8 None None O
was None None O
UV None None O
- None None O
B None None O
dose None None O
dependent None None O
and None None O
blocked None None O
by None None O
cyclohexamide None None O
, None None O
indicating None None O
that None None O
de None None O
novo None None O
protein None None O
synthesis None None O
is None None O
required None None O
for None None O
its None None O
expression None None O
. None None O

The None None O
UV None None O
- None None O
irradiated None None O
cells None None O
demonstrated None None O
enhanced None None O
tumorigenicity None None O
and None None O
metastatic None None O
potential None None O
in None None O
nude None None O
mice None None O
. None None O

The None None O
increase None None O
in None None O
tumorigenicity None None O
and None None O
metastatic None None O
ability None None O
could None None O
be None None O
explained None None O
by None None O
the None None O
increase None None O
in None None O
Mr None None O
72 None None O
, None None O
000 None None O
type None None O
IV None None O
collagenase None None O
activity None None O
and None None O
angiogenesis None None O
attributed None None O
to None None O
the None None O
induction None None O
of None None O
IL None None O
- None None O
8 None None O
after None None O
irradiation None None O
. None None O

The None None O
acquisition None None O
of None None O
the None None O
metastatic None None O
phenotype None None O
induced None None O
by None None O
UV None None O
- None None O
B None None O
could None None O
not None None O
be None None O
attributed None None O
to None None O
abnormalities None None O
in None None O
the None None O
p53 None None O
or None None O
MTS None None O
- None None O
1 None None O
( None None O
p16INK4 None None O
) None None O
genes None None O
. None None O

To None None O
the None None O
best None None O
of None None O
our None None O
knowledge None None O
, None None O
this None None O
is None None O
the None None O
first None None O
report None None O
to None None O
show None None O
that None None O
UV None None O
- None None O
B None None O
can None None O
increase None None O
the None None O
aggressiveness None None O
of None None O
human None None O
cutaneous None None O
melanoma None None O
for None None O
growth None None O
and None None O
metastasis None None O
. None None O

Brainstem None None O
auditory None None O
- None None O
evoked None None O
potential None None O
evaluation None None O
in None None O
children None None O
with None None O
meningitis None None O
. None None O

Brainstem None None O
auditory None None O
- None None O
evoked None None O
potential None None O
( None None O
BAEP None None O
) None None O
was None None O
performed None None O
on None None O
101 None None O
children None None O
with None None O
meningitis None None O
to None None O
assess None None O
the None None O
incidence None None O
of None None O
hearing None None O
impairment None None O
. None None O

Fifty None None O
- None None O
two None None O
( None None O
51 None None O
. None None O
5 None None O
% None None O
) None None O
children None None O
had None None O
bacterial None None O
meningitis None None O
, None None O
six None None O
( None None O
5 None None O
. None None O
9 None None O
% None None O
) None None O
had None None O
viral None None O
meningitis None None O
, None None O
and None None O
43 None None O
( None None O
42 None None O
. None None O
6 None None O
% None None O
) None None O
had None None O
aseptic None None O
meningitis None None O
. None None O

Fifty None None O
- None None O
one None None O
( None None O
50 None None O
. None None O
5 None None O
% None None O
) None None O
patients None None O
were None None O
assessed None None O
before None None O
discharge None None O
and None None O
50 None None O
( None None O
49 None None O
. None None O
5 None None O
% None None O
) None None O
9 None None O
days None None O
to None None O
17 None None O
months None None O
later None None O
( None None O
mean None None O
= None None O
4 None None O
months None None O
) None None O
. None None O

BAEP None None O
impairment None None O
was None None O
found None None O
in None None O
28 None None O
( None None O
27 None None O
. None None O
7 None None O
% None None O
) None None O
of None None O
101 None None O
patients None None O
; None None O
24 None None O
had None None O
sensorineural None None O
and None None O
four None None O
had None None O
conductive None None O
type None None O
of None None O
hearing None None O
loss None None O
, None None O
and None None O
17 None None O
( None None O
60 None None O
. None None O
7 None None O
% None None O
) None None O
had None None O
unilateral None None O
and None None O
11 None None O
( None None O
39 None None O
. None None O
3 None None O
% None None O
) None None O
had None None O
bilateral None None O
impairment None None O
. None None O

Hearing None None O
threshold None None O
was None None O
elevated None None O
in None None O
22 None None O
( None None O
21 None None O
. None None O
8 None None O
% None None O
) None None O
patients None None O
, None None O
and None None O
the None None O
other None None O
six None None O
had None None O
increased None None O
latency None None O
and None None O
interpeak None None O
latencies None None O
with None None O
normal None None O
threshold None None O
. None None O

Frequency None None O
of None None O
BAEP None None O
impairment None None O
or None None O
hearing None None O
loss None None O
associated None None O
with None None O
bacterial None None O
meningitis None None O
was None None O
34 None None O
. None None O
6 None None O
% None None O
and None None O
30 None None O
. None None O
8 None None O
% None None O
, None None O
respectively None None O
; None None O
frequency None None O
associated None None O
with None None O
aseptic None None O
meningitis None None O
was None None O
20 None None O
. None None O
9 None None O
% None None O
and None None O
13 None None O
. None None O
9 None None O
% None None O
, None None O
respectively None None O
. None None O

One None None O
child None None O
with None None O
viral None None O
meningitis None None O
( None None O
coxsackie None None O
virus None None O
) None None O
had None None O
mild None None O
BAEP None None O
impairment None None O
. None None O

Most None None O
of None None O
the None None O
BAEP None None O
impairment None None O
in None None O
the None None O
bacterial None None O
meningitis None None O
group None None O
was None None O
associated None None O
with None None O
H None None O
. None None O
influenzae None None O
. None None O

Prospective None None O
BAEP None None O
study None None O
was None None O
performed None None O
in None None O
20 None None O
patients None None O
randomly None None O
at None None O
0 None None O
. None None O
3 None None O
to None None O
18 None None O
months None None O
to None None O
assess None None O
hearing None None O
status None None O
after None None O
antibiotic None None O
treatment None None O
, None None O
10 None None O
with None None O
normal None None O
and None None O
10 None None O
with None None O
abnormal None None O
BAEP None None O
. None None O

All None None O
the None None O
initially None None O
normal None None O
BAEP None None O
patients None None O
remained None None O
normal None None O
. None None O

Of None None O
the None None O
10 None None O
patients None None O
with None None O
abnormal None None O
BAEP None None O
results None None O
initially None None O
, None None O
four None None O
returned None None O
to None None O
normal None None O
, None None O
two None None O
improved None None O
, None None O
three None None O
remained None None O
unchanged None None O
, None None O
and None None O
one None None O
deteriorated None None O
. None None O

The None None O
incidence None None O
of None None O
hearing None None O
loss None None O
after None None O
bacterial None None O
and None None O
aseptic None None O
meningitis None None O
is None None O
high None None O
. None None O

BAEP None None O
is None None O
useful None None O
to None None O
screen None None O
for None None O
possible None None O
hearing None None O
loss None None O
in None None O
children None None O
with None None O
meningitis None None O
, None None O
and None None O
follow None None O
- None None O
up None None O
BAEP None None O
is None None O
necessary None None O
for None None O
those None None O
patients None None O
with None None O
initially None None O
abnormal None None O
BAEP None None O
. None None O

Hedgehog None None O
signaling None None O
in None None O
the None None O
murine None None O
melanoma None None O
microenvironment None None O
. None None O

The None None O
Hedgehog None None O
intercellular None None O
signaling None None O
pathway None None O
regulates None None O
cell None None O
proliferation None None O
and None None O
differentiation None None O
. None None O

This None None O
pathway None None O
has None None O
been None None O
implicated None None O
to None None O
play None None O
a None None O
role None None O
in None None O
the None None O
pathogenesis None None O
of None None O
cancer None None O
and None None O
in None None O
embryonic None None O
blood None None O
vessel None None O
development None None O
. None None O

In None None O
the None None O
current None None O
study None None O
, None None O
Hedgehog None None O
signaling None None O
in None None O
tumor None None O
related None None O
vasculature None None O
and None None O
microenvironment None None O
was None None O
examined None None O
using None None O
human None None O
umbilical None None O
vein None None O
endothelial None None O
cells None None O
and None None O
B16F0 None None I-Cell-line-name
( None None O
murine None None O
melanoma None None O
) None None O
tumors None None O
models None None O
. None None O

Use None None O
of None None O
exogenous None None O
Sonic None None O
hedgehog None None O
( None None O
Shh None None O
) None None O
peptide None None O
significantly None None O
increased None None O
BrdU None None O
incorporation None None O
in None None O
endothelial None None O
cells None None O
in None None O
vitro None None O
by None None O
a None None O
factor None None O
of None None O
2 None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

The None None O
Hedgehog None None O
pathway None None O
antagonist None None O
cyclopamine None None O
effectively None None O
reduced None None O
Shh None None O
- None None O
induced None None O
proliferation None None O
to None None O
control None None O
levels None None O
. None None O

To None None O
study None None O
Hedgehog None None O
signaling None None O
in None None O
vivo None None O
a None None O
hind None None O
limb None None O
tumor None None O
model None None O
with None None O
the None None O
B16F0 None None I-Cell-line-name
cell None None O
line None None O
was None None O
used None None O
. None None O

Treatment None None O
with None None O
25 None None O
mg None None O
/ None None O
kg None None O
cyclopamine None None O
significantly None None O
attenuated None None O
BrdU None None O
incorporation None None O
in None None O
tumor None None O
cells None None O
threefold None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
, None None O
in None None O
tumor None None O
related None None O
endothelial None None O
cells None None O
threefold None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
004 None None O
) None None O
, None None O
and None None O
delayed None None O
tumor None None O
growth None None O
by None None O
4 None None O
days None None O
. None None O

Immunohistochemistry None None O
revealed None None O
that None None O
the None None O
Hedgehog None None O
receptor None None O
Patched None None O
was None None O
localized None None O
to None None O
the None None O
tumor None None O
stroma None None O
and None None O
that None None O
B16F0 None None I-Cell-line-name
cells None None O
expressed None None O
Shh None None O
peptide None None O
. None None O

Furthermore None None O
, None None O
mouse None None O
embryonic None None O
fibroblasts None None O
required None None O
the None None O
presence None None O
of None None O
B16F0 None None I-Cell-line-name
cells None None O
to None None O
express None None O
Patched None None O
in None None O
a None None O
co None None O
- None None O
culture None None O
assay None None O
system None None O
. None None O

These None None O
studies None None O
indicate None None O
that None None O
Shh None None O
peptide None None O
produced None None O
by None None O
melanoma None None O
cells None None O
induces None None O
Patched None None O
expression None None O
in None None O
fibroblasts None None O
. None None O

To None None O
study None None O
tumor None None O
related None None O
angiogenesis None None O
a None None O
vascular None None O
window None None O
model None None O
was None None O
used None None O
to None None O
monitor None None O
tumor None None O
vascularity None None O
. None None O

Treatment None None O
with None None O
cyclopamine None None O
significantly None None O
attenuated None None O
vascular None None O
formation None None O
by None None O
a None None O
factor None None O
of None None O
2 None None O
. None None O
5 None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
and None None O
altered None None O
vascular None None O
morphology None None O
. None None O

Furthermore None None O
, None None O
cyclopamine None None O
reduced None None O
tumor None None O
blood None None O
vessel None None O
permeability None None O
to None None O
FITC None None O
labeled None None O
dextran None None O
while None None O
having None None O
no None None O
effect None None O
on None None O
normal None None O
blood None None O
vessels None None O
. None None O

These None None O
studies None None O
suggest None None O
that None None O
Hedgehog None None O
signaling None None O
regulates None None O
melanoma None None O
related None None O
vascular None None O
formation None None O
and None None O
function None None O
. None None O

Roles None None O
of None None O
brca2 None None O
( None None O
fancd1 None None O
) None None O
in None None O
oocyte None None O
nuclear None None O
architecture None None O
, None None O
gametogenesis None None O
, None None O
gonad None None O
tumors None None O
, None None O
and None None O
genome None None O
stability None None O
in None None O
zebrafish None None O
. None None O

Mild None None O
mutations None None O
in None None O
BRCA2 None None O
( None None O
FANCD1 None None O
) None None O
cause None None O
Fanconi None None O
anemia None None O
( None None O
FA None None O
) None None O
when None None O
homozygous None None O
, None None O
while None None O
severe None None O
mutations None None O
cause None None O
common None None O
cancers None None O
including None None O
breast None None O
, None None O
ovarian None None O
, None None O
and None None O
prostate None None O
cancers None None O
when None None O
heterozygous None None O
. None None O

Here None None O
we None None O
report None None O
a None None O
zebrafish None None O
brca2 None None O
insertional None None O
mutant None None O
that None None O
shares None None O
phenotypes None None O
with None None O
human None None O
patients None None O
and None None O
identifies None None O
a None None O
novel None None O
brca2 None None O
function None None O
in None None O
oogenesis None None O
. None None O

Experiments None None O
showed None None O
that None None O
mutant None None O
embryos None None O
and None None O
mutant None None O
cells None None O
in None None O
culture None None O
experienced None None O
genome None None O
instability None None O
, None None O
as None None O
do None None O
cells None None O
in None None O
FA None None O
patients None None O
. None None O

In None None O
wild None None O
- None None O
type None None O
zebrafish None None O
, None None O
meiotic None None O
cells None None O
expressed None None O
brca2 None None O
; None None O
and None None O
, None None O
unexpectedly None None O
, None None O
transcripts None None O
in None None O
oocytes None None O
localized None None O
asymmetrically None None O
to None None O
the None None O
animal None None O
pole None None O
. None None O

In None None O
juvenile None None O
brca2 None None O
mutants None None O
, None None O
oocytes None None O
failed None None O
to None None O
progress None None O
through None None O
meiosis None None O
, None None O
leading None None O
to None None O
female None None O
- None None O
to None None O
- None None O
male None None O
sex None None O
reversal None None O
. None None O

Adult None None O
mutants None None O
became None None O
sterile None None O
males None None O
due None None O
to None None O
the None None O
meiotic None None O
arrest None None O
of None None O
spermatocytes None None O
, None None O
which None None O
then None None O
died None None O
by None None O
apoptosis None None O
, None None O
followed None None O
by None None O
neoplastic None None O
proliferation None None O
of None None O
gonad None None O
somatic None None O
cells None None O
that None None O
was None None O
similar None None O
to None None O
neoplasia None None O
observed None None O
in None None O
ageing None None O
dead None None O
end None None O
( None None O
dnd None None O
) None None O
- None None O
knockdown None None O
males None None O
, None None O
which None None O
lack None None O
germ None None O
cells None None O
. None None O

The None None O
construction None None O
of None None O
animals None None O
doubly None None O
mutant None None O
for None None O
brca2 None None O
and None None O
the None None O
apoptotic None None O
gene None None O
tp53 None None O
( None None O
p53 None None O
) None None O
rescued None None O
brca2 None None O
- None None O
dependent None None O
sex None None O
reversal None None O
. None None O

Double None None O
mutants None None O
developed None None O
oocytes None None O
and None None O
became None None O
sterile None None O
females None None O
that None None O
produced None None O
only None None O
aberrant None None O
embryos None None O
and None None O
showed None None O
elevated None None O
risk None None O
for None None O
invasive None None O
ovarian None None O
tumors None None O
. None None O

Oocytes None None O
in None None O
double None None O
- None None O
mutant None None O
females None None O
showed None None O
normal None None O
localization None None O
of None None O
brca2 None None O
and None None O
pou5f1 None None O
transcripts None None O
to None None O
the None None O
animal None None O
pole None None O
and None None O
vasa None None O
transcripts None None O
to None None O
the None None O
vegetal None None O
pole None None O
, None None O
but None None O
had None None O
a None None O
polarized None None O
rather None None O
than None None O
symmetrical None None O
nucleus None None O
with None None O
the None None O
distribution None None O
of None None O
nucleoli None None O
and None None O
chromosomes None None O
to None None O
opposite None None O
nuclear None None O
poles None None O
; None None O
this None None O
result None None O
revealed None None O
a None None O
novel None None O
role None None O
for None None O
Brca2 None None O
in None None O
establishing None None O
or None None O
maintaining None None O
oocyte None None O
nuclear None None O
architecture None None O
. None None O

Mutating None None O
tp53 None None O
did None None O
not None None O
rescue None None O
the None None O
infertility None None O
phenotype None None O
in None None O
brca2 None None O
mutant None None O
males None None O
, None None O
suggesting None None O
that None None O
brca2 None None O
plays None None O
an None None O
essential None None O
role None None O
in None None O
zebrafish None None O
spermatogenesis None None O
. None None O

Overall None None O
, None None O
this None None O
work None None O
verified None None O
zebrafish None None O
as None None O
a None None O
model None None O
for None None O
the None None O
role None None O
of None None O
Brca2 None None O
in None None O
human None None O
disease None None O
and None None O
uncovered None None O
a None None O
novel None None O
function None None O
of None None O
Brca2 None None O
in None None O
vertebrate None None O
oocyte None None O
nuclear None None O
architecture None None O
. None None O

Crystal None None O
data None None O

C16H20N4 None None O

M None None O
r None None O
= None None O
268 None None O
. None None O
36 None None O

Monoclinic None None O
, None None O

a None None O
= None None O
12 None None O
. None None O
819 None None O
( None None O
4 None None O
) None None O
A None None O

b None None O
= None None O
8 None None O
. None None O
441 None None O
( None None O
3 None None O
) None None O
A None None O

c None None O
= None None O
13 None None O
. None None O
310 None None O
( None None O
4 None None O
) None None O
A None None O

beta None None O
= None None O
95 None None O
. None None O
462 None None O
( None None O
5 None None O
) None None O
degrees None None O

V None None O
= None None O
1433 None None O
. None None O
7 None None O
( None None O
8 None None O
) None None O
A3 None None O

Z None None O
= None None O
4 None None O

Mo None None O
Kalpha None None O
radiation None None O

mu None None O
= None None O
0 None None O
. None None O
08 None None O
mm None None O
- None None O
1 None None O

T None None O
= None None O
298 None None O
( None None O
2 None None O
) None None O
K None None O

0 None None O
. None None O
33 None None O
x None None O
0 None None O
. None None O
28 None None O
x None None O
0 None None O
. None None O
21 None None O
mm None None O

Introduction None None O

Yeast None None O
infections None None O
cause None None O
significant None None O
mortality None None O
in None None O
critically None None O
ill None None O
and None None O
immunocompromised None None O
patients None None O
. None None O

In None None O
particular None None O
, None None O
Candida None None O
species None None O
are None None O
the None None O
4th None None O
most None None O
common None None O
cause None None O
of None None O
nosocomial None None O
bloodstream None None O
infections None None O
in None None O
the None None O
United None None O
States None None O
, None None O
and None None O
Cryptococcus None None O
neoformans None None O
, None None O
the None None O
commonest None None O
cause None None O
of None None O
fungal None None O
meningitis None None O
worldwide None None O
[ None None O
1 None None O
] None None O
, None None O
[ None None O
2 None None O
] None None O
. None None O

Whilst None None O
Candida None None O
albicans None None O
remains None None O
the None None O
leading None None O
pathogenic None None O
yeast None None O
, None None O
infections None None O
due None None O
to None None O
non None None O
- None None O
C None None O
. None None O
albicans None None O
species None None O
such None None O
as None None O
Candida None None O
glabrata None None O
, None None O
as None None O
well None None O
as None None O
previously None None O
rare None None O
opportunists None None O
such None None O
as None None O
Trichosporon None None O
and None None O
Geotrichum None None O
species None None O
, None None O
are None None O
increasingly None None O
reported None None O
[ None None O
1 None None O
] None None O
, None None O
[ None None O
3 None None O
] None None O
- None None O
[ None None O
6 None None O
] None None O
. None None O

Novel None None O
pathogenic None None O
Candida None None O
species None None O
such None None O
as None None O
Candida None None O
nivariensis None None O
and None None O
Candida None None O
bracarensis None None O
have None None O
also None None O
been None None O
described None None O
[ None None O
7 None None O
] None None O
. None None O

Since None None O
many None None O
non None None O
- None None O
C None None O
. None None O
albicans None None O
Candida None None O
and None None O
non None None O
- None None O
Candida None None O
yeasts None None O
are None None O
resistant None None O
or None None O
less None None O
susceptible None None O
to None None O
antifungal None None O
agents None None O
, None None O
rapid None None O
accurate None None O
species None None O
identification None None O
is None None O
central None None O
to None None O
timely None None O
, None None O
effective None None O
antifungal None None O
therapy None None O
[ None None O
3 None None O
] None None O
- None None O
[ None None O
6 None None O
] None None O
, None None O
[ None None O
8 None None O
] None None O
, None None O
[ None None O
9 None None O
] None None O
. None None O

Conventional None None O
phenotypic None None O
- None None O
based None None O
methods None None O
for None None O
yeast None None O
identification None None O
, None None O
however None None O
, None None O
are None None O
slow None None O
( None None O
24 None None O
- None None O
72 None None O
h None None O
) None None O
, None None O
insensitive None None O
and None None O
often None None O
unable None None O
to None None O
identify None None O
more None None O
unusual None None O
species None None O
. None None O

Various None None O
molecular None None O
techniques None None O
including None None O
real None None O
- None None O
time None None O
PCR None None O
, None None O
DNA None None O
sequence None None O
analysis None None O
, None None O
microarray None None O
analysis None None O
, None None O
and None None O
fluorescence None None O
in None None O
- None None O
situ None None O
hybridization None None O
provide None None O
accurate None None O
identification None None O
[ None None O
10 None None O
] None None O
, None None O
[ None None O
11 None None O
] None None O
but None None O
are None None O
expensive None None O
, None None O
require None None O
substantial None None O
specimen None None O
processing None None O
time None None O
( None None O
hours None None O
to None None O
a None None O
day None None O
) None None O
and None None O
are None None O
not None None O
easily None None O
implemented None None O
as None None O
routine None None O
techniques None None O
in None None O
the None None O
clinical None None O
laboratory None None O
. None None O

Matrix None None O
- None None O
assisted None None O
laser None None O
desorption None None O
ionization None None O
- None None O
time None None O
of None None O
flight None None O
mass None None O
spectrometry None None O
( None None O
MALDI None None O
- None None O
TOF None None O
MS None None O
) None None O
has None None O
emerged None None O
as None None O
a None None O
powerful None None O
and None None O
rapid None None O
tool None None O
for None None O
the None None O
identification None None O
of None None O
bacterial None None O
and None None O
yeast None None O
pathogens None None O
[ None None O
12 None None O
] None None O
- None None O
[ None None O
17 None None O
] None None O
. None None O

Using None None O
MALDI None None O
- None None O
TOF None None O
MS None None O
, None None O
the None None O
protein None None O
spectral None None O
" None None O
fingerprint None None O
" None None O
of None None O
an None None O
isolate None None O
is None None O
compared None None O
to None None O
a None None O
reference None None O
spectral None None O
database None None O
for None None O
identification None None O
[ None None O
18 None None O
] None None O
. None None O

Previous None None O
studies None None O
have None None O
reported None None O
species None None O
identification None None O
rates None None O
of None None O
92 None None O
- None None O
99 None None O
% None None O
amongst None None O
collections None None O
of None None O
yeasts None None O
and None None O
yeast None None O
- None None O
like None None O
organisms None None O
[ None None O
14 None None O
] None None O
- None None O
[ None None O
17 None None O
] None None O
, None None O
[ None None O
19 None None O
] None None O
, None None O
[ None None O
20 None None O
] None None O
. None None O

However None None O
, None None O
taken None None O
collectively None None O
, None None O
the None None O
results None None O
may None None O
not None None O
be None None O
directly None None O
comparable None None O
since None None O
these None None O
studies None None O
have None None O
used None None O
different None None O
approaches None None O
to None None O
assign None None O
species None None O
- None None O
from None None O
comparing None None O
spectra None None O
from None None O
test None None O
organisms None None O
to None None O
reference None None O
spectra None None O
in None None O
MALDI None None O
- None None O
TOF None None O
MS None None O
databases None None O
[ None None O
16 None None O
] None None O
, None None O
[ None None O
20 None None O
] None None O
, None None O
to None None O
enhancing None None O
these None None O
databases None None O
, None None O
and None None O
in None None O
some None None O
instances None None O
developing None None O
study None None O
- None None O
specific None None O
databases None None O
, None None O
with None None O
" None None O
in None None O
- None None O
house None None O
" None None O
spectral None None O
signatures None None O
[ None None O
14 None None O
] None None O
, None None O
[ None None O
15 None None O
] None None O
. None None O

There None None O
also None None O
is None None O
a None None O
continuing None None O
need None None O
to None None O
extend None None O
the None None O
repository None None O
of None None O
reference None None O
spectra None None O
in None None O
MALDI None None O
- None None O
TOF None None O
MS None None O
databases None None O
. None None O

We None None O
therefore None None O
undertook None None O
the None None O
present None None O
study None None O
to None None O
evaluate None None O
the None None O
utility None None O
of None None O
the None None O
MALDI None None O
Biotyper None None O
2 None None O
. None None O
0 None None O
Microflex None None O
LT None None O
spectrometer None None O
( None None O
Bruker None None O
Daltonik None None O
GmbH None None O
; None None O
Bremen None None O
, None None O
Germany None None O
) None None O
with None None O
its None None O
current None None O
spectral None None O
database None None O
in None None O
comparison None None O
with None None O
phenotypic None None O
- None None O
based None None O
methods None None O
for None None O
the None None O
identification None None O
of None None O
a None None O
broad None None O
range None None O
of None None O
yeasts None None O
in None None O
a None None O
diagnostic None None O
laboratory None None O
. None None O

The None None O
first None None O
part None None O
of None None O
the None None O
study None None O
comprised None None O
testing None None O
of None None O
reference None None O
and None None O
clinical None None O
strains None None O
from None None O
our None None O
culture None None O
collection None None O
. None None O

The None None O
second None None O
was None None O
a None None O
blinded None None O
prospective None None O
analysis None None O
of None None O
freshly None None O
- None None O
collected None None O
yeast None None O
isolates None None O
recovered None None O
during None None O
routine None None O
laboratory None None O
work None None O
flow None None O
; None None O
discrepant None None O
results None None O
between None None O
MALDI None None O
TOF None None O
MS None None O
and None None O
phenotypic None None O
methods None None O
were None None O
resolved None None O
using None None O
sequence None None O
analysis None None O
of None None O
the None None O
fungal None None O
internal None None O
transcribed None None O
spacer None None O
( None None O
ITS None None O
) None None O
regions None None O
[ None None O
21 None None O
] None None O
, None None O
[ None None O
22 None None O
] None None O
. None None O

Results None None O
obtained None None O
by None None O
preparation None None O
of None None O
yeasts None None O
by None None O
extraction None None O
of None None O
fungal None None O
proteins None None O
and None None O
by None None O
direct None None O
application None None O
of None None O
yeast None None O
colonies None None O
onto None None O
the None None O
MALDI None None O
TOF None None O
MS None None O
plate None None O
were None None O
also None None O
compared None None O
. None None O

Encoding None None O
methods None None O
of None None O
SOLiDzipper None None O
. None None O

Notes None None O
: None None O
A None None O
) None None O
The None None O
quality None None O
value None None O
in None None O
QV None None O
files None None O
from None None O
ABI None None O
SOLiD None None O
system None None O
ranges None None O
from None None O
- None None O
1 None None O
to None None O
40 None None O
, None None O
which None None O
requires None None O
6 None None O
bit None None O
space None None O
. None None O

The None None O
remaining None None O
2 None None O
bit None None O
space None None O
out None None O
of None None O
1 None None O
byte None None O
can None None O
be None None O
used None None O
for None None O
storing None None O
another None None O
quality None None O
value None None O
in None None O
part None None O
. None None O

B None None O
) None None O
Csfasta None None O
files None None O
contain None None O
the None None O
sequence None None O
information None None O
in None None O
four None None O
digits None None O
, None None O
' None None O
0123 None None O
' None None O
, None None O
which None None O
require None None O
2 None None O
bit None None O
space None None O
. None None O

Provided None None O
that None None O
' None None O
0 None None O
' None None O
, None None O
1 None None O
byte None None O
character None None O
in None None O
csfasta None None O
files None None O
, None None O
is None None O
mapped None None O
as None None O
binary None None O
data None None O
' None None O
00 None None O
' None None O
, None None O
' None None O
1 None None O
' None None O
as None None O
' None None O
01 None None O
' None None O
, None None O
' None None O
2 None None O
' None None O
as None None O
' None None O
10 None None O
' None None O
, None None O
' None None O
3 None None O
' None None O
as None None O
' None None O
11 None None O
' None None O
, None None O
4 None None O
byte None None O
data None None O
' None None O
0113 None None O
' None None O
can None None O
be None None O
encoded None None O
into None None O
1 None None O
byte None None O
character None None O
0x17 None None O
( None None O
00010111 None None O
) None None O
through None None O
shift None None O
operation None None O
. None None O

C None None O
) None None O
Sequence None None O
IDs None None O
are None None O
extracted None None O
from None None O
QV None None O
and None None O
csfasta None None O
files None None O
, None None O
combined None None O
, None None O
and None None O
compressed None None O
using None None O
the None None O
general None None O
purpose None None O
compression None None O
methods None None O
. None None O

D None None O
) None None O
Encoded None None O
data None None O
are None None O
stored None None O
as None None O
data None None O
blocks None None O
of None None O
fixed None None O
size None None O
. None None O

This None None O
allows None None O
for None None O
selective None None O
decoding None None O
. None None O

Scanning None None O
electron None None O
microscopy None None O
of None None O
vascular None None O
casts None None O
in None None O
experimental None None O
ocular None None O
vasoproliferation None None O
. None None O

Scanning None None O
electron None None O
microscopy None None O
of None None O
vascular None None O
casts None None O
was None None O
used None None O
to None None O
investigate None None O
three None None O
experimental None None O
models None None O
of None None O
neovascularization None None O
. None None O

In None None O
each None None O
experimental None None O
situation None None O
, None None O
the None None O
casts None None O
provided None None O
a None None O
valuable None None O
three None None O
dimensional None None O
representation None None O
of None None O
the None None O
newly None None O
formed None None O
blood None None O
vessels None None O
and None None O
permitted None None O
subclassification None None O
of None None O
the None None O
vessels None None O
within None None O
normal None None O
and None None O
proliferating None None O
vascular None None O
networks None None O
. None None O

They None None O
defined None None O
also None None O
the None None O
predominant None None O
origin None None O
of None None O
new None None O
vessels None None O
from None None O
venules None None O
and None None O
capillaries None None O
, None None O
and None None O
enabled None None O
the None None O
evolution None None O
of None None O
proliferating None None O
vessels None None O
into None None O
arterioles None None O
and None None O
venules None None O
to None None O
be None None O
documented None None O
. None None O

Although None None O
vascular None None O
casts None None O
must None None O
be None None O
interpreted None None O
with None None O
caution None None O
in None None O
light None None O
of None None O
the None None O
possibility None None O
of None None O
incomplete None None O
filling None None O
and None None O
other None None O
artifacts None None O
, None None O
they None None O
are None None O
a None None O
valuable None None O
tool None None O
in None None O
the None None O
study None None O
of None None O
ocular None None O
vasoproliferation None None O
. None None O

Troponin None None O
I None None O
inhibits None None O
capillary None None O
endothelial None None O
cell None None O
proliferation None None O
by None None O
interaction None None O
with None None O
the None None O
cell None None O
' None None O
s None None O
bFGF None None O
receptor None None O
. None None O

Troponin None None O
I None None O
( None None O
TnI None None O
) None None O
is None None O
a None None O
novel None None O
cartilage None None O
- None None O
derived None None O
angiogenesis None None O
inhibitor None None O
, None None O
first None None O
demonstrated None None O
by None None O
Moses None None O
et None None O
al None None O
. None None O

( None None O
1999 None None O
, None None O
Proc None None O
. None None O
Natl None None O
. None None O
Acad None None O
. None None O
Sci None None O
. None None O
USA None None O
2645 None None O
- None None O
2650 None None O
) None None O
to None None O
inhibit None None O
endothelial None None O
cell None None O
proliferation None None O
and None None O
angiogenesis None None O
, None None O
both None None O
in None None O
vivo None None O
and None None O
in None None O
vitro None None O
, None None O
and None None O
to None None O
inhibit None None O
metastasis None None O
of None None O
a None None O
wide None None O
variety None None O
of None None O
tumors None None O
in None None O
vivo None None O
. None None O

Despite None None O
convincing None None O
evidence None None O
of None None O
its None None O
efficacy None None O
, None None O
little None None O
is None None O
known None None O
about None None O
the None None O
mechanism None None O
of None None O
action None None O
of None None O
TnI None None O
as None None O
an None None O
anti None None O
- None None O
proliferative None None O
and None None O
anti None None O
- None None O
angiogenic None None O
agent None None O
. None None O

In None None O
the None None O
current None None O
article None None O
we None None O
demonstrate None None O
that None None O
TnI None None O
inhibits None None O
both None None O
bFGF None None O
- None None O
stimulated None None O
and None None O
basal None None O
levels None None O
of None None O
endothelial None None O
cell None None O
proliferation None None O
, None None O
and None None O
we None None O
hypothesize None None O
that None None O
this None None O
inhibition None None O
is None None O
occurring None None O
, None None O
at None None O
least None None O
in None None O
part None None O
, None None O
via None None O
an None None O
interaction None None O
of None None O
TnI None None O
with None None O
the None None O
cell None None O
- None None O
surface None None O
bFGF None None O
receptor None None O
on None None O
capillary None None O
endothelial None None O
cells None None O
. None None O

We None None O
further None None O
support None None O
this None None O
hypothesis None None O
by None None O
providing None None O
the None None O
first None None O
evidence None None O
that None None O
TnI None None O
can None None O
act None None O
on None None O
nonendothelial None None O
as None None O
well None None O
as None None O
endothelial None None O
cells None None O
and None None O
by None None O
demonstrating None None O
that None None O
this None None O
inhibitory None None O
action None None O
is None None O
specific None None O
for None None O
the None None O
bFGF None None O
receptor None None O
on None None O
the None None O
target None None O
cells None None O
. None None O

Preliminary None None O
data None None O
suggest None None O
that None None O
TnI None None O
may None None O
be None None O
competing None None O
with None None O
bFGF None None O
for None None O
interaction None None O
with None None O
the None None O
bFGF None None O
receptor None None O
on None None O
responsive None None O
cells None None O
. None None O

Interaction None None O
between None None O
cellular None None O
and None None O
viral None None O
genes None None O
in None None O
the None None O
expression None None O
of None None O
the None None O
RSV None None O
- None None O
induced None None O
transformation None None O
- None None O
specific None None O
cell None None O
- None None O
surface None None O
antigen None None O
VCSA None None O
. None None O

Transformation None None O
of None None O
BHK None None I-Cell-line-name
hamster None None O
fibroblasts None None O
by None None O
an None None O
env None None O
- None None O
strain None None O
of None None O
Rous None None O
sarcoma None None O
virus None None O
( None None O
RSV None None O
) None None O
leads None None O
to None None O
the None None O
appearance None None O
at None None O
the None None O
cell None None O
surface None None O
of None None O
a None None O
virus None None O
- None None O
induced None None O
nonvirion None None O
antigen None None O
( None None O
VCSA None None O
) None None O
, None None O
specific None None O
for None None O
transformation None None O
, None None O
whose None None O
expression None None O
is None None O
controlled None None O
by None None O
the None None O
transforming None None O
src None None O
gene None None O
. None None O

Previous None None O
work None None O
has None None O
shown None None O
that None None O
a None None O
rabbit None None O
anti None None O
- None None O
VCSA None None O
serum None None O
lyses None None O
specifically None None O
, None None O
in None None O
the None None O
presence None None O
of None None O
complement None None O
, None None O
51Cr None None O
- None None O
labelled None None O
RSV None None O
- None None O
transformed None None O
cells None None O
from None None O
different None None O
animal None None O
species None None O
. None None O

Now None None O
, None None O
by None None O
competition None None O
experiments None None O
with None None O
a None None O
panel None None O
of None None O
different None None O
unlabelled None None O
cells None None O
we None None O
show None None O
that None None O
the None None O
VCSA None None O
expressed None None O
on None None O
RSV None None O
- None None O
transformed None None O
hamster None None O
fibroblasts None None O
is None None O
a None None O
complex None None O
of None None O
at None None O
least None None O
three None None O
distinct None None O
antigenic None None O
specificities None None O
: None None O
( None None O
1 None None O
) None None O
one None None O
expressed None None O
on None None O
all None None O
RSV None None O
- None None O
transformed None None O
fibroblasts None None O
, None None O
regardless None None O
their None None O
species None None O
and None None O
the None None O
subgroup None None O
or None None O
strain None None O
of None None O
the None None O
transforming None None O
virus None None O
; None None O
( None None O
2 None None O
) None None O
one None None O
cross None None O
- None None O
reacting None None O
with None None O
a None None O
cell None None O
- None None O
surface None None O
antigen None None O
( None None O
CSA None None O
) None None O
expressed None None O
at None None O
various None None O
degrees None None O
on None None O
untransformed None None O
avian None None O
fibroblasts None None O
, None None O
but None None O
not None None O
on None None O
mammalian None None O
fibroblasts None None O
; None None O
( None None O
3 None None O
) None None O
one None None O
species None None O
- None None O
specific None None O
, None None O
present None None O
only None None O
on None None O
RSV None None O
- None None O
transformed None None O
hamster None None O
fibroblasts None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
VCSA None None O
is None None O
a None None O
complex None None O
of None None O
several None None O
antigenic None None O
determinants None None O
, None None O
and None None O
that None None O
some None None O
of None None O
these None None O
differ None None O
in None None O
different None None O
cells None None O
transformed None None O
by None None O
RSV None None O
. None None O

This None None O
observation None None O
indicates None None O
that None None O
VCSA None None O
expression None None O
at None None O
the None None O
cell None None O
surface None None O
is None None O
likely None None O
to None None O
be None None O
the None None O
result None None O
of None None O
the None None O
interaction None None O
between None None O
the None None O
viral None None O
src None None O
gene None None O
product None None O
pp60src None None O
with None None O
host None None O
cell None None O
gene None None O
( None None O
s None None O
) None None O
or None None O
gene None None O
product None None O
( None None O
s None None O
) None None O
, None None O
rather None None O
than None None O
the None None O
simple None None O
expression None None O
of None None O
this None None O
molecule None None O
at None None O
the None None O
cell None None O
surface None None O
. None None O

Regulation None None O
of None None O
thrombospondin None None O
- None None O
1 None None O
by None None O
natural None None O
and None None O
synthetic None None O
progestins None None O
in None None O
human None None O
breast None None O
cancer None None O
cells None None O
. None None O

Our None None O
recent None None O
studies None None O
show None None O
that None None O
progestins None None O
induce None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
in None None O
breast None None O
cancer None None O
cells None None O
that None None O
express None None O
mutant None None O
p53 None None O
protein None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
natural None None O
and None None O
synthetic None None O
progestins None None O
also None None O
induce None None O
thrombospondin None None O
- None None O
1 None None O
( None None O
TSP None None O
- None None O
1 None None O
) None None O
mRNA None None O
and None None O
protein None None O
in None None O
T47 None None I-Cell-line-name
- None None I-Cell-line-name
D None None I-Cell-line-name
and None None O
BT None None I-Cell-line-name
- None None I-Cell-line-name
474 None None I-Cell-line-name
breast None None O
cancer None None O
cells None None O
. None None O

Antiprogestin None None O
RU None None O
- None None O
486 None None O
inhibits None None O
the None None O
induction None None O
of None None O
VEGF None None O
and None None O
TSP None None O
- None None O
1 None None O
by None None O
progestins None None O
, None None O
suggesting None None O
that None None O
this None None O
effect None None O
of None None O
progestin None None O
is None None O
mediated None None O
by None None O
the None None O
progesterone None None O
receptor None None O
( None None O
PR None None O
) None None O
. None None O

Actinomycin None None O
- None None O
D None None O
, None None O
but None None O
not None None O
puromycin None None O
, None None O
also None None O
blocks None None O
progestin None None O
- None None O
dependent None None O
induction None None O
of None None O
TSP None None O
- None None O
1 None None O
. None None O

A None None O
putative None None O
progestin None None O
- None None O
response None None O
element None None O
was None None O
identified None None O
in None None O
the None None O
human None None O
TSP None None O
- None None O
1 None None O
promoter None None O
, None None O
which None None O
is None None O
consistent None None O
with None None O
the None None O
hypothesis None None O
that None None O
a None None O
progestin None None O
- None None O
PR None None O
complex None None O
might None None O
directly None None O
regulate None None O
transcription None None O
of None None O
the None None O
TSP None None O
- None None O
1 None None O
gene None None O
in None None O
human None None O
cells None None O
. None None O

Conditioned None None O
medium None None O
from None None O
progestin None None O
- None None O
treated None None O
breast None None O
cancer None None O
cells None None O
stimulates None None O
endothelial None None O
cell None None O
proliferation None None O
in None None O
the None None O
absence None None O
though None None O
not None None O
in None None O
the None None O
presence None None O
of None None O
antibody None None O
to None None O
TSP None None O
- None None O
1 None None O
, None None O
indicating None None O
that None None O
TSP None None O
- None None O
1 None None O
secreted None None O
by None None O
breast None None O
cancer None None O
cells None None O
could None None O
be None None O
pro None None O
- None None O
angiogenic None None O
. None None O

Since None None O
tumor None None O
cell None None O
- None None O
derived None None O
TSP None None O
- None None O
1 None None O
has None None O
the None None O
potential None None O
to None None O
promote None None O
angiogenesis None None O
in None None O
the None None O
tumor None None O
microenvironment None None O
, None None O
it None None O
could None None O
be None None O
a None None O
potential None None O
target None None O
for None None O
breast None None O
cancer None None O
therapy None None O
. None None O

( None None O
a None None O
) None None O
Sequence None None O
alignment None None O
of None None O
PY None None O
- None None O
NLSs None None O
. None None O

The None None O
homologous None None O
regions None None O
of None None O
C None None O
- None None O
NLS None None O
of None None O
the None None O
EWS None None O
protein None None O
, None None O
NLS None None O
of None None O
Sam68 None None O
and None None O
FUS None None O
/ None None O
TLS None None O
protein None None O
and None None O
M9 None None O
NLS None None O
of None None O
hnRNP None None O
A1 None None O
and None None O
hnRNP None None O
M None None O
, None None O
classified None None O
as None None O
PY None None O
- None None O
NLS None None O
are None None O
in None None O
yellow None None O
boxes None None O
. None None O

Phosphorylated None None O
Y656 None None O
of None None O
the None None O
EWS None None O
protein None None O
and None None O
Y440 None None O
of None None O
Sam68 None None O
are None None O
indicated None None O
( None None O
in None None O
red None None O
) None None O
. None None O

Positions None None O
of None None O
identical None None O
residues None None O
in None None O
SAM68 None None O
and None None O
EWS None None O
C None None O
- None None O
NLS None None O
are None None O
indicated None None O
in None None O
bold None None O
and None None O
residues None None O
with None None O
identical None None O
charges None None O
are None None O
underlined None None O
. None None O

Known None None O
positions None None O
of None None O
the None None O
FUS None None O
/ None None O
TLS None None O
mutations None None O
in None None O
ALS None None O
are None None O
in None None O
bold None None O
. None None O

( None None O
b None None O
) None None O
Subcellular None None O
localization None None O
of None None O
YFP None None O
, None None O
the None None O
C None None O
- None None O
terminally None None O
tagged None None O
EWS None None O
- None None O
YFP None None O
, None None O
EWS None None O
( None None O
Y656A None None O
) None None O
- None None O
YFP None None O
, None None O
EWS None None O
( None None O
Y656F None None O
) None None O
- None None O
YFP None None O
, None None O
and None None O
EWS None None O
( None None O
Y656D None None O
) None None O
- None None O
YFP None None O
( None None O
in None None O
green None None O
) None None O
. None None O

Nuclei None None O
are None None O
shown None None O
by None None O
DAPI None None O
staining None None O
( None None O
in None None O
blue None None O
) None None O
. None None O

Bars None None O
, None None O
15 None None O
mum None None O
. None None O

Postpartum None None O
rubella None None O
immunization None None O
: None None O
association None None O
with None None O
development None None O
of None None O
prolonged None None O
arthritis None None O
, None None O
neurological None None O
sequelae None None O
, None None O
and None None O
chronic None None O
rubella None None O
viremia None None O
. None None O

Six None None O
women None None O
developed None None O
chronic None None O
long None None O
- None None O
term None None O
arthropathy None None O
after None None O
postpartum None None O
immunization None None O
against None None O
rubella None None O
. None None O

All None None O
individuals None None O
developed None None O
acute None None O
polyarticular None None O
arthritis None None O
within None None O
12 None None O
days None None O
to None None O
three None None O
weeks None None O
postimmunization None None O
and None None O
have None None O
had None None O
continuing None None O
chronic None None O
or None None O
recurrent None None O
arthralgia None None O
or None None O
arthritis None None O
for None None O
two None None O
to None None O
seven None None O
years None None O
after None None O
vaccination None None O
. None None O

Acute None None O
neurological None None O
manifestations None None O
, None None O
consisting None None O
of None None O
carpal None None O
tunnel None None O
syndrome None None O
or None None O
multiple None None O
paresthesiae None None O
, None None O
developed None None O
postvaccination None None O
in None None O
three None None O
women None None O
. None None O

Two None None O
have None None O
developed None None O
continuing None None O
active None None O
or None None O
chronic None None O
recurrent None None O
episodes None None O
of None None O
blurred None None O
vision None None O
, None None O
paresthesiae None None O
, None None O
and None None O
painful None None O
limb None None O
syndromes None None O
together None None O
with None None O
recurrent None None O
joint None None O
symptoms None None O
. None None O

Chronic None None O
rubella None None O
viremia None None O
has None None O
been None None O
detected None None O
in None None O
peripheral None None O
blood None None O
mononuclear None None O
cell None None O
( None None O
MNC None None O
) None None O
populations None None O
in None None O
five None None O
of None None O
the None None O
six None None O
women None None O
up None None O
to None None O
six None None O
years None None O
after None None O
vaccination None None O
. None None O

In None None O
addition None None O
rubella None None O
virus None None O
was None None O
isolated None None O
from None None O
breast None None O
milk None None O
MNCs None None O
in None None O
one None None O
individual None None O
at None None O
nine None None O
months None None O
postvaccination None None O
and None None O
from None None O
peripheral None None O
blood None None O
MNCs None None O
in None None O
two None None O
of None None O
four None None O
breast None None O
- None None O
fed None None O
infants None None O
studied None None O
at None None O
12 None None O
- None None O
18 None None O
months None None O
of None None O
age None None O
. None None O

Immune None None O
responses None None O
to None None O
rubella None None O
virus None None O
studied None None O
at None None O
sequential None None O
intervals None None O
after None None O
vaccination None None O
correlated None None O
with None None O
development None None O
of None None O
rheumatologic None None O
and None None O
neurological None None O
manifestations None None O
. None None O

Temporary None None O
migration None None O
module None None O

A None None O
temporary None None O
migration None None O
census None None O
module None None O
was None None O
conducted None None O
in None None O
2002 None None O
and None None O
2007 None None O
. None None O

People None None O
who None None O
were None None O
identified None None O
as None None O
temporary None None O
migrants None None O
were None None O
entered None None O
into None None O
the None None O
module None None O
, None None O
and None None O
a None None O
household None None O
respondent None None O
answered None None O
questions None None O
about None None O
the None None O
migration None None O
. None None O

Key None None O
areas None None O
included None None O
the None None O
duration None None O
of None None O
migration None None O
, None None O
destination None None O
, None None O
reasons None None O
for None None O
migration None None O
, None None O
return None None O
pattern None None O
, None None O
communication None None O
pattern None None O
, None None O
remittances None None O
, None None O
linked None None O
moves None None O
and None None O
child None None O
care None None O
arrangements None None O
. None None O

A None None O
generative None None O
model None None O
for None None O
image None None O
segmentation None None O
based None None O
on None None O
label None None O
fusion None None O
. None None O

We None None O
propose None None O
a None None O
nonparametric None None O
, None None O
probabilistic None None O
model None None O
for None None O
the None None O
automatic None None O
segmentation None None O
of None None O
medical None None O
images None None O
, None None O
given None None O
a None None O
training None None O
set None None O
of None None O
images None None O
and None None O
corresponding None None O
label None None O
maps None None O
. None None O

The None None O
resulting None None O
inference None None O
algorithms None None O
rely None None O
on None None O
pairwise None None O
registrations None None O
between None None O
the None None O
test None None O
image None None O
and None None O
individual None None O
training None None O
images None None O
. None None O

The None None O
training None None O
labels None None O
are None None O
then None None O
transferred None None O
to None None O
the None None O
test None None O
image None None O
and None None O
fused None None O
to None None O
compute None None O
the None None O
final None None O
segmentation None None O
of None None O
the None None O
test None None O
subject None None O
. None None O

Such None None O
label None None O
fusion None None O
methods None None O
have None None O
been None None O
shown None None O
to None None O
yield None None O
accurate None None O
segmentation None None O
, None None O
since None None O
the None None O
use None None O
of None None O
multiple None None O
registrations None None O
captures None None O
greater None None O
inter None None O
- None None O
subject None None O
anatomical None None O
variability None None O
and None None O
improves None None O
robustness None None O
against None None O
occasional None None O
registration None None O
failures None None O
. None None O

To None None O
the None None O
best None None O
of None None O
our None None O
knowledge None None O
, None None O
this None None O
manuscript None None O
presents None None O
the None None O
first None None O
comprehensive None None O
probabilistic None None O
framework None None O
that None None O
rigorously None None O
motivates None None O
label None None O
fusion None None O
as None None O
a None None O
segmentation None None O
approach None None O
. None None O

The None None O
proposed None None O
framework None None O
allows None None O
us None None O
to None None O
compare None None O
different None None O
label None None O
fusion None None O
algorithms None None O
theoretically None None O
and None None O
practically None None O
. None None O

In None None O
particular None None O
, None None O
recent None None O
label None None O
fusion None None O
or None None O
multiatlas None None O
segmentation None None O
algorithms None None O
are None None O
interpreted None None O
as None None O
special None None O
cases None None O
of None None O
our None None O
framework None None O
. None None O

We None None O
conduct None None O
two None None O
sets None None O
of None None O
experiments None None O
to None None O
validate None None O
the None None O
proposed None None O
methods None None O
. None None O

In None None O
the None None O
first None None O
set None None O
of None None O
experiments None None O
, None None O
we None None O
use None None O
39 None None O
brain None None O
MRI None None O
scans None None O
- None None O
with None None O
manually None None O
segmented None None O
white None None O
matter None None O
, None None O
cerebral None None O
cortex None None O
, None None O
ventricles None None O
and None None O
subcortical None None O
structures None None O
- None None O
to None None O
compare None None O
different None None O
label None None O
fusion None None O
algorithms None None O
and None None O
the None None O
widely None None O
- None None O
used None None O
FreeSurfer None None O
whole None None O
- None None O
brain None None O
segmentation None None O
tool None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
the None None O
proposed None None O
framework None None O
yields None None O
more None None O
accurate None None O
segmentation None None O
than None None O
FreeSurfer None None O
and None None O
previous None None O
label None None O
fusion None None O
algorithms None None O
. None None O

In None None O
a None None O
second None None O
experiment None None O
, None None O
we None None O
use None None O
brain None None O
MRI None None O
scans None None O
of None None O
282 None None O
subjects None None O
to None None O
demonstrate None None O
that None None O
the None None O
proposed None None O
segmentation None None O
tool None None O
is None None O
sufficiently None None O
sensitive None None O
to None None O
robustly None None O
detect None None O
hippocampal None None O
volume None None O
changes None None O
in None None O
a None None O
study None None O
of None None O
aging None None O
and None None O
Alzheimer None None O
' None None O
s None None O
Disease None None O
. None None O

a None None O
, None None O
b None None O
Radiographs None None O
of None None O
the None None O
left None None O
elbow None None O
and None None O
forearm None None O
5 None None O
months None None O
after None None O
the None None O
surgery None None O

( None None O
a None None O
) None None O
Schematic None None O
drawing None None O
of None None O
the None None O
magnetic None None O
tweezers None None O
. None None O

A None None O
DNA None None O
molecule None None O
is None None O
attached None None O
at None None O
one None None O
end None None O
to None None O
the None None O
bottom None None O
of None None O
the None None O
flow None None O
cell None None O
and None None O
at None None O
the None None O
other None None O
end None None O
to None None O
a None None O
magnetic None None O
bead None None O
. None None O

This None None O
molecule None None O
can None None O
be None None O
pulled None None O
and None None O
twisted None None O
using None None O
small None None O
magnets None None O
placed None None O
above None None O
the None None O
flow None None O
cell None None O
. None None O

The None None O
position None None O
of None None O
the None None O
magnetic None None O
bead None None O
is None None O
measured None None O
using None None O
an None None O
inverted None None O
microscope None None O
placed None None O
beneath None None O
the None None O
flow None None O
cell None None O
. None None O

The None None O
bead None None O
position None None O
and None None O
thus None None O
the None None O
end None None O
- None None O
to None None O
- None None O
end None None O
distance None None O
of None None O
the None None O
DNA None None O
molecule None None O
is None None O
determined None None O
using None None O
video None None O
microscopy None None O
and None None O
image None None O
analysis None None O
. None None O

( None None O
b None None O
) None None O
Extension None None O
of None None O
a None None O
DNA None None O
molecule None None O
versus None None O
the None None O
number None None O
of None None O
turns None None O
applied None None O
by None None O
the None None O
magnets None None O
for None None O
various None None O
stretching None None O
forces None None O
. None None O

At None None O
low None None O
force None None O
, None None O
contraction None None O
of None None O
the None None O
molecule None None O
is None None O
symmetrical None None O
under None None O
positive None None O
and None None O
negative None None O
applied None None O
turns None None O
. None None O

At None None O
higher None None O
force None None O
, None None O
the None None O
molecule None None O
' None None O
s None None O
extension None None O
initially None None O
remains None None O
constant None None O
for None None O
positive None None O
applied None None O
turns None None O
. None None O

The None None O
induced None None O
torque None None O
increases None None O
linearly None None O
with None None O
the None None O
number None None O
of None None O
applied None None O
turns None None O
, None None O
as None None O
depicted None None O
in None None O
the None None O
top None None O
graph None None O
until None None O
a None None O
buckling None None O
transition None None O
allows None None O
the None None O
system None None O
to None None O
saturate None None O
its None None O
torsional None None O
constraint None None O
through None None O
the None None O
formation None None O
of None None O
plectonemes None None O
. None None O

Systemic None None O
regulation None None O
of None None O
distraction None None O
osteogenesis None None O
: None None O
a None None O
cascade None None O
of None None O
biochemical None None O
factors None None O
. None None O

This None None O
study None None O
investigates None None O
the None None O
systemic None None O
biochemical None None O
regulation None None O
of None None O
fracture None None O
healing None None O
in None None O
distraction None None O
osteogenesis None None O
compared None None O
with None None O
rigid None None O
osteotomy None None O
in None None O
a None None O
prospective None None O
in None None O
vivo None None O
study None None O
in None None O
humans None None O
. None None O

To None None O
further None None O
clarify None None O
the None None O
influence None None O
of None None O
mechanical None None O
strain None None O
on None None O
the None None O
regulation None None O
of None None O
bone None None O
formation None None O
, None None O
bone None None O
growth None None O
factors None None O
( None None O
insulin None None O
- None None O
like None None O
growth None None O
factor None None O
[ None None O
IGF None None O
] None None O
I None None O
, None None O
IGF None None O
binding None None O
protein None None O
[ None None O
IGFBP None None O
] None None O
3 None None O
, None None O
transforming None None O
growth None None O
factor None None O
[ None None O
TGF None None O
] None None O
beta1 None None O
, None None O
and None None O
basic None None O
FGF None None O
[ None None O
bFGF None None O
] None None O
) None None O
, None None O
bone None None O
matrix None None O
degrading None None O
enzymes None None O
( None None O
matrix None None O
- None None O
metalloproteinases None None O
[ None None O
MMPs None None O
] None None O
1 None None O
, None None O
2 None None O
, None None O
and None None O
3 None None O
) None None O
, None None O
human None None O
growth None None O
hormone None None O
( None None O
hGH None None O
) None None O
, None None O
and None None O
bone None None O
formation None None O
markers None None O
( None None O
ALP None None O
, None None O
bone None None O
- None None O
specific None None O
ALP None None O
[ None None O
BAP None None O
] None None O
, None None O
and None None O
osteocalcin None None O
[ None None O
OC None None O
] None None O
) None None O
have None None O
been None None O
analyzed None None O
in None None O
serum None None O
samples None None O
from None None O
10 None None O
patients None None O
in None None O
each None None O
group None None O
pre None None O
- None None O
and None None O
postoperatively None None O
. None None O

In None None O
the None None O
distraction None None O
group None None O
, None None O
a None None O
significant None None O
postoperative None None O
increase None None O
in None None O
MMP None None O
- None None O
1 None None O
, None None O
bFGF None None O
, None None O
ALP None None O
, None None O
and None None O
BAP None None O
could None None O
be None None O
observed None None O
during None None O
the None None O
lengthening None None O
and None None O
the None None O
consolidation None None O
period None None O
when None None O
compared None None O
with None None O
the None None O
baseline None None O
levels None None O
. None None O

Osteotomy None None O
fracture None None O
healing None None O
without None None O
the None None O
traction None None O
stimulus None None O
failed None None O
to None None O
induce None None O
a None None O
corresponding None None O
increase None None O
in None None O
these None None O
factors None None O
. None None O

In None None O
addition None None O
, None None O
comparison None None O
of None None O
both None None O
groups None None O
revealed None None O
a None None O
significantly None None O
higher None None O
increase None None O
in None None O
TGF None None O
- None None O
beta1 None None O
, None None O
IGF None None O
- None None O
I None None O
, None None O
IGFBP None None O
- None None O
3 None None O
, None None O
and None None O
hGH None None O
in None None O
the None None O
lengthening None None O
group None None O
during None None O
the None None O
distraction None None O
period None None O
, None None O
indicating None None O
key None None O
regulatory None None O
functions None None O
in None None O
mechanotransduction None None O
. None None O

The None None O
time None None O
courses None None O
of None None O
changes None None O
in None None O
MMP None None O
- None None O
1 None None O
, None None O
bone None None O
growth None None O
factors None None O
( None None O
TGF None None O
- None None O
beta1 None None O
and None None O
bFGF None None O
) None None O
, None None O
and None None O
hGH None None O
, None None O
respectively None None O
, None None O
correlated None None O
significantly None None O
during None None O
the None None O
lengthening None None O
phase None None O
, None None O
indicating None None O
common None None O
regulatory None None O
pathways None None O
for None None O
these None None O
factors None None O
in None None O
distraction None None O
osteogenesis None None O
. None None O

Significant None None O
correlation None None O
between None None O
the None None O
osteoblastic None None O
marker None None O
BAP None None O
, None None O
TGF None None O
- None None O
beta1 None None O
, None None O
and None None O
bFGF None None O
suggests None None O
strain None None O
- None None O
activated None None O
osteoblastic None None O
cells None None O
as None None O
a None None O
major None None O
source None None O
of None None O
systemically None None O
increased None None O
bone None None O
growth None None O
factors None None O
during None None O
callus None None O
distraction None None O
. None None O

The None None O
systemic None None O
increase None None O
in None None O
bFGF None None O
and None None O
MMP None None O
- None None O
1 None None O
might None None O
reflect None None O
an None None O
increased None None O
local None None O
stimulation None None O
of None None O
angiogenesis None None O
during None None O
distraction None None O
osteogenesis None None O
. None None O

The None None O
effects None None O
of None None O
radiation None None O
on None None O
neovascularization None None O
in None None O
a None None O
rat None None O
model None None O
. None None O

It None None O
is None None O
thought None None O
that None None O
radiation None None O
treatment None None O
inhibits None None O
neovascularization None None O
of None None O
recipient None None O
and None None O
/ None None O
or None None O
graft None None O
tissues None None O
, None None O
and None None O
this None None O
may None None O
account None None O
in None None O
part None None O
for None None O
abnormalities None None O
in None None O
wound None None O
healing None None O
associated None None O
with None None O
radiation None None O
therapy None None O
. None None O

We None None O
have None None O
examined None None O
this None None O
hypothesis None None O
using None None O
a None None O
model None None O
that None None O
measures None None O
the None None O
neovascularization None None O
of None None O
an None None O
implanted None None O
foreign None None O
material None None O
. None None O

Expanded None None O
polytetrafluoroethylene None None O
( None None O
PTFE None None O
) None None O
sheets None None O
were None None O
implanted None None O
adjacent None None O
to None None O
both None None O
superficial None None O
epigastric None None O
vascular None None O
pedicles None None O
of None None O
63 None None O
rats None None O
distributed None None O
into None None O
7 None None O
groups None None O
( None None O
n None None O
= None None O
7 None None O
) None None O
that None None O
differed None None O
with None None O
respect None None O
to None None O
dose None None O
and None None O
timing None None O
of None None O
irradiation None None O
. None None O

Zero None None O
to None None O
10 None None O
daily None None O
fractions None None O
of None None O
electron None None O
- None None O
beam None None O
radiation None None O
( None None O
300 None None O
cGy None None O
each None None O
) None None O
were None None O
delivered None None O
to None None O
the None None O
implant None None O
in None None O
the None None O
right None None O
groin None None O
, None None O
while None None O
the None None O
implant None None O
in None None O
the None None O
left None None O
groin None None O
served None None O
as None None O
a None None O
nonirradiated None None O
internal None None O
control None None O
. None None O

Unirradiated None None O
animals None None O
showed None None O
equal None None O
neovascularization None None O
of None None O
both None None O
implants None None O
. None None O

Rats None None O
that None None O
were None None O
irradiated None None O
twice None None O
( None None O
single None None O
fractions None None O
at None None O
0 None None O
and None None O
24 None None O
hours None None O
after None None O
implantation None None O
) None None O
did None None O
not None None O
show None None O
a None None O
significant None None O
decrease None None O
in None None O
the None None O
neovascularization None None O
of None None O
the None None O
irradiated None None O
implant None None O
compared None None O
with None None O
the None None O
contralateral None None O
control None None O
implant None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
implants None None O
that None None O
were None None O
irradiated None None O
three None None O
times None None O
( None None O
single None None O
fractions None None O
at None None O
0 None None O
, None None O
24 None None O
, None None O
and None None O
48 None None O
hours None None O
after None None O
implantation None None O
) None None O
demonstrated None None O
significantly None None O
diminished None None O
( None None O
greater None None O
than None None O
25 None None O
percent None None O
, None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
neovascularization None None O
beyond None None O
day None None O
7 None None O
, None None O
whereas None None O
implants None None O
irradiated None None O
only None None O
at None None O
48 None None O
hours None None O
after None None O
implantation None None O
did None None O
not None None O
. None None O

Interestingly None None O
, None None O
neovascularization None None O
of None None O
the None None O
implants None None O
irradiated None None O
with None None O
10 None None O
fractions None None O
( None None O
3000 None None O
cGy None None O
) None None O
was None None O
not None None O
significantly None None O
decreased None None O
compared None None O
with None None O
irradiation None None O
with None None O
three None None O
fractions None None O
( None None O
900 None None O
cGy None None O
) None None O
. None None O

Irradiation None None O
delivered None None O
before None None O
implantation None None O
( None None O
900 None None O
cGy None None O
) None None O
inhibited None None O
neovascularization None None O
significantly None None O
less None None O
than None None O
the None None O
same None None O
dose None None O
administered None None O
after None None O
implantation None None O
. None None O

The None None O
results None None O
of None None O
this None None O
study None None O
suggest None None O
that None None O
a None None O
subclinical None None O
cumulative None None O
dose None None O
of None None O
900 None None O
cGy None None O
is None None O
the None None O
threshold None None O
for None None O
impaired None None O
tissue None None O
revascularization None None O
provided None None O
that None None O
treatment None None O
is None None O
delivered None None O
immediately None None O
after None None O
implantation None None O
over None None O
a None None O
48 None None O
- None None O
hour None None O
interval None None O
. None None O

Effects None None O
of None None O
cyclooxygenase None None O
- None None O
2 None None O
non None None O
- None None O
selective None None O
and None None O
selective None None O
inhibitors None None O
on None None O
proliferation None None O
inhibition None None O
and None None O
apoptosis None None O
induction None None O
of None None O
esophageal None None O
squamous None None O
carcinoma None None O
cells None None O
. None None O

The None None O
objective None None O
of None None O
this None None O
study None None O
is None None O
to None None O
investigate None None O
the None None O
effects None None O
of None None O
aspirin None None O
and None None O
nimesulide None None O
on None None O
cell None None O
proliferation None None O
, None None O
apoptosis None None O
and None None O
its None None O
potential None None O
mechanisms None None O
in None None O
EC9706 None None I-Cell-line-name
and None None O
EC109 None None I-Cell-line-name
esophageal None None O
squamous None None O
carcinoma None None O
cells None None O
. None None O

EC9706 None None I-Cell-line-name
and None None O
EC109 None None I-Cell-line-name
cells None None O
were None None O
incubated None None O
with None None O
varying None None O
concentrations None None O
of None None O
aspirin None None O
and None None O
nimesulide None None O
, None None O
and None None O
the None None O
effects None None O
on None None O
cell None None O
proliferation None None O
and None None O
apoptosis None None O
were None None O
monitored None None O
by None None O
3 None None O
- None None O
( None None O
4 None None O
, None None O
5 None None O
- None None O
dimethyl None None O
- None None O
thiazol None None O
- None None O
2yl None None O
) None None O
- None None O
2 None None O
, None None O
5 None None O
- None None O
diphenyltetrazolium None None O
bromide None None O
and None None O
flow None None O
cytometry None None O
. None None O

Reverse None None O
transcription None None O
- None None O
polymerase None None O
chain None None O
reaction None None O
and None None O
Western None None O
blot None None O
assays None None O
were None None O
used None None O
to None None O
investigate None None O
expression None None O
of None None O
Bcl None None O
- None None O
2 None None O
and None None O
Bax None None O
. None None O

Prostaglandin None None O
E2 None None O
production None None O
was None None O
measured None None O
by None None O
enzyme None None O
linked None None O
immunosorbent None None O
assay None None O
. None None O

Pretreatment None None O
with None None O
aspirin None None O
and None None O
nimesulide None None O
inhibited None None O
EC9706 None None I-Cell-line-name
and None None O
EC109 None None I-Cell-line-name
cell None None O
growth None None O
in None None O
a None None O
time None None O
and None None O
dose None None O
- None None O
dependent None None O
manner None None O
, None None O
accompanied None None O
with None None O
a None None O
decrease None None O
of None None O
prostaglandin None None O
E2 None None O
production None None O
. None None O

In None None O
EC9706 None None I-Cell-line-name
cells None None O
, None None O
the None None O
mechanism None None O
of None None O
aspirin None None O
and None None O
nimesulide None None O
induced None None O
growth None None O
inhibition None None O
was None None O
a None None O
consequence None None O
of None None O
cell None None O
cycle None None O
arrest None None O
at None None O
the None None O
G None None O
( None None O
0 None None O
) None None O
/ None None O
G None None O
( None None O
1 None None O
) None None O
check None None O
point None None O
. None None O

In None None O
EC109 None None I-Cell-line-name
cells None None O
, None None O
growth None None O
arrest None None O
was None None O
by None None O
induction None None O
of None None O
apoptosis None None O
, None None O
associated None None O
with None None O
downregulation None None O
of None None O
Bcl None None O
- None None O
2 None None O
, None None O
but None None O
not None None O
Bax None None O
. None None O

In None None O
conclusion None None O
, None None O
aspirin None None O
and None None O
nimesulide None None O
could None None O
inhibit None None O
cell None None O
proliferation None None O
and None None O
induce None None O
apoptosis None None O
in None None O
esophageal None None O
squamous None None O
carcinoma None None O
cells None None O
. None None O

Cyclooxygenase None None O
- None None O
2 None None O
inhibitor None None O
may None None O
be None None O
a None None O
promising None None O
therapeutic None None O
agent None None O
for None None O
human None None O
esophageal None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

Regulation None None O
of None None O
the None None O
resident None None O
chromosomal None None O
copy None None O
of None None O
c None None O
- None None O
myc None None O
by None None O
c None None O
- None None O
Myb None None O
is None None O
involved None None O
in None None O
myeloid None None O
leukemogenesis None None O
. None None O

c None None O
- None None O
myb None None O
is None None O
a None None O
frequent None None O
target None None O
of None None O
retroviral None None O
insertional None None O
mutagenesis None None O
in None None O
murine None None O
leukemia None None O
virus None None O
- None None O
induced None None O
myeloid None None O
leukemia None None O
. None None O

Induction None None O
of None None O
the None None O
leukemogenic None None O
phenotype None None O
is None None O
generally None None O
associated None None O
with None None O
inappropriate None None O
expression None None O
of None None O
this None None O
transcriptional None None O
regulator None None O
. None None O

Despite None None O
intensive None None O
investigations None None O
, None None O
the None None O
target None None O
genes None None O
of None None O
c None None O
- None None O
myb None None O
that None None O
are None None O
specifically None None O
involved None None O
in None None O
development None None O
of None None O
these None None O
myeloid None None O
lineage None None O
neoplasms None None O
are None None O
still None None O
unknown None None O
. None None O

In None None O
vitro None None O
assays None None O
have None None O
indicated None None O
that None None O
c None None O
- None None O
myc None None O
may None None O
be None None O
a None None O
target None None O
gene None None O
of None None O
c None None O
- None None O
Myb None None O
; None None O
however None None O
, None None O
regulation None None O
of None None O
the None None O
resident None None O
chromosomal None None O
gene None None O
has None None O
not None None O
yet None None O
been None None O
demonstrated None None O
. None None O

To None None O
address None None O
this None None O
question None None O
further None None O
, None None O
we None None O
analyzed None None O
the None None O
expression None None O
of None None O
c None None O
- None None O
myc None None O
in None None O
a None None O
myeloblastic None None O
cell None None O
line None None O
, None None O
M1 None None I-Cell-line-name
, None None O
expressing None None O
a None None O
conditionally None None O
active None None O
c None None O
- None None O
Myb None None O
- None None O
estrogen None None O
receptor None None O
fusion None None O
protein None None O
( None None O
MybER None None O
) None None O
. None None O

Activation None None O
of None None O
MybER None None O
both None None O
prevented None None O
the None None O
growth None None O
arrest None None O
induced None None O
by None None O
interleukin None None O
- None None O
6 None None O
( None None O
IL None None O
- None None O
6 None None O
) None None O
and None None O
rapidly None None O
restored None None O
c None None O
- None None O
myc None None O
expression None None O
in None None O
nearly None None O
terminal None None O
differentiated None None O
cells None None O
that None None O
had None None O
been None None O
exposed None None O
to None None O
IL None None O
- None None O
6 None None O
for None None O
3 None None O
days None None O
. None None O

Restoration None None O
occurred None None O
in None None O
the None None O
presence None None O
of None None O
a None None O
protein None None O
synthesis None None O
inhibitor None None O
but None None O
not None None O
after None None O
a None None O
transcriptional None None O
block None None O
, None None O
indicating None None O
that None None O
c None None O
- None None O
myc None None O
is None None O
a None None O
direct None None O
, None None O
transcriptionally None None O
regulated None None O
target None None O
of None None O
c None None O
- None None O
Myb None None O
. None None O

c None None O
- None None O
myc None None O
is None None O
a None None O
major None None O
target None None O
that None None O
transduces None None O
Myb None None O
' None None O
s None None O
proliferative None None O
signal None None O
, None None O
as None None O
shown None None O
by None None O
the None None O
ability None None O
of None None O
a None None O
c None None O
- None None O
Myc None None O
- None None O
estrogen None None O
receptor None None O
fusion None None O
protein None None O
alone None None O
to None None O
also None None O
reverse None None O
growth None None O
arrest None None O
in None None O
this None None O
system None None O
. None None O

To None None O
investigate None None O
the None None O
possibility None None O
that None None O
this None None O
regulatory None None O
connection None None O
contributes None None O
to None None O
Myb None None O
' None None O
s None None O
oncogenicity None None O
, None None O
we None None O
expressed None None O
a None None O
dominant None None O
negative None None O
Myb None None O
in None None O
the None None O
myeloid None None O
leukemic None None O
cell None None O
line None None O
RI None None I-Cell-line-name
- None None I-Cell-line-name
4 None None I-Cell-line-name
- None None I-Cell-line-name
11 None None I-Cell-line-name
. None None O

In None None O
this None None O
cell None None O
line None None O
, None None O
c None None O
- None None O
myb None None O
is None None O
activated None None O
by None None O
insertional None None O
mutagenesis None None O
and None None O
cannot None None O
be None None O
effectively None None O
down None None O
regulated None None O
by None None O
cytokine None None O
. None None O

Myb None None O
' None None O
s None None O
ability None None O
to None None O
regulate None None O
c None None O
- None None O
myc None None O
' None None O
s None None O
expression None None O
was None None O
also None None O
demonstrated None None O
in None None O
these None None O
cells None None O
, None None O
showing None None O
a None None O
mechanism None None O
through None None O
which None None O
the None None O
proto None None O
- None None O
oncogene None None O
c None None O
- None None O
myb None None O
can None None O
exert None None O
its None None O
oncogenic None None O
potential None None O
in None None O
myeloid None None O
lineage None None O
hematopoietic None None O
cells None None O
. None None O

Pharmacokinetic None None O
- None None O
pharmacodynamic None None O
analysis None None O
. None None O

The None None O
mean None None O
( None None O
90 None None O
% None None O
CI None None O
) None None O
slope None None O
estimate None None O
from None None O
the None None O
linezolid None None O
concentration None None O
- None None O
R None None O
- None None O
R None None O
interval None None O
analysis None None O
was None None O
- None None O
0 None None O
. None None O
0017 None None O
( None None O
- None None O
0 None None O
. None None O
0022 None None O
to None None O
- None None O
0 None None O
. None None O
0011 None None O
) None None O
ms None None O
/ None None O
ng None None O
/ None None O
ml None None O
. None None O

This None None O
translates None None O
to None None O
mean None None O
( None None O
90 None None O
% None None O
CI None None O
) None None O
predicted None None O
decreases None None O
in None None O
heart None None O
rate None None O
of None None O
approximately None None O
1 None None O
. None None O
5 None None O
( None None O
1 None None O
. None None O
0 None None O
to None None O
2 None None O
. None None O
0 None None O
) None None O
and None None O
3 None None O
. None None O
0 None None O
( None None O
2 None None O
. None None O
1 None None O
to None None O
4 None None O
. None None O
1 None None O
) None None O
beats None None O
/ None None O
min None None O
at None None O
the None None O
mean None None O
Cmax None None O
following None None O
the None None O
administration None None O
of None None O
600 None None O
- None None O
and None None O
1 None None O
, None None O
200 None None O
- None None O
mg None None O
linezolid None None O
doses None None O
, None None O
respectively None None O
. None None O

The None None O
study None None O
- None None O
specific None None O
mean None None O
correction None None O
factor None None O
estimated None None O
from None None O
baseline None None O
data None None O
was None None O
0 None None O
. None None O
278 None None O
, None None O
which None None O
is None None O
slightly None None O
less None None O
than None None O
Fridericia None None O
' None None O
s None None O
correction None None O
( None None O
0 None None O
. None None O
333 None None O
) None None O
. None None O

Evaluation None None O
of None None O
the None None O
various None None O
correction None None O
factors None None O
showed None None O
that None None O
QTcF None None O
most None None O
appropriately None None O
resolves None None O
the None None O
relationship None None O
between None None O
the None None O
QT None None O
interval None None O
and None None O
the None None O
heart None None O
rate None None O
in None None O
the None None O
baseline None None O
data None None O
from None None O
the None None O
present None None O
study None None O
. None None O

This None None O
is None None O
evident None None O
upon None None O
inspection None None O
of None None O
Fig None None O
. None None O

4 None None O
, None None O
since None None O
the None None O
slope None None O
between None None O
the None None O
QTcF None None O
interval None None O
and None None O
the None None O
R None None O
- None None O
R None None O
interval None None O
is None None O
closest None None O
to None None O
zero None None O
when None None O
this None None O
correction None None O
is None None O
applied None None O
. None None O

Fig None None O
. None None O

4 None None O
. None None O

Evaluation None None O
of None None O
various None None O
heart None None O
rate None None O
correction None None O
factors None None O
for None None O
the None None O
QT None None O
interval None None O
versus None None O
the None None O
R None None O
- None None O
R None None O
interval None None O
. None None O

The None None O
predicted None None O
line None None O
in None None O
each None None O
figure None None O
represents None None O
the None None O
fit None None O
from None None O
a None None O
linear None None O
mixed None None O
- None None O
effect None None O
model None None O
with None None O
R None None O
- None None O
R None None O
interval None None O
as None None O
a None None O
fixed None None O
effect None None O
and None None O
subject None None O
- None None O
specific None None O
random None None O
effects None None O
for None None O
intercept None None O
and None None O
slope None None O
. None None O

The None None O
results None None O
from None None O
the None None O
concentration None None O
- None None O
QTcF None None O
analysis None None O
are None None O
graphically None None O
depicted None None O
in None None O
Fig None None O
. None None O

5 None None O
. None None O

The None None O
mean None None O
( None None O
90 None None O
% None None O
CI None None O
) None None O
slope None None O
estimate None None O
from None None O
the None None O
linezolid None None O
concentration None None O
- None None O
QTcF None None O
analysis None None O
was None None O
- None None O
0 None None O
. None None O
0145 None None O
( None None O
- None None O
0 None None O
. None None O
0768 None None O
to None None O
0 None None O
. None None O
0477 None None O
) None None O
ms None None O
/ None None O
mug None None O
/ None None O
ml None None O
. None None O

At None None O
the None None O
geometric None None O
mean None None O
Cmax None None O
following None None O
the None None O
infusion None None O
of None None O
linezolid None None O
at None None O
600 None None O
mg None None O
( None None O
14 None None O
. None None O
9 None None O
mug None None O
/ None None O
ml None None O
) None None O
and None None O
1 None None O
, None None O
200 None None O
mg None None O
( None None O
30 None None O
. None None O
5 None None O
mug None None O
/ None None O
ml None None O
) None None O
, None None O
the None None O
mean None None O
( None None O
90 None None O
% None None O
CI None None O
) None None O
predicted None None O
placebo None None O
- None None O
adjusted None None O
changes None None O
from None None O
the None None O
baseline None None O
QTcF None None O
were None None O
- None None O
0 None None O
. None None O
217 None None O
( None None O
- None None O
1 None None O
. None None O
14 None None O
to None None O
0 None None O
. None None O
710 None None O
) None None O
and None None O
- None None O
0 None None O
. None None O
444 None None O
( None None O
- None None O
2 None None O
. None None O
34 None None O
to None None O
1 None None O
. None None O
45 None None O
) None None O
ms None None O
, None None O
respectively None None O
, None None O
thus None None O
confirming None None O
a None None O
lack None None O
of None None O
a None None O
relationship None None O
between None None O
linezolid None None O
concentrations None None O
and None None O
QTc None None O
interval None None O
. None None O

Fig None None O
. None None O

5 None None O
. None None O

QTcF None None O
interval None None O
versus None None O
plasma None None O
linezolid None None O
concentrations None None O
. None None O

Expression None None O
of None None O
KISS1 None None O
and None None O
MMP None None O
- None None O
9 None None O
in None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
cancer None None O
and None None O
their None None O
relations None None O
to None None O
metastasis None None O
and None None O
survival None None O
. None None O

KISS1 None None O
and None None O
matrix None None O
metalloproteinase None None O
- None None O
9 None None O
( None None O
MMP None None O
- None None O
9 None None O
) None None O
may None None O
play None None O
important None None O
roles None None O
as None None O
metastasis None None O
suppressor None None O
and None None O
metastasis None None O
promoter None None O
genes None None O
, None None O
respectively None None O
, None None O
in None None O
a None None O
variety None None O
of None None O
malignancies None None O
. None None O

However None None O
, None None O
there None None O
is None None O
little None None O
information None None O
about None None O
their None None O
possible None None O
roles None None O
in None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
cancer None None O
( None None O
NSCLC None None O
) None None O
. None None O

The None None O
goals None None O
of None None O
this None None O
study None None O
were None None O
to None None O
determine None None O
the None None O
mRNA None None O
and None None O
protein None None O
expressions None None O
of None None O
KISS1 None None O
and None None O
MMP None None O
- None None O
9 None None O
in None None O
NSCLC None None O
and None None O
their None None O
relations None None O
to None None O
metastasis None None O
and None None O
prognosis None None O
. None None O

The None None O
mRNA None None O
and None None O
protein None None O
expressions None None O
of None None O
KISS1 None None O
and None None O
of None None O
MMP None None O
- None None O
9 None None O
protein None None O
were None None O
detected None None O
by None None O
in None None O
situ None None O
hybridization None None O
and None None O
immunohistochemistry None None O
respectively None None O
in None None O
85 None None O
cases None None O
of None None O
NSCLC None None O
, None None O
and None None O
their None None O
matched None None O
lymph None None O
node None None O
metastases None None O
. None None O

Expressions None None O
of None None O
KISS1 None None O
mRNA None None O
and None None O
protein None None O
were None None O
significantly None None O
higher None None O
in None None O
low None None O
TNM None None O
stages None None O
of None None O
NSCLC None None O
( None None O
I None None O
- None None O
II None None O
) None None O
compared None None O
to None None O
more None None O
advanced None None O
stages None None O
( None None O
III None None O
- None None O
IV None None O
) None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Moreover None None O
, None None O
in None None O
advanced None None O
TNM None None O
stages None None O
, None None O
cases None None O
without None None O
metastasis None None O
had None None O
higher None None O
KISS1 None None O
gene None None O
expression None None O
compared None None O
to None None O
those None None O
with None None O
lymph None None O
node None None O
metastasis None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
MMP None None O
- None None O
9 None None O
expression None None O
was None None O
higher None None O
in None None O
stage None None O
III None None O
- None None O
IV None None O
NSCLC None None O
cases None None O
compared None None O
to None None O
stage None None O
I None None O
- None None O
II None None O
tumors None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
and None None O
higher None None O
in None None O
NSCLC None None O
cases None None O
with None None O
metastasis None None O
than None None O
those None None O
without None None O
metastasis None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

There None None O
was None None O
negative None None O
correction None None O
between None None O
KISS1 None None O
and None None O
MMP None None O
- None None O
9 None None O
protein None None O
expression None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

The None None O
5 None None O
- None None O
year None None O
survival None None O
rate None None O
in None None O
cases None None O
with None None O
higher None None O
KISS1 None None O
protein None None O
expression None None O
was None None O
significantly None None O
higher None None O
than None None O
in None None O
those None None O
with None None O
low None None O
expression None None O
( None None O
20 None None O
. None None O
9 None None O
vs None None O
. None None O
2 None None O
. None None O
4 None None O
% None None O
, None None O
p None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

However None None O
, None None O
the None None O
5 None None O
- None None O
year None None O
survival None None O
rate None None O
of None None O
patients None None O
with None None O
high None None O
MMP None None O
- None None O
9 None None O
protein None None O
expression None None O
were None None O
lower None None O
than None None O
those None None O
with None None O
low None None O
expression None None O
( None None O
19 None None O
vs None None O
. None None O
4 None None O
. None None O
7 None None O
% None None O
, None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Our None None O
data None None O
suggest None None O
that None None O
KISS1 None None O
and None None O
MMP None None O
- None None O
9 None None O
may None None O
serve None None O
as None None O
potential None None O
prognostic None None O
and None None O
therapeutic None None O
markers None None O
in None None O
lung None None O
cancer None None O
. None None O

Tumor None None O
endothelial None None O
cell None None O
targeted None None O
cyclic None None O
RGD None None O
- None None O
modified None None O
heparin None None O
derivative None None O
: None None O
inhibition None None O
of None None O
angiogenesis None None O
and None None O
tumor None None O
growth None None O
. None None O

PURPOSE None None O
: None None O
We None None O
prepared None None O
tumor None None O
endothelium None None O
targeted None None O
cRGD None None O
- None None O
modified None None O
heparin None None O
derivative None None O
( None None O
cRGD None None O
- None None O
HL None None O
) None None O
by None None O
coupling None None O
heparin None None O
- None None O
lithocholic None None O
acid None None O
( None None O
HL None None O
) None None O
with None None O
cRGDyK None None O
, None None O
and None None O
evaluated None None O
inhibition None None O
effects None None O
of None None O
cRGD None None O
- None None O
HL None None O
on None None O
angiogenesis None None O
and None None O
tumor None None O
growth None None O
. None None O

METHODS None None O
: None None O
To None None O
evaluate None None O
antiangiogenic None None O
activity None None O
of None None O
cRGD None None O
- None None O
HL None None O
, None None O
we None None O
performed None None O
tests None None O
on None None O
endothelial None None O
cell None None O
adhesion None None O
and None None O
migration None None O
to None None O
vitronectin None None O
, None None O
tube None None O
formation None None O
, None None O
binding None None O
affinity None None O
to None None O
purified None None O
alpha None None O
( None None O
v None None O
) None None O
beta None None O
( None None O
3 None None O
) None None O
integrin None None O
, None None O
and None None O
in None None O
vivo None None O
Matrigel None None O
plug None None O
assay None None O
. None None O

The None None O
antitumor None None O
activity None None O
of None None O
cRGD None None O
- None None O
HL None None O
was None None O
also None None O
evaluated None None O
by None None O
monitoring None None O
tumor None None O
growth None None O
and None None O
microvessel None None O
formation None None O
in None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
SCC7 None None O
) None None O
tumor None None O
. None None O

RESULTS None None O
: None None O
The None None O
cRGD None None O
- None None O
HL None None O
significantly None None O
inhibited None None O
adhesion None None O
and None None O
migration None None O
of None None O
endothelial None None O
cells None None O
to None None O
vitronectin None None O
, None None O
and None None O
tubular None None O
structures None None O
of None None O
endothelial None None O
cells None None O
. None None O

Compared None None O
to None None O
cRGDyK None None O
and None None O
HL None None O
, None None O
cRGD None None O
- None None O
HL None None O
has None None O
high None None O
binding None None O
affinity None None O
to None None O
purified None None O
alpha None None O
( None None O
v None None O
) None None O
beta None None O
( None None O
3 None None O
) None None O
integrin None None O
. None None O

The None None O
enhanced None None O
antiangiogenic None None O
effect None None O
of None None O
cRGD None None O
- None None O
HL None None O
was None None O
confirmed None None O
in None None O
Matrigel None None O
assay None None O
by None None O
showing None None O
the None None O
significant None None O
inhibition None None O
of None None O
bFGF None None O
- None None O
driven None None O
angiogenesis None None O
and None None O
blood None None O
vessel None None O
formation None None O
. None None O

It None None O
was None None O
thought None None O
that None None O
potent None None O
antiangiogenic None None O
effect None None O
of None None O
cRGD None None O
- None None O
HL None None O
was None None O
probably None None O
due None None O
to None None O
the None None O
interference None None O
of None None O
alpha None None O
( None None O
v None None O
) None None O
beta None None O
( None None O
3 None None O
) None None O
- None None O
mediated None None O
interaction None None O
, None None O
resulting None None O
in None None O
the None None O
enhanced None None O
antitumoral None None O
activity None None O
against None None O
SCC7 None None I-Cell-line-name
tumor None None O
. None None O

CONCLUSION None None O
: None None O
These None None O
results None None O
demonstrated None None O
that None None O
cRGD None None O
- None None O
modified None None O
heparin None None O
derivative None None O
enhanced None None O
anti None None O
- None None O
angiotherapeutic None None O
effects None None O
against None None O
solid None None O
tumor None None O
, None None O
and None None O
therefore None None O
, None None O
it None None O
could None None O
be None None O
applied None None O
to None None O
treat None None O
various None None O
cancers None None O
and None None O
angiogenic None None O
diseases None None O
as None None O
a None None O
potent None None O
angiogenesis None None O
inhibitor None None O
. None None O

3 None None O
- None None O
[ None None O
( None None O
Methyl None None O
- None None O
carbamo None None O
- None None O
yl None None O
) None None O
amino None None O
] None None O
- None None O
1H None None O
- None None O
isoindolium None None O
chloride None None O
. None None O

The None None O
title None None O
compound None None O
, None None O
C None None O
( None None O
10 None None O
) None None O
H None None O
( None None O
12 None None O
) None None O
N None None O
( None None O
3 None None O
) None None O
O None None O
( None None O
+ None None O
) None None O
. None None O
Cl None None O
( None None O
- None None O
) None None O
, None None O
is None None O
a None None O
derivative None None O
of None None O
o None None O
- None None O
phthaldehyde None None O
and None None O
methyl None None O
- None None O
thio None None O
- None None O
urea None None O
. None None O

The None None O
mol None None O
- None None O
ecules None None O
form None None O
dimers None None O
through None None O
intra None None O
- None None O
and None None O
inter None None O
- None None O
molecular None None O
N None None O
- None None O
H None None O
. None None O
. None None O
. None None O
O None None O
hydrogen None None O
bonds None None O
. None None O

The None None O
dimers None None O
are None None O
further None None O
linked None None O
into None None O
chains None None O
through None None O
one None None O
C None None O
- None None O
H None None O
. None None O
. None None O
. None None O
Cl None None O
and None None O
two None None O
N None None O
- None None O
H None None O
. None None O
. None None O
. None None O
Cl None None O
hydrogen None None O
bonds None None O
. None None O

Immunoglobulins None None O
associated None None O
with None None O
elevated None None O
riboflavin None None O
binding None None O
by None None O
plasma None None O
from None None O
cancer None None O
patients None None O
. None None O

Plasma None None O
from None None O
182 None None O
patients None None O
with None None O
different None None O
malignant None None O
diseases None None O
was None None O
tested None None O
for None None O
riboflavin None None O
binding None None O
by None None O
immunoglobulins None None O
, None None O
which None None O
have None None O
been None None O
recently None None O
identified None None O
as None None O
major None None O
carriers None None O
of None None O
this None None O
micronutrient None None O
. None None O

A None None O
wide None None O
range None None O
of None None O
binding None None O
( None None O
5 None None O
. None None O
9 None None O
to None None O
130 None None O
pmole None None O
/ None None O
ml None None O
plasma None None O
) None None O
was None None O
observed None None O
, None None O
and None None O
significant None None O
elevations None None O
were None None O
found None None O
for None None O
patients None None O
having None None O
breast None None O
cancer None None O
( None None O
21 None None O
. None None O
2 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
9 None None O
, None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
and None None O
melanoma None None O
( None None O
25 None None O
. None None O
7 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
9 None None O
, None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
compared None None O
to None None O
controls None None O
( None None O
15 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
9 None None O
) None None O
. None None O

The None None O
proteins None None O
responsible None None O
for None None O
a None None O
majority None None O
of None None O
the None None O
higher None None O
binding None None O
were None None O
identified None None O
as None None O
immunoglobulins None None O
, None None O
based None None O
on None None O
their None None O
elution None None O
from None None O
gel None None O
filtration None None O
columns None None O
and None None O
the None None O
removal None None O
of None None O
57 None None O
- None None O
88 None None O
% None None O
of None None O
the None None O
non None None O
- None None O
albumin None None O
binding None None O
by None None O
treating None None O
of None None O
plasma None None O
with None None O
Protein None None O
A None None O
- None None O
agarose None None O
. None None O

The None None O
binding None None O
was None None O
only None None O
weakly None None O
related None None O
to None None O
the None None O
total None None O
concentration None None O
of None None O
immunoglobulins None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
11 None None O
by None None O
linear None None O
regression None None O
analysis None None O
) None None O
, None None O
however None None O
, None None O
and None None O
is None None O
apparently None None O
due None None O
to None None O
a None None O
subclass None None O
that None None O
is None None O
elevated None None O
in None None O
some None None O
types None None O
of None None O
cancer None None O
. None None O

Elevated None None O
levels None None O
of None None O
these None None O
immunoglobulins None None O
may None None O
contribute None None O
to None None O
the None None O
lower None None O
urinary None None O
levels None None O
and None None O
clearance None None O
of None None O
riboflavin None None O
in None None O
cancer None None O
. None None O

The None None O
effect None None O
of None None O
early None None O
diagnosis None None O
and None None O
treatment None None O
in None None O
cystic None None O
fibrosis None None O
: None None O
a None None O
seven None None O
- None None O
year None None O
study None None O
of None None O
16 None None O
sibling None None O
pairs None None O
. None None O

Data None None O
on None None O
16 None None O
sibling None None O
pairs None None O
with None None O
cystic None None O
fibrosis None None O
were None None O
analyzed None None O
to None None O
test None None O
the None None O
hypothesis None None O
that None None O
early None None O
treatment None None O
of None None O
this None None O
condition None None O
improves None None O
prognosis None None O
. None None O

Younger None None O
siblings None None O
' None None O
conditions None None O
were None None O
diagnosed None None O
before None None O
1 None None O
year None None O
of None None O
age None None O
, None None O
usually None None O
before None None O
the None None O
onset None None O
of None None O
pulmonary None None O
disease None None O
. None None O

Older None None O
siblings None None O
' None None O
conditions None None O
were None None O
diagnosed None None O
after None None O
1 None None O
year None None O
of None None O
age None None O
and None None O
after None None O
the None None O
onset None None O
of None None O
pulmonary None None O
disease None None O
. None None O

Although None None O
the None None O
sibling None None O
pairs None None O
received None None O
similar None None O
treatment None None O
, None None O
comparison None None O
at None None O
7 None None O
years None None O
of None None O
age None None O
showed None None O
that None None O
the None None O
younger None None O
siblings None None O
had None None O
significantly None None O
better None None O
chest None None O
roentgenogram None None O
scores None None O
, None None O
total None None O
clinical None None O
scores None None O
, None None O
residual None None O
lung None None O
volumes None None O
, None None O
and None None O
ratios None None O
of None None O
residual None None O
volume None None O
to None None O
total None None O
lung None None O
volume None None O
. None None O

Younger None None O
siblings None None O
also None None O
required None None O
fewer None None O
hospital None None O
admissions None None O
to None None O
control None None O
their None None O
lung None None O
disease None None O
. None None O

The None None O
results None None O
suggest None None O
that None None O
, None None O
in None None O
general None None O
, None None O
early None None O
initiation None None O
of None None O
therapy None None O
is None None O
beneficial None None O
for None None O
patients None None O
with None None O
cystic None None O
fibrosis None None O
. None None O

Definition None None O
of None None O
pathogens None None O

It None None O
remains None None O
difficult None None O
to None None O
determine None None O
whether None None O
the None None O
organisms None None O
detected None None O
by None None O
the None None O
DNA None None O
Detection None None O
Kit None None O
are None None O
true None None O
pathogens None None O
. None None O

This None None O
also None None O
applies None None O
, None None O
although None None O
to None None O
a None None O
much None None O
lesser None None O
degree None None O
, None None O
to None None O
conventional None None O
blood None None O
culture None None O
analysis None None O
. None None O

However None None O
, None None O
detected None None O
organisms None None O
were None None O
considered None None O
to None None O
be None None O
pathogens None None O
if None None O
the None None O
results None None O
of None None O
culture None None O
tests None None O
from None None O
samples None None O
of None None O
the None None O
suspected None None O
infectious None None O
sites None None O
coincided None None O
with None None O
the None None O
results None None O
of None None O
DNA None None O
Detection None None O
Kit None None O
or None None O
blood None None O
culture None None O
analysis None None O
. None None O

The None None O
culture None None O
data None None O
of None None O
sputum None None O
, None None O
urine None None O
, None None O
pus None None O
and None None O
drainage None None O
fluid None None O
were None None O
used None None O
to None None O
define None None O
the None None O
pathogens None None O
. None None O

A None None O
decision None None O
as None None O
to None None O
whether None None O
an None None O
identified None None O
organism None None O
was None None O
a None None O
pathogen None None O
was None None O
taken None None O
based None None O
on None None O
the None None O
decision None None O
tree None None O
shown None None O
in None None O
Figure None None O
1 None None O
. None None O

Thus None None O
, None None O
when None None O
the None None O
same None None O
organism None None O
was None None O
detected None None O
by None None O
both None None O
DNA None None O
Detection None None O
Kit None None O
and None None O
blood None None O
culture None None O
analysis None None O
, None None O
the None None O
detected None None O
organism None None O
was None None O
considered None None O
an None None O
infectious None None O
pathogen None None O
. None None O

If None None O
there None None O
was None None O
a None None O
discrepancy None None O
between None None O
the None None O
organism None None O
that None None O
was None None O
detected None None O
by None None O
SeptiFast None None O
analysis None None O
and None None O
that None None O
detected None None O
by None None O
blood None None O
culture None None O
analysis None None O
, None None O
or None None O
if None None O
an None None O
organism None None O
was None None O
only None None O
detected None None O
in None None O
one None None O
of None None O
these None None O
tests None None O
, None None O
then None None O
other None None O
samples None None O
taken None None O
from None None O
the None None O
infection None None O
site None None O
were None None O
analyzed None None O
. None None O

If None None O
this None None O
second None None O
culture None None O
test None None O
of None None O
the None None O
suspected None None O
infectious None None O
site None None O
revealed None None O
the None None O
presence None None O
of None None O
the None None O
same None None O
organism None None O
, None None O
this None None O
organism None None O
was None None O
considered None None O
to None None O
be None None O
a None None O
pathogen None None O
. None None O

If None None O
the None None O
microbial None None O
strain None None O
was None None O
only None None O
detected None None O
once None None O
for None None O
a None None O
sample None None O
, None None O
we None None O
then None None O
checked None None O
the None None O
second None None O
culture None None O
results None None O
in None None O
the None None O
suspected None None O
infectious None None O
sites None None O
. None None O

If None None O
this None None O
result None None O
identified None None O
the None None O
same None None O
strain None None O
as None None O
that None None O
identified None None O
by None None O
SeptiFast None None O
analysis None None O
then None None O
it None None O
was None None O
decided None None O
that None None O
this None None O
strain None None O
was None None O
a None None O
pathogen None None O
. None None O

However None None O
, None None O
if None None O
the None None O
strain None None O
was None None O
still None None O
only None None O
detected None None O
in None None O
some None None O
of None None O
the None None O
assays None None O
, None None O
we None None O
next None None O
determined None None O
if None None O
the None None O
patient None None O
involved None None O
suffered None None O
from None None O
sepsis None None O
. None None O

Sepsis None None O
is None None O
defined None None O
as None None O
SIRS None None O
caused None None O
by None None O
infection None None O
. None None O

The None None O
definition None None O
of None None O
sepsis None None O
that None None O
we None None O
used None None O
was None None O
based None None O
on None None O
the None None O
International None None O
Sepsis None None O
Forum None None O
Definition None None O
of None None O
Infection None None O
at None None O
the None None O
ICU None None O
Consensus None None O
Conference None None O
[ None None O
7 None None O
] None None O
. None None O

However None None O
, None None O
if None None O
the None None O
underlying None None O
disease None None O
is None None O
acute None None O
lymphoma None None O
leukemia None None O
( None None O
ALL None None O
) None None O
, None None O
malignant None None O
lymphoma None None O
( None None O
ML None None O
) None None O
, None None O
or None None O
acute None None O
myelogenous None None O
leukemia None None O
( None None O
AML None None O
) None None O
, None None O
the None None O
definition None None O
of None None O
infection None None O
is None None O
defined None None O
as None None O
the None None O
ability None None O
to None None O
detect None None O
infectious None None O
organisms None None O
by None None O
blood None None O
culture None None O
analysis None None O
. None None O

If None None O
the None None O
patient None None O
was None None O
not None None O
defined None None O
as None None O
having None None O
sepsis None None O
when None None O
whole None None O
blood None None O
was None None O
administered None None O
to None None O
the None None O
patient None None O
, None None O
we None None O
decided None None O
that None None O
the None None O
strain None None O
detected None None O
by None None O
subsequent None None O
DNA None None O
Detection None None O
Kit None None O
or None None O
blood None None O
culture None None O
analysis None None O
was None None O
not None None O
a None None O
pathogen None None O
. None None O

Figure None None O
1 None None O

Flowchart None None O
for None None O
pathogen None None O
decision None None O
. None None O

Samples None None O
were None None O
defined None None O
as None None O
negative None None O
for None None O
pathogens None None O
if None None O
a None None O
pathogen None None O
could None None O
not None None O
be None None O
detected None None O
by None None O
any None None O
method None None O
of None None O
analysis None None O
within None None O
seven None None O
days None None O
, None None O
and None None O
if None None O
another None None O
type None None O
of None None O
culture None None O
test None None O
did None None O
not None None O
detect None None O
this None None O
pathogen None None O
but None None O
could None None O
detect None None O
other None None O
organisms None None O
. None None O

CoNS None None O
bacteria None None O
, None None O
which None None O
are None None O
represented None None O
by None None O
the None None O
Staphylococcus None None O
epidermidis None None O
( None None O
S None None O
. None None O
epidermidis None None O
) None None O
and None None O
Streptococcus None None O
spp None None O
. None None O
are None None O
indigenous None None O
bacteria None None O
and None None O
often None None O
cause None None O
contamination None None O
in None None O
assays None None O
of None None O
pathogens None None O
. None None O

Therefore None None O
, None None O
when None None O
CoNS None None O
or None None O
Streptococcus None None O
spp None None O
. None None O
were None None O
detected None None O
by None None O
blood None None O
culture None None O
and None None O
SeptiFast None None O
analysis None None O
, None None O
the None None O
following None None O
criteria None None O
were None None O
applied None None O
to None None O
define None None O
whether None None O
these None None O
strains None None O
represented None None O
a None None O
pathogenic None None O
infection None None O
: None None O
( None None O
1 None None O
) None None O
Tests None None O
were None None O
performed None None O
at None None O
least None None O
twice None None O
within None None O
48 None None O
hours None None O
before None None O
and None None O
after None None O
CoNS None None O
were None None O
detected None None O
by None None O
blood None None O
culture None None O
or None None O
SeptiFast None None O
analysis None None O
; None None O
( None None O
2 None None O
) None None O
CoNS None None O
or None None O
Streptococcus None None O
spp None None O
. None None O
were None None O
detected None None O
in None None O
two None None O
different None None O
blood None None O
culture None None O
tests None None O
that None None O
were None None O
separately None None O
performed None None O
twice None None O
within None None O
48 None None O
hours None None O
; None None O
and None None O
, None None O
( None None O
3 None None O
) None None O
CoNS None None O
or None None O
Streptococcus None None O
spp None None O
. None None O
were None None O
detected None None O
twice None None O
or None None O
more None None O
in None None O
tests None None O
that None None O
were None None O
performed None None O
three None None O
times None None O
[ None None O
11 None None O
- None None O
15 None None O
] None None O
. None None O

If None None O
a None None O
sample None None O
' None None O
s None None O
results None None O
met None None O
any None None O
of None None O
these None None O
three None None O
criteria None None O
, None None O
then None None O
the None None O
sample None None O
was None None O
evaluated None None O
as None None O
a None None O
pathogen None None O
. None None O

The None None O
distinction None None O
between None None O
pathogen None None O
and None None O
contamination None None O
was None None O
also None None O
determined None None O
for None None O
CoNS None None O
or None None O
Streptococcus None None O
spp None None O
. None None O
from None None O
the None None O
crossing None None O
point None None O
( None None O
Cp None None O
) None None O
obtained None None O
using None None O
the None None O
LightCycler None None O
analysis None None O
software None None O
v4 None None O
. None None O
05 None None O
. None None O

The None None O
Cp None None O
represents None None O
the None None O
point None None O
in None None O
the None None O
amplification None None O
cycle None None O
where None None O
the None None O
amplification None None O
curve None None O
crosses None None O
the None None O
detection None None O
threshold None None O
. None None O

When None None O
CoNS None None O
or None None O
Streptococcus None None O
spp None None O
. None None O
were None None O
detected None None O
using None None O
the None None O
LightCycler None None O
analysis None None O
software None None O
v4 None None O
. None None O
05 None None O
, None None O
a None None O
Cp None None O
of None None O
less None None O
than None None O
20 None None O
was None None O
defined None None O
as None None O
indicating None None O
a None None O
pathogen None None O
and None None O
a None None O
Cp None None O
of None None O
over None None O
20 None None O
was None None O
defined None None O
as None None O
contamination None None O
by None None O
checking None None O
the None None O
amplification None None O
curve None None O
. None None O

Incidence None None O
of None None O
BRAF None None O
p None None O
. None None O
Val600Glu None None O
and None None O
p None None O
. None None O
Val600Lys None None O
mutations None None O
in None None O
a None None O
consecutive None None O
series None None O
of None None O
183 None None O
metastatic None None O
melanoma None None O
patients None None O
from None None O
a None None O
high None None O
incidence None None O
region None None O
. None None O

AIM None None O
: None None O
Approximately None None O
40 None None O
- None None O
60 None None O
% None None O
of None None O
melanomas None None O
from None None O
Caucasian None None O
populations None None O
carry None None O
activating None None O
mutations None None O
in None None O
the None None O
BRAF None None O
oncogene None None O
, None None O
with None None O
the None None O
most None None O
common None None O
being None None O
the None None O
p None None O
. None None O
Val600Glu None None O
( None None O
V600E None None O
) None None O
hotspot None None O
mutation None None O
in None None O
exon None None O
15 None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
frequency None None O
of None None O
the None None O
less None None O
common None None O
p None None O
. None None O
Val600Lys None None O
( None None O
V600K None None O
) None None O
mutation None None O
in None None O
metastatic None None O
melanoma None None O
from None None O
a None None O
high None None O
incidence None None O
region None None O
. None None O

METHOD None None O
: None None O
Dideoxy None None O
sequencing None None O
and None None O
fluorescent None None O
single None None O
strand None None O
conformation None None O
analysis None None O
were None None O
used None None O
to None None O
screen None None O
for None None O
mutations None None O
in None None O
exon None None O
15 None None O
of None None O
BRAF None None O
in None None O
183 None None O
cases None None O
of None None O
metastatic None None O
melanoma None None O
. None None O

RESULTS None None O
: None None O
The None None O
overall None None O
incidence None None O
of None None O
BRAF None None O
mutation None None O
( None None O
89 None None O
/ None None O
183 None None O
, None None O
49 None None O
% None None O
) None None O
was None None O
very None None O
similar None None O
to None None O
other None None O
large None None O
studies None None O
of None None O
Caucasian None None O
populations None None O
. None None O

However None None O
, None None O
the None None O
frequency None None O
of None None O
the None None O
p None None O
. None None O
Val600Lys None None O
mutation None None O
was None None O
higher None None O
than None None O
in None None O
most None None O
other None None O
studies None None O
and None None O
comprised None None O
almost None None O
one None None O
- None None O
third None None O
of None None O
all None None O
BRAF None None O
mutations None None O
in None None O
our None None O
cohort None None O
( None None O
27 None None O
/ None None O
89 None None O
, None None O
30 None None O
% None None O
) None None O
. None None O

CONCLUSION None None O
: None None O
BRAF None None O
p None None O
. None None O
Val600Lys None None O
mutations None None O
were None None O
present None None O
at None None O
a None None O
relatively None None O
high None None O
frequency None None O
in None None O
this None None O
cohort None None O
of None None O
metastatic None None O
melanoma None None O
patients None None O
( None None O
27 None None O
/ None None O
183 None None O
, None None O
15 None None O
% None None O
) None None O
. None None O

Assays None None O
used None None O
to None None O
screen None None O
for None None O
BRAF None None O
mutations None None O
in None None O
the None None O
clinic None None O
should None None O
be None None O
robust None None O
enough None None O
to None None O
detect None None O
the None None O
p None None O
. None None O
Val600Lys None None O
mutation None None O
, None None O
as None None O
this None None O
may None None O
have None None O
therapeutic None None O
implications None None O
. None None O

Cooccurrence None None O
of None None O
reduced None None O
expression None None O
of None None O
alpha None None O
- None None O
catenin None None O
and None None O
overexpression None None O
of None None O
p53 None None O
is None None O
a None None O
predictor None None O
of None None O
lymph None None O
node None None O
metastasis None None O
in None None O
early None None O
gastric None None O
cancer None None O
. None None O

BACKGROUND None None O
AND None None O
OBJECTIVES None None O
: None None O
Even None None O
though None None O
the None None O
pathological None None O
background None None O
contributes None None O
to None None O
lymph None None O
node None None O
metastasis None None O
, None None O
the None None O
biological None None O
characteristics None None O
of None None O
tumors None None O
have None None O
also None None O
gained None None O
wide None None O
attention None None O
. None None O

In None None O
this None None O
study None None O
, None None O
the None None O
expression None None O
of None None O
the None None O
cadherin None None O
- None None O
catenin None None O
complex None None O
and None None O
p53 None None O
was None None O
studied None None O
in None None O
early None None O
gastric None None O
cancer None None O
. None None O

Their None None O
correlation None None O
with None None O
lymph None None O
node None None O
metastasis None None O
and None None O
the None None O
predictability None None O
of None None O
lymph None None O
node None None O
metastases None None O
, None None O
by None None O
combining None None O
these None None O
factors None None O
, None None O
were None None O
also None None O
discussed None None O
. None None O

METHODS None None O
: None None O
One None None O
hundred None None O
and None None O
one None None O
specimens None None O
obtained None None O
from None None O
surgery None None O
were None None O
studied None None O
by None None O
immunohistochemistry None None O
using None None O
monoclonal None None O
anti None None O
- None None O
E None None O
- None None O
cadherin None None O
, None None O
anti None None O
- None None O
alpha None None O
- None None O
catenin None None O
and None None O
anti None None O
- None None O
p53 None None O
antibodies None None O
. None None O

RESULTS None None O
: None None O
Expression None None O
of None None O
E None None O
- None None O
cadherin None None O
and None None O
alpha None None O
- None None O
catenin None None O
was None None O
reduced None None O
in None None O
50 None None O
. None None O
5 None None O
and None None O
64 None None O
. None None O
4 None None O
% None None O
, None None O
respectively None None O
. None None O

p53 None None O
protein None None O
staining None None O
was None None O
positive None None O
in None None O
29 None None O
. None None O
7 None None O
% None None O
. None None O

There None None O
was None None O
a None None O
significant None None O
correlation None None O
between None None O
E None None O
- None None O
cadherin None None O
and None None O
alpha None None O
- None None O
catenin None None O
expression None None O
, None None O
but None None O
no None None O
correlation None None O
was None None O
found None None O
between None None O
p53 None None O
expression None None O
and None None O
E None None O
- None None O
cadherin None None O
or None None O
alpha None None O
- None None O
catenin None None O
expression None None O
. None None O

A None None O
reduction None None O
in None None O
alpha None None O
- None None O
catenin None None O
expression None None O
and None None O
p53 None None O
overexpression None None O
correlated None None O
to None None O
lymph None None O
node None None O
metastases None None O
, None None O
respectively None None O
. None None O

Multivariate None None O
analysis None None O
showed None None O
that None None O
cooccurrence None None O
of None None O
reduced None None O
expression None None O
of None None O
alpha None None O
- None None O
catenin None None O
and None None O
overexpression None None O
of None None O
p53 None None O
was None None O
an None None O
independent None None O
factor None None O
indicating None None O
lymph None None O
node None None O
metastases None None O
. None None O

CONCLUSION None None O
: None None O
A None None O
study None None O
of None None O
both None None O
alpha None None O
- None None O
catenin None None O
and None None O
p53 None None O
expression None None O
may None None O
be None None O
helpful None None O
to None None O
predict None None O
lymph None None O
node None None O
metastases None None O
in None None O
early None None O
gastric None None O
cancer None None O
. None None O

Absence None None O
of None None O
antisperm None None O
antibodies None None O
in None None O
anejaculatory None None O
men None None O
. None None O

Antisperm None None O
antibodies None None O
were None None O
assessed None None O
in None None O
the None None O
serum None None O
samples None None O
of None None O
73 None None O
men None None O
unable None None O
to None None O
ejaculate None None O
naturally None None O
and None None O
on None None O
the None None O
sperm None None O
cells None None O
of None None O
13 None None O
of None None O
these None None O
men None None O
. None None O

None None None O
of None None O
the None None O
serum None None O
samples None None O
were None None O
found None None O
to None None O
be None None O
positive None None O
by None None O
sperm None None O
agglutination None None O
or None None O
sperm None None O
immobilization None None O
methods None None O
and None None O
antibodies None None O
were None None O
detected None None O
by None None O
an None None O
immunobead None None O
assay None None O
on None None O
the None None O
sperm None None O
cells None None O
of None None O
one None None O
of None None O
the None None O
13 None None O
men None None O
examined None None O
. None None O

CONCLUSION None None O

Intra None None O
- None None O
operative None None O
monitoring None None O
of None None O
partial None None O
pressure None None O
of None None O
tissue None None O
oxygen None None O
( None None O
PtiO2 None None O
) None None O
is None None O
a None None O
very None None O
sensitive None None O
method None None O
of None None O
detecting None None O
the None None O
decrease None None O
of None None O
oxygen None None O
for None None O
cell None None O
utilization None None O
, None None O
due None None O
to None None O
decreased None None O
blood None None O
flow None None O
, None None O
during None None O
temporary None None O
clipping None None O
and None None O
after None None O
definitive None None O
clipping None None O
, None None O
in None None O
middle None None O
cerebral None None O
artery None None O
incidental None None O
unruptured None None O
aneurysm None None O
surgery None None O
. None None O

" None None O
Basal None None O
values None None O
" None None O
, None None O
obtained None None O
without None None O
the None None O
influence None None O
of None None O
subarachnoid None None O
blood None None O
, None None O
were None None O
lower None None O
than None None O
expected None None O
in None None O
" None None O
uninjured None None O
" None None O
brain None None O
, None None O
and None None O
this None None O
fact None None O
, None None O
although None None O
unexplained None None O
, None None O
should None None O
be None None O
kept None None O
in None None O
mind None None O
in None None O
future None None O
investigation None None O
in None None O
this None None O
field None None O
. None None O

Although None None O
values None None O
that None None O
could None None O
be None None O
predictive None None O
of None None O
brain None None O
ischemia None None O
could None None O
not None None O
be None None O
established None None O
, None None O
an None None O
incomplete None None O
recovery None None O
or None None O
continuous None None O
decrease None None O
in None None O
PtiO2 None None O
values None None O
after None None O
definitive None None O
clipping None None O
should None None O
be None None O
considered None None O
an None None O
indicator None None O
of None None O
high None None O
risk None None O
for None None O
the None None O
development None None O
of None None O
post None None O
- None None O
operative None None O
brain None None O
infarction None None O
, None None O
and None None O
, None None O
therefore None None O
, None None O
an None None O
indication None None O
for None None O
verification None None O
of None None O
the None None O
position None None O
of None None O
the None None O
clip None None O
. None None O

Endoscopic None None O
injection None None O
therapy None None O
for None None O
acute None None O
upper None None O
GI None None O
bleeding None None O
. None None O

In None None O
summary None None O
, None None O
we None None O
have None None O
found None None O
this None None O
technique None None O
to None None O
be None None O
useful None None O
in None None O
patients None None O
in None None O
whom None None O
coagulation None None O
therapy None None O
is None None O
not None None O
possible None None O
or None None O
effective None None O
. None None O

It None None O
must None None O
still None None O
be None None O
considered None None O
a None None O
technique None None O
which None None O
is None None O
undergoing None None O
evaluation None None O
. None None O

Prospective None None O
randomized None None O
trials None None O
comparing None None O
this None None O
therapy None None O
with None None O
other None None O
currently None None O
available None None O
therapies None None O
such None None O
a None None O
electrocoagulation None None O
, None None O
laser None None O
and None None O
conservative None None O
management None None O
must None None O
be None None O
completed None None O
to None None O
firmly None None O
define None None O
its None None O
place None None O
in None None O
treatment None None O
strategy None None O
for None None O
acute None None O
upper None None O
GI None None O
bleeding None None O
. None None O

Authors None None O
' None None O
contributions None None O

MBH None None O
made None None O
the None None O
pathological None None O
diagnosis None None O
and None None O
was None None O
responsible None None O
for None None O
conception None None O
and None None O
final None None O
approval None None O
of None None O
the None None O
manuscript None None O
. None None O

MB None None O
carried None None O
out None None O
the None None O
literature None None O
search None None O
and None None O
drafted None None O
the None None O
manuscript None None O
. None None O

IC None None O
carried None None O
out None None O
the None None O
surgical None None O
procedure None None O
and None None O
reviewed None None O
the None None O
manuscript None None O
. None None O

RM None None O
carried None None O
out None None O
the None None O
surgical None None O
procedure None None O
, None None O
provided None None O
clinical None None O
details None None O
, None None O
followed None None O
up None None O
our None None O
patient None None O
and None None O
obtained None None O
her None None O
consent None None O
to None None O
publish None None O
this None None O
case None None O
report None None O
. None None O

All None None O
authors None None O
read None None O
and None None O
approved None None O
the None None O
final None None O
manuscript None None O
. None None O

Multiple None None O
phosphotyrosine None None O
phosphatase None None O
mRNAs None None O
are None None O
expressed None None O
in None None O
the None None O
human None None O
lung None None O
fibroblast None None O
cell None None O
line None None O
WI None None I-Cell-line-name
- None None I-Cell-line-name
38 None None I-Cell-line-name
. None None O

Protein None None O
tyrosine None None O
phosphatases None None O
are None None O
important None None O
components None None O
of None None O
signal None None O
transduction None None O
pathways None None O
. None None O

The None None O
authors None None O
have None None O
used None None O
reverse None None O
transcription None None O
/ None None O
polymerase None None O
chain None None O
reactions None None O
to None None O
accomplish None None O
a None None O
comprehensive None None O
examination None None O
of None None O
the None None O
RNA None None O
expression None None O
for None None O
58 None None O
distinct None None O
mammalian None None O
protein None None O
tyrosine None None O
and None None O
dual None None O
specificity None None O
phosphatase None None O
( None None O
PTPase None None O
) None None O
and None None O
PTPase None None O
- None None O
like None None O
genes None None O
in None None O
the None None O
normal None None O
human None None O
diploid None None O
fibroblast None None O
cell None None O
line None None O
WI None None I-Cell-line-name
- None None I-Cell-line-name
38 None None I-Cell-line-name
. None None O

Thirty None None O
- None None O
seven None None O
of None None O
these None None O
PTPase None None O
genes None None O
express None None O
easily None None O
measurable None None O
RNA None None O
, None None O
and None None O
four None None O
simultaneously None None O
express None None O
the None None O
RNA None None O
for None None O
two None None O
or None None O
more None None O
isoforms None None O
. None None O

Messages None None O
for None None O
an None None O
additional None None O
eight None None O
PTPase None None O
genes None None O
are None None O
detectable None None O
at None None O
low None None O
levels None None O
. None None O

Only None None O
14 None None O
known None None O
PTPase None None O
genes None None O
do None None O
not None None O
express None None O
measurable None None O
RNA None None O
under None None O
our None None O
conditions None None O
. None None O

For None None O
purposes None None O
of None None O
comparison None None O
, None None O
the None None O
authors None None O
also None None O
assessed None None O
the None None O
PTPases None None O
expressed None None O
in None None O
the None None O
WI None None I-Cell-line-name
- None None I-Cell-line-name
38 None None I-Cell-line-name
cell None None O
line None None O
using None None O
highly None None O
degenerate None None O
primers None None O
to None None O
conserved None None O
motifs None None O
found None None O
in None None O
the None None O
classical None None O
tyrosine None None O
- None None O
specific None None O
PTPases None None O
. None None O

Only None None O
eight None None O
of None None O
the None None O
22 None None O
classic None None O
tyrosine None None O
- None None O
specific None None O
PTPases None None O
detected None None O
using None None O
the None None O
specific None None O
primers None None O
were None None O
detected None None O
using None None O
these None None O
degenerate None None O
primers None None O
. None None O

Our None None O
panel None None O
of None None O
specific None None O
PTPase None None O
primers None None O
should None None O
be None None O
very None None O
useful None None O
for None None O
semiquantitatively None None O
assessing None None O
the None None O
repertoire None None O
of None None O
PTPases None None O
expressed None None O
by None None O
cells None None O
. None None O

Relationship None None O
between None None O
of None None O
blood None None O
flow None None O
, None None O
glucose None None O
metabolism None None O
, None None O
protein None None O
synthesis None None O
, None None O
glucose None None O
and None None O
ATP None None O
content None None O
in None None O
experimentally None None O
- None None O
induced None None O
glioma None None O
( None None O
RG1 None None O
2 None None O
. None None O
2 None None O
) None None O
of None None O
rat None None O
brain None None O
. None None O

In None None O
experimental None None O
RG1 None None O
2 None None O
. None None O
2 None None O
glioma None None O
of None None O
rat None None O
brain None None O
, None None O
local None None O
blood None None O
flow None None O
, None None O
glucose None None O
utilization None None O
, None None O
protein None None O
synthesis None None O
, None None O
glucose None None O
and None None O
ATP None None O
content None None O
were None None O
measured None None O
by None None O
means None None O
of None None O
triple None None O
tracer None None O
autoradiography None None O
and None None O
bioluminescence None None O
technique None None O
, None None O
respectively None None O
, None None O
to None None O
determine None None O
hemodynamic None None O
and None None O
metabolic None None O
thresholds None None O
for None None O
local None None O
tumor None None O
energy None None O
failure None None O
. None None O

Perfusion None None O
thresholds None None O
were None None O
estimated None None O
at None None O
tumor None None O
blood None None O
flow None None O
values None None O
of None None O
69 None None O
. None None O
0 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
1 None None O
ml None None O
/ None None O
100 None None O
g None None O
/ None None O
min None None O
( None None O
estimate None None O
+ None None O
/ None None O
- None None O
standard None None O
error None None O
) None None O
and None None O
of None None O
69 None None O
+ None None O
/ None None O
- None None O
7 None None O
. None None O
1 None None O
ml None None O
/ None None O
100 None None O
g None None O
/ None None O
min None None O
for None None O
the None None O
beginning None None O
of None None O
the None None O
decline None None O
in None None O
regional None None O
ATP None None O
and None None O
glucose None None O
content None None O
, None None O
respectively None None O
. None None O

Metabolic None None O
thresholds None None O
were None None O
derived None None O
at None None O
tumor None None O
glucose None None O
utilization None None O
values None None O
of None None O
70 None None O
. None None O
6 None None O
+ None None O
/ None None O
- None None O
8 None None O
. None None O
3 None None O
mumol None None O
/ None None O
100 None None O
g None None O
/ None None O
min None None O
for None None O
reduced None None O
protein None None O
synthesis None None O
, None None O
of None None O
55 None None O
. None None O
0 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
2 None None O
mumol None None O
/ None None O
100 None None O
g None None O
/ None None O
min None None O
for None None O
the None None O
decrease None None O
in None None O
glucose None None O
content None None O
, None None O
and None None O
34 None None O
. None None O
7 None None O
+ None None O
/ None None O
- None None O
4 None None O
. None None O
7 None None O
mumol None None O
/ None None O
100 None None O
g None None O
/ None None O
min None None O
for None None O
decline None None O
in None None O
ATP None None O
content None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
blood None None O
flow None None O
limits None None O
glucose None None O
supply None None O
to None None O
tumor None None O
tissue None None O
at None None O
much None None O
higher None None O
flow None None O
rates None None O
than None None O
in None None O
normal None None O
brain None None O
which None None O
, None None O
in None None O
turn None None O
, None None O
is None None O
associated None None O
with None None O
a None None O
decrease None None O
in None None O
tumor None None O
glucose None None O
utilization None None O
. None None O

A None None O
reduction None None O
and None None O
not None None O
an None None O
increase None None O
in None None O
tumor None None O
glucose None None O
availability None None O
could None None O
be None None O
a None None O
more None None O
appropriate None None O
strategy None None O
for None None O
the None None O
induction None None O
of None None O
energy None None O
failure None None O
in None None O
tumors None None O
. None None O

Conclusions None None O

Myocardial None None O
ischaemia None None O
during None None O
DCMR None None O
is None None O
independently None None O
predictive None None O
of None None O
cardiac None None O
events None None O
among None None O
patients None None O
with None None O
previous None None O
myocardial None None O
revascularisation None None O
. None None O

Mast None None O
cell None None O
heparin None None O
stimulates None None O
migration None None O
of None None O
capillary None None O
endothelial None None O
cells None None O
in None None O
vitro None None O
. None None O

Migration None None O
of None None O
capillary None None O
endothelial None None O
cells None None O
is None None O
an None None O
important None None O
component None None O
of None None O
angiogenesis None None O
in None None O
vivo None None O
. None None O

Increased None None O
numbers None None O
of None None O
mast None None O
cells None None O
have None None O
been None None O
associated None None O
with None None O
several None None O
types None None O
of None None O
angiogenesis None None O
. None None O

We None None O
have None None O
used None None O
a None None O
quantitative None None O
assay None None O
in None None O
vitro None None O
to None None O
demonstrate None None O
that None None O
mast None None O
cells None None O
release None None O
a None None O
factor None None O
that None None O
significantly None None O
increases None None O
bovine None None O
capillary None None O
endothelial None None O
cell None None O
migration None None O
. None None O

The None None O
factor None None O
is None None O
present None None O
in None None O
medium None None O
conditioned None None O
by None None O
mast None None O
cells None None O
as None None O
well None None O
as None None O
lysates None None O
of None None O
mast None None O
cells None None O
. None None O

The None None O
stimulatory None None O
effect None None O
of None None O
mast None None O
cells None None O
on None None O
migration None None O
is None None O
specific None None O
for None None O
capillary None None O
endothelial None None O
cells None None O
. None None O

Furthermore None None O
, None None O
mast None None O
cells None None O
have None None O
no None None O
mitogenic None None O
activity None None O
for None None O
capillary None None O
endothelial None None O
cells None None O
. None None O

Of None None O
all None None O
the None None O
secretory None None O
products None None O
of None None O
mast None None O
cells None None O
tested None None O
, None None O
only None None O
heparin None None O
stimulated None None O
capillary None None O
endothelial None None O
cell None None O
migration None None O
in None None O
vitro None None O
. None None O

Heparin None None O
preparations None None O
from None None O
a None None O
variety None None O
of None None O
sources None None O
stimulated None None O
capillary None None O
endothelial None None O
cell None None O
migration None None O
to None None O
the None None O
same None None O
degree None None O
but None None O
did None None O
not None None O
stimulate None None O
migration None None O
of None None O
several None None O
other None None O
cell None None O
types None None O
. None None O

The None None O
migration None None O
activity None None O
of None None O
heparin None None O
and None None O
mast None None O
cell None None O
conditioned None None O
medium None None O
was None None O
blocked None None O
by None None O
specific None None O
antagonists None None O
of None None O
heparin None None O
( None None O
protamine None None O
and None None O
heparinase None None O
) None None O
, None None O
but None None O
not None None O
by None None O
chondroitinase None None O
ABC None None O
. None None O

The None None O
migration None None O
activity None None O
of None None O
mast None None O
cell None None O
conditioned None None O
medium None None O
was None None O
resistant None None O
to None None O
heat None None O
( None None O
100 None None O
degrees None None O
C None None O
) None None O
and None None O
incubation None None O
with None None O
proteolytic None None O
enzymes None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
role None None O
of None None O
mast None None O
cells None None O
in None None O
angiogenesis None None O
may None None O
be None None O
to None None O
enhance None None O
migration None None O
of None None O
the None None O
endothelial None None O
cells None None O
of None None O
growing None None O
capillaries None None O
. None None O

The None None O
contribution None None O
of None None O
Harold None None O
F None None O
. None None O
Dvorak None None O
to None None O
the None None O
study None None O
of None None O
tumor None None O
angiogenesis None None O
and None None O
stroma None None O
generation None None O
mechanisms None None O
. None None O

In None None O
1983 None None O
, None None O
Harold None None O
Dvorak None None O
and None None O
his None None O
colleagues None None O
were None None O
the None None O
first None None O
to None None O
show None None O
that None None O
tumor None None O
cells None None O
secreted None None O
vascular None None O
permeability None None O
factor None None O
( None None O
VPF None None O
) None None O
and None None O
that None None O
a None None O
blocking None None O
antibody None None O
to None None O
VPF None None O
could None None O
prevent None None O
the None None O
edema None None O
and None None O
fluid None None O
accumulation None None O
that None None O
is None None O
characteristic None None O
of None None O
human None None O
cancers None None O
. None None O

In None None O
1986 None None O
, None None O
Dvorak None None O
went None None O
on None None O
to None None O
demonstrate None None O
that None None O
VPF None None O
was None None O
secreted None None O
by None None O
a None None O
variety None None O
of None None O
human None None O
tumor None None O
cell None None O
lines None None O
and None None O
proposed None None O
that None None O
VPF None None O
was None None O
in None None O
part None None O
responsible None None O
for None None O
the None None O
abnormal None None O
vasculature None None O
seen None None O
in None None O
human None None O
tumors None None O
. None None O

As None None O
a None None O
result None None O
, None None O
he None None O
and None None O
other None None O
investigators None None O
demonstrated None None O
that None None O
VPF None None O
was None None O
capable None None O
of None None O
stimulating None None O
endothelial None None O
cell None None O
growth None None O
and None None O
angiogenesis None None O
. None None O

These None None O
fundamental None None O
discoveries None None O
led None None O
to None None O
additional None None O
research None None O
conducted None None O
by None None O
Napoleone None None O
Ferrara None None O
and None None O
his None None O
laboratory None None O
, None None O
confirming None None O
the None None O
cloning None None O
of None None O
VPF None None O
and None None O
renaming None None O
the None None O
protein None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
. None None O

In None None O
1986 None None O
, None None O
Dvorak None None O
proposed None None O
that None None O
by None None O
secreting None None O
VPF None None O
, None None O
tumors None None O
induce None None O
angiogenesis None None O
by None None O
turning None None O
on None None O
the None None O
wound None None O
healing None None O
response None None O
. None None O

He None None O
noted None None O
that None None O
wounds None None O
, None None O
like None None O
tumors None None O
, None None O
secrete None None O
VPF None None O
, None None O
causing None None O
blood None None O
vessels None None O
to None None O
leak None None O
plasma None None O
fibrinogen None None O
, None None O
which None None O
stimulates None None O
blood None None O
vessel None None O
growth None None O
and None None O
provides None None O
a None None O
matrix None None O
on None None O
which None None O
they None None O
can None None O
spread None None O
. None None O

Unlike None None O
wounds None None O
, None None O
however None None O
, None None O
that None None O
turn None None O
off None None O
VPF None None O
production None None O
after None None O
healing None None O
, None None O
tumors None None O
did None None O
not None None O
turn None None O
off None None O
their None None O
VPF None None O
production None None O
and None None O
instead None None O
continued None None O
to None None O
make None None O
large None None O
amounts None None O
of None None O
VPF None None O
, None None O
allowing None None O
malignant None None O
cells None None O
to None None O
continue None None O
to None None O
induce None None O
new None None O
blood None None O
vessels None None O
and None None O
so None None O
to None None O
grow None None O
and None None O
spread None None O
. None None O

Thus None None O
, None None O
tumors None None O
behave None None O
like None None O
wounds None None O
that None None O
fail None None O
to None None O
heal None None O
. None None O

This None None O
work None None O
is None None O
again None None O
extremely None None O
significant None None O
for None None O
patients None None O
worldwide None None O
, None None O
as None None O
Dvorak None None O
' None None O
s None None O
scientific None None O
research None None O
is None None O
leading None None O
his None None O
colleagues None None O
all None None O
over None None O
the None None O
world None None O
to None None O
examine None None O
how None None O
to None None O
treat None None O
a None None O
tumor None None O
through None None O
its None None O
blood None None O
supply None None O
. None None O

The None None O
impact None None O
of None None O
tracheal None None O
intubation None None O
on None None O
host None None O
defenses None None O
and None None O
risks None None O
for None None O
nosocomial None None O
pneumonia None None O
. None None O

Nosocomial None None O
pneumonia None None O
remains None None O
a None None O
common None None O
complication None None O
in None None O
patients None None O
treated None None O
with None None O
endotracheal None None O
intubation None None O
and None None O
mechanical None None O
ventilation None None O
and None None O
continues None None O
to None None O
have None None O
a None None O
significant None None O
impact None None O
on None None O
the None None O
mortality None None O
rate None None O
of None None O
these None None O
patients None None O
. None None O

Epidemiologic None None O
studies None None O
have None None O
shown None None O
that None None O
the None None O
risk None None O
of None None O
pneumonia None None O
increases None None O
with None None O
the None None O
duration None None O
of None None O
intubation None None O
but None None O
that None None O
the None None O
period None None O
of None None O
highest None None O
risk None None O
is None None O
the None None O
first None None O
2 None None O
weeks None None O
of None None O
therapy None None O
. None None O

Gram None None O
- None None O
negative None None O
bacteria None None O
account None None O
for None None O
most None None O
nosocomial None None O
pneumonias None None O
in None None O
intubated None None O
patients None None O
, None None O
but None None O
Staphylococcus None None O
aureus None None O
may None None O
also None None O
play None None O
a None None O
role None None O
in None None O
what None None O
may None None O
be None None O
a None None O
polymicrobial None None O
infection None None O
. None None O

In None None O
the None None O
most None None O
seriously None None O
ill None None O
individuals None None O
, None None O
and None None O
in None None O
those None None O
treated None None O
with None None O
long None None O
- None None O
term None None O
mechanical None None O
ventilation None None O
, None None O
Pseudomonas None None O
aeruginosa None None O
is None None O
a None None O
common None None O
pathogen None None O
. None None O

Endotracheal None None O
intubation None None O
and None None O
mechanical None None O
ventilation None None O
predispose None None O
to None None O
pneumonia None None O
for None None O
a None None O
variety None None O
of None None O
reasons None None O
( None None O
see None None O
Fig None None O
. None None O
1 None None O
) None None O
. None None O

The None None O
endotracheal None None O
tube None None O
can None None O
have None None O
direct None None O
effects None None O
on None None O
the None None O
airway None None O
that None None O
result None None O
in None None O
a None None O
reduction None None O
in None None O
local None None O
host None None O
defenses None None O
. None None O

Thus None None O
, None None O
mucosal None None O
injury None None O
can None None O
reduce None None O
mucociliary None None O
function None None O
, None None O
while None None O
upper None None O
airway None None O
defenses None None O
are None None O
bypassed None None O
and None None O
the None None O
effectiveness None None O
of None None O
cough None None O
is None None O
reduced None None O
. None None O

Indirectly None None O
, None None O
intubation None None O
can None None O
result None None O
in None None O
an None None O
enhanced None None O
capacity None None O
of None None O
tracheobronchial None None O
cells None None O
to None None O
bind None None O
gram None None O
- None None O
negative None None O
bacteria None None O
, None None O
an None None O
effect None None O
that None None O
favors None None O
airway None None O
colonization None None O
and None None O
pneumonia None None O
. None None O

The None None O
injury None None O
to None None O
the None None O
airway None None O
can None None O
create None None O
binding None None O
sites None None O
for None None O
bacteria None None O
in None None O
the None None O
basement None None O
membrane None None O
of None None O
the None None O
bronchial None None O
tree None None O
and None None O
the None None O
stimulation None None O
of None None O
the None None O
secretion None None O
of None None O
mucus None None O
, None None O
which None None O
then None None O
stagnates None None O
and None None O
can None None O
create None None O
potential None None O
sites None None O
for None None O
bacterial None None O
adherence None None O
. None None O

The None None O
endotracheal None None O
tube None None O
also None None O
enhances None None O
bacterial None None O
entry None None O
to None None O
the None None O
lung None None O
by None None O
serving None None O
as None None O
a None None O
reservoir None None O
for None None O
bacteria None None O
to None None O
remain None None O
sequestered None None O
, None None O
safe None None O
from None None O
host None None O
defenses None None O
. None None O

Respiratory None None O
therapy None None O
devices None None O
can None None O
allow None None O
bacteria None None O
to None None O
proliferate None None O
and None None O
can None None O
then None None O
introduce None None O
them None None O
into None None O
the None None O
patient None None O
if None None O
not None None O
handled None None O
properly None None O
. None None O

Finally None None O
, None None O
patients None None O
who None None O
are None None O
ill None None O
enough None None O
to None None O
require None None O
intubation None None O
also None None O
have None None O
disease None None O
- None None O
associated None None O
impairments None None O
in None None O
systemic None None O
host None None O
defense None None O
, None None O
which None None O
add None None O
to None None O
the None None O
impairments None None O
caused None None O
by None None O
the None None O
use None None O
of None None O
an None None O
artificial None None O
airway None None O
. None None O

The None None O
host None None O
defense None None O
impairments None None O
that None None O
occur None None O
in None None O
mechanically None None O
ventilated None None O
patients None None O
can None None O
lead None None O
to None None O
respiratory None None O
tract None None O
infection None None O
in None None O
the None None O
form None None O
of None None O
either None None O
febrile None None O
tracheobronchitis None None O
or None None O
pneumonia None None O
. None None O

The None None O
diagnosis None None O
of None None O
pneumonia None None O
in None None O
intubated None None O
patients None None O
is None None O
difficult None None O
and None None O
controversial None None O
. None None O

It None None O
can None None O
be None None O
made None None O
by None None O
either None None O
clinical None None O
criteria None None O
or None None O
microbiologic None None O
criteria None None O
, None None O
the None None O
latter None None O
by None None O
using None None O
a None None O
bronchoscopically None None O
directed None None O
protected None None O
specimen None None O
brush None None O
. None None O

Therapy None None O
of None None O
pneumonia None None O
in None None O
mechanically None None O
ventilated None None O
patients None None O
is None None O
not None None O
always None None O
successful None None O
, None None O
and None None O
systemic None None O
antibiotics None None O
may None None O
need None None O
to None None O
be None None O
supplemented None None O
by None None O
topical None None O
antimicrobials None None O
. None None O

No None None O
clearly None None O
effective None None O
prophylactic None None O
strategy None None O
currently None None O
exists None None O
, None None O
but None None O
our None None O
understanding None None O
of None None O
pneumonia None None O
pathogenesis None None O
has None None O
led None None O
to None None O
some None None O
promising None None O
directions None None O
. None None O

As None None O
more None None O
data None None O
are None None O
collected None None O
, None None O
inhaled None None O
antibiotics None None O
, None None O
selective None None O
digestive None None O
decontamination None None O
, None None O
and None None O
enhancement None None O
of None None O
host None None O
defenses None None O
by None None O
cytokines None None O
and None None O
pre None None O
- None None O
formed None None O
antibodies None None O
may None None O
emerge None None O
as None None O
useful None None O
approaches None None O
. None None O

Expression None None O
of None None O
epidermal None None O
growth None None O
factor None None O
receptor None None O
, None None O
transforming None None O
growth None None O
factor None None O
- None None O
alpha None None O
and None None O
Ki None None O
- None None O
67 None None O
in None None O
relationship None None O
to None None O
malignant None None O
transformation None None O
of None None O
pleomorphic None None O
adenoma None None O
. None None O

CONCLUSION None None O
: None None O
Quantitative None None O
assessment None None O
is None None O
more None None O
sensitive None None O
as None None O
a None None O
measure None None O
of None None O
cellular None None O
protein None None O
content None None O
as None None O
compared None None O
with None None O
standard None None O
optical None None O
density None None O
measurements None None O
. None None O

The None None O
data None None O
support None None O
the None None O
hypothesis None None O
that None None O
increased None None O
epidermal None None O
growth None None O
factor None None O
receptor None None O
( None None O
EGFR None None O
) None None O
and None None O
transforming None None O
growth None None O
factor None None O
( None None O
TGF None None O
) None None O
- None None O
alpha None None O
expression None None O
is None None O
associated None None O
with None None O
early None None O
events None None O
in None None O
malignant None None O
transformation None None O
of None None O
pleomorphic None None O
adenoma None None O
( None None O
PA None None O
) None None O
. None None O

OBJECTIVE None None O
: None None O
In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
attempted None None O
to None None O
identify None None O
EGFR None None O
and None None O
TGF None None O
- None None O
alpha None None O
expression None None O
and None None O
Ki None None O
- None None O
67 None None O
index None None O
in None None O
carcinoma None None O
ex None None O
- None None O
pleomorphic None None O
adenoma None None O
( None None O
Ca None None O
ex None None O
- None None O
PA None None O
) None None O
and None None O
PA None None O
. None None O

We None None O
also None None O
compared None None O
the None None O
presence None None O
of None None O
EGFR None None O
and None None O
TGF None None O
- None None O
alpha None None O
and None None O
Ki None None O
- None None O
67 None None O
index None None O
with None None O
clinical None None O
data None None O
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O
The None None O
tissues None None O
were None None O
stained None None O
with None None O
monoclonal None None O
antibodies None None O
to None None O
EGFR None None O
, None None O
TGF None None O
- None None O
alpha None None O
and None None O
Ki None None O
- None None O
67 None None O
. None None O

The None None O
results None None O
were None None O
analysed None None O
using None None O
quantitative None None O
immunohistochemical None None O
analysis None None O
. None None O

We None None O
also None None O
analysed None None O
the None None O
association None None O
of None None O
patients None None O
' None None O
prognosis None None O
with None None O
clinical None None O
parameters None None O
and None None O
the None None O
histological None None O
classification None None O
of None None O
the None None O
carcinomatous None None O
component None None O
. None None O

RESULTS None None O
: None None O
As None None O
regards None None O
the None None O
association None None O
of None None O
patients None None O
' None None O
prognosis None None O
with None None O
EGFR None None O
staining None None O
and None None O
Ki None None O
- None None O
67 None None O
index None None O
, None None O
a None None O
significant None None O
increase None None O
was None None O
observed None None O
in None None O
patients None None O
who None None O
died None None O
or None None O
had None None O
residual None None O
disease None None O
compared None None O
with None None O
patients None None O
who None None O
were None None O
alive None None O
without None None O
disease None None O
. None None O

In None None O
the None None O
immunohistochemical None None O
analysis None None O
of None None O
EGFR None None O
and None None O
TGF None None O
- None None O
alpha None None O
and None None O
Ki67 None None O
index None None O
, None None O
a None None O
significant None None O
increase None None O
was None None O
observed None None O
in None None O
Ca None None O
ex None None O
- None None O
PA None None O
, None None O
especially None None O
with None None O
adenocarcinoma None None O
, None None O
compared None None O
with None None O
PA None None O
and None None O
sialadenitis None None O
. None None O

Integration None None O
of None None O
interferon None None O
- None None O
alpha None None O
/ None None O
beta None None O
signalling None None O
to None None O
p53 None None O
responses None None O
in None None O
tumour None None O
suppression None None O
and None None O
antiviral None None O
defence None None O
. None None O

Swift None None O
elimination None None O
of None None O
undesirable None None O
cells None None O
is None None O
an None None O
important None None O
feature None None O
in None None O
tumour None None O
suppression None None O
and None None O
immunity None None O
. None None O

The None None O
tumour None None O
suppressor None None O
p53 None None O
and None None O
interferon None None O
- None None O
alpha None None O
and None None O
- None None O
beta None None O
( None None O
IFN None None O
- None None O
alpha None None O
/ None None O
beta None None O
) None None O
are None None O
essential None None O
for None None O
the None None O
induction None None O
of None None O
apoptosis None None O
in None None O
cancerous None None O
cells None None O
and None None O
in None None O
antiviral None None O
immune None None O
responses None None O
, None None O
respectively None None O
, None None O
but None None O
little None None O
is None None O
known None None O
about None None O
their None None O
interrelationship None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
transcription None None O
of None None O
the None None O
p53 None None O
gene None None O
is None None O
induced None None O
by None None O
IFN None None O
- None None O
alpha None None O
/ None None O
beta None None O
, None None O
accompanied None None O
by None None O
an None None O
increase None None O
in None None O
p53 None None O
protein None None O
level None None O
. None None O

IFN None None O
- None None O
alpha None None O
/ None None O
beta None None O
signalling None None O
itself None None O
does None None O
not None None O
activate None None O
p53 None None O
; None None O
rather None None O
, None None O
it None None O
contributes None None O
to None None O
boosting None None O
p53 None None O
responses None None O
to None None O
stress None None O
signals None None O
. None None O

We None None O
show None None O
examples None None O
in None None O
which None None O
p53 None None O
gene None None O
induction None None O
by None None O
IFN None None O
- None None O
alpha None None O
/ None None O
beta None None O
contributes None None O
to None None O
tumour None None O
suppression None None O
. None None O

Furthermore None None O
, None None O
we None None O
show None None O
that None None O
p53 None None O
is None None O
activated None None O
in None None O
virally None None O
infected None None O
cells None None O
to None None O
evoke None None O
an None None O
apoptotic None None O
response None None O
and None None O
that None None O
p53 None None O
is None None O
critical None None O
for None None O
antiviral None None O
defence None None O
of None None O
the None None O
host None None O
. None None O

Our None None O
study None None O
reveals None None O
a None None O
hitherto None None O
unrecognized None None O
link None None O
between None None O
p53 None None O
and None None O
IFN None None O
- None None O
alpha None None O
/ None None O
beta None None O
in None None O
tumour None None O
suppression None None O
and None None O
antiviral None None O
immunity None None O
, None None O
which None None O
may None None O
have None None O
therapeutic None None O
implications None None O
. None None O

[ None None O
Histopathologic None None O
examination None None O
of None None O
rectal None None O
carcinoma None None O
] None None O
. None None O

In None None O
patients None None O
with None None O
rectal None None O
carcinoma None None O
, None None O
the None None O
histopathological None None O
evaluation None None O
of None None O
the None None O
surgical None None O
specimen None None O
provides None None O
pivotal None None O
prognostic None None O
and None None O
therapeutic None None O
information None None O
. None None O

Important None None O
parameters None None O
are None None O
tumor None None O
site None None O
, None None O
depth None None O
of None None O
invasion None None O
, None None O
histological None None O
type None None O
and None None O
grade None None O
, None None O
pattern None None O
of None None O
invasion None None O
( None None O
diffusely None None O
infiltrating None None O
versus None None O
expanding None None O
margin None None O
) None None O
, None None O
degree None None O
of None None O
peritumoral None None O
lymphocytic None None O
infiltration None None O
, None None O
and None None O
tumor None None O
involvement None None O
of None None O
surgical None None O
margins None None O
and None None O
lymph None None O
nodes None None O
. None None O

Evaluation None None O
of None None O
the None None O
circumferential None None O
( None None O
deep None None O
, None None O
lateral None None O
) None None O
margin None None O
is None None O
of None None O
utmost None None O
importance None None O
. None None O

It None None O
should None None O
be None None O
labeled None None O
with None None O
ink None None O
in None None O
the None None O
gross None None O
specimen None None O
and None None O
should None None O
be None None O
examined None None O
histologically None None O
using None None O
several None None O
tissue None None O
blocks None None O
. None None O

The None None O
number None None O
of None None O
lymph None None O
node None None O
metastases None None O
and None None O
the None None O
total None None O
number None None O
of None None O
lymph None None O
nodes None None O
examined None None O
should None None O
be None None O
reported None None O
. None None O

A None None O
histological None None O
evaluation None None O
of None None O
the None None O
distal None None O
mesorectum None None O
in None None O
its None None O
entirety None None O
is None None O
recommended None None O
to None None O
detect None None O
discontinuous None None O
distal None None O
mesorectal None None O
tumor None None O
spread None None O
. None None O

The None None O
histopathological None None O
findings None None O
should None None O
be None None O
summarized None None O
using None None O
the None None O
TNM None None O
- None None O
classification None None O
. None None O

Angiogenesis None None O
in None None O
the None None O
caprine None None O
caruncles None None O
in None None O
non None None O
- None None O
pregnant None None O
and None None O
pregnant None None O
normal None None O
and None None O
swainsonine None None O
- None None O
treated None None O
does None None O
. None None O

Microvascular None None O
corrosion None None O
casts None None O
of None None O
caruncles None None O
from None None O
non None None O
- None None O
pregnant None None O
and None None O
pregnant None None O
doe None None O
goats None None O
at None None O
4 None None O
, None None O
7 None None O
, None None O
10 None None O
, None None O
13 None None O
, None None O
16 None None O
, None None O
and None None O
18 None None O
weeks None None O
were None None O
examined None None O
with None None O
scanning None None O
electron None None O
microscopy None None O
. None None O

The None None O
internal None None O
convex None None O
surface None None O
of None None O
the None None O
caruncles None None O
of None None O
non None None O
- None None O
pregnant None None O
does None None O
was None None O
covered None None O
with None None O
capillary None None O
meshes None None O
of None None O
regular None None O
diameter None None O
and None None O
form None None O
, None None O
without None None O
crypts None None O
. None None O

As None None O
pregnancy None None O
advanced None None O
the None None O
complexity None None O
of None None O
the None None O
vasculature None None O
increased None None O
: None None O
at None None O
4 None None O
weeks None None O
the None None O
surface None None O
showed None None O
a None None O
pattern None None O
of None None O
ridges None None O
separated None None O
by None None O
troughs None None O
. None None O

At None None O
later None None O
stages None None O
, None None O
branches None None O
of None None O
radial None None O
arteries None None O
penetrated None None O
the None None O
periphery None None O
forming None None O
an None None O
extensive None None O
mesh None None O
of None None O
capillaries None None O
on None None O
the None None O
concave None None O
surface None None O
. None None O

Capillary None None O
diameters None None O
increased None None O
significantly None None O
during None None O
pregnancy None None O
, None None O
especially None None O
after None None O
4 None None O
weeks None None O
, None None O
when None None O
large None None O
flattened None None O
sinusoids None None O
formed None None O
. None None O

These None None O
sinusoids None None O
had None None O
a None None O
great None None O
deal None None O
of None None O
surface None None O
area None None O
for None None O
potential None None O
contact None None O
with None None O
the None None O
fetal None None O
component None None O
. None None O

The None None O
caprine None None O
placenta None None O
is None None O
usually None None O
considered None None O
to None None O
have None None O
increased None None O
interhemal None None O
distance None None O
compared None None O
with None None O
endotheliochorial None None O
and None None O
hemochorial None None O
types None None O
: None None O
our None None O
results None None O
suggest None None O
that None None O
the None None O
very None None O
extensive None None O
development None None O
of None None O
sinusoids None None O
and None None O
crypts None None O
may None None O
compensate None None O
for None None O
any None None O
negative None None O
consequences None None O
of None None O
the None None O
placental None None O
architecture None None O
. None None O

Placental None None O
angiogenesis None None O
, None None O
which None None O
is None None O
physiologically None None O
normal None None O
, None None O
may None None O
serve None None O
as None None O
a None None O
general None None O
model None None O
of None None O
this None None O
process None None O
in None None O
other None None O
circumstances None None O
, None None O
such None None O
as None None O
tumor None None O
. None None O

The None None O
effect None None O
of None None O
swainsonine None None O
( None None O
active None None O
compound None None O
of None None O
locoweed None None O
and None None O
a None None O
potential None None O
anticancer None None O
drug None None O
) None None O
on None None O
vascular None None O
development None None O
showed None None O
no None None O
differences None None O
in None None O
sinusoidal None None O
diameters None None O
at None None O
7 None None O
weeks None None O
, None None O
but None None O
a None None O
decrease None None O
in None None O
capillary None None O
density None None O
was None None O
noted None None O
. None None O

Swainsonine None None O
caused None None O
a None None O
great None None O
distortion None None O
to None None O
the None None O
vasculature None None O
at None None O
18 None None O
weeks None None O
. None None O

The None None O
effects None None O
of None None O
this None None O
compound None None O
on None None O
the None None O
vascular None None O
development None None O
lend None None O
credibility None None O
to None None O
its None None O
potential None None O
as None None O
an None None O
anticancer None None O
agent None None O
. None None O

Insulin None None O
- None None O
like None None O
growth None None O
factor None None O
I None None O
induces None None O
tumor None None O
hexokinase None None O
RNA None None O
expression None None O
in None None O
cancer None None O
cells None None O
. None None O

Increased None None O
glycolysis None None O
is None None O
a None None O
characteristic None None O
of None None O
cancer None None O
cells None None O
. None None O

Though None None O
less None None O
efficient None None O
in None None O
energy None None O
production None None O
, None None O
it None None O
ensures None None O
continuous None None O
supply None None O
of None None O
energy None None O
and None None O
phosphometabolites None None O
for None None O
biosynthesis None None O
enabling None None O
metastatic None None O
and None None O
less None None O
vascularized None None O
cancer None None O
cells None None O
to None None O
proliferate None None O
even None None O
under None None O
hypoxic None None O
conditions None None O
. None None O

Since None None O
hexokinase None None O
is None None O
the None None O
first None None O
rate None None O
limiting None None O
enzyme None None O
in None None O
the None None O
glycolytic None None O
pathway None None O
, None None O
elevated None None O
levels None None O
of None None O
Type None None O
II None None O
like None None O
hexokinase None None O
in None None O
tumors None None O
are None None O
of None None O
great None None O
significance None None O
in None None O
this None None O
context None None O
. None None O

Under None None O
normal None None O
conditions None None O
insulin None None O
regulates None None O
expression None None O
of None None O
hexokinase None None O
Type None None O
II None None O
isoenzyme None None O
, None None O
which None None O
is None None O
predominantly None None O
expressed None None O
in None None O
muscle None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
cancer None None O
cells None None O
overexpress None None O
insulin None None O
- None None O
like None None O
growth None None O
factors None None O
and None None O
their None None O
receptors None None O
which None None O
mimic None None O
many None None O
activities None None O
of None None O
insulin None None O
. None None O

This None None O
prompted None None O
us None None O
to None None O
examine None None O
a None None O
hypothesis None None O
that None None O
insulin None None O
- None None O
like None None O
growth None None O
factors None None O
may None None O
be None None O
responsible None None O
for None None O
overexpression None None O
of None None O
tumor None None O
hexokinase None None O
. None None O

Our None None O
experiments None None O
demonstrate None None O
that None None O
insulin None None O
- None None O
like None None O
growth None None O
factor None None O
I None None O
indeed None None O
induces None None O
hexokinase None None O
gene None None O
expression None None O
in None None O
a None None O
concentration None None O
and None None O
time None None O
dependent None None O
manner None None O
in None None O
two None None O
cancer None None O
cell None None O
lines None None O
we None None O
studied None None O
. None None O

[ None None O
Synthetic None None O
fragments None None O
of None None O
the None None O
NS1 None None O
protein None None O
of None None O
the None None O
tick None None O
- None None O
borne None None O
encephalitis None None O
virus None None O
exhibiting None None O
a None None O
protective None None O
effect None None O
] None None O
. None None O

Potentially None None O
immunoactive None None O
regions None None O
of None None O
the None None O
NS1 None None O
nonstructural None None O
protein None None O
of None None O
the None None O
tick None None O
- None None O
borne None None O
encephalitis None None O
virus None None O
that None None O
can None None O
stimulate None None O
the None None O
antibody None None O
formation None None O
in None None O
vivo None None O
and None None O
protect None None O
animals None None O
from None None O
this None None O
disease None None O
were None None O
chosen None None O
on None None O
the None None O
basis None None O
of None None O
theoretical None None O
calculations None None O
. None None O

Eleven None None O
16 None None O
- None None O
to None None O
27 None None O
- None None O
aa None None O
peptides None None O
containing None None O
the None None O
chosen None None O
regions None None O
were None None O
synthesized None None O
. None None O

The None None O
ability None None O
of None None O
the None None O
free None None O
peptides None None O
( None None O
without None None O
any None None O
high None None O
- None None O
molecular None None O
- None None O
mass None None O
carrier None None O
) None None O
to None None O
stimulate None None O
the None None O
production None None O
of None None O
antipeptide None None O
antibodies None None O
in None None O
mice None None O
of None None O
three None None O
lines None None O
and None None O
ensure None None O
the None None O
formation None None O
of None None O
protective None None O
immunity None None O
was None None O
studied None None O
. None None O

Most None None O
of None None O
these None None O
peptides None None O
were None None O
shown None None O
to None None O
exhibit None None O
the None None O
immunogenic None None O
activity None None O
in None None O
a None None O
free None None O
state None None O
. None None O

Five None None O
fragments None None O
that None None O
can None None O
protect None None O
mice None None O
from None None O
the None None O
infection None None O
by None None O
a None None O
lethal None None O
dose None None O
of None None O
tick None None O
- None None O
borne None None O
encephalitis None None O
virus None None O
were None None O
found None None O
. None None O

The None None O
effects None None O
of None None O
oxidative None None O
stress None None O
on None None O
in None None O
vivo None None O
brain None None O
GSH None None O
turnover None None O
in None None O
young None None O
and None None O
mature None None O
mice None None O
. None None O

Glutathione None None O
( None None O
GSH None None O
) None None O
synthetase None None O
activities None None O
and None None O
GSH None None O
turnover None None O
rates None None O
were None None O
examined None None O
during None None O
severe None None O
oxidative None None O
stress None None O
in None None O
the None None O
mouse None None O
brain None None O
as None None O
induced None None O
by None None O
t None None O
- None None O
butylhydroperoxide None None O
( None None O
t None None O
- None None O
BuOOH None None O
) None None O
. None None O

Brain None None O
GSH None None O
synthetase None None O
activities None None O
in None None O
8 None None O
- None None O
mo None None O
- None None O
old None None O
mice None None O
in None None O
the None None O
cortex None None O
, None None O
striatum None None O
, None None O
thalamus None None O
, None None O
hippocampus None None O
, None None O
midbrain None None O
, None None O
and None None O
cerebellum None None O
were None None O
found None None O
to None None O
increase None None O
following None None O
t None None O
- None None O
BuOOH None None O
treatment None None O
. None None O

The None None O
effect None None O
of None None O
GSH None None O
synthesis None None O
on None None O
brain None None O
GSH None None O
turnover None None O
rates None None O
for None None O
2 None None O
- None None O
and None None O
8 None None O
- None None O
mo None None O
- None None O
old None None O
mice None None O
were None None O
determined None None O
after None None O
intracerebroventricular None None O
( None None O
icv None None O
) None None O
injection None None O
of None None O
[ None None O
35S None None O
] None None O
cysteine None None O
. None None O

Rate None None O
constants None None O
for None None O
GSH None None O
turnover None None O
were None None O
determined None None O
by None None O
least None None O
- None None O
squares None None O
iterative None None O
minimization None None O
from None None O
the None None O
specific None None O
activity None None O
data None None O
from None None O
20 None None O
min None None O
to None None O
108 None None O
h None None O
after None None O
[ None None O
35S None None O
] None None O
cysteine None None O
administration None None O
. None None O

GSH None None O
and None None O
glutathione None None O
disulfide None None O
( None None O
GSSG None None O
) None None O
specific None None O
activities None None O
were None None O
determined None None O
after None None O
separation None None O
by None None O
high None None O
- None None O
pressure None None O
liquid None None O
chromatography None None O
( None None O
HPLC None None O
) None None O
. None None O

The None None O
half None None O
- None None O
life None None O
of None None O
GSH None None O
in None None O
the None None O
2 None None O
- None None O
mo None None O
- None None O
old None None O
mouse None None O
was None None O
59 None None O
. None None O
5 None None O
h None None O
and None None O
in None None O
the None None O
8 None None O
- None None O
mo None None O
- None None O
old None None O
mouse None None O
was None None O
79 None None O
. None None O
1 None None O
h None None O
. None None O

In None None O
summary None None O
, None None O
defense None None O
mechanisms None None O
against None None O
oxidative None None O
stress None None O
in None None O
the None None O
brain None None O
differ None None O
with None None O
age None None O
. None None O

Young None None O
mice None None O
can None None O
increase None None O
the None None O
cellular None None O
availability None None O
of None None O
GSH None None O
, None None O
whereas None None O
mature None None O
mice None None O
can None None O
increase None None O
GSH None None O
synthetase None None O
activity None None O
during None None O
oxidative None None O
stress None None O
. None None O

These None None O
differences None None O
make None None O
mature None None O
mice None None O
more None None O
susceptible None None O
to None None O
brain None None O
oxidative None None O
damage None None O
. None None O

Regulation None None O
of None None O
glucosyl None None O
- None None O
and None None O
fructosyltransferase None None O
synthesis None None O
by None None O
continuous None None O
cultures None None O
of None None O
Streptococcus None None O
mutans None None O
. None None O

Streptococcus None None O
mutans None None O
strains None None O
Ingbritt None None O
, None None O
and None None O
its None None O
derivative None None O
B7 None None O
which None None O
had None None O
been None None O
passaged None None O
through None None O
monkeys None None O
, None None O
have None None O
been None None O
used None None O
to None None O
investigate None None O
how None None O
the None None O
synthesis None None O
of None None O
extracellular None None O
glucosyl None None O
- None None O
and None None O
fructosyltransferases None None O
is None None O
regulated None None O
. None None O

The None None O
most None None O
active None None O
enzyme None None O
from None None O
carbon None None O
- None None O
limited None None O
continuous None None O
cultures None None O
was None None O
a None None O
fructosyltransferase None None O
; None None O
enzymes None None O
catalysing None None O
the None None O
formation None None O
of None None O
water None None O
- None None O
insoluble None None O
glucans None None O
from None None O
sucrose None None O
were None None O
relatively None None O
inactive None None O
. None None O

Dextransucrase None None O
( None None O
EC None None O
2 None None O
. None None O
4 None None O
. None None O
1 None None O
. None None O
5 None None O
) None None O
, None None O
which None None O
catalyses None None O
soluble None None O
glucan None None O
synthesis None None O
, None None O
was None None O
most None None O
active None None O
in None None O
the None None O
supernatant None None O
fluid None None O
from None None O
cultures None None O
grown None None O
with None None O
excess None None O
glucose None None O
, None None O
fructose None None O
or None None O
sucrose None None O
, None None O
but None None O
full None None O
activity None None O
was None None O
detected None None O
only None None O
when None None O
the None None O
enzyme None None O
was None None O
incubated None None O
with None None O
both None None O
sucrose None None O
and None None O
dextran None None O
. None None O

Little None None O
dextransucrase None None O
activity None None O
was None None O
detected None None O
in None None O
carbon None None O
- None None O
limited None None O
cultures None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
glucosyl None None O
- None None O
and None None O
fructosyltransferases None None O
are None None O
constitutive None None O
enzymes None None O
in None None O
that None None O
they None None O
are None None O
synthesized None None O
at None None O
similar None None O
rates None None O
during None None O
growth None None O
with None None O
an None None O
excess None None O
of None None O
the None None O
substrate None None O
or None None O
of None None O
the None None O
products None None O
of None None O
the None None O
reactions None None O
which None None O
they None None O
catalyse None None O
. None None O

Although None None O
the None None O
Ingbritt None None O
strain None None O
was None None O
originally None None O
isolated None None O
from None None O
a None None O
carious None None O
lesion None None O
, None None O
it None None O
is None None O
now None None O
a None None O
poor None None O
source None None O
of None None O
glucosyltransferase None None O
activity None None O
. None None O

Glucosyltransferases None None O
were None None O
extremely None None O
active None None O
in None None O
cultures None None O
of None None O
a None None O
recent None None O
clinical None None O
isolate None None O
, None None O
strain None None O
3209 None None O
, None None O
and None None O
were None None O
apparently None None O
induced None None O
during None None O
growth None None O
with None None O
excess None None O
glucose None None O
. None None O

[ None None O
Treatment None None O
of None None O
squamous None None O
intraepithelial None None O
lesion None None O
of None None O
type None None O
CIN2 None None O
et None None O
CIN3 None None O
with None None O
laser None None O
CO2 None None O
vaporization None None O
: None None O
retrospective None None O
study None None O
of None None O
52 None None O
cases None None O
] None None O
. None None O

OBJECTIVES None None O
: None None O

This None None O
study None None O
was None None O
carried None None O
out None None O
over None None O
an None None O
8 None None O
- None None O
year None None O
period None None O
in None None O
order None None O
to None None O
evaluate None None O
the None None O
long None None O
- None None O
term None None O
effectiveness None None O
of None None O
laser None None O
CO2 None None O
vaporization None None O
in None None O
the None None O
treatment None None O
of None None O
squamous None None O
intraepithelial None None O
lesion None None O
of None None O
type None None O
CIN2 None None O
and None None O
CIN3 None None O
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O

A None None O
retrospective None None O
study None None O
of None None O
52 None None O
cases None None O
of None None O
cervical None None O
lesions None None O
of None None O
type None None O
CIN2 None None O
and None None O
CIN3 None None O
treated None None O
in None None O
first None None O
intention None None O
by None None O
laser None None O
CO2 None None O
vaporization None None O
was None None O
carried None None O
out None None O
at None None O
the None None O
hospital None None O
Jeanne None None O
- None None O
de None None O
- None None O
Flandre None None O
in None None O
CHRU None None O
of None None O
Lille None None O
from None None O
1996 None None O
to None None O
2003 None None O
. None None O

This None None O
treatment None None O
was None None O
performed None None O
on None None O
only None None O
high None None O
- None None O
grade None None O
exo None None O
- None None O
cervical None None O
lesions None None O
, None None O
of None None O
small None None O
size None None O
( None None O
< None None O
2cm2 None None O
) None None O
, None None O
after None None O
a None None O
complete None None O
colposcopic None None O
examination None None O
. None None O

RESULTS None None O
: None None O

Fifty None None O
- None None O
two None None O
patients None None O
were None None O
treated None None O
by None None O
first None None O
- None None O
intention None None O
laser None None O
vaporization None None O
only None None O
. None None O

Mean None None O
age None None O
was None None O
29 None None O
. None None O
4 None None O
years None None O
and None None O
51 None None O
. None None O
9 None None O
% None None O
were None None O
nulliparous None None O
. None None O

At None None O
the None None O
first None None O
cyto None None O
- None None O
colposcopic None None O
control None None O
, None None O
there None None O
were None None O
17 None None O
persistent None None O
lesions None None O
( None None O
32 None None O
. None None O
7 None None O
% None None O
) None None O
. None None O

Among None None O
the None None O
35 None None O
patients None None O
without None None O
persistent None None O
lesion None None O
, None None O
29 None None O
achieved None None O
cure None None O
( None None O
absence None None O
of None None O
recurrence None None O
) None None O
, None None O
4 None None O
presented None None O
a None None O
recurrence None None O
and None None O
2 None None O
were None None O
lost None None O
to None None O
follow None None O
- None None O
up None None O
. None None O

CONCLUSION None None O
: None None O

The None None O
current None None O
data None None O
of None None O
the None None O
literature None None O
concerning None None O
the None None O
treatment None None O
by None None O
laser None None O
CO2 None None O
vaporization None None O
authorize None None O
application None None O
of None None O
this None None O
method None None O
for None None O
certain None None O
high None None O
- None None O
grade None None O
exocervical None None O
lesions None None O
after None None O
a None None O
complete None None O
colposcopic None None O
examination None None O
. None None O

This None None O
type None None O
of None None O
treatment None None O
remains None None O
less None None O
aggressive None None O
than None None O
a None None O
surgical None None O
treatment None None O
. None None O

The None None O
high None None O
rate None None O
of None None O
residual None None O
lesions None None O
in None None O
particular None None O
in None None O
the None None O
event None None O
of None None O
CIN3 None None O
can None None O
be None None O
due None None O
to None None O
an None None O
incomplete None None O
destruction None None O
of None None O
the None None O
lesion None None O
. None None O

Patients None None O
should None None O
thus None None O
be None None O
advised None None O
that None None O
monitoring None None O
is None None O
an None None O
integral None None O
part None None O
of None None O
the None None O
treatment None None O
. None None O

Laser None None O
vaporization None None O
could None None O
be None None O
limited None None O
to None None O
CIN1 None None O
and None None O
CIN2 None None O
lesions None None O
. None None O

Expression None None O
profiling None None O
in None None O
progressive None None O
stages None None O
of None None O
fumarate None None O
- None None O
hydratase None None O
deficiency None None O
: None None O
the None None O
contribution None None O
of None None O
metabolic None None O
changes None None O
to None None O
tumorigenesis None None O
. None None O

Hereditary None None O
leiomyomatosis None None O
and None None O
renal None None O
cell None None O
carcinoma None None O
( None None O
HLRCC None None O
) None None O
is None None O
caused None None O
by None None O
mutations None None O
in None None O
the None None O
Krebs None None O
cycle None None O
enzyme None None O
fumarate None None O
hydratase None None O
( None None O
FH None None O
) None None O
. None None O

It None None O
has None None O
been None None O
proposed None None O
that None None O
" None None O
pseudohypoxic None None O
" None None O
stabilization None None O
of None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
- None None O
alpha None None O
( None None O
HIF None None O
- None None O
alpha None None O
) None None O
by None None O
fumarate None None O
accumulation None None O
contributes None None O
to None None O
tumorigenesis None None O
in None None O
HLRCC None None O
. None None O

We None None O
hypothesized None None O
that None None O
an None None O
additional None None O
direct None None O
consequence None None O
of None None O
FH None None O
deficiency None None O
is None None O
the None None O
establishment None None O
of None None O
a None None O
biosynthetic None None O
milieu None None O
. None None O

To None None O
investigate None None O
this None None O
hypothesis None None O
, None None O
we None None O
isolated None None O
primary None None O
mouse None None O
embryonic None None O
fibroblast None None O
( None None O
MEF None None O
) None None O
lines None None O
from None None O
Fh1 None None O
- None None O
deficient None None O
mice None None O
. None None O

As None None O
predicted None None O
, None None O
these None None O
MEFs None None O
upregulated None None O
Hif None None O
- None None O
1alpha None None O
and None None O
HIF None None O
target None None O
genes None None O
directly None None O
as None None O
a None None O
result None None O
of None None O
FH None None O
deficiency None None O
. None None O

In None None O
addition None None O
, None None O
detailed None None O
metabolic None None O
assessment None None O
of None None O
these None None O
MEFs None None O
confirmed None None O
their None None O
dependence None None O
on None None O
glycolysis None None O
, None None O
and None None O
an None None O
elevated None None O
rate None None O
of None None O
lactate None None O
efflux None None O
, None None O
associated None None O
with None None O
the None None O
upregulation None None O
of None None O
glycolytic None None O
enzymes None None O
known None None O
to None None O
be None None O
associated None None O
with None None O
tumorigenesis None None O
. None None O

Correspondingly None None O
, None None O
Fh1 None None O
- None None O
deficient None None O
benign None None O
murine None None O
renal None None O
cysts None None O
and None None O
an None None O
advanced None None O
human None None O
HLRCC None None O
- None None O
related None None O
renal None None O
cell None None O
carcinoma None None O
manifested None None O
a None None O
prominent None None O
and None None O
progressive None None O
increase None None O
in None None O
the None None O
expression None None O
of None None O
HIF None None O
- None None O
alpha None None O
target None None O
genes None None O
and None None O
in None None O
genes None None O
known None None O
to None None O
be None None O
relevant None None O
to None None O
tumorigenesis None None O
and None None O
metastasis None None O
. None None O

In None None O
accord None None O
with None None O
our None None O
hypothesis None None O
, None None O
in None None O
a None None O
variety None None O
of None None O
different None None O
FH None None O
- None None O
deficient None None O
tissues None None O
, None None O
including None None O
a None None O
novel None None O
murine None None O
model None None O
of None None O
Fh1 None None O
- None None O
deficient None None O
smooth None None O
muscle None None O
, None None O
we None None O
show None None O
a None None O
striking None None O
and None None O
progressive None None O
upregulation None None O
of None None O
a None None O
tumorigenic None None O
metabolic None None O
profile None None O
, None None O
as None None O
manifested None None O
by None None O
increased None None O
PKM2 None None O
and None None O
LDHA None None O
protein None None O
. None None O

Based None None O
on None None O
the None None O
models None None O
assessed None None O
herein None None O
, None None O
we None None O
infer None None O
that None None O
that None None O
FH None None O
deficiency None None O
compels None None O
cells None None O
to None None O
adopt None None O
an None None O
early None None O
, None None O
reversible None None O
, None None O
and None None O
progressive None None O
protumorigenic None None O
metabolic None None O
milieu None None O
that None None O
is None None O
reminiscent None None O
of None None O
that None None O
driving None None O
the None None O
Warburg None None O
effect None None O
. None None O

Targets None None O
identified None None O
in None None O
these None None O
novel None None O
and None None O
diverse None None O
FH None None O
- None None O
deficient None None O
models None None O
represent None None O
excellent None None O
potential None None O
candidates None None O
for None None O
further None None O
mechanistic None None O
investigation None None O
and None None O
therapeutic None None O
metabolic None None O
manipulation None None O
in None None O
tumors None None O
. None None O

Coexpression None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
and None None O
p53 None None O
protein None None O
in None None O
squamous None None O
cell None None O
carcinoma None None O
of None None O
the None None O
esophagus None None O
. None None O

OBJECTIVE None None O
: None None O
p53 None None O
plays None None O
a None None O
role None None O
in None None O
tumor None None O
angiogenesis None None O
, None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
tumor None None O
angiogenesis None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
clarify None None O
how None None O
expression None None O
of None None O
p53 None None O
protein None None O
participates None None O
in None None O
angiogenesis None None O
, None None O
and None None O
whether None None O
the None None O
coexpression None None O
of None None O
VEGF None None O
and None None O
p53 None None O
protein None None O
has None None O
a None None O
significance None None O
for None None O
angiogenesis None None O
and None None O
the None None O
clinicopathological None None O
features None None O
in None None O
esophageal None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
SCC None None O
) None None O
. None None O

METHODS None None O
: None None O
Tissues None None O
samples None None O
were None None O
taken None None O
from None None O
60 None None O
patients None None O
with None None O
esophageal None None O
SCC None None O
after None None O
surgery None None O
. None None O

The None None O
expression None None O
of None None O
VEGF None None O
and None None O
p53 None None O
protein None None O
in None None O
these None None O
SCC None None O
was None None O
examined None None O
immunohistochemically None None O
. None None O

Microvessel None None O
density None None O
( None None O
MVD None None O
) None None O
was None None O
determined None None O
by None None O
counting None None O
microvessels None None O
in None None O
tumor None None O
sections None None O
stained None None O
for None None O
Factor None None O
VIII None None O
- None None O
related None None O
antigen None None O
. None None O

Ki None None O
- None None O
67 None None O
labeling None None O
index None None O
( None None O
LI None None O
) None None O
was None None O
calculated None None O
, None None O
based None None O
on None None O
Ki None None O
- None None O
67 None None O
antigen None None O
immunostaining None None O
, None None O
as None None O
a None None O
proliferative None None O
marker None None O
. None None O

Apoptotic None None O
index None None O
( None None O
AI None None O
) None None O
was None None O
calculated None None O
, None None O
based None None O
on None None O
the None None O
terminal None None O
deoxynucleotidyl None None O
transferase None None O
- None None O
mediated None None O
deoxyuridine None None O
triphosphate None None O
biotin None None O
nick None None O
end None None O
labeling None None O
, None None O
to None None O
evaluate None None O
apoptosis None None O
. None None O

RESULTS None None O
: None None O
VEGF None None O
expression None None O
was None None O
observed None None O
in None None O
58 None None O
. None None O
3 None None O
% None None O
, None None O
and None None O
p53 None None O
protein None None O
expression None None O
was None None O
observed None None O
in None None O
61 None None O
. None None O
7 None None O
% None None O
of None None O
the None None O
60 None None O
patients None None O
. None None O

VEGF None None O
and None None O
p53 None None O
protein None None O
were None None O
significantly None None O
coexpressed None None O
in None None O
26 None None O
( None None O
43 None None O
. None None O
4 None None O
% None None O
) None None O
. None None O

Histological None None O
venous None None O
invasion None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
) None None O
and None None O
distant None None O
metastasis None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
were None None O
significantly None None O
correlated None None O
with None None O
p53 None None O
protein None None O
expression None None O
. None None O

The None None O
two None None O
parameters None None O
were None None O
more None None O
frequently None None O
observed None None O
in None None O
the None None O
SCC None None O
with None None O
VEGF None None O
/ None None O
p53 None None O
coexpression None None O
than None None O
in None None O
those None None O
without None None O
the None None O
coexpression None None O
. None None O

The None None O
MVD None None O
and None None O
Ki None None O
- None None O
67 None None O
LI None None O
were None None O
significantly None None O
higher None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
and None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
, None None O
and None None O
the None None O
AI None None O
was None None O
significantly None None O
lower None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
in None None O
the None None O
SCC None None O
with None None O
p53 None None O
protein None None O
expression None None O
than None None O
in None None O
the None None O
SCC None None O
without None None O
it None None O
. None None O

The None None O
MVD None None O
and None None O
Ki None None O
- None None O
67 None None O
LI None None O
were None None O
higher None None O
, None None O
and None None O
the None None O
AI None None O
was None None O
lower None None O
in None None O
the None None O
SCC None None O
with None None O
VEGF None None O
/ None None O
p53 None None O
coexpression None None O
than None None O
in None None O
those None None O
without None None O
the None None O
coexpression None None O
. None None O

The None None O
5 None None O
- None None O
yr None None O
survival None None O
rate None None O
in None None O
patients None None O
with None None O
the None None O
coexpression None None O
was None None O
poorer None None O
than None None O
in None None O
the None None O
other None None O
patients None None O
. None None O

CONCLUSION None None O
: None None O
These None None O
results None None O
suggest None None O
that None None O
mutant None None O
p53 None None O
expression None None O
is None None O
associated None None O
with None None O
angiogenesis None None O
and None None O
distant None None O
metastasis None None O
in None None O
esophageal None None O
SCC None None O
, None None O
and None None O
that None None O
the None None O
coexpression None None O
of None None O
p53 None None O
and None None O
VEGF None None O
may None None O
play None None O
an None None O
important None None O
role None None O
in None None O
angiogenesis None None O
, None None O
and None None O
have None None O
important None None O
clinical None None O
significance None None O
. None None O
